<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1063" width="918">
	<fontspec id="0" size="25" family="Times" color="#000000"/>
	<fontspec id="1" size="13" family="Times" color="#000000"/>
	<fontspec id="2" size="13" family="Times" color="#0000ff"/>
	<fontspec id="3" size="13" family="Helvetica" color="#000000"/>
	<fontspec id="4" size="13" family="Times" color="#000000"/>
<text top="103" left="105" width="252" height="37" font="0">Accepted Manuscript</text>
<text top="189" left="105" width="523" height="21" font="1">2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart</text>
<text top="207" left="105" width="54" height="21" font="1">Disease</text>
<text top="248" left="105" width="530" height="21" font="1">Karen K. Stout, MD, FACC, Chair, Writing Committee, Curt J. Daniels, MD, Vice</text>
<text top="266" left="105" width="569" height="21" font="1">Chair, Writing Committee, Jamil A. Aboulhosn, MD, FACC, FSCAI, Writing Committee</text>
<text top="284" left="105" width="569" height="21" font="1">Member, Biykem Bozkurt, MD, PhD, FACC, FAHA, Writing Committee Member, Craig</text>
<text top="302" left="105" width="544" height="21" font="1">S. Broberg, MD, FACC, Writing Committee Member, Jack M. Colman, MD, FACC,</text>
<text top="320" left="105" width="536" height="21" font="1">Writing Committee Member, Stephen R. Crumb, DNP, AACC, Writing Committee</text>
<text top="338" left="105" width="534" height="21" font="1">Member, Joseph A. Dearani, MD, FACC, Writing Committee Member, Stephanie</text>
<text top="356" left="105" width="540" height="21" font="1">Fuller, MD, MS, FACC, Writing Committee Member, Michelle Gurvitz, MD, FACC,</text>
<text top="374" left="105" width="531" height="21" font="1">Writing Committee Member, Paul Khairy, MD, PhD, Writing Committee Member,</text>
<text top="392" left="105" width="569" height="21" font="1">Michael J. Landzberg, MD, FACC, Writing Committee Member, Arwa Saidi, MB, BCH,</text>
<text top="410" left="105" width="552" height="21" font="1">FACC, Writing Committee Member, Anne Marie Valente, MD, FACC, FAHA, FASE,</text>
<text top="428" left="105" width="548" height="21" font="1">Writing Committee Member, George F. Van Hare, MD, Writing Committee Member</text>
<text top="483" left="105" width="22" height="21" font="1">PII:</text>
<text top="483" left="216" width="163" height="21" font="1">S0735-1097(18)36846-3</text>
<text top="512" left="105" width="31" height="21" font="1">DOI:</text>
<text top="512" left="216" width="188" height="21" font="2"><a href="https://doi.org/10.1016/j.jacc.2018.08.1029">10.1016/j.jacc.2018.08.1029</a></text>
<text top="540" left="105" width="73" height="21" font="1">Reference:</text>
<text top="540" left="216" width="74" height="21" font="1">JAC 25255</text>
<text top="588" left="105" width="88" height="21" font="1">To appear in:</text>
<text top="593" left="216" width="306" height="14" font="3"><i>Journal of the American College of Cardiology</i></text>
<text top="705" left="105" width="662" height="21" font="1">Please cite this article as: Stout KK, Daniels CJ, Aboulhosn JA, Bozkurt B, Broberg CS, Colman JM,</text>
<text top="723" left="105" width="666" height="21" font="1">Crumb SR, Dearani JA, Fuller S, Gurvitz M, Khairy P, Landzberg MJ, Saidi A, Valente AM, Van Hare</text>
<text top="741" left="105" width="685" height="21" font="1">GF, 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease, <i>Journal of</i></text>
<text top="760" left="105" width="236" height="20" font="4"><i>the American College of Cardiology</i></text>
<text top="759" left="341" width="277" height="21" font="1"> (2018), doi: 10.1016/j.jacc.2018.08.1029.</text>
<text top="815" left="105" width="654" height="21" font="1">This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to</text>
<text top="833" left="105" width="641" height="21" font="1">our customers we are providing this early version of the manuscript. The manuscript will undergo</text>
<text top="851" left="105" width="675" height="21" font="1">copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please</text>
<text top="869" left="105" width="687" height="21" font="1">note that during the production process errors may be discovered which could affect the content, and all</text>
<text top="887" left="105" width="325" height="21" font="1">legal disclaimers that apply to the journal pertain.</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="5" size="67" family="Times" color="#e5e5e5"/>
	<fontspec id="6" size="18" family="Times" color="#ffffff"/>
	<fontspec id="7" size="12" family="Times" color="#000000"/>
	<fontspec id="8" size="12" family="Times" color="#000000"/>
	<fontspec id="9" size="11" family="Times" color="#000000"/>
	<fontspec id="10" size="21" family="Times" color="#000000"/>
	<fontspec id="11" size="14" family="Times" color="#000000"/>
	<fontspec id="12" size="15" family="Times" color="#000000"/>
	<fontspec id="13" size="14" family="Times" color="#000000"/>
	<fontspec id="14" size="14" family="Times" color="#000000"/>
	<fontspec id="15" size="14" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 1 </text>
<text top="164" left="149" width="601" height="21" font="10"><b>2018 AHA/ACC Guideline for the Management of Adults With </b></text>
<text top="197" left="325" width="243" height="21" font="10"><b>Congenital Heart Disease</b></text>
<text top="202" left="568" width="4" height="14" font="11"> </text>
<text top="237" left="119" width="659" height="16" font="12"><b>A Report of the American College of Cardiology/American Heart Association Task Force on </b></text>
<text top="259" left="349" width="199" height="16" font="12"><b>Clinical Practice Guidelines </b></text>
<text top="279" left="447" width="4" height="14" font="11"> </text>
<text top="310" left="113" width="671" height="15" font="13"><i><b>Developed in Collaboration With the American Association for Thoracic Surgery, American Society of </b></i></text>
<text top="333" left="118" width="661" height="15" font="13"><i><b>Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, </b></i></text>
<text top="356" left="142" width="614" height="15" font="13"><i><b>Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons</b></i> </text>
<text top="387" left="447" width="4" height="14" font="11"> </text>
<text top="418" left="332" width="233" height="15" font="14"><b>WRITING COMMITTEE MEMBERS* </b></text>
<text top="438" left="338" width="219" height="14" font="11">Karen K. Stout, MD, FACC, <i>Chair</i>† </text>
<text top="458" left="335" width="224" height="14" font="11">Curt J. Daniels, MD, <i>Vice Chair</i>*†‡ </text>
<text top="477" left="138" width="260" height="14" font="11">Jamil A. Aboulhosn, MD, FACC, FSCAI*§ </text>
<text top="477" left="446" width="219" height="14" font="11">Stephanie Fuller, MD, MS, FACC# </text>
<text top="497" left="138" width="253" height="14" font="11">Biykem Bozkurt, MD, PhD, FACC, FAHA</text>
<text top="494" left="390" width="15" height="20" font="11">║ </text>
<text top="497" left="446" width="199" height="14" font="11">Michelle Gurvitz, MD, FACC** </text>
<text top="516" left="138" width="197" height="14" font="11">Craig S. Broberg, MD, FACC*† </text>
<text top="516" left="446" width="158" height="14" font="11">Paul Khairy, MD, PhD*† </text>
<text top="536" left="138" width="186" height="14" font="11">Jack M. Colman, MD, FACC† </text>
<text top="536" left="446" width="228" height="14" font="11">Michael J. Landzberg, MD, FACC*† </text>
<text top="556" left="138" width="209" height="14" font="11">Stephen R. Crumb, DNP, AACC† </text>
<text top="556" left="446" width="195" height="14" font="11">Arwa Saidi, MB, BCH, FACC*† </text>
<text top="575" left="138" width="202" height="14" font="11">Joseph A. Dearani, MD, FACC¶ </text>
<text top="575" left="446" width="306" height="14" font="11">Anne Marie Valente, MD, FACC, FAHA, FASE†† </text>
<text top="595" left="359" width="158" height="14" font="11">George F. Van Hare, MD</text>
<text top="596" left="517" width="14" height="13" font="8">‡‡</text>
<text top="595" left="531" width="4" height="14" font="11"> </text>
<text top="615" left="105" width="4" height="14" font="11"> </text>
<text top="651" left="336" width="225" height="15" font="14"><b>ACC/AHA TASK FORCE MEMBERS </b></text>
<text top="671" left="316" width="264" height="14" font="11">Glenn N. Levine, MD, FACC, FAHA, <i>Chair</i> </text>
<text top="691" left="292" width="314" height="14" font="11">Patrick T. O’Gara, MD, MACC, FAHA, <i>Chair-Elect</i> </text>
<text top="710" left="248" width="401" height="14" font="11">Jonathan L. Halperin, MD, FACC, FAHA, <i>Immediate Past Chair</i> </text>
<text top="730" left="133" width="211" height="14" font="11">Nancy M. Albert, PhD, RN, FAHA</text>
<text top="731" left="343" width="14" height="13" font="8">§§</text>
<text top="730" left="358" width="4" height="14" font="11"> </text>
<text top="730" left="455" width="295" height="14" font="11">Zachary D. Goldberger, MD, MS, FACC, FAHA </text>
<text top="749" left="133" width="275" height="14" font="11">Sana M. Al-Khatib, MD, MHS, FACC, FAHA </text>
<text top="749" left="455" width="172" height="14" font="11">Mark A. Hlatky, MD, FACC </text>
<text top="769" left="133" width="232" height="14" font="11">Joshua A. Beckman, MD, MS, FAHA </text>
<text top="769" left="455" width="218" height="14" font="11">John Ikonomidis, MD, PhD, FAHA </text>
<text top="789" left="133" width="233" height="14" font="11">Kim K. Birtcher, PharmD, MS, AACC </text>
<text top="789" left="455" width="190" height="14" font="11">José Joglar, MD, FACC, FAHA </text>
<text top="808" left="133" width="253" height="14" font="11">Biykem Bozkurt, MD, PhD, FACC, FAHA</text>
<text top="809" left="385" width="14" height="13" font="8">§§</text>
<text top="808" left="399" width="4" height="14" font="11"> </text>
<text top="808" left="455" width="227" height="14" font="11">Richard J. Kovacs, MD, FACC, FAHA</text>
<text top="809" left="682" width="14" height="13" font="8">§§</text>
<text top="808" left="696" width="4" height="14" font="11"> </text>
<text top="828" left="133" width="222" height="14" font="11">Ralph G. Brindis, MD, MPH, MACC</text>
<text top="829" left="355" width="14" height="13" font="8">§§</text>
<text top="828" left="369" width="4" height="14" font="11"> </text>
<text top="828" left="455" width="193" height="14" font="11">Laura Mauri, MD, MSc, FAHA </text>
<text top="848" left="133" width="201" height="14" font="11">Joaquin E. Cigarroa, MD, FACC </text>
<text top="848" left="455" width="192" height="14" font="11">E. Magnus Ohman, MD, FACC</text>
<text top="849" left="647" width="14" height="13" font="8">§§</text>
<text top="848" left="661" width="4" height="14" font="11"> </text>
<text top="867" left="133" width="177" height="14" font="11">Lesley H. Curtis, PhD, FAHA</text>
<text top="868" left="310" width="14" height="13" font="8">§§</text>
<text top="867" left="324" width="4" height="14" font="11"> </text>
<text top="867" left="455" width="264" height="14" font="11">Mariann R. Piano, RN, PhD, FAHA, FAAN </text>
<text top="887" left="133" width="245" height="14" font="11">Anita Deswal, MD, MPH, FACC, FAHA </text>
<text top="887" left="455" width="211" height="14" font="11">Susan J. Pressler, PhD, RN, FAHA</text>
<text top="888" left="666" width="14" height="13" font="8">§§</text>
<text top="887" left="680" width="4" height="14" font="11"> </text>
<text top="906" left="133" width="214" height="14" font="11">Lee A. Fleisher, MD, FACC, FAHA </text>
<text top="906" left="455" width="203" height="14" font="11">Barbara Riegel, PhD, RN, FAHA </text>
<text top="926" left="133" width="183" height="14" font="11">Federico Gentile, MD, FACC </text>
<text top="926" left="455" width="217" height="14" font="11">Frank W. Sellke, MD, FACC, FAHA</text>
<text top="927" left="671" width="14" height="13" font="8">§§</text>
<text top="926" left="686" width="4" height="14" font="11"> </text>
<text top="946" left="133" width="192" height="14" font="11">Samuel S. Gidding, MD, FAHA</text>
<text top="947" left="325" width="14" height="13" font="8">§§</text>
<text top="946" left="339" width="4" height="14" font="11"> </text>
<text top="946" left="455" width="224" height="14" font="11">Win-Kuang Shen, MD, FACC, FAHA</text>
<text top="947" left="679" width="14" height="13" font="8">§§</text>
<text top="946" left="693" width="4" height="14" font="11"> </text>
<text top="965" left="328" width="240" height="14" font="11">Duminda N. Wijeysundera, MD, PhD </text>
<text top="985" left="105" width="3" height="13" font="8"> </text>
<text top="1020" left="105" width="687" height="13" font="8">*Writing  committee  members  are  required  to  recuse  themselves  from  voting  on  sections  to  which  their  specific </text>
<text top="1038" left="105" width="687" height="13" font="8">relationships  with  industry  may  apply;  see  Appendix  1  for  recusal  information.  †ACC/AHA  Representa@ve. </text>
<text top="1055" left="105" width="687" height="13" font="8">‡Interna@onal Society for Adult Congenital Heart Disease Representa@ve. §Society for Cardiovascular Angiography </text>
<text top="1073" left="105" width="213" height="13" font="8">and  Interventions  Representative. </text>
<text top="1070" left="322" width="469" height="18" font="8">║ACC/AHA  Task  Force  on  Clinical  Practice  Guidelines  Liaison.  ¶Society  of </text>
<text top="1091" left="105" width="687" height="13" font="8">Thoracic  Surgeons  Representative.  #American  Association  for  Thoracic  Surgery  Representative.  **ACC/AHA  Task </text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="16" size="12" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 2 </text>
<text top="162" left="105" width="687" height="13" font="8">Force  on  Performance  Measures  Liaison.  ††American  Society  of  Echocardiography  Representa@ve.  ‡‡Heart </text>
<text top="180" left="105" width="633" height="13" font="8">Rhythm Society Representative. §§Former Task Force member; current member during the writing effort.  </text>
<text top="198" left="105" width="3" height="13" font="8"> </text>
<text top="215" left="105" width="687" height="13" font="8">This  document  was  approved  by  the  American  College  of  Cardiology  Clinical  Policy  Approval  Committee  in  May </text>
<text top="233" left="105" width="687" height="13" font="8">2018,  the  American  Heart  Association  Science  Advisory  and  Coordinating  Committee  in  June  2018,  and  the </text>
<text top="251" left="105" width="374" height="13" font="8">American Heart Association Executive Committee in July 2018. </text>
<text top="269" left="105" width="3" height="13" font="8"> </text>
<text top="287" left="105" width="687" height="13" font="8">The  American  College  of  Cardiology  requests  that  this  document  be  cited  as  follows:  Stout  KK,  Daniels  CJ, </text>
<text top="305" left="105" width="687" height="13" font="8">Aboulhosn JA, Bozkurt  B, Broberg CS, Colman JM,  Crumb SR, Dearani  JA, Fuller  S, Gurvitz M, Khairy  P, Landzberg </text>
<text top="323" left="105" width="687" height="13" font="8">MJ,  Saidi  A,  Valente  AM,  Van  Hare  GF.  2018  AHA/ACC  guideline  for  the  management  of  adults  with  congenital </text>
<text top="340" left="105" width="687" height="13" font="8">heart  disease:  a  report  of  the  American  College  of  Cardiology/American  Heart  Association  Task  Force  on  Clinical </text>
<text top="358" left="105" width="259" height="13" font="8">Practice Guidelines. J Am Coll Cardiol 2018. </text>
<text top="376" left="105" width="3" height="13" font="8"> </text>
<text top="394" left="105" width="285" height="13" font="8">This article has been copublished in <i>Circulation</i>. </text>
<text top="411" left="105" width="3" height="13" font="8"> </text>
<text top="429" left="105" width="687" height="13" font="8">Copies:  This  document  is  available  on  the  World  Wide  Web  sites  of  the  American  College  of  Cardiology </text>
<text top="447" left="105" width="687" height="13" font="8">(www.acc.org)  and  the  American  Heart  Association  (professional.heart.org).  For  copies  of  this  document,  please </text>
<text top="465" left="105" width="611" height="13" font="8">contact the Elsevier Inc. Reprint Department via fax (212-633-3820) or e-mail (reprints@elsevier.com). </text>
<text top="483" left="105" width="3" height="13" font="8"> </text>
<text top="501" left="105" width="687" height="13" font="8">Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not </text>
<text top="519" left="105" width="687" height="13" font="8">permitted  without  the  express  permission  of  the  American  College  of  Cardiology.  Requests  may  be  completed </text>
<text top="536" left="105" width="661" height="13" font="8">online via the Elsevier site (http://www.elsevier.com/about/policies/author-agreement/obtaining-permission). </text>
<text top="554" left="105" width="3" height="13" font="8"> </text>
<text top="572" left="105" width="601" height="13" font="8">© 2018 by the American Heart Association, Inc., and the American College of Cardiology Foundation. </text>
<text top="590" left="105" width="4" height="14" font="11"> </text>
<text top="610" left="105" width="4" height="14" font="11"> </text>
<text top="610" left="315" width="4" height="14" font="11"> </text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 3 </text>
<text top="162" left="388" width="121" height="15" font="14"><b>Table of Contents </b></text>
<text top="182" left="105" width="686" height="15" font="14"><b>Preamble ........................................................................................................................................... 5</b> </text>
<text top="201" left="105" width="686" height="15" font="14"><b>1. Introduction ................................................................................................................................... 9</b> </text>
<text top="221" left="121" width="670" height="14" font="11">1.1. Methodology and Evidence Review ............................................................................................... 9 </text>
<text top="241" left="121" width="670" height="14" font="11">1.2. Organization of the Writing Committee ........................................................................................ 9 </text>
<text top="260" left="121" width="670" height="14" font="11">1.3. Document Review and Approval ................................................................................................. 10 </text>
<text top="280" left="121" width="670" height="14" font="11">1.4. Scope of the Guideline ................................................................................................................ 10 </text>
<text top="299" left="121" width="670" height="14" font="11">1.5. Abbreviations ............................................................................................................................. 13 </text>
<text top="319" left="105" width="686" height="15" font="14"><b>2. Background and Pathophysiology ................................................................................................. 14</b> </text>
<text top="339" left="121" width="670" height="14" font="11">2.1. Anatomic and Physiological Terms .............................................................................................. 14 </text>
<text top="358" left="121" width="670" height="14" font="11">2.2. Severity of ACHD ......................................................................................................................... 14 </text>
<text top="378" left="121" width="670" height="14" font="11">2.3. The ACHD Anatomic and Physiological Classification ................................................................... 18 </text>
<text top="397" left="105" width="686" height="15" font="14"><b>3. General Principles ........................................................................................................................ 19</b> </text>
<text top="417" left="121" width="670" height="14" font="11">3.1. ACHD Program ............................................................................................................................ 19 </text>
<text top="437" left="121" width="670" height="14" font="11">3.2. Access to Care ............................................................................................................................. 21 </text>
<text top="456" left="121" width="670" height="14" font="11">3.3. Delivery of Care .......................................................................................................................... 21 </text>
<text top="476" left="121" width="670" height="14" font="11">3.4. Evaluation of Suspected and Known CHD .................................................................................... 26 </text>
<text top="496" left="137" width="654" height="14" font="11">3.4.1. Electrocardiogram ................................................................................................................ 26 </text>
<text top="515" left="137" width="654" height="14" font="11">3.4.2. Ionizing Radiation Principles ................................................................................................. 27 </text>
<text top="535" left="137" width="654" height="14" font="11">3.4.3. Echocardiography ................................................................................................................ 27 </text>
<text top="554" left="137" width="654" height="14" font="11">3.4.4. CMR Imaging ........................................................................................................................ 28 </text>
<text top="574" left="137" width="654" height="14" font="11">3.4.5. Cardiac Computed Tomography ........................................................................................... 29 </text>
<text top="594" left="137" width="654" height="14" font="11">3.4.6. Cardiac Catheterization ........................................................................................................ 30 </text>
<text top="613" left="137" width="654" height="14" font="11">3.4.7. Exercise Testing .................................................................................................................... 31 </text>
<text top="633" left="121" width="670" height="14" font="11">3.5. Transition Education ................................................................................................................... 31 </text>
<text top="652" left="121" width="670" height="14" font="11">3.6. Exercise and Sports ..................................................................................................................... 32 </text>
<text top="672" left="121" width="670" height="14" font="11">3.7. Mental Health and Neurodevelopmental Issues .......................................................................... 34 </text>
<text top="692" left="121" width="670" height="14" font="11">3.8. Endocarditis Prevention .............................................................................................................. 34 </text>
<text top="711" left="121" width="670" height="14" font="11">3.9. Concomitant Syndromes ............................................................................................................. 35 </text>
<text top="731" left="121" width="670" height="14" font="11">3.10. Acquired Cardiovascular Disease ............................................................................................... 36 </text>
<text top="750" left="121" width="670" height="14" font="11">3.11. Noncardiac Medical Issues ........................................................................................................ 37 </text>
<text top="770" left="121" width="670" height="14" font="11">3.12. Noncardiac Surgery ................................................................................................................... 37 </text>
<text top="790" left="121" width="670" height="14" font="11">3.13. Pregnancy, Reproduction, and Sexual Health ............................................................................ 39 </text>
<text top="809" left="137" width="654" height="14" font="11">3.13.1. Pregnancy .......................................................................................................................... 39 </text>
<text top="829" left="137" width="654" height="14" font="11">3.13.2. Contraception .................................................................................................................... 41 </text>
<text top="848" left="137" width="654" height="14" font="11">3.13.3. Infertility Treatment ........................................................................................................... 42 </text>
<text top="868" left="137" width="654" height="14" font="11">3.13.4. Sexual Function .................................................................................................................. 42 </text>
<text top="888" left="121" width="670" height="14" font="11">3.14. Heart Failure and Transplant ..................................................................................................... 44 </text>
<text top="907" left="137" width="654" height="14" font="11">3.14.1. Heart Failure ...................................................................................................................... 44 </text>
<text top="927" left="137" width="654" height="14" font="11">3.14.2. Heart Transplant ................................................................................................................ 44 </text>
<text top="946" left="137" width="654" height="14" font="11">3.14.3. Multiorgan Transplant ........................................................................................................ 45 </text>
<text top="966" left="121" width="670" height="14" font="11">3.15. Palliative Care ........................................................................................................................... 45 </text>
<text top="986" left="121" width="670" height="14" font="11">3.16. Cyanosis .................................................................................................................................... 47 </text>
<text top="1005" left="121" width="670" height="14" font="11">3.17. Pharmacological Therapy for ACHD ........................................................................................... 49 </text>
<text top="1025" left="105" width="686" height="15" font="14"><b>4. Specific Lesions ............................................................................................................................ 49</b> </text>
<text top="1044" left="121" width="670" height="14" font="11">4.1. Shunt Lesions .............................................................................................................................. 49 </text>
<text top="1064" left="137" width="654" height="14" font="11">4.1.1. Atrial Septal Defect .............................................................................................................. 50 </text>
<text top="1084" left="137" width="654" height="14" font="11">4.1.2. Anomalous Pulmonary Venous Connections ......................................................................... 54 </text>
<text top="1103" left="137" width="654" height="14" font="11">4.1.3. Ventricular Septal Defect...................................................................................................... 56 </text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 4 </text>
<text top="162" left="137" width="654" height="14" font="11">4.1.4. Atrioventricular Septal Defect .............................................................................................. 59 </text>
<text top="182" left="137" width="654" height="14" font="11">4.1.5. Patent Ductus Arteriosus ...................................................................................................... 62 </text>
<text top="202" left="121" width="670" height="14" font="11">4.2. Left-Sided Obstructive Lesions .................................................................................................... 64 </text>
<text top="221" left="137" width="654" height="14" font="11">4.2.1. Cor Triatriatum..................................................................................................................... 64 </text>
<text top="241" left="137" width="654" height="14" font="11">4.2.2. Congenital Mitral Stenosis .................................................................................................... 65 </text>
<text top="260" left="137" width="654" height="14" font="11">4.2.3. Subaortic Stenosis ................................................................................................................ 67 </text>
<text top="280" left="137" width="654" height="14" font="11">4.2.4. Congenital Valvular Aortic Stenosis ...................................................................................... 68 </text>
<text top="299" left="153" width="638" height="14" font="11">4.2.4.1. Turner Syndrome .......................................................................................................... 70 </text>
<text top="319" left="153" width="638" height="14" font="11">4.2.4.2. Aortopathies ................................................................................................................. 71 </text>
<text top="339" left="137" width="654" height="14" font="11">4.2.5. Supravalvular Aortic Stenosis ............................................................................................... 71 </text>
<text top="358" left="137" width="654" height="14" font="11">4.2.6. Coarctation of the Aorta ....................................................................................................... 73 </text>
<text top="378" left="121" width="670" height="14" font="11">4.3. Right-Sided Lesions ..................................................................................................................... 75 </text>
<text top="398" left="137" width="654" height="14" font="11">4.3.1. Valvular Pulmonary Stenosis ................................................................................................ 76 </text>
<text top="417" left="153" width="638" height="14" font="11">4.3.1.1. Isolated PR After Repair of PS ........................................................................................ 77 </text>
<text top="437" left="137" width="654" height="14" font="11">4.3.2. Branch and Peripheral Pulmonary Stenosis .......................................................................... 80 </text>
<text top="456" left="137" width="654" height="14" font="11">4.3.3. Double-Chambered Right Ventricle ...................................................................................... 81 </text>
<text top="476" left="137" width="654" height="14" font="11">4.3.4. Ebstein Anomaly .................................................................................................................. 83 </text>
<text top="496" left="137" width="654" height="14" font="11">4.3.5. Tetralogy of Fallot ................................................................................................................ 86 </text>
<text top="515" left="137" width="654" height="14" font="11">4.3.6. Right Ventricle to Pulmonary Artery Conduit ........................................................................ 91 </text>
<text top="535" left="121" width="670" height="14" font="11">4.4. Complex Lesions ......................................................................................................................... 93 </text>
<text top="554" left="137" width="654" height="14" font="11">4.4.1. Transposition of the Great Arteries ...................................................................................... 93 </text>
<text top="574" left="153" width="638" height="14" font="11">4.4.1.1. Transposition of the Great Arteries With Atrial Switch ................................................... 93 </text>
<text top="594" left="153" width="638" height="14" font="11">4.4.1.2. Transposition of the Great Arteries With Arterial Switch ................................................ 96 </text>
<text top="613" left="153" width="638" height="14" font="11">4.4.1.3. Transposition of the Great Arteries With Rastelli Type Repair ........................................ 98 </text>
<text top="633" left="153" width="638" height="14" font="11">4.4.1.4. Congenitally Corrected Transposition of the Great Arteries ........................................... 99 </text>
<text top="652" left="137" width="641" height="14" font="11">4.4.2. Fontan Palliation of Single Ventricle Physiology (Including Tricuspid Atresia and Double Inlet </text>
<text top="672" left="137" width="654" height="14" font="11">Left Ventricle) .............................................................................................................................. 101 </text>
<text top="691" left="137" width="654" height="15" font="11">4.4.3. Hypoplastic Left Heart Syndrome/Norwood Repair ............................................................ 106 </text>
<text top="711" left="137" width="654" height="15" font="11">4.4.4. Truncus Arteriosus ............................................................................................................. 106 </text>
<text top="730" left="137" width="654" height="15" font="11">4.4.5. Double Outlet Right Ventricle ............................................................................................. 106 </text>
<text top="750" left="137" width="654" height="15" font="11">4.4.6. Severe PAH and Eisenmenger Syndrome ............................................................................ 106 </text>
<text top="770" left="153" width="638" height="15" font="11">4.4.6.1. Severe PAH .................................................................................................................. 107 </text>
<text top="789" left="153" width="638" height="15" font="11">4.4.6.2. Eisenmenger Syndrome ............................................................................................... 109 </text>
<text top="809" left="137" width="654" height="15" font="11">4.4.7. Coronary Anomalies ........................................................................................................... 111 </text>
<text top="828" left="153" width="638" height="15" font="11">4.4.7.1 Anomalous Coronary Artery Evaluation ........................................................................ 113 </text>
<text top="848" left="153" width="638" height="15" font="11">4.4.7.2. Anomalous Aortic Origin of Coronary Artery ................................................................ 114 </text>
<text top="868" left="153" width="638" height="15" font="11">4.4.7.3. Anomalous Coronary Artery Arising From the PA ......................................................... 116 </text>
<text top="887" left="137" width="654" height="15" font="11">4.4.8. Coronary Artery Fistula ...................................................................................................... 116 </text>
<text top="907" left="105" width="686" height="15" font="14"><b>5. Evidence Gaps and Future Directions .......................................................................................... 117</b> </text>
<text top="927" left="105" width="686" height="15" font="14"><b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)................................ 120</b> </text>
<text top="946" left="105" width="686" height="15" font="14"><b>Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive) .................. 124</b> </text>
<text top="966" left="105" width="686" height="15" font="14"><b>References ..................................................................................................................................... 132</b> </text>
<text top="985" left="105" width="4" height="15" font="11"> </text>
<text top="985" left="315" width="4" height="15" font="11"> </text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 5 </text>
<text top="164" left="105" width="98" height="21" font="10"><b>Preamble </b></text>
<text top="190" left="105" width="687" height="15" font="11">Since  1980,  the  American  College  of  Cardiology  (ACC)  and  American  Heart  Association  (AHA)  have </text>
<text top="210" left="105" width="687" height="15" font="11">translated  scientific  evidence  into  clinical  practice  guidelines  (guidelines)  with  recommendations  to </text>
<text top="230" left="105" width="687" height="15" font="11">improve  cardiovascular  health.  These  guidelines,  which  are  based  on  systematic  methods  to  evaluate </text>
<text top="249" left="105" width="687" height="15" font="11">and classify evidence, provide a cornerstone for quality cardiovascular care. The ACC and AHA sponsor </text>
<text top="269" left="105" width="687" height="15" font="11">the  development  and  publication  of  guidelines  without  commercial  support,  and  members  of  each </text>
<text top="288" left="105" width="687" height="15" font="11">organization volunteer their time to the writing and review efforts. Guidelines are official policy of the </text>
<text top="308" left="105" width="95" height="15" font="11">ACC and AHA. </text>
<text top="341" left="105" width="96" height="15" font="14"><b>Intended Use  </b></text>
<text top="360" left="105" width="687" height="15" font="11">Practice  guidelines  provide  recommendations  applicable  to  patients  with  or  at  risk  of  developing </text>
<text top="380" left="105" width="687" height="15" font="11">cardiovascular disease. The focus is on medical practice in the United States, but guidelines developed in </text>
<text top="400" left="105" width="687" height="15" font="11">collaboration  with  other  organizations  can  have  a  global  impact.  Although  guidelines  may  be  used  to </text>
<text top="419" left="105" width="687" height="15" font="11">inform  regulatory  or  payer  decisions,  they  are  intended  to  improve  patients’  quality  of  care  and  align </text>
<text top="439" left="105" width="687" height="15" font="11">with  patients’  interests.  Guidelines  are  intended  to  define  practices  meeting  the  needs  of  patients  in </text>
<text top="458" left="105" width="487" height="15" font="11">most, but not all, circumstances and should not replace clinical judgment.  </text>
<text top="491" left="105" width="166" height="15" font="14"><b>Clinical Implementation  </b></text>
<text top="511" left="105" width="687" height="15" font="11">Management  in  accordance  with  guideline  recommendations  is  effective  only  when  followed  by  both </text>
<text top="530" left="105" width="687" height="15" font="11">practitioners and patients. Adherence to recommendations can be enhanced by shared decision-making </text>
<text top="550" left="105" width="687" height="15" font="11">between  clinicians  and  patients,  with  patient  engagement  in  selecting  interventions  on  the  basis  of </text>
<text top="570" left="105" width="503" height="15" font="11">individual values, preferences, and associated conditions and comorbidities.  </text>
<text top="603" left="105" width="229" height="15" font="14"><b>Methodology and Modernization  </b></text>
<text top="622" left="105" width="687" height="15" font="11">The ACC/AHA Task Force on Clinical Practice Guidelines (Task Force) continuously reviews, updates, and </text>
<text top="642" left="105" width="687" height="15" font="11">modifies  guideline methodology  on  the  basis  of  published  standards  from  organizations, including  the </text>
<text top="661" left="105" width="687" height="15" font="11">Institute of Medicine (P-1, P-2), and on the basis of internal reevaluation. Similarly, the presentation and </text>
<text top="681" left="105" width="687" height="15" font="11">delivery  of  guidelines  are  reevaluated  and  modified  on  the  basis  of  evolving  technologies  and  other </text>
<text top="700" left="105" width="687" height="15" font="11">factors  to  facilitate  optimal  dissemination  of  information  to  healthcare  professionals  at  the  point  of </text>
<text top="720" left="105" width="36" height="15" font="11">care. </text>
<text top="748" left="158" width="634" height="15" font="11">Toward  this goal, this guideline continues the introduction  of an  evolved format of  presenting </text>
<text top="768" left="105" width="687" height="15" font="11">guideline  recommendations  and  associated  text  called  the  “modular  knowledge  chunk  format.”  Each </text>
<text top="788" left="105" width="683" height="15" font="11">modular  “chunk”  includes  a  table  of  related  recommendations,  a  brief  synopsis,  recommendation-</text>
<text top="807" left="105" width="687" height="15" font="11">specific  supportive  text,  and  when  appropriate,  flow  diagrams  or  additional  tables.  References  are </text>
<text top="827" left="105" width="687" height="15" font="11">provided at the end of the document in their respective sections. Additionally, this format will facilitate </text>
<text top="846" left="105" width="687" height="15" font="11">seamless updating of guidelines with focused updates as new evidence is published, as well as content </text>
<text top="866" left="105" width="687" height="15" font="11">tagging  for  rapid  electronic  retrieval  of  related  recommendations  on  a  topic  of  interest.  This  evolved </text>
<text top="886" left="105" width="687" height="15" font="11">approach  format  was  instituted  when  this  guideline  was  near  completion;  therefore,  the  present </text>
<text top="905" left="105" width="687" height="15" font="11">document represents a transitional format that best suits the text as written. Future guidelines will fully </text>
<text top="925" left="105" width="588" height="15" font="11">implement this format, including provisions for limiting the amount of text in a guideline.  </text>
<text top="953" left="158" width="634" height="15" font="11">Recognizing  the  importance  of  cost–value  considerations  in  certain  guidelines,  when </text>
<text top="973" left="105" width="687" height="15" font="11">appropriate and feasible, an analysis of the value of a drug, device, or intervention may be performed in </text>
<text top="992" left="105" width="334" height="15" font="11">accordance with the ACC/AHA methodology (P-3).  </text>
<text top="1021" left="158" width="634" height="15" font="11">To  ensure  that  guideline  recommendations  remain  current,  new  data  are  reviewed  on  an </text>
<text top="1040" left="105" width="687" height="15" font="11">ongoing basis, with full guideline revisions commissioned in approximately 6-year cycles. Publication of </text>
<text top="1060" left="105" width="687" height="15" font="11">new, potentially practice-changing study results that are relevant to an existing or new drug, device, or </text>
<text top="1079" left="105" width="687" height="15" font="11">management  strategy  will  prompt  evaluation  by  the  Task  Force,  in  consultation  with  the  relevant </text>
<text top="1099" left="105" width="687" height="15" font="11">guideline  writing  committee,  to  determine  whether  a  focused  update  should  be  commissioned.  For </text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 6 </text>
<text top="162" left="105" width="687" height="15" font="11">additional information and policies regarding guideline development, we encourage readers to consult </text>
<text top="182" left="105" width="609" height="15" font="11">the ACC/AHA guideline methodology manual (P-4) and other methodology articles (P-5–P-8). </text>
<text top="215" left="105" width="285" height="15" font="14"><b>Selection of Writing Committee Members  </b></text>
<text top="234" left="105" width="687" height="15" font="11">The  Task  Force  strives  to  avoid  bias  by  selecting  experts  from  a  broad  array  of  backgrounds.  Writing </text>
<text top="254" left="105" width="687" height="15" font="11">committee  members  represent  different  geographic  regions,  sexes,  ethnicities,  races,  intellectual </text>
<text top="273" left="105" width="687" height="15" font="11">perspectives/biases,  and  scopes  of  clinical  practice.  The  Task  Force  may  also  invite  organizations  and </text>
<text top="293" left="105" width="687" height="15" font="11">professional  societies  with  related  interests  and  expertise  to  participate  as  partners,  collaborators,  or </text>
<text top="312" left="105" width="76" height="15" font="11">endorsers.  </text>
<text top="345" left="105" width="317" height="15" font="14"><b>Relationships With Industry and Other Entities  </b></text>
<text top="365" left="105" width="687" height="15" font="11">The ACC and AHA have rigorous policies and methods to ensure that guidelines are developed without </text>
<text top="384" left="105" width="687" height="15" font="11">bias or improper influence. The complete relationships with industry and other entities (RWI) policy can </text>
<text top="404" left="105" width="683" height="15" font="11">be found at http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-</text>
<text top="423" left="105" width="687" height="15" font="11">industry-policy.  Appendix  1  of  the  present  document  lists  writing  committee  members’  relevant  RWI. </text>
<text top="443" left="105" width="687" height="15" font="11">For  the  purposes  of  full  transparency,  writing  committee  members’  comprehensive  disclosure </text>
<text top="463" left="105" width="81" height="15" font="11">information </text>
<text top="463" left="348" width="14" height="15" font="11">is </text>
<text top="463" left="524" width="61" height="15" font="11">available </text>
<text top="463" left="748" width="44" height="15" font="11">online </text>
<text top="482" left="105" width="522" height="15" font="11">(http://jaccjacc.acc.org/Clinical_Document/ACHD_Exec_Summ_and_Full_Text_ </text>
<text top="482" left="642" width="146" height="15" font="11">Comp_RWI_Table_08-</text>
<text top="502" left="105" width="687" height="15" font="11">02-18.pdf  ).  Comprehensive  disclosure  information  for  the  Task  Force  is  available  at </text>
<text top="521" left="105" width="659" height="15" font="11">http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-</text>
<text top="541" left="105" width="79" height="15" font="11">task-forces. </text>
<text top="574" left="105" width="348" height="15" font="14"><b>Evidence Review and Evidence Review Committees  </b></text>
<text top="593" left="105" width="687" height="15" font="11">In  developing  recommendations,  the  writing  committee  uses  evidence-based  methodologies  that  are </text>
<text top="613" left="105" width="687" height="15" font="11">based  on  all  available  data  (P-4–P-7).  Literature  searches  focus  on  randomized  controlled  trials  (RCTs) </text>
<text top="633" left="105" width="687" height="15" font="11">but  also  include  registries,  nonrandomized  comparative  and  descriptive  studies,  case  series,  cohort </text>
<text top="652" left="105" width="518" height="15" font="11">studies, systematic reviews, and expert opinion. Only key references are cited.  </text>
<text top="681" left="158" width="634" height="15" font="11">An  independent evidence review committee (ERC) is commissioned  when there are 1 or more </text>
<text top="700" left="105" width="687" height="15" font="11">questions  deemed  of  utmost  clinical  importance  that  merit  formal  systematic  review.  The  systematic </text>
<text top="720" left="105" width="687" height="15" font="11">review  will  determine  which  patients  are  most  likely  to  benefit  from  a  drug,  device,  or  treatment </text>
<text top="739" left="105" width="687" height="15" font="11">strategy and to what degree. Criteria for commissioning an ERC and formal systematic review include: a) </text>
<text top="759" left="105" width="687" height="15" font="11">the  absence  of  a  current  authoritative systematic  review,  b) the  feasibility  of  defining  the  benefit  and </text>
<text top="779" left="105" width="687" height="15" font="11">risk in a time frame consistent with the writing of a guideline, c) the relevance to a substantial number </text>
<text top="798" left="105" width="687" height="15" font="11">of patients, and d) the likelihood that the findings can be translated into actionable recommendations. </text>
<text top="818" left="105" width="687" height="15" font="11">ERC  members may include  methodologists,  epidemiologists,  healthcare  providers,  and  biostatisticians. </text>
<text top="837" left="105" width="687" height="15" font="11">The  recommendations  developed  by  the  writing  committee  on  the  basis  of  the  systematic  review  are </text>
<text top="857" left="105" width="123" height="15" font="11">marked with “SR”. </text>
<text top="890" left="105" width="313" height="15" font="14"><b>Guideline-Directed Management and Therapy  </b></text>
<text top="909" left="105" width="687" height="15" font="11">The  term  guideline-directed  management  and  therapy  (GDMT)  encompasses  clinical  evaluation, </text>
<text top="929" left="105" width="687" height="15" font="11">diagnostic  testing,  and  pharmacological  and  procedural  treatments.  For  these  and  all  recommended </text>
<text top="949" left="105" width="687" height="15" font="11">drug  treatment  regimens,  the  reader  should  confirm  the  dosage  by  reviewing  product  insert  material </text>
<text top="968" left="105" width="687" height="15" font="11">and  evaluate the treatment regimen for contraindications and interactions.  The recommendations are </text>
<text top="988" left="105" width="575" height="15" font="11">limited to drugs, devices, and treatments approved for clinical use in the United States.  </text>
<text top="1021" left="105" width="327" height="15" font="14"><b>Class of Recommendation and Level of Evidence  </b></text>
<text top="1040" left="105" width="687" height="15" font="11">The Class of Recommendation (COR) indicates the strength of the recommendation, encompassing the </text>
<text top="1060" left="105" width="687" height="15" font="11">estimated magnitude and certainty of benefit in proportion to risk. The Level of Evidence (LOE) rates the </text>
<text top="1079" left="105" width="687" height="15" font="11">quality  of  scientific  evidence  that  supports  the  intervention  on  the  basis  of  the  type,  quantity,  and </text>
<text top="1099" left="105" width="499" height="15" font="11">consistency of data from clinical trials and other sources (Table 1) (P-4–P-6). </text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 7 </text>
<text top="162" left="571" width="221" height="14" font="15"><i>Glenn N. Levine, MD, FACC, FAHA </i></text>
<text top="182" left="416" width="372" height="14" font="15"><i>Chair, ACC/AHA Task Force on Clinical Practice Guidelines</i></text>
<text top="183" left="788" width="3" height="13" font="8"> </text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 8 </text>
<text top="162" left="105" width="683" height="15" font="14"><b>Table 1. Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, </b></text>
<text top="182" left="105" width="496" height="15" font="14"><b>Treatments, or Diagnostic Testing in Patient Care* (Updated August 2015) </b></text>
<text top="210" left="105" width="4" height="14" font="11"> </text>
<text top="919" left="788" width="4" height="14" font="11"> </text>
<text top="952" left="105" width="7" height="14" font="11">  </text>
<text top="989" left="105" width="4" height="14" font="11"> </text>
<text top="989" left="315" width="4" height="14" font="11"> </text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="17" size="19" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="429" width="38" height="12" font="9">Page 9 </text>
<text top="164" left="105" width="150" height="21" font="10"><b>1. Introduction </b></text>
<text top="214" left="105" width="363" height="20" font="17"><b>1.1. Methodology and Evidence Review </b></text>
<text top="248" left="105" width="687" height="15" font="11">The  recommendations  listed  in  this  guideline  are,  whenever  possible,  evidence-based.  An  initial </text>
<text top="267" left="105" width="687" height="15" font="11">extensive  evidence  review,  which  included  literature  derived  from  research  involving  human  subjects, </text>
<text top="287" left="105" width="687" height="15" font="11">published  in  English,  and  indexed  in  MEDLINE  (through  PubMed),  EMBASE,  the  Cochrane  Library,  the </text>
<text top="306" left="105" width="687" height="15" font="11">Agency  for  Healthcare  Research  and  Quality,  and  other  selected  databases  relevant  to  this  guideline, </text>
<text top="326" left="105" width="687" height="15" font="11">was conducted from April 2014 to November 2014. Key search words included but were not limited to </text>
<text top="346" left="105" width="687" height="15" font="11">the following: <i>adult congenital heart disease, anesthesia, aortic aneurysm, aortic stenosis, atrial septal </i></text>
<text top="366" left="105" width="687" height="14" font="15"><i>defect,  arterial  switch  operation,  bradycardia,  bicuspid  aortic  valve,  cardiac  catheterization,  cardiac </i></text>
<text top="385" left="105" width="687" height="14" font="15"><i>imaging,  cardiovascular  magnetic  resonance,  cardiac  reoperation,  cardiovascular  surgery,  chest  x-ray, </i></text>
<text top="405" left="105" width="687" height="14" font="15"><i>cirrhosis, coarctation of the aorta,  congenital heart defects, congenitally corrected transposition of the </i></text>
<text top="425" left="105" width="683" height="14" font="15"><i>great  arteries,  contraception,  coronary  artery  abnormalities,  cyanotic  congenital  heart  disease,  dextro-</i></text>
<text top="444" left="105" width="687" height="14" font="15"><i>transposition  of  the  great  arteries,  double  inlet  left  ventricle,  Ebstein  anomaly,  echocardiography, </i></text>
<text top="464" left="105" width="687" height="14" font="15"><i>Eisenmenger  syndrome,  electrocardiogram,  endocarditis,  exercise  test,  Fontan,  heart  catheterization, </i></text>
<text top="483" left="105" width="687" height="14" font="15"><i>heart  defect,  heart  failure,  infertility,  l-transposition  of  the  great  arteries,  medical  therapy,  myocardial </i></text>
<text top="503" left="105" width="687" height="14" font="15"><i>infarction,  noncardiac  surgery,  patent  ductus  arteriosus,  perioperative  care,  physical  activity, </i></text>
<text top="523" left="105" width="687" height="14" font="15"><i>postoperative  complications,  pregnancy,  preoperative  assessment,  psychosocial,  pulmonary  arterial </i></text>
<text top="542" left="105" width="687" height="14" font="15"><i>hypertension, hypoplastic left heart syndrome, pulmonary regurgitation, pulmonary stenosis, pulmonary </i></text>
<text top="562" left="105" width="687" height="14" font="15"><i>valve replacement, right heart obstruction, right ventricle to pulmonary artery conduit, single ventricle, </i></text>
<text top="581" left="105" width="687" height="14" font="15"><i>supravalvular  pulmonary  stenosis,  surgical  therapy,  tachyarrhythmia,  tachycardia,  tetralogy  of  Fallot, </i></text>
<text top="601" left="105" width="687" height="14" font="15"><i>transplantation,  tricuspid  atresia,  Turner  syndrome,</i>  and  <i>ventricular  septal  defect.</i>  Additional  relevant </text>
<text top="620" left="105" width="687" height="15" font="11">studies published through January 2018, during the guideline writing process, were also considered by </text>
<text top="640" left="105" width="687" height="15" font="11">the writing committee, and added to the evidence tables when appropriate. The final evidence tables, </text>
<text top="659" left="105" width="687" height="15" font="11">included  in  the  Online  Data  Supplement,  summarize  the  evidence  used  by  the  writing  committee  to </text>
<text top="679" left="105" width="687" height="15" font="11">formulate  recommendations.  References  selected  and  published  in  this  document  are  representative </text>
<text top="698" left="105" width="138" height="15" font="11">and not all-inclusive. </text>
<text top="727" left="158" width="634" height="15" font="11">As  noted  in  the  preamble,  an  independent  ERC  was  commissioned  to  perform  a  formal </text>
<text top="747" left="105" width="687" height="15" font="11">systematic  review  of  critical  clinical  questions  related  to  adult  congenital  heart  disease  (ACHD),  the </text>
<text top="766" left="105" width="687" height="15" font="11">results  of  which  were  considered  by  the  writing  committee  for  incorporation  into  this  guideline. </text>
<text top="786" left="105" width="687" height="15" font="11">Concurrent with this process, writing committee members evaluated study data relevant to the rest of </text>
<text top="805" left="105" width="687" height="15" font="11">the guideline. The findings of the ERC and the writing committee members were formally presented and </text>
<text top="825" left="105" width="687" height="15" font="11">discussed,  and  then  recommendations  were  developed.  The  systematic  review  reports  on  “Medical </text>
<text top="845" left="105" width="687" height="15" font="11">Therapy for Systemic Right Ventricles: A Systematic Review (Part 1) for the 2018 AHA/ACC Guideline for </text>
<text top="864" left="105" width="687" height="15" font="11">the Management of Adults With Congenital Heart Disease” (S1.1-1) and “Interventional Therapy Versus </text>
<text top="884" left="105" width="687" height="15" font="11">Medical Therapy for Secundum Atrial Septal Defect: A Systematic Review (Part 2) for the 2018 AHA/ACC </text>
<text top="903" left="105" width="687" height="15" font="11">Guideline  for  the  Management  of  Adults  With  Congenital  Heart  Disease”  (S1.1-2)  are  published  in </text>
<text top="923" left="105" width="208" height="15" font="11">conjunction with this guideline. </text>
<text top="962" left="105" width="404" height="20" font="17"><b>1.2. Organization of the Writing Committee  </b></text>
<text top="996" left="105" width="687" height="15" font="11">The  writing  committee  consisted  of  pediatric  and  adult  congenital  cardiologists,  interventional </text>
<text top="1015" left="105" width="687" height="15" font="11">cardiologists,  electrophysiologists,  surgeons,  and  an  advance  practice  nurse.  The  writing  committee </text>
<text top="1035" left="105" width="687" height="15" font="11">included  representatives  from  the  ACC,  AHA,  and  American  Association  for  Thoracic  Surgery  (AATS), </text>
<text top="1054" left="105" width="687" height="15" font="11">American Society of Echocardiography (ASE), Heart Rhythm Society (HRS), International Society for Adult </text>
<text top="1074" left="105" width="687" height="15" font="11">Congenital Heart Disease (ISACHD), Society for Cardiovascular Angiography and Interventions (SCAI), and </text>
<text top="1094" left="105" width="259" height="15" font="11">the Society of Thoracic Surgeons (STS).  </text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="426" width="45" height="12" font="9">Page 10 </text>
<text top="164" left="105" width="342" height="20" font="17"><b>1.3. Document Review and Approval  </b></text>
<text top="197" left="105" width="687" height="15" font="11">This  document  was  reviewed  by  3  official  reviewers each  nominated  by the  ACC  and  AHA,  and  1  to 2 </text>
<text top="217" left="105" width="687" height="15" font="11">reviewers  each  from  the  AATS,  ASE,  HRS,  ISACHD,  SCAI,  STS;  and  32  individual  content  reviewers. </text>
<text top="236" left="105" width="687" height="15" font="11">Reviewers’ RWI information was distributed to the writing committee and is published in this document </text>
<text top="256" left="105" width="91" height="15" font="11">(Appendix 2). </text>
<text top="284" left="158" width="634" height="15" font="11">This document was  approved for publication by  the governing bodies  of the  ACC and the AHA </text>
<text top="304" left="105" width="398" height="15" font="11">and endorsed by the AATS, ASE, HRS, ISACHD, SCAI, and STS. </text>
<text top="343" left="105" width="249" height="20" font="17"><b>1.4. Scope of the Guideline </b></text>
<text top="377" left="105" width="687" height="15" font="11">The  2018  ACHD  guideline  is  a  full  revision  of  the  “2008  ACC/AHA  Guidelines  for  the  Management  of </text>
<text top="396" left="105" width="687" height="15" font="11">Adults with Congenital Heart Disease” (S1.4-1), which was the first U.S. guideline to be published on the </text>
<text top="416" left="105" width="687" height="15" font="11">topic.  This  revision  uses  the  2008  ACHD  guideline  as  a  framework  and  incorporates  new  data  and </text>
<text top="436" left="105" width="687" height="15" font="11">growing ACHD  expertise  to develop recommendations.  Congenital heart disease (CHD) encompasses a </text>
<text top="455" left="105" width="687" height="15" font="11">range  of  structural  cardiac  abnormalities  present  before  birth  attributable  to  abnormal  fetal  cardiac </text>
<text top="475" left="105" width="687" height="15" font="11">development  but  does  not  include  inherited  disorders  that  may  have  cardiac  manifestations  such  as </text>
<text top="494" left="105" width="687" height="15" font="11">Marfan  syndrome  or  hypertrophic  cardiomyopathy.  Also  not  included  are  anatomic  variants  such  as </text>
<text top="514" left="105" width="687" height="15" font="11">patent  foramen  ovale.  Valvular  heart  disease  (VHD) may  be  congenital,  so  management  overlaps with </text>
<text top="534" left="105" width="687" height="15" font="11">the “2014 AHA/ACC Guidelines for the Management of Patients With Valvular Heart Disease” (S1.4-2), </text>
<text top="553" left="105" width="687" height="15" font="11">particularly for bicuspid aortic valve (BAV) disease. Where overlap exists, this document focuses on the </text>
<text top="573" left="105" width="687" height="15" font="11">diagnosis  and  treatment  of  congenital  valve  disease  when  it  differs  from  acquired  valve  disease, </text>
<text top="592" left="105" width="687" height="15" font="11">whether  because  of  anatomic  differences,  presence  of  concomitant lesions,  or  differences  to  consider </text>
<text top="612" left="105" width="687" height="15" font="11">given the relatively young age of patients with ACHD. This guideline is not intended to apply to children </text>
<text top="632" left="105" width="687" height="15" font="11">(&lt;18  years  of  age)  with  CHD  or  adults  with  acquired  VHD,  heart  failure  (HF),  or  other  cardiovascular </text>
<text top="651" left="105" width="62" height="15" font="11">diseases. </text>
<text top="680" left="158" width="634" height="15" font="11">The prevalence of ACHD is growing because of the success of pediatric cardiology and congenital </text>
<text top="699" left="105" width="687" height="15" font="11">cardiac  surgery  in  diagnosing  and  treating  congenital  heart  defects  in  children.  Improved  survival  to </text>
<text top="719" left="105" width="687" height="15" font="11">adulthood  is  most  striking  for  those  with  the  most  severe  disease,  with  survival  to  age  18  years  now </text>
<text top="738" left="105" width="687" height="15" font="11">expected  for  90%  of  children  diagnosed  with  severe  CHD  (S1.4-3–S1.4-5).  Patients  with  ACHD  are  a </text>
<text top="758" left="105" width="687" height="15" font="11">heterogeneous  population,  both  in  underlying  anatomy  and  physiology,  as  well  as  surgical  repair  or </text>
<text top="778" left="105" width="687" height="15" font="11">palliation. Consequently, although the prevalence of ACHD is increasing, the population of patients with </text>
<text top="797" left="105" width="625" height="15" font="11">a given congenital abnormality or specific repair may be relatively small (S1.4-3, S1.4-6–S1.4-8). </text>
<text top="826" left="158" width="634" height="15" font="11">Patients with CHD are not cured of their disease after successful treatment in childhood. Almost </text>
<text top="845" left="105" width="687" height="15" font="11">all patients with ACHD will have  sequelae of either their native CHD or its surgical repair or palliation, </text>
<text top="865" left="105" width="687" height="15" font="11">although  these  sequelae  can  take  decades  to  manifest.  The  heterogeneity  of  the  population  and  the </text>
<text top="884" left="105" width="687" height="15" font="11">long, symptom-free intervals constrain the ability to generate data applicable across the population of </text>
<text top="904" left="105" width="687" height="15" font="11">ACHD or  to  adults with  specific lesions or repairs.  Despite the difficulty in studying ACHD populations, </text>
<text top="924" left="105" width="687" height="15" font="11">there is a growing body of high-quality data in these patients to guide the care of this relatively “new” </text>
<text top="943" left="105" width="687" height="15" font="11">population  and,  whenever  feasible,  these  data  were  used  to  develop  recommendations. </text>
<text top="963" left="105" width="687" height="15" font="11">Recommendations  are  made  based  on  the  available  data;  however,  when  important  clinical  issues </text>
<text top="982" left="105" width="687" height="15" font="11">lacked  data,  first  principles,  extrapolation  from  data  in  other  populations,  and  expert  consensus  are </text>
<text top="1002" left="105" width="687" height="15" font="11">used to guide care. Patients with ACHD may have concomitant disease to which other existing guidelines </text>
<text top="1022" left="105" width="687" height="15" font="11">apply,  such  as  coronary  artery  disease,  HF,  and  arrhythmias.  The  data  from  acquired  heart  disease </text>
<text top="1041" left="105" width="687" height="15" font="11">populations may apply to some patients with ACHD, and those circumstances are acknowledged in these </text>
<text top="1061" left="105" width="309" height="15" font="11">recommendations and referenced accordingly. </text>
<text top="1089" left="158" width="634" height="15" font="11">Patients with ACHD who are cared for in ACHD centers have better outcomes than those cared </text>
<text top="1109" left="105" width="687" height="15" font="11">for in centers  without ACHD expertise (S1.4-9), and this need  for specialized care is noted throughout </text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="426" width="45" height="12" font="9">Page 11 </text>
<text top="162" left="105" width="687" height="15" font="11">the guideline. These recommendations are intended to provide guidance to a wide variety of providers </text>
<text top="182" left="105" width="687" height="15" font="11">caring for patients with ACHD, including general, pediatric, and ACHD cardiologists, as well as surgeons, </text>
<text top="201" left="105" width="367" height="15" font="11">primary care providers, and other healthcare providers. </text>
<text top="229" left="158" width="634" height="15" font="11">In  developing  the  2018  ACHD  guideline,  the  writing  committee  reviewed  previously  published </text>
<text top="249" left="105" width="687" height="15" font="11">guidelines  and  related  scientific  statements.  Table  2  contains  a  list  of  publications  and  scientific </text>
<text top="268" left="105" width="687" height="15" font="11">statements  deemed  pertinent  to  this  writing  effort;  it  is  intended  for  use  as  a  resource  and  does  not </text>
<text top="288" left="105" width="291" height="15" font="11">repeat existing guideline recommendations. </text>
<text top="317" left="105" width="4" height="15" font="11"> </text>
<text top="345" left="105" width="315" height="15" font="14"><b>Table 2. Associated Guidelines and Statements </b></text>
<text top="377" left="225" width="30" height="13" font="7"><b>Title </b></text>
<text top="377" left="475" width="81" height="13" font="7"><b>Organization </b></text>
<text top="368" left="673" width="102" height="13" font="7"><b>Publication Year </b></text>
<text top="386" left="687" width="74" height="13" font="7"><b>(Reference) </b></text>
<text top="408" left="105" width="67" height="13" font="7"><b>Guidelines </b></text>
<text top="429" left="105" width="53" height="13" font="8">Syncope </text>
<text top="429" left="472" width="88" height="13" font="8">ACC/AHA/HRS </text>
<text top="429" left="680" width="89" height="13" font="8">2017 (S1.4-10) </text>
<text top="448" left="105" width="173" height="13" font="8">Supraventricular tachycardia </text>
<text top="448" left="472" width="88" height="13" font="8">ACC/AHA/HRS </text>
<text top="448" left="680" width="89" height="13" font="8">2015 (S1.4-11) </text>
<text top="467" left="105" width="212" height="13" font="8">Cardiopulmonary resuscitation and </text>
<text top="484" left="105" width="239" height="13" font="8">emergency cardiovascular care—Part 8: </text>
<text top="502" left="105" width="139" height="13" font="8">postcardiac arrest care </text>
<text top="467" left="501" width="29" height="13" font="8">AHA </text>
<text top="467" left="680" width="89" height="13" font="8">2015 (S1.4.12) </text>
<text top="521" left="105" width="267" height="13" font="8">Non-ST-elevation acute coronary syndromes </text>
<text top="521" left="486" width="59" height="13" font="8">AHA/ACC </text>
<text top="521" left="680" width="89" height="13" font="8">2014 (S1.4-13) </text>
<text top="539" left="105" width="264" height="13" font="8">Perioperative cardiovascular evaluation and </text>
<text top="557" left="105" width="117" height="13" font="8">noncardiac surgery </text>
<text top="539" left="486" width="59" height="13" font="8">ACC/AHA </text>
<text top="539" left="680" width="89" height="13" font="8">2014 (S1.4-14) </text>
<text top="576" left="105" width="100" height="13" font="8">Atrial fibrillation </text>
<text top="576" left="472" width="88" height="13" font="8">AHA/ACC/HRS </text>
<text top="576" left="680" width="89" height="13" font="8">2014 (S1.4-15) </text>
<text top="594" left="105" width="177" height="13" font="8">Stable ischemic heart disease </text>
<text top="594" left="405" width="222" height="13" font="8">ACC/AHA/ACP/AATS/PCNA/SCAI/STS </text>
<text top="594" left="678" width="97" height="13" font="8">2014 (S1.4-16),  </text>
<text top="612" left="680" width="89" height="13" font="8">2012 (S1.4-17) </text>
<text top="631" left="105" width="202" height="13" font="8">Assessment of cardiovascular risk </text>
<text top="631" left="486" width="59" height="13" font="8">ACC/AHA </text>
<text top="631" left="680" width="89" height="13" font="8">2014 (S1.4-18) </text>
<text top="649" left="105" width="260" height="13" font="8">Blood cholesterol to reduce atherosclerotic </text>
<text top="667" left="105" width="167" height="13" font="8">cardiovascular risk in adults </text>
<text top="649" left="486" width="59" height="13" font="8">ACC/AHA </text>
<text top="649" left="680" width="89" height="13" font="8">2014 (S1.4-19) </text>
<text top="685" left="105" width="198" height="13" font="8">Overweight and obesity in adults </text>
<text top="685" left="472" width="88" height="13" font="8">AHA/ACC/TOS </text>
<text top="685" left="680" width="89" height="13" font="8">2014 (S1.4-20) </text>
<text top="708" left="105" width="195" height="13" font="8">Lifestyle management to reduce </text>
<text top="726" left="105" width="113" height="13" font="8">cardiovascular risk </text>
<text top="708" left="486" width="59" height="13" font="8">AHA/ACC </text>
<text top="708" left="680" width="89" height="13" font="8">2014 (S1.4-21) </text>
<text top="744" left="105" width="134" height="13" font="8">Valvular heart disease </text>
<text top="744" left="486" width="59" height="13" font="8">AHA/ACC </text>
<text top="744" left="680" width="89" height="13" font="8">2017 (S1.4-22) </text>
<text top="763" left="105" width="176" height="13" font="8">High blood pressure in adults </text>
<text top="763" left="413" width="205" height="13" font="8">ACC/AHA/AAPA/ABC/ACPM/AGS/ </text>
<text top="781" left="428" width="176" height="13" font="8">APhA/ASH/ASPC/NMA/PCNA </text>
<text top="763" left="680" width="89" height="13" font="8">2017 (S1.4-23) </text>
<text top="800" left="105" width="200" height="13" font="8">Aortic valve and ascending aorta  </text>
<text top="800" left="504" width="24" height="13" font="8">STS </text>
<text top="800" left="680" width="89" height="13" font="8">2013 (S1.4-24) </text>
<text top="818" left="105" width="206" height="13" font="8">ST-elevation myocardial infarction </text>
<text top="818" left="486" width="59" height="13" font="8">ACC/AHA </text>
<text top="818" left="680" width="89" height="13" font="8">2013 (S1.4-25) </text>
<text top="841" left="105" width="78" height="13" font="8">Heart failure </text>
<text top="841" left="468" width="96" height="13" font="8">ACC/AHA/HFSA </text>
<text top="841" left="680" width="89" height="13" font="8">2017 (S1.4-26) </text>
<text top="860" left="105" width="246" height="13" font="8">Device-based therapy for cardiac rhythm </text>
<text top="877" left="105" width="85" height="13" font="8">abnormalities </text>
<text top="860" left="472" width="88" height="13" font="8">ACC/AHA/HRS </text>
<text top="860" left="680" width="89" height="13" font="8">2012 (S1.4-27) </text>
<text top="896" left="105" width="220" height="13" font="8">Coronary artery bypass graft surgery </text>
<text top="896" left="486" width="59" height="13" font="8">ACC/AHA </text>
<text top="896" left="680" width="89" height="13" font="8">2011 (S1.4-28) </text>
<text top="915" left="105" width="218" height="13" font="8">Percutaneous coronary intervention </text>
<text top="915" left="470" width="91" height="13" font="8">ACC/AHA/SCAI </text>
<text top="915" left="680" width="89" height="13" font="8">2011 (S1.4-29) </text>
<text top="933" left="105" width="244" height="13" font="8">Secondary prevention and risk reduction </text>
<text top="951" left="105" width="50" height="13" font="8">therapy </text>
<text top="933" left="486" width="59" height="13" font="8">AHA/ACC </text>
<text top="933" left="680" width="89" height="13" font="8">2011 (S1.4-30) </text>
<text top="969" left="105" width="200" height="13" font="8">Cardiovascular disease in women </text>
<text top="969" left="486" width="59" height="13" font="8">AHA/ACC </text>
<text top="969" left="680" width="89" height="13" font="8">2011 (S1.4-31) </text>
<text top="988" left="105" width="211" height="13" font="8">Grown-up congenital heart disease </text>
<text top="988" left="503" width="25" height="13" font="8">ESC </text>
<text top="988" left="680" width="89" height="13" font="8">2010 (S1.4-32) </text>
<text top="1007" left="105" width="138" height="13" font="8">Thoracic aortic disease </text>
<text top="1007" left="422" width="189" height="13" font="8">ACC/AHA/AATS/ACR/ASA/SCA/ </text>
<text top="1025" left="459" width="113" height="13" font="8">SCAI/SIR/STS/SVM </text>
<text top="1007" left="680" width="89" height="13" font="8">2010 (S1.4-33) </text>
<text top="1043" left="105" width="183" height="13" font="8">Adult congenital heart disease </text>
<text top="1043" left="503" width="26" height="13" font="8">CCS </text>
<text top="1043" left="680" width="89" height="13" font="8">2010 (S1.4-34) </text>
<text top="1062" left="105" width="132" height="13" font="8">Infective endocarditis </text>
<text top="1062" left="503" width="25" height="13" font="8">ESC </text>
<text top="1062" left="680" width="89" height="13" font="8">2009 (S1.4-35) </text>
<text top="1081" left="105" width="4" height="15" font="11"> </text>
<text top="1081" left="315" width="4" height="15" font="11"> </text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="18" size="12" family="Times" color="#221e1f"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="426" width="45" height="12" font="9">Page 12 </text>
<text top="167" left="105" width="130" height="13" font="7"><b>Scientific statements </b></text>
<text top="190" left="105" width="250" height="13" font="8">Imaging for patients with transposition of </text>
<text top="208" left="105" width="106" height="13" font="8">the great arteries </text>
<text top="190" left="503" width="26" height="13" font="8">ASE </text>
<text top="190" left="680" width="89" height="13" font="8">2016 (S1.4-36) </text>
<text top="226" left="105" width="207" height="13" font="8">Cardiac chamber quantification by </text>
<text top="244" left="105" width="107" height="13" font="8">echocardiography</text>
<text top="244" left="211" width="3" height="13" font="18"> </text>
<text top="226" left="503" width="26" height="13" font="8">ASE </text>
<text top="226" left="680" width="89" height="13" font="8">2015 (S1.4-37) </text>
<text top="263" left="105" width="251" height="13" font="8">Consensus on arrhythmia management in </text>
<text top="281" left="105" width="34" height="13" font="8">ACHD</text>
<text top="281" left="139" width="3" height="13" font="18"> </text>
<text top="263" left="481" width="70" height="13" font="8">PACES/HRS </text>
<text top="263" left="680" width="89" height="13" font="8">2014 (S1.4-38) </text>
<text top="299" left="105" width="263" height="13" font="8">Imaging for patients with repaired tetralogy </text>
<text top="317" left="105" width="52" height="13" font="8">of Fallot </text>
<text top="299" left="503" width="26" height="13" font="8">ASE </text>
<text top="299" left="680" width="89" height="13" font="8">2014 (S1.4-39) </text>
<text top="335" left="105" width="138" height="13" font="8">Thoracic aortic disease </text>
<text top="335" left="503" width="26" height="13" font="8">CCS </text>
<text top="335" left="680" width="89" height="13" font="8">2014 (S1.4-40) </text>
<text top="361" left="105" width="251" height="13" font="8">Promotion of physical activity for children </text>
<text top="379" left="105" width="124" height="13" font="8">and adults with CHD </text>
<text top="361" left="501" width="29" height="13" font="8">AHA </text>
<text top="361" left="680" width="89" height="13" font="8">2013 (S1.4-41) </text>
<text top="398" left="105" width="258" height="13" font="8">Neurodevelopmental outcomes in children </text>
<text top="415" left="105" width="59" height="13" font="8">with CHD </text>
<text top="398" left="501" width="29" height="13" font="8">AHA </text>
<text top="398" left="680" width="89" height="13" font="8">2012 (S1.4-42) </text>
<text top="434" left="105" width="240" height="13" font="8">Pregnancy in women with heart disease </text>
<text top="434" left="503" width="25" height="13" font="8">ESC </text>
<text top="434" left="680" width="89" height="13" font="8">2011 (S1.4-43) </text>
<text top="460" left="105" width="267" height="13" font="8">Transition to adulthood for adolescents with </text>
<text top="478" left="105" width="29" height="13" font="8">CHD </text>
<text top="460" left="501" width="29" height="13" font="8">AHA </text>
<text top="460" left="680" width="89" height="13" font="8">2011 (S1.4-44) </text>
<text top="496" left="105" width="149" height="13" font="8">Pulmonary hypertension </text>
<text top="496" left="486" width="59" height="13" font="8">ACC/AHA </text>
<text top="496" left="680" width="89" height="13" font="8">2009 (S1.4-45) </text>
<text top="522" left="105" width="215" height="13" font="8">Prevention of infective endocarditis </text>
<text top="522" left="501" width="29" height="13" font="8">AHA </text>
<text top="522" left="680" width="89" height="13" font="8">2007 (S1.4-46) </text>
<text top="548" left="105" width="686" height="12" font="9">AATS  indicates  American  Association  for  Thoracic  Surgery;  ABC,  Association  of  Black  Cardiologists;  ACC,  American  College  of </text>
<text top="564" left="105" width="686" height="12" font="9">Cardiology; ACHD, adult congenital heart disease; ACP, American College of Physicians; ACPM, American College of Preventive </text>
<text top="580" left="105" width="686" height="12" font="9">Medicine;  ACR,  American  College  of  Radiology;  AGS,  American  Geriatrics  Society;  AHA,  American  Heart  Association;  APhA, </text>
<text top="596" left="105" width="686" height="12" font="9">American  Pharmacists  Association;  ASA,  American  Stroke  Association;  ASE,  American  Society  of  Echocardiography;  ASH, </text>
<text top="612" left="105" width="686" height="12" font="9">American  Society  of  Hypertension;  ASPC,  American  Society  of  Preventive  Cardiology;  CCS,  Canadian  Cardiovascular  Society; </text>
<text top="628" left="105" width="686" height="12" font="9">CHD, congenital heart disease; ESC, European Society of Cardiology; HFSA, Heart Failure Society of America; HRS, Heart Rhythm </text>
<text top="644" left="105" width="686" height="12" font="9">Society;  NMA,  National  Medical  Association;  PACES,  Pediatric  and  Congenital  Electrophysiology  Society;  PCNA,  Preventive </text>
<text top="660" left="105" width="686" height="12" font="9">Cardiovascular  Nurses  Association;  SCA,  Society  of  Cardiovascular  Anesthesiologists;  SCAI,  Society  for  Cardiovascular </text>
<text top="676" left="105" width="686" height="12" font="9">Angiography  and  Interventions;  SIR,  Society  of  Interventional  Radiology;  STS,  Society  of  Thoracic  Surgeons;  SVM,  Society  for </text>
<text top="692" left="105" width="269" height="12" font="9">Vascular Medicine; and TOS, The Obesity Society.  </text>
<text top="709" left="105" width="3" height="13" font="8"> </text>
<text top="709" left="315" width="3" height="13" font="8"> </text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1171" left="426" width="45" height="12" font="9">Page 13 </text>
<text top="164" left="105" width="171" height="20" font="17"><b>1.5. Abbreviations </b></text>
<text top="198" left="105" width="82" height="13" font="7"><b>Abbreviation </b></text>
<text top="198" left="216" width="104" height="13" font="7"><b>Meaning/Phrase </b></text>
<text top="217" left="105" width="20" height="13" font="8">3D </text>
<text top="217" left="216" width="88" height="13" font="8">3-dimensional </text>
<text top="235" left="105" width="46" height="13" font="8">AAOCA </text>
<text top="235" left="216" width="278" height="13" font="8">anomalous aortic origin of the coronary artery </text>
<text top="253" left="105" width="41" height="13" font="8">ACHD  </text>
<text top="253" left="216" width="182" height="13" font="8">adult congenital heart disease </text>
<text top="272" left="105" width="19" height="13" font="8">AP </text>
<text top="272" left="216" width="164" height="13" font="8">anatomic and physiological </text>
<text top="291" left="105" width="23" height="13" font="8">AR  </text>
<text top="291" left="216" width="119" height="13" font="8">aortic regurgitation </text>
<text top="309" left="105" width="31" height="13" font="8">ASD  </text>
<text top="309" left="216" width="114" height="13" font="8">atrial septal defect </text>
<text top="328" left="105" width="39" height="13" font="8">AVSD  </text>
<text top="328" left="216" width="176" height="13" font="8">atrioventricular septal defect </text>
<text top="346" left="105" width="31" height="13" font="8">BAV  </text>
<text top="346" left="216" width="124" height="13" font="8">bicuspid aortic valve </text>
<text top="365" left="105" width="29" height="13" font="8">CCT  </text>
<text top="365" left="216" width="186" height="13" font="8">cardiac computed tomography </text>
<text top="383" left="105" width="47" height="13" font="8">CCTGA  </text>
<text top="383" left="216" width="340" height="13" font="8">congenitally corrected transposition of the great arteries </text>
<text top="402" left="105" width="32" height="13" font="8">CHD  </text>
<text top="402" left="216" width="148" height="13" font="8">congenital heart disease </text>
<text top="420" left="105" width="35" height="13" font="8">CMR  </text>
<text top="420" left="216" width="212" height="13" font="8">cardiovascular magnetic resonance </text>
<text top="439" left="105" width="30" height="13" font="8">CoA  </text>
<text top="439" left="216" width="145" height="13" font="8">coarctation of the aorta </text>
<text top="458" left="105" width="36" height="13" font="8">CPET  </text>
<text top="458" left="216" width="183" height="13" font="8">cardiopulmonary exercise test </text>
<text top="476" left="105" width="21" height="13" font="8">CT  </text>
<text top="476" left="216" width="140" height="13" font="8">computed tomography </text>
<text top="495" left="105" width="30" height="13" font="8">CTA  </text>
<text top="495" left="216" width="217" height="13" font="8">computed tomography angiography </text>
<text top="513" left="105" width="44" height="13" font="8">d-TGA  </text>
<text top="513" left="216" width="247" height="13" font="8">dextro-transposition of the great arteries </text>
<text top="532" left="105" width="31" height="13" font="8">ECG  </text>
<text top="532" left="216" width="113" height="13" font="8">electrocardiogram </text>
<text top="550" left="105" width="29" height="13" font="8">ERC  </text>
<text top="550" left="216" width="168" height="13" font="8">evidence review committee </text>
<text top="569" left="105" width="45" height="13" font="8">GDMT  </text>
<text top="569" left="216" width="269" height="13" font="8">guideline-directed management and therapy </text>
<text top="587" left="105" width="22" height="13" font="8">HF  </text>
<text top="587" left="216" width="77" height="13" font="8">heart failure </text>
<text top="606" left="105" width="27" height="13" font="8">ICD  </text>
<text top="606" left="216" width="225" height="13" font="8">implantable cardioverter-defibrillator </text>
<text top="624" left="105" width="18" height="13" font="8">IE  </text>
<text top="624" left="216" width="131" height="13" font="8">infective endocarditis </text>
<text top="643" left="105" width="21" height="13" font="8">LV  </text>
<text top="643" left="216" width="91" height="13" font="8">left ventricular </text>
<text top="662" left="105" width="38" height="13" font="8">LVOT  </text>
<text top="662" left="216" width="171" height="13" font="8">left ventricular outflow tract </text>
<text top="680" left="105" width="23" height="13" font="8">PA  </text>
<text top="680" left="216" width="107" height="13" font="8">pulmonary artery </text>
<text top="699" left="105" width="32" height="13" font="8">PAH  </text>
<text top="699" left="216" width="196" height="13" font="8">pulmonary arterial hypertension </text>
<text top="717" left="105" width="32" height="13" font="8">PDA  </text>
<text top="717" left="216" width="149" height="13" font="8">patent ductus arteriosus </text>
<text top="736" left="105" width="22" height="13" font="8">PR  </text>
<text top="736" left="216" width="149" height="13" font="8">pulmonary regurgitation </text>
<text top="755" left="105" width="21" height="13" font="8">PS  </text>
<text top="755" left="216" width="119" height="13" font="8">pulmonary stenosis </text>
<text top="773" left="105" width="30" height="13" font="8">QoL  </text>
<text top="773" left="216" width="81" height="13" font="8">quality of life </text>
<text top="791" left="105" width="44" height="13" font="8">Qp:Qs  </text>
<text top="791" left="216" width="224" height="13" font="8">pulmonary–systemic blood flow ratio </text>
<text top="810" left="105" width="29" height="13" font="8">RCT  </text>
<text top="810" left="216" width="165" height="13" font="8">randomized controlled trial </text>
<text top="829" left="105" width="23" height="13" font="8">RV  </text>
<text top="829" left="216" width="99" height="13" font="8">right ventricular </text>
<text top="847" left="105" width="40" height="13" font="8">RVOT  </text>
<text top="847" left="216" width="180" height="13" font="8">right ventricular outflow tract </text>
<text top="866" left="105" width="30" height="13" font="8">SCD  </text>
<text top="866" left="216" width="131" height="13" font="8">sudden cardiac death </text>
<text top="884" left="105" width="44" height="13" font="8">SubAS  </text>
<text top="884" left="216" width="110" height="13" font="8">subaortic stenosis </text>
<text top="903" left="105" width="28" height="13" font="8">TEE  </text>
<text top="903" left="216" width="211" height="13" font="8">transesophageal echocardiography </text>
<text top="921" left="105" width="31" height="13" font="8">TGA  </text>
<text top="921" left="216" width="204" height="13" font="8">transposition of the great arteries </text>
<text top="940" left="105" width="30" height="13" font="8">TOF  </text>
<text top="940" left="216" width="109" height="13" font="8">tetralogy of Fallot </text>
<text top="958" left="105" width="22" height="13" font="8">TR  </text>
<text top="958" left="216" width="136" height="13" font="8">tricuspid regurgitation </text>
<text top="977" left="105" width="28" height="13" font="8">TTE  </text>
<text top="977" left="216" width="192" height="13" font="8">transthoracic echocardiography </text>
<text top="996" left="105" width="33" height="13" font="8">VHD  </text>
<text top="996" left="216" width="132" height="13" font="8">valvular heart disease </text>
<text top="1014" left="105" width="31" height="13" font="8">VSD  </text>
<text top="1014" left="216" width="148" height="13" font="8">ventricular septal defect </text>
<text top="1033" left="105" width="22" height="13" font="8">VT  </text>
<text top="1033" left="216" width="139" height="13" font="8">ventricular tachycardia </text>
<text top="1051" left="105" width="3" height="13" font="8"> </text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="19" size="12" family="Symbol" color="#000000"/>
	<fontspec id="20" size="12" family="Helvetica" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 14 </text>
<text top="182" left="105" width="352" height="21" font="10"><b>2. Background and Pathophysiology </b></text>
<text top="231" left="105" width="360" height="20" font="17"><b>2.1. Anatomic and Physiological Terms  </b></text>
<text top="265" left="105" width="687" height="15" font="11">The International Society for Nomenclature of Pediatric and Congenital Heart Disease (also known as the </text>
<text top="285" left="105" width="687" height="15" font="11">Nomenclature Working Group) defined, codified, mapped, and archived examples of nomenclatures and </text>
<text top="304" left="105" width="687" height="15" font="11">developed  standards  for  terminology  (S2.1-1–  S2.1-5).  The  International  Paediatric  and  Congenital </text>
<text top="324" left="105" width="687" height="15" font="11">Cardiac  Code  (IPCCC)  nomenclature  for  anatomic  lesions  and  repairs  is  used  in  this  guideline </text>
<text top="344" left="105" width="174" height="15" font="11">(http://ipccc.net) (S2.1-6). </text>
<text top="382" left="105" width="199" height="20" font="17"><b>2.2. Severity of ACHD </b></text>
<text top="416" left="105" width="687" height="15" font="11">In a patient with CHD, severity of disease is determined by native anatomy, surgical repair, and current </text>
<text top="436" left="105" width="687" height="15" font="11">physiology. Prior documents, including the 2008 ACHD guideline (S2.2-1), relied primarily  on anatomic </text>
<text top="455" left="105" width="687" height="15" font="11">classifications  to  rank  severity  of  disease.  However,  patients  with  the  same  underlying  anatomy  may </text>
<text top="475" left="105" width="687" height="15" font="11">have  very  different  repairs  and  experienced  variable  physiological  consequences  of  those  repairs.  For </text>
<text top="495" left="105" width="687" height="15" font="11">example, a patient with tetralogy of Fallot (TOF) after a valve-sparing primary repair may have excellent </text>
<text top="514" left="105" width="687" height="15" font="11">biventricular function with normal exercise capacity and no arrhythmias, whereas another patient of the </text>
<text top="534" left="105" width="687" height="15" font="11">same age with TOF may have had palliative shunting followed by a transannular patch repair resulting in </text>
<text top="553" left="105" width="687" height="15" font="11">severe pulmonary regurgitation (PR) with right ventricular (RV) enlargement, biventricular dysfunction, </text>
<text top="573" left="105" width="687" height="15" font="11">and  ventricular  tachycardia  (VT).  To  categorize  disease  severity in  CHD in  a more  comprehensive  way, </text>
<text top="593" left="105" width="687" height="15" font="11">the writing committee developed an ACHD Anatomic and Physiological (AP) classification system (Tables </text>
<text top="612" left="105" width="687" height="15" font="11">3  and  4)  that  incorporates  the  previously  described  CHD  anatomic  variables  as  well  as  physiological </text>
<text top="632" left="105" width="462" height="15" font="11">variables, many of which have prognostic value in patients with ACHD. </text>
<text top="660" left="105" width="4" height="15" font="11"> </text>
<text top="689" left="105" width="439" height="15" font="14"><b>Table 3. Physiological Variables as Used in ACHD AP Classification </b></text>
<text top="712" left="105" width="54" height="13" font="7"><b>Variable </b></text>
<text top="712" left="301" width="73" height="13" font="7"><b>Description </b></text>
<text top="730" left="105" width="73" height="13" font="7"><b>Aortopathy </b></text>
<text top="730" left="301" width="458" height="13" font="8">Aortic enlargement is common in some types of CHD and after some repairs. </text>
<text top="748" left="301" width="465" height="13" font="8">Aortic enlargement may be progressive over a lifetime. There is no universally </text>
<text top="766" left="301" width="452" height="13" font="8">accepted threshold for repair, nor is the role of indexing to body size clearly </text>
<text top="784" left="301" width="412" height="13" font="8">defined in adults, as is done in pediatric populations. For purposes of </text>
<text top="802" left="301" width="378" height="13" font="8">categorization and timing of follow-up imaging (S2.2-2–S2.2-4): </text>
<text top="816" left="315" width="7" height="19" font="19">•</text>
<text top="821" left="322" width="4" height="13" font="20"> </text>
<text top="820" left="341" width="413" height="13" font="8">Mild aortic enlargement is defined as maximum diameter 3.5–3.9 cm </text>
<text top="835" left="315" width="7" height="19" font="19">•</text>
<text top="839" left="322" width="4" height="13" font="20"> </text>
<text top="839" left="341" width="424" height="13" font="8">Moderate aortic enlargement is defined as maximum diameter 4.0–4.9 </text>
<text top="856" left="341" width="21" height="13" font="8">cm </text>
<text top="871" left="315" width="7" height="19" font="19">•</text>
<text top="876" left="322" width="4" height="13" font="20"> </text>
<text top="875" left="341" width="408" height="13" font="8">Severe aortic enlargement is defined as maximum diameter ≥5.0 cm </text>
<text top="894" left="105" width="73" height="13" font="7"><b>Arrhythmia </b></text>
<text top="894" left="301" width="444" height="13" font="8">Arrhythmias are very common in patients with ACHD and may be both the </text>
<text top="912" left="301" width="465" height="13" font="8">cause and consequence of deteriorating hemodynamics, valvular dysfunction, </text>
<text top="929" left="301" width="423" height="13" font="8">or ventricular dysfunction. Arrhythmias are associated with symptoms, </text>
<text top="947" left="301" width="431" height="13" font="8">outcomes, and prognosis (S2.2-5–S2.2-8), thus are categorized based on </text>
<text top="965" left="301" width="224" height="13" font="8">presence and response to treatment. </text>
<text top="980" left="315" width="7" height="19" font="19">•</text>
<text top="984" left="322" width="4" height="13" font="20"> </text>
<text top="984" left="341" width="417" height="13" font="8">No arrhythmia: No documented clinically relevant atrial or ventricular </text>
<text top="1001" left="341" width="107" height="13" font="8">tachyarrhythmias </text>
<text top="1016" left="315" width="7" height="19" font="19">•</text>
<text top="1020" left="322" width="4" height="13" font="20"> </text>
<text top="1020" left="341" width="377" height="13" font="8">Arrhythmia not requiring treatment: Bradyarrhythmia, atrial or </text>
<text top="1038" left="341" width="394" height="13" font="8">ventricular tachyarrhythmia not requiring antiarrhythmic therapy, </text>
<text top="1056" left="341" width="155" height="13" font="8">cardioversion, or ablation </text>
<text top="1070" left="315" width="7" height="19" font="19">•</text>
<text top="1075" left="322" width="4" height="13" font="20"> </text>
<text top="1074" left="341" width="221" height="13" font="8">Arrhythmia controlled with therapy:  </text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="21" size="12" family="Courier" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 15 </text>
<text top="164" left="340" width="9" height="11" font="21">o</text>
<text top="163" left="349" width="4" height="13" font="20"> </text>
<text top="162" left="366" width="309" height="13" font="8">Bradyarrhythmia requiring pacemaker implantation </text>
<text top="182" left="340" width="9" height="11" font="21">o</text>
<text top="181" left="349" width="4" height="13" font="20"> </text>
<text top="180" left="366" width="369" height="13" font="8">Atrial or ventricular tachyarrhythmia requiring antiarrhythmic </text>
<text top="198" left="366" width="212" height="13" font="8">therapy, cardioversion, or ablation  </text>
<text top="217" left="340" width="9" height="11" font="21">o</text>
<text top="216" left="349" width="4" height="13" font="20"> </text>
<text top="216" left="366" width="233" height="13" font="8">AF and controlled ventricular response </text>
<text top="235" left="340" width="9" height="11" font="21">o</text>
<text top="234" left="349" width="4" height="13" font="20"> </text>
<text top="234" left="366" width="123" height="13" font="8">Patients with an ICD </text>
<text top="248" left="315" width="7" height="19" font="19">•</text>
<text top="253" left="322" width="4" height="13" font="20"> </text>
<text top="252" left="341" width="148" height="13" font="8">Refractory arrhythmias:  </text>
<text top="272" left="340" width="9" height="11" font="21">o</text>
<text top="270" left="349" width="4" height="13" font="20"> </text>
<text top="270" left="366" width="392" height="13" font="8">Atrial or ventricular tachyarrhythmia currently unresponsive to or </text>
<text top="288" left="366" width="287" height="13" font="8">refractory to antiarrhythmic therapy or ablation </text>
<text top="307" left="105" width="112" height="13" font="7"><b>Concomitant VHD </b></text>
<text top="307" left="301" width="373" height="13" font="8">Severity defined according to the 2014 VHD guideline (S2.2-2). </text>
<text top="321" left="315" width="7" height="19" font="19">•</text>
<text top="325" left="322" width="4" height="13" font="20"> </text>
<text top="325" left="341" width="60" height="13" font="8">Mild VHD </text>
<text top="340" left="315" width="7" height="19" font="19">•</text>
<text top="344" left="322" width="4" height="13" font="20"> </text>
<text top="344" left="341" width="92" height="13" font="8">Moderate VHD </text>
<text top="358" left="315" width="7" height="19" font="19">•</text>
<text top="363" left="322" width="4" height="13" font="20"> </text>
<text top="362" left="341" width="73" height="13" font="8">Severe VHD </text>
<text top="381" left="105" width="140" height="13" font="7"><b>End-organ dysfunction </b></text>
<text top="381" left="301" width="466" height="13" font="8">Clinical and/or laboratory evidence of end-organ dysfunction (S2.2-9–S2.2-11) </text>
<text top="399" left="301" width="61" height="13" font="8">including: </text>
<text top="413" left="315" width="7" height="19" font="19">•</text>
<text top="418" left="322" width="4" height="13" font="20"> </text>
<text top="417" left="341" width="91" height="13" font="8">Renal (kidney)  </text>
<text top="432" left="315" width="7" height="19" font="19">•</text>
<text top="436" left="322" width="4" height="13" font="20"> </text>
<text top="436" left="341" width="90" height="13" font="8">Hepatic (liver)  </text>
<text top="451" left="315" width="7" height="19" font="19">•</text>
<text top="455" left="322" width="4" height="13" font="20"> </text>
<text top="454" left="341" width="105" height="13" font="8">Pulmonary (lung) </text>
<text top="473" left="105" width="106" height="13" font="7"><b>Exercise capacity </b></text>
<text top="473" left="301" width="417" height="13" font="8">Patients with ACHD are often asymptomatic notwithstanding exercise </text>
<text top="491" left="301" width="441" height="13" font="8">limitations demonstrated as diminished exercise capacity when evaluated </text>
<text top="508" left="301" width="422" height="13" font="8">objectively (S2.2-12–S2.2-14). Thus, assessment of both subjective and </text>
<text top="526" left="301" width="427" height="13" font="8">objective exercise capacity is important (see NYHA classification system </text>
<text top="544" left="301" width="432" height="13" font="8">below). Exercise capacity is associated with prognosis (S2.2-15–S2.2-17). </text>
<text top="559" left="314" width="7" height="19" font="19">•</text>
<text top="563" left="321" width="4" height="13" font="20"> </text>
<text top="563" left="340" width="389" height="13" font="8">Abnormal objective cardiac limitation to exercise is defined as an </text>
<text top="581" left="340" width="409" height="13" font="8">exercise maximum ventilatory equivalent of oxygen below the range </text>
<text top="598" left="340" width="356" height="13" font="8">expected for the specific CHD anatomic diagnosis (S2.2-18). </text>
<text top="613" left="314" width="7" height="19" font="19">•</text>
<text top="618" left="321" width="4" height="13" font="20"> </text>
<text top="617" left="340" width="423" height="13" font="8">Expected norms for CPET values should take into account age, sex, and </text>
<text top="635" left="340" width="396" height="13" font="8">underlying congenital diagnosis. Published studies with institution-</text>
<text top="653" left="340" width="426" height="13" font="8">specific norms can be used as guides, bearing in mind variability among </text>
<text top="670" left="340" width="188" height="13" font="8">institutional norms and ranges. </text>
<text top="689" left="105" width="183" height="13" font="7"><b>Hypoxemia/hypoxia/cyanosis </b></text>
<text top="689" left="301" width="313" height="13" font="8">See Section 3.16. for detailed definition of cyanosis.  </text>
<text top="704" left="315" width="7" height="19" font="19">•</text>
<text top="708" left="322" width="4" height="13" font="20"> </text>
<text top="708" left="341" width="428" height="13" font="8">Hypoxemia is defined as oxygen saturation measured by pulse oximetry </text>
<text top="726" left="341" width="81" height="13" font="8">at rest ≤90%. </text>
<text top="740" left="315" width="7" height="19" font="19">•</text>
<text top="744" left="322" width="4" height="13" font="20"> </text>
<text top="744" left="341" width="383" height="13" font="8">Severe hypoxemia is defined as oxygen saturation at rest &lt;85%.  </text>
<text top="759" left="315" width="7" height="19" font="19">•</text>
<text top="763" left="322" width="4" height="13" font="20"> </text>
<text top="763" left="341" width="399" height="13" font="8">In patients with normal or high hemoglobin concentrations, severe </text>
<text top="781" left="341" width="413" height="13" font="8">hypoxemia will be associated with visible cyanosis (which requires ≥5 </text>
<text top="798" left="341" width="291" height="13" font="8">g/L desaturated hemoglobin to be appreciated).  </text>
<text top="813" left="315" width="7" height="19" font="19">•</text>
<text top="817" left="322" width="4" height="13" font="20"> </text>
<text top="817" left="341" width="408" height="13" font="8">The terms cyanosis and hypoxemia (or hypoxia) are sometimes used </text>
<text top="835" left="341" width="421" height="13" font="8">interchangeably. Such interchangeability would not apply; however, in </text>
<text top="853" left="341" width="399" height="13" font="8">the presence of anemia, severe hypoxemia can be present without </text>
<text top="870" left="341" width="98" height="13" font="8">visible cyanosis. </text>
<text top="889" left="105" width="103" height="13" font="7"><b>NYHA functional </b></text>
<text top="907" left="105" width="162" height="13" font="7"><b>classification system (S2.2-</b></text>
<text top="925" left="105" width="23" height="13" font="7"><b>19) </b></text>
<text top="889" left="301" width="34" height="13" font="7"><b>Class </b></text>
<text top="889" left="353" width="122" height="13" font="7"><b>Functional Capacity </b></text>
<text top="907" left="308" width="7" height="13" font="7"><b>I</b> </text>
<text top="907" left="353" width="413" height="13" font="8">Patients with cardiac disease but resulting in no limitation of physical </text>
<text top="925" left="353" width="384" height="13" font="8">activity. Ordinary physical activity does not cause undue fatigue, </text>
<text top="942" left="353" width="223" height="13" font="8">palpitation, dyspnea, or anginal pain. </text>
<text top="961" left="308" width="11" height="13" font="7"><b>II</b> </text>
<text top="960" left="353" width="406" height="13" font="8">Patients with cardiac disease resulting in slight limitation of physical </text>
<text top="978" left="353" width="422" height="13" font="8">activity. They are comfortable at rest. Ordinary physical activity results </text>
<text top="996" left="353" width="286" height="13" font="8">in fatigue, palpitation, dyspnea, or anginal pain. </text>
<text top="1014" left="308" width="15" height="13" font="7"><b>III</b> </text>
<text top="1014" left="353" width="420" height="13" font="8">Patients with cardiac disease resulting in marked limitation of physical </text>
<text top="1032" left="353" width="385" height="13" font="8">activity. They are comfortable at rest. Less than ordinary activity </text>
<text top="1049" left="353" width="314" height="13" font="8">causes fatigue, palpitation, dyspnea, or anginal pain. </text>
<text top="1067" left="308" width="16" height="13" font="7"><b>IV</b> </text>
<text top="1067" left="353" width="387" height="13" font="8">Patients with cardiac disease resulting in inability to carry on any </text>
<text top="1085" left="353" width="404" height="13" font="8">physical activity without discomfort. Symptoms of HF or the anginal </text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="22" size="15" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 16 </text>
<text top="162" left="353" width="381" height="13" font="8">syndrome may be present even at rest. If any physical activity is </text>
<text top="180" left="353" width="206" height="13" font="8">undertaken, discomfort increases. </text>
<text top="199" left="105" width="153" height="13" font="7"><b>Pulmonary hypertension </b></text>
<text top="199" left="301" width="467" height="13" font="8">Pulmonary hypertension is a broad term that encompasses pulmonary arterial </text>
<text top="217" left="301" width="444" height="13" font="8">hypertension, which is pulmonary hypertension with increased pulmonary </text>
<text top="234" left="301" width="468" height="13" font="8">vascular resistance. This document defines PH and PAH as they are used in the </text>
<text top="252" left="301" width="198" height="13" font="8">field of pulmonary hypertension. </text>
<text top="270" left="301" width="234" height="13" font="8">Pulmonary hypertension is defined as:  </text>
<text top="285" left="314" width="7" height="19" font="19">•</text>
<text top="289" left="321" width="4" height="13" font="20"> </text>
<text top="289" left="340" width="367" height="13" font="8">Mean PA pressure by right heart catheterization ≥25 mm Hg.  </text>
<text top="307" left="301" width="109" height="13" font="8">PAH is defined as: </text>
<text top="321" left="314" width="7" height="19" font="19">•</text>
<text top="325" left="321" width="4" height="13" font="20"> </text>
<text top="325" left="340" width="396" height="13" font="8">Mean PA pressure by right heart catheterization ≥25 mm Hg and a </text>
<text top="343" left="340" width="435" height="13" font="8">pulmonary capillary wedge pressure ≤15 mm Hg and pulmonary vascular </text>
<text top="361" left="340" width="210" height="13" font="8">resistance ≥3 Wood units (S2.2-20) </text>
<text top="380" left="105" width="154" height="13" font="7"><b>Shunt (hemodynamically </b></text>
<text top="397" left="105" width="108" height="13" font="7"><b>significant shunt) </b></text>
<text top="379" left="301" width="329" height="13" font="8">An intracardiac shunt is hemodynamically significant if: </text>
<text top="394" left="315" width="7" height="19" font="19">•</text>
<text top="398" left="322" width="4" height="13" font="20"> </text>
<text top="398" left="341" width="368" height="13" font="8">There is evidence of chamber enlargement distal to the shunt </text>
<text top="413" left="315" width="7" height="19" font="19">•</text>
<text top="417" left="322" width="4" height="13" font="20"> </text>
<text top="417" left="341" width="258" height="13" font="8">And/or evidence of sustained Qp:Qs ≥1.5:1 </text>
<text top="431" left="315" width="7" height="19" font="19">•</text>
<text top="435" left="322" width="4" height="13" font="20"> </text>
<text top="435" left="341" width="423" height="13" font="8">An intracardiac shunt not meeting these criteria would be described as </text>
<text top="453" left="341" width="87" height="13" font="8">small or trivial </text>
<text top="472" left="105" width="175" height="13" font="7"><b>Venous and arterial stenosis </b></text>
<text top="468" left="315" width="7" height="19" font="19">•</text>
<text top="473" left="322" width="4" height="13" font="20"> </text>
<text top="472" left="341" width="220" height="13" font="8">Aortic recoarctation after CoA repair </text>
<text top="487" left="315" width="7" height="19" font="19">•</text>
<text top="491" left="322" width="4" height="13" font="20"> </text>
<text top="491" left="341" width="193" height="13" font="8">Supravalvular aortic obstruction </text>
<text top="506" left="315" width="7" height="19" font="19">•</text>
<text top="510" left="322" width="4" height="13" font="20"> </text>
<text top="509" left="341" width="157" height="13" font="8">Venous baffle obstruction </text>
<text top="524" left="315" width="7" height="19" font="19">•</text>
<text top="528" left="322" width="4" height="13" font="20"> </text>
<text top="528" left="341" width="203" height="13" font="8">Supravalvular pulmonary stenosis </text>
<text top="543" left="315" width="7" height="19" font="19">•</text>
<text top="547" left="322" width="4" height="13" font="20"> </text>
<text top="547" left="341" width="115" height="13" font="8">Branch PA stenosis </text>
<text top="561" left="315" width="7" height="19" font="19">•</text>
<text top="566" left="322" width="4" height="13" font="20"> </text>
<text top="565" left="341" width="232" height="13" font="8">Stenosis of cavopulmonary connection </text>
<text top="580" left="315" width="7" height="19" font="19">•</text>
<text top="584" left="322" width="4" height="13" font="20"> </text>
<text top="584" left="341" width="147" height="13" font="8">Pulmonary vein stenosis </text>
<text top="602" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  AF,  atrial  fibrillation;  AP,  anatomic  and  physiological;  CHD,  congenital  heart </text>
<text top="618" left="105" width="683" height="12" font="9">disease;  CoA,  coarctation  of  the  aorta;  CPET,  cardiopulmonary  exercise  test;  HF,  heart  failure;  ICD,  implantable  cardioverter-</text>
<text top="634" left="105" width="686" height="12" font="9">defibrillator;  NYHA,  New  York  Heart  Association;  PA,  pulmonary  artery;  PAH,  pulmonary  arterial  hypertension;  Qp:Qs, </text>
<text top="650" left="105" width="381" height="12" font="9">pulmonary–systemic blood flow ratio; and VHD, valvular heart disease. </text>
<text top="682" left="105" width="4" height="16" font="22"> </text>
<text top="712" left="105" width="211" height="15" font="14"><b>Table 4. ACHD AP Classification </b></text>
<text top="734" left="105" width="416" height="15" font="14"><b>(CHD Anatomy + Physiological Stage = ACHD AP Classification) </b></text>
<text top="757" left="105" width="96" height="13" font="7"><b>CHD Anatomy* </b></text>
<text top="776" left="105" width="56" height="13" font="7"><b>I: Simple </b></text>
<text top="794" left="105" width="91" height="13" font="7"><b>Native disease </b></text>
<text top="809" left="118" width="7" height="19" font="19">•</text>
<text top="813" left="125" width="4" height="13" font="20"> </text>
<text top="813" left="143" width="113" height="13" font="8">Isolated small ASD </text>
<text top="828" left="118" width="7" height="19" font="19">•</text>
<text top="832" left="125" width="4" height="13" font="20"> </text>
<text top="831" left="143" width="112" height="13" font="8">Isolated small VSD </text>
<text top="846" left="118" width="7" height="19" font="19">•</text>
<text top="850" left="125" width="4" height="13" font="20"> </text>
<text top="850" left="143" width="190" height="13" font="8">Mild isolated pulmonic stenosis </text>
<text top="868" left="105" width="125" height="13" font="7"><b>Repaired conditions </b></text>
<text top="883" left="118" width="7" height="19" font="19">•</text>
<text top="887" left="125" width="4" height="13" font="20"> </text>
<text top="886" left="143" width="287" height="13" font="8">Previously ligated or occluded ductus arteriosus </text>
<text top="901" left="118" width="7" height="19" font="19">•</text>
<text top="905" left="125" width="4" height="13" font="20"> </text>
<text top="905" left="143" width="341" height="13" font="8">Repaired secundum ASD or sinus venosus defect without </text>
<text top="923" left="143" width="302" height="13" font="8">significant residual shunt or chamber enlargement </text>
<text top="938" left="118" width="7" height="19" font="19">•</text>
<text top="942" left="125" width="4" height="13" font="20"> </text>
<text top="941" left="143" width="357" height="13" font="8">Repaired VSD without significant residual shunt or chamber </text>
<text top="959" left="143" width="79" height="13" font="8">enlargement </text>
<text top="978" left="105" width="151" height="13" font="7"><b>II: Moderate Complexity </b></text>
<text top="997" left="105" width="211" height="13" font="7"><b>Repaired or unrepaired conditions </b></text>
<text top="1011" left="118" width="7" height="19" font="19">•</text>
<text top="1015" left="125" width="4" height="13" font="20"> </text>
<text top="1015" left="143" width="169" height="13" font="8">Aorto-left ventricular fistula </text>
<text top="1030" left="118" width="7" height="19" font="19">•</text>
<text top="1034" left="125" width="4" height="13" font="20"> </text>
<text top="1034" left="143" width="346" height="13" font="8">Anomalous pulmonary venous connection, partial or total </text>
<text top="1048" left="118" width="7" height="19" font="19">•</text>
<text top="1052" left="125" width="4" height="13" font="20"> </text>
<text top="1052" left="143" width="370" height="13" font="8">Anomalous coronary artery arising from the pulmonary artery </text>
<text top="1067" left="118" width="7" height="19" font="19">•</text>
<text top="1071" left="125" width="4" height="13" font="20"> </text>
<text top="1071" left="143" width="377" height="13" font="8">Anomalous aortic origin of a coronary artery from the opposite </text>
<text top="1089" left="143" width="34" height="13" font="8">sinus </text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 17 </text>
<text top="159" left="118" width="7" height="19" font="19">•</text>
<text top="164" left="125" width="4" height="13" font="20"> </text>
<text top="163" left="143" width="300" height="13" font="8">AVSD (partial or complete, including primum ASD) </text>
<text top="178" left="118" width="7" height="19" font="19">•</text>
<text top="182" left="125" width="4" height="13" font="20"> </text>
<text top="182" left="143" width="186" height="13" font="8">Congenital aortic valve disease </text>
<text top="196" left="118" width="7" height="19" font="19">•</text>
<text top="201" left="125" width="4" height="13" font="20"> </text>
<text top="200" left="143" width="187" height="13" font="8">Congenital mitral valve disease </text>
<text top="215" left="118" width="7" height="19" font="19">•</text>
<text top="219" left="125" width="4" height="13" font="20"> </text>
<text top="219" left="143" width="146" height="13" font="8">Coarctation of the aorta </text>
<text top="234" left="118" width="7" height="19" font="19">•</text>
<text top="238" left="125" width="4" height="13" font="20"> </text>
<text top="238" left="143" width="363" height="13" font="8">Ebstein anomaly (disease spectrum includes mild, moderate, </text>
<text top="255" left="143" width="134" height="13" font="8">and severe variations) </text>
<text top="270" left="118" width="7" height="19" font="19">•</text>
<text top="274" left="125" width="4" height="13" font="20"> </text>
<text top="274" left="143" width="296" height="13" font="8">Infundibular right ventricular outflow obstruction </text>
<text top="289" left="118" width="7" height="19" font="19">•</text>
<text top="293" left="125" width="4" height="13" font="20"> </text>
<text top="293" left="143" width="124" height="13" font="8">Ostium primum ASD </text>
<text top="307" left="118" width="7" height="19" font="19">•</text>
<text top="312" left="125" width="4" height="13" font="20"> </text>
<text top="311" left="143" width="282" height="13" font="8">Moderate and large unrepaired secundum ASD </text>
<text top="326" left="118" width="7" height="19" font="19">•</text>
<text top="330" left="125" width="4" height="13" font="20"> </text>
<text top="330" left="143" width="343" height="13" font="8">Moderate and large persistently patent ductus arteriosus </text>
<text top="345" left="118" width="7" height="19" font="19">•</text>
<text top="349" left="125" width="4" height="13" font="20"> </text>
<text top="348" left="143" width="316" height="13" font="8">Pulmonary valve regurgitation (moderate or greater) </text>
<text top="363" left="118" width="7" height="19" font="19">•</text>
<text top="367" left="125" width="4" height="13" font="20"> </text>
<text top="367" left="143" width="287" height="13" font="8">Pulmonary valve stenosis (moderate or greater) </text>
<text top="382" left="118" width="7" height="19" font="19">•</text>
<text top="386" left="125" width="4" height="13" font="20"> </text>
<text top="386" left="143" width="184" height="13" font="8">Peripheral pulmonary stenosis </text>
<text top="400" left="118" width="7" height="19" font="19">•</text>
<text top="405" left="125" width="4" height="13" font="20"> </text>
<text top="404" left="143" width="205" height="13" font="8">Sinus of Valsalva fistula/aneurysm </text>
<text top="419" left="118" width="7" height="19" font="19">•</text>
<text top="423" left="125" width="4" height="13" font="20"> </text>
<text top="423" left="143" width="127" height="13" font="8">Sinus venosus defect </text>
<text top="437" left="118" width="7" height="19" font="19">•</text>
<text top="442" left="125" width="4" height="13" font="20"> </text>
<text top="441" left="143" width="371" height="13" font="8">Subvalvar aortic stenosis (excluding HCM; HCM not addressed </text>
<text top="459" left="143" width="118" height="13" font="8">in these guidelines) </text>
<text top="474" left="118" width="7" height="19" font="19">•</text>
<text top="478" left="125" width="4" height="13" font="20"> </text>
<text top="478" left="143" width="162" height="13" font="8">Supravalvar aortic stenosis </text>
<text top="493" left="118" width="7" height="19" font="19">•</text>
<text top="497" left="125" width="4" height="13" font="20"> </text>
<text top="496" left="143" width="193" height="13" font="8">Straddling atrioventricular valve </text>
<text top="511" left="118" width="7" height="19" font="19">•</text>
<text top="515" left="125" width="4" height="13" font="20"> </text>
<text top="515" left="143" width="165" height="13" font="8">Repaired tetralogy of Fallot </text>
<text top="530" left="118" width="7" height="19" font="19">•</text>
<text top="534" left="125" width="4" height="13" font="20"> </text>
<text top="534" left="143" width="367" height="13" font="8">VSD with associated abnormality and/or moderate or greater </text>
<text top="552" left="143" width="37" height="13" font="8">shunt </text>
<text top="570" left="105" width="210" height="13" font="7"><b>III: Great Complexity (or Complex) </b></text>
<text top="585" left="103" width="7" height="19" font="19">•</text>
<text top="590" left="110" width="4" height="13" font="20"> </text>
<text top="589" left="130" width="361" height="13" font="8">Cyanotic congenital heart defect (unrepaired or palliated, all </text>
<text top="607" left="130" width="42" height="13" font="8">forms) </text>
<text top="622" left="103" width="7" height="19" font="19">•</text>
<text top="626" left="110" width="4" height="13" font="20"> </text>
<text top="626" left="130" width="141" height="13" font="8">Double-outlet ventricle </text>
<text top="640" left="103" width="7" height="19" font="19">•</text>
<text top="645" left="110" width="4" height="13" font="20"> </text>
<text top="644" left="130" width="110" height="13" font="8">Fontan procedure </text>
<text top="659" left="103" width="7" height="19" font="19">•</text>
<text top="663" left="110" width="4" height="13" font="20"> </text>
<text top="663" left="130" width="139" height="13" font="8">Interrupted aortic arch </text>
<text top="678" left="103" width="7" height="19" font="19">•</text>
<text top="682" left="110" width="4" height="13" font="20"> </text>
<text top="682" left="130" width="83" height="13" font="8">Mitral atresia </text>
<text top="696" left="103" width="7" height="19" font="19">•</text>
<text top="701" left="110" width="4" height="13" font="20"> </text>
<text top="700" left="130" width="366" height="13" font="8">Single ventricle (including double inlet left ventricle, tricuspid </text>
<text top="718" left="130" width="375" height="13" font="8">atresia, hypoplastic left heart, any other anatomic abnormality </text>
<text top="736" left="130" width="210" height="13" font="8">with a functionally single ventricle) </text>
<text top="751" left="103" width="7" height="19" font="19">•</text>
<text top="755" left="110" width="4" height="13" font="20"> </text>
<text top="755" left="130" width="175" height="13" font="8">Pulmonary atresia (all forms) </text>
<text top="769" left="103" width="7" height="19" font="19">•</text>
<text top="773" left="110" width="4" height="13" font="20"> </text>
<text top="773" left="130" width="233" height="13" font="8">TGA (classic or d-TGA; CCTGA or l-TGA) </text>
<text top="788" left="103" width="7" height="19" font="19">•</text>
<text top="792" left="110" width="4" height="13" font="20"> </text>
<text top="792" left="130" width="113" height="13" font="8">Truncus arteriosus </text>
<text top="806" left="103" width="7" height="19" font="19">•</text>
<text top="811" left="110" width="4" height="13" font="20"> </text>
<text top="810" left="130" width="366" height="13" font="8">Other abnormalities of atrioventricular and ventriculoarterial </text>
<text top="828" left="130" width="334" height="13" font="8">connection (i.e., crisscross heart, isomerism, heterotaxy </text>
<text top="846" left="130" width="202" height="13" font="8">syndromes, ventricular inversion) </text>
<text top="865" left="105" width="127" height="15" font="14"><b>Physiological Stage</b></text>
<text top="866" left="232" width="3" height="13" font="7"><b> </b></text>
<text top="885" left="105" width="12" height="13" font="7"><b>A </b></text>
<text top="900" left="105" width="7" height="19" font="19">•</text>
<text top="904" left="111" width="4" height="13" font="20"> </text>
<text top="904" left="130" width="127" height="13" font="8">NYHA FC I symptoms </text>
<text top="919" left="105" width="7" height="19" font="19">•</text>
<text top="923" left="111" width="4" height="13" font="20"> </text>
<text top="923" left="130" width="239" height="13" font="8">No hemodynamic or anatomic sequelae </text>
<text top="937" left="105" width="7" height="19" font="19">•</text>
<text top="942" left="111" width="4" height="13" font="20"> </text>
<text top="941" left="130" width="95" height="13" font="8">No arrhythmias </text>
<text top="941" left="262" width="3" height="13" font="8"> </text>
<text top="956" left="105" width="7" height="19" font="19">•</text>
<text top="960" left="111" width="4" height="13" font="20"> </text>
<text top="960" left="130" width="151" height="13" font="8">Normal exercise capacity </text>
<text top="975" left="105" width="7" height="19" font="19">•</text>
<text top="979" left="111" width="4" height="13" font="20"> </text>
<text top="978" left="130" width="254" height="13" font="8">Normal renal/hepatic/pulmonary function </text>
<text top="997" left="105" width="12" height="13" font="7"><b>B </b></text>
<text top="1013" left="105" width="7" height="19" font="19">•</text>
<text top="1017" left="111" width="4" height="13" font="20"> </text>
<text top="1016" left="130" width="131" height="13" font="8">NYHA FC II symptoms </text>
<text top="1031" left="105" width="7" height="19" font="19">•</text>
<text top="1035" left="111" width="4" height="13" font="20"> </text>
<text top="1035" left="130" width="358" height="13" font="8">Mild hemodynamic sequelae (mild aortic enlargement, mild </text>
<text top="1053" left="130" width="324" height="13" font="8">ventricular enlargement, mild ventricular dysfunction) </text>
<text top="1067" left="105" width="7" height="19" font="19">•</text>
<text top="1072" left="111" width="4" height="13" font="20"> </text>
<text top="1071" left="130" width="131" height="13" font="8">Mild valvular disease  </text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 18 </text>
<text top="159" left="105" width="7" height="19" font="19">•</text>
<text top="164" left="111" width="4" height="13" font="20"> </text>
<text top="163" left="130" width="331" height="13" font="8">Trivial or small shunt (not hemodynamically significant) </text>
<text top="178" left="105" width="7" height="19" font="19">•</text>
<text top="182" left="111" width="4" height="13" font="20"> </text>
<text top="182" left="130" width="216" height="13" font="8">Arrhythmia not requiring treatment </text>
<text top="196" left="105" width="7" height="19" font="19">•</text>
<text top="201" left="111" width="4" height="13" font="20"> </text>
<text top="200" left="130" width="293" height="13" font="8">Abnormal objective cardiac limitation to exercise </text>
<text top="219" left="105" width="11" height="13" font="7"><b>C </b></text>
<text top="234" left="105" width="7" height="19" font="19">•</text>
<text top="239" left="111" width="4" height="13" font="20"> </text>
<text top="238" left="130" width="134" height="13" font="8">NYHA FC III symptoms </text>
<text top="253" left="105" width="7" height="19" font="19">•</text>
<text top="257" left="111" width="4" height="13" font="20"> </text>
<text top="257" left="130" width="377" height="13" font="8">Significant (moderate or greater) valvular disease; moderate or </text>
<text top="275" left="130" width="364" height="13" font="8">greater ventricular dysfunction (systemic, pulmonic, or both) </text>
<text top="290" left="105" width="7" height="19" font="19">•</text>
<text top="294" left="111" width="4" height="13" font="20"> </text>
<text top="293" left="130" width="179" height="13" font="8">Moderate aortic enlargement </text>
<text top="308" left="105" width="7" height="19" font="19">•</text>
<text top="312" left="111" width="4" height="13" font="20"> </text>
<text top="312" left="130" width="161" height="13" font="8">Venous or arterial stenosis </text>
<text top="327" left="105" width="7" height="19" font="19">•</text>
<text top="331" left="111" width="4" height="13" font="20"> </text>
<text top="330" left="130" width="232" height="13" font="8">Mild or moderate hypoxemia/cyanosis </text>
<text top="345" left="105" width="7" height="19" font="19">•</text>
<text top="349" left="111" width="4" height="13" font="20"> </text>
<text top="349" left="130" width="210" height="13" font="8">Hemodynamically significant shunt </text>
<text top="364" left="105" width="7" height="19" font="19">•</text>
<text top="368" left="111" width="4" height="13" font="20"> </text>
<text top="368" left="130" width="234" height="13" font="8">Arrhythmias controlled with treatment </text>
<text top="383" left="105" width="7" height="19" font="19">•</text>
<text top="387" left="111" width="4" height="13" font="20"> </text>
<text top="386" left="130" width="257" height="13" font="8">Pulmonary hypertension (less than severe) </text>
<text top="401" left="105" width="7" height="19" font="19">•</text>
<text top="405" left="111" width="4" height="13" font="20"> </text>
<text top="405" left="130" width="270" height="13" font="8">End-organ dysfunction responsive to therapy </text>
<text top="424" left="105" width="13" height="13" font="7"><b>D </b></text>
<text top="439" left="105" width="7" height="19" font="19">•</text>
<text top="443" left="111" width="4" height="13" font="20"> </text>
<text top="443" left="130" width="135" height="13" font="8">NYHA FC IV symptoms </text>
<text top="457" left="105" width="7" height="19" font="19">•</text>
<text top="462" left="111" width="4" height="13" font="20"> </text>
<text top="461" left="130" width="160" height="13" font="8">Severe aortic enlargement </text>
<text top="476" left="105" width="7" height="19" font="19">•</text>
<text top="480" left="111" width="4" height="13" font="20"> </text>
<text top="480" left="130" width="219" height="13" font="8">Arrhythmias refractory to treatment </text>
<text top="495" left="105" width="7" height="19" font="19">•</text>
<text top="499" left="111" width="4" height="13" font="20"> </text>
<text top="499" left="130" width="357" height="13" font="8">Severe hypoxemia (almost always associated with cyanosis) </text>
<text top="513" left="105" width="7" height="19" font="19">•</text>
<text top="518" left="111" width="4" height="13" font="20"> </text>
<text top="517" left="130" width="193" height="13" font="8">Severe pulmonary hypertension </text>
<text top="532" left="105" width="7" height="19" font="19">•</text>
<text top="536" left="111" width="4" height="13" font="20"> </text>
<text top="536" left="130" width="143" height="13" font="8">Eisenmenger syndrome </text>
<text top="551" left="105" width="7" height="19" font="19">•</text>
<text top="555" left="111" width="4" height="13" font="20"> </text>
<text top="554" left="130" width="203" height="13" font="8">Refractory end-organ dysfunction </text>
<text top="573" left="105" width="437" height="12" font="9">*This list is not meant to be comprehensive; other conditions may be important </text>
<text top="589" left="105" width="118" height="12" font="9">in individual patients. </text>
<text top="605" left="105" width="437" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  AP,  anatomic  and  physiological; </text>
<text top="621" left="105" width="437" height="12" font="9">ASD,  atrial  septal  defect;  AVSD,  atrioventricular  septal  defect;  CCTGA, </text>
<text top="637" left="105" width="437" height="12" font="9">congenitally corrected transposition of the great arteries; CHD, congenital heart </text>
<text top="653" left="105" width="437" height="12" font="9">disease;  d-TGA,  dextro-transposition  of  the  great  arteries;  FC,  functional  class; </text>
<text top="669" left="105" width="437" height="12" font="9">HCM,  hypertrophic  cardiomyopathy;  l-TGA,  levo-transposition  of  the  great </text>
<text top="685" left="105" width="437" height="12" font="9">arteries;  NYHA,  New  York  Heart  Association;  TGA,  transposition  of  the  great </text>
<text top="701" left="105" width="235" height="12" font="9">arteries; and VSD, ventricular septal defect. </text>
<text top="726" left="105" width="3" height="13" font="8"> </text>
<text top="763" left="105" width="289" height="20" font="17"><b>2.3. The ACHD AP Classification </b></text>
<text top="797" left="105" width="687" height="15" font="11">The  ACHD AP classification (Tables 3 and 4), newly elaborated in this guideline,  is intended  to  capture </text>
<text top="817" left="105" width="687" height="15" font="11">the  complexity  of  ACHD  anatomy  and  physiology,  which  are  not  always  correlated.  Certain  anatomic </text>
<text top="836" left="105" width="687" height="15" font="11">abnormalities of clinical importance are shared across diagnoses (e.g., aortic enlargement), which may </text>
<text top="856" left="105" width="687" height="15" font="11">be  found  in  patients  with BAV,  coarctation  of  the  aorta  (CoA),  transposition  of the  great arteries,  and </text>
<text top="875" left="105" width="687" height="15" font="11">TOF,  amongst  others.  In  every  patient,  anatomic  and  physiological  variables  should  be  considered.  In </text>
<text top="895" left="105" width="687" height="15" font="11">using  Tables  3  and  4,  a  patient  should  be  classified  based  on  the  “highest”  relevant  anatomic  or </text>
<text top="915" left="105" width="687" height="15" font="11">physiological feature. For example, a normotensive patient with repaired CoA, normal exercise capacity, </text>
<text top="934" left="105" width="687" height="15" font="11">and  normal  end-organ  function  would  be  ACHD  AP  classification  IIA,  whereas  an  otherwise  similar </text>
<text top="954" left="105" width="687" height="15" font="11">patient with ascending aortic diameter of 4.0 cm would be ACHD AP classification IIB, and if moderate </text>
<text top="974" left="105" width="486" height="15" font="11">aortic stenosis were also present, the ACHD AP classification would be IIC. </text>
<text top="1002" left="158" width="634" height="15" font="11">Patients with ACHD may have baseline exercise limitations, cyanosis, end-organ dysfunction, or </text>
<text top="1021" left="105" width="687" height="15" font="11">other  clinically  important  comorbidities  related  to  their  CHD.  They  are  also  at  risk  of  HF,  arrhythmias, </text>
<text top="1041" left="105" width="687" height="15" font="11">sudden  cardiac  death  (SCD),  and  development  or  progression  of  cardiac  symptoms  such  as  dyspnea, </text>
<text top="1061" left="105" width="687" height="15" font="11">chest pain, and exercise intolerance. Concomitant valvular disease or aortic pathology may be present. </text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 19 </text>
<text top="162" left="105" width="687" height="15" font="11">There are growing data regarding the prognostic implications of these variables in patients with ACHD, </text>
<text top="182" left="105" width="647" height="15" font="11">but not the abundance of data available for patients with acquired heart disease (S2.3-1–S2.3-16).  </text>
<text top="210" left="158" width="634" height="15" font="11">The  variables forming part of  the ACHD AP classification (Table 3) were selected because data </text>
<text top="229" left="105" width="687" height="15" font="11">exist  suggesting  their  importance  in  prognosis,  management,  or  quality  of  life  (QoL).  As  new  data </text>
<text top="249" left="105" width="687" height="15" font="11">become available, we expect changes in the relative weights attributed to the components of the ACHD </text>
<text top="268" left="105" width="687" height="15" font="11">AP  classification  and  perhaps  new  components,  resulting  in  a  scheme  that  ever  more  precisely  tracks </text>
<text top="288" left="105" width="595" height="15" font="11">overall severity of disease and need for more or less intensive follow-up and management. </text>
<text top="317" left="158" width="634" height="15" font="11">Similar  to  the  New  York  Heart  Association  (NYHA)  classification  of  functional  status,  patients </text>
<text top="336" left="105" width="687" height="15" font="11">may  move  from  one  ACHD  AP  classification  to  another  over  time.  If  clinical  status  worsens,  the </text>
<text top="356" left="105" width="687" height="15" font="11">classification  will  change  to  a  higher  severity  group,  but  improvement  in  status,  for  example  after  an </text>
<text top="375" left="105" width="687" height="15" font="11">intervention such as valve replacement or control of arrhythmia, can result in change to a lower severity </text>
<text top="395" left="105" width="687" height="15" font="11">classification.  Such  movement  among  classes  is  unlike  the  AHA  HF  A  to  D  classification  (S2.3-17),  in </text>
<text top="415" left="105" width="687" height="15" font="11">which  patients  move  in  only  one  direction.  This  ACHD  AP  classification  is  used  throughout  this </text>
<text top="434" left="105" width="687" height="15" font="11">document,  particularly  when  considering  follow-up  visits  and  need  for  testing.  As  the  ACHD  AP </text>
<text top="454" left="105" width="683" height="15" font="11">classification  worsens  because  of  changes  in  physiology  (e.g.,  development  of  arrhythmias,  HF,  end-</text>
<text top="473" left="105" width="687" height="15" font="11">organ disease), the nature and frequency of recommended follow-up visits and testing will also change, </text>
<text top="493" left="105" width="687" height="15" font="11">adapting  to  the  patient’s  changing  circumstance  instead  of  depending  solely  on  a  description  of </text>
<text top="513" left="105" width="687" height="15" font="11">anatomic disease, which may not adequately discriminate physiological changes that alter severity over </text>
<text top="532" left="105" width="38" height="15" font="11">time. </text>
<text top="561" left="158" width="634" height="15" font="11">Some patients with ACHD may have substantial acquired comorbidities unrelated to CHD and, as </text>
<text top="580" left="105" width="687" height="15" font="11">a  consequence,  their  follow-up  strategies  might  be  more  appropriately  based  on  other  existing </text>
<text top="600" left="105" width="687" height="15" font="11">guidelines for acquired heart disease. For example, an 80-year-old patient who has a small atrial septal </text>
<text top="619" left="105" width="687" height="15" font="11">defect  (ASD),  but  whose  symptoms  are  related  to  diastolic  HF,  chronic  kidney  disease  caused  by </text>
<text top="639" left="105" width="687" height="15" font="11">hypertension and diabetes mellitus, and moderate aortic stenosis is well-suited to be followed according </text>
<text top="659" left="105" width="687" height="15" font="11">to existing guidelines for those diseases, rather than according to the ACHD AP classification for the ASD. </text>
<text top="678" left="105" width="612" height="15" font="11">Nevertheless, the added hemodynamic complexity brought by the ASD must be kept in mind. </text>
<text top="707" left="158" width="634" height="15" font="11">Throughout this document, the ACHD AP classification is used to help guide resource utilization, </text>
<text top="726" left="105" width="397" height="15" font="11">including ACHD consultation and routine diagnostic studies.  </text>
<text top="755" left="105" width="4" height="16" font="22"> </text>
<text top="804" left="105" width="204" height="21" font="10"><b>3. General Principles </b></text>
<text top="844" left="105" width="530" height="15" font="11">See Online Data Supplements 1 and 2 for additional data supporting this section. </text>
<text top="882" left="105" width="179" height="20" font="17"><b>3.1. ACHD Program </b></text>
<text top="916" left="105" width="687" height="15" font="11">Patients  with  complex  CHD  have  generally  better  outcomes  when  cared  for  in  an  integrated, </text>
<text top="936" left="105" width="687" height="15" font="11">collaborative, and multidisciplinary program (S3.1-1). Many medical issues in patients with ACHD involve </text>
<text top="956" left="105" width="687" height="15" font="11">cardiac  sequelae,  and  the  diagnosis  and  management  may  require  cardiac  anesthesiologists, </text>
<text top="975" left="105" width="687" height="15" font="11">electrophysiologists, and interventional cardiologists; imaging services such as cardiovascular magnetic </text>
<text top="995" left="105" width="687" height="15" font="11">resonance  (CMR)/cardiac  computed  tomography  (CCT);  and  pulmonary  hypertension  services  with </text>
<text top="1014" left="105" width="687" height="15" font="11">expertise  in  ACHD  (Table  5).  Appropriate  specialty  care  must  be  available  to  address  pregnancy, </text>
<text top="1034" left="105" width="687" height="15" font="11">acquired cardiovascular disease, and acute noncardiac illness complicating CHD, management of which </text>
<text top="1054" left="105" width="358" height="15" font="11">is frequently more complicated in patients with ACHD. </text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 20 </text>
<text top="162" left="158" width="634" height="15" font="11">Although individual providers may be community-based affiliates, ACHD programs are inpatient, </text>
<text top="182" left="105" width="687" height="15" font="11">outpatient, and hospital-based with staffing and expertise available on-site or accessible when needed </text>
<text top="201" left="105" width="65" height="15" font="11">(Table 5). </text>
<text top="229" left="158" width="4" height="15" font="11"> </text>
<text top="258" left="105" width="478" height="15" font="14"><b>Table 5. Key Personnel and Services Recommended for ACHD Programs </b></text>
<text top="281" left="105" width="64" height="13" font="7"><b>Personnel </b></text>
<text top="299" left="105" width="296" height="13" font="8">ACHD board-eligible/board-certified cardiologists </text>
<text top="318" left="105" width="170" height="13" font="8">Congenital cardiac surgeons </text>
<text top="336" left="105" width="284" height="13" font="8">Nurses/physician assistants/nurse practitioners </text>
<text top="355" left="105" width="321" height="13" font="8">Cardiac anesthesiologists with CHD training/expertise </text>
<text top="374" left="105" width="146" height="13" font="8">Multidisciplinary teams: </text>
<text top="389" left="131" width="7" height="19" font="19">•</text>
<text top="393" left="138" width="4" height="13" font="20"> </text>
<text top="392" left="157" width="117" height="13" font="8">High-risk obstetrics </text>
<text top="407" left="131" width="7" height="19" font="19">•</text>
<text top="411" left="138" width="4" height="13" font="20"> </text>
<text top="411" left="157" width="149" height="13" font="8">Pulmonary hypertension </text>
<text top="426" left="131" width="7" height="19" font="19">•</text>
<text top="430" left="138" width="4" height="13" font="20"> </text>
<text top="429" left="157" width="86" height="13" font="8">HF/transplant </text>
<text top="444" left="131" width="7" height="19" font="19">•</text>
<text top="448" left="138" width="4" height="13" font="20"> </text>
<text top="448" left="157" width="55" height="13" font="8">Genetics </text>
<text top="463" left="131" width="7" height="19" font="19">•</text>
<text top="467" left="138" width="4" height="13" font="20"> </text>
<text top="467" left="157" width="71" height="13" font="8">Hepatology </text>
<text top="481" left="131" width="7" height="19" font="19">•</text>
<text top="486" left="138" width="4" height="13" font="20"> </text>
<text top="485" left="157" width="110" height="13" font="8">Cardiac pathology </text>
<text top="500" left="131" width="7" height="19" font="19">•</text>
<text top="504" left="138" width="4" height="13" font="20"> </text>
<text top="504" left="157" width="137" height="13" font="8">Rehabilitation services </text>
<text top="519" left="131" width="7" height="19" font="19">•</text>
<text top="523" left="138" width="4" height="13" font="20"> </text>
<text top="523" left="157" width="88" height="13" font="8">Social services </text>
<text top="537" left="131" width="7" height="19" font="19">•</text>
<text top="541" left="138" width="4" height="13" font="20"> </text>
<text top="541" left="157" width="133" height="13" font="8">Psychological services </text>
<text top="556" left="131" width="7" height="19" font="19">•</text>
<text top="560" left="138" width="4" height="13" font="20"> </text>
<text top="560" left="157" width="123" height="13" font="8">Financial counselors </text>
<text top="578" left="105" width="53" height="13" font="7"><b>Services </b></text>
<text top="597" left="105" width="341" height="13" font="8">Echocardiography, including TEE and intraoperative TEE* </text>
<text top="615" left="105" width="306" height="13" font="8">CHD diagnostic and interventional catheterization* </text>
<text top="634" left="105" width="298" height="13" font="8">CHD electrophysiology/pacing/ICD implantation*: </text>
<text top="649" left="131" width="7" height="19" font="19">•</text>
<text top="653" left="138" width="4" height="13" font="20"> </text>
<text top="652" left="157" width="96" height="13" font="8">Exercise testing </text>
<text top="667" left="131" width="7" height="19" font="19">•</text>
<text top="671" left="138" width="4" height="13" font="20"> </text>
<text top="671" left="157" width="113" height="13" font="8">Echocardiographic </text>
<text top="686" left="131" width="7" height="19" font="19">•</text>
<text top="690" left="138" width="4" height="13" font="20"> </text>
<text top="690" left="157" width="80" height="13" font="8">Radionuclide </text>
<text top="704" left="131" width="7" height="19" font="19">•</text>
<text top="709" left="138" width="4" height="13" font="20"> </text>
<text top="708" left="157" width="106" height="13" font="8">Cardiopulmonary </text>
<text top="727" left="105" width="170" height="13" font="8">Cardiac imaging/radiology*: </text>
<text top="741" left="131" width="7" height="19" font="19">•</text>
<text top="746" left="138" width="4" height="13" font="20"> </text>
<text top="745" left="157" width="32" height="13" font="8">CMR </text>
<text top="760" left="131" width="7" height="19" font="19">•</text>
<text top="764" left="138" width="4" height="13" font="20"> </text>
<text top="764" left="157" width="26" height="13" font="8">CCT </text>
<text top="779" left="131" width="7" height="19" font="19">•</text>
<text top="783" left="138" width="4" height="13" font="20"> </text>
<text top="783" left="157" width="107" height="13" font="8">Nuclear medicine </text>
<text top="801" left="105" width="147" height="13" font="8">Information technology: </text>
<text top="816" left="131" width="7" height="19" font="19">•</text>
<text top="820" left="138" width="4" height="13" font="20"> </text>
<text top="820" left="157" width="92" height="13" font="8">Data collection </text>
<text top="835" left="131" width="7" height="19" font="19">•</text>
<text top="839" left="138" width="4" height="13" font="20"> </text>
<text top="838" left="157" width="109" height="13" font="8">Database support </text>
<text top="853" left="131" width="7" height="19" font="19">•</text>
<text top="857" left="138" width="4" height="13" font="20"> </text>
<text top="857" left="157" width="223" height="13" font="8">Quality assessment review/protocols </text>
<text top="875" left="105" width="496" height="12" font="9">*These  modalities  must  be  supervised/performed  and  interpreted  by  clinicians  with </text>
<text top="891" left="105" width="179" height="12" font="9">expertise and/or training in CHD. </text>
<text top="907" left="105" width="496" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CCT,  cardiac  computed  tomography;  CHD, </text>
<text top="923" left="105" width="496" height="12" font="9">congenital  heart  disease;  CMR,  cardiovascular  magnetic  resonance;  HF,  heart  failure;  ICD, </text>
<text top="940" left="105" width="448" height="12" font="9">implantable cardioverter-defibrillator; and TEE, transesophageal echocardiography. </text>
<text top="956" left="105" width="3" height="13" font="8"> </text>
<text top="991" left="105" width="3" height="13" font="8"> </text>
<text top="991" left="315" width="3" height="13" font="8"> </text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="23" size="14" family="Times" color="#0000ff"/>
	<fontspec id="24" size="14" family="Helvetica" color="#000000"/>
	<fontspec id="25" size="14" family="Symbol" color="#000000"/>
	<fontspec id="26" size="14" family="Helvetica" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 21 </text>
<text top="164" left="105" width="174" height="20" font="17"><b>3.2. Access to Care </b></text>
<text top="200" left="280" width="4" height="14" font="11"> </text>
<text top="199" left="333" width="267" height="16" font="12"><b>Recommendation for Access to Care </b></text>
<text top="220" left="110" width="481" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="220" left="591" width="172" height="15" font="23">Online Data Supplement 3</text>
<text top="220" left="762" width="8" height="15" font="11">. </text>
<text top="240" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="240" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="240" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="300" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="267" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="260" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="261" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="260" left="281" width="495" height="15" font="14"><b>Physicians caring for patients with ACHD should support access to care by </b></text>
<text top="280" left="281" width="495" height="15" font="14"><b>a)  assuring  smooth  transitions  for  adolescents  and  young  adults  from </b></text>
<text top="300" left="281" width="495" height="15" font="14"><b>pediatric to adult providers (S3.2-1, S3.2-2) (Level of Evidence: B-NR); and </b></text>
<text top="319" left="281" width="495" height="15" font="14"><b>b) promoting awareness of the need for lifelong specialized care through </b></text>
<text top="339" left="281" width="415" height="15" font="14"><b>outreach and educational programs (Level of Evidence: C-EO). </b></text>
<text top="317" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="368" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="396" left="105" width="687" height="15" font="11">As  patients  with  ACHD  grow  beyond  the  pediatric  age  group,  continued  access  to  specialized </text>
<text top="416" left="105" width="316" height="15" font="11">cardiovascular care presents several challenges: </text>
<text top="441" left="131" width="7" height="21" font="25">•</text>
<text top="445" left="139" width="4" height="15" font="26"> </text>
<text top="445" left="158" width="340" height="15" font="11">Lack of guided transfer from pediatric to adult care; </text>
<text top="461" left="131" width="7" height="21" font="25">•</text>
<text top="466" left="139" width="4" height="15" font="26"> </text>
<text top="465" left="158" width="279" height="15" font="11">Insufficient availability of ACHD programs; </text>
<text top="481" left="131" width="7" height="21" font="25">•</text>
<text top="486" left="139" width="4" height="15" font="26"> </text>
<text top="486" left="158" width="212" height="15" font="11">Inadequate insurance coverage; </text>
<text top="502" left="131" width="7" height="21" font="25">•</text>
<text top="507" left="139" width="4" height="15" font="26"> </text>
<text top="506" left="158" width="415" height="15" font="11">Deficient education of patients and caregivers regarding ACHD; </text>
<text top="522" left="131" width="7" height="21" font="25">•</text>
<text top="527" left="139" width="4" height="15" font="26"> </text>
<text top="527" left="158" width="512" height="15" font="11">Inadequate resources for patients with cognitive or psychosocial impairment;  </text>
<text top="543" left="131" width="7" height="21" font="25">•</text>
<text top="548" left="139" width="4" height="15" font="26"> </text>
<text top="547" left="158" width="309" height="15" font="11">Lack of comprehensive case management; and </text>
<text top="563" left="131" width="7" height="21" font="25">•</text>
<text top="568" left="139" width="4" height="15" font="26"> </text>
<text top="568" left="158" width="634" height="15" font="11">Different  needs  for  evaluation  and  management  compared  with  adults  with  acquired </text>
<text top="587" left="158" width="154" height="15" font="11">cardiovascular disease. </text>
<text top="616" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="644" left="105" width="687" height="15" font="11">1.  Many  patients  with  CHD  face  gaps  in  care  during  and  after  adolescence  (S3.2-2).  Common  reasons </text>
<text top="663" left="105" width="687" height="15" font="11">include lack of knowledge regarding need for follow-up, inability to find specialized providers, insurance </text>
<text top="683" left="105" width="687" height="15" font="11">issues, and feeling well (S3.2-1). Patients with gaps in care are more likely to develop medical problems </text>
<text top="703" left="105" width="687" height="15" font="11">requiring intervention than those receiving continuous care (S3.2-3, S3.2-4). Canadian patients with CHD </text>
<text top="722" left="105" width="687" height="15" font="11">in specialized care programs had lower mortality than those in centers without ACHD expertise (S3.2-5). </text>
<text top="742" left="105" width="687" height="15" font="11">Improving transition programs and recognizing the importance of long-term care will hopefully improve </text>
<text top="761" left="105" width="687" height="15" font="11">access  to  specialty  care.  Insurance  barriers  and  lack  of  specialty  providers  for  the  large  number  of </text>
<text top="781" left="105" width="687" height="15" font="11">patients  are  issues;  thus,  relationships  with  regulatory  agencies  to  address  these  challenges  are </text>
<text top="801" left="105" width="73" height="15" font="11">important. </text>
<text top="840" left="105" width="189" height="20" font="17"><b>3.3. Delivery of Care </b></text>
<text top="876" left="271" width="4" height="15" font="11"> </text>
<text top="875" left="324" width="285" height="16" font="12"><b>Recommendations for Delivery of Care </b></text>
<text top="895" left="109" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="895" left="570" width="201" height="15" font="23">Online Data Supplements 3, 4, </text>
<text top="915" left="418" width="36" height="15" font="23">and 5</text>
<text top="915" left="454" width="8" height="15" font="11">. </text>
<text top="936" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="936" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="936" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="966" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="966" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="956" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="956" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="956" left="280" width="495" height="15" font="14"><b>Patients  with  ACHD  AP  classification  IB-D,  IIA-D,  and  IIIA-D*  should  be </b></text>
<text top="976" left="280" width="411" height="15" font="14"><b>managed in collaboration with an ACHD cardiologist (S3.3-1). </b></text>
<text top="1035" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1035" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="996" left="255" width="13" height="15" font="14"><b>2.</b></text>
<text top="996" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="996" left="281" width="495" height="15" font="14"><b>Cardiac  surgery,  catheter-based  interventional  cardiac  procedures,  and </b></text>
<text top="1016" left="281" width="495" height="15" font="14"><b>electrophysiological  procedures  involving  congenital  heart  lesions  in </b></text>
<text top="1035" left="281" width="495" height="15" font="14"><b>patients with ACHD should be performed by operators with expertise in </b></text>
<text top="1055" left="281" width="495" height="15" font="14"><b>CHD  procedures  and  in  collaboration  with  an  ACHD  cardiologist  (S3.3-1, </b></text>
<text top="1074" left="281" width="54" height="15" font="14"><b>S3.3-2). </b></text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 22 </text>
<text top="161" left="105" width="501" height="12" font="9">*See Tables 3 and 4 for details on the ACHD Anatomic and Physiological classification system. </text>
<text top="187" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="215" left="105" width="687" height="15" font="11">1. Patients with  ACHD,  particularly  those  with more severe  CHD,  cared  for in  specialized  centers  have </text>
<text top="235" left="105" width="687" height="15" font="11">lower  mortality  than  those  managed  without  specialized  care  (S3.3-1).  Although  clinical  practice </text>
<text top="254" left="105" width="687" height="15" font="11">guidelines  can  be  helpful,  many  management  decisions  for  patients  with  ACHD  must  be  based  on </text>
<text top="274" left="105" width="687" height="15" font="11">insufficient data or care guidelines and require clinical experience often involving multiple members of </text>
<text top="293" left="105" width="687" height="15" font="11">an ACHD team. Patients with complex anatomic and physiological forms of ACHD may need approaches </text>
<text top="313" left="105" width="687" height="15" font="11">to evaluation and treatment that  differ from those applicable to adults without ACHD who  have valve </text>
<text top="333" left="105" width="189" height="15" font="11">disease, HF, or arrhythmias.  </text>
<text top="361" left="158" width="634" height="15" font="11">From a practical perspective, it may be difficult to identify clinicians with expertise in ACHD, and </text>
<text top="381" left="105" width="687" height="15" font="11">expertise in ACHD varies across medical and surgical specialties. Some specialties, such as cardiology and </text>
<text top="400" left="105" width="687" height="15" font="11">congenital  heart  surgery,  have  defined  ACHD  fellowship  training  and  board  certification,  whereas  for </text>
<text top="420" left="105" width="554" height="15" font="11">others, ACHD expertise is gained by focused experience during training and practice. </text>
<text top="448" left="158" width="634" height="15" font="11">In 2012, the American Board of Medical Specialties approved ACHD as a subspecialty of internal </text>
<text top="468" left="105" width="687" height="15" font="11">medicine (“adult”) cardiology and pediatric cardiology. Therefore, for cardiologists, one marker of ACHD </text>
<text top="487" left="105" width="687" height="15" font="11">expertise is board eligibility/board certification in ACHD. There are expert ACHD clinicians who are not </text>
<text top="507" left="105" width="687" height="15" font="11">board-certified,  including  those  whose  expertise  was  acquired  before  the  development  of  formal </text>
<text top="527" left="105" width="687" height="15" font="11">certification  programs  and  those  trained  outside  the  United  States  who  may  also  have  different </text>
<text top="546" left="105" width="687" height="15" font="11">pathways to achieve ACHD expertise. Expertise in the surgical management of patients with ACHD may </text>
<text top="566" left="105" width="687" height="15" font="11">be identified through  board eligibility/board certification in congenital heart surgery. There are expert </text>
<text top="585" left="105" width="687" height="15" font="11">ACHD surgeons who are not board-certified, including those surgeons trained in other countries who are </text>
<text top="605" left="105" width="318" height="15" font="11">not eligible for certification in the United States. </text>
<text top="633" left="158" width="634" height="15" font="11">Specific  ACHD  training  options  are  not  generally  available  for  cardiac  anesthesiologists,  but </text>
<text top="653" left="105" width="687" height="15" font="11">many  of  them  develop  expertise  through  training  in  pediatric  anesthesiology,  cardiac  anesthesiology, </text>
<text top="673" left="105" width="687" height="15" font="11">mentoring,  and  practice  experience.  Other  providers  involved  in  the  care  of  patients  with  ACHD  (e.g., </text>
<text top="692" left="105" width="687" height="15" font="11">obstetricians,  pulmonologists,  radiologists,  nurse  practitioners,  physician  assistants)  derive  expertise </text>
<text top="712" left="105" width="687" height="15" font="11">from  training  and/or  practice.  Individual  providers  may  gain  ACHD  expertise  in  a  specific  area  or </text>
<text top="731" left="105" width="655" height="15" font="11">discipline, such as intraoperative transesophageal echocardiography (TEE) or interpretation of CMR. </text>
<text top="760" left="105" width="687" height="15" font="11">2.  Patients  with  ACHD  who  are  undergoing  invasive  cardiovascular  procedures  in  specialized  ACHD </text>
<text top="779" left="105" width="687" height="15" font="11">centers generally have better outcomes, including survival, than those  managed in other care settings </text>
<text top="799" left="105" width="687" height="15" font="11">(S3.3-2). Special attention is required to ensure appropriate periprocedural care, including identification </text>
<text top="819" left="105" width="562" height="15" font="11">of procedure-related risk factors and availability of ancillary imaging (S3.3-3–S3.3-10). </text>
<text top="847" left="105" width="687" height="15" font="11">Table  6  addresses  delivery  of  care  where  circumstances  of  ACHD  expertise  may  improve  patient </text>
<text top="866" left="105" width="72" height="15" font="11">outcomes. </text>
</page>
<page number="24" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="27" size="52" family="Times" color="#e5e5e5"/>
	<fontspec id="28" size="13" family="Times" color="#ffffff"/>
	<fontspec id="29" size="12" family="Times" color="#000000"/>
	<fontspec id="30" size="12" family="Times" color="#000000"/>
	<fontspec id="31" size="11" family="Times" color="#000000"/>
	<fontspec id="32" size="14" family="Times" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="611" width="45" height="12" font="31">Page 23 </text>
<text top="109" left="159" width="591" height="15" font="32"><b>Table 6. Delivery of Care: Circumstances Where ACHD Expertise May Improve Outcomes </b></text>
<text top="131" left="178" width="85" height="13" font="29"><b>Circumstance </b></text>
<text top="131" left="335" width="107" height="13" font="29"><b>Possible Solution </b></text>
<text top="131" left="621" width="61" height="13" font="29"><b>Rationale </b></text>
<text top="131" left="929" width="55" height="13" font="29"><b>Example </b></text>
<text top="150" left="158" width="112" height="13" font="30">Care of patients in </text>
<text top="168" left="158" width="123" height="13" font="30">the lowest ACHD AP </text>
<text top="185" left="158" width="111" height="13" font="30">classification (IA)* </text>
<text top="150" left="295" width="168" height="13" font="30">1. Face-to-face consultation </text>
<text top="168" left="295" width="164" height="13" font="30">with an ACHD cardiologist.  </text>
<text top="185" left="295" width="3" height="13" font="30"> </text>
<text top="203" left="295" width="180" height="13" font="30">2. Collaborative care planning </text>
<text top="221" left="295" width="167" height="13" font="30">between an ACHD patient’s </text>
<text top="239" left="295" width="186" height="13" font="30">general cardiologist or primary </text>
<text top="257" left="295" width="164" height="13" font="30">care provider and an ACHD </text>
<text top="275" left="295" width="76" height="13" font="30">cardiologist. </text>
<text top="150" left="493" width="311" height="13" font="30">1. Patients in ACHD AP classification IA* are likely to </text>
<text top="168" left="493" width="304" height="13" font="30">be asymptomatic and not require frequent routine </text>
<text top="185" left="493" width="147" height="13" font="30">congenital cardiac care.  </text>
<text top="203" left="493" width="290" height="13" font="30">2. The very long-term outcomes of patients with </text>
<text top="221" left="493" width="291" height="13" font="30">ACHD AP classification IA* lesions have not been </text>
<text top="239" left="493" width="310" height="13" font="30">well described, although available data suggest that </text>
<text top="257" left="493" width="272" height="13" font="30">patients with simple CHD have higher cardiac </text>
<text top="275" left="493" width="306" height="13" font="30">mortality in long-term follow-up than age-matched </text>
<text top="292" left="493" width="115" height="13" font="30">controls (S3.3-11).  </text>
<text top="310" left="493" width="294" height="13" font="30">3. Consultation with an ACHD cardiologist should </text>
<text top="328" left="493" width="286" height="13" font="30">help to accurately assess the patient’s ACHD AP </text>
<text top="346" left="493" width="305" height="13" font="30">class, provide information regarding potential long-</text>
<text top="364" left="493" width="304" height="13" font="30">term outcomes, and reinforce signs and symptoms </text>
<text top="381" left="493" width="234" height="13" font="30">that should prompt further evaluation. </text>
<text top="150" left="822" width="270" height="13" font="30">Patients with small VSDs are thought to have </text>
<text top="168" left="822" width="228" height="13" font="30">excellent long-term survival, although </text>
<text top="185" left="822" width="233" height="13" font="30">complications (double-chamber RV, IE, </text>
<text top="203" left="822" width="190" height="13" font="30">aortic valve prolapse and aortic </text>
<text top="221" left="822" width="252" height="13" font="30">regurgitation) may manifest in adulthood; </text>
<text top="239" left="822" width="235" height="13" font="30">consequently, patients with small VSDs </text>
<text top="257" left="822" width="218" height="13" font="30">warrant lifelong follow-up (S3.3-12). </text>
<text top="400" left="158" width="113" height="13" font="30">Cardiac imaging of </text>
<text top="418" left="158" width="119" height="13" font="30">patients with ACHD </text>
<text top="400" left="295" width="157" height="13" font="30">Imaging studies should be </text>
<text top="418" left="295" width="182" height="13" font="30">performed and interpreted by </text>
<text top="436" left="295" width="169" height="13" font="30">individuals with expertise in </text>
<text top="453" left="295" width="83" height="13" font="30">CHD imaging. </text>
<text top="400" left="493" width="307" height="13" font="30">1. The complexity and variability of lesions, repairs, </text>
<text top="418" left="493" width="303" height="13" font="30">and sequelae in CHD constrain the use of standard </text>
<text top="436" left="493" width="258" height="13" font="30">protocols and sequences and often require </text>
<text top="453" left="493" width="302" height="13" font="30">modification of plans during acquisition of images, </text>
<text top="471" left="493" width="299" height="13" font="30">as well as specialized skills in interpretation. Thus, </text>
<text top="489" left="493" width="283" height="13" font="30">CHD expertise is helpful for optimal quality and </text>
<text top="507" left="493" width="247" height="13" font="30">interpretation of cardiac imaging studies. </text>
<text top="525" left="493" width="307" height="13" font="30">2. Use of a multimodality cardiac imaging approach </text>
<text top="543" left="493" width="306" height="13" font="30">can be used for patients with ACHD, accounting for </text>
<text top="561" left="493" width="273" height="13" font="30">patient-specific considerations, strengths and </text>
<text top="578" left="493" width="255" height="13" font="30">weaknesses of each modality, institutional </text>
<text top="596" left="493" width="155" height="13" font="30">resources, and expertise.  </text>
<text top="614" left="493" width="298" height="13" font="30">3. ACHD programs need a dedicated CMR service, </text>
<text top="632" left="493" width="306" height="13" font="30">and CMR expertise is integral to an ACHD program, </text>
<text top="650" left="493" width="276" height="13" font="30">as is expertise in ACHD CCT (S3.3-13, S3.3-14). </text>
<text top="400" left="822" width="264" height="13" font="30">Although imaging of a patient with TOF may </text>
<text top="418" left="822" width="252" height="13" font="30">seem straightforward because many have </text>
<text top="436" left="822" width="204" height="13" font="30">familiar chamber and great vessel </text>
<text top="453" left="822" width="210" height="13" font="30">relationships, there are nuances to </text>
<text top="471" left="822" width="249" height="13" font="30">echocardiographic imaging of RV size and </text>
<text top="489" left="822" width="240" height="13" font="30">function, PR severity, and/or location of </text>
<text top="507" left="822" width="251" height="13" font="30">right ventricular outflow tract obstruction </text>
<text top="525" left="822" width="244" height="13" font="30">that affect clinical care and are thus best </text>
<text top="543" left="822" width="196" height="13" font="30">carried out by sonographers and </text>
<text top="561" left="822" width="225" height="13" font="30">echocardiographers with appropriate </text>
<text top="578" left="822" width="257" height="13" font="30">expertise. Similarly, expertise in congenital </text>
<text top="596" left="822" width="268" height="13" font="30">CMR is important in evaluating patients with </text>
<text top="614" left="822" width="244" height="13" font="30">TOF, as RV volumes and function are key </text>
<text top="632" left="822" width="235" height="13" font="30">components in evaluation for timing of </text>
<text top="650" left="822" width="266" height="13" font="30">pulmonary valve replacement (S3.3-15, S3.3-</text>
<text top="667" left="822" width="30" height="13" font="30">16).  </text>
<text top="686" left="158" width="122" height="13" font="30">Electrophysiological </text>
<text top="704" left="158" width="96" height="13" font="30">care of patients </text>
<text top="722" left="158" width="67" height="13" font="30">with ACHD </text>
<text top="686" left="295" width="137" height="13" font="30">Perform procedures in </text>
<text top="704" left="295" width="183" height="13" font="30">electrophysiology laboratories </text>
<text top="722" left="295" width="181" height="13" font="30">equipped for 3D mapping and </text>
<text top="739" left="295" width="123" height="13" font="30">ablation and involve </text>
<text top="757" left="295" width="177" height="13" font="30">specialists experienced in the </text>
<text top="686" left="493" width="307" height="13" font="30">Examples of diagnostic questions best answered by </text>
<text top="704" left="493" width="161" height="13" font="30">electrophysiological study: </text>
<text top="722" left="493" width="299" height="13" font="30">a) evaluation of the conduction system in cases of </text>
<text top="739" left="493" width="293" height="13" font="30">suspected postsurgical conduction abnormalities </text>
<text top="757" left="493" width="149" height="13" font="30">b) evaluation of syncope </text>
<text top="686" left="822" width="259" height="13" font="30">Bradyarrhythmia and tachyarrhythmias are </text>
<text top="704" left="822" width="255" height="13" font="30">common in TGA with atrial switch patients </text>
<text top="722" left="822" width="248" height="13" font="30">and may seem “straightforward,” but the </text>
<text top="739" left="822" width="240" height="13" font="30">altered anatomy adds complexity to the </text>
<text top="757" left="822" width="245" height="13" font="30">procedures and emphasizes the need for </text>
</page>
<page number="25" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="611" width="45" height="12" font="31">Page 24 </text>
<text top="109" left="295" width="173" height="13" font="30">management of arrhythmias </text>
<text top="127" left="295" width="137" height="13" font="30">in patients with ACHD. </text>
<text top="109" left="493" width="298" height="13" font="30">c) diagnosis of the mechanism of supraventricular </text>
<text top="127" left="493" width="245" height="13" font="30">tachycardia or wide complex tachycardia </text>
<text top="144" left="493" width="305" height="13" font="30">d) programmed ventricular stimulation particularly </text>
<text top="162" left="493" width="299" height="13" font="30">in patients following repair of TOF and its variants </text>
<text top="180" left="493" width="304" height="13" font="30">(Section 4.4.1.) as well as preoperative assessment </text>
<text top="198" left="493" width="302" height="13" font="30">of arrhythmia substrates that may be amenable to </text>
<text top="216" left="493" width="274" height="13" font="30">operative intervention, such as an atrial maze </text>
<text top="233" left="493" width="259" height="13" font="30">procedure for atrial arrhythmias. The latter </text>
<text top="251" left="493" width="259" height="13" font="30">procedure is commonly used at the time of </text>
<text top="269" left="493" width="297" height="13" font="30">conversion of atriopulmonary connection Fontan, </text>
<text top="287" left="493" width="296" height="13" font="30">and may also be useful in other forms of repaired </text>
<text top="305" left="493" width="300" height="13" font="30">CHD with postoperative atrial arrhythmias such as </text>
<text top="323" left="493" width="30" height="13" font="30">TOF. </text>
<text top="109" left="822" width="236" height="13" font="30">specialized equipment and expertise to </text>
<text top="127" left="822" width="230" height="13" font="30">ensure the best chance for procedural </text>
<text top="144" left="822" width="216" height="13" font="30">success. For example: 1) pacemaker </text>
<text top="162" left="822" width="258" height="13" font="30">placement in a patient with TGA with atrial </text>
<text top="180" left="822" width="245" height="13" font="30">switch can be challenging because of the </text>
<text top="198" left="822" width="261" height="13" font="30">altered atrial anatomy and interatrial baffle </text>
<text top="216" left="822" width="256" height="13" font="30">that will necessitate placement of an atrial </text>
<text top="233" left="822" width="230" height="13" font="30">lead in the anatomic left atrium, often </text>
<text top="251" left="822" width="264" height="13" font="30">scarred such that tissue amenable to pacing </text>
<text top="269" left="822" width="245" height="13" font="30">is difficult to find; and 2) atrial flutter is a </text>
<text top="287" left="822" width="231" height="13" font="30">common arrhythmia in TGA with atrial </text>
<text top="305" left="822" width="261" height="13" font="30">switch, but the flutter circuit may be on the </text>
<text top="323" left="822" width="246" height="13" font="30">systemic side of the interatrial baffle and </text>
<text top="341" left="822" width="215" height="13" font="30">thus may require baffle puncture or </text>
<text top="358" left="822" width="248" height="13" font="30">retrograde approach to effectively ablate </text>
<text top="376" left="822" width="70" height="13" font="30">the circuit.  </text>
<text top="395" left="158" width="91" height="13" font="30">Diagnostic and </text>
<text top="413" left="158" width="87" height="13" font="30">interventional </text>
<text top="430" left="158" width="120" height="13" font="30">cardiac procedures, </text>
<text top="448" left="158" width="57" height="13" font="30">including </text>
<text top="466" left="158" width="108" height="13" font="30">electrophysiology </text>
<text top="484" left="158" width="71" height="13" font="30">procedures </text>
<text top="395" left="295" width="156" height="13" font="30">1. Perform procedure in a </text>
<text top="413" left="295" width="162" height="13" font="30">hospital with cardiologists, </text>
<text top="430" left="295" width="170" height="13" font="30">anesthesiologists, surgeons, </text>
<text top="448" left="295" width="151" height="13" font="30">and other providers with </text>
<text top="466" left="295" width="178" height="13" font="30">expertise in the management </text>
<text top="484" left="295" width="138" height="13" font="30">of patients with ACHD. </text>
<text top="501" left="295" width="182" height="13" font="30">2. Consultation with providers </text>
<text top="519" left="295" width="172" height="13" font="30">with ACHD expertise may be </text>
<text top="537" left="295" width="182" height="13" font="30">substituted if the procedure is </text>
<text top="555" left="295" width="142" height="13" font="30">urgent such that timely </text>
<text top="573" left="295" width="140" height="13" font="30">transfer is not feasible. </text>
<text top="395" left="493" width="254" height="13" font="30">1. Patients with ACHD often have complex </text>
<text top="413" left="493" width="267" height="13" font="30">underlying cardiac anatomy and physiology.  </text>
<text top="430" left="493" width="257" height="13" font="30">2. The data obtained and the interventions </text>
<text top="448" left="493" width="285" height="13" font="30">performed during ACHD cardiac procedures are </text>
<text top="466" left="493" width="301" height="13" font="30">difficult to sort out without specialized knowledge </text>
<text top="484" left="493" width="75" height="13" font="30">of the CHD.  </text>
<text top="501" left="493" width="304" height="13" font="30">3. An ACHD program has additional resources such </text>
<text top="519" left="493" width="295" height="13" font="30">as cardiac anesthesia, congenital cardiac surgery, </text>
<text top="537" left="493" width="300" height="13" font="30">and specialty cardiac imaging, should the need for </text>
<text top="555" left="493" width="300" height="13" font="30">those services arise during or after the procedure. </text>
<text top="395" left="822" width="225" height="13" font="30">In patients with CHD, the presence of </text>
<text top="413" left="822" width="265" height="13" font="30">anatomic and physiological complexity from </text>
<text top="430" left="822" width="267" height="13" font="30">the specific defect or surgical palliation, may </text>
<text top="448" left="822" width="264" height="13" font="30">change the overall care plan and procedural </text>
<text top="466" left="822" width="265" height="13" font="30">decision-making. Procedures that may seem </text>
<text top="484" left="822" width="216" height="13" font="30">straightforward, such as pacemaker </text>
<text top="501" left="822" width="255" height="13" font="30">implantation or ASD closure, may be more </text>
<text top="519" left="822" width="254" height="13" font="30">complex when accounting for the nuances </text>
<text top="537" left="822" width="108" height="13" font="30">imparted by CHD. </text>
<text top="591" left="158" width="107" height="13" font="30">Administration of </text>
<text top="609" left="158" width="88" height="13" font="30">anesthesia for </text>
<text top="627" left="158" width="121" height="13" font="30">invasive procedures </text>
<text top="645" left="158" width="96" height="13" font="30">in patients with </text>
<text top="663" left="158" width="57" height="13" font="30">ACHD AP </text>
<text top="681" left="158" width="111" height="13" font="30">classification IB-D, </text>
<text top="698" left="158" width="105" height="13" font="30">IIA-D, and IIIA-D* </text>
<text top="591" left="295" width="133" height="13" font="30">1. Performed by, or in </text>
<text top="609" left="295" width="133" height="13" font="30">collaboration with, an </text>
<text top="627" left="295" width="129" height="13" font="30">anesthesiologist with </text>
<text top="645" left="295" width="178" height="13" font="30">expertise in the management </text>
<text top="663" left="295" width="141" height="13" font="30">of patients with ACHD.  </text>
<text top="681" left="295" width="181" height="13" font="30">2. If clinical urgency precludes </text>
<text top="698" left="295" width="179" height="13" font="30">transfer, consultation with an </text>
<text top="716" left="295" width="167" height="13" font="30">anesthesiologist with ACHD </text>
<text top="734" left="295" width="178" height="13" font="30">expertise would be of benefit </text>
<text top="752" left="295" width="167" height="13" font="30">to on-site providers who do </text>
<text top="769" left="295" width="155" height="13" font="30">not have ACHD expertise. </text>
<text top="591" left="493" width="307" height="13" font="30">1. ACHD-specific issues need to be addressed when </text>
<text top="609" left="493" width="312" height="13" font="30">considering anesthesia, including underlying cardiac </text>
<text top="627" left="493" width="297" height="13" font="30">physiology and hemodynamics, and the effects of </text>
<text top="645" left="493" width="298" height="13" font="30">anesthetic medications and ventilation strategies. </text>
<text top="663" left="493" width="300" height="13" font="30">2. Many patients with ACHD have had surgeries in </text>
<text top="681" left="493" width="280" height="13" font="30">the past, which may have created or identified </text>
<text top="698" left="493" width="294" height="13" font="30">airway or vascular access concerns. Patients with </text>
<text top="716" left="493" width="294" height="13" font="30">ACHD can also have underlying restrictive and/or </text>
<text top="734" left="493" width="304" height="13" font="30">obstructive lung disease that should be considered </text>
<text top="752" left="493" width="112" height="13" font="30">(S3.3-17, S3.3-18). </text>
<text top="591" left="822" width="197" height="13" font="30">The application of anesthesia for </text>
<text top="609" left="822" width="252" height="13" font="30">laparoscopic procedures can be especially </text>
<text top="627" left="822" width="250" height="13" font="30">challenging in Fontan patients. Significant </text>
<text top="645" left="822" width="250" height="13" font="30">cardiovascular and respiratory alterations </text>
<text top="663" left="822" width="237" height="13" font="30">may occur as a result of increased intra-</text>
<text top="681" left="822" width="257" height="13" font="30">abdominal pressure and decreased venous </text>
<text top="698" left="822" width="256" height="13" font="30">return. Abdominal insufflation may lead to </text>
<text top="716" left="822" width="266" height="13" font="30">lower preload and hypotension, while at the </text>
<text top="734" left="822" width="230" height="13" font="30">same time elevating systemic vascular </text>
<text top="752" left="822" width="223" height="13" font="30">resistance and compromising cardiac </text>
<text top="769" left="822" width="245" height="13" font="30">output. Elevations in pulmonary vascular </text>
</page>
<page number="26" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="33" size="7" family="Times" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="611" width="45" height="12" font="31">Page 25 </text>
<text top="109" left="822" width="270" height="13" font="30">resistance attributable to hypercarbia can be </text>
<text top="127" left="822" width="230" height="13" font="30">caused by either direct carbon dioxide </text>
<text top="144" left="822" width="241" height="13" font="30">absorption or hypoventilation (S3.3-19). </text>
<text top="163" left="158" width="119" height="13" font="30">Patients with ACHD </text>
<text top="181" left="158" width="93" height="13" font="30">and pulmonary </text>
<text top="199" left="158" width="85" height="13" font="30">hypertension  </text>
<text top="163" left="295" width="185" height="13" font="30">1. Consultation with experts in </text>
<text top="181" left="295" width="175" height="13" font="30">pulmonary hypertension and </text>
<text top="199" left="295" width="127" height="13" font="30">ACHD to assist in the </text>
<text top="216" left="295" width="166" height="13" font="30">interpretation of diagnostic </text>
<text top="234" left="295" width="148" height="13" font="30">and invasive studies and </text>
<text top="252" left="295" width="176" height="13" font="30">determine the best course of </text>
<text top="270" left="295" width="86" height="13" font="30">management. </text>
<text top="163" left="493" width="287" height="13" font="30">1. PAH imparts a poor prognosis compared with </text>
<text top="181" left="493" width="314" height="13" font="30">CHD without PAH. Because of the complexity of PAH </text>
<text top="199" left="493" width="295" height="13" font="30">in the setting of CHD, patients with ACHD benefit </text>
<text top="216" left="493" width="283" height="13" font="30">from the expertise of both ACHD providers and </text>
<text top="234" left="493" width="295" height="13" font="30">pulmonary hypertension providers (S3.3-20–S3.3-</text>
<text top="252" left="493" width="26" height="13" font="30">28). </text>
<text top="163" left="822" width="265" height="13" font="30">Management of PAH in patients with shunts </text>
<text top="181" left="822" width="262" height="13" font="30">can be difficult. For example, in patients for </text>
<text top="199" left="822" width="255" height="13" font="30">whom PAH treatment is expected to allow </text>
<text top="216" left="822" width="265" height="13" font="30">subsequent closure of a shunt, cohort series </text>
<text top="234" left="822" width="237" height="13" font="30">demonstrate progression of pulmonary </text>
<text top="252" left="822" width="226" height="13" font="30">vascular resistance or late mortality if </text>
<text top="270" left="822" width="262" height="13" font="30">defects with associated pulmonary vascular </text>
<text top="288" left="822" width="264" height="13" font="30">resistance elevation beyond 2.5 Wood units </text>
<text top="305" left="822" width="108" height="13" font="30">(≥4 Wood units/m</text>
<text top="302" left="930" width="5" height="9" font="33">2</text>
<text top="305" left="935" width="157" height="13" font="30">) or Qp:Qs ≥3 were closed </text>
<text top="323" left="822" width="226" height="13" font="30">(S3.3-29, S3.3-30). The utility of acute </text>
<text top="341" left="822" width="243" height="13" font="30">administration of pulmonary vasodilator </text>
<text top="359" left="822" width="226" height="13" font="30">therapy as a marker of reversibility of </text>
<text top="377" left="822" width="234" height="13" font="30">pulmonary vascular resistance remains </text>
<text top="395" left="822" width="229" height="13" font="30">uncertain. “Treat-to-repair” strategies </text>
<text top="413" left="822" width="233" height="13" font="30">involving use of PAH therapies to bring </text>
<text top="430" left="822" width="257" height="13" font="30">pulmonary vascular resistance into a range </text>
<text top="448" left="822" width="256" height="13" font="30">where repair can be considered have been </text>
<text top="466" left="822" width="269" height="13" font="30">applied, but the utility of such strategies also </text>
<text top="484" left="822" width="115" height="13" font="30">remains uncertain. </text>
<text top="502" left="159" width="369" height="12" font="31">*See Tables 3 and 4 for details on the ACHD AP classification system. </text>
<text top="518" left="159" width="949" height="12" font="31">3D indicates 3-dimensional; ACHD, adult congenital heart disease; AP, anatomic and physiological; ASD, atrial septal defect; CCT, cardiac computed tomography; CHD, congenital </text>
<text top="534" left="159" width="946" height="12" font="31">heart  disease;  CMR,  cardiovascular  magnetic  resonance;  IE,  infective  endocarditis;  PAH,  pulmonary  arterial  hypertension;  PR,  pulmonary  regurgitation;  Qp:Qs,  pulmonary–</text>
<text top="550" left="159" width="774" height="12" font="31">systemic blood flow ratio; RV, right ventricle; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; and VSD, ventricular septal defect. </text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="34" size="18" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 26 </text>
<text top="172" left="105" width="414" height="20" font="17"><b>3.4. Evaluation of Suspected and Known CHD </b></text>
<text top="206" left="105" width="687" height="15" font="11">Tools  commonly  used  in  the  evaluation  of  adults  with  suspected  or  known  acquired  cardiovascular </text>
<text top="226" left="105" width="687" height="15" font="11">disease are also valuable in the evaluation of patients with ACHD. Some tools (e.g., echocardiography) </text>
<text top="245" left="105" width="687" height="15" font="11">are  regularly  used  in  the  serial  evaluation  of  patients  with  ACHD,  whereas  other  tools  (e.g.,  CMR  and </text>
<text top="265" left="105" width="687" height="15" font="11">CCT) may have more utility in the evaluation and management of patients with ACHD than in patients </text>
<text top="284" left="105" width="687" height="15" font="11">with  acquired  cardiovascular  disease  (Tables  7  and  8).  Cost  and  risk  to  patients  can  be  minimized  by </text>
<text top="304" left="105" width="604" height="15" font="11">ensuring studies are acquired and interpreted by centers and providers with CHD expertise.  </text>
<text top="343" left="105" width="212" height="19" font="34"><b>3.4.1. Electrocardiogram </b></text>
<text top="378" left="262" width="4" height="15" font="11"> </text>
<text top="377" left="315" width="303" height="16" font="12"><b>Recommendations for Electrocardiogram </b></text>
<text top="398" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="398" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="398" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="438" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="438" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="418" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="419" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="418" left="281" width="495" height="15" font="14"><b>A  standard  12-lead  electrocardiogram  (ECG)  is  recommended  in  adults </b></text>
<text top="438" left="281" width="494" height="15" font="14"><b>with  CHD  with  serial  assessment  depending  on  the  specific  ACHD  AP </b></text>
<text top="458" left="281" width="354" height="15" font="14"><b>classification or when symptoms develop or worsen. </b></text>
<text top="498" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="498" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="478" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="478" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="478" left="281" width="495" height="15" font="14"><b>Ambulatory  electrocardiographic  monitoring  should  be  performed  in </b></text>
<text top="498" left="281" width="495" height="15" font="14"><b>patients with CHD  who  are  at  risk  of  tachyarrhythmia,  bradyarrhythmia </b></text>
<text top="517" left="281" width="489" height="15" font="14"><b>or heart block, or when symptoms possibly of arrhythmic origin develop. </b></text>
<text top="546" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="574" left="105" width="687" height="15" font="11">1. The ECG is an essential part of a complete cardiovascular evaluation of a patient with ACHD, similar to </text>
<text top="594" left="105" width="687" height="15" font="11">elements of the physical examination. Regardless of anatomic diagnosis, it is important to obtain an ECG </text>
<text top="614" left="105" width="687" height="15" font="11">at  baseline  for  comparison  to  any  subsequently  obtained  ECG,  because  an  abnormal  baseline  ECG  is </text>
<text top="633" left="105" width="687" height="15" font="11">expected in many forms of CHD, particularly those who have undergone surgical repair. A follow-up ECG </text>
<text top="653" left="105" width="687" height="15" font="11">is  recommended  in  specific  lesions  and  in  the  setting  of  new  or  worsening  congestion  or  low  cardiac </text>
<text top="672" left="105" width="182" height="15" font="11">output syndrome (Table 7). </text>
<text top="701" left="105" width="687" height="15" font="11">2.  Asymptomatic  arrhythmias  seen  in  patients  with  ACHD  may  be  associated  with  development  of </text>
<text top="720" left="105" width="687" height="15" font="11">symptoms  and  increased  risk  of  death,  and  are  more  common  in  particular  lesions  or  repairs. </text>
<text top="740" left="105" width="687" height="15" font="11">Bradyarrhythmias  or  tachyarrhythmias  may  occur,  with  some  requiring  treatment  even  when </text>
<text top="760" left="105" width="687" height="15" font="11">asymptomatic. For example, sinus node dysfunction is common in patients with atrial switch repairs of </text>
<text top="779" left="105" width="687" height="15" font="11">transposition  of  the  great  arteries  (TGA),  whereas  complete  heart  block  is  seen  in  patients  with </text>
<text top="799" left="105" width="687" height="15" font="11">congenitally  corrected  transposition  of  the  great  arteries  (CCTGA)  or  late  after  atrioventricular  septal </text>
<text top="818" left="105" width="683" height="15" font="11">defect  (AVSD)  repair,  especially  in  those  patients  with  transient  postoperative  heart  block  (S3.4.1-1–</text>
<text top="838" left="105" width="687" height="15" font="11">S3.4.1-3).  Some  of  these  events  have  occurred  as  late  as  15  years  after  surgery.  The  atrioventricular </text>
<text top="858" left="105" width="687" height="15" font="11">node  is  typically  displaced  inferiorly  in  AVSD,  which  is  associated  with  relative  hypoplasia  of  the  left </text>
<text top="877" left="105" width="687" height="15" font="11">anterior fascicle (S3.4.1-4). Atrial tachyarrhythmias are common in atrial switch repairs of TGA, Fontan </text>
<text top="897" left="105" width="687" height="15" font="11">repairs,  and  Ebstein  anomaly  (S3.4.1-5–S3.4.1-7).  Thus,  baseline  and  periodic  screening  for </text>
<text top="916" left="105" width="687" height="15" font="11">asymptomatic  arrhythmias  with  ambulatory  electrocardiographic  monitoring  is  advised  to  ensure  that </text>
<text top="936" left="105" width="687" height="15" font="11">asymptomatic  arrhythmias  that  would  warrant  a  change  in  therapy  are  not  present  (S3.4.1-8), </text>
<text top="956" left="105" width="687" height="15" font="11">acknowledging  the  limitations  of  monitoring  over  short  periods  of  time.  Any  symptoms  of  arrhythmia </text>
<text top="975" left="105" width="619" height="15" font="11">should prompt investigation to establish an accurate diagnosis and direct subsequent therapy. </text>
<text top="1004" left="105" width="4" height="15" font="11"> </text>
<text top="1032" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="1032" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 27 </text>
<text top="162" left="105" width="271" height="15" font="14"><b>Table 7. Use of ECGs in ACHD Evaluation </b></text>
<text top="182" left="105" width="7" height="19" font="19">•</text>
<text top="186" left="111" width="4" height="13" font="20"> </text>
<text top="186" left="131" width="345" height="13" font="8">Identification of sinus bradycardia or junctional rhythm in </text>
<text top="204" left="131" width="367" height="13" font="8">patients at risk of sinus node dysfunction (especially after the </text>
<text top="221" left="131" width="284" height="13" font="8">Mustard, Senning, Glenn, or Fontan procedure) </text>
<text top="236" left="105" width="7" height="19" font="19">•</text>
<text top="240" left="111" width="4" height="13" font="20"> </text>
<text top="240" left="131" width="338" height="13" font="8">Identification of clinically inapparent intra-atrial re-entry </text>
<text top="258" left="131" width="287" height="13" font="8">tachycardia in patients who have had atriotomy </text>
<text top="272" left="105" width="7" height="19" font="19">•</text>
<text top="277" left="111" width="4" height="13" font="20"> </text>
<text top="276" left="131" width="354" height="13" font="8">Identification of atrioventricular block in patients at risk for </text>
<text top="294" left="131" width="347" height="13" font="8">progression of atrioventricular conduction system disease </text>
<text top="312" left="131" width="113" height="13" font="8">(especially CCTGA) </text>
<text top="327" left="105" width="7" height="19" font="19">•</text>
<text top="331" left="111" width="4" height="13" font="20"> </text>
<text top="331" left="131" width="298" height="13" font="8">Evaluation of rhythm in patients with pacemakers </text>
<text top="345" left="105" width="7" height="19" font="19">•</text>
<text top="350" left="111" width="4" height="13" font="20"> </text>
<text top="349" left="131" width="389" height="13" font="8">Measurement of QRS duration in patients after repair of TOF and </text>
<text top="367" left="131" width="151" height="13" font="8">as part of CRT evaluation </text>
<text top="382" left="105" width="7" height="19" font="19">•</text>
<text top="386" left="111" width="4" height="13" font="20"> </text>
<text top="386" left="131" width="377" height="13" font="8">Preoperatively to compare with postoperative ECGs in patients </text>
<text top="403" left="131" width="296" height="13" font="8">undergoing heart surgery and noncardiac surgery </text>
<text top="418" left="105" width="7" height="19" font="19">•</text>
<text top="422" left="111" width="4" height="13" font="20"> </text>
<text top="422" left="131" width="349" height="13" font="8">Postoperatively to identify arrhythmias (e.g., atrial ectopic </text>
<text top="440" left="131" width="361" height="13" font="8">tachycardia, atrial flutter, AF, junctional ectopic tachycardia, </text>
<text top="458" left="131" width="135" height="13" font="8">atrioventricular block) </text>
<text top="472" left="105" width="7" height="19" font="19">•</text>
<text top="477" left="111" width="4" height="13" font="20"> </text>
<text top="476" left="131" width="374" height="13" font="8">Diagnosis of Wolff-Parkinson-White Syndrome in patients with </text>
<text top="494" left="131" width="101" height="13" font="8">Ebstein anomaly </text>
<text top="509" left="105" width="7" height="19" font="19">•</text>
<text top="513" left="111" width="4" height="13" font="20"> </text>
<text top="513" left="131" width="342" height="13" font="8">Initial evaluation of suspected acute coronary syndromes </text>
<text top="531" left="105" width="437" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  AF,  atrial  fibrillation;  CCTGA, </text>
<text top="547" left="105" width="437" height="12" font="9">congenitally  corrected  transposition  of  the  great  arteries;  CRT,  cardiac </text>
<text top="563" left="105" width="431" height="12" font="9">resynchronization therapy; ECG, electrocardiogram; and TOF, tetralogy of Fallot. </text>
<text top="598" left="105" width="296" height="19" font="34"><b>3.4.2. Ionizing Radiation Principles </b></text>
<text top="633" left="230" width="4" height="15" font="11"> </text>
<text top="633" left="283" width="368" height="16" font="12"><b>Recommendation for Ionizing Radiation Principles </b></text>
<text top="653" left="110" width="481" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="653" left="591" width="172" height="15" font="23">Online Data Supplement 6</text>
<text top="653" left="762" width="8" height="15" font="11">. </text>
<text top="674" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="674" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="674" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="714" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="714" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="694" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="694" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="694" left="281" width="494" height="15" font="14"><b>Strategies  to  limit  and  monitor  radiation  exposure  are  recommended </b></text>
<text top="714" left="281" width="495" height="15" font="14"><b>during imaging of patients with ACHD, with studies not involving ionizing </b></text>
<text top="733" left="281" width="402" height="15" font="14"><b>radiation chosen whenever appropriate (S3.4.2-1–S3.4.2-4). </b></text>
<text top="762" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="790" left="105" width="687" height="15" font="11">1. Low-dose ionizing radiation is a known carcinogen, and certain levels of exposure similar to medical </text>
<text top="810" left="105" width="687" height="15" font="11">exposure  have  been  associated  with  later  malignancy  (S3.4.2-5,  S3.4.2-6).  Patients  with  ACHD  have </text>
<text top="830" left="105" width="687" height="15" font="11">multiple  potential  exposures  to  low-dose  ionizing  radiation  throughout  their  lifetimes  from  cardiac </text>
<text top="849" left="105" width="683" height="15" font="11">catheterizations,  computed  tomographic  (CT)  scans,  nuclear  perfusion  scans,  stress  tests,  and  chest  x-</text>
<text top="869" left="105" width="687" height="15" font="11">rays. It remains unclear whether there is an increased risk of malignancy among patients with ACHD, but </text>
<text top="888" left="105" width="687" height="15" font="11">the exposure levels from multiple procedures are in the range of concern. Every effort should be made </text>
<text top="908" left="105" width="687" height="15" font="11">to use tests without radiation whenever possible or to select protocols with the lowest possible doses of </text>
<text top="927" left="105" width="442" height="15" font="11">radiation compatible with securing the needed clinical information. </text>
<text top="966" left="105" width="209" height="19" font="34"><b>3.4.3. Echocardiography </b></text>
<text top="1001" left="264" width="4" height="15" font="11"> </text>
<text top="1000" left="317" width="300" height="16" font="12"><b>Recommendations for Echocardiography </b></text>
<text top="1021" left="120" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="1021" left="581" width="172" height="15" font="23">Online Data Supplement 7</text>
<text top="1021" left="753" width="8" height="15" font="11">. </text>
<text top="1041" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="1041" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="1041" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="1071" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1071" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1061" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="1062" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1061" left="288" width="488" height="15" font="14"><b>Intraoperative  TEE  is  recommended  to  guide  surgical  repair  of  CHD  in </b></text>
<text top="1081" left="288" width="116" height="15" font="14"><b>adults (S3.4.3-1). </b></text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 28 </text>
<text top="183" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="183" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="163" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="163" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="163" left="288" width="488" height="15" font="14"><b>Patients  with  ACHD  should  undergo  transthoracic  echocardiography </b></text>
<text top="183" left="288" width="488" height="15" font="14"><b>(TTE)  for  initial  assessment,  with  timing  of  serial  assessment  based  on </b></text>
<text top="202" left="288" width="368" height="15" font="14"><b>anatomic and physiological severity and clinical status. </b></text>
<text top="231" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="259" left="105" width="687" height="15" font="11">1.  A  large  retrospective  study  has  shown  that  the  routine  use  of  intraoperative  TEE  has  a  substantial </text>
<text top="279" left="105" width="687" height="15" font="11">impact on patient care, leading to alteration of planned procedure or revision of the initial repair in 14% </text>
<text top="299" left="105" width="423" height="15" font="11">of cases and was also determined to be cost-effective (S3.4.3-1). </text>
<text top="327" left="105" width="687" height="15" font="11">2.  For  patients  with  ACHD  in  whom  abnormalities  and  changes  that  may  be  identified  on </text>
<text top="347" left="105" width="687" height="15" font="11">echocardiography  (e.g.,  valvular  or  ventricular  function  or  pulmonary  pressures)  commonly  influence </text>
<text top="366" left="105" width="687" height="15" font="11">management  decisions;  echocardiography  is  an  indispensable  tool  in  the  initial  and  serial  follow-up </text>
<text top="386" left="105" width="687" height="15" font="11">evaluation.  TTE  is  also  valuable  in  the  initial  and  serial  evaluation  of  patients  without  symptoms  or </text>
<text top="405" left="105" width="226" height="15" font="11">changes in examination (Table 8).  </text>
<text top="444" left="105" width="169" height="19" font="34"><b>3.4.4. CMR Imaging </b></text>
<text top="482" left="281" width="4" height="15" font="11"> </text>
<text top="482" left="334" width="266" height="16" font="12"><b>Recommendations for CMR Imaging </b></text>
<text top="502" left="120" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="502" left="581" width="172" height="15" font="23">Online Data Supplement 8</text>
<text top="502" left="753" width="8" height="15" font="11">. </text>
<text top="523" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="523" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="523" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="562" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="562" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="543" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="543" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="543" left="281" width="495" height="15" font="14"><b>In  patients  with  ACHD  who  have  or  who  are  at  risk  of  developing  RV </b></text>
<text top="562" left="281" width="494" height="15" font="14"><b>enlargement  and  dysfunction,  serial  CMR  is  recommended  for </b></text>
<text top="582" left="281" width="456" height="15" font="14"><b>quantitative assessment of RV size and function (S3.4.4-1–S3.4.4-3). </b></text>
<text top="622" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="622" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="602" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="603" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="602" left="281" width="495" height="15" font="14"><b>CMR  can  be  useful  in  the  initial  evaluation  and  serial  assessment  of </b></text>
<text top="622" left="281" width="495" height="15" font="14"><b>selected  patients  with  CHD  based  on  anatomic  complexity  and  clinical </b></text>
<text top="642" left="281" width="309" height="15" font="14"><b>status (S3.4.4-1, S3.4.4-2, S3.4.4-4–S3.4.4-10). </b></text>
<text top="671" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="699" left="105" width="687" height="15" font="11">1.  CMR  plays  a  valuable  role in  assessment  of  RV  size  and  function,  because it  provides  data  that  are </text>
<text top="718" left="105" width="683" height="15" font="11">reproducible and more reliable than data obtained with alternative imaging techniques (S3.4.4-1–S3.4.4-</text>
<text top="738" left="105" width="687" height="15" font="11">4). Real-time 3-dimensional (3D) echocardiography is an emerging technique that shows some promise </text>
<text top="758" left="105" width="687" height="15" font="11">for replacing CCT and even CMR for serial studies, especially when focusing on ventricular volumes and </text>
<text top="777" left="105" width="617" height="15" font="11">intracardiac structures only, and if reasonably complete data sets can be obtained (S3.4.4-11). </text>
<text top="806" left="105" width="687" height="15" font="11">2. CMR has unique value in the assessment and serial follow-up of patients with ACHD, because it offers </text>
<text top="825" left="105" width="687" height="15" font="11">unrestricted  access  to  the  heart  and  great  vessels  noninvasively  and  without  ionizing  radiation.  The </text>
<text top="845" left="105" width="687" height="15" font="11">complexity  and  variability  of  lesions,  repairs,  and  sequelae  in  CHD  constrain  the  use  of  standard </text>
<text top="864" left="105" width="687" height="15" font="11">protocols and sequences, and often require modification of plans during acquisition of images, as well as </text>
<text top="884" left="105" width="687" height="15" font="11">specialized skills in interpretation (S3.4.4-12, S3.4.4-13). Thus, a dedicated CMR service is integral to an </text>
<text top="904" left="105" width="687" height="15" font="11">ACHD program (S3.4.4-4, S3.4.4-5). CMR can provide exquisite anatomic detail and unique physiological </text>
<text top="923" left="105" width="687" height="15" font="11">information in many forms of CHD. It has a particularly important role in the assessment of extracardiac </text>
<text top="943" left="105" width="687" height="15" font="11">cardiovascular defects (e.g., CoA, aortic aneurysm, and abnormalities of the thoracic arterial and venous </text>
<text top="963" left="105" width="687" height="15" font="11">anatomy  and  connections)  (S3.4.4-6,  S3.4.4-7).  The  elucidation  of  uncommon,  complex  forms  and </text>
<text top="982" left="105" width="687" height="15" font="11">variations  of  CHD  is  routinely  facilitated  by  a  CMR  study  (S3.4.4-5).  Contraindications  to  CMR  are </text>
<text top="1002" left="105" width="687" height="15" font="11">common in  patients  with  ACHD,  so  they  should  be sought  and  confirmed. However,  the  high  value  of </text>
<text top="1021" left="105" width="687" height="15" font="11">serial  CMR  has  encouraged  modification  of  newer  pacemakers,  leads,  and  other  devices  and  imaging </text>
<text top="1041" left="105" width="687" height="15" font="11">protocols  to  facilitate  imaging  in  an  expanding  subset  of  patients  with  ACHD  who  have  had  previous </text>
<text top="1060" left="105" width="687" height="15" font="11">instrumentation.  If  a  contraindication  is  confirmed,  alternative  forms  of  imaging,  especially  CCT,  can </text>
<text top="1080" left="105" width="687" height="15" font="11">obtain  much  of  the  information  otherwise  obtained  from  CMR  and  some  unique  information  not </text>
</page>
<page number="30" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 29 </text>
<text top="162" left="105" width="687" height="15" font="11">provided  by  CMR  (S3.4.4-14).  However,  CCT  has  the  disadvantage  of  substantial  patient  exposure  to </text>
<text top="182" left="105" width="687" height="15" font="11">ionizing radiation, especially when serial studies are contemplated over a lifetime (S3.4.4-9). Real-time </text>
<text top="201" left="105" width="687" height="15" font="11">3D echocardiography shows promise for replacing CCT and even CMR for serial studies, especially when </text>
<text top="221" left="105" width="687" height="15" font="11">focusing on ventricular volumes and intracardiac structures only, and if reasonably complete data sets </text>
<text top="240" left="105" width="363" height="15" font="11">can be obtained (Tables 8 and 9) (S3.4.4-11, S3.4.4-15). </text>
<text top="268" left="105" width="4" height="15" font="11"> </text>
<text top="297" left="105" width="677" height="15" font="14"><b>Table 8. Circumstances Where CMR, CCT, TEE, and/or Cardiac Catheterization May be Superior to TTE </b></text>
<text top="524" left="105" width="686" height="12" font="9">CCT  indicates  cardiac  computed  tomography;  CMR,  cardiovascular  magnetic  resonance;  PA,  pulmonary  artery;  RV,  right </text>
<text top="540" left="105" width="435" height="12" font="9">ventricular; TEE, transesophageal echocardiography; and TOF, tetralogy of Fallot. </text>
<text top="556" left="105" width="4" height="15" font="11"> </text>
<text top="585" left="105" width="468" height="15" font="14"><b>Table 9. Comparison of Imaging Modalities Useful in ACHD Evaluation </b></text>
<text top="661" left="161" width="3" height="13" font="7"><b> </b></text>
<text top="644" left="238" width="62" height="13" font="7"><b>Radiation </b></text>
<text top="661" left="240" width="59" height="13" font="7"><b>Exposure </b></text>
<text top="644" left="323" width="53" height="13" font="7"><b>Relative </b></text>
<text top="661" left="335" width="30" height="13" font="7"><b>Cost </b></text>
<text top="644" left="417" width="71" height="13" font="7"><b>Ventricular </b></text>
<text top="661" left="395" width="115" height="13" font="7"><b>Volumes/Function </b></text>
<text top="626" left="533" width="53" height="13" font="7"><b>Valvular </b></text>
<text top="644" left="527" width="66" height="13" font="7"><b>Structure/ </b></text>
<text top="661" left="532" width="56" height="13" font="7"><b>Function </b></text>
<text top="608" left="613" width="59" height="13" font="7"><b>Coronary </b></text>
<text top="626" left="613" width="59" height="13" font="7"><b>Anatomy </b></text>
<text top="644" left="630" width="26" height="13" font="7"><b>and </b></text>
<text top="661" left="620" width="45" height="13" font="7"><b>Course </b></text>
<text top="626" left="694" width="78" height="13" font="7"><b>Extracardiac </b></text>
<text top="644" left="705" width="55" height="13" font="7"><b>Vascular </b></text>
<text top="661" left="703" width="59" height="13" font="7"><b>Anatomy </b></text>
<text top="680" left="105" width="110" height="13" font="8">Echocardiography </text>
<text top="680" left="233" width="20" height="13" font="8">No </text>
<text top="680" left="318" width="11" height="13" font="8">$ </text>
<text top="680" left="394" width="18" height="13" font="8">++ </text>
<text top="680" left="524" width="25" height="13" font="8">+++ </text>
<text top="680" left="608" width="21" height="13" font="8">+/- </text>
<text top="680" left="690" width="21" height="13" font="8">+/- </text>
<text top="698" left="105" width="32" height="13" font="8">CMR </text>
<text top="698" left="233" width="20" height="13" font="8">No </text>
<text top="698" left="318" width="18" height="13" font="8">$$ </text>
<text top="698" left="394" width="25" height="13" font="8">+++ </text>
<text top="698" left="524" width="18" height="13" font="8">++ </text>
<text top="698" left="608" width="25" height="13" font="8">++* </text>
<text top="698" left="690" width="25" height="13" font="8">+++ </text>
<text top="717" left="105" width="26" height="13" font="8">CCT </text>
<text top="717" left="233" width="23" height="13" font="8">Yes </text>
<text top="717" left="318" width="18" height="13" font="8">$$ </text>
<text top="717" left="394" width="18" height="13" font="8">+* </text>
<text top="717" left="524" width="11" height="13" font="8">+ </text>
<text top="717" left="608" width="25" height="13" font="8">+++ </text>
<text top="717" left="690" width="25" height="13" font="8">+++ </text>
<text top="735" left="105" width="47" height="13" font="8">Cardiac </text>
<text top="753" left="105" width="93" height="13" font="8">catheterization </text>
<text top="735" left="233" width="23" height="13" font="8">Yes </text>
<text top="735" left="318" width="18" height="13" font="8">$$ </text>
<text top="735" left="394" width="11" height="13" font="8">+ </text>
<text top="735" left="524" width="18" height="13" font="8">++ </text>
<text top="735" left="608" width="25" height="13" font="8">+++ </text>
<text top="735" left="690" width="18" height="13" font="8">++ </text>
<text top="771" left="105" width="197" height="12" font="9">*In specific gated imaging protocols. </text>
<text top="787" left="105" width="586" height="12" font="9">$ indicates less expensive; $$, more expensive; +/-, possible value; +, good; ++, very good; and +++, excellent. </text>
<text top="803" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CCT,  cardiac  computed  tomography;  and  CMR,  cardiovascular  magnetic </text>
<text top="820" left="105" width="62" height="12" font="9">resonance. </text>
<text top="855" left="105" width="325" height="19" font="34"><b>3.4.5. Cardiac Computed Tomography </b></text>
<text top="890" left="218" width="4" height="15" font="11"> </text>
<text top="889" left="270" width="392" height="16" font="12"><b>Recommendation for Cardiac Computed Tomography </b></text>
<text top="909" left="110" width="481" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="909" left="591" width="172" height="15" font="23">Online Data Supplement 9</text>
<text top="909" left="762" width="8" height="15" font="11">. </text>
<text top="930" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="930" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="930" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="970" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="970" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="950" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="951" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="950" left="281" width="495" height="15" font="14"><b>CCT imaging can be useful in patients with ACHD when information that </b></text>
<text top="970" left="281" width="495" height="15" font="14"><b>cannot  be  obtained  by  other  diagnostic  modalities  is  important  enough </b></text>
<text top="990" left="281" width="425" height="15" font="14"><b>to justify the exposure to ionizing radiation (S3.4.5-1, S3.4.5-2). </b></text>
<text top="1019" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="1047" left="105" width="687" height="15" font="11">1.  The  most important  disadvantage  of  CCT  (including  CT  angiography)  as an imaging  technique  is  the </text>
<text top="1066" left="105" width="687" height="15" font="11">associated exposure to ionizing radiation. This is especially problematic in patients with ACHD in whom </text>
<text top="1086" left="105" width="687" height="15" font="11">serial  assessments  are  contemplated  over  a  lifetime  (S3.4.5-1).  Gating  CCT  to  the  ECG  allows  image </text>
<text top="317" left="103" width="7" height="19" font="19">•</text>
<text top="321" left="110" width="4" height="13" font="20"> </text>
<text top="321" left="130" width="588" height="13" font="8">Assessment of RV size and function in repaired TOF, systemic right ventricles, and other conditions </text>
<text top="339" left="130" width="414" height="13" font="8">associated with RV volume and pressure overload (S3.4.4-1, S3.4.4-3) </text>
<text top="353" left="105" width="7" height="19" font="19">•</text>
<text top="358" left="112" width="4" height="13" font="20"> </text>
<text top="357" left="131" width="423" height="13" font="8">Identification of anomalous pulmonary venous connections (S3.4.4-16) </text>
<text top="372" left="130" width="7" height="19" font="19">•</text>
<text top="376" left="136" width="4" height="13" font="20"> </text>
<text top="376" left="156" width="605" height="13" font="8">Serial assessment of thoracic aortic aneurysms, especially when the dilation might extend beyond the </text>
<text top="394" left="156" width="229" height="13" font="8">echocardiographic windows (S3.4.4-7) </text>
<text top="409" left="105" width="7" height="19" font="19">•</text>
<text top="413" left="112" width="4" height="13" font="20"> </text>
<text top="413" left="131" width="426" height="13" font="8">Accurate assessment of PA pressure and pulmonary vascular resistance </text>
<text top="427" left="105" width="7" height="19" font="19">•</text>
<text top="431" left="112" width="4" height="13" font="20"> </text>
<text top="431" left="131" width="251" height="13" font="8">Assessment for recoarctation of the aorta </text>
<text top="446" left="105" width="7" height="19" font="19">•</text>
<text top="450" left="112" width="4" height="13" font="20"> </text>
<text top="450" left="131" width="133" height="13" font="8">Sinus venosus defects </text>
<text top="464" left="105" width="7" height="19" font="19">•</text>
<text top="469" left="112" width="4" height="13" font="20"> </text>
<text top="468" left="131" width="86" height="13" font="8">Vascular rings </text>
<text top="483" left="105" width="7" height="19" font="19">•</text>
<text top="487" left="112" width="4" height="13" font="20"> </text>
<text top="487" left="131" width="201" height="13" font="8">Evaluation of coronary anomalies </text>
<text top="502" left="105" width="7" height="19" font="19">•</text>
<text top="506" left="112" width="4" height="13" font="20"> </text>
<text top="505" left="131" width="235" height="13" font="8">Quantification of valvular regurgitation </text>
</page>
<page number="31" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 30 </text>
<text top="162" left="105" width="687" height="15" font="11">acquisition during multiple phases of the cardiac cycle, thereby providing cine imaging and the ability to </text>
<text top="182" left="105" width="687" height="15" font="11">select  phases  of  the  cycle  of  specific  interest  (usually  end-systole  and  end-diastole),  at  the  cost  of </text>
<text top="201" left="105" width="687" height="15" font="11">increased  radiation  dose.  Electrocardiographic  gating  is  generally  unnecessary  when  the  focus  is </text>
<text top="221" left="105" width="687" height="15" font="11">assessment  of  extracardiac  vascular  structures,  which  can  consequently  be  imaged  using  substantially </text>
<text top="240" left="105" width="687" height="15" font="11">lower  doses  of  ionizing  radiation.  Ongoing  development  of  protocols  and  equipment  that  reduce </text>
<text top="260" left="105" width="349" height="15" font="11">radiation exposure are welcome advances (S3.4.5-2). </text>
<text top="298" left="105" width="255" height="19" font="34"><b>3.4.6. Cardiac Catheterization </b></text>
<text top="333" left="244" width="4" height="15" font="11"> </text>
<text top="333" left="297" width="340" height="16" font="12"><b>Recommendations for Cardiac Catheterization </b></text>
<text top="353" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="353" left="577" width="180" height="15" font="23">Online Data Supplement 10</text>
<text top="353" left="757" width="8" height="15" font="11">. </text>
<text top="373" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="373" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="373" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="433" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="433" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="394" left="255" width="13" height="15" font="14"><b>2.</b></text>
<text top="394" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="394" left="281" width="495" height="15" font="14"><b>Cardiac  catheterization  (hemodynamic  and/or  angiographic)  in  patients </b></text>
<text top="413" left="281" width="495" height="15" font="14"><b>with  ACHD  AP  classification  II  and  III,  or  interventional  cardiac </b></text>
<text top="433" left="281" width="495" height="15" font="14"><b>catheterization in patients with ACHD AP  classification I to III  should be </b></text>
<text top="453" left="281" width="495" height="15" font="14"><b>performed  by,  or  in  collaboration  with,  cardiologists  with  expertise  in </b></text>
<text top="472" left="281" width="175" height="15" font="14"><b>ACHD (S3.4.6-1–S3.4.6-4). </b></text>
<text top="522" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="522" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="492" left="255" width="13" height="15" font="14"><b>3.</b></text>
<text top="493" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="492" left="281" width="495" height="15" font="14"><b>In  patients  with  a  low  or  intermediate  pretest  probability  of  coronary </b></text>
<text top="512" left="281" width="495" height="15" font="14"><b>artery  disease  (CAD),  use  of  CT  coronary  angiography  is  reasonable  to </b></text>
<text top="532" left="281" width="495" height="15" font="14"><b>exclude  significant  obstructive  CAD  when  cardiac  catheterization  has </b></text>
<text top="551" left="281" width="455" height="15" font="14"><b>significant risk or because of patient preference (S3.4.6-5–S3.4.6-9). </b></text>
<text top="580" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="608" left="105" width="687" height="15" font="11">1. Cardiac catheterization remains a standard tool when diagnosis, prognosis, or management require a) </text>
<text top="628" left="105" width="687" height="15" font="11">more precise definition of anatomy than is achievable via advanced noninvasive imaging (e.g., structures </text>
<text top="648" left="105" width="687" height="15" font="11">with low flow or those shielded from other techniques), b) calculation of pressures and resistances, or c) </text>
<text top="667" left="105" width="687" height="15" font="11">physiological  or  anatomic  simulation  to  allow  additional  calculation  or  anatomic  visualization.  Cardiac </text>
<text top="687" left="105" width="687" height="15" font="11">catheterization  can  provide  unique information  not  reliably  available  from  other  diagnostic modalities </text>
<text top="707" left="105" width="687" height="15" font="11">(e.g.,  direct  pressure  measurement  in  a  vessel  or  chamber,  determination  of  pulmonary  artery  (PA) </text>
<text top="726" left="105" width="687" height="15" font="11">pressures  and  resistance,  and  optimal  imaging  of  vessels  in  which  flow  is  compromised).  Procedures </text>
<text top="746" left="105" width="687" height="15" font="11">should be planned with appreciation of the anatomy and physiology likely to be encountered, including </text>
<text top="765" left="105" width="370" height="15" font="11">sequelae and residua of prior surgery and interventions. </text>
<text top="794" left="158" width="634" height="15" font="11">The expansion of interventional catheter techniques has dramatically expanded possibilities for </text>
<text top="813" left="105" width="687" height="15" font="11">interventional treatment for an increasing number of conditions. Operators require specialized training </text>
<text top="833" left="105" width="687" height="15" font="11">and  expertise  in  ACHD.  In  addition,  catheterization  laboratories  specially  equipped  with  devices  and </text>
<text top="853" left="105" width="687" height="15" font="11">tools  used  in  ACHD  intervention  are  needed  and  personnel  trained  in  their  use.  Such  equipment  and </text>
<text top="872" left="105" width="687" height="15" font="11">expertise  differ  from  those  found  in  catheterization  laboratories  devoted  primarily  to  diagnostic </text>
<text top="892" left="105" width="287" height="15" font="11">catheterization and coronary interventions. </text>
<text top="920" left="105" width="687" height="15" font="11">2. For patients at low or intermediate risk of obstructive coronary disease, CT coronary angiography can </text>
<text top="940" left="105" width="611" height="15" font="11">be an alternative to cardiac catheterization for assessing coronary artery course and patency. </text>
<text top="972" left="105" width="4" height="15" font="11"> </text>
<text top="970" left="315" width="5" height="19" font="34"><b> </b></text>
</page>
<page number="32" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 31 </text>
<text top="163" left="105" width="192" height="19" font="34"><b>3.4.7. Exercise Testing </b></text>
<text top="199" left="271" width="4" height="14" font="11"> </text>
<text top="197" left="324" width="285" height="16" font="12"><b>Recommendations for Exercise Testing </b></text>
<text top="218" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="218" left="577" width="180" height="15" font="23">Online Data Supplement 11</text>
<text top="218" left="757" width="8" height="15" font="11">. </text>
<text top="238" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="238" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="238" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="278" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="278" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="259" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="259" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="259" left="281" width="495" height="15" font="14"><b>In  patients  with  ACHD,  cardiopulmonary  exercise  testing  (CPET)  can  be </b></text>
<text top="278" left="281" width="495" height="15" font="14"><b>useful  for  baseline  functional  assessment  and  serial  testing  (S3.4.7-1, </b></text>
<text top="298" left="281" width="67" height="15" font="14"><b>S3.4.7-2). </b></text>
<text top="338" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="338" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="318" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="318" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="318" left="281" width="495" height="15" font="14"><b>In  symptomatic patients with ACHD, a 6-minute  walk test can be useful </b></text>
<text top="338" left="281" width="495" height="15" font="14"><b>to objectively assess symptom severity, functional capacity, and response </b></text>
<text top="357" left="281" width="207" height="15" font="14"><b>to therapy (S3.4.7-3, S3.4.7-4). </b></text>
<text top="387" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="414" left="105" width="687" height="15" font="11">1.  Patients  with  ACHD  often  overestimate  their  physical  capabilities  and  underreport  limitations.  In </text>
<text top="434" left="105" width="687" height="15" font="11">contrast  to  patients  with  acquired  heart  disease,  patients  with  ACHD  may  never  have  experienced </text>
<text top="454" left="105" width="687" height="15" font="11">”normal”  function.  Decline  in  physical  capacity  may  occur  imperceptibly  over  many  years  (S3.4.7-1, </text>
<text top="473" left="105" width="687" height="15" font="11">S3.4.7-2). Consequently, tools more precise than patient history are necessary for evaluation and serial </text>
<text top="493" left="105" width="687" height="15" font="11">follow-up  of  functional  capacity.  CPET  provides  objective,  reproducible,  and  repeatable  assessment  of </text>
<text top="513" left="105" width="687" height="15" font="11">the cardiovascular, respiratory, and muscular systems and has been shown to have prognostic value in </text>
<text top="532" left="105" width="385" height="15" font="11">patients with a wide variety of ACHD conditions (S3.4.7-1). </text>
<text top="561" left="105" width="687" height="15" font="11">2. In severely impaired patients with ACHD, or those who cannot complete CPET for other reasons, the </text>
<text top="580" left="105" width="687" height="15" font="11">6-minute walk test provides a more limited set of data, which nevertheless has prognostic value beyond </text>
<text top="600" left="105" width="220" height="15" font="11">history alone (S3.4.7-3, S3.4.7-4). </text>
<text top="639" left="105" width="231" height="20" font="17"><b>3.5. Transition Education </b></text>
<text top="675" left="258" width="4" height="15" font="11"> </text>
<text top="674" left="310" width="313" height="16" font="12"><b>Recommendation for Transition Education </b></text>
<text top="695" left="106" width="480" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="695" left="587" width="180" height="15" font="23">Online Data Supplement 12</text>
<text top="695" left="766" width="8" height="15" font="11">. </text>
<text top="715" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="715" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="715" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="755" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="755" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="735" left="249" width="13" height="15" font="14"><b>1.</b></text>
<text top="735" left="262" width="4" height="15" font="24"><b> </b></text>
<text top="735" left="281" width="495" height="15" font="14"><b>Clinicians  caring  for  patients  with  CHD  should  deliver  developmentally </b></text>
<text top="755" left="281" width="495" height="15" font="14"><b>appropriate  transition  education  to  adolescent  and young  patients with </b></text>
<text top="775" left="281" width="402" height="15" font="14"><b>CHD, and to their families/support network (S3.5-1, S3.5-2). </b></text>
<text top="804" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="832" left="105" width="687" height="15" font="11">1.  Preparing  a  patient  for  independent  cardiac  care  is  an  ongoing  process  that  should  start  in  early </text>
<text top="851" left="105" width="687" height="15" font="11">adolescence  if  not  sooner  (S3.5-3)  and  may  extend  beyond  18  years  of  age  in  many  patients.  The </text>
<text top="871" left="105" width="687" height="15" font="11">recommendation  and  goals  for  transition  and  transition  education  have  been  described  and  include </text>
<text top="891" left="105" width="687" height="15" font="11">verbal, written, and experiential efforts to teach patients and families about their specific heart disease, </text>
<text top="910" left="105" width="687" height="15" font="11">expectations, and concerns regarding CHD, as well as skills to navigate the healthcare system as an adult </text>
<text top="930" left="105" width="687" height="15" font="11">(S3.5-4). Lack of education about the need for transition and lifelong cardiac care leads to gaps in care </text>
<text top="949" left="105" width="687" height="15" font="11">that  can  result  in  increased  hospitalizations,  need  for  urgent  intervention,  and  increased  morbidity </text>
<text top="969" left="105" width="687" height="15" font="11">(S3.5-5, S3.5-6). A structured approach to transition education improves health related knowledge and </text>
<text top="989" left="105" width="687" height="15" font="11">self-management (S3.5-1, S3.5-2). This education is a continual process that includes after transfer to an </text>
<text top="1008" left="105" width="194" height="15" font="11">ACHD care provider (S3.5-4).  </text>
<text top="1042" left="105" width="4" height="15" font="11"> </text>
<text top="1038" left="315" width="5" height="20" font="17"><b> </b></text>
</page>
<page number="33" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 32 </text>
<text top="164" left="105" width="220" height="20" font="17"><b>3.6. Exercise and Sports </b></text>
<text top="200" left="259" width="4" height="14" font="11"> </text>
<text top="199" left="311" width="310" height="16" font="12"><b>Recommendations for Exercise and Sports </b></text>
<text top="220" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="220" left="577" width="180" height="15" font="23">Online Data Supplement 13</text>
<text top="220" left="757" width="8" height="15" font="11">. </text>
<text top="240" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="240" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="240" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="280" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="280" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="260" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="261" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="260" left="281" width="495" height="15" font="14"><b>Clinicians  should  assess  activity  levels  at  regular  intervals  and  counsel </b></text>
<text top="280" left="281" width="494" height="15" font="14"><b>patients with ACHD about the types and intensity of exercise appropriate </b></text>
<text top="300" left="281" width="255" height="15" font="14"><b>to their clinical status (S3.6-1–S3.6-9). </b></text>
<text top="330" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="330" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="320" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="320" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="320" left="281" width="495" height="15" font="14"><b>CPET can be useful to guide  activity recommendations for patients with </b></text>
<text top="340" left="281" width="167" height="15" font="14"><b>ACHD (S3.6-10, S3.6-11). </b></text>
<text top="370" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="370" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="360" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="360" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="360" left="281" width="495" height="15" font="14"><b>Cardiac  rehabilitation  can  be  useful  to  increase  exercise  capacity  in </b></text>
<text top="380" left="281" width="259" height="15" font="14"><b>patients with ACHD (S3.6-12, S3.6-13). </b></text>
<text top="409" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="437" left="105" width="687" height="15" font="11">Historically, guidelines for physical activity among patients with CHD have focused on restriction, rather </text>
<text top="456" left="105" width="687" height="15" font="11">than promotion of activity (S3.6-14, S3.6-15). Because of fears of adverse events such as SCD or aortic </text>
<text top="476" left="105" width="687" height="15" font="11">dissection, recommendations derived from those that apply to competitive sports (S3.6-16) have been </text>
<text top="495" left="105" width="687" height="15" font="11">applied  to  recreational  activities  despite  the  absence  of  evidence  on  the  risk  or  safety  of  moderate </text>
<text top="515" left="105" width="687" height="15" font="11">activity.  The  2015  “Eligibility  and  Disqualification  Recommendations  for  Competitive  Athletes  With </text>
<text top="535" left="105" width="687" height="15" font="11">Cardiovascular  Abnormalities:  Task  Force  4:  Congenital  Heart  Disease”  (S3.6-14)  does  work  toward </text>
<text top="554" left="105" width="687" height="15" font="11">encouraging  participation  and  shared  decision-making  with  patients  regarding  competitive  sports </text>
<text top="574" left="105" width="687" height="15" font="11">participation. Most patients with ACHD can safely engage in regular, moderate physical activity. A few </text>
<text top="594" left="105" width="687" height="15" font="11">conditions,  such  as  systemic  ventricular  systolic  dysfunction,  systemic  ventricular  outflow  tract </text>
<text top="613" left="105" width="687" height="15" font="11">obstruction,  hemodynamically  significant  arrhythmias,  or  aortic  dilation,  warrant  more  cautious </text>
<text top="633" left="105" width="189" height="15" font="11">recommendations (S3.6-17). </text>
<text top="661" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="689" left="105" width="687" height="15" font="11">1. Physical  activity  is widely  recognized  as  being  beneficial  to  the  physical  and mental  health  of  those </text>
<text top="709" left="105" width="687" height="15" font="11">who  participate  (S3.6-2–S3.6-4).  There  is  conflicting  evidence  regarding  physical  activity  levels  in </text>
<text top="729" left="105" width="687" height="15" font="11">patients  with  CHD,  with  some  suggesting  the  tendency  for  less  activity  (S3.6-5,  S3.6-9)  and  a  greater </text>
<text top="748" left="105" width="687" height="15" font="11">prevalence of obesity (S3.6-1) than in the general population. Studies describe the beneficial effects and </text>
<text top="768" left="105" width="687" height="15" font="11">safety  of  exercise  programs  for  patients  across  the  spectrum  of  CHD  (S3.6-18,  S3.6-19).  Activity </text>
<text top="788" left="105" width="687" height="15" font="11">recommendations  should  be  individualized  based  on  the  patient’s  clinical  status  and  their  interests </text>
<text top="807" left="105" width="66" height="15" font="11">(S3.6-20). </text>
<text top="835" left="105" width="687" height="15" font="11">2. There is evidence that exercise capacity varies among congenital heart defects, with declining capacity </text>
<text top="855" left="105" width="687" height="15" font="11">(generally)  as  complexity  increases  (S3.6-10,  S3.6-11).  Knowledge  of  the  typical  exercise  capacity  for </text>
<text top="875" left="105" width="683" height="15" font="11">patients  with  a  specific  lesion  is  important  when  making  appropriate  activity  recommendations  (S3.6-</text>
<text top="894" left="105" width="687" height="15" font="11">10). Self-directed activity is usually at 40% to 60% of maximal exercise capacity, whereas fitness training </text>
<text top="914" left="105" width="687" height="15" font="11">occurs at 60% to 80% of maximal capacity (S3.6-20). Exercise capacity is defined in relation to maximal </text>
<text top="933" left="105" width="687" height="15" font="11">oxygen  consumption.  The  writing  committee  recognizes  that  not  all  ACHD  centers  will  have  the </text>
<text top="953" left="105" width="687" height="15" font="11">resources to conduct CPET, which is the preferred method of evaluation. If CPET cannot be performed, </text>
<text top="973" left="105" width="687" height="15" font="11">other  exercise  tests  using  an  established  treadmill  or  bicycle  ergometer  protocol  are  an  acceptable </text>
<text top="992" left="105" width="687" height="15" font="11">alternative  for  assessing  exercise  capacity,  recognizing  that  valuable  information  may  be  unavailable </text>
<text top="1012" left="105" width="143" height="15" font="11">compared with CPET. </text>
<text top="1040" left="105" width="687" height="15" font="11">3.  As  with  other  populations  of  cardiac  patients,  inactivity  leads  to  reduced  exercise  performance. </text>
<text top="1060" left="105" width="687" height="15" font="11">Regular exercise and cardiac rehabilitation may improve exercise capacity and HF symptoms, and ought </text>
<text top="1079" left="105" width="338" height="15" font="11">to be encouraged (S3.6-6, S3.6-7, S3.6-21, S3.6-22). </text>
</page>
<page number="34" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 34 </text>
<text top="164" left="105" width="473" height="20" font="17"><b>3.7. Mental Health and Neurodevelopmental Issues </b></text>
<text top="200" left="157" width="4" height="14" font="11"> </text>
<text top="199" left="210" width="513" height="16" font="12"><b>Recommendations for Mental Health and Neurodevelopmental Issues </b></text>
<text top="220" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="220" left="577" width="180" height="15" font="23">Online Data Supplement 14</text>
<text top="220" left="757" width="8" height="15" font="11">. </text>
<text top="240" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="240" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="240" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="270" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="270" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="260" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="261" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="260" left="281" width="495" height="15" font="14"><b>Patients  with  ACHD  should  be  evaluated  for  depression  and  anxiety </b></text>
<text top="280" left="281" width="108" height="15" font="14"><b>(S3.7-1–S3.7-3). </b></text>
<text top="310" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="310" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="300" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="301" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="300" left="281" width="495" height="15" font="14"><b>Referral  for  mental  health  evaluation  and  treatment  is  reasonable  in </b></text>
<text top="320" left="281" width="243" height="15" font="14"><b>patients with ACHD (S3.7-1–S3.7-4). </b></text>
<text top="360" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="360" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="340" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="341" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="340" left="281" width="495" height="15" font="14"><b>Neurodevelopmental or neuropsychological testing may be considered in </b></text>
<text top="360" left="281" width="494" height="15" font="14"><b>some  patients  with  ACHD  to  guide  therapies  that  enhance  academic, </b></text>
<text top="380" left="281" width="450" height="15" font="14"><b>behavioral, psychosocial, and adaptive functioning (S3.7-5–S3.7-9). </b></text>
<text top="409" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="437" left="105" width="687" height="15" font="11">Mental health and neurodevelopmental issues are common in patients with ACHD and may significantly </text>
<text top="456" left="105" width="687" height="15" font="11">affect QoL. Neurodevelopmental abnormalities are more frequently seen in children who have complex </text>
<text top="476" left="105" width="687" height="15" font="11">disease,  complex  surgical  repairs,  and  other  characteristics  (S3.7-10–S3.7-12).  There  is  extensive </text>
<text top="495" left="105" width="687" height="15" font="11">literature  in  the  pediatric  population  on  the  frequency  and  importance  of  neurodevelopmental </text>
<text top="515" left="105" width="687" height="15" font="11">abnormalities,  However,  many  adults  may  not  have  been  evaluated  as  children  in  accordance  with </text>
<text top="535" left="105" width="687" height="15" font="11">current diagnostic and  treatment  strategies (S3.7-13,  S3.7-14). Neurodevelopmental disorders, such as </text>
<text top="554" left="105" width="687" height="15" font="11">impairment  of  cognition,  social  skills  and  communication,  and  attention  disorders,  are  often </text>
<text top="574" left="105" width="687" height="15" font="11">underrecognized even though appropriate diagnosis, treatment, and rehabilitation may be beneficial in </text>
<text top="594" left="105" width="687" height="15" font="11">optimizing function and QoL. An AHA scientific statement  describes the common neurodevelopmental </text>
<text top="613" left="105" width="687" height="15" font="11">disorders affecting children with CHD and may inform neurodevelopmental issues related to adults with </text>
<text top="633" left="105" width="98" height="15" font="11">CHD (S3.7-13). </text>
<text top="661" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="689" left="105" width="687" height="15" font="11">1. Anxiety and depression are underrecognized in the ACHD population. Point-of-care assessment with </text>
<text top="709" left="105" width="595" height="15" font="11">simple questions about anxiety and depression should be included in the symptom review. </text>
<text top="737" left="105" width="687" height="15" font="11">2.  Anxiety  and  depression  are  prevalent  among  patients  with  ACHD.  Self-reported  symptoms  are </text>
<text top="757" left="105" width="687" height="15" font="11">incomplete to identify the existence of mood disorders. Structured professional psychological evaluation </text>
<text top="777" left="105" width="442" height="15" font="11">can identify up to 50% more patients with mood disorders (S3.7-1). </text>
<text top="805" left="105" width="687" height="15" font="11">3. Although there is limited evidence on neurodevelopmental and neuropsychological issues in patients </text>
<text top="825" left="105" width="687" height="15" font="11">with  ACHD,  there  is  increasing  evidence  of  the  neurodevelopmental  impact  of  CHD  and  surgery  in </text>
<text top="844" left="105" width="687" height="15" font="11">childhood  (S3.7-6,  S3.7-8,  S3.7-9).  It  is  likely  that  this  impact  will  persist  into  adulthood  and  may </text>
<text top="864" left="105" width="687" height="15" font="11">manifest in lower educational and occupational achievement. This is particularly evident in patients with </text>
<text top="883" left="105" width="382" height="15" font="11">genetic conditions such as 22q11 deletion and trisomy 21. </text>
<text top="922" left="105" width="261" height="20" font="17"><b>3.8. Endocarditis Prevention </b></text>
<text top="956" left="105" width="687" height="15" font="11">Patients with ACHD have an increased risk of developing infective endocarditis (IE) (S3.8-1, S3.8-2). The </text>
<text top="976" left="105" width="687" height="15" font="11">most common pathogens responsible for IE include <i>Streptococcus viridans,</i> <i>Staphylococcus</i> species, and </text>
<text top="996" left="105" width="687" height="14" font="15"><i>Enterococcus</i>  species.  Despite  advances  in  antimicrobial  therapy  and  surgical  techniques,  IE  remains  a </text>
<text top="1015" left="105" width="687" height="15" font="11">condition  associated  with  significant  morbidity  and  mortality.  Numerous  guidelines  are  available  with </text>
<text top="1035" left="105" width="687" height="15" font="11">recommendations  on  the  prevention  and  diagnosis  of  IE  (S3.8-3–S3.8-5).  These  guidelines  include </text>
<text top="1054" left="105" width="687" height="15" font="11">consistent  descriptions  of  the  patients  at  highest  risk  of  adverse  effects  from  endocarditis.  Antibiotic </text>
</page>
<page number="35" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 35 </text>
<text top="162" left="105" width="687" height="15" font="11">prophylaxis  continues  to  be  recommended  for  patients  with  high-risk  characteristics,  which  are  often </text>
<text top="182" left="105" width="402" height="15" font="11">found in patients with ACHD (S3.8-2). These patients include: </text>
<text top="206" left="131" width="7" height="21" font="25">•</text>
<text top="211" left="139" width="4" height="15" font="26"> </text>
<text top="211" left="158" width="155" height="15" font="11">Those with previous IE; </text>
<text top="227" left="131" width="7" height="21" font="25">•</text>
<text top="232" left="139" width="4" height="15" font="26"> </text>
<text top="231" left="158" width="567" height="15" font="11">Patients with prosthetic valves (biological and mechanical, surgical and transcatheter); </text>
<text top="247" left="131" width="7" height="21" font="25">•</text>
<text top="252" left="139" width="4" height="15" font="26"> </text>
<text top="252" left="158" width="406" height="15" font="11">Patients within 6 months of placement of prosthetic material; </text>
<text top="268" left="131" width="7" height="21" font="25">•</text>
<text top="272" left="139" width="4" height="15" font="26"> </text>
<text top="272" left="158" width="634" height="15" font="11">Patients  with  residual  intracardiac  shunts  at  the  site  of  or  adjacent  to  previous  repair  with </text>
<text top="292" left="158" width="220" height="15" font="11">prosthetic material or devices; or </text>
<text top="308" left="131" width="7" height="21" font="25">•</text>
<text top="313" left="139" width="4" height="15" font="26"> </text>
<text top="312" left="158" width="326" height="15" font="11">Patients with uncorrected cyanotic heart disease. </text>
<text top="341" left="105" width="362" height="15" font="11">See Online Data Supplement 15 for referenced studies. </text>
<text top="379" left="105" width="267" height="20" font="17"><b>3.9. Concomitant Syndromes </b></text>
<text top="416" left="243" width="4" height="15" font="11"> </text>
<text top="415" left="296" width="341" height="16" font="12"><b>Recommendation for Concomitant Syndromes </b></text>
<text top="435" left="106" width="480" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="435" left="587" width="180" height="15" font="23">Online Data Supplement 16</text>
<text top="435" left="766" width="8" height="15" font="11">. </text>
<text top="456" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="456" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="456" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="486" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="486" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="476" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="476" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="476" left="281" width="495" height="15" font="14"><b>Genetic  testing  for  22q11  deletions  is  reasonable  for  patients  with </b></text>
<text top="496" left="281" width="295" height="15" font="14"><b>conotruncal cardiac defects (S3.9-1, S3.9-2). </b></text>
<text top="525" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="553" left="105" width="687" height="15" font="11">Patients  with  genetic  syndromes  may  have  phenotypic  manifestations  and  associated  CHD  as  clinical </text>
<text top="572" left="105" width="687" height="15" font="11">features  of  the  genetic  abnormality.  An  underlying  chromosomal  abnormality exists  in  at  least  10%  of </text>
<text top="592" left="105" width="687" height="15" font="11">infants  with  CHD  and  may  not  have  been  previously  tested  in  patients  with  ACHD  (S3.9-3).  Clinicians </text>
<text top="612" left="105" width="687" height="15" font="11">caring for patients with ACHD should recognize the potential for undiagnosed genetic abnormalities that </text>
<text top="631" left="105" width="469" height="15" font="11">may affect overall health (Table 10) and pursue appropriate evaluation. </text>
<text top="660" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="688" left="105" width="687" height="15" font="11">1. Several forms of CHD may be associated with underlying genetic syndromes (Table 10). Some genetic </text>
<text top="708" left="105" width="687" height="15" font="11">syndromes may not be phenotypically apparent in adults, and prior childhood genetic workup may not </text>
<text top="727" left="105" width="687" height="15" font="11">be readily available; therefore, genetic syndromes may be missed in patients with ACHD. Many of these </text>
<text top="747" left="105" width="687" height="15" font="11">syndromes may have important clinical comorbidities, including but not limited to learning disabilities, </text>
<text top="767" left="105" width="687" height="15" font="11">psychiatric conditions, and reproductive disorders. Up to 5% of children born with CHD have DiGeorge </text>
<text top="786" left="105" width="687" height="15" font="11">syndrome  (22q11.2  deletion),  the  congenital  heart  defects  most  commonly  associated  being  those  of </text>
<text top="806" left="105" width="687" height="15" font="11">conotruncal origin. DiGeorge syndrome is an autosomal dominant condition. Therefore, genetic testing </text>
<text top="825" left="105" width="687" height="15" font="11">is  reasonable  for  patients  with  ACHD  with  conotruncal  defects  for  recognition  and  management  of </text>
<text top="845" left="105" width="629" height="15" font="11">comorbidities and for counseling on the potential risk of recurrence in offspring (S3.9-4, S3.9-5). </text>
<text top="873" left="105" width="4" height="15" font="11"> </text>
<text top="902" left="105" width="598" height="15" font="14"><b>Table 10. Underlying Genetic Syndromes Commonly Associated With CHD (S3.9-4, S3.9-6) </b></text>
<text top="943" left="135" width="65" height="13" font="7"><b>Syndrome </b></text>
<text top="925" left="277" width="50" height="13" font="7"><b>Genetic </b></text>
<text top="943" left="262" width="79" height="13" font="7"><b>Abnormality </b></text>
<text top="943" left="438" width="102" height="13" font="7"><b>Clinical Features </b></text>
<text top="925" left="643" width="106" height="13" font="7"><b>Common Cardiac </b></text>
<text top="943" left="670" width="53" height="13" font="7"><b>Findings </b></text>
<text top="961" left="105" width="122" height="13" font="8">DiGeorge syndrome </text>
<text top="979" left="105" width="101" height="13" font="8">(velocardiofacial </text>
<text top="997" left="105" width="67" height="13" font="8">syndrome) </text>
<text top="961" left="243" width="104" height="13" font="8">22q11.2 deletion </text>
<text top="961" left="374" width="215" height="13" font="8">Thymic and parathyroid hypoplasia, </text>
<text top="979" left="374" width="196" height="13" font="8">immunodeficiency, low-set ears, </text>
<text top="997" left="374" width="211" height="13" font="8">hypocalcemia, speech and learning </text>
<text top="1014" left="374" width="231" height="13" font="8">disorders, renal anomalies, psychiatric </text>
<text top="1032" left="374" width="47" height="13" font="8">disease </text>
<text top="1050" left="374" width="211" height="13" font="8">25%–75% have CHD, depending on </text>
<text top="1068" left="374" width="165" height="13" font="8">age studied (S3.9-7, S3.9-8) </text>
<text top="961" left="617" width="135" height="13" font="8">IAA type B, aortic arch </text>
<text top="979" left="617" width="116" height="13" font="8">anomalies, truncus </text>
<text top="997" left="617" width="93" height="13" font="8">arteriosus, TOF </text>
<text top="1086" left="105" width="101" height="13" font="8">Down syndrome </text>
<text top="1086" left="243" width="69" height="13" font="8">Trisomy 21 </text>
<text top="1086" left="374" width="154" height="13" font="8">Developmental disability, </text>
<text top="1086" left="617" width="128" height="13" font="8">ASD, VSD, AVSD, TOF </text>
</page>
<page number="36" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 36 </text>
<text top="162" left="374" width="174" height="13" font="8">characteristic facial features, </text>
<text top="180" left="374" width="154" height="13" font="8">hypotonia, palmar crease </text>
<text top="198" left="374" width="122" height="13" font="8">40%–50% have CHD </text>
<text top="217" left="105" width="69" height="13" font="8">Holt–Oram </text>
<text top="234" left="105" width="112" height="13" font="8">syndrome (S3.9-9) </text>
<text top="217" left="243" width="33" height="13" font="8">TBX5 </text>
<text top="217" left="374" width="203" height="13" font="8">Upper limb skeletal abnormalities </text>
<text top="234" left="374" width="90" height="13" font="8">75% have CHD </text>
<text top="217" left="617" width="133" height="13" font="8">ASD, VSD, MV disease </text>
<text top="253" left="105" width="65" height="13" font="8">Klinefelter </text>
<text top="271" left="105" width="63" height="13" font="8">syndrome </text>
<text top="253" left="243" width="44" height="13" font="8">47 XXY </text>
<text top="253" left="374" width="187" height="13" font="8">Tall stature, hypoplastic testes, </text>
<text top="271" left="374" width="197" height="13" font="8">delayed puberty, developmental </text>
<text top="289" left="374" width="56" height="13" font="8">disability </text>
<text top="306" left="374" width="90" height="13" font="8">50% have CHD </text>
<text top="253" left="617" width="142" height="13" font="8">PDA, ASD, MV prolapse </text>
<text top="325" left="105" width="113" height="13" font="8">Noonan syndrome </text>
<text top="343" left="105" width="57" height="13" font="8">(S3.9-10) </text>
<text top="325" left="243" width="91" height="13" font="8">PTPN11, KRAS, </text>
<text top="343" left="243" width="111" height="13" font="8">SOS1 RAF1, NRAS, </text>
<text top="361" left="243" width="92" height="13" font="8">BRAF, MAP2K1 </text>
<text top="325" left="374" width="225" height="13" font="8">Facial anomalies, webbed neck, chest </text>
<text top="343" left="374" width="211" height="13" font="8">deformity, short stature, lymphatic </text>
<text top="361" left="374" width="228" height="13" font="8">abnormalities, bleeding abnormalities </text>
<text top="378" left="374" width="90" height="13" font="8">80% have CHD </text>
<text top="325" left="617" width="85" height="13" font="8">PS, ASD, HCM </text>
<text top="397" left="105" width="106" height="13" font="8">Turner syndrome </text>
<text top="397" left="243" width="26" height="13" font="8">45X </text>
<text top="397" left="374" width="171" height="13" font="8">Short stature, webbed neck, </text>
<text top="415" left="374" width="211" height="13" font="8">lymphedema, primary amenorrhea </text>
<text top="433" left="374" width="90" height="13" font="8">30% have CHD </text>
<text top="450" left="374" width="143" height="13" font="8">Risk of aortic dissection </text>
<text top="397" left="617" width="145" height="13" font="8">Coarctation, BAV, aortic </text>
<text top="415" left="617" width="149" height="13" font="8">stenosis, hypoplastic left </text>
<text top="433" left="617" width="102" height="13" font="8">heart, ascending </text>
<text top="450" left="617" width="70" height="13" font="8">aortopathy </text>
<text top="469" left="105" width="117" height="13" font="8">Williams syndrome </text>
<text top="469" left="243" width="104" height="13" font="8">7q11.23 deletion </text>
<text top="469" left="374" width="219" height="13" font="8">Elfin face, social personality, hearing </text>
<text top="487" left="374" width="213" height="13" font="8">loss, developmental delay, infantile </text>
<text top="505" left="374" width="90" height="13" font="8">hypercalcemia </text>
<text top="523" left="374" width="122" height="13" font="8">50%–80% have CHD </text>
<text top="469" left="617" width="111" height="13" font="8">Supravalvar aortic </text>
<text top="487" left="617" width="137" height="13" font="8">stenosis, peripheral PS </text>
<text top="541" left="105" width="686" height="12" font="9">ASD  indicates  atrial  septal  defect;  AVSD,  atrioventricular  septal  defect;  BAV,  bicuspid  aortic  valve;  CHD,  congenital  heart </text>
<text top="557" left="105" width="686" height="12" font="9">disease; HCM, hypertrophic cardiomyopathy; IAA, interrupted aortic arch; MV, mitral valve; PDA, patent ductus arteriosus; PS, </text>
<text top="573" left="105" width="426" height="12" font="9">pulmonary stenosis; TOF, tetralogy of Fallot; and VSD, ventricular septal defect. </text>
<text top="609" left="105" width="350" height="20" font="17"><b>3.10. Acquired Cardiovascular Disease </b></text>
<text top="643" left="105" width="687" height="15" font="11">Patients  with  ACHD  can  acquire  other  cardiovascular  diseases  such  as  hypertension,  atherosclerotic </text>
<text top="662" left="105" width="687" height="15" font="11">coronary  artery  disease,  vascular  disease,  stroke,  and  HF  (S3.10-1–S3.10-3).  The  impact  of  acquired </text>
<text top="682" left="105" width="687" height="15" font="11">heart disease is increasing as the lifespan of patients with ACHD extends. Myocardial infarction is one of </text>
<text top="701" left="105" width="687" height="15" font="11">the  leading  contributing  causes  of  death  for  late  surviving  adults  with  acyanotic  CHD  (S3.10-4).  Major </text>
<text top="721" left="105" width="687" height="15" font="11">adverse  cardiac  events,  such  as  HF,  percutaneous  coronary  intervention,  coronary  artery  bypass  graft </text>
<text top="740" left="105" width="687" height="15" font="11">surgery, malignant arrhythmia, cardiac shock, and placement of an implantable cardioverter-defibrillator </text>
<text top="760" left="105" width="687" height="15" font="11">(ICD),  are  also  quite  prevalent  (S3.10-5,  S3.10-6).  Overall,  cardiovascular  reasons  account  for </text>
<text top="780" left="105" width="687" height="15" font="11">approximately 77% of all deaths in patients with ACHD, with approximately half attributable to chronic </text>
<text top="799" left="105" width="687" height="15" font="11">HF  (S3.10-7).  Evaluation  for  acquired  cardiac  conditions  is  warranted  in  patients  with  risk  factors, </text>
<text top="819" left="105" width="687" height="15" font="11">although  results  of  testing  (e.g., stress  perfusion  studies)  should  account  for  preexisting  abnormalities </text>
<text top="839" left="105" width="687" height="15" font="11">caused  by  CHD,  recognizing  prior  interventions  can  mimic  abnormalities  otherwise  suggestive  of </text>
<text top="858" left="105" width="218" height="15" font="11">acquired heart disease (S3.10-8). </text>
<text top="886" left="158" width="634" height="15" font="11">In  patients  with  ACHD,  prevention  and  treatment  of  conditions  predisposing  to  acquired </text>
<text top="906" left="105" width="687" height="15" font="11">cardiovascular  disease  such  as  diabetes  mellitus,  obesity,  hypertension,  dyslipidemia,  and/or  similar </text>
<text top="925" left="105" width="687" height="15" font="11">comorbidities  are  important.  Given  the  increased  risk  of  acquired  cardiovascular  disease  with  age, </text>
<text top="945" left="105" width="687" height="15" font="11">promoting  a  healthy  lifestyle  is  important  in  all  patients  with  ACHD,  although  there  are  not  data </text>
<text top="965" left="105" width="687" height="15" font="11">demonstrating  the  effects  of  risk  reduction  on  clinical  outcomes  specific  to  the  ACHD  population. </text>
<text top="985" left="105" width="687" height="15" font="11">Emphasizing  the  importance  of  daily  physical  activity  according  to  functional  capacity,  and  decreasing </text>
<text top="1004" left="105" width="687" height="15" font="11">sedentary behavior as appropriate for the patient’s clinical status is essential when counseling patients </text>
<text top="1024" left="105" width="687" height="15" font="11">with congenital heart defects (S3.10-9). Interestingly, most patients with ACHD lead healthier lifestyles </text>
<text top="1043" left="105" width="687" height="15" font="11">compared with control patients (S3.10-10), suggesting that this patient population may be receptive to </text>
<text top="1063" left="105" width="687" height="15" font="11">advice  and  may  continue  to  benefit  from  recommendations  about  diet,  activity,  and  modifiable  risk </text>
<text top="1082" left="105" width="56" height="15" font="11">factors.  </text>
</page>
<page number="37" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="35" size="14" family="Times" color="#0000ff"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 37 </text>
<text top="162" left="105" width="362" height="15" font="11">See Online Data Supplement 17 for referenced studies. </text>
<text top="201" left="105" width="295" height="20" font="17"><b>3.11. Noncardiac Medical Issues </b></text>
<text top="237" left="237" width="4" height="15" font="11"> </text>
<text top="236" left="289" width="355" height="16" font="12"><b>Recommendation for Noncardiac Medical Issues </b></text>
<text top="257" left="106" width="480" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="257" left="587" width="180" height="15" font="23">Online Data Supplement 18</text>
<text top="257" left="766" width="8" height="15" font="11">. </text>
<text top="277" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="277" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="277" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="307" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="307" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="298" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="298" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="298" left="281" width="494" height="15" font="14"><b>Patients  with  ACHD  at  risk  for  hepatitis  C  should  be  screened  and </b></text>
<text top="317" left="281" width="444" height="15" font="14"><b>vaccinated for viral hepatitis and treated as appropriate (S3.11-1). </b></text>
<text top="346" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="374" left="105" width="687" height="15" font="11">1.  Patients  with  ACHD  are  at  risk  of  hepatitis  C  because  of  blood  exposure  during  cardiac  surgery. </text>
<text top="394" left="105" width="687" height="15" font="11">Hepatitis  screening  is  warranted  especially  in  those  with  exposure  to  blood  products  before  universal </text>
<text top="414" left="105" width="687" height="15" font="11">screening  for  hepatitis  C,  which  began  in  1992.  Hepatitis  vaccination  and/or  consultation  with  a </text>
<text top="433" left="105" width="687" height="15" font="11">hepatologist  should  also  be  offered  where  appropriate,  particularly  in  patients  with  ACHD  with </text>
<text top="453" left="105" width="321" height="15" font="11">concomitant liver disease (e.g., Fontan patients). </text>
<text top="492" left="105" width="232" height="20" font="17"><b>3.12. Noncardiac Surgery </b></text>
<text top="528" left="258" width="4" height="15" font="11"> </text>
<text top="527" left="311" width="311" height="16" font="12"><b>Recommendations for Noncardiac Surgery </b></text>
<text top="547" left="116" width="461" height="15" font="11">Referenced studies that support recommendations<b> </b>are summarized in </text>
<text top="547" left="577" width="180" height="15" font="23">Online Data Supplement<b> </b>18</text>
<text top="547" left="757" width="8" height="15" font="11">. </text>
<text top="568" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="568" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="568" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="608" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="608" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="588" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="589" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="588" left="281" width="494" height="15" font="14"><b>Optimization  before  and  close  surveillance  after  invasive  procedures, </b></text>
<text top="608" left="281" width="494" height="15" font="14"><b>regardless of the complexity of the anatomic defect or type of procedure </b></text>
<text top="628" left="281" width="364" height="15" font="14"><b>is beneficial for patients with ACHD (S3.12-1–S3.12-4). </b></text>
<text top="677" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="677" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="648" left="255" width="13" height="15" font="14"><b>2.</b></text>
<text top="648" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="648" left="274" width="501" height="15" font="14"><b>In patients with ACHD AP classification IB-D, IIA-D, and IIIA-D* noncardiac </b></text>
<text top="668" left="274" width="501" height="15" font="14"><b>surgical and interventional procedures should be performed in a hospital </b></text>
<text top="687" left="274" width="501" height="15" font="14"><b>with  or  in  consultation  with  experts  in  ACHD  when  possible  (S3.12-1, </b></text>
<text top="707" left="274" width="177" height="15" font="14"><b>S3.12-3, S3.12-5–S3.12-9). </b></text>
<text top="726" left="105" width="369" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system. </text>
<text top="752" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="780" left="105" width="687" height="15" font="11">Patients with ACHD may have greater operative  risk than patients without  ACHD.  The ”2014 ACC/AHA </text>
<text top="800" left="105" width="687" height="15" font="11">Guideline  on  Perioperative  Cardiovascular  Evaluation  and  Management  of  Patients  Undergoing </text>
<text top="819" left="105" width="687" height="15" font="11">Noncardiac Surgery” (S3.12-10) may be applied; however, those guidelines may not apply directly. One </text>
<text top="839" left="105" width="687" height="15" font="11">must  remain  cognizant  that  there  are  differences in cardiac issues  commonly  present in  patients  with </text>
<text top="859" left="105" width="687" height="15" font="11">ACHD,  such  as  mechanisms  for  ventricular  dysfunction,  type  and  mechanisms  of  arrhythmia,  and  the </text>
<text top="878" left="105" width="687" height="15" font="11">probability  of  coronary  artery  disease.  The  2014  guideline  (S3.12-10)  was  developed  primarily  with </text>
<text top="898" left="105" width="687" height="15" font="11">evidence and experience derived from,  and related to, patients with  acquired heart disease. Thus, the </text>
<text top="917" left="105" width="687" height="15" font="11">evidence supporting recommendations regarding risk indices and management strategies may not apply </text>
<text top="937" left="105" width="192" height="15" font="11">to many patients with ACHD. </text>
<text top="965" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="994" left="105" width="687" height="15" font="11">1.  A  checklist  of  issues  to  consider  in  the  assessment  and  management  of  patients  with  ACHD </text>
<text top="1013" left="105" width="687" height="15" font="11">undergoing  noncardiac  surgery  is  presented  in  Table  11.  Patients  with  ACHD  may  present  with </text>
<text top="1033" left="105" width="687" height="15" font="11">nonroutine  and  unusual  physiological  challenges  (e.g.,  those  related  to  fluid  balance  in  the  setting  of </text>
<text top="1052" left="105" width="687" height="15" font="11">single ventricle or the impact of vascular resistances on shunts in cyanotic patients) (S3.12-2–S3.12-4). </text>
</page>
<page number="38" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 38 </text>
<text top="162" left="105" width="687" height="15" font="11">Heightened  surveillance  may  mandate  extended  postoperative  intensive  or  other  high-acuity  care </text>
<text top="182" left="105" width="66" height="15" font="11">(S3.12-2). </text>
<text top="210" left="105" width="687" height="15" font="11">2. Case series and analysis of administrative databases confirm that surgical procedures in patients with </text>
<text top="229" left="105" width="684" height="15" font="11">ACHD  carry  greater  risk  than  in  patients  without  ACHD  (S3.12-1–S3.12-3,  S3.12-6,  S3.12-8,  S3.12-11–</text>
<text top="249" left="105" width="687" height="15" font="11">S3.12-13).  Risk  relates  to  the  specific  type  of  ACHD,  surgical  procedure,  urgency  of  intervention,  and </text>
<text top="268" left="105" width="687" height="15" font="11">availability of specialized resources (S3.12-1, S3.12-3–S3.12-6, S3.12-8, S3.12-14). Noncardiac surgery is </text>
<text top="288" left="105" width="687" height="15" font="11">usually  accomplished  without  substantial  morbidity  or  mortality,  but  even  minor  surgery  can  be </text>
<text top="308" left="105" width="687" height="15" font="11">complicated in patients with ACHD. Surgery that is low risk in the general population may be associated </text>
<text top="328" left="105" width="687" height="15" font="11">with  higher  risk  in  the  ACHD  population  (S3.12-1,  S3.12-6).  Patients  with  ACHD  may  present  with </text>
<text top="347" left="105" width="687" height="15" font="11">nonroutine  and  unusual  physiological  challenges  (e.g.,  those  related  to  fluid  balance  in  the  setting  of </text>
<text top="367" left="105" width="669" height="15" font="11">single ventricle or the impact of vascular resistances on shunts in cyanotic patients) (S3.12-2, S3.12-4). </text>
<text top="395" left="158" width="634" height="15" font="11">When  possible,  patients  with  ACHD,  especially  those  with  complex  disease  (ACHD  AP </text>
<text top="415" left="105" width="687" height="15" font="11">classification  II  and  III)  and/or  whose  disease  has  progressed  (stages  B,  C,  D)  (Tables  3  and  4),  should </text>
<text top="434" left="105" width="687" height="15" font="11">receive preoperative evaluation and surgery or other nonsurgical intervention within an ACHD program. </text>
<text top="454" left="105" width="687" height="15" font="11">Because  the  inability  to  access  resources  or  urgent  conditions  may  preclude  transfer  or  timely </text>
<text top="473" left="105" width="687" height="15" font="11">consultation,  collaboration  with  members  of  the  multidisciplinary  ACHD  team  may  be  helpful.  Clear </text>
<text top="493" left="105" width="687" height="15" font="11">processes  for  timely  consultation  and  support  are  needed  to  manage  the  physiological  challenges </text>
<text top="513" left="105" width="687" height="15" font="11">presented  by  patients  with  ACHD  related  to  fluid  balance,  vascular  resistance,  and  shunts  (S3.12-3, </text>
<text top="532" left="105" width="687" height="15" font="11">S3.12-4).  A  checklist  of  issues  to  consider  in  assessment  and  management  of  patients  with  ACHD </text>
<text top="552" left="105" width="369" height="15" font="11">undergoing noncardiac surgery is presented in Table 11. </text>
<text top="580" left="105" width="400" height="15" font="14"><b>Table 11. ACHD Management Issues for Noncardiac Surgery </b></text>
<text top="604" left="105" width="131" height="13" font="7"><b>Clarify CHD diagnosis </b></text>
<text top="622" left="105" width="12" height="16" font="8"></text>
<text top="622" left="116" width="4" height="13" font="20"> </text>
<text top="622" left="131" width="374" height="13" font="8">Clarify prior procedures, residua, sequelae, and current status, </text>
<text top="640" left="131" width="193" height="13" font="8">including ACHD AP classification </text>
<text top="658" left="105" width="12" height="16" font="8"></text>
<text top="658" left="116" width="4" height="13" font="20"> </text>
<text top="658" left="131" width="343" height="13" font="8">Be aware that history obtained from only the patient and </text>
<text top="676" left="131" width="210" height="13" font="8">family may be faulty or incomplete </text>
<text top="695" left="105" width="12" height="16" font="8"></text>
<text top="695" left="116" width="4" height="13" font="20"> </text>
<text top="695" left="131" width="297" height="13" font="8">Obtain and review old records to ensure accurate </text>
<text top="712" left="131" width="316" height="13" font="8">understanding of past procedures and clinical course </text>
<text top="731" left="105" width="12" height="16" font="8"></text>
<text top="731" left="116" width="4" height="13" font="20"> </text>
<text top="731" left="131" width="358" height="13" font="8">Complete additional investigations required to define ACHD </text>
<text top="749" left="131" width="98" height="13" font="8">AP classification </text>
<text top="768" left="105" width="12" height="16" font="8"></text>
<text top="768" left="116" width="4" height="13" font="20"> </text>
<text top="767" left="131" width="374" height="13" font="8">Develop management strategies to minimize risk and optimize </text>
<text top="785" left="131" width="56" height="13" font="8">outcome </text>
<text top="804" left="105" width="396" height="13" font="7"><b>Factors associated with increased risk of perioperative morbidity </b></text>
<text top="822" left="105" width="155" height="13" font="7"><b>and mortality (S3.12-12): </b></text>
<text top="836" left="117" width="7" height="19" font="19">•</text>
<text top="841" left="123" width="4" height="13" font="20"> </text>
<text top="840" left="143" width="55" height="13" font="8">Cyanosis </text>
<text top="855" left="117" width="7" height="19" font="19">•</text>
<text top="859" left="123" width="4" height="13" font="20"> </text>
<text top="859" left="143" width="88" height="13" font="8">Congestive HF </text>
<text top="874" left="117" width="7" height="19" font="19">•</text>
<text top="878" left="123" width="4" height="13" font="20"> </text>
<text top="877" left="143" width="120" height="13" font="8">Poor general health </text>
<text top="892" left="117" width="7" height="19" font="19">•</text>
<text top="896" left="123" width="4" height="13" font="20"> </text>
<text top="896" left="143" width="77" height="13" font="8">Younger age </text>
<text top="911" left="117" width="7" height="19" font="19">•</text>
<text top="915" left="123" width="4" height="13" font="20"> </text>
<text top="915" left="143" width="149" height="13" font="8">Pulmonary hypertension </text>
<text top="929" left="117" width="7" height="19" font="19">•</text>
<text top="934" left="123" width="4" height="13" font="20"> </text>
<text top="933" left="143" width="307" height="13" font="8">Operations on the respiratory and nervous systems </text>
<text top="948" left="117" width="7" height="19" font="19">•</text>
<text top="952" left="123" width="4" height="13" font="20"> </text>
<text top="952" left="143" width="84" height="13" font="8">Complex CHD </text>
<text top="966" left="117" width="7" height="19" font="19">•</text>
<text top="971" left="123" width="4" height="13" font="20"> </text>
<text top="970" left="143" width="187" height="13" font="8">Urgent/emergency procedures </text>
<text top="989" left="105" width="115" height="13" font="7"><b>Issues to consider: </b></text>
<text top="1004" left="117" width="7" height="19" font="19">•</text>
<text top="1008" left="123" width="4" height="13" font="20"> </text>
<text top="1007" left="143" width="148" height="13" font="8">Endocarditis prophylaxis </text>
<text top="1022" left="117" width="7" height="19" font="19">•</text>
<text top="1027" left="123" width="4" height="13" font="20"> </text>
<text top="1026" left="143" width="309" height="13" font="8">Complications related to underlying hemodynamics </text>
<text top="1041" left="117" width="7" height="19" font="19">•</text>
<text top="1045" left="123" width="4" height="13" font="20"> </text>
<text top="1045" left="143" width="356" height="13" font="8">Abnormal venous and/or arterial anatomy affecting venous </text>
<text top="1063" left="143" width="113" height="13" font="8">and arterial access </text>
<text top="1077" left="117" width="7" height="19" font="19">•</text>
<text top="1082" left="123" width="4" height="13" font="20"> </text>
<text top="1081" left="143" width="105" height="13" font="8">Persistent shunts </text>
</page>
<page number="39" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 39 </text>
<text top="159" left="117" width="7" height="19" font="19">•</text>
<text top="164" left="123" width="4" height="13" font="20"> </text>
<text top="163" left="143" width="99" height="13" font="8">Valvular disease </text>
<text top="178" left="117" width="7" height="19" font="19">•</text>
<text top="182" left="123" width="4" height="13" font="20"> </text>
<text top="182" left="143" width="246" height="13" font="8">Arrhythmias, including bradyarrhythmias </text>
<text top="196" left="117" width="7" height="19" font="19">•</text>
<text top="201" left="123" width="4" height="13" font="20"> </text>
<text top="200" left="143" width="88" height="13" font="8">Erythrocytosis </text>
<text top="215" left="117" width="7" height="19" font="19">•</text>
<text top="219" left="123" width="4" height="13" font="20"> </text>
<text top="219" left="143" width="167" height="13" font="8">Pulmonary vascular disease </text>
<text top="234" left="117" width="7" height="19" font="19">•</text>
<text top="238" left="123" width="4" height="13" font="20"> </text>
<text top="238" left="143" width="359" height="13" font="8">Meticulous line care (also consider air filters for intravenous </text>
<text top="255" left="143" width="346" height="13" font="8">lines) to reduce risk of paradoxic embolus in patients who </text>
<text top="273" left="143" width="258" height="13" font="8">are cyanotic because of right-to-left shunts </text>
<text top="288" left="117" width="7" height="19" font="19">•</text>
<text top="292" left="123" width="4" height="13" font="20"> </text>
<text top="292" left="143" width="327" height="13" font="8">Adjustment of anticoagulant volume in tubes for some </text>
<text top="310" left="143" width="193" height="13" font="8">blood work in cyanotic patients  </text>
<text top="324" left="117" width="7" height="19" font="19">•</text>
<text top="329" left="123" width="4" height="13" font="20"> </text>
<text top="328" left="143" width="200" height="13" font="8">Prevention of venous thrombosis </text>
<text top="343" left="117" width="7" height="19" font="19">•</text>
<text top="347" left="123" width="4" height="13" font="20"> </text>
<text top="347" left="143" width="227" height="13" font="8">Monitoring of renal and liver function </text>
<text top="362" left="117" width="7" height="19" font="19">•</text>
<text top="366" left="123" width="4" height="13" font="20"> </text>
<text top="366" left="143" width="184" height="13" font="8">Periprocedure anticoagulation </text>
<text top="380" left="117" width="7" height="19" font="19">•</text>
<text top="384" left="123" width="4" height="13" font="20"> </text>
<text top="384" left="143" width="281" height="13" font="8">Possible need for nonconventional drug dosing </text>
<text top="399" left="117" width="7" height="19" font="19">•</text>
<text top="403" left="123" width="4" height="13" font="20"> </text>
<text top="403" left="143" width="334" height="13" font="8">Increased prevalence of hepatitis C infection because of </text>
<text top="420" left="143" width="289" height="13" font="8">prior procedures and remote blood transfusions </text>
<text top="435" left="117" width="7" height="19" font="19">•</text>
<text top="440" left="123" width="4" height="13" font="20"> </text>
<text top="439" left="143" width="150" height="13" font="8">Developmental disability </text>
<text top="457" left="105" width="417" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  AP,  anatomic  and </text>
<text top="474" left="105" width="357" height="12" font="9">physiological; CHD, congenital heart disease; and HF, heart failure. </text>
<text top="509" left="105" width="459" height="20" font="17"><b>3.13. Pregnancy, Reproduction, and Sexual Health </b></text>
<text top="557" left="105" width="155" height="19" font="34"><b>3.13.1. Pregnancy </b></text>
<text top="592" left="291" width="4" height="15" font="11"> </text>
<text top="591" left="344" width="245" height="16" font="12"><b>Recommendations for Pregnancy </b></text>
<text top="611" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="611" left="577" width="180" height="15" font="23">Online Data Supplement 19</text>
<text top="611" left="757" width="8" height="15" font="11">. </text>
<text top="632" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="632" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="632" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="682" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="682" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="652" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="653" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="652" left="281" width="495" height="15" font="14"><b>Women  with  CHD  should  receive  prepregnancy  counseling  with  input </b></text>
<text top="672" left="281" width="495" height="15" font="14"><b>from an ACHD cardiologist to determine maternal cardiac, obstetrical and </b></text>
<text top="692" left="281" width="491" height="15" font="14"><b>fetal  risks,  and  potential  long-term  risks  to  the  mother  (S3.13.1-1–</b></text>
<text top="711" left="281" width="75" height="15" font="14"><b>S3.13.1-4). </b></text>
<text top="761" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="761" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="732" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="732" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="732" left="281" width="495" height="15" font="14"><b>An  individualized  plan  of  care  that  addresses  expectations  and </b></text>
<text top="751" left="281" width="495" height="15" font="14"><b>contingencies  should  be  developed  for  and  with  women  with  CHD  who </b></text>
<text top="771" left="281" width="495" height="15" font="14"><b>are pregnant or who may become pregnant and shared with the patient </b></text>
<text top="790" left="281" width="269" height="15" font="14"><b>and all caregivers (S3.13.1-2, S3.13.1-3). </b></text>
<text top="830" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="830" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="811" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="811" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="811" left="281" width="495" height="15" font="14"><b>Women with CHD receiving chronic anticoagulation should be counseled, </b></text>
<text top="830" left="281" width="494" height="15" font="14"><b>ideally  before  conception,  on  the  risks  and  benefits  of  specific </b></text>
<text top="850" left="281" width="371" height="15" font="14"><b>anticoagulants during pregnancy (S3.13.1-5, S3.13.1-6). </b></text>
<text top="900" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="900" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="870" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="870" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="870" left="281" width="495" height="15" font="14"><b>Women  with  ACHD  AP  classification  IB-D,  IIA-D,  and  IIIA-D*  should  be </b></text>
<text top="890" left="281" width="495" height="15" font="14"><b>managed  collaboratively  during  pregnancy  by  ACHD  cardiologists, </b></text>
<text top="910" left="281" width="495" height="15" font="14"><b>obstetricians,  and  anesthesiologists  experienced  in  ACHD  (S3.13.1-2, </b></text>
<text top="929" left="281" width="144" height="15" font="14"><b>S3.13.1-7, S3.13.1-8). </b></text>
<text top="1008" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1008" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="949" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="950" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="949" left="281" width="494" height="15" font="14"><b>In  collaboration  with  an  ACHD  cardiologist  to  ensure  accurate </b></text>
<text top="969" left="281" width="495" height="15" font="14"><b>assessment of pregnancy risk, patients at high risk of maternal morbidity </b></text>
<text top="989" left="281" width="495" height="15" font="14"><b>or  mortality,  including  women  with  pulmonary  arterial  hypertension </b></text>
<text top="1008" left="281" width="495" height="15" font="14"><b>(PAH),  Eisenmenger  syndrome,  severe  systemic  ventricular  dysfunction, </b></text>
<text top="1028" left="281" width="495" height="15" font="14"><b>severe  left-sided  obstructive  lesions,  and/or  ACHD  AP  classification  ID, </b></text>
<text top="1047" left="281" width="495" height="15" font="14"><b>IID, IIID* should be counseled against becoming pregnant or be given the </b></text>
<text top="1067" left="281" width="225" height="15" font="14"><b>option of terminating pregnancy. </b></text>
<text top="1087" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1087" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1087" left="256" width="13" height="15" font="14"><b>6.</b></text>
<text top="1088" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1087" left="281" width="495" height="15" font="14"><b>Men  and  women  of  childbearing  age  with  CHD  should  be  counseled  on </b></text>
</page>
<page number="40" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 40 </text>
<text top="163" left="281" width="342" height="15" font="14"><b>the risk of CHD recurrence in offspring (S3.13.1-9).  </b></text>
<text top="203" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="203" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="183" left="256" width="13" height="15" font="14"><b>7.</b></text>
<text top="183" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="183" left="281" width="495" height="15" font="14"><b>Exercise  testing  can  be  useful  for  risk  assessment  in  women  with ACHD </b></text>
<text top="203" left="281" width="495" height="15" font="14"><b>AP  classification  IC-D,  IIA-D,  and  IIIA-D*  who  are  considering  pregnancy </b></text>
<text top="222" left="281" width="166" height="15" font="14"><b>(S3.13.1-10, S3.13.1-11). </b></text>
<text top="253" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="253" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="243" left="256" width="13" height="15" font="14"><b>8.</b></text>
<text top="243" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="243" left="281" width="494" height="15" font="14"><b>When  either  parent  has  CHD,  it  is  reasonable  to  perform  fetal </b></text>
<text top="262" left="281" width="289" height="15" font="14"><b>echocardiography (S3.13.1-12, S3.13.1-13). </b></text>
<text top="282" left="105" width="314" height="12" font="9">*See Tables 3 and 4 for the ACHD AP classification system. </text>
<text top="308" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="336" left="105" width="687" height="15" font="11">Most  data  regarding  cardiac  and  obstetric  risk  to  women  with  CHD  during  pregnancy  derive  from </text>
<text top="355" left="105" width="683" height="15" font="11">retrospective  case  series  (S3.13.1-2–S3.13.1-5,  S3.13.1-8,  S3.13.1-10,  S3.13.1-12,  S3.13.1-14–S3.13.1-</text>
<text top="375" left="105" width="687" height="15" font="11">20). Many women with CHD considering pregnancy may have received inconsistent guidance regarding </text>
<text top="394" left="105" width="687" height="15" font="11">pregnancy risks (S3.13.1-21). Several risk scores have been developed to risk-stratify women with heart </text>
<text top="414" left="105" width="687" height="15" font="11">disease desiring pregnancy (S3.13.1-2,  S3.13.1-7), and a prospective validation study  suggests that the </text>
<text top="434" left="105" width="687" height="15" font="11">World  Health  Organization  classification  is  the  most  accurate  prediction  model  (S3.13.1-11).  Although </text>
<text top="453" left="105" width="687" height="15" font="11">many  women  with  CHD  tolerate  the  hemodynamic  changes  of  pregnancy,  others  may  face  significant </text>
<text top="473" left="105" width="687" height="15" font="11">immediate  or  late  risks  of  pregnancy  including  volume  overload,  arrhythmias,  progressive  cardiac </text>
<text top="492" left="105" width="687" height="15" font="11">dysfunction, and death. Cardiac medications may need to be adjusted during pregnancy and counseling </text>
<text top="512" left="105" width="687" height="15" font="11">provided to discuss the options for and potential impact of those changes. Some specific complications </text>
<text top="531" left="105" width="687" height="15" font="11">may  be  more  common  in  women  with  certain  types  of  CHD,  such  as  hypertension,  which  is  more </text>
<text top="551" left="105" width="687" height="15" font="11">common in women with coarctation (S3.13.1-22, S3.13.1-23). The offspring of patients with ACHD have </text>
<text top="571" left="105" width="687" height="15" font="11">an increased risk of CHD and other events such as prematurity (S3.13.1-24). All women with CHD should </text>
<text top="590" left="105" width="687" height="15" font="11">receive appropriate counseling regarding contraception choices. A multidisciplinary team that includes </text>
<text top="610" left="105" width="687" height="15" font="11">ACHD  specialists  and  maternal-fetal  medicine  obstetricians  with  expertise  in  caring  for  women  with </text>
<text top="630" left="105" width="399" height="15" font="11">heart disease is appropriate for achieving optimal outcomes. </text>
<text top="658" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="686" left="105" width="687" height="15" font="11">1.  Prepregnancy  counseling  allows  for  an  individualized  risk  assessment.  This  will  include  discussing </text>
<text top="706" left="105" width="687" height="15" font="11">maternal risks for pregnancy, delivery, and postpartum period, and medications that may be teratogenic </text>
<text top="726" left="105" width="687" height="15" font="11">and  require  alternative  therapies  (e.g.,  angiotensin-converting  enzyme  inhibitors/angiotensin-receptor </text>
<text top="745" left="105" width="687" height="15" font="11">blockers).  Additionally,  counseling  should  include  a  discussion  related  to  fetal  risk  in  regard  to  CHD </text>
<text top="765" left="105" width="687" height="15" font="11">transmission  and  overall  risk  to  the  health  of  the  fetus.  ACHD  cardiologists  are  valuable  in  accurately </text>
<text top="784" left="105" width="687" height="15" font="11">assessing pregnancy risks. Risk may be overestimated or underestimated by providers without expertise </text>
<text top="804" left="105" width="687" height="15" font="11">in CHD and pregnancy, leading to patients’ receiving inaccurate recommendations on risks of pregnancy, </text>
<text top="824" left="105" width="687" height="15" font="11">risks of delivery, and the type of delivery (e.g., the incorrect notion that most women with CHD require </text>
<text top="843" left="105" width="254" height="15" font="11">cesarean delivery for cardiac reasons). </text>
<text top="872" left="105" width="687" height="15" font="11">2. This care plan should address maternal cardiac risks on the basis of the individual patient’s anatomy </text>
<text top="891" left="105" width="687" height="15" font="11">and physiology. Clear documentation is important so that all providers are well aware of the risks and </text>
<text top="911" left="105" width="687" height="15" font="11">expected outcomes, including risk of maternal volume shifts, arrhythmias, labor and delivery plan, and </text>
<text top="931" left="105" width="687" height="15" font="11">need for maternal cardiac monitoring when indicated. Contingency plans for anticipated complications </text>
<text top="950" left="105" width="379" height="15" font="11">related to the presence of CHD should also be developed. </text>
<text top="978" left="105" width="687" height="15" font="11">3. Chronic anticoagulation during pregnancy is associated with increased risk of maternal bleeding and </text>
<text top="998" left="105" width="687" height="15" font="11">thrombotic  events  as  well  as  a  higher  risk  of  fetal  loss,  and  in  the  case  of  warfarin,  the  risk  of </text>
<text top="1017" left="105" width="683" height="15" font="11">teratogenicity (S3.13.1-5, S3.13.1-14). The choice of specific anticoagulant must balance maternal well-</text>
<text top="1037" left="105" width="687" height="15" font="11">being  and  risks  for  mother  and  fetus,  and  should  be  individualized.  Patients  with  mechanical  valves </text>
<text top="1057" left="105" width="336" height="15" font="11">should be treated according to GDMT (S3.13.1-25). </text>
</page>
<page number="41" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 41 </text>
<text top="162" left="105" width="687" height="15" font="11">4.  The  hemodynamic  changes  of  pregnancy,  labor,  and  delivery  can  result  in  hemodynamic </text>
<text top="182" left="105" width="687" height="15" font="11">decompensation for some women with CHD (S3.13.1-1, S3.13.1-7, S3.13.1-15, S3.13.1-24). Management </text>
<text top="201" left="105" width="687" height="15" font="11">involving the expertise of ACHD, maternal-fetal medicine, and anesthesiology should help anticipate and </text>
<text top="221" left="105" width="480" height="15" font="11">mitigate some of the potentially detrimental maternal or fetal outcomes. </text>
<text top="249" left="105" width="687" height="15" font="11">5. Women at high risk include, but are not limited to, those diagnosed with cardiac conditions that meet </text>
<text top="268" left="105" width="512" height="15" font="11">World Health Organization maternal cardiac risk classification IV (S3.13.1-26).  </text>
<text top="297" left="131" width="12" height="15" font="11">a.</text>
<text top="297" left="143" width="4" height="15" font="26"> </text>
<text top="297" left="158" width="120" height="15" font="11">PAH of any cause  </text>
<text top="317" left="131" width="13" height="15" font="11">b.</text>
<text top="317" left="144" width="4" height="15" font="26"> </text>
<text top="317" left="158" width="638" height="15" font="11">Severe systemic ventricular dysfunction: LV ejection fraction &lt;30% and/or NYHA III–IV symptoms  </text>
<text top="336" left="131" width="11" height="15" font="11">c.</text>
<text top="337" left="142" width="4" height="15" font="26"> </text>
<text top="336" left="158" width="191" height="15" font="11">Severe left heart obstruction </text>
<text top="356" left="131" width="13" height="15" font="11">d.</text>
<text top="356" left="144" width="4" height="15" font="26"> </text>
<text top="356" left="158" width="406" height="15" font="11">Severe native coarctation (S3.13.1-16, S3.13.1-27, S3.13.1-28) </text>
<text top="384" left="105" width="687" height="15" font="11">These patients have an extremely high risk of maternal mortality or severe morbidity, and if pregnant, </text>
<text top="404" left="105" width="376" height="15" font="11">the option of pregnancy termination should be discussed </text>
<text top="432" left="105" width="687" height="15" font="11">6.  Prepregnancy  counseling  regarding  the  risk  of  CHD  recurrence  in  offspring  provides  helpful </text>
<text top="452" left="105" width="687" height="15" font="11">information  to  parents  to  inform  decision-making  regarding  family  planning  and  delivery  options,  and </text>
<text top="472" left="105" width="597" height="15" font="11">should allow adequate time dedicated to answering important questions from the parents. </text>
<text top="500" left="105" width="687" height="15" font="11">7. CPET performed before conception can predict maternal and neonatal outcomes in pregnant women </text>
<text top="519" left="105" width="687" height="15" font="11">with CHD. A blunted heart rate response to exercise in women with CHD is associated with a higher risk </text>
<text top="539" left="105" width="408" height="15" font="11">of maternal cardiac and neonatal adverse events (S3.13.1-11). </text>
<text top="567" left="105" width="687" height="15" font="11">8. If the patient with CHD or their partner is pregnant, there is an increased risk of CHD in the offspring </text>
<text top="587" left="105" width="687" height="15" font="11">and  fetal  echocardiography  can  be  useful  in  defining  whether  CHD  is  present,  and  if  so,  help  to </text>
<text top="607" left="105" width="687" height="15" font="11">determine the  course of  action  at the  time of  delivery. There are data  to  suggest a prenatal diagnosis </text>
<text top="626" left="105" width="687" height="15" font="11">improves  neonatal  survival,  although  selection  bias  (e.g.,  preoperative  deaths,  family  preference)  is  a </text>
<text top="646" left="105" width="687" height="15" font="11">limitation  for  many  studies,  so  benefit  has  been  more  difficult  than  expected  to  prove  (S3.13.1-13, </text>
<text top="665" left="105" width="159" height="15" font="11">S3.13.1-29, S3.13.1-30). </text>
<text top="704" left="105" width="188" height="19" font="34"><b>3.13.2. Contraception </b></text>
<text top="739" left="277" width="4" height="15" font="11"> </text>
<text top="738" left="330" width="273" height="16" font="12"><b>Recommendations for Contraception </b></text>
<text top="758" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="758" left="577" width="180" height="15" font="23">Online Data Supplement 20</text>
<text top="758" left="757" width="8" height="15" font="11">. </text>
<text top="779" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="779" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="779" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="819" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="819" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="799" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="799" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="799" left="288" width="488" height="15" font="14"><b>Women  of childbearing  potential with  CHD  should be  counseled  about </b></text>
<text top="819" left="288" width="488" height="15" font="14"><b>the  risks  associated  with  pregnancy  and  appropriate  contraceptive </b></text>
<text top="838" left="288" width="204" height="15" font="14"><b>options (S3.13.2-1–S3.13.2-3). </b></text>
<text top="878" left="124" width="21" height="15" font="14"><b>III: </b></text>
<text top="898" left="115" width="40" height="15" font="14"><b>Harm </b></text>
<text top="888" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="859" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="859" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="859" left="288" width="488" height="15" font="14"><b>Estrogen-containing  contraceptives  are  potentially  harmful  for  women </b></text>
<text top="878" left="288" width="488" height="15" font="14"><b>with CHD who are at high risk of thromboembolic events (e.g., cyanosis, </b></text>
<text top="898" left="288" width="488" height="15" font="14"><b>Fontan  physiology,  mechanical  valves,  prior  thrombotic  events,  PAH) </b></text>
<text top="918" left="288" width="149" height="15" font="14"><b>(S3.13.2-4, S3.13.2-5). </b></text>
<text top="947" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="975" left="105" width="687" height="15" font="11">The use of contraceptive agents should be balanced against the risks of pregnancy in every woman with </text>
<text top="994" left="105" width="687" height="15" font="11">CHD after menarche (S3.13.2-6). There are no data on the safety of various contraceptive techniques in </text>
<text top="1014" left="105" width="135" height="15" font="11">patients with ACHD. </text>
<text top="1043" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
</page>
<page number="42" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 42 </text>
<text top="162" left="105" width="687" height="15" font="11">1. The individualized benefits and risks of each contraceptive therapy must be determined based on the </text>
<text top="182" left="105" width="687" height="15" font="11">patient’s anatomy and physiology in consultation with a gynecologist. This counseling should include the </text>
<text top="201" left="105" width="687" height="15" font="11">expected  failure  rates  of  contraceptive  options  and  the  anticipated  maternal  and  fetal  risks  of </text>
<text top="221" left="105" width="446" height="15" font="11">unplanned pregnancy, with these issues revisited on a regular basis. </text>
<text top="249" left="158" width="634" height="15" font="11">Contraceptive  choices  include  combined  hormonal  (estrogen/progesterone)  contraception, </text>
<text top="268" left="105" width="687" height="15" font="11">progesterone-only agents, intrauterine devices, barrier methods, and permanent sterilization. Low-dose </text>
<text top="288" left="105" width="687" height="15" font="11">combination oral contraceptive (≤20 mcg of ethinyl estradiol) is an option except in women who are at </text>
<text top="308" left="105" width="687" height="15" font="11">increased  risk  of  thrombosis  (S3.13.2-4).  Medroxyprogesterone  acetate  is  a  less  effective  method  of </text>
<text top="328" left="105" width="687" height="15" font="11">contraception, and the potential for fluid retention must be considered (S3.13.2-5). Intrauterine devices </text>
<text top="347" left="105" width="687" height="15" font="11">are highly effective methods of contraception; however, women may experience vasovagal reactions at </text>
<text top="367" left="105" width="687" height="15" font="11">the time of implant. Tubal ligation is generally safe with recognized risks associated with anesthesia and </text>
<text top="386" left="105" width="683" height="15" font="11">abdominal  insufflation.  An  efficacious  option  is  a  vasectomy  for  the  male  partner;  however,  the  long-</text>
<text top="406" left="105" width="687" height="15" font="11">term prognosis of the female patient with CHD must be considered and discussed openly. In the case of </text>
<text top="426" left="105" width="687" height="15" font="11">unplanned  pregnancy  with  desire  for  termination,  the  morning-after  pill  (levonorgestrel)  is  safe  for </text>
<text top="445" left="105" width="389" height="15" font="11">women, but acute fluid retention is a risk to be considered. </text>
<text top="473" left="105" width="687" height="15" font="11">2. Women with CHD who are at high risk of thrombosis include those with cyanosis, Fontan physiology, </text>
<text top="493" left="105" width="687" height="15" font="11">mechanical valves, prior thrombotic events, and PAH. In women who are at high risk of thrombosis and </text>
<text top="513" left="105" width="687" height="15" font="11">who  receive  warfarin,  there  are  no  data  on  which  to  base  a  recommendation  or  counseling  as  to </text>
<text top="532" left="105" width="687" height="15" font="11">whether  it  is  safe  to  use  estrogen-containing  contraception.  It  is  unclear  whether  the  use  of  warfarin </text>
<text top="552" left="105" width="616" height="15" font="11">offsets adequately the additional risk of thrombosis related to pregnancy in high-risk patients. </text>
<text top="590" left="105" width="241" height="19" font="34"><b>3.13.3. Infertility Treatment </b></text>
<text top="623" left="105" width="687" height="15" font="11">Menstrual cycle disorders are not uncommon in women with CHD. In small case series of women with </text>
<text top="642" left="105" width="687" height="15" font="11">CHD,  various  causes  for  infertility  were  documented  including  primary  and  secondary  amenorrhea, </text>
<text top="662" left="105" width="687" height="15" font="11">oligomenorrhea, and uterine anomalies (S3.13.3-1, S3.13.3-2). In more complex forms of CHD (e.g., the </text>
<text top="682" left="105" width="687" height="15" font="11">population  with  Fontan  palliation),  the  prevalence  of  primary  amenorrhea  may  be  as  high  as  40% </text>
<text top="701" left="105" width="687" height="15" font="11">(S3.13.3-2). Menarche occurs at an older age in these women than in the general population (S3.13.3-2). </text>
<text top="721" left="105" width="687" height="15" font="11">Women with CHD also have higher rates of spontaneous abortion and miscarriage (S3.13.3-3–S3.13.3-5). </text>
<text top="740" left="105" width="687" height="15" font="11">The prevalence of infertility in men with CHD is unknown. Each patient with ACHD should be counseled </text>
<text top="760" left="105" width="687" height="15" font="11">regarding  the  potential  for  infertility  and  referral  to  a  specialized  reproductive  endocrinologist  when </text>
<text top="780" left="105" width="687" height="15" font="11">appropriate,  although  there  is  little  specific  guidance  for  women  based  on  types  of  CHD.  Alternative </text>
<text top="799" left="105" width="687" height="15" font="11">options  for  family  planning  including  assisted  reproductive  technologies  and  adoption  is  appropriate, </text>
<text top="819" left="105" width="474" height="15" font="11">and risks versus benefits of all options are addressed during counseling.<b> </b> </text>
<text top="857" left="105" width="201" height="19" font="34"><b>3.13.4. Sexual Function </b></text>
<text top="890" left="105" width="687" height="15" font="11">Sexuality is an important element of QoL. Although there are data that sexual function is a concern in </text>
<text top="909" left="105" width="687" height="15" font="11">both  women  and  men,  there  is minimal  evidence  on  the  prevalence  of  sexual  concerns  among  adults </text>
<text top="929" left="105" width="369" height="15" font="11">with CHD and far less to guide interventions (S3.13.4-1). </text>
<text top="957" left="158" width="634" height="15" font="11">Concerns with sexual health are present in 20% to 40% of men with CHD (S3.13.4-2–S3.13.4-4). </text>
<text top="977" left="105" width="687" height="15" font="11">Erectile  dysfunction  is  reported  by  up  to  42%  of  men  with  CHD  (S3.13.4-1,  S3.13.4-3).  Men  with  CHD </text>
<text top="996" left="105" width="687" height="15" font="11">report  being  in  sexual  relationships  significantly  less  often  than  the  general  population  (S3.13.4-1, </text>
<text top="1016" left="105" width="687" height="15" font="11">S3.13.4-4).  Among  men  with  CHD  who  report  sexual  health  concerns,  there  is  a  high  level  of </text>
<text top="1036" left="105" width="687" height="15" font="11">psychological  distress  and  diminished  QoL  (S3.13.4-1,  S3.13.4-2,  S3.13.4-4,  S3.13.4-5).  The  ACHD </text>
<text top="1055" left="105" width="687" height="15" font="11">provider  should  be  mindful  of  this  often-unspoken  concern  and  create  an  environment  in  which  the </text>
<text top="1075" left="105" width="447" height="15" font="11">patient feels comfortable addressing concerns about their sexuality. </text>
</page>
<page number="43" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 43 </text>
<text top="162" left="105" width="362" height="15" font="11">See Online Data Supplement 21 for referenced studies. </text>
<text top="196" left="105" width="4" height="15" font="11"> </text>
<text top="192" left="315" width="5" height="20" font="17"><b> </b></text>
</page>
<page number="44" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 44 </text>
<text top="164" left="105" width="315" height="20" font="17"><b>3.14. Heart Failure and Transplant </b></text>
<text top="207" left="105" width="177" height="19" font="34"><b>3.14.1. Heart Failure </b></text>
<text top="243" left="286" width="4" height="14" font="11"> </text>
<text top="241" left="338" width="261" height="16" font="12"><b>Recommendation for Heart Failure  </b></text>
<text top="262" left="106" width="480" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="262" left="587" width="180" height="15" font="23">Online Data Supplement 22</text>
<text top="262" left="766" width="8" height="15" font="11">. </text>
<text top="282" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="282" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="282" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="322" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="322" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="303" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="303" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="303" left="281" width="495" height="15" font="14"><b>Consultation with ACHD and HF specialists is recommended for patients </b></text>
<text top="322" left="281" width="491" height="15" font="14"><b>with ACHD  and  HF  or  severe  ventricular  dysfunction  (S3.14.1-1–S3.14.1-</b></text>
<text top="342" left="281" width="21" height="15" font="14"><b>4). </b></text>
<text top="371" left="105" width="61" height="15" font="14"><b>Synopsis </b></text>
<text top="399" left="105" width="687" height="15" font="11">HF is a significant issue in patients with ACHD. It is common, associated with morbidity and mortality, </text>
<text top="419" left="105" width="687" height="15" font="11">and is anticipated to increase in prevalence. However, despite the clinical importance of HF in patients </text>
<text top="439" left="105" width="687" height="15" font="11">with ACHD and efforts to study the effects of medication and device therapy in these patients, there are </text>
<text top="458" left="105" width="687" height="15" font="11">no data to support treatment recommendations. For patients with biventricular physiology, systemic left </text>
<text top="478" left="105" width="687" height="15" font="11">ventricular  (LV)  dysfunction,  no  repairable  residual  hemodynamic  abnormalities,  and  persistent  HF </text>
<text top="497" left="105" width="687" height="15" font="11">symptoms,  standard  GDMT  is  ostensibly  preferable  to  no  treatment.  However,  expectations  of  its </text>
<text top="517" left="105" width="687" height="15" font="11">benefit  should  be  tempered,  and  risk  may  be  different  in  patients  with  acquired  CVD,  because  CHD </text>
<text top="536" left="105" width="576" height="15" font="11">patients have not been included in the trials by which those guidelines were developed. </text>
<text top="565" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="593" left="105" width="687" height="15" font="11">1.  HF  is  common  in  patients  with  ACHD  and  is  associated  with  increased  morbidity  and  mortality </text>
<text top="613" left="105" width="687" height="15" font="11">(S3.14.1-1–S3.14.1-4).  There  are  many  causes  of  HF  symptoms  that  may  be  reversible,  including  valve </text>
<text top="632" left="105" width="687" height="15" font="11">dysfunction,  shunts,  arrhythmias,  venous  obstruction,  and  systolic  and/or  diastolic  ventricular </text>
<text top="652" left="105" width="687" height="15" font="11">dysfunction, which require evaluation and treatment when possible. Unlike acquired HF, and despite the </text>
<text top="672" left="105" width="687" height="15" font="11">clinical importance of HF in ACHD, data to support  a  treatment  recommendations including typical HF </text>
<text top="691" left="105" width="687" height="15" font="11">medical  therapy  (e.g.,  angiotensin-converting  enzyme  inhibitors,  angiotensin-receptor  blockers,  beta </text>
<text top="711" left="105" width="683" height="15" font="11">blockers, and aldosterone antagonists) (S3.14.1-5) are limited in patients with ACHD (S3.14.1-6–S3.14.1-</text>
<text top="730" left="105" width="687" height="15" font="11">22).  HF  in  patients  with  ACHD  is  multifactorial  and  may  manifest  as  variable  response  to </text>
<text top="750" left="105" width="687" height="15" font="11">pharmacotherapy.  Advanced  HF  therapies  may  be  technically  difficult  or  considered  too  late  in  the </text>
<text top="770" left="105" width="661" height="15" font="11">course. Thus, timely evaluation by ACHD and HF specialists is crucial to optimal care of such patients. </text>
<text top="808" left="105" width="210" height="19" font="34"><b>3.14.2. Heart Transplant </b></text>
<text top="841" left="105" width="687" height="15" font="11">Because  of  the  prevalence  of  HF  among  patients  with  CHD,  heart  transplantation  is increasingly  being </text>
<text top="860" left="105" width="687" height="15" font="11">considered as a therapeutic option. Data on proper timing of transplantation are limited, particularly for </text>
<text top="880" left="105" width="687" height="15" font="11">individual lesions. Larger studies based on transplant databases do not allow for analysis based on the </text>
<text top="899" left="105" width="687" height="15" font="11">type  of  CHD  (S3.14.2-1–S3.14.2-4).  Currently,  patients  with  ACHD  may  have  fewer  mechanical </text>
<text top="919" left="105" width="687" height="15" font="11">circulatory  devices  (e.g.,  ventricular-assist  devices),  which  may  lower  their  listing  status  and  hence </text>
<text top="939" left="105" width="461" height="15" font="11">potential for organ receipt (S3.14.2-1, S3.14.2-2, S3.14.2-4–S3.14.2-7). </text>
<text top="967" left="158" width="634" height="15" font="11">Although  specific  criteria  for  timing  of  referral  for  transplantation  are  desirable,  universal </text>
<text top="986" left="105" width="687" height="15" font="11">recommendations  cannot  be  made  based  on  current  data.  Generally,  published  data  show  that </text>
<text top="1006" left="105" width="687" height="15" font="11">immediate and early posttransplantation risk is higher in ACHD than in acquired heart disease because </text>
<text top="1026" left="105" width="687" height="15" font="11">of  increased  perioperative  mortality  (S3.14.2-2).  However,  once  beyond  the  perioperative  period, </text>
<text top="1045" left="105" width="684" height="15" font="11">patients with ACHD do as well as or better than those with  acquired heart disease, with expected 10-</text>
<text top="1065" left="105" width="687" height="15" font="11">year survival equivalent to or better than that of patients without ACHD (S3.14.2-2–S3.14.2-4, S3.14.2-6, </text>
<text top="1084" left="105" width="683" height="15" font="11">S3.14.2-7).  Risks  for  poor  outcomes  include  single  ventricle  anatomy,  anatomic  complexity,  protein-</text>
</page>
<page number="45" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 45 </text>
<text top="162" left="105" width="687" height="15" font="11">losing  enteropathy,  or  high  titers  of  panel  reactive  antibodies  (S3.14.2-8,  S3.14.2-9).  The  current </text>
<text top="182" left="105" width="687" height="15" font="11">allocation system puts patients with ACHD at a disadvantage. Rather than priority dictated by the usual </text>
<text top="201" left="105" width="687" height="15" font="11">accepted risk markers, patients with ACHD are often listed by “exception,” a process that requires the </text>
<text top="221" left="105" width="687" height="15" font="11">clinician to argue that the patient warrants higher priority than would be evident by applying the used </text>
<text top="240" left="105" width="687" height="15" font="11">risk markers. There is also significant mortality for patients with ACHD while on the waitlist (S3.14.2-10, </text>
<text top="260" left="105" width="687" height="15" font="11">S3.14.2-11).  Surgical  alternatives  to  transplantation  exist  for  some  patients  with  CHD  (e.g.,  valve </text>
<text top="279" left="105" width="687" height="15" font="11">replacement, shunt closure), but these patients are at high risk of perioperative mortality (S3.14.2-12). </text>
<text top="299" left="105" width="687" height="15" font="11">Ideally,  providers  will  consider  early  referral  to  a  transplant  center  with  expertise  in  ACHD </text>
<text top="319" left="105" width="687" height="15" font="11">transplantation  when  transplantation  becomes  a  relevant  clinical  consideration.  Additionally,  it  is </text>
<text top="338" left="105" width="687" height="15" font="11">advisable  to  consider  options  for  transplantation  or  ventricular  assist  device  as  a  backup  before  other </text>
<text top="358" left="105" width="187" height="15" font="11">high-risk surgery is pursued. </text>
<text top="386" left="105" width="362" height="15" font="11">See Online Data Supplement 23 for referenced studies. </text>
<text top="425" left="105" width="258" height="19" font="34"><b>3.14.3. Multiorgan Transplant </b></text>
<text top="457" left="105" width="687" height="15" font="11">Recognizing the vulnerability of many organ systems in patients with CHD, multiorgan transplantation is </text>
<text top="477" left="105" width="687" height="15" font="11">often  considered,  although  infrequently  performed.  Multiorgan  transplantation  requires  a </text>
<text top="496" left="105" width="687" height="15" font="11">multidisciplinary  and  comprehensive  approach  with  thoughtful  planning  and  communication  among </text>
<text top="516" left="105" width="91" height="15" font="11">practitioners. </text>
<text top="544" left="158" width="634" height="15" font="11">Multiorgan transplantation may be performed as sequential operations or as a single operation. </text>
<text top="564" left="105" width="687" height="15" font="11">Typically, simultaneous multiorgan procedure in patients with CHD will be heart-lung transplantation for </text>
<text top="584" left="105" width="683" height="15" font="11">conditions that result in irreversible pulmonary hypertension such as Eisenmenger syndrome. (S3.14.3-</text>
<text top="603" left="105" width="687" height="15" font="11">1,  S3.14.3-2).  Fewer  than  100  heart-lung  transplants  are  performed  internationally  each  year,  with  a </text>
<text top="623" left="105" width="687" height="15" font="11">median  survival  of  3.3  years  and  10-year  survival  of  32%  (S3.14.3-3).  Survival  is  worse  for  heart-lung </text>
<text top="642" left="105" width="687" height="15" font="11">recipients  than  single-organ  heart  or  lung  recipients  possibly,  in  part,  because  of  longer  wait  times </text>
<text top="662" left="105" width="79" height="15" font="11">(S3.14.3-4). </text>
<text top="690" left="158" width="634" height="15" font="11">The occurrence of simultaneous heart-liver transplantation is an option in patients with severe </text>
<text top="710" left="105" width="687" height="15" font="11">right-sided HF and in single ventricle patients after Fontan palliation. Given the recognized vulnerability </text>
<text top="729" left="105" width="687" height="15" font="11">of  the  liver  to  injury  in  Fontan  patients  and  the  fact  that  heart  alone  transplantation  outcomes  have </text>
<text top="749" left="105" width="687" height="15" font="11">been  poor  in  patients  with  concomitant  liver  dysfunction,  transplant  centers  may  favor  heart-liver </text>
<text top="769" left="105" width="687" height="15" font="11">transplantation in those with cirrhosis, but this policy is  not universal. Fewer than 15  such procedures </text>
<text top="788" left="105" width="687" height="15" font="11">are performed annually in the United States, and approximately 20% of patients are referred because of </text>
<text top="808" left="105" width="687" height="15" font="11">underlying  CHD  (S3.14.3-5,  S3.14.3-6).  Consequently,  experience  with  these  procedures  is  limited </text>
<text top="827" left="105" width="687" height="15" font="11">(S3.14.3-5, S3.14.3-7), and heterogeneity makes generalizability difficult. Data are insufficient to support </text>
<text top="847" left="105" width="683" height="15" font="11">recommendations. For all patients, survival mimics that for liver transplantation alone with 1-, 2-, and 5-</text>
<text top="867" left="105" width="687" height="15" font="11">year  survival  at  84%,  74%,  and  72%,  respectively  (S3.14.3-6).  Outcomes  in  Fontan  patients  with  or </text>
<text top="886" left="105" width="683" height="15" font="11">without cirrhosis are not necessarily different in those who receive heart transplantation alone (S3.14.3-</text>
<text top="906" left="105" width="687" height="15" font="11">5,  S3.14.3-8).  Multicenter  data  gathering  on  patients  considered  for  multiorgan  transplantation  are </text>
<text top="925" left="105" width="417" height="15" font="11">needed to inform future recommendations for these therapies. </text>
<text top="964" left="105" width="185" height="20" font="17"><b>3.15. Palliative Care </b></text>
<text top="1001" left="281" width="4" height="15" font="11"> </text>
<text top="1000" left="333" width="266" height="16" font="12"><b>Recommendation for Palliative Care </b></text>
<text top="1020" left="106" width="480" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="1020" left="587" width="180" height="15" font="23">Online Data Supplement 24</text>
<text top="1020" left="766" width="8" height="15" font="11">. </text>
<text top="1041" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="1041" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="1041" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="1071" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="1071" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1061" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="1061" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1061" left="281" width="495" height="15" font="14"><b>Discussion  of  end-of-life issues  and  advance  directives can  be  beneficial </b></text>
<text top="1081" left="281" width="410" height="15" font="14"><b>for patients with ACHD or their surrogates (S3.15-1–S3.15-3). </b></text>
</page>
<page number="46" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 47 </text>
<text top="162" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="190" left="105" width="687" height="15" font="11">1.  Patients  with  ACHD  sometimes  have  significant  morbidities  not  amenable  to  effective  medical  or </text>
<text top="210" left="105" width="687" height="15" font="11">surgical  treatment  and  may  be  best  managed  using  the  consultative  expertise  of  palliative  care </text>
<text top="229" left="105" width="687" height="15" font="11">specialists.  Accurate  predictions  of  prognosis  in  ACHD  are  difficult,  and  patients  commonly  receive </text>
<text top="249" left="105" width="687" height="15" font="11">aggressive  treatments  during  their  terminal  admission  (S3.15-4).  There  is  a  discrepancy  between </text>
<text top="268" left="105" width="687" height="15" font="11">patient-reported  interest  in  discussing  advanced  directives  and  physician-reported  discussions,  with </text>
<text top="288" left="105" width="687" height="15" font="11">more  patients  interested  in  such  discussions  than  recognized  by  providers  (S3.15-1,  S3.15-2).  Early </text>
<text top="308" left="105" width="687" height="15" font="11">discussion of advance planning is favored by nearly twice as many patients as physicians (S3.15-3). Early </text>
<text top="328" left="105" width="687" height="15" font="11">discussion of end-of-life issues is consistent with patient-centered care and patient satisfaction and can </text>
<text top="347" left="105" width="687" height="15" font="11">facilitate palliative care. Although discussing end-of-life options would seem appropriate for all patients, </text>
<text top="367" left="105" width="687" height="15" font="11">there are circumstances (e.g., cultural or cognitive) when those conversations may not be appropriate. </text>
<text top="386" left="105" width="687" height="15" font="11">Similarly, although the goal is not to wait to discuss end-of-life until death is imminent, such discussion </text>
<text top="406" left="105" width="687" height="15" font="11">may not have the same benefit for young patients who are clinically well with low-risk disease. Thus, it is </text>
<text top="426" left="105" width="687" height="15" font="11">important  to  always  have  and  encourage  the  option  to  discuss  end-of-life  issues,  but  timing  of </text>
<text top="445" left="105" width="199" height="15" font="11">conversation is individualized. </text>
<text top="484" left="105" width="134" height="20" font="17"><b>3.16. Cyanosis </b></text>
<text top="518" left="105" width="687" height="15" font="11">The definition of cyanosis is “blueish discoloration of the skin and/or mucous membranes resulting from </text>
<text top="537" left="105" width="687" height="15" font="11">inadequate oxygenation of the blood.” Generally, for cyanosis to be visible, at least 5 g/L of unsaturated </text>
<text top="557" left="105" width="687" height="15" font="11">hemoglobin  in  tissue  is  needed  (S3.16-1).  Anemia  may  result  in  hypoxemia  that  is  not  manifest  as </text>
<text top="577" left="105" width="683" height="15" font="11">cyanosis. In this guideline, “cyanosis” is used as a generic term to identify hypoxemia caused by right-to-</text>
<text top="596" left="105" width="578" height="15" font="11">left shunting of blood, but not all hypoxemic patients will be visibly cyanotic at all times. </text>
<text top="625" left="158" width="634" height="15" font="11">Cyanotic heart disease encompasses a widely heterogeneous group; therefore, an individualized </text>
<text top="644" left="105" width="448" height="15" font="11">approach is needed for each patient according to the clinical details. </text>
<text top="672" left="158" width="634" height="15" font="11">Secondary  erythrocytosis  (a  physiological  increase  in  red  blood  cell  mass  in  response  to </text>
<text top="692" left="105" width="687" height="15" font="11">hypoxemia) and polycythemia (a neoplastic proliferation of hematopoietic cells including the red blood </text>
<text top="712" left="105" width="687" height="15" font="11">cell  line)  are  fundamentally  different  conditions  that  require  different  treatments.  In  secondary </text>
<text top="731" left="105" width="687" height="15" font="11">erythrocytosis,  the  patient’s  own  homeostatic  processes  generally  direct  achievement  of  an  optimal </text>
<text top="751" left="105" width="484" height="15" font="11">level of red cell mass, estimated by hemoglobin and hematocrit (S3.16-2). </text>
<text top="779" left="158" width="634" height="15" font="11">Iron  deficiency  is  frequently  encountered  in  cyanotic  individuals  (S3.16-3).  In  addition  to </text>
<text top="799" left="105" width="687" height="15" font="11">contributing  to  symptoms,  iron  deficiency  causes  a  reduction  of  hemoglobin  without  a  proportional </text>
<text top="819" left="105" width="687" height="15" font="11">change  in  hematocrit  and  thus  compromises  systemic  oxygen  transport  without  lowering  viscosity </text>
<text top="838" left="105" width="687" height="15" font="11">(S3.16-3). Symptoms mimic those of hyperviscosity. Consequences of iron deficiency may include stroke </text>
<text top="858" left="105" width="687" height="15" font="11">and myocardial ischemia (S3.16-4–S3.16-6), although published findings are inconsistent. Iron deficiency </text>
<text top="877" left="105" width="687" height="15" font="11">requires assessment of serum iron, ferritin, and transferrin levels, because mean corpuscular volume is </text>
<text top="897" left="105" width="687" height="15" font="11">not  a  reliable  screening  test  (S3.16-7).  Limited  data  suggest  that  treatment  of  transferrin  saturation </text>
<text top="916" left="105" width="591" height="15" font="11">&lt;20% with iron supplementation until iron stores are replete can be done safely (S3.16-8). </text>
<text top="945" left="158" width="634" height="15" font="11">Although there is an exponential relationship between viscosity and hematocrit, available data </text>
<text top="965" left="105" width="687" height="15" font="11">do  not  justify  a  cut  point  for  a  ”safe”  hematocrit  (S3.16-3).  There  is  no  clear  correlation  between </text>
<text top="984" left="105" width="687" height="15" font="11">viscosity, iron deficiency, and a patient’s symptoms or clinical condition (S3.16-3). The nature and cause </text>
<text top="1004" left="105" width="687" height="15" font="11">of  hyperviscosity  symptoms  are  not  well  understood.  The  severity  and  frequency  of  symptoms  of </text>
<text top="1023" left="105" width="687" height="15" font="11">hyperviscosity do not correlate with measured hematocrit. Phlebotomy is, therefore, rarely necessary in </text>
<text top="1043" left="105" width="687" height="15" font="11">patients with secondary erythrocytosis, and routine phlebotomy is not supported by data. Patients with </text>
<text top="1062" left="105" width="687" height="15" font="11">suspected  hyperviscosity  need  to  be  rehydrated  either  with  oral  fluids  or  intravenous  normal  saline </text>
<text top="1082" left="105" width="687" height="15" font="11">solution  as  a  first-line  therapy,  evaluated  for  iron  deficiency,  and  treated  if  appropriate.  Phlebotomy </text>
</page>
<page number="47" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 48 </text>
<text top="162" left="105" width="687" height="15" font="11">(with equal volume fluid replacement) is sometimes performed in special cases wherein, after adequate </text>
<text top="182" left="105" width="687" height="15" font="11">hydration,  hematocrit  remains  higher  than  the  patient’s  baseline  and  symptoms  persist,  or  there  is </text>
<text top="201" left="105" width="687" height="15" font="11">evidence  of  end-organ  damage  attributable  to  hyperviscosity  (e.g.,  myocardial  ischemia,  transient </text>
<text top="221" left="105" width="287" height="15" font="11">ischemic attack/stroke) (S3.16-9, S3.16-10). </text>
<text top="249" left="158" width="634" height="15" font="11">Observational  studies  in  cyanotic  individuals  have  shown  evidence  of  altered  synthesis  and </text>
<text top="268" left="105" width="683" height="15" font="11">function of clotting factors that may contribute to both hypo- and hypercoagulability (S3.16-11, S3.16-</text>
<text top="288" left="105" width="687" height="15" font="11">12), and thrombosis and bleeding (particularly epistaxis or hemoptysis) have been described in patients </text>
<text top="308" left="105" width="687" height="15" font="11">with Eisenmenger syndrome, which may be life-threatening (S3.16-13–S3.16-15). These disparate trends </text>
<text top="328" left="105" width="687" height="15" font="11">preclude  developing  universally  applicable  recommendations,  including  use  of  antiplatelet  or </text>
<text top="347" left="105" width="687" height="15" font="11">anticoagulant  therapy  in  these  patients  (S3.16-16).  Similarly,  there  is  not  a  clear  role  for  preoperative </text>
<text top="367" left="105" width="317" height="15" font="11">phlebotomy to improve coagulation properties.  </text>
<text top="395" left="158" width="634" height="15" font="11">Cyanotic  heart  disease  is  a  multisystem  disorder.  Manifestations,  in  addition  to  those  already </text>
<text top="415" left="105" width="687" height="15" font="11">discussed, include renal dysfunction, gout, infections, and osteoarthropathy. Alterations can be found of </text>
<text top="434" left="105" width="687" height="15" font="11">myocardial  (S3.16-17,  S3.16-18),  cerebral  (S3.16-19),  and  retinal  blood  flow  (S3.16-20),  and  kidney </text>
<text top="454" left="105" width="687" height="15" font="11">function (S3.16-21). Providers should recognize multiorgan susceptibility and avoid treatments that may </text>
<text top="473" left="105" width="687" height="15" font="11">have adverse noncardiac effects. Additional practices that may  contribute to effective management of </text>
<text top="493" left="105" width="258" height="15" font="11">cyanotic patients are listed in Table 12. </text>
<text top="522" left="105" width="4" height="16" font="22"> </text>
<text top="552" left="105" width="392" height="15" font="14"><b>Table 12. Specific Management Practices for Cyanotic CHD </b></text>
<text top="572" left="117" width="7" height="19" font="19">•</text>
<text top="576" left="123" width="4" height="13" font="20"> </text>
<text top="575" left="143" width="610" height="13" font="8">Recording clinical oxygen saturation at rest (&gt;5 min) rather than immediately after effort (e.g., walking </text>
<text top="593" left="143" width="191" height="13" font="8">into a clinic examination room). </text>
<text top="608" left="117" width="7" height="19" font="19">•</text>
<text top="612" left="123" width="4" height="13" font="20"> </text>
<text top="612" left="143" width="616" height="13" font="8">Meticulous intravenous care to avoid air or particulate matter, which may include use of air/particulate </text>
<text top="630" left="143" width="505" height="13" font="8">filters on all intravenous access lines, when feasible, and careful de-airing of all lines. </text>
<text top="644" left="117" width="7" height="19" font="19">•</text>
<text top="649" left="123" width="4" height="13" font="20"> </text>
<text top="648" left="143" width="581" height="13" font="8">Cerebral imaging for any new headache or neurologic sign to assess for possible cerebral abscess, </text>
<text top="666" left="143" width="141" height="13" font="8">hemorrhage, or stroke. </text>
<text top="681" left="117" width="7" height="19" font="19">•</text>
<text top="685" left="123" width="4" height="13" font="20"> </text>
<text top="685" left="143" width="587" height="13" font="8">Measurement of serum uric acid and treatment with allopurinol in a patient with a history of gout. </text>
<text top="699" left="117" width="7" height="19" font="19">•</text>
<text top="704" left="123" width="4" height="13" font="20"> </text>
<text top="703" left="143" width="623" height="13" font="8">Supplemental oxygen as needed for symptom relief but not to a target oxygen saturation level and not if </text>
<text top="721" left="143" width="283" height="13" font="8">there is no demonstrable symptomatic benefit. </text>
<text top="736" left="117" width="7" height="19" font="19">•</text>
<text top="740" left="123" width="4" height="13" font="20"> </text>
<text top="740" left="143" width="588" height="13" font="8">Avoidance of or cautious use of therapies that may reduce the patient’s hypoxia-mediated drive to </text>
<text top="757" left="143" width="567" height="13" font="8">ventilation, such as narcotics or, in rare circumstances, excess supplemental oxygen (S3.16-22). </text>
<text top="772" left="117" width="7" height="19" font="19">•</text>
<text top="777" left="123" width="4" height="13" font="20"> </text>
<text top="776" left="143" width="619" height="13" font="8">Anesthesia by providers with expertise in anesthesia for patients with ACHD for any noncardiac surgery. </text>
<text top="791" left="117" width="7" height="19" font="19">•</text>
<text top="795" left="123" width="4" height="13" font="20"> </text>
<text top="795" left="143" width="632" height="13" font="8">Non-estrogen–containing birth control for women of child-bearing potential (intrauterine device may be a </text>
<text top="813" left="143" width="509" height="13" font="8">preferred option). Avoidance of birth control entirely is not a safe, acceptable option. </text>
<text top="827" left="117" width="7" height="19" font="19">•</text>
<text top="832" left="123" width="4" height="13" font="20"> </text>
<text top="831" left="143" width="591" height="13" font="8">Patients can travel safely on commercial airlines without undue risk (S3.16-23). Preflight simulation </text>
<text top="849" left="143" width="610" height="13" font="8">testing or mandated supplemental oxygen are not usually indicated, although adequate hydration and </text>
<text top="867" left="143" width="267" height="13" font="8">movement during the flight are appropriate. </text>
<text top="882" left="117" width="7" height="19" font="19">•</text>
<text top="886" left="123" width="4" height="13" font="20"> </text>
<text top="885" left="143" width="590" height="13" font="8">Measurement of coagulation parameters (e.g., activated partial thromboplastin time, international </text>
<text top="903" left="143" width="616" height="13" font="8">normalized ratio, thrombin time) in a patient with an elevated hematocrit &gt;55% requires adjustment of </text>
<text top="921" left="143" width="600" height="13" font="8">anticoagulant volume in the blood collection vials to account for reduced plasma volume in the draw </text>
<text top="939" left="143" width="68" height="13" font="8">(S3.16-24). </text>
<text top="957" left="105" width="437" height="12" font="9">ACHD indicates adult congenital heart disease and CHD, congenital heart disease. </text>
<text top="974" left="105" width="4" height="16" font="22"> </text>
<text top="1004" left="105" width="362" height="15" font="11">See Online Data Supplement 25 for referenced studies. </text>
</page>
<page number="48" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 49 </text>
<text top="164" left="105" width="373" height="20" font="17"><b>3.17. Pharmacological Therapy for ACHD </b></text>
<text top="197" left="105" width="687" height="15" font="11">Patients  with  ACHD  are  commonly  excluded  from  clinical  trials,  and  there  are  few  data  to  guide </text>
<text top="217" left="105" width="687" height="15" font="11">pharmacological  therapies.  Although  it  may  be  tempting  to  extrapolate  from  management  guidelines </text>
<text top="236" left="105" width="687" height="15" font="11">developed for patients without CHD (e.g., HF guidelines) (S3.17-1), treatments may not have the same </text>
<text top="256" left="105" width="687" height="15" font="11">benefit in the heterogeneous population of patients with ACHD and in some cases may cause harm. The </text>
<text top="276" left="105" width="687" height="15" font="11">evaluation of new symptoms in a patient with ACHD must be tailored to the patient’s anatomy, surgical </text>
<text top="295" left="105" width="687" height="15" font="11">repair,  and  physiology.  Before  considering  pharmacological  therapies,  evaluation  for  residual  shunts, </text>
<text top="315" left="105" width="687" height="15" font="11">baffle stenosis, valvular or conduit dysfunction, and collateral vessels, any of which may be amenable to </text>
<text top="335" left="105" width="295" height="15" font="11">interventions, is an important consideration. </text>
<text top="363" left="158" width="634" height="15" font="11">The literature documenting pharmacological therapies for patients with ACHD is limited to small </text>
<text top="383" left="105" width="687" height="15" font="11">studies with limited duration of drug administration and follow-up. Additionally, the endpoints used are </text>
<text top="402" left="105" width="687" height="15" font="11">often surrogate markers that have not been validated for clinical decision-making, and studies are also </text>
<text top="422" left="105" width="687" height="15" font="11">often  underpowered.  However,  studies  in  patients  with  ACHD  do  exist  and  evaluate  conventional </text>
<text top="441" left="105" width="683" height="15" font="11">pharmacological  therapy,  especially  for  HF  and  for  arrhythmia,  including  beta  blockers,  angiotensin-</text>
<text top="461" left="105" width="687" height="15" font="11">converting  enzyme  inhibitors,  angiotensin-receptor  blockers,  and  aldosterone  antagonists,  although </text>
<text top="481" left="105" width="202" height="15" font="11">results vary (S3.17-2–S3.17-9). </text>
<text top="509" left="158" width="634" height="15" font="11">Pharmacological therapies in patients with ACHD are often directed to specific conditions (i.e., </text>
<text top="529" left="105" width="687" height="15" font="11">beta blockers for arrhythmia treatment). However, there are limited data examining the benefits of beta </text>
<text top="548" left="105" width="687" height="15" font="11">blockers in specific ACHD populations. Results from a small study indicate that beta-blocker therapy may </text>
<text top="568" left="105" width="687" height="15" font="11">have potential  to improve functional class in patients with a systemic right ventricle  and a pacemaker </text>
<text top="587" left="105" width="687" height="15" font="11">(S3.17-2).  Angiotensin-converting  enzyme  inhibitors  and  angiotensin-receptor  blockers  have  also  been </text>
<text top="607" left="105" width="687" height="15" font="11">assessed  in  small  studies  in  specific  ACHD  populations  in  which  no  significant  benefit  on  ventricular </text>
<text top="626" left="105" width="687" height="15" font="11">function  or  exercise  capacity  has  been  proven  (S3.17-6–S3.17-8).  Data  from  1  small  trial  with  a  short </text>
<text top="646" left="105" width="687" height="15" font="11">follow-up interval in patients with a systemic right ventricle suggest that eplerenone may be associated </text>
<text top="666" left="105" width="440" height="15" font="11">with reduced myocardial fibrosis, as assessed by imaging (S3.17-3). </text>
<text top="694" left="158" width="634" height="15" font="11">Some pharmacological therapies affecting the pulmonary vasculature (e.g., endothelin-receptor </text>
<text top="714" left="105" width="687" height="15" font="11">antagonists  and  phosphodiesterase  type-5  [PDE-5]  inhibitors)  have  a  beneficial  effect  on  long-term </text>
<text top="733" left="105" width="687" height="15" font="11">outcomes in patients with Eisenmenger syndrome (S3.17-10). Similarly, there are limited data on the use </text>
<text top="753" left="105" width="687" height="15" font="11">of pulmonary  vasodilator therapy in  Fontan patients,  in whom the  pulmonary vascular resistance may </text>
<text top="773" left="105" width="687" height="15" font="11">be  abnormal  (S3.17-11–S3.17-13).  Because  of  the  lack  of  data,  clinical  recommendations  regarding </text>
<text top="792" left="105" width="687" height="15" font="11">pharmacological  therapy  for  patients  with  ACHD  are  unsupported.  Individualized  care  is  needed, </text>
<text top="812" left="105" width="687" height="15" font="11">recognizing  the  potential  benefits  and  risks  of  the  therapy  relative  to  patient-specific  anatomic  and </text>
<text top="831" left="105" width="134" height="15" font="11">physiological issues. </text>
<text top="860" left="105" width="362" height="15" font="11">See Online Data Supplement 22 for referenced studies. </text>
<text top="908" left="105" width="179" height="21" font="10"><b>4. Specific Lesions </b></text>
<text top="953" left="105" width="169" height="20" font="17"><b>4.1. Shunt Lesions </b></text>
<text top="992" left="105" width="4" height="15" font="11"> </text>
<text top="989" left="315" width="5" height="19" font="34"><b> </b></text>
</page>
<page number="49" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="36" size="8" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 50 </text>
<text top="163" left="105" width="222" height="19" font="34"><b>4.1.1. Atrial Septal Defect </b></text>
<text top="199" left="259" width="4" height="14" font="11"> </text>
<text top="197" left="311" width="311" height="16" font="12"><b>Recommendations for Atrial Septal Defect </b></text>
<text top="218" left="118" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="218" left="579" width="180" height="15" font="23">Online Data Supplement 26</text>
<text top="218" left="759" width="4" height="15" font="11"> </text>
<text top="237" left="295" width="290" height="15" font="11">and the systematic review report (S4.1.1-1). </text>
<text top="258" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="258" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="258" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="278" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="318" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="318" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="299" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="299" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="299" left="281" width="494" height="15" font="14"><b>Pulse  oximetry  at  rest  and  during  exercise  is  recommended  for </b></text>
<text top="318" left="281" width="495" height="15" font="14"><b>evaluation of adults with unrepaired or repaired ASD with residual shunt </b></text>
<text top="338" left="281" width="374" height="15" font="14"><b>to determine the direction and magnitude of the shunt. </b></text>
<text top="368" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="368" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="358" left="282" width="13" height="15" font="14"><b>2.</b></text>
<text top="358" left="294" width="4" height="15" font="24"><b> </b></text>
<text top="358" left="308" width="467" height="15" font="14"><b>CMR,  CCT,  and/or  TEE  are  useful  to  evaluate  pulmonary  venous </b></text>
<text top="378" left="308" width="343" height="15" font="14"><b>connections in adults with ASD (S4.1.1-2–S4.1.1-4). </b></text>
<text top="408" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="408" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="398" left="255" width="13" height="15" font="14"><b>3.</b></text>
<text top="398" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="398" left="281" width="495" height="15" font="14"><b>Echocardiographic  imaging  is  recommended  to  guide  percutaneous  ASD </b></text>
<text top="418" left="281" width="185" height="15" font="14"><b>closure (S4.1.1-5, S4.1.1-6). </b></text>
<text top="438" left="411" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="537" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="537" left="186" width="34" height="15" font="14"><b>B-NR</b></text>
<text top="534" left="220" width="10" height="9" font="36"><b>SR</b></text>
<text top="537" left="231" width="4" height="15" font="14"><b> </b></text>
<text top="458" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="459" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="458" left="281" width="495" height="15" font="14"><b>In  adults  with  isolated  secundum  ASD  causing  impaired  functional </b></text>
<text top="478" left="281" width="495" height="15" font="14"><b>capacity, right  atrial  and/or  RV  enlargement,  and  net  left-to-right  shunt </b></text>
<text top="498" left="281" width="491" height="15" font="14"><b>sufficiently  large  to  cause  physiological  sequelae  (e.g.,  pulmonary–</b></text>
<text top="517" left="281" width="495" height="15" font="14"><b>systemic  blood  flow  ratio  [Qp:Qs]  ≥1.5:1)  without  cyanosis  at  rest  or </b></text>
<text top="537" left="281" width="494" height="15" font="14"><b>during  exercise,  transcatheter  or  surgical  closure  to  reduce  RV  volume </b></text>
<text top="556" left="281" width="495" height="15" font="14"><b>and  improve  exercise  tolerance  is  recommended,  provided  that  systolic </b></text>
<text top="576" left="281" width="495" height="15" font="14"><b>PA pressure is less than 50% of systolic systemic pressure and pulmonary </b></text>
<text top="596" left="281" width="495" height="15" font="14"><b>vascular  resistance  is  less  than  one  third  of  the  systemic  vascular </b></text>
<text top="615" left="281" width="212" height="15" font="14"><b>resistance (S4.1.1-7–S4.1.1-12). </b></text>
<text top="704" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="704" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="636" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="636" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="636" left="281" width="495" height="15" font="14"><b>Adults with  primum  ASD, sinus venosus  defect  or coronary  sinus  defect </b></text>
<text top="655" left="281" width="495" height="15" font="14"><b>causing impaired functional capacity, right atrial and/or RV enlargement </b></text>
<text top="675" left="281" width="495" height="15" font="14"><b>and  net  left-to-right  shunt  sufficiently  large  to  cause  physiological </b></text>
<text top="694" left="281" width="494" height="15" font="14"><b>sequelae (e.g., Qp:Qs ≥1.5:1) without cyanosis at rest or during exercise, </b></text>
<text top="714" left="281" width="495" height="15" font="14"><b>should  be  surgically  repaired  unless  precluded  by  comorbidities, </b></text>
<text top="733" left="281" width="494" height="15" font="14"><b>provided that systolic PA pressure is less than 50% of systemic pressure </b></text>
<text top="753" left="281" width="495" height="15" font="14"><b>and pulmonary vascular resistance is less than one third of the systemic </b></text>
<text top="773" left="281" width="279" height="15" font="14"><b>vascular resistance (S4.1.1-13, S4.1.1-14). </b></text>
<text top="862" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="862" left="188" width="30" height="15" font="14"><b>C-LD</b></text>
<text top="859" left="219" width="10" height="9" font="36"><b>SR</b></text>
<text top="862" left="229" width="4" height="15" font="14"><b> </b></text>
<text top="793" left="256" width="13" height="15" font="14"><b>6.</b></text>
<text top="793" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="793" left="281" width="495" height="15" font="14"><b>In asymptomatic adults with isolated secundum ASD, right atrial and RV </b></text>
<text top="813" left="281" width="495" height="15" font="14"><b>enlargement,  and  net  left-to-right  shunt  sufficiently  large  to  cause </b></text>
<text top="832" left="281" width="495" height="15" font="14"><b>physiological sequelae (e.g., Qp:Qs 1.5:1 or greater), without cyanosis at </b></text>
<text top="852" left="281" width="495" height="15" font="14"><b>rest or during exercise, transcatheter or surgical closure is reasonable to </b></text>
<text top="872" left="281" width="495" height="15" font="14"><b>reduce  RV  volume  and/or  improve  functional  capacity,  provided  that </b></text>
<text top="891" left="281" width="495" height="15" font="14"><b>systolic PA pressure is less than 50% of systemic pressure and pulmonary </b></text>
<text top="911" left="281" width="491" height="15" font="14"><b>vascular  resistance  is  less  than  one  third  systemic  resistance  (S4.1.1-7–</b></text>
<text top="930" left="281" width="144" height="15" font="14"><b>S4.1.1-10, S4.1.1-12). </b></text>
<text top="990" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="990" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="951" left="256" width="13" height="15" font="14"><b>7.</b></text>
<text top="951" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="951" left="281" width="495" height="15" font="14"><b>Surgical  closure  of  a  secundum  ASD  in  adults  is  reasonable  when  a </b></text>
<text top="970" left="281" width="495" height="15" font="14"><b>concomitant  surgical  procedure  is  being  performed  and  there  is  a  net </b></text>
<text top="990" left="281" width="495" height="15" font="14"><b>left-to-right shunt sufficiently large to cause physiological sequelae (e.g., </b></text>
<text top="1009" left="281" width="495" height="15" font="14"><b>Qp:Qs  1.5:1  or  greater)  and  right  atrial  and  RV  enlargement  without </b></text>
<text top="1029" left="281" width="379" height="15" font="14"><b>cyanosis at rest or during exercise (S4.1.1-15–S4.1.1-18). </b></text>
<text top="1059" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="1059" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1049" left="256" width="13" height="15" font="14"><b>8.</b></text>
<text top="1050" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1049" left="281" width="495" height="15" font="14"><b>Percutaneous or surgical closure may be considered for adults with ASD </b></text>
<text top="1069" left="281" width="495" height="15" font="14"><b>when  net  left-to-right  shunt  (Qp:Qs)  is  1.5:1  or  greater,  PA  systolic </b></text>
</page>
<page number="50" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="37" size="8" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 51 </text>
<text top="163" left="281" width="495" height="15" font="14"><b>pressure  is  50%  or  more  of  systemic  arterial  systolic  pressure,  and/or </b></text>
<text top="183" left="281" width="495" height="15" font="14"><b>pulmonary  vascular  resistance  is  greater  than  one  third  of  the  systemic </b></text>
<text top="202" left="281" width="221" height="15" font="14"><b>resistance (S4.1.1-19, S4.1.1-20). </b></text>
<text top="242" left="124" width="21" height="15" font="14"><b>III: </b></text>
<text top="262" left="115" width="40" height="15" font="14"><b>Harm </b></text>
<text top="252" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="222" left="256" width="13" height="15" font="14"><b>9.</b></text>
<text top="223" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="222" left="281" width="495" height="15" font="14"><b>ASD closure should not be performed in adults with PA systolic pressure </b></text>
<text top="242" left="281" width="494" height="15" font="14"><b>greater than  two thirds systemic, pulmonary vascular resistance greater </b></text>
<text top="262" left="281" width="495" height="15" font="14"><b>than  two  thirds  systemic,  and/or  a  net  right-to-left  shunt  (S4.1.1-21, </b></text>
<text top="281" left="281" width="78" height="15" font="14"><b>S4.1.1-22).  </b></text>
<text top="310" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="338" left="105" width="687" height="15" font="11">ASDs are common and may occur as a consequence of different anatomic defects, including secundum </text>
<text top="358" left="105" width="687" height="15" font="11">ASD, primum ASD, sinus venosus defect (not properly a defect in the atrial septum but considered in this </text>
<text top="378" left="105" width="687" height="15" font="11">section), and coronary sinus septal defect. Left-to-right shunting may result in right heart enlargement </text>
<text top="397" left="105" width="687" height="15" font="11">and RV dysfunction and, in a minority of patients, PAH. Some patients may have right-to-left shunting or </text>
<text top="417" left="105" width="687" height="15" font="11">paradoxical embolism, and some may develop arrhythmias. Percutaneous device or surgical closure are </text>
<text top="436" left="105" width="687" height="15" font="11">the mainstays of therapy in those with hemodynamic or clinical consequences of the defect. Severe PAH </text>
<text top="456" left="105" width="683" height="15" font="11">is a contraindication to closure, and its presence must be accurately excluded before closure (S4.1.1-21–</text>
<text top="476" left="105" width="74" height="15" font="11">S4.1.1-23). </text>
<text top="504" left="158" width="634" height="15" font="11">ASD may occur with other  congenital cardiac abnormalities. In some  circumstances, such  as in </text>
<text top="524" left="105" width="687" height="15" font="11">patients  with  Ebstein  anomaly  and  pulmonary  stenosis  (PS)  or  right  HF,  the  physiology  related  to  the </text>
<text top="543" left="105" width="687" height="15" font="11">ASD  is  substantially  more  complex,  and  ASD  closure  could  result  in  clinical  deterioration.  Therefore, </text>
<text top="563" left="105" width="687" height="15" font="11">these recommendations regarding ASD address only isolated ASDs and not ASD associated with complex </text>
<text top="582" left="105" width="40" height="15" font="11">CHD.  </text>
<text top="611" left="158" width="634" height="15" font="11">The  “Interventional  Therapy  Versus  Medical  Therapy  for  Secundum  Atrial  Septal  Defect:  A </text>
<text top="630" left="105" width="687" height="15" font="11">Systematic  Review  (Part  2)  for  the  2018  AHA/ACC  Guideline  for  the  Management  of  Adults  With </text>
<text top="650" left="105" width="687" height="15" font="11">Congenital  Heart  Disease”  (S4.1.1-1)  has  additional  data  and  analyses.  The  results  from  the  question </text>
<text top="670" left="105" width="687" height="15" font="11">“are  outcomes  in  asymptomatic  patients  with  unoperated  secundum  ASD  and  RV  dilatation  improved </text>
<text top="689" left="105" width="687" height="15" font="11">after  percutaneous  or  surgical  closure?”  and  the  writing  committee’s  review  of  the  totality  of  the </text>
<text top="709" left="105" width="687" height="15" font="11">literature were used to frame decision-making. Recommendations that are based on a body of evidence </text>
<text top="728" left="105" width="687" height="15" font="11">that includes the systematic review conducted by the ERC are denoted by the superscript SR (e.g., LOE </text>
<text top="748" left="105" width="23" height="15" font="11">B-R</text>
<text top="745" left="128" width="10" height="9" font="37">SR</text>
<text top="748" left="138" width="12" height="15" font="11">). </text>
<text top="776" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="796" left="105" width="687" height="15" font="11">other procedures in these patients; Section 3.4 for recommendations on diagnostic evaluation; Section </text>
<text top="815" left="105" width="687" height="15" font="11">4.4.6  for  evaluation  and  management  of  severe  PAH  and  Eisenmenger  syndrome;  and  Figure  1  for  a </text>
<text top="835" left="105" width="687" height="15" font="11">diagnostic and  treatment algorithm for  secundum  ASD. See Table  13 for  routine  follow-up and testing </text>
<text top="855" left="105" width="64" height="15" font="11">intervals. </text>
<text top="883" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="912" left="105" width="687" height="15" font="11">1.  Pulse  oximetry  is  useful  in  defining  shunt  direction  at  rest  and  with  exercise,  which  will  help  guide </text>
<text top="931" left="105" width="687" height="15" font="11">decisions regarding therapeutic options. Pulse oximetry at rest and with exercise may identify patients </text>
<text top="951" left="105" width="687" height="15" font="11">with  increased  pulmonary  arterial  resistance  and  shunt  reversal.  In  a  subset  of  patients  with  resting </text>
<text top="970" left="105" width="687" height="15" font="11">systemic  oxygen  saturation  &gt;90%,  a  decrease  in  oxygen  saturation  with  activity  to  &lt;90%  may  occur, </text>
<text top="990" left="105" width="623" height="15" font="11">emphasizing the importance of performing resting and ambulatory pulse oximetry assessment. </text>
<text top="1018" left="105" width="687" height="15" font="11">2. TTE has limited use in assessment of anomalous  pulmonary venous connections in  adults with  ASD. </text>
<text top="1038" left="105" width="687" height="15" font="11">Moreover,  the  poor  visualization  of  the  superior  and  posterior  atrial  septum  by  TTE  in  adults  may </text>
<text top="1057" left="105" width="687" height="15" font="11">require  testing  with  other  imaging  modalities  to  clearly  define  septal  anatomy.  TEE  is  excellent  for </text>
<text top="1077" left="105" width="687" height="15" font="11">visualization  of  the  entire  atrial  septum  as  well  as  pulmonary  venous  connections.  Anomalous  right </text>
</page>
<page number="51" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 52 </text>
<text top="162" left="105" width="687" height="15" font="11">upper and middle lobe pulmonary venous  connections  often  occur in  combination with superior sinus </text>
<text top="182" left="105" width="687" height="15" font="11">venosus  defect;  TEE  is  excellent  for  visualization  of  this  combination  but  may  not  visualize  other </text>
<text top="201" left="105" width="687" height="15" font="11">anomalous  pulmonary  venous  connections.  Cross-sectional  imaging  with  CMR  or  CCT  is  ideal  for </text>
<text top="221" left="105" width="687" height="15" font="11">delineating pulmonary venous connections, particularly those that are associated with veins that may be </text>
<text top="240" left="105" width="687" height="15" font="11">difficult  or  impossible  to  image  by  echocardiography  (e.g.,  innominate  vein  or  vertical  vein).  CMR  has </text>
<text top="260" left="105" width="603" height="15" font="11">the advantages of not involving ionizing radiation and ability to quantify degree of shunting. </text>
<text top="288" left="105" width="687" height="15" font="11">3.  It  is  considered  standard  of  care  to  use  echocardiographic  imaging  to  guide  closure  of  interatrial </text>
<text top="308" left="105" width="687" height="15" font="11">communications.  TEE  and  intracardiac  echocardiography  are  the  most  widely  studied  and  used </text>
<text top="328" left="105" width="687" height="15" font="11">modalities for guidance of ASD closure. Defect size, defect morphology, atrial rim adequacy, pulmonary </text>
<text top="347" left="105" width="687" height="15" font="11">venous anomalies, and left atrial appendage thrombus can all be evaluated using TEE. Echocardiography </text>
<text top="367" left="105" width="687" height="15" font="11">is also used to determine sizing either by balloon diameter producing complete occlusion of the defect </text>
<text top="386" left="105" width="687" height="15" font="11">(”stop flow” diameter) or by direct visualization and measurement using intracardiac echocardiography. </text>
<text top="406" left="105" width="687" height="15" font="11">Echocardiography can assess for pericardial effusion and for thrombi on wires or devices. TTE has also </text>
<text top="426" left="105" width="595" height="15" font="11">been studied for guiding percutaneous ASD closure but is not widely used for this purpose. </text>
<text top="454" left="105" width="687" height="15" font="11">4. Cardiac catheterization is performed at the time of transcatheter ASD closure. Provided noninvasive </text>
<text top="473" left="105" width="687" height="15" font="11">imaging is of sufficiently high quality to estimate pulmonary artery pressures and shunt magnitude, not </text>
<text top="493" left="105" width="687" height="15" font="11">every  patient  with  an  ASD  requires  a  diagnostic  catheterization  before  surgical  closure.  However,  a </text>
<text top="513" left="105" width="687" height="15" font="11">diagnostic catheterization may be necessary to determine detailed hemodynamics for decision-making </text>
<text top="532" left="105" width="687" height="15" font="11">or  to  clarify  discrepant  or  inconclusive  noninvasive  imaging  data.  Patients  with  reduced  functional </text>
<text top="552" left="105" width="684" height="15" font="11">capacity  presumed  caused  by  hemodynamically  important  secundum  ASD  (moderate  or  large  left-to-</text>
<text top="571" left="105" width="687" height="15" font="11">right shunt and evidence of right heart volume overload in the absence of significant PAH) benefit from </text>
<text top="591" left="105" width="687" height="15" font="11">surgical  or  transcatheter  closure  of  the  secundum  ASD  (S4.1.1-8,  S4.1.1-10).  Patients  who  do  not </text>
<text top="611" left="105" width="687" height="15" font="11">undergo  ASD  closure  have  worse  long-term  outcomes,  including  more  atrial  arrhythmias,  reduced </text>
<text top="630" left="105" width="687" height="15" font="11">functional  capacity,  and  eventually  greater  degrees  of  PAH.  Older  adults  should  be  evaluated  for  left </text>
<text top="650" left="105" width="687" height="15" font="11">atrial  hypertension  resulting  from  diastolic  dysfunction,  which  may  cause  similar  symptoms  but  could </text>
<text top="669" left="105" width="687" height="15" font="11">result  in  clinical  worsening  after  ASD  closure  because  of  further  increase  in  left  atrial  pressures  when </text>
<text top="689" left="105" width="687" height="15" font="11">blood from the relatively restrictive and higher pressure left atrium can no longer decompress into the </text>
<text top="709" left="105" width="687" height="15" font="11">lower pressure right atrium. Cyanosis with exercise typically occurs in association with poor RV diastolic </text>
<text top="728" left="105" width="687" height="15" font="11">compliance  and  hemodynamics  with  exercise,  and  the  ASD  acts  as  a  “pop-off”  to  maintain  cardiac </text>
<text top="748" left="105" width="687" height="15" font="11">output. However, exercise-induced cyanosis is not an absolute contraindication to ASD closure, because </text>
<text top="768" left="105" width="687" height="15" font="11">there are rare cases of either streaming  or  directed  tricuspid regurgitation (TR)  leading  to  right-to-left </text>
<text top="787" left="105" width="687" height="15" font="11">shunting  with exercise  not related to  abnormal RV diastolic pressures that  may  allow for closure after </text>
<text top="807" left="105" width="687" height="15" font="11">expert  evaluation.  Data  are  most  compelling  that  closure  improves  functional  status,  although  some </text>
<text top="826" left="105" width="660" height="15" font="11">descriptive studies support improved long-term outcomes after closure as well (S4.1.1-7–S4.1.1-12).  </text>
<text top="855" left="105" width="687" height="15" font="11">5.  Available  percutaneously  deployed  ASD closure  devices  are  approved  for  closure  of  secundum-type </text>
<text top="874" left="105" width="687" height="15" font="11">defects.  Primum,  sinus  venosus,  and  coronary  sinus  ASDs  should  be  closed  surgically  because  of  the </text>
<text top="894" left="105" width="687" height="15" font="11">absence  of  appropriate  rims  for  percutaneous  device  placement  and  the  proximity  of  the </text>
<text top="913" left="105" width="687" height="15" font="11">atrioventricular  valves  and  conduction  system  to  the  closure  device.  Congenital  heart  surgeons  are </text>
<text top="933" left="105" width="687" height="15" font="11">trained  in  the  nuances  of  repair  of  such  defects,  including  common  association  with  anomalous </text>
<text top="953" left="105" width="662" height="15" font="11">pulmonary venous connection and abnormalities of the atrioventricular valves (S4.1.1-24, S4.1.1-25). </text>
<text top="981" left="105" width="687" height="15" font="11">6.  Patients  who  do  not  undergo  ASD  closure  have  worse  long-term  outcomes,  including  more  atrial </text>
<text top="1001" left="105" width="687" height="15" font="11">arrhythmias,  reduced  functional  capacity,  and  eventually  greater  degrees  of  PAH  (S4.1.1-7–S4.1.1-10, </text>
<text top="1020" left="105" width="687" height="15" font="11">S4.1.1-12).  However,  concomitant  diseases  may  influence  the  anticipated  benefit  of  ASD  closure  in </text>
<text top="1040" left="105" width="687" height="15" font="11">ameliorating  symptoms  and  improving  functional  capacity,  and  it  has  not  been  clearly  demonstrated </text>
<text top="1060" left="105" width="687" height="15" font="11">that  ASD  closure  in  asymptomatic  adults  prevents  long-term  complications.  Data  suggest  that  ASD </text>
<text top="1079" left="105" width="687" height="15" font="11">closure  improves  functional  capacity  but,  in  patients  with  normal  functional  capacity,  the  long-term </text>
</page>
<page number="52" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 53 </text>
<text top="162" left="105" width="687" height="15" font="11">benefit of ASD closure is less clear (S4.1.1-1, S4.1.1-9). Pending further study, it is reasonable to close an </text>
<text top="182" left="105" width="687" height="15" font="11">ASD  that  is  hemodynamically  important  in  the  absence  of  significant  PAH.  Older  adults  should  be </text>
<text top="201" left="105" width="687" height="15" font="11">evaluated  for  left  atrial  hypertension  resulting  from  diastolic  dysfunction  that  may  cause  symptoms </text>
<text top="221" left="105" width="687" height="15" font="11">simulating those from an ASD alone, in whom ASD closure could result in clinical worsening because of </text>
<text top="240" left="105" width="687" height="15" font="11">further increase in left atrial pressure because the relatively restrictive and higher pressure left atrium </text>
<text top="260" left="105" width="687" height="15" font="11">can no longer decompress into the lower pressure right atrium. Concomitant tricuspid annuloplasty can </text>
<text top="279" left="105" width="687" height="15" font="11">be of benefit in patients with moderate or more TR, as the additional volume load may adversely affect </text>
<text top="299" left="105" width="107" height="15" font="11">RV remodeling.  </text>
<text top="328" left="105" width="687" height="15" font="11">7. If surgical treatment is necessary for other congenital or acquired cardiac conditions and the patient </text>
<text top="347" left="105" width="687" height="15" font="11">has  a  secundum  ASD,  it  is  reasonable  to  perform  ASD  closure  at  the  time  of  surgery.  When  there  is </text>
<text top="367" left="105" width="495" height="15" font="11">moderate or greater TR, tricuspid valve repair may improve RV remodeling. </text>
<text top="395" left="105" width="687" height="15" font="11">8.  To  evaluate  the  patient  with  PAH  and  ASD,  ensure  the  shunt  remains  left  to  right  despite  elevated </text>
<text top="415" left="105" width="687" height="15" font="11">pulmonary  vascular  resistance  and/or  pulmonary  pressure  and  that  pulmonary  pressure  and  PVR  are </text>
<text top="434" left="105" width="687" height="15" font="11">accurately  measured.  In  this  circumstance,  data  derived  from  invasive  hemodynamic  assessment  are </text>
<text top="454" left="105" width="687" height="15" font="11">important in clarifying the appropriate course of action. The exclusion of patients with severe PAH from </text>
<text top="473" left="105" width="687" height="15" font="11">ASD closure may eventually be obviated by PA vasodilator and remodeling therapy with prostaglandins, </text>
<text top="493" left="105" width="687" height="15" font="11">endothelin  blockers,  and  PDE-5  inhibitors.  Because  of  the  complexity  of  the  hemodynamics  in  such </text>
<text top="513" left="105" width="687" height="15" font="11">patients,  collaboration  between  ACHD  and  pulmonary  hypertension  providers  is  important. </text>
<text top="532" left="105" width="687" height="15" font="11">Pretreatment  with  PAH  therapies  and  pulmonary  arterial  remodeling  agents,  with  a  demonstrated </text>
<text top="552" left="105" width="687" height="15" font="11">reduction  in  pulmonary  arterial  resistance  of  &gt;20%,  portends  a  favorable  prognosis  after  ASD  closure </text>
<text top="571" left="105" width="79" height="15" font="11">(S4.1.1-26). </text>
<text top="600" left="105" width="687" height="15" font="11">9. Morbidity and mortality are prohibitively high when surgical repair is attempted in patients with open </text>
<text top="619" left="105" width="544" height="15" font="11">shunts, such as ASD when Eisenmenger syndrome is present (S4.1.1-21, S4.1.1-22). </text>
<text top="648" left="105" width="4" height="15" font="11"> </text>
<text top="676" left="105" width="370" height="15" font="14"><b>Table 13. ASD: Routine Follow-Up and Testing Intervals </b></text>
<text top="699" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="717" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="699" left="333" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="330" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="699" left="451" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="449" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="699" left="570" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="567" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="699" left="685" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="681" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="736" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="736" left="321" width="40" height="13" font="8">36–60 </text>
<text top="736" left="440" width="18" height="13" font="8">24 </text>
<text top="736" left="558" width="33" height="13" font="8">6–12 </text>
<text top="736" left="676" width="25" height="13" font="8">3–6 </text>
<text top="754" left="105" width="27" height="13" font="8">ECG </text>
<text top="754" left="321" width="40" height="13" font="8">36–60 </text>
<text top="754" left="440" width="18" height="13" font="8">24 </text>
<text top="754" left="558" width="18" height="13" font="8">12 </text>
<text top="754" left="676" width="18" height="13" font="8">12 </text>
<text top="773" left="105" width="25" height="13" font="8">TTE </text>
<text top="773" left="321" width="40" height="13" font="8">36–60 </text>
<text top="773" left="440" width="18" height="13" font="8">24 </text>
<text top="773" left="558" width="18" height="13" font="8">12 </text>
<text top="773" left="676" width="18" height="13" font="8">12 </text>
<text top="791" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="791" left="321" width="66" height="13" font="8">As needed </text>
<text top="791" left="440" width="66" height="13" font="8">As needed </text>
<text top="791" left="558" width="59" height="13" font="8">Each visit </text>
<text top="791" left="676" width="59" height="13" font="8">Each visit </text>
<text top="810" left="105" width="85" height="13" font="8">Exercise test† </text>
<text top="810" left="321" width="66" height="13" font="8">As needed </text>
<text top="810" left="440" width="66" height="13" font="8">As needed </text>
<text top="810" left="558" width="40" height="13" font="8">12–24 </text>
<text top="810" left="676" width="33" height="13" font="8">6–12 </text>
<text top="828" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="844" left="105" width="353" height="12" font="9">†6-minute walk test or CPET, depending on the clinical indication. </text>
<text top="860" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CPET,  cardiopulmonary  exercise  test;  ECG,  electrocardiogram;  and  TTE, </text>
<text top="876" left="105" width="167" height="12" font="9">transthoracic echocardiogram. </text>
<text top="893" left="105" width="3" height="13" font="8"> </text>
<text top="910" left="105" width="3" height="13" font="8"> </text>
<text top="929" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="929" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="53" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="128" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1145" left="426" width="45" height="12" font="9">Page 54 </text>
<text top="162" left="105" width="166" height="15" font="14"><b>Figure 1. Secundum ASD</b> </text>
<text top="191" left="105" width="3" height="13" font="8"> </text>
<text top="697" left="789" width="4" height="14" font="11"> </text>
<text top="714" left="105" width="647" height="12" font="9">*Combination therapy with bosentan and PDE-5 inhibitor if symptomatic improvement does not occur with either alone. </text>
<text top="730" left="105" width="686" height="12" font="9">ACHD indicates adult congenital heart disease; ASD, atrial septal defect; PAH, pulmonary artery hypertension; PASP, pulmonary </text>
<text top="746" left="105" width="683" height="12" font="9">artery  systolic  pressure;  PDE-5,  phosphodiesterase  type-5  inhibitors;  PH,  pulmonary  hypertension;  and  Qp:Qs,  pulmonary–</text>
<text top="762" left="105" width="141" height="12" font="9">systemic blood flow ratio. </text>
<text top="779" left="105" width="4" height="16" font="22"> </text>
<text top="819" left="105" width="428" height="19" font="34"><b>4.1.2. Anomalous Pulmonary Venous Connections </b></text>
<text top="854" left="171" width="4" height="15" font="11"> </text>
<text top="853" left="223" width="487" height="16" font="12"><b>Recommendations for Anomalous Pulmonary Venous Connections </b></text>
<text top="873" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="873" left="577" width="180" height="15" font="23">Online Data Supplement 27</text>
<text top="873" left="757" width="8" height="15" font="11">. </text>
<text top="894" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="894" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="894" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="914" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="945" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="945" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="935" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="935" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="935" left="281" width="494" height="15" font="14"><b>CMR  or  CTA  is  recommended  for  evaluation  of  partial  anomalous </b></text>
<text top="954" left="281" width="339" height="15" font="14"><b>pulmonary venous connection (S4.1.2-1–S4.1.2-4). </b></text>
<text top="994" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="994" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="975" left="255" width="13" height="15" font="14"><b>2.</b></text>
<text top="975" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="975" left="281" width="494" height="15" font="14"><b>Cardiac  catheterization  can  be  useful  in  adults  with  partial  anomalous </b></text>
<text top="994" left="281" width="494" height="15" font="14"><b>pulmonary venous connection to further define hemodynamics (S4.1.2-5, </b></text>
<text top="1014" left="281" width="67" height="15" font="14"><b>S4.1.2-6). </b></text>
<text top="1034" left="399" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="1064" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1064" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1055" left="255" width="13" height="15" font="14"><b>3.</b></text>
<text top="1055" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="1055" left="281" width="494" height="15" font="14"><b>Surgical  repair  is  recommended  for  patients  with  partial  anomalous </b></text>
<text top="1074" left="281" width="494" height="15" font="14"><b>pulmonary venous connection when  functional  capacity is impaired and </b></text>
</page>
<page number="54" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 55 </text>
<text top="163" left="281" width="495" height="15" font="14"><b>RV  enlargement  is  present,  there  is  a  net  left-to-right  shunt  sufficiently </b></text>
<text top="183" left="281" width="495" height="15" font="14"><b>large  to  cause  physiological  sequelae  (e.g.,  Qp:Qs  ≥1.5:1),  PA  systolic </b></text>
<text top="202" left="281" width="495" height="15" font="14"><b>pressure  is  less  than  50%  systemic  pressure,  and  pulmonary  vascular </b></text>
<text top="222" left="281" width="435" height="15" font="14"><b>resistance is less than one third of systemic resistance (S4.1.2-5). </b></text>
<text top="262" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="262" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="242" left="255" width="13" height="15" font="14"><b>4.</b></text>
<text top="242" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="242" left="281" width="495" height="15" font="14"><b>Repair  of  partial  anomalous  pulmonary  venous  connection  is </b></text>
<text top="262" left="281" width="494" height="15" font="14"><b>recommended  at  the  time  of  closure  of  a  sinus  venosus  defect  or  ASD </b></text>
<text top="281" left="281" width="72" height="15" font="14"><b>(S4.1.2-7). </b></text>
<text top="351" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="351" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="302" left="255" width="13" height="15" font="14"><b>5.</b></text>
<text top="302" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="302" left="281" width="495" height="15" font="14"><b>Repair  of  a  scimitar  vein  is  recommended  in  adults  when  functional </b></text>
<text top="321" left="281" width="495" height="15" font="14"><b>capacity is impaired, evidence of RV volume overload is present, there is </b></text>
<text top="341" left="281" width="495" height="15" font="14"><b>a net left-to-right shunt sufficiently large to cause physiological sequelae </b></text>
<text top="360" left="281" width="495" height="15" font="14"><b>(e.g.,  Qp:Qs  ≥1.5:1),  PA  systolic  pressure  is  less  than  50%  systemic </b></text>
<text top="380" left="281" width="495" height="15" font="14"><b>pressure  and  pulmonary  vascular  resistance  is  less  than  one  third </b></text>
<text top="400" left="281" width="260" height="15" font="14"><b>systemic (S4.1.2-5, S4.1.2-8, S4.1.2-9).  </b></text>
<text top="469" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="469" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="420" left="255" width="13" height="15" font="14"><b>6.</b></text>
<text top="420" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="420" left="281" width="495" height="15" font="14"><b>Surgery  can  be  useful  for  right-  or  left-sided  partial  anomalous </b></text>
<text top="440" left="281" width="495" height="15" font="14"><b>pulmonary  venous  connection  in  asymptomatic  adults  with  RV  volume </b></text>
<text top="459" left="281" width="495" height="15" font="14"><b>overload,  net  left-to-right  shunt  sufficiently  large  to  cause  physiological </b></text>
<text top="479" left="281" width="495" height="15" font="14"><b>sequelae  (e.g.,  Qp:Qs  ≥1.5:1),  pulmonary  pressures  less  than  50% </b></text>
<text top="498" left="281" width="495" height="15" font="14"><b>systemic and pulmonary vascular resistance less than one third systemic </b></text>
<text top="518" left="281" width="72" height="15" font="14"><b>(S4.1.2-5). </b></text>
<text top="548" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="548" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="538" left="255" width="13" height="15" font="14"><b>7.</b></text>
<text top="538" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="538" left="281" width="495" height="15" font="14"><b>Surgery can be useful for repair of a scimitar vein in adults with evidence </b></text>
<text top="558" left="281" width="479" height="15" font="14"><b>of RV volume overload, with Qp:Qs 1.5:1 or greater (S4.1.2-5, S4.1.2-9). </b></text>
<text top="587" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="615" left="105" width="687" height="15" font="11">Abnormal connection between a pulmonary vein and systemic vein will result in volume overload of the </text>
<text top="635" left="105" width="687" height="15" font="11">right  heart,  with  a  physiological  effect  similar  to  that  of  an  ASD.  However,  in  the  absence  of  an </text>
<text top="654" left="105" width="683" height="15" font="11">associated ASD, anomalous pulmonary venous connection differs in that there is no potential for right-</text>
<text top="674" left="105" width="687" height="15" font="11">to-left shunting, and the magnitude of the left-to-right shunt is not exacerbated by the development of </text>
<text top="693" left="105" width="687" height="15" font="11">acquired left heart disease. The most common anomalous pulmonary venous connection is of the right </text>
<text top="713" left="105" width="687" height="15" font="11">upper  pulmonary  vein  to  the  superior  vena  cava  (S4.1.2-10),  which  may  be  associated  with  a  sinus </text>
<text top="733" left="105" width="687" height="15" font="11">venosus  defect. Other  abnormal  connections  include  right  pulmonary  vein(s)  to  the inferior vena  cava </text>
<text top="752" left="105" width="687" height="15" font="11">(often  via  a  so-called  ”scimitar  vein”  and  associated  with  sequestration  of  the  right  lower  lobe),  left </text>
<text top="772" left="105" width="687" height="15" font="11">upper pulmonary vein(s) to the left innominate vein, and right upper pulmonary vein(s) connecting high </text>
<text top="792" left="105" width="687" height="15" font="11">on the superior vena cava. Long-term sequelae of anomalous pulmonary venous connections reflect the </text>
<text top="811" left="105" width="687" height="15" font="11">impact  of  right  heart  volume  overload  and  are  similar  to  the  sequelae  of  ASDs.  Surgical  repair  can  be </text>
<text top="831" left="105" width="641" height="15" font="11">challenging as low-velocity venous flow imparts risk of thrombosis of the surgically operated vein. </text>
<text top="859" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="879" left="105" width="687" height="15" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="898" left="105" width="586" height="15" font="11">Section 4.4.6 for evaluation and management of severe PAH and Eisenmenger syndrome. </text>
<text top="927" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="955" left="105" width="687" height="15" font="11">1. Cross-sectional imaging with CMR or CTA is ideal for delineating pulmonary venous connections. CMR </text>
<text top="975" left="105" width="687" height="15" font="11">has  the  advantage  of  not  using  ionizing  radiation  and  may  also  quantify  the  degree  of  shunting. </text>
<text top="994" left="105" width="683" height="15" font="11">Echocardiography is an important part of the evaluation and may identify the anomalous veins (S4.1.2-</text>
<text top="1014" left="105" width="687" height="15" font="11">11),  particularly  in  patients  with  excellent  acoustic  windows;  however,  CMR  and  CTA  are  superior  for </text>
<text top="1033" left="105" width="278" height="15" font="11">evaluating extracardiac vascular anatomy. </text>
<text top="1062" left="105" width="687" height="15" font="11">2.  In  higher-risk  patients,  invasive  hemodynamic  assessment  can  be  useful  for  direct  measurement  of </text>
<text top="1082" left="105" width="687" height="15" font="11">pressures,  quantification  of  shunt  magnitude,  and  measurement  of  pulmonary  arterial  resistance  and </text>
</page>
<page number="55" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 56 </text>
<text top="162" left="105" width="687" height="15" font="11">responsiveness  to  pulmonary  vasodilator  therapy.  Invasive  hemodynamic  assessment  is  especially </text>
<text top="182" left="105" width="503" height="15" font="11">important in adult patients who are being considered for surgical correction. </text>
<text top="210" left="105" width="687" height="15" font="11">3. It is unusual for a single anomalous pulmonary venous connection of only 1 pulmonary lobe to result </text>
<text top="229" left="105" width="687" height="15" font="11">in a sufficient volume load to justify surgical repair. However, if a patient has symptoms referable to the </text>
<text top="249" left="105" width="687" height="15" font="11">shunt,  there  is  &gt;1  anomalous  vein,  and  a  moderate  or  large  left-to-right  shunt,  then  surgical  repair  is </text>
<text top="268" left="105" width="687" height="15" font="11">associated with a reduction in RV size and PA pressure (S4.1.2-5). Pulmonary hypertension is a risk for </text>
<text top="288" left="105" width="212" height="15" font="11">adverse outcomes with surgery. </text>
<text top="317" left="105" width="687" height="15" font="11">4.  Surgery  usually  involves  intracaval  baffling  into  the  left  atrium,  Warden  procedure  (S4.1.2-12),  or </text>
<text top="336" left="105" width="551" height="15" font="11">direct reimplantation of the anomalous pulmonary vein directly into the left atrium. </text>
<text top="365" left="105" width="687" height="15" font="11">5.  Surgical  repair  of  a  scimitar  vein  includes  direct  reimplantation  of  the  scimitar  vein  into  the  left </text>
<text top="384" left="105" width="687" height="15" font="11">atrium,  conduit  placement  to  the  left  atrium,  or  intracaval  baffling.  This  surgery  can  be  technically </text>
<text top="404" left="105" width="687" height="15" font="11">challenging with a greater risk of postoperative vein thrombosis than is associated with more common </text>
<text top="423" left="105" width="687" height="15" font="11">and simpler anomalous pulmonary vein abnormalities (S4.1.2-10). Pulmonary hypertension is associated </text>
<text top="443" left="105" width="140" height="15" font="11">with poor outcomes. </text>
<text top="472" left="105" width="687" height="15" font="11">6. It is unusual for a single anomalous pulmonary venous connection from only one pulmonary lobe to </text>
<text top="491" left="105" width="687" height="15" font="11">result in a sufficient volume load to justify surgical repair. However, if there is &gt;1 anomalous vein and a </text>
<text top="511" left="105" width="687" height="15" font="11">moderate or large left-to-right shunt, then surgical repair is associated with a reduction in RV size and </text>
<text top="530" left="105" width="270" height="15" font="11">PA pressure and can be useful (S4.1.2-5). </text>
<text top="558" left="105" width="687" height="15" font="11">7.  Surgical  repair  of  a  scimitar  vein  includes  direct  reimplantation  of  the  scimitar  vein  into  the  left </text>
<text top="578" left="105" width="687" height="15" font="11">atrium, side-to-side anastomosis of the scimitar vein to the left atrium and closure of its connection to </text>
<text top="598" left="105" width="687" height="15" font="11">the inferior  vena  cava  or intracaval  baffling.  This  surgery  can  be  technically  challenging  with  a  greater </text>
<text top="617" left="105" width="687" height="15" font="11">risk  of  postoperative  vein  thrombosis  than  is  associated  with  simpler  anomalous  pulmonary  vein </text>
<text top="637" left="105" width="172" height="15" font="11">abnormalities (S4.1.2-10). </text>
<text top="675" left="105" width="269" height="19" font="34"><b>4.1.3. Ventricular Septal Defect </b></text>
<text top="710" left="238" width="4" height="15" font="11"> </text>
<text top="709" left="291" width="352" height="16" font="12"><b>Recommendations for Ventricular Septal Defect </b></text>
<text top="730" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="730" left="577" width="180" height="15" font="23">Online Data Supplement 28</text>
<text top="730" left="757" width="8" height="15" font="11">. </text>
<text top="750" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="750" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="750" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="771" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="821" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="821" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="791" left="255" width="13" height="15" font="14"><b>1)</b></text>
<text top="791" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="791" left="281" width="495" height="15" font="14"><b>Adults with a VSD and evidence of left ventricular volume overload and </b></text>
<text top="811" left="281" width="495" height="15" font="14"><b>hemodynamically  significant  shunts  (Qp:Qs  ≥1.5:1)  should  undergo  VSD </b></text>
<text top="830" left="281" width="495" height="15" font="14"><b>closure, if PA systolic pressure is less than 50% systemic and pulmonary </b></text>
<text top="850" left="281" width="405" height="15" font="14"><b>vascular resistance is less than one third systemic (S4.1.3-1). </b></text>
<text top="890" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="890" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="870" left="255" width="13" height="15" font="14"><b>2)</b></text>
<text top="870" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="870" left="281" width="495" height="15" font="14"><b>Surgical  closure of  perimembranous or supracristal VSD is reasonable in </b></text>
<text top="890" left="281" width="495" height="15" font="14"><b>adults when  there is  worsening  aortic  regurgitation (AR) caused  by  VSD </b></text>
<text top="910" left="281" width="133" height="15" font="14"><b>(S4.1.3-1, S4.1.3-2). </b></text>
<text top="940" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="940" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="930" left="255" width="13" height="15" font="14"><b>3)</b></text>
<text top="930" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="930" left="281" width="495" height="15" font="14"><b>Surgical closure of a VSD may be reasonable in adults with a history of IE </b></text>
<text top="949" left="281" width="391" height="15" font="14"><b>caused by VSD if not otherwise contraindicated (S4.1.3-3). </b></text>
<text top="999" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="999" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="970" left="255" width="13" height="15" font="14"><b>4)</b></text>
<text top="970" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="970" left="281" width="495" height="15" font="14"><b>Closure of a VSD may be considered in the presence of a net left-to-right </b></text>
<text top="989" left="281" width="495" height="15" font="14"><b>shunt  (Qp:Qs  ≥1.5:1)  when  PA  systolic  pressure  is  50%  or  more  than </b></text>
<text top="1009" left="281" width="495" height="15" font="14"><b>systemic and/or pulmonary vascular resistance is greater than one third </b></text>
<text top="1029" left="281" width="195" height="15" font="14"><b>systemic (S4.1.3-4–S4.1.3-6). </b></text>
<text top="1049" left="124" width="21" height="15" font="14"><b>III: </b></text>
<text top="1069" left="115" width="40" height="15" font="14"><b>Harm </b></text>
<text top="1059" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="1049" left="255" width="13" height="15" font="14"><b>5)</b></text>
<text top="1049" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1049" left="281" width="494" height="15" font="14"><b>VSD closure should not be performed in adults with severe PAH with PA </b></text>
<text top="1069" left="281" width="495" height="15" font="14"><b>systolic  pressure  greater  than  two  thirds  systemic,  pulmonary  vascular </b></text>
</page>
<page number="56" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 57 </text>
<text top="163" left="281" width="494" height="15" font="14"><b>resistance  greater  than  two  thirds  systemic  and/or  a  net  right-to-left </b></text>
<text top="183" left="281" width="178" height="15" font="14"><b>shunt (S4.1.3-7–S4.1.3-9).  </b></text>
<text top="211" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="240" left="105" width="687" height="15" font="11">Ventricular septal defects (VSDs) initially create a volume load to the left heart, and  the  magnitude of </text>
<text top="259" left="105" width="687" height="15" font="11">hemodynamic impact is directly related to the size of the shunt and afterload to the ventricles. Isolated </text>
<text top="279" left="105" width="683" height="15" font="11">VSDs are the most commonly encountered form of CHD in the pediatric population (S4.1.3-10– S4.1.3-</text>
<text top="299" left="105" width="687" height="15" font="11">14).  Most  isolated  muscular  and  perimembranous  VSDs  are  small  and  close  spontaneously.  The </text>
<text top="318" left="105" width="508" height="15" font="11">spectrum of isolated residual VSDs encountered in the adult patient includes: </text>
<text top="347" left="131" width="12" height="15" font="11">1.</text>
<text top="347" left="144" width="4" height="15" font="26"> </text>
<text top="347" left="158" width="634" height="15" font="11">Small restrictive defects. The pulmonary vascular resistance is not significantly elevated and the </text>
<text top="366" left="158" width="274" height="15" font="11">left-to-right shunt is small (Qp:Qs &lt;1.5:1). </text>
<text top="386" left="131" width="12" height="15" font="11">2.</text>
<text top="386" left="144" width="4" height="15" font="26"> </text>
<text top="386" left="158" width="634" height="15" font="11">Large  nonrestrictive  defects  in  cyanotic  patients  who  have  developed  Eisenmenger  syndrome, </text>
<text top="405" left="158" width="570" height="15" font="11">with pulmonary vascular resistance at systemic levels and shunt reversal (right-to-left). </text>
<text top="425" left="131" width="12" height="15" font="11">3.</text>
<text top="425" left="144" width="4" height="15" font="26"> </text>
<text top="425" left="158" width="634" height="15" font="11">Patients with moderately  restrictive  defects (Qp:Qs ≥1.5:1  and  &lt;2:1)  who  have not  undergone </text>
<text top="445" left="158" width="493" height="15" font="11">closure for some reason. These patients often have mild-to-moderate PAH. </text>
<text top="464" left="131" width="12" height="15" font="11">4.</text>
<text top="465" left="144" width="4" height="15" font="26"> </text>
<text top="464" left="158" width="634" height="15" font="11">Patients  who  have  had  their  defects  closed  in  childhood.  These  patients  may  have  VSD  patch </text>
<text top="484" left="158" width="41" height="15" font="11">leaks. </text>
<text top="512" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="532" left="105" width="687" height="15" font="11">other procedures in these patients; Section 3.4 for recommendations on diagnostic evaluation; Section </text>
<text top="551" left="105" width="687" height="15" font="11">4.4.6  for  evaluation  and  management  of  severe  PAH  and  Eisenmenger  syndrome;  Figure  2  for  a </text>
<text top="571" left="105" width="687" height="15" font="11">diagnostic  and  treatment  algorithm  for  ventricular  level  shunt;  and  Table  14  for  routine  testing  and </text>
<text top="590" left="105" width="130" height="15" font="11">follow-up intervals. </text>
<text top="619" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="647" left="105" width="687" height="15" font="11">1.  In  the  absence  of  aortic  valve  prolapse  and  regurgitation  or  IE,  small  restrictive  defects  of  the </text>
<text top="667" left="105" width="687" height="15" font="11">muscular  or  membranous  septum  may  be  watched  conservatively  without  need  for  operative </text>
<text top="686" left="105" width="687" height="15" font="11">intervention.  In  a  long-term  follow-up  registry,  the  overall  survival  rate  was  87%  for  all  patients  with </text>
<text top="706" left="105" width="687" height="15" font="11">unoperated  VSD  at  25  years  (S4.1.3-1).  For  patients  with  small  defects  (Qp:Qs  &lt;1.5:1  and  low  PA </text>
<text top="726" left="105" width="687" height="15" font="11">pressure), the survival rate was 96%. Patients with moderate and large defects fared worse with 25-year </text>
<text top="745" left="105" width="687" height="15" font="11">survival of 86% and 61%, respectively. Those with Eisenmenger syndrome (cyanosis/hypoxemia caused </text>
<text top="765" left="105" width="687" height="15" font="11">by  reversal  of  shunt  to  right-to-left)  had  a  much  lower  25-year  survival  (42%).  Larger  defects  may  be </text>
<text top="784" left="105" width="687" height="15" font="11">repaired but only in the absence of severe PAH and severely elevated pulmonary vascular resistance, the </text>
<text top="804" left="105" width="404" height="15" font="11">presence of which incurs a high perioperative risk  S4.1.3-15). </text>
<text top="832" left="158" width="634" height="15" font="11">Life expectancy  after VSD closure in an  adult is not normal but has improved over  the past 50 </text>
<text top="852" left="105" width="687" height="15" font="11">years. Transcatheter device occlusion of muscular and perimembranous VSD is feasible, and trials have </text>
<text top="872" left="105" width="687" height="15" font="11">demonstrated a good safety and efficacy profile (S4.1.3-16, S4.1.3-17). VSD in adults is most commonly </text>
<text top="891" left="105" width="687" height="15" font="11">either  small,  or  large  and  associated  with  Eisenmenger  syndrome;  therefore,  data  regarding  optimal </text>
<text top="911" left="105" width="687" height="15" font="11">management  of  moderate  VSD  in  adults  are  lacking  because  of  relative  infrequency  of  a </text>
<text top="931" left="105" width="419" height="15" font="11">hemodynamically significant VSD for which closure is an option. </text>
<text top="959" left="105" width="687" height="15" font="11">2.  Small  restrictive  defects  of  the  muscular  or  membranous  septum  may  be  managed  by  observation </text>
<text top="978" left="105" width="687" height="15" font="11">without need for operative intervention. However, 6% of patients with small supracristal (subaortic) or </text>
<text top="998" left="105" width="687" height="15" font="11">perimembranous defects may develop aortic valve prolapse and resultant AR  that  may  be progressive </text>
<text top="1017" left="105" width="687" height="15" font="11">(S4.1.3-1, S4.1.3-2, S4.1.3-18). There is a paucity of data supporting the timing of VSD closure in patients </text>
<text top="1037" left="105" width="687" height="15" font="11">with AR. Ideally, the VSD is closed if AR is progressive to avoid the continued worsening of AR and the </text>
<text top="1057" left="105" width="687" height="15" font="11">need  for  aortic  valve  replacement.  In  the  presence  of  a  VSD,  an  aortic  valve  cusp  (usually  the  right </text>
<text top="1076" left="105" width="687" height="15" font="11">coronary cusp) may prolapse and partially or completely close the VSD, often with associated AR. At the </text>
</page>
<page number="57" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 58 </text>
<text top="162" left="105" width="687" height="15" font="11">time  of  VSD  closure,  aortic  valve  repair may  be  performed  in  an  effort  to  stabilize  or improve  AR.  For </text>
<text top="182" left="105" width="687" height="15" font="11">patients who meet GDMT criteria for aortic valve replacement, this may be performed concomitant with </text>
<text top="201" left="105" width="159" height="15" font="11">VSD closure (S4.1.3-19). </text>
<text top="229" left="105" width="687" height="15" font="11">3. In patients with unrepaired VSD, there is an increased risk of IE, typically involving the tricuspid and </text>
<text top="249" left="105" width="112" height="15" font="11">pulmonic valves. </text>
<text top="277" left="105" width="687" height="15" font="11">4. Early attempts at surgical closure of nonrestrictive VSD in patients with Eisenmenger syndrome were </text>
<text top="297" left="105" width="687" height="15" font="11">associated  with  an  unacceptably  high  risk  of  mortality,  and  the  practice  was  quickly  abandoned. </text>
<text top="317" left="105" width="687" height="15" font="11">However, there are adult patients with large VSD and PAH who may benefit from closure of the VSD if </text>
<text top="336" left="105" width="687" height="15" font="11">the net shunt is left-to-right either at baseline or with PAH therapies. The use of fenestrated devices and </text>
<text top="356" left="105" width="687" height="15" font="11">fenestrated  surgical patches in these patients leaves a small residual shunt to allow decompression of </text>
<text top="375" left="105" width="687" height="15" font="11">the  right  heart  (S4.1.3-5,  S4.1.3-6).  In  theory,  treatment  of  these  patients  with  PAH  therapies  before </text>
<text top="395" left="105" width="220" height="15" font="11">closure could improve outcomes. </text>
<text top="423" left="105" width="683" height="15" font="11">5. Closure of nonrestrictive VSD in adults with Eisenmenger syndrome who do not demonstrate left-to-</text>
<text top="443" left="105" width="687" height="15" font="11">right  shunting and  a decline in pulmonary  vascular resistance with PAH therapies  carries a high risk of </text>
<text top="463" left="105" width="391" height="15" font="11">mortality and should not be performed (S4.1.3-7- S4.1.3-9). </text>
<text top="491" left="105" width="4" height="15" font="11"> </text>
<text top="519" left="105" width="370" height="15" font="14"><b>Table 14. VSD: Routine Follow-Up and Testing Intervals </b></text>
<text top="543" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="560" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="543" left="322" width="119" height="13" font="7"><b>Physiological Stage </b></text>
<text top="560" left="355" width="52" height="13" font="7"><b>A* (mo) </b></text>
<text top="543" left="465" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="560" left="462" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="543" left="580" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="560" left="577" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="543" left="688" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="560" left="685" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="579" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="579" left="321" width="18" height="13" font="8">36 </text>
<text top="579" left="453" width="18" height="13" font="8">24 </text>
<text top="579" left="571" width="33" height="13" font="8">6–12 </text>
<text top="579" left="683" width="25" height="13" font="8">3–6 </text>
<text top="597" left="105" width="27" height="13" font="8">ECG </text>
<text top="597" left="321" width="18" height="13" font="8">36 </text>
<text top="597" left="453" width="18" height="13" font="8">24 </text>
<text top="597" left="571" width="18" height="13" font="8">12 </text>
<text top="597" left="683" width="18" height="13" font="8">12 </text>
<text top="616" left="105" width="25" height="13" font="8">TTE </text>
<text top="616" left="321" width="18" height="13" font="8">36 </text>
<text top="616" left="453" width="18" height="13" font="8">24 </text>
<text top="616" left="571" width="18" height="13" font="8">12 </text>
<text top="616" left="683" width="18" height="13" font="8">12 </text>
<text top="634" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="634" left="321" width="66" height="13" font="8">As needed </text>
<text top="634" left="453" width="66" height="13" font="8">As needed </text>
<text top="634" left="571" width="59" height="13" font="8">Each visit </text>
<text top="634" left="683" width="59" height="13" font="8">Each visit </text>
<text top="653" left="105" width="85" height="13" font="8">Exercise test† </text>
<text top="653" left="321" width="66" height="13" font="8">As needed </text>
<text top="653" left="453" width="66" height="13" font="8">As needed </text>
<text top="653" left="571" width="40" height="13" font="8">12–24 </text>
<text top="653" left="683" width="33" height="13" font="8">6–12 </text>
<text top="671" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="687" left="105" width="371" height="12" font="9">†6-minute walk test or CPET, depending on the clinical circumstance. </text>
<text top="703" left="105" width="686" height="12" font="9">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; TTE, transthoracic </text>
<text top="719" left="105" width="280" height="12" font="9">echocardiogram; and VSD, ventricular septal defect. </text>
<text top="737" left="105" width="4" height="16" font="22"> </text>
<text top="772" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="772" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="58" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="128" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1145" left="426" width="45" height="12" font="9">Page 59 </text>
<text top="162" left="105" width="416" height="15" font="14"><b>Figure 2. Hemodynamically Significant Ventricular Level Shunt </b></text>
<text top="795" left="789" width="4" height="14" font="11"> </text>
<text top="813" left="105" width="650" height="12" font="9">*Combination therapy with bosentan and PDE-5 inhibitor, if symptomatic improvement does not occur with either alone. </text>
<text top="829" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  AR,  aortic  regurgitation;  IE,  infective  endocarditis;  LV,  left  ventricular;  PAH, </text>
<text top="845" left="105" width="686" height="12" font="9">pulmonary  artery  hypertension;  PASP,  pulmonary  artery  systolic  pressure;  PDE-5,  phosphodiesterase  type-5  inhibitors;  PH, </text>
<text top="861" left="105" width="570" height="12" font="9">pulmonary hypertension; Qp:Qs, pulmonary–systemic blood flow ratio; and VSD, ventricular septal defect. </text>
<text top="877" left="105" width="3" height="13" font="8"> </text>
<text top="914" left="105" width="310" height="19" font="34"><b>4.1.4. Atrioventricular Septal Defect </b></text>
<text top="949" left="221" width="4" height="15" font="11"> </text>
<text top="948" left="274" width="386" height="16" font="12"><b>Recommendations for Atrioventricular Septal Defect </b></text>
<text top="968" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="968" left="577" width="180" height="15" font="23">Online Data Supplement 29</text>
<text top="968" left="757" width="8" height="15" font="11">. </text>
<text top="989" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="989" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="989" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="1009" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="1039" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="1039" left="193" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="1030" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="1030" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1030" left="281" width="494" height="15" font="14"><b>Cardiac  catheterization  can  be  useful  in  adults  with  atrioventricular </b></text>
<text top="1049" left="281" width="389" height="15" font="14"><b>septal defect when pulmonary hypertension is suspected. </b></text>
<text top="1070" left="425" width="84" height="15" font="14"><b>Therapeutic </b></text>
</page>
<page number="59" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 60 </text>
<text top="183" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="183" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="163" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="163" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="163" left="281" width="495" height="15" font="14"><b>Surgery  for  severe  left  atrioventricular  valve  regurgitation  is </b></text>
<text top="183" left="281" width="491" height="15" font="14"><b>recommended  per  GDMT  indications  for  mitral  regurgitation  (S4.1.4-1–</b></text>
<text top="202" left="281" width="67" height="15" font="14"><b>S4.1.4-4). </b></text>
<text top="262" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="262" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="222" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="223" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="222" left="281" width="494" height="15" font="14"><b>Surgery  for primary repair of  atrioventricular septal defect  or closure  of </b></text>
<text top="242" left="281" width="495" height="15" font="14"><b>residual  shunts  in  adults  with  repaired  atrioventricular  septal  defect  is </b></text>
<text top="262" left="281" width="495" height="15" font="14"><b>recommended when there is a net left-to-right shunt (Qp:Qs ≥1.5:1), PA </b></text>
<text top="281" left="281" width="495" height="15" font="14"><b>systolic  pressure  less  than  50%  systemic  and  pulmonary  vascular </b></text>
<text top="301" left="281" width="265" height="15" font="14"><b>resistance less than one third systemic. </b></text>
<text top="351" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="351" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="321" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="321" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="321" left="281" width="495" height="15" font="14"><b>Operation  for  discrete  LVOT  obstruction  in  adults  with  atrioventricular </b></text>
<text top="341" left="281" width="494" height="15" font="14"><b>septal  defect  is  reasonable  with  a  maximum  gradient  of  50  mm  Hg  or </b></text>
<text top="360" left="281" width="495" height="15" font="14"><b>greater, a lesser gradient if HF symptoms  are  present, or if concomitant </b></text>
<text top="380" left="281" width="306" height="15" font="14"><b>moderate-to-severe mitral or AR are present. </b></text>
<text top="440" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="440" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="400" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="400" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="400" left="281" width="494" height="15" font="14"><b>Surgery  for primary repair of  atrioventricular septal defect  or closure  of </b></text>
<text top="420" left="281" width="495" height="15" font="14"><b>residual shunts in adults with repaired atrioventricular septal defect may </b></text>
<text top="440" left="281" width="495" height="15" font="14"><b>be considered in the presence of a net left-to-right shunt (Qp:Qs ≥1.5:1), </b></text>
<text top="459" left="281" width="495" height="15" font="14"><b>if  PA  systolic  pressure  is  50%  or  more  systemic,  and/or  pulmonary </b></text>
<text top="479" left="281" width="361" height="15" font="14"><b>vascular resistance is greater than one third systemic. </b></text>
<text top="528" left="124" width="21" height="15" font="14"><b>III: </b></text>
<text top="548" left="115" width="40" height="15" font="14"><b>Harm </b></text>
<text top="538" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="499" left="256" width="13" height="15" font="14"><b>6.</b></text>
<text top="499" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="499" left="281" width="494" height="15" font="14"><b>Surgery  for primary repair of  atrioventricular septal defect  or closure  of </b></text>
<text top="519" left="281" width="495" height="15" font="14"><b>residual  shunts  in  adults  with  repaired  atrioventricular  septal  defect </b></text>
<text top="538" left="281" width="495" height="15" font="14"><b>should  not  be  performed  with  PA  systolic  pressure  greater  than  two </b></text>
<text top="558" left="281" width="495" height="15" font="14"><b>thirds  systemic,  pulmonary  vascular  resistance  greater  than  two  thirds </b></text>
<text top="578" left="281" width="381" height="15" font="14"><b>systemic, or a net right-to-left shunt (S4.1.4-5, S4.1.4-6).  </b></text>
<text top="607" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="635" left="105" width="687" height="15" font="11">AVSDs represent about 4% to 5% of congenital heart defects and include a primum ASD, inlet VSD, and </text>
<text top="654" left="105" width="687" height="15" font="11">common  atrioventricular  valve.  They  can  occur  in  several  anatomic  variations  including  partial  AVSD </text>
<text top="674" left="105" width="687" height="15" font="11">with only a primum ASD component and typically a cleft left atrioventricular valve, complete AVSD with </text>
<text top="693" left="105" width="687" height="15" font="11">both  ASD  and  VSD  and a  common  atrioventricular valve,  and  transitional and intermediate  AVSD  with </text>
<text top="713" left="105" width="687" height="15" font="11">incomplete  atrial  and  VSDs  and/or  incomplete  abnormalities  of  the  common  atrioventricular  valve. </text>
<text top="733" left="105" width="687" height="15" font="11">AVSD anatomy is also commonly described by the Rastelli classification (S4.1.4-7, S4.1.4-8). The Rastelli </text>
<text top="752" left="105" width="687" height="15" font="11">classification describes anatomic variations of the superior bridging leaflet of the atrioventricular valve. </text>
<text top="772" left="105" width="687" height="15" font="11">In addition to the Rastelli classification or other similar descriptors, the relative sizes of the ventricles as </text>
<text top="792" left="105" width="687" height="15" font="11">balanced  or  unbalanced  guide  the  type  of  repair  (e.g.,  biventricular  or  single  ventricle  repair).  This </text>
<text top="811" left="105" width="687" height="15" font="11">section refers to patients with balanced AVSD and biventricular repair. AVSD also occurs in association </text>
<text top="831" left="105" width="687" height="15" font="11">with other congenital lesions including TOF, CoA, and heterotaxy. There is also a strong association with </text>
<text top="850" left="105" width="386" height="15" font="11">syndromes, most commonly trisomy 21 (Down syndrome). </text>
<text top="879" left="158" width="634" height="15" font="11">From  a  management  perspective,  most  adults  with  AVSD  will  have  had  surgical  repair  as </text>
<text top="898" left="105" width="687" height="15" font="11">children. If those with complete AVSD (with large ASD and VSD) are not repaired early in life (typically &lt;6 </text>
<text top="918" left="105" width="687" height="15" font="11">months  of  age),  irreversible  pulmonary  vascular  disease  usually  develops  resulting  in  Eisenmenger </text>
<text top="938" left="105" width="687" height="15" font="11">physiology, precluding complete repair. For those who underwent a surgical repair, long-term follow-up </text>
<text top="957" left="105" width="687" height="15" font="11">is required to monitor for left atrioventricular valve regurgitation and stenosis, left ventricular outflow </text>
<text top="977" left="105" width="687" height="15" font="11">tract  (LVOT)  obstruction  attributable  to  the  abnormal  shape  of  the  LVOT,  and  tachyarrhythmias  and </text>
<text top="996" left="105" width="687" height="15" font="11">bradyarrhythmias. Left atrioventricular valve regurgitation is the most common reason for later surgical </text>
<text top="1016" left="105" width="687" height="15" font="11">reintervention. There are few long-term follow-up studies of patients after AVSD repair in childhood, so </text>
<text top="1036" left="105" width="576" height="15" font="11">the most effective and efficient timing and type of surveillance are still being evaluated. </text>
<text top="1064" left="158" width="634" height="15" font="11">The atrioventricular node is typically displaced inferiorly in AVSD and is associated with relative </text>
<text top="1083" left="105" width="687" height="15" font="11">hypoplasia  of  the  left  anterior  fascicle  (S4.1.4-9).  Late-onset  complete  heart  block  (as  late  as  15  years </text>
</page>
<page number="60" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 61 </text>
<text top="162" left="105" width="687" height="15" font="11">after surgery) has been noted after surgery in patients operated on for AVSD who were discharged from </text>
<text top="182" left="105" width="687" height="15" font="11">the  hospital  with  normal  conduction,  although  more  commonly  seen  in  those  patients  with  transient </text>
<text top="201" left="105" width="687" height="15" font="11">postoperative heart block. Regular monitoring for symptoms and screening with an ECG are important </text>
<text top="221" left="105" width="349" height="15" font="11">to evaluate for conduction abnormalities (S4.1.4-10). </text>
<text top="249" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="268" left="105" width="687" height="15" font="11">other procedures in these patients; Section 3.4 for recommendations on diagnostic evaluation; Section </text>
<text top="288" left="105" width="687" height="15" font="11">4.1.1  for  recommendations  on  primum  ASD;  Section  4.4.6  for  evaluation  and  management  of  severe </text>
<text top="308" left="105" width="687" height="15" font="11">PAH and Eisenmenger syndrome associated with AVSD; and Table 15 for routine testing and follow-up </text>
<text top="328" left="105" width="64" height="15" font="11">intervals. </text>
<text top="356" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="384" left="105" width="687" height="15" font="11">1.  Invasive  hemodynamic  assessment  still  has  an  important  role  as  a  confirmatory  tool  and  for  the </text>
<text top="404" left="105" width="678" height="15" font="11">evaluation of pulmonary vasoreactivity, which does carry prognostic significance for adults with shunts. </text>
<text top="432" left="105" width="687" height="15" font="11">2.  Although  the  left  atrioventricular  valve in  an  AVSD  malformation  is  not  anatomically  the  same  as  a </text>
<text top="452" left="105" width="687" height="15" font="11">mitral valve, one can extrapolate the criteria for consideration of left atrioventricular valve surgery from </text>
<text top="472" left="105" width="687" height="15" font="11">the VHD guideline for mitral regurgitation and mitral stenosis (S4.1.4-1). In extrapolating these criteria, </text>
<text top="491" left="105" width="687" height="15" font="11">there are important potential differences in this patient population compared with those with acquired </text>
<text top="511" left="105" width="687" height="15" font="11">mitral valve disease. There are anatomic differences in position of the annulus, papillary muscles and the </text>
<text top="530" left="105" width="687" height="15" font="11">morphology of the LVOT, which is  an anterior, narrow, and potentially  obstructed structure, such that </text>
<text top="550" left="105" width="687" height="15" font="11">congenital surgical expertise is needed. Patients with an AVSD have typically had at least 1 prior attempt </text>
<text top="569" left="105" width="687" height="15" font="11">to  repair  the  AVSD,  have  different  risks  of  arrhythmia,  and  may  have  other  anatomic  lesions  (e.g., </text>
<text top="589" left="105" width="687" height="15" font="11">subaortic  stenosis  [subAS]).  In  1  meta-analysis  of  studies  of  adult  left  atrioventricular  valve  surgery  in </text>
<text top="609" left="105" width="687" height="15" font="11">patients  with  AVSD,  the  risk  of  needing  a  pacemaker  was  higher  in  those  who  underwent  valve </text>
<text top="628" left="105" width="687" height="15" font="11">replacement than in those who underwent repair (S4.1.4-2). In another single-center study, one third of </text>
<text top="648" left="105" width="687" height="15" font="11">repaired  patients  required  an  additional  reoperation  (S4.1.4-3).  When  replacement  is  required,  the </text>
<text top="668" left="105" width="687" height="15" font="11">choice to use mechanical versus  bioprosthetic  valve is individualized, but a mechanical valve is usually </text>
<text top="687" left="105" width="687" height="15" font="11">necessary  because  of  the  potential  for  LVOT  obstruction  from  the  struts  of  the  bioprosthetic  valve. </text>
<text top="707" left="105" width="592" height="15" font="11">Nevertheless, valve repair is preferred to valve replacement when it is technically feasible. </text>
<text top="735" left="105" width="687" height="15" font="11">3.  There  are  no  large  studies  on  residual  shunts  in  patients  with  AVSD,  but  extrapolating  from </text>
<text top="755" left="105" width="687" height="15" font="11">information  on  residual  isolated  ASD  or  isolated  VSD,  a  moderate  or  large  residual  shunt  is  likely  to </text>
<text top="774" left="105" width="683" height="15" font="11">result  in worsening  clinical  status  over  time  and  thus  merits consideration  of  repair (S4.1.4-11–S4.1.4-</text>
<text top="794" left="105" width="687" height="15" font="11">13). See Sections 4.1.1 and 4.1.3 for related considerations regarding ASD and/or VSD. Pulse oximetry at </text>
<text top="814" left="105" width="687" height="15" font="11">rest and with ambulation may identify patients with increased pulmonary resistance and shunt reversal. </text>
<text top="833" left="105" width="687" height="15" font="11">There is a subset of patients with resting systemic oxygen saturation &gt;90% who will have a decrease in </text>
<text top="853" left="105" width="687" height="15" font="11">oxygen  saturation  with  activity  to  &lt;90%,  emphasizing  the  importance  of  performing  resting  and </text>
<text top="872" left="105" width="263" height="15" font="11">ambulatory pulse oximetry assessment. </text>
<text top="900" left="105" width="687" height="15" font="11">4. Patients  with  AVSD  are  at  risk  of  LVOT  obstruction  because  of  the  abnormal  anatomy  of  the  LVOT. </text>
<text top="920" left="105" width="683" height="15" font="11">Surgical resection of LVOT obstruction in association with AVSD is reasonable when there is moderate-</text>
<text top="940" left="105" width="687" height="15" font="11">to-severe  obstruction  or  less  obstruction  but  associated  HF  or  mitral  regurgitation  or  AR.  In  isolated </text>
<text top="959" left="105" width="687" height="15" font="11">subAS studies, worse outcomes were revealed in patients with maximum gradients ≥50 mm Hg or with </text>
<text top="979" left="105" width="687" height="15" font="11">gradients &lt;50 mm Hg in association with symptoms of HF (S4.1.4-14–S4.1.4-17). Importantly the LVOT </text>
<text top="999" left="105" width="687" height="15" font="11">obstruction  in  AVSD  may  not  be  discrete  and,  therefore,  surgical  repair  may  be  more  complex.  When </text>
<text top="1018" left="105" width="687" height="15" font="11">evaluating  patients  with  tunnel-like  or  complex  LVOT  obstruction,  the  peak  Doppler  gradients  and </text>
<text top="1038" left="105" width="687" height="15" font="11">Bernoulli equation may inaccurately reflect the severity of obstruction, and cardiac catheterization may </text>
<text top="1057" left="105" width="77" height="15" font="11">be needed. </text>
</page>
<page number="61" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 62 </text>
<text top="162" left="105" width="687" height="15" font="11">5. Patients with AVSD, particularly those with Down syndrome, are at high risk of developing pulmonary </text>
<text top="182" left="105" width="687" height="15" font="11">vascular  disease  resulting  in  Eisenmenger  syndrome  (S4.1.4-18,  S4.1.4-19).  For  those  who  continue  to </text>
<text top="201" left="105" width="687" height="15" font="11">have  a  net  left-to-right  shunt  despite  elevated  PA  pressures,  closure  of  the  defect  may  prevent </text>
<text top="221" left="105" width="687" height="15" font="11">exacerbation  of  PAH.  This is an  unusual circumstance  and  decision-making  requires  collaboration with </text>
<text top="240" left="105" width="303" height="15" font="11">ACHD and pulmonary hypertension providers. </text>
<text top="268" left="105" width="687" height="15" font="11">6. Morbidity and mortality are prohibitively high when surgical repair is attempted in patients with open </text>
<text top="288" left="105" width="533" height="15" font="11">shunts such as AVSD when Eisenmenger syndrome is present (S4.1.4-5, S4.1.4-6). </text>
<text top="317" left="105" width="4" height="15" font="11"> </text>
<text top="345" left="105" width="380" height="15" font="14"><b>Table 15. AVSD: Routine Follow-Up and Testing Intervals </b></text>
<text top="368" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="386" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="368" left="322" width="119" height="13" font="7"><b>Physiological Stage </b></text>
<text top="386" left="355" width="52" height="13" font="7"><b>A* (mo) </b></text>
<text top="368" left="465" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="386" left="462" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="368" left="580" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="386" left="577" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="368" left="688" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="386" left="685" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="404" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="404" left="321" width="40" height="13" font="8">24–36 </text>
<text top="404" left="453" width="18" height="13" font="8">24 </text>
<text top="404" left="571" width="33" height="13" font="8">6–12 </text>
<text top="404" left="683" width="25" height="13" font="8">3–6 </text>
<text top="423" left="105" width="27" height="13" font="8">ECG </text>
<text top="423" left="321" width="40" height="13" font="8">24–36 </text>
<text top="423" left="453" width="18" height="13" font="8">24 </text>
<text top="423" left="571" width="18" height="13" font="8">12 </text>
<text top="423" left="683" width="18" height="13" font="8">12 </text>
<text top="441" left="105" width="25" height="13" font="8">TTE </text>
<text top="441" left="321" width="40" height="13" font="8">24–36 </text>
<text top="441" left="453" width="18" height="13" font="8">24 </text>
<text top="441" left="571" width="18" height="13" font="8">12 </text>
<text top="441" left="683" width="18" height="13" font="8">12 </text>
<text top="460" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="460" left="321" width="66" height="13" font="8">As needed </text>
<text top="460" left="453" width="66" height="13" font="8">As needed </text>
<text top="460" left="571" width="59" height="13" font="8">Each visit </text>
<text top="460" left="683" width="59" height="13" font="8">Each visit </text>
<text top="479" left="105" width="85" height="13" font="8">Exercise test† </text>
<text top="479" left="321" width="66" height="13" font="8">As needed </text>
<text top="479" left="453" width="66" height="13" font="8">As needed </text>
<text top="479" left="571" width="40" height="13" font="8">12–24 </text>
<text top="479" left="683" width="33" height="13" font="8">6–12 </text>
<text top="497" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="513" left="105" width="353" height="12" font="9">†6-minute walk test or CPET, depending on the clinical indication. </text>
<text top="529" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  AVSD,  atrioventricular  septal  defect;  CPET,  cardiopulmonary  exercise  testing; </text>
<text top="545" left="105" width="348" height="12" font="9">ECG, electrocardiogram; and TTE, transthoracic echocardiogram. </text>
<text top="561" left="105" width="3" height="13" font="8"> </text>
<text top="598" left="105" width="269" height="19" font="34"><b>4.1.5. Patent Ductus Arteriosus </b></text>
<text top="633" left="238" width="4" height="15" font="11"> </text>
<text top="632" left="291" width="351" height="16" font="12"><b>Recommendations for Patent Ductus Arteriosus </b></text>
<text top="653" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="653" left="577" width="180" height="15" font="23">Online Data Supplement 30</text>
<text top="653" left="757" width="8" height="15" font="11">. </text>
<text top="673" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="673" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="673" left="256" width="4" height="15" font="14"><b> </b></text>
<text top="673" left="397" width="4" height="15" font="14"><b> </b></text>
<text top="673" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="694" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="734" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="734" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="714" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="714" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="714" left="281" width="495" height="15" font="14"><b>Measurement of oxygen saturation should be performed in feet and both </b></text>
<text top="734" left="281" width="494" height="15" font="14"><b>hands  in  adults  with  a  PDA  to  assess  for  the  presence  of  right-to-left </b></text>
<text top="753" left="281" width="66" height="15" font="14"><b>shunting. </b></text>
<text top="793" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="793" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="774" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="774" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="774" left="281" width="495" height="15" font="14"><b>In  addition  to  the  standard  diagnostic  tools,  cardiac  catheterization  can </b></text>
<text top="793" left="281" width="495" height="15" font="14"><b>be  useful  in  patients  with  PDA  and  suspected  pulmonary  hypertension </b></text>
<text top="813" left="281" width="91" height="15" font="14"><b>(Section 3.5). </b></text>
<text top="833" left="411" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="883" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="883" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="854" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="854" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="854" left="281" width="494" height="15" font="14"><b>PDA closure in adults is recommended  if left atrial or LV enlargement is </b></text>
<text top="873" left="281" width="495" height="15" font="14"><b>present  and  attributable  to  PDA with  net left-to-right  shunt,  PA systolic </b></text>
<text top="893" left="281" width="495" height="15" font="14"><b>pressure  less  than  50%  systemic  and  pulmonary  vascular resistance  less </b></text>
<text top="912" left="281" width="294" height="15" font="14"><b>than one third systemic (S4.1.5-1–S4.1.5-3). </b></text>
<text top="962" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="962" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="932" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="933" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="932" left="281" width="491" height="15" font="14"><b>PDA closure in adults may be considered in the presence of a net left-to-</b></text>
<text top="952" left="281" width="495" height="15" font="14"><b>right  shunt  if  PA  systolic  pressure  is  50%  or  greater  systemic,  and/or </b></text>
<text top="972" left="281" width="491" height="15" font="14"><b>pulmonary vascular resistance is greater than one third systemic (S4.1.5-</b></text>
<text top="991" left="281" width="83" height="15" font="14"><b>3, S4.1.5-4). </b></text>
<text top="1031" left="124" width="21" height="15" font="14"><b>III: </b></text>
<text top="1051" left="115" width="40" height="15" font="14"><b>Harm </b></text>
<text top="1041" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="1012" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="1012" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1012" left="281" width="494" height="15" font="14"><b>PDA  closure  should  not  be  performed  in  adults  with  a  net  right-to-left </b></text>
<text top="1031" left="281" width="494" height="15" font="14"><b>shunt  and  PA  systolic  pressure  greater  than  two  thirds  systemic  or </b></text>
<text top="1051" left="281" width="491" height="15" font="14"><b>pulmonary  vascular  resistance  greater  than  two  thirds  systemic  (S4.1.5-</b></text>
<text top="1070" left="281" width="21" height="15" font="14"><b>5). </b></text>
</page>
<page number="62" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 63 </text>
<text top="162" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="190" left="105" width="687" height="15" font="11">The ductus arteriosus is a vascular connection between the aorta and PA that is present in fetal life. It </text>
<text top="210" left="105" width="687" height="15" font="11">typically  closes  shortly  after  birth  but,  in  some  people,  it  will  remain  patent.  Patent  ductus  arteriosus </text>
<text top="229" left="105" width="687" height="15" font="11">(PDA)  is  found  in  about  0.3%  to  0.8%  of  term  infants  and  is  twice  as  common  in  females  as  males </text>
<text top="249" left="105" width="687" height="15" font="11">(S4.1.5-6–S4.1.5-8). The clinical and physiological manifestations of the PDA are dependent on the size </text>
<text top="268" left="105" width="687" height="15" font="11">of the vessel and the relative systemic and pulmonary vascular resistances. The PDA can range from a </text>
<text top="288" left="105" width="687" height="15" font="11">small  hemodynamically  insignificant  lesion  that  is  not  heard  on  auscultation  to  one  that  without </text>
<text top="308" left="105" width="687" height="15" font="11">intervention is large enough to cause congestive HF and pulmonary hypertension. Many PDAs are now </text>
<text top="328" left="105" width="687" height="15" font="11">closed  in  infancy  or  childhood  with  catheter-based  or  surgical  approaches.  For  those  whose  ductus </text>
<text top="347" left="105" width="687" height="15" font="11">remains  patent  in  adulthood,  catheter-based  or  surgical  intervention  consideration  depends  on  the </text>
<text top="367" left="105" width="687" height="15" font="11">symptoms and physiological expression of the lesion. Follow-up of these patients as adults is important </text>
<text top="386" left="105" width="412" height="15" font="11">for all, although timing and testing will vary among individuals. </text>
<text top="415" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="434" left="105" width="687" height="15" font="11">other procedures in these patients; Section 3.4 for recommendations on diagnostic evaluation; Section </text>
<text top="454" left="105" width="687" height="15" font="11">4.4.6 for recommendations on severe PAH (4.4.6.1) and Eisenmenger syndrome (4.4.6.2) associated with </text>
<text top="473" left="105" width="403" height="15" font="11">PDA; and Table 16 for routine testing and follow-up intervals. </text>
<text top="502" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="530" left="105" width="687" height="15" font="11">1.  Because  cyanosis  caused  by  right-to-left  shunting  in  PDA  may  manifest  predominantly  downstream </text>
<text top="550" left="105" width="687" height="15" font="11">from  the  ductal  insertion  into  the  aorta,  accurate  assessment  of  oxygen  saturation  by  oximetry  and </text>
<text top="569" left="105" width="687" height="15" font="11">assessment of cyanosis should be done in the feet and both hands. As with other types of shunts, pulse </text>
<text top="589" left="105" width="687" height="15" font="11">oximetry  with  ambulation  as  well  as  at  rest  may  identify  patients  with  increased  pulmonary  arterial </text>
<text top="609" left="105" width="687" height="15" font="11">resistance  and  dynamic  shunt  reversal induced  by exercise.  A  subset  of  patients  with  resting  systemic </text>
<text top="628" left="105" width="687" height="15" font="11">oxygen saturation &gt;90% will have a decrease in oxygen saturation with activity to &lt;90%, emphasizing the </text>
<text top="648" left="105" width="513" height="15" font="11">importance of performing resting and ambulatory pulse oximetry assessment. </text>
<text top="676" left="105" width="687" height="15" font="11">2.  Invasive  hemodynamic  assessment  still  has  an  important  role  as  a  confirmatory  tool  and  for  the </text>
<text top="696" left="105" width="635" height="15" font="11">evaluation of pulmonary vasoreactivity, which carries prognostic significance (S4.1.5-1, S4.1.5-4). </text>
<text top="724" left="105" width="687" height="15" font="11">3. When signs of volume overload are indicative of significant left-to-right shunt, closing the PDA is likely </text>
<text top="744" left="105" width="687" height="15" font="11">to  prevent  further  left  atrial  or  LV  enlargement,  progression  or  development  of  PAH,  and  pulmonary </text>
<text top="763" left="105" width="687" height="15" font="11">hypertension  secondary  to  left  HF  and  will  possibly  provide  symptom  relief  if  symptoms  are  present. </text>
<text top="783" left="105" width="687" height="15" font="11">Closure is typically performed percutaneously with good success and minimal complications (S4.1.5-2). </text>
<text top="803" left="105" width="687" height="15" font="11">Pulmonary blood flow and thus Qp:Qs can be difficult to calculate accurately because of differences in </text>
<text top="822" left="105" width="687" height="15" font="11">right/left PA blood flow caused by the flow from the PDA. Invasive hemodynamics including pulmonary </text>
<text top="842" left="105" width="687" height="15" font="11">vascular resistance are generally relied on for decision-making. Surgical closure can be performed but is </text>
<text top="861" left="105" width="487" height="15" font="11">potentially hazardous in adults because of calcification and tissue fragility. </text>
<text top="890" left="105" width="687" height="15" font="11">4. Even with elevated pulmonary pressure and elevated pulmonary vascular resistance, closure of a PDA </text>
<text top="909" left="105" width="687" height="15" font="11">may improve clinical status  in some patients with  persistent left-to-right  shunting and  prevent further </text>
<text top="929" left="105" width="687" height="15" font="11">progression of PAH (S4.1.5-3, S4.1.5-4). Consultation with ACHD and pulmonary hypertension providers </text>
<text top="949" left="105" width="638" height="15" font="11">is important given the low frequency of this circumstance and the complexity of decision-making. </text>
<text top="977" left="105" width="687" height="15" font="11">5. Morbidity and mortality are high when closure of a shunt is attempted in patients with Eisenmenger </text>
<text top="997" left="105" width="565" height="15" font="11">physiology with elevated pulmonary pressure and net right-to-left shunting (S4.1.5-5). </text>
<text top="1025" left="105" width="4" height="15" font="11"> </text>
<text top="1054" left="105" width="372" height="15" font="14"><b>Table 16. PDA: Routine Follow-Up and Testing Intervals </b></text>
<text top="1077" left="114" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="1077" left="350" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1077" left="468" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1077" left="580" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1077" left="688" width="82" height="13" font="7"><b>Physiological </b></text>
</page>
<page number="63" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 64 </text>
<text top="163" left="177" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="163" left="346" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="163" left="465" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="163" left="577" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="163" left="685" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="181" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="181" left="335" width="40" height="13" font="8">36–60 </text>
<text top="181" left="460" width="18" height="13" font="8">24 </text>
<text top="181" left="571" width="33" height="13" font="8">6–12 </text>
<text top="181" left="683" width="25" height="13" font="8">3–6 </text>
<text top="199" left="105" width="27" height="13" font="8">ECG </text>
<text top="199" left="335" width="40" height="13" font="8">36–60 </text>
<text top="199" left="460" width="18" height="13" font="8">24 </text>
<text top="199" left="571" width="18" height="13" font="8">12 </text>
<text top="199" left="683" width="18" height="13" font="8">12 </text>
<text top="218" left="105" width="25" height="13" font="8">TTE </text>
<text top="218" left="335" width="40" height="13" font="8">36–60 </text>
<text top="218" left="460" width="18" height="13" font="8">24 </text>
<text top="218" left="571" width="18" height="13" font="8">12 </text>
<text top="218" left="683" width="18" height="13" font="8">12 </text>
<text top="237" left="105" width="98" height="13" font="8">Pulse oximetry† </text>
<text top="237" left="335" width="66" height="13" font="8">As needed </text>
<text top="237" left="460" width="66" height="13" font="8">As needed </text>
<text top="237" left="571" width="59" height="13" font="8">Each visit </text>
<text top="237" left="683" width="59" height="13" font="8">Each visit </text>
<text top="255" left="105" width="85" height="13" font="8">Exercise test‡ </text>
<text top="255" left="335" width="66" height="13" font="8">As needed </text>
<text top="255" left="460" width="66" height="13" font="8">As needed </text>
<text top="255" left="571" width="40" height="13" font="8">12–24 </text>
<text top="255" left="683" width="33" height="13" font="8">6–12 </text>
<text top="274" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="290" left="105" width="157" height="12" font="9">†Upper and lower extremity. </text>
<text top="306" left="105" width="353" height="12" font="9">‡6-minute walk test or CPET, depending on the clinical indication. </text>
<text top="322" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  ECG,  electrocardiogram;  CPET,  cardiopulmonary  exercise  test;  PDA,  patent </text>
<text top="338" left="105" width="314" height="12" font="9">ductus arteriosus; and TTE, transthoracic echocardiogram. </text>
<text top="373" left="105" width="318" height="20" font="17"><b>4.2. Left-Sided Obstructive Lesions </b></text>
<text top="417" left="105" width="187" height="19" font="34"><b>4.2.1. Cor Triatriatum </b></text>
<text top="452" left="273" width="4" height="15" font="11"> </text>
<text top="451" left="326" width="281" height="16" font="12"><b>Recommendations for Cor Triatriatum </b></text>
<text top="472" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="472" left="577" width="180" height="15" font="23">Online Data Supplement 31</text>
<text top="472" left="757" width="8" height="15" font="11">. </text>
<text top="492" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="492" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="492" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="513" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="553" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="553" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="533" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="533" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="533" left="281" width="495" height="15" font="14"><b>Adults  presenting  with  cor  triatriatum  sinister  should  be  evaluated  for </b></text>
<text top="553" left="281" width="495" height="15" font="14"><b>other  congenital  abnormalities,  particularly  ASD,  VSD,  and  anomalous </b></text>
<text top="572" left="281" width="278" height="15" font="14"><b>pulmonary venous connection (S4.2.1-1). </b></text>
<text top="612" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="612" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="593" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="593" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="593" left="281" width="494" height="15" font="14"><b>In  adults  with  prior  repair  of  cor  triatriatum  sinister  and  recurrent </b></text>
<text top="612" left="281" width="495" height="15" font="14"><b>symptoms,  it  is  reasonable  to  evaluate  for  pulmonary  vein  stenosis </b></text>
<text top="632" left="281" width="72" height="15" font="14"><b>(S4.2.1-2). </b></text>
<text top="652" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="692" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="692" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="672" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="673" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="672" left="281" width="495" height="15" font="14"><b>Surgical  repair  is  indicated  for  adults  with  cor  triatriatum  sinister  for </b></text>
<text top="692" left="281" width="495" height="15" font="14"><b>symptoms attributable to the obstruction or a substantial gradient across </b></text>
<text top="712" left="281" width="170" height="15" font="14"><b>the membrane (S4.2.1-3) </b></text>
<text top="741" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="769" left="105" width="687" height="15" font="11">Cor  triatriatum  occurs  when  a  membrane  divides  either  the  left  atrium  (sinister),  or  right  atrium </text>
<text top="788" left="105" width="687" height="15" font="11">(dexter).  Cor  triatriatum  sinister is  usually  associated  with  other  congenital malformations,  specifically </text>
<text top="808" left="105" width="687" height="15" font="11">ASD,  VSD,  or  anomalous  pulmonary  venous  connection  (partial  or  total)  (S4.2.1-1–S4.2.1-4).  The  left </text>
<text top="828" left="105" width="687" height="15" font="11">atrial appendage is invariably in the same chamber as the mitral valve, separated from the pulmonary </text>
<text top="847" left="105" width="687" height="15" font="11">veins by the membrane. Supravalvular mitral stenosis is typically caused by a fibrous ring on the atrial </text>
<text top="867" left="105" width="687" height="15" font="11">side  of  the  mitral  valve,  separating  the  mitral  valve  from  both  the  left  atrial  appendage  and  the </text>
<text top="886" left="105" width="687" height="15" font="11">pulmonary  veins.  The  finding  will  have  similar  physiology  to  cor  triatriatum  and  similar  indications  for </text>
<text top="906" left="105" width="687" height="15" font="11">intervention.  It  can  be  associated  with  an  abnormal  mitral  valve  that  may  also  require  intervention. </text>
<text top="925" left="105" width="687" height="15" font="11">Supravalvular mitral stenosis often comprises one part of a more complex sequence of serial left-sided </text>
<text top="945" left="105" width="357" height="15" font="11">inflow and outflow obstructions (i.e., Shone complex). </text>
<text top="974" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="993" left="105" width="650" height="15" font="11">other procedures in these patients; and Section 3.4 for recommendations on diagnostic evaluation. </text>
<text top="1022" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="1050" left="105" width="687" height="15" font="11">1. Cor triatriatum  sinister is a membrane  spanning the left atrium.  Surgery has been largely successful </text>
<text top="1070" left="105" width="687" height="15" font="11">with  relatively  few  early  or  late  deaths,  which  are  usually  attributable  to  associated  congenital </text>
</page>
<page number="64" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 65 </text>
<text top="162" left="105" width="687" height="15" font="11">abnormalities  (S4.2.1-4).  The  gradient  across  the  defect  at  the  time  of  surgery  was  at  least  8  mm  Hg </text>
<text top="182" left="105" width="687" height="15" font="11">(mean 17 mm Hg; range 8 to 40 mm Hg) (S4.2.1-3). After repair, recurrence of stenosis is not expected. </text>
<text top="201" left="105" width="687" height="15" font="11">Although pulmonary vein stenosis has been demonstrated before and after surgery (S4.2.1-2), it is not </text>
<text top="221" left="105" width="451" height="15" font="11">usually progressive over time and has not been associated with PAH. </text>
<text top="249" left="105" width="687" height="15" font="11">2.  Pulmonary  venous  stenosis  has  been  demonstrated  before  and  after  surgery,  but  it  is  not  usually </text>
<text top="268" left="105" width="402" height="15" font="11">progressive over time and has not been associated with PAH. </text>
<text top="297" left="105" width="687" height="15" font="11">3. Although risks of isolated cor triatriatum sinister surgery is low, it should be performed when there is </text>
<text top="317" left="105" width="687" height="15" font="11">evidence of  a  substantial gradient. In 1 series, the mean gradient  at the time  of surgical repair  was at </text>
<text top="336" left="105" width="687" height="15" font="11">least  8  mm  Hg  (S4.2.1-3).  It  is  conceivable  that  on  occasion,  clinical  circumstances  (i.e.,  symptoms, </text>
<text top="356" left="105" width="480" height="15" font="11">arrhythmia) would warrant intervention in patients with lower gradients. </text>
<text top="394" left="105" width="280" height="19" font="34"><b>4.2.2. Congenital Mitral Stenosis </b></text>
<text top="429" left="237" width="4" height="15" font="11"> </text>
<text top="428" left="290" width="354" height="16" font="12"><b>Recommendation for Congenital Mitral Stenosis </b></text>
<text top="449" left="106" width="480" height="15" font="11">Referenced studies that support the recommendation are summarized in </text>
<text top="449" left="587" width="180" height="15" font="23">Online Data Supplement 32</text>
<text top="449" left="766" width="8" height="15" font="11">. </text>
<text top="469" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="469" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="469" left="454" width="122" height="15" font="14"><b>Recommendation </b></text>
<text top="499" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="499" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="490" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="490" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="490" left="281" width="495" height="15" font="14"><b>Adults with congenital mitral stenosis or a parachute mitral valve should </b></text>
<text top="509" left="281" width="482" height="15" font="14"><b>be evaluated for other left-sided obstructive lesions (S4.2.2-1, S4.2.2-2). </b></text>
<text top="538" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="567" left="105" width="687" height="15" font="11">Congenital mitral valve disease may be anatomically complex and is often accompanied by other lesions. </text>
<text top="586" left="105" width="687" height="15" font="11">Indications  for  intervention  in  mitral  stenosis  are  described  in  the  2014  VHD  guideline  (S4.2.2-3)  and </text>
<text top="606" left="105" width="687" height="15" font="11">apply  to  those  patients  with  congenital  mitral  stenosis.  Balloon  mitral  valvuloplasty  is  rarely,  if  ever, </text>
<text top="625" left="105" width="333" height="15" font="11">indicated or effective in congenital mitral stenosis. </text>
<text top="654" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="673" left="105" width="687" height="15" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="693" left="105" width="340" height="15" font="11">Table 17 for routine testing and follow-up intervals. </text>
<text top="722" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="750" left="105" width="687" height="15" font="11">1.  Parachute  mitral  valve  is  most  commonly  found  in  the  presence  of  other  congenital  abnormalities </text>
<text top="769" left="105" width="687" height="15" font="11">such as the components of Shone complex. Recurrence and progression of the various associated lesions </text>
<text top="789" left="105" width="687" height="15" font="11">are  expected,  subsequent surgeries  are  common,  and  mortality  may  be  associated  with  other  defects </text>
<text top="808" left="105" width="687" height="15" font="11">(S4.2.2-2).  Therefore,  these  patients  require  follow-up  at  a  center  where  such  abnormalities  can  be </text>
<text top="828" left="105" width="687" height="15" font="11">followed  and future interventions  considered.  Choices  and  techniques  for valve  repair  or  replacement </text>
<text top="848" left="105" width="634" height="15" font="11">are based on consideration of coexisting abnormalities including the likelihood of future surgery. </text>
<text top="876" left="105" width="4" height="15" font="11"> </text>
<text top="905" left="105" width="518" height="15" font="14"><b>Table 17. Congenital Mitral Stenosis: Routine Follow-Up and Testing Intervals </b></text>
<text top="928" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="946" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="928" left="333" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="946" left="330" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="928" left="451" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="946" left="449" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="928" left="566" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="946" left="564" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="928" left="681" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="946" left="678" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="964" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="964" left="321" width="18" height="13" font="8">24 </text>
<text top="964" left="440" width="18" height="13" font="8">24 </text>
<text top="964" left="558" width="33" height="13" font="8">6–12 </text>
<text top="964" left="670" width="25" height="13" font="8">3–6 </text>
<text top="982" left="105" width="27" height="13" font="8">ECG </text>
<text top="982" left="321" width="18" height="13" font="8">24 </text>
<text top="982" left="440" width="18" height="13" font="8">24 </text>
<text top="982" left="558" width="18" height="13" font="8">12 </text>
<text top="982" left="670" width="18" height="13" font="8">12 </text>
<text top="1001" left="105" width="25" height="13" font="8">TTE </text>
<text top="1001" left="321" width="18" height="13" font="8">24 </text>
<text top="1001" left="440" width="18" height="13" font="8">24 </text>
<text top="1001" left="558" width="18" height="13" font="8">12 </text>
<text top="1001" left="670" width="18" height="13" font="8">12 </text>
<text top="1019" left="105" width="85" height="13" font="8">Exercise test† </text>
<text top="1019" left="321" width="66" height="13" font="8">As needed </text>
<text top="1019" left="440" width="18" height="13" font="8">24 </text>
<text top="1019" left="558" width="18" height="13" font="8">24 </text>
<text top="1019" left="670" width="18" height="13" font="8">12 </text>
<text top="1038" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="1054" left="105" width="353" height="12" font="9">†6-minute walk test or CPET, depending on the clinical indication. </text>
<text top="1070" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CPET,  cardiopulmonary  exercise  test;  ECG,  electrocardiogram;  and  TTE, </text>
<text top="1086" left="105" width="167" height="12" font="9">transthoracic echocardiogram. </text>
</page>
<page number="65" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 67 </text>
<text top="163" left="105" width="212" height="19" font="34"><b>4.2.3. Subaortic Stenosis </b></text>
<text top="199" left="263" width="4" height="14" font="11"> </text>
<text top="197" left="315" width="303" height="16" font="12"><b>Recommendations for Subaortic Stenosis </b></text>
<text top="218" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="218" left="577" width="180" height="15" font="23">Online Data Supplement 33</text>
<text top="218" left="757" width="8" height="15" font="11">. </text>
<text top="238" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="238" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="238" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="259" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="308" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="308" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="279" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="279" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="279" left="281" width="494" height="15" font="14"><b>Stress  testing  for  adults  with  LVOT  obstruction  to  determine  exercise </b></text>
<text top="299" left="281" width="495" height="15" font="14"><b>capacity,  symptoms,  electrocardiographic  changes,  or  arrhythmias  may </b></text>
<text top="318" left="281" width="495" height="15" font="14"><b>be  reasonable  in  the  presence  of  otherwise  equivocal  indications  for </b></text>
<text top="338" left="281" width="220" height="15" font="14"><b>intervention (S4.2.3-1, S4.2.3-2). </b></text>
<text top="358" left="411" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="388" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="388" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="379" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="379" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="379" left="281" width="495" height="15" font="14"><b>Surgical intervention is recommended for adults with subAS, a maximum </b></text>
<text top="398" left="281" width="466" height="15" font="14"><b>gradient 50 mm Hg or more and symptoms attributable to the subAS. </b></text>
<text top="438" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="438" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="418" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="419" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="418" left="281" width="495" height="15" font="14"><b>Surgical  intervention  is  recommended  for  adults  with  subAS  and  less </b></text>
<text top="438" left="281" width="495" height="15" font="14"><b>than 50 mm Hg maximum gradient and HF or ischemic symptoms, and/or </b></text>
<text top="458" left="281" width="373" height="15" font="14"><b>LV systolic dysfunction attributable to subAS (S4.2.3-3). </b></text>
<text top="498" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="498" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="478" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="478" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="478" left="281" width="495" height="15" font="14"><b>To  prevent  the  progression  of  AR,  surgical  intervention  may  be </b></text>
<text top="498" left="281" width="495" height="15" font="14"><b>considered for asymptomatic adults with subAS and at least mild AR and </b></text>
<text top="517" left="281" width="421" height="15" font="14"><b>a maximum gradient of 50 mm Hg or more (S4.2.3-4–S4.2.3-6). </b></text>
<text top="546" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="574" left="105" width="687" height="15" font="11">SubAS  may  occur  as  a  discrete  membrane  below  the  aortic  valve  in  the  LVOT,  as  a  longer  tunnel-like </text>
<text top="594" left="105" width="687" height="15" font="11">obstruction, as a consequence of chordal attachments in patients with abnormalities such as AVSD, or </text>
<text top="614" left="105" width="687" height="15" font="11">because  of  surgical  repairs  involving  VSD  baffled  to  a  transposed  aorta,  such  as  seen  in  the  Rastelli </text>
<text top="633" left="105" width="687" height="15" font="11">operation.  SubAS  may  occur  in  isolation  or  as  part  of  a  suite  of  abnormalities.  In  adults  with  Shone </text>
<text top="653" left="105" width="687" height="15" font="11">complex  or  its  variants,  subAS  may  be  one  of  several  LV  obstructive  lesions,  including  variants  of </text>
<text top="672" left="105" width="687" height="15" font="11">congenital  mitral  stenosis,  supravalvular  mitral  stenosis,  valvular  aortic  stenosis,  supravalvular  aortic </text>
<text top="692" left="105" width="189" height="15" font="11">stenosis, and CoA (S4.2.3-7). </text>
<text top="720" left="158" width="634" height="15" font="11">SubAS tends to recur, particularly when initial resection is needed in childhood. Surgical repair </text>
<text top="740" left="105" width="687" height="15" font="11">for subAS carries a 10% to 15% risk of complete heart block (S4.2.3-6). SubAS may be first diagnosed in </text>
<text top="760" left="105" width="687" height="15" font="11">adulthood and may be confused with hypertrophic obstructive cardiomyopathy when LV hypertrophy of </text>
<text top="779" left="105" width="621" height="15" font="11">sufficient severity has developed such that the subaortic membrane is less evident on imaging. </text>
<text top="807" left="158" width="634" height="15" font="11">The  recommendations  in  this  guideline  apply  to  subAS  caused  by  a  discrete  membrane  or </text>
<text top="827" left="105" width="687" height="15" font="11">tunnel-like obstruction. Similar principles may apply to more complex causes of subAS, but insufficient </text>
<text top="847" left="105" width="687" height="15" font="11">data exist to support recommendations for more complex lesions, and extrapolation needs to take the </text>
<text top="866" left="105" width="298" height="15" font="11">additional anatomic complexity into account. </text>
<text top="895" left="158" width="634" height="15" font="11">Turbulent  flow  created  distal  to  the  subaortic  obstruction  may  cause  barotrauma  to  the </text>
<text top="914" left="105" width="687" height="15" font="11">adjacent aortic valve leaflets and result in progressive AR, which may itself become clinically significant. </text>
<text top="934" left="105" width="687" height="15" font="11">Resection  of  the  subaortic  obstruction  ideally  delays  or  prevents  the  eventual  need  for  aortic  valve </text>
<text top="953" left="105" width="687" height="15" font="11">replacement,  and  concomitant  aortic  valve  repair  could  also  help  delay  the  need  for  aortic  valve </text>
<text top="973" left="105" width="185" height="15" font="11">replacement in these cases. </text>
<text top="1001" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="1021" left="105" width="687" height="15" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="1041" left="105" width="340" height="15" font="11">Table 18 for routine testing and follow-up intervals. </text>
<text top="1069" left="105" width="4" height="15" font="11"> </text>
</page>
<page number="66" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 68 </text>
<text top="162" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="190" left="105" width="687" height="15" font="11">1.  Exercise  stress  testing  may  be  reasonable  in  the  assessment  of  exercise  capacity,  stress-induced </text>
<text top="210" left="105" width="687" height="15" font="11">arrhythmias,  and  ischemia  in  patients  with  subAS  and  may  be  considered  as  an  adjunct  to </text>
<text top="229" left="105" width="183" height="15" font="11">echocardiographic imaging. </text>
<text top="258" left="105" width="687" height="15" font="11">2. Patients with symptomatic subAS should attain symptomatic improvement from surgical relief of the </text>
<text top="277" left="105" width="616" height="15" font="11">obstruction. In some cases, concomitant AVR may be needed, if indicated according to GDMT. </text>
<text top="306" left="105" width="687" height="15" font="11">3. Patients with depressed LV systolic function and severe subAS may not manifest a resting gradient of </text>
<text top="325" left="105" width="687" height="15" font="11">≥50 mm Hg. In this population, evaluation and decisions regarding surgical relief of LVOT obstruction can </text>
<text top="345" left="105" width="687" height="15" font="11">be  extrapolated  from  the existing  aortic  stenosis  data  and  should  be  considered  as  per  the 2014  VHD </text>
<text top="365" left="105" width="687" height="15" font="11">guideline  (S4.2.3-8).  Additionally,  patients  with  preserved  LV  systolic  function  but  poor  LV  compliance </text>
<text top="384" left="105" width="687" height="15" font="11">may present with signs or symptoms of HF and a resting maximum gradient &lt;50 mm Hg. These patients </text>
<text top="404" left="105" width="687" height="15" font="11">may benefit from surgical relief of LVOT obstruction. Patients with evidence of resting or stress-induced </text>
<text top="423" left="105" width="687" height="15" font="11">ischemia in the absence of obstructive coronary artery disease and in the presence of moderate subAS </text>
<text top="443" left="105" width="661" height="15" font="11">(maximum gradient &gt;30 mm Hg and &lt;50 mm Hg) may benefit from surgical relief of subAS (S4.2.3-9). </text>
<text top="472" left="105" width="687" height="15" font="11">4. Discrete subAS tends to be progressive with age, and patients with a resting maximum gradient ≥50 </text>
<text top="491" left="105" width="687" height="15" font="11">mm  Hg  are  more  likely  to  have  progressive  subAS  and  concomitant  moderate  or  severe  aortic  valve </text>
<text top="511" left="105" width="687" height="15" font="11">regurgitation (S4.2.3-4). Therefore, surgical intervention may be considered in the asymptomatic patient </text>
<text top="530" left="105" width="687" height="15" font="11">with  severe  subAS.  Tunnel-type  subAS,  which  is  often  associated  with  a  small  aortic  valve  annulus,  is </text>
<text top="550" left="105" width="687" height="15" font="11">associated  with  worse  long-term  outcomes  and  a  higher  risk  of  recurrence  after  surgical  resection </text>
<text top="569" left="105" width="687" height="15" font="11">compared with subAS caused by a discrete membrane (S4.2.3-5). Surgical intervention on patients with </text>
<text top="589" left="105" width="687" height="15" font="11">asymptomatic  subAS  (maximum  gradient  ≥50  mm  Hg)  with  preserved  LV  ejection  fraction  may  delay </text>
<text top="609" left="105" width="687" height="15" font="11">progression of, or improve the degree of, aortic valve regurgitation. SubAS in adults may progress more </text>
<text top="628" left="105" width="687" height="15" font="11">slowly  than  in  children,  and  although  mild  AR  is  common,  it  may  not  be  progressive  in  medium-term </text>
<text top="648" left="105" width="145" height="15" font="11">follow-up (S4.2.3-10). </text>
<text top="676" left="105" width="4" height="15" font="11"> </text>
<text top="705" left="105" width="469" height="15" font="14"><b>Table 18. Subaortic Stenosis: Routine Follow-Up and Testing Intervals  </b></text>
<text top="728" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="746" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="728" left="333" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="746" left="330" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="728" left="455" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="746" left="452" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="728" left="573" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="746" left="571" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="728" left="685" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="746" left="681" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="764" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="764" left="321" width="18" height="13" font="8">24 </text>
<text top="764" left="440" width="18" height="13" font="8">24 </text>
<text top="764" left="565" width="33" height="13" font="8">6–12 </text>
<text top="764" left="676" width="25" height="13" font="8">3–6 </text>
<text top="782" left="105" width="27" height="13" font="8">ECG </text>
<text top="782" left="321" width="18" height="13" font="8">24 </text>
<text top="782" left="440" width="18" height="13" font="8">24 </text>
<text top="782" left="565" width="18" height="13" font="8">12 </text>
<text top="782" left="676" width="18" height="13" font="8">12 </text>
<text top="801" left="105" width="25" height="13" font="8">TTE </text>
<text top="801" left="321" width="18" height="13" font="8">24 </text>
<text top="801" left="440" width="18" height="13" font="8">24 </text>
<text top="801" left="565" width="18" height="13" font="8">12 </text>
<text top="801" left="676" width="18" height="13" font="8">12 </text>
<text top="820" left="105" width="85" height="13" font="8">Exercise test† </text>
<text top="820" left="321" width="66" height="13" font="8">As needed </text>
<text top="820" left="440" width="18" height="13" font="8">24 </text>
<text top="820" left="565" width="18" height="13" font="8">24 </text>
<text top="820" left="676" width="18" height="13" font="8">12 </text>
<text top="838" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="854" left="105" width="353" height="12" font="9">†6-minute walk test or CPET, depending on the clinical indication. </text>
<text top="870" left="105" width="686" height="12" font="9">ACHD indicates adult congenital heart disease; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; SubAS, subaortic </text>
<text top="886" left="105" width="265" height="12" font="9">stenosis; and TTE, transthoracic echocardiogram. </text>
<text top="921" left="105" width="354" height="19" font="34"><b>4.2.4. Congenital Valvular Aortic Stenosis </b></text>
<text top="956" left="202" width="4" height="15" font="11"> </text>
<text top="956" left="255" width="424" height="16" font="12"><b>Recommendations for Congenital Valvular Aortic Stenosis </b></text>
<text top="976" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="976" left="577" width="180" height="15" font="23">Online Data Supplement 34</text>
<text top="976" left="757" width="8" height="15" font="11">. </text>
<text top="996" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="996" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="996" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="1017" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="1047" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1047" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1037" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="1037" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1037" left="281" width="495" height="15" font="14"><b>Adults with  bicuspid aortic valve  should be  evaluated for coarctation  of </b></text>
<text top="1057" left="281" width="430" height="15" font="14"><b>the aorta by clinical examination and imaging studies (S4.2.4-1). </b></text>
<text top="1077" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="1077" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1077" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="1077" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1077" left="281" width="495" height="15" font="14"><b>It is reasonable to screen first-degree relatives of patients with bicuspid </b></text>
</page>
<page number="67" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 69 </text>
<text top="163" left="281" width="494" height="15" font="14"><b>aortic  valve  or  unicuspid  aortic  valve  with  echocardiography  for  valve </b></text>
<text top="183" left="281" width="294" height="15" font="14"><b>disease and aortopathy (S4.2.4-2–S4.2.4-4). </b></text>
<text top="203" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="253" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="253" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="223" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="223" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="223" left="281" width="495" height="15" font="14"><b>In adults with bicuspid aortic valve stenosis and a noncalcified valve with </b></text>
<text top="243" left="281" width="495" height="15" font="14"><b>no  more  than  mild  AR  meeting  indications  for  intervention  per  GDMT </b></text>
<text top="262" left="281" width="495" height="15" font="14"><b>(S4.2.4-5),  it  may  be  reasonable  to  treat  with  balloon  valvuloplasty </b></text>
<text top="282" left="281" width="72" height="15" font="14"><b>(S4.2.4-6). </b></text>
<text top="311" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="339" left="105" width="687" height="15" font="11">Indications for aortic valve replacement according to the 2014 VHD guideline (S4.2.4-5) generally apply. </text>
<text top="359" left="105" width="687" height="15" font="11">Recommendations  above  deal  with  issues  specific  to  congenital  aortic  valve  disease,  which  includes </text>
<text top="378" left="105" width="687" height="15" font="11">BAV,  as  well  as  unicuspid  aortic  valve  and  aortic  stenosis  caused  by  hypoplastic  aortic  annulus.  The </text>
<text top="398" left="105" width="687" height="15" font="11">underlying  anatomy  must  be  taken  into  account  in  patients  with  congenital  aortic  stenosis,  as </text>
<text top="418" left="105" width="687" height="15" font="11">intervention  may  need  to  include  annular  enlarging  procedures  and  other  surgical  techniques  not </text>
<text top="437" left="105" width="687" height="15" font="11">commonly  used  in  valvular  aortic  stenosis.  These  patients  are  often  young  adults,  for  whom  lifestyle </text>
<text top="457" left="105" width="687" height="15" font="11">considerations  such  as  athletic  endeavors,  employment,  and  childbearing  may  influence  the  type  of </text>
<text top="476" left="105" width="88" height="15" font="11">intervention. </text>
<text top="505" left="105" width="687" height="15" font="11">See  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and  Table  19  for  routine  testing  and </text>
<text top="524" left="105" width="130" height="15" font="11">follow-up intervals. </text>
<text top="553" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="581" left="105" width="687" height="15" font="11">1. CoA has a male-to-female ratio of 1.5:1 (S4.2.4-7–S4.2.4-13). A BAV is present in 50% to 70% of cases </text>
<text top="601" left="105" width="687" height="15" font="11">of  CoA.  Given  the  association  of  these  abnormalities,  evaluation  of  patients  with  BAV  for  CoA  is </text>
<text top="620" left="105" width="76" height="15" font="11">warranted. </text>
<text top="649" left="105" width="687" height="15" font="11">2.  BAV  is  the  most  prevalent  congenital  cardiac  abnormality  with  an  estimated  prevalence  of  4.6  per </text>
<text top="668" left="105" width="687" height="15" font="11">1,000 live births, and is 1.5 times more prevalent in males than females (S4.2.4-7–S4.2.4-13). Most cases </text>
<text top="688" left="105" width="687" height="15" font="11">are  spontaneous;  however,  familial  inheritance  may  occur  in  an  autosomal  dominant  pattern  with </text>
<text top="707" left="105" width="687" height="15" font="11">variable penetrance. On echocardiographic screening, 1 study reports the prevalence of asymptomatic </text>
<text top="727" left="105" width="687" height="15" font="11">BAV in first-degree relatives of patients is 9%, and 32% of first-degree relatives without a BAV will have </text>
<text top="747" left="105" width="195" height="15" font="11">an abnormal aorta (S4.2.4-4). </text>
<text top="775" left="105" width="687" height="15" font="11">3.  Calcification  of  the  aortic  valve  in  adults  necessitates  that  most  patients  who  require  therapy  for </text>
<text top="795" left="105" width="687" height="15" font="11">aortic stenosis will require aortic valve replacement per GDMT (S4.2.4-5). However, young patients with </text>
<text top="814" left="105" width="687" height="15" font="11">congenitally  abnormal  valves  and  relatively  little  calcification  may  be  candidates  for  balloon </text>
<text top="834" left="105" width="687" height="15" font="11">valvuloplasty. Balloon valvuloplasty may improve the degree of stenosis and symptoms in patients with </text>
<text top="853" left="105" width="687" height="15" font="11">mobile noncalcified  BAV  stenosis. In  general, the  valves that would be  amenable to successful balloon </text>
<text top="873" left="105" width="687" height="15" font="11">valvuloplasty  are  found  in  young  patients,  who  are  often  &lt;25  years  of  age.  Restenosis  will  occur  over </text>
<text top="893" left="105" width="687" height="15" font="11">time and in a relatively short time in some patients. Balloon valvuloplasty of calcified BAV is associated </text>
<text top="912" left="105" width="687" height="15" font="11">with  decreased  efficacy  and  an  increased  risk  of  AR  (S4.2.4-14,  S4.2.4-15).  Although  transcatheter </text>
<text top="932" left="105" width="687" height="15" font="11">interventions for aortic stenosis are increasingly commonly performed in older adults and, thus, there </text>
<text top="952" left="105" width="687" height="15" font="11">are increasing numbers of interventional cardiologists technically skilled at balloon aortic valvuloplasty </text>
<text top="971" left="105" width="687" height="15" font="11">and  transcatheter  aortic  valve  replacement,  the  differences  in  anatomy  and  patient  population </text>
<text top="991" left="105" width="482" height="15" font="11">necessitate collaboration with an ACHD cardiologist for younger patients. </text>
<text top="1019" left="105" width="4" height="15" font="11"> </text>
<text top="1048" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="1048" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="68" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="38" size="16" family="Times" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 70 </text>
<text top="162" left="105" width="526" height="15" font="14"><b>Table 19. Congenital Aortic Stenosis: Routine Follow-Up and Testing Intervals* </b></text>
<text top="185" left="169" width="37" height="13" font="7"><b>Stage </b></text>
<text top="185" left="361" width="183" height="13" font="7"><b>Frequency of Echocardiogram </b></text>
<text top="204" left="105" width="128" height="13" font="8">Progressive (Stage B) </text>
<text top="204" left="282" width="274" height="13" font="8">Every 3–5 y (mild severity, Vmax 2.0–2.9 m/s) </text>
<text top="221" left="282" width="306" height="13" font="8">Every 1–2 y (moderate severity, Vmax 3.0–3.9 m/s) </text>
<text top="240" left="105" width="99" height="13" font="8">Severe (Stage C) </text>
<text top="240" left="282" width="192" height="13" font="8">Every 6–12 mo (Vmax ≥4.0 m/s) </text>
<text top="258" left="105" width="138" height="13" font="8">Aortic dilation &gt;4.5 cm </text>
<text top="258" left="282" width="251" height="13" font="8">Every 12 mo (echocardiogram, MRI or CT) </text>
<text top="277" left="105" width="363" height="12" font="9">*Modified from existing GDMT for valvular heart disease (S4.2.4-5). </text>
<text top="293" left="105" width="535" height="12" font="9">CT  indicates  computed  tomography;  GDMT,  guideline-directed  management  and  therapy;  MRI, </text>
<text top="309" left="105" width="323" height="12" font="9">magnetic resonance imaging; and Vmax, maximum velocity. </text>
<text top="325" left="105" width="4" height="15" font="11"> </text>
<text top="355" left="105" width="203" height="17" font="38"><i><b>4.2.4.1. Turner Syndrome </b></i></text>
<text top="388" left="266" width="4" height="15" font="11"> </text>
<text top="387" left="319" width="296" height="16" font="12"><b>Recommendations for Turner Syndrome </b></text>
<text top="408" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="408" left="577" width="180" height="15" font="23">Online Data Supplement 35</text>
<text top="408" left="757" width="8" height="15" font="11">. </text>
<text top="428" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="428" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="428" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="449" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="489" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="489" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="469" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="469" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="469" left="281" width="495" height="15" font="14"><b>Women  with  Turner  syndrome  should  be  evaluated  for  bicuspid  aortic </b></text>
<text top="489" left="281" width="495" height="15" font="14"><b>valve, coarctation of the aorta, and  enlargement of the ascending aorta </b></text>
<text top="508" left="281" width="84" height="15" font="14"><b>(S4.2.4.1-1). </b></text>
<text top="528" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="568" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="568" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="549" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="549" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="549" left="281" width="495" height="15" font="14"><b>Prophylactic replacement of the aortic root  or  ascending  aorta in adults </b></text>
<text top="568" left="281" width="495" height="15" font="14"><b>with  Turner  syndrome  is  reasonable  when  the  aortic  diameter  is  2.5 </b></text>
<text top="588" left="281" width="40" height="15" font="14"><b>cm/m</b></text>
<text top="585" left="321" width="5" height="9" font="36"><b>2</b></text>
<text top="588" left="326" width="158" height="15" font="14"><b> or greater (S4.2.4.1-2). </b></text>
<text top="617" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="645" left="105" width="687" height="15" font="11">The  management  of  valve dysfunction is generally as directed by the 2014 VHD guideline (S4.2.4.1-3). </text>
<text top="665" left="105" width="687" height="15" font="11">Aortopathy is a commonly associated condition, and frequently involves the mid-ascending aorta, which </text>
<text top="684" left="105" width="687" height="15" font="11">may  not  be  reliably  seen  on  TTE.  Measurement  of  aortic  dimensions  with  magnetic  resonance </text>
<text top="704" left="105" width="687" height="15" font="11">angiography  and  CCT  has  not  been  standardized,  and  clinicians  should  be  wary  of  comparisons  of </text>
<text top="724" left="105" width="687" height="15" font="11">reported  diameters  between  modalities.  Side-by-side  comparisons  are  more  reliable  for  detecting </text>
<text top="743" left="105" width="687" height="15" font="11">changes over time. Baseline and routine serial measurements of the aortic size are useful, with imaging </text>
<text top="763" left="105" width="687" height="15" font="11">interval determined by the indexed size and rate of progression. Pregnancy in Turner syndrome, which </text>
<text top="782" left="105" width="687" height="15" font="11">often requires assisted reproductive technology, is associated with an increased risk of aortic dissection, </text>
<text top="802" left="105" width="562" height="15" font="11">especially if there is a preexisting abnormality of the aortic valve or aorta (S4.2.4.1-4). </text>
<text top="831" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="859" left="105" width="687" height="15" font="11">1. Women with Turner syndrome are at substantial risk of BAV, CoA, and aortic enlargement, which can </text>
<text top="878" left="105" width="687" height="15" font="11">result in morbidity and mortality if left untreated. Therefore, evaluation is necessary to help decide what </text>
<text top="898" left="105" width="687" height="15" font="11">interventions may be necessary and provide accurate risk assessment for exercise, pregnancy, or other </text>
<text top="918" left="105" width="395" height="15" font="11">considerations that could be influenced by aortic pathology. </text>
<text top="946" left="105" width="687" height="15" font="11">2. Because of case series reporting dissection at smaller aortic diameters than in non-Turner aortopathy, </text>
<text top="966" left="105" width="687" height="15" font="11">prophylactic  surgery  is  reasonable  at  lower  diameters,  particularly  if  rapid  dilation  is  present. </text>
<text top="985" left="105" width="687" height="15" font="11">Measurements  must  take  into  account  the  patient's  stature  either  by  indexing  to  body  surface  area </text>
<text top="1005" left="105" width="683" height="15" font="11">utilizing  Turner-specific  normative  data  or  by  using  ratio  of  aortic  area  to  body  height  (S4.2.4.1-5–</text>
<text top="1024" left="105" width="78" height="15" font="11">S4.2.4.1-7). </text>
<text top="1056" left="105" width="4" height="15" font="11"> </text>
<text top="1054" left="315" width="4" height="17" font="38"><i><b> </b></i></text>
</page>
<page number="69" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 71 </text>
<text top="163" left="105" width="170" height="17" font="38"><i><b>4.2.4.2. Aortopathies </b></i></text>
<text top="194" left="105" width="687" height="15" font="11">Several CHD subtypes and/or repairs are associated with enlargement of the aorta. The management of </text>
<text top="213" left="105" width="687" height="15" font="11">these varies by condition, as some are perceived to have a stronger association with aortic dissection or </text>
<text top="233" left="105" width="687" height="15" font="11">rupture than others, although the true natural history of most is unknown. There is wide heterogeneity </text>
<text top="253" left="105" width="608" height="15" font="11">of timing of surgical referral, which makes interpretation of longitudinal studies problematic. </text>
<text top="281" left="158" width="634" height="15" font="11">BAV is the most common CHD, is associated with aortopathy, and is of high concern for aortic </text>
<text top="301" left="105" width="687" height="15" font="11">complications,  as  discussed  in  other  guideline  statements  (S4.2.4.2-1–S4.2.4.2-3).  Although  in  many </text>
<text top="320" left="105" width="687" height="15" font="11">published  series  of  aortic  dissection,  BAV  patients  account  for  a  higher  proportion  of  dissections  than </text>
<text top="340" left="105" width="687" height="15" font="11">expected  from  prevalence  of  BAV  in  the  general  population  alone,  the  risk  of  dissection  or  rupture </text>
<text top="359" left="105" width="687" height="15" font="11">amongst all BAV patients is less clear. The largest population study reported a 0.5% risk of aortic rupture </text>
<text top="379" left="105" width="687" height="15" font="11">or dissection after a mean of 16 years of follow-up (S4.2.4.2-4), although 11% underwent elective aortic </text>
<text top="399" left="105" width="687" height="15" font="11">surgery. Risk factors for aortic complications were age and an enlarged aorta at baseline. Frequency of </text>
<text top="418" left="105" width="439" height="15" font="11">dissection in BAV disease is higher in adults with Turner syndrome. </text>
<text top="446" left="158" width="634" height="15" font="11">A  dilated  neoaortic  root  after  a  Ross  procedure  is  not  uncommon,  although  only  a  single </text>
<text top="466" left="105" width="687" height="15" font="11">dissection has been reported (S4.2.4.2-5). Because of this, it is generally believed that prophylactic root </text>
<text top="486" left="105" width="687" height="15" font="11">replacement  strategies  based  on  sinus  of  Valsalva  diameters  can  be  less  aggressive  after  a  Ross </text>
<text top="505" left="105" width="687" height="15" font="11">procedure than in a native BAV patient, but practice patterns vary. Most patients with a Ross repair had </text>
<text top="525" left="105" width="687" height="15" font="11">underlying congenitally abnormal aortic valves (BAV or unicuspid aortic valve) and, therefore, are at risk </text>
<text top="545" left="105" width="687" height="15" font="11">of  the  ascending  aortic  dilation  typical  of  those  abnormalities.  Thus,  in  addition  to  the  dilation  at  the </text>
<text top="564" left="105" width="687" height="15" font="11">sinuses  of  Valsalva  associated  with  the  Ross  repair,  dilation  of  the  native  ascending  aorta  above  the </text>
<text top="584" left="105" width="235" height="15" font="11">sinotubular junction can also occur. </text>
<text top="612" left="158" width="634" height="15" font="11">Although patients with conotruncal abnormalities (TOF, dextrotransposition of the great arteries </text>
<text top="632" left="105" width="687" height="15" font="11">[d-TGA]  after  arterial  switch  (S4.2.4.2-6–S4.2.4.2-8),  pulmonary  atresia  with  VSD,  truncus  arteriosus) </text>
<text top="651" left="105" width="687" height="15" font="11">commonly have aortic  diameters of 40 mm to 50 mm, aortic complications  are  extremely rare (only 6 </text>
<text top="671" left="105" width="687" height="15" font="11">published  case  reports)  (S4.2.4.2-9–S4.2.4.2-14).  Therefore,  there  is  no  strong  justification  for  empiric </text>
<text top="691" left="105" width="687" height="15" font="11">prophylactic  surgery  in  such  patients  based  solely  on  aortic  diameter.  Watchful  observation  has  often </text>
<text top="710" left="105" width="687" height="15" font="11">been  recommended  unless  surgery  is  being  undertaken  for  other  indications  (S4.2.4.2-15).  However, </text>
<text top="730" left="105" width="687" height="15" font="11">there are rare patients who develop substantially greater aortic enlargement and for whom prophylactic </text>
<text top="749" left="105" width="687" height="15" font="11">surgery may have more of a role. Risk factor management such as control of hypertension is important. </text>
<text top="769" left="105" width="687" height="15" font="11">There are no RCTs evaluating the efficacy of medical therapy to reduce the rate of progression of aortic </text>
<text top="788" left="105" width="386" height="15" font="11">dilation or incidence of aortic dissection in this population. </text>
<text top="817" left="105" width="362" height="15" font="11">See Online Data Supplement 36 for referenced studies. </text>
<text top="855" left="105" width="304" height="19" font="34"><b>4.2.5. Supravalvular Aortic Stenosis </b></text>
<text top="890" left="223" width="4" height="15" font="11"> </text>
<text top="890" left="276" width="382" height="16" font="12"><b>Recommendations for Supravalvular Aortic Stenosis </b></text>
<text top="910" left="116" width="461" height="15" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="910" left="577" width="180" height="15" font="23">Online Data Supplement 37</text>
<text top="910" left="757" width="8" height="15" font="11">. </text>
<text top="931" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="931" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="931" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="951" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="991" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="991" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="971" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="971" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="971" left="281" width="495" height="15" font="14"><b>Aortic  imaging  using  TTE,  TEE,  CMR,  or  CTA  is  recommended  in  adults </b></text>
<text top="991" left="281" width="495" height="15" font="14"><b>with  Williams  syndrome  or  patients  suspected  of  having  supravalvular </b></text>
<text top="1011" left="281" width="172" height="15" font="14"><b>aortic stenosis (S4.2.5-1). </b></text>
<text top="1050" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1050" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="1031" left="255" width="13" height="15" font="14"><b>2.</b></text>
<text top="1031" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="1031" left="281" width="495" height="15" font="14"><b>Coronary  imaging  is  recommended  in  patients  with  Williams  syndrome </b></text>
<text top="1050" left="281" width="495" height="15" font="14"><b>and supravalvular aortic stenosis presenting with symptoms of coronary </b></text>
<text top="1070" left="281" width="196" height="15" font="14"><b>ischemia (S4.2.5-2–S4.2.5-4). </b></text>
</page>
<page number="70" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 72 </text>
<text top="163" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="203" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="203" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="183" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="183" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="183" left="281" width="495" height="15" font="14"><b>Surgical  repair  is  recommended  for  adults  with  supravalvular  aortic </b></text>
<text top="203" left="281" width="495" height="15" font="14"><b>stenosis  (discrete  or  diffuse)  and  symptoms  or  decreased  LV  systolic </b></text>
<text top="222" left="281" width="464" height="15" font="14"><b>function deemed secondary to aortic obstruction (S4.2.5-5–S4.2.5-8). </b></text>
<text top="262" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="262" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="243" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="243" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="243" left="281" width="495" height="15" font="14"><b>Coronary artery revascularization is recommended in symptomatic adults </b></text>
<text top="262" left="281" width="495" height="15" font="14"><b>with supravalvular aortic stenosis and coronary ostial stenosis (S4.2.5-4, </b></text>
<text top="282" left="281" width="67" height="15" font="14"><b>S4.2.5-9). </b></text>
<text top="311" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="339" left="105" width="687" height="15" font="11">Supravalvular aortic stenosis is a relatively rare condition overall but is seen commonly in patients with </text>
<text top="359" left="105" width="687" height="15" font="11">Williams  syndrome  or  homozygous  familial  hypercholesterolemia.  The  stenotic  ridge  tends  to  occur </text>
<text top="378" left="105" width="687" height="15" font="11">distal to the coronary artery orifices at the sinotubular junction. In addition to pressure load physiology </text>
<text top="398" left="105" width="687" height="15" font="11">similar  to  other  causes  of  LVOT  obstruction,  coronary  abnormalities  can  occur,  including  significant </text>
<text top="418" left="105" width="687" height="15" font="11">coronary ostial stenosis resulting in risk of SCD and anesthesia risk (S4.2.5-10–S4.2.5-14). Unlike subAS </text>
<text top="437" left="105" width="687" height="15" font="11">or  valvular  aortic  stenosis,  the  coronary  arteries  are exposed  to  the  higher  pressure  generated  by  the </text>
<text top="457" left="105" width="174" height="15" font="11">supravalvular obstruction. </text>
<text top="485" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="505" left="105" width="687" height="15" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="524" left="105" width="340" height="15" font="11">Table 20 for routine testing and follow-up intervals. </text>
<text top="553" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="581" left="105" width="687" height="15" font="11">1. TTE with Doppler imaging is useful in deriving peak and mean pressure gradients across the area of </text>
<text top="601" left="105" width="687" height="15" font="11">supravalvular  aortic  stenosis  from  apical,  suprasternal,  and  right  parasternal  views;  however, </text>
<text top="620" left="105" width="687" height="15" font="11">visualization of the full extent of supravalvular aortic stenosis with TTE is limited. TEE is superior in this </text>
<text top="640" left="105" width="687" height="15" font="11">regard, and 3D TEE allows excellent visualization of the narrowed ascending aorta. CMR and CTA provide </text>
<text top="659" left="105" width="687" height="15" font="11">comprehensive and detailed images of supravalvular aortic stenosis and are used with echocardiography </text>
<text top="679" left="105" width="426" height="15" font="11">in the assessment of patients before and after repair (S4.2.5-15). </text>
<text top="707" left="105" width="687" height="15" font="11">2. Impaired coronary perfusion may occur because of varying degrees of aortic valve leaflet adhesion to </text>
<text top="727" left="105" width="687" height="15" font="11">the narrowed sinotubular junction or because of fibrotic thickening in the area immediately surrounding </text>
<text top="747" left="105" width="687" height="15" font="11">the coronary ostia. This causes ostial stenosis with restriction in diastolic filling of the coronary arteries; </text>
<text top="766" left="105" width="687" height="15" font="11">the  left  coronary  is  most  frequently  involved.  TEE  with  Doppler  can  be  used  in  the  assessment  of </text>
<text top="786" left="105" width="687" height="15" font="11">proximal  coronary  patency  and  to  search  for  flow  turbulence.  CMR  can  also  be  used  in  assessing  the </text>
<text top="806" left="105" width="687" height="15" font="11">coronary  ostia.  Electrocardiographic-gated  CT  coronary  angiography  or  invasive  selective  coronary </text>
<text top="825" left="105" width="512" height="15" font="11">angiography provides excellent visualization of the coronary arterial anatomy. </text>
<text top="853" left="105" width="687" height="15" font="11">3. Supravalvular aortic stenosis is usually a progressive problem with a progressive increase in LV systolic </text>
<text top="873" left="105" width="687" height="15" font="11">pressure resulting in exertional symptoms and, if the stenosis is severe, eventual decreases in LV systolic </text>
<text top="893" left="105" width="62" height="15" font="11">function. </text>
<text top="921" left="105" width="687" height="15" font="11">4. Impaired coronary perfusion may occur because of varying degrees of aortic valve leaflet adhesion to </text>
<text top="941" left="105" width="687" height="15" font="11">the  narrowed  sinotubular  junction  with  restriction  in  diastolic  filling  of  the  coronary  arteries;  the  left </text>
<text top="960" left="105" width="687" height="15" font="11">coronary is most frequently involved. Surgical coronary revascularization is recommended for patients </text>
<text top="980" left="105" width="248" height="15" font="11">with symptoms of coronary ischemia. </text>
<text top="1008" left="105" width="4" height="15" font="11"> </text>
<text top="1037" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="1037" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="71" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 73 </text>
<text top="162" left="105" width="538" height="15" font="14"><b>Table 20. Supravalvular Aortic Stenosis: Routine Follow-Up and Testing Intervals </b></text>
<text top="185" left="111" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="203" left="174" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="185" left="343" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="340" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="185" left="461" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="459" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="185" left="573" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="571" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="185" left="685" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="681" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="221" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="221" left="328" width="18" height="13" font="8">24 </text>
<text top="221" left="453" width="18" height="13" font="8">24 </text>
<text top="221" left="565" width="33" height="13" font="8">6–12 </text>
<text top="221" left="676" width="25" height="13" font="8">3–6 </text>
<text top="240" left="105" width="27" height="13" font="8">ECG </text>
<text top="240" left="328" width="18" height="13" font="8">24 </text>
<text top="240" left="453" width="18" height="13" font="8">24 </text>
<text top="240" left="565" width="18" height="13" font="8">12 </text>
<text top="240" left="676" width="18" height="13" font="8">12 </text>
<text top="258" left="105" width="32" height="13" font="8">TTE† </text>
<text top="258" left="328" width="18" height="13" font="8">24 </text>
<text top="258" left="453" width="18" height="13" font="8">24 </text>
<text top="258" left="565" width="18" height="13" font="8">12 </text>
<text top="258" left="676" width="18" height="13" font="8">12 </text>
<text top="277" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="277" left="328" width="40" height="13" font="8">36–60 </text>
<text top="277" left="453" width="40" height="13" font="8">36–60 </text>
<text top="277" left="565" width="40" height="13" font="8">36–60 </text>
<text top="277" left="676" width="40" height="13" font="8">36–60 </text>
<text top="296" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="293" left="179" width="14" height="18" font="8">║ </text>
<text top="296" left="328" width="66" height="13" font="8">As needed </text>
<text top="296" left="453" width="18" height="13" font="8">24 </text>
<text top="296" left="565" width="18" height="13" font="8">24 </text>
<text top="296" left="676" width="18" height="13" font="8">12 </text>
<text top="314" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="330" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="346" left="105" width="686" height="12" font="9">‡CMR may be indicated for assessment of aor@c anatomy. Baseline study is recommended with periodic follow-up CMR, with </text>
<text top="362" left="105" width="432" height="12" font="9">frequency of repeat imaging determined by anatomic and physiological findings. </text>
<text top="378" left="105" width="542" height="12" font="9">§If CCT is used instead of CMR imaging, the frequency should be weighed against radiation exposure. </text>
<text top="392" left="105" width="356" height="16" font="9">║6-minute walk test or CPET, depending on the clinical indication. </text>
<text top="410" left="105" width="686" height="12" font="9">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance; </text>
<text top="427" left="105" width="549" height="12" font="9">CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic echocardiogram. </text>
<text top="461" left="105" width="263" height="19" font="34"><b>4.2.6. Coarctation of the Aorta </b></text>
<text top="497" left="241" width="4" height="14" font="11"> </text>
<text top="496" left="293" width="347" height="16" font="12"><b>Recommendations for Coarctation of the Aorta </b></text>
<text top="516" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="516" left="577" width="180" height="14" font="23">Online Data Supplement 38</text>
<text top="516" left="757" width="8" height="14" font="11">. </text>
<text top="537" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="537" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="537" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="557" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="597" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="597" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="577" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="577" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="577" left="281" width="495" height="15" font="14"><b>Initial and follow-up aortic imaging using CMR or CTA is recommended in </b></text>
<text top="597" left="281" width="495" height="15" font="14"><b>adults  with  coarctation  of  the  aorta,  including  those  who  have  had </b></text>
<text top="616" left="281" width="352" height="15" font="14"><b>surgical or catheter intervention (S4.2.6-1–S4.2.6-3). </b></text>
<text top="647" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="647" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="637" left="255" width="13" height="15" font="14"><b>2.</b></text>
<text top="637" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="637" left="281" width="495" height="15" font="14"><b>Resting  blood  pressure  should  be  measured  in  upper  and  lower </b></text>
<text top="656" left="281" width="360" height="15" font="14"><b>extremities in all adults with coarctation of the aorta. </b></text>
<text top="696" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="696" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="677" left="255" width="13" height="15" font="14"><b>3.</b></text>
<text top="677" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="677" left="281" width="495" height="15" font="14"><b>Ambulatory blood pressure monitoring in adults with coarctation of the </b></text>
<text top="696" left="281" width="495" height="15" font="14"><b>aorta  can  be  useful  for  diagnosis  and  management  of  hypertension </b></text>
<text top="716" left="281" width="72" height="15" font="14"><b>(S4.2.6-4). </b></text>
<text top="756" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="756" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="736" left="255" width="13" height="15" font="14"><b>4.</b></text>
<text top="736" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="736" left="281" width="495" height="15" font="14"><b>Screening for intracranial aneurysms by magnetic resonance angiography </b></text>
<text top="756" left="281" width="491" height="15" font="14"><b>or CTA may be reasonable in adults with coarctation of the aorta (S4.2.6-</b></text>
<text top="775" left="281" width="83" height="15" font="14"><b>5, S4.2.6-6). </b></text>
<text top="815" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="815" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="796" left="255" width="13" height="15" font="14"><b>5.</b></text>
<text top="796" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="796" left="281" width="495" height="15" font="14"><b>Exercise  testing  to  evaluate  for  exercise-induced  hypertension  may  be </b></text>
<text top="815" left="281" width="494" height="15" font="14"><b>reasonable in adults with coarctation of the aorta who exercise (S4.2.6-4, </b></text>
<text top="835" left="281" width="67" height="15" font="14"><b>S4.2.6-7). </b></text>
<text top="855" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="895" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="895" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="876" left="256" width="13" height="15" font="14"><b>6.</b></text>
<text top="876" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="876" left="281" width="495" height="15" font="14"><b>Surgical  repair  or  catheter-based  stenting  is  recommended  for  adults </b></text>
<text top="895" left="281" width="495" height="15" font="14"><b>with  hypertension  and  significant  native  or  recurrent  coarctation  of  the </b></text>
<text top="915" left="281" width="307" height="15" font="14"><b>aorta (S4.2.6-1, S4.2.6-2, S4.2.6-8–S4.2.6-12).  </b></text>
<text top="945" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="945" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="935" left="256" width="13" height="15" font="14"><b>7.</b></text>
<text top="935" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="935" left="281" width="495" height="15" font="14"><b>GDMT  is  recommended  for  treatment  of  hypertension  in  patients  with </b></text>
<text top="955" left="281" width="242" height="15" font="14"><b>coarctation of the aorta (S4.2.6-13). </b></text>
<text top="995" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="995" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="975" left="256" width="13" height="15" font="14"><b>8.</b></text>
<text top="975" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="975" left="281" width="495" height="15" font="14"><b>Balloon  angioplasty  for  adults  with  native  and  recurrent  coarctation  of </b></text>
<text top="995" left="281" width="495" height="15" font="14"><b>the  aorta  may  be  considered  if  stent  placement  is  not  feasible  and </b></text>
<text top="1014" left="281" width="329" height="15" font="14"><b>surgical intervention is not an option (S4.2.6-14). </b></text>
<text top="1043" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="1072" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="1072" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="72" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 74 </text>
<text top="162" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="191" left="105" width="687" height="14" font="11">CoA  typically  occurs  near  the  ductal  remnant  and  left  subclavian  artery.  Hypertension  is  the  most </text>
<text top="210" left="105" width="687" height="15" font="11">common sequela of CoA, whether repaired or unrepaired. BAV is commonly associated with CoA and is </text>
<text top="229" left="105" width="687" height="15" font="11">present  in  more  than  half  of  CoA  patients  (S4.2.6-15–S4.2.6-21).  Intracranial  aneurysms  may  occur. </text>
<text top="249" left="105" width="687" height="15" font="11">Ascending aortic  aneurysms are often found in  those with BAV,  and aneurysms  are seen at the site of </text>
<text top="268" left="105" width="687" height="15" font="11">coarctation repair in the descending thoracic aorta or arch. Dissection can occur, presumably more likely </text>
<text top="288" left="105" width="687" height="15" font="11">in  the  setting  of  poorly  controlled  hypertension.  Even  with  excellent  repair,  hypertension  remains </text>
<text top="308" left="105" width="471" height="15" font="11">common and predisposes to later myocardial infarction, stroke, and HF. </text>
<text top="336" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="356" left="105" width="687" height="15" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="375" left="105" width="340" height="15" font="11">Table 21 for routine testing and follow-up intervals. </text>
<text top="404" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="432" left="105" width="683" height="15" font="11">1. Complications of CoA repair include recoarctation, aneurysm, pseudoaneurysm, and dissection. Long-</text>
<text top="452" left="105" width="687" height="15" font="11">term  follow-up  after  successful  surgical intervention for  CoA  reveals that 11% of  patients may  require </text>
<text top="472" left="105" width="687" height="15" font="11">reintervention for restenosis, visualized by CMR or CTA (if CMR is contraindicated or there is a history of </text>
<text top="491" left="105" width="687" height="15" font="11">stent  therapy)  and  supported  by  physical  examination  findings  (S4.2.6-1).  Although  evidence  of </text>
<text top="511" left="105" width="687" height="15" font="11">recoarctation  can  be  found  on  clinical  examination  and  echocardiography,  aneurysms  near  the  site  of </text>
<text top="530" left="105" width="687" height="15" font="11">repair may  not  be well  seen  by  echocardiography.  Patients who  have  undergone  surgical  patch  repair </text>
<text top="550" left="105" width="687" height="15" font="11">are at an increased risk of developing aneurysms that can be evaluated by CMR or CTA. After successful </text>
<text top="569" left="105" width="687" height="15" font="11">transcatheter  intervention  with  stenting  or  balloon  angioplasty,  follow-up  CMR  or  CTA  imaging  is </text>
<text top="589" left="105" width="687" height="15" font="11">recommended  to  evaluate  for  long-term  complications  (e.g.,  aneurysm  formation,  stent  fracture,  or </text>
<text top="609" left="105" width="687" height="15" font="11">stent  migration)  (S4.2.6-1).  The  same  CMR  or  CTA  study  will  also  evaluate  the ascending  aorta,  which </text>
<text top="628" left="105" width="351" height="15" font="11">may become aneurysmal over the years of follow-up. </text>
<text top="657" left="105" width="687" height="15" font="11">2. Unoperated adults with CoA almost invariably present with systemic arterial hypertension measured </text>
<text top="676" left="105" width="687" height="15" font="11">in  the  upper  extremities.  Brachial  and  femoral  pulse  timing  and  amplitude  evaluation  on  physical </text>
<text top="696" left="105" width="687" height="15" font="11">examination reveals a delay or decrease in amplitude of the femoral pulse. Upper and lower extremity </text>
<text top="715" left="105" width="687" height="15" font="11">noninvasive  blood  pressure  measurement  is  recommended  in  all  patients  with  unoperated  or </text>
<text top="735" left="105" width="175" height="15" font="11">operated/intervened CoA. </text>
<text top="763" left="105" width="687" height="15" font="11">3. Upper body systemic hypertension is prevalent in patients with unoperated coarctation and may be </text>
<text top="783" left="105" width="687" height="15" font="11">present  in  up  to  one  third  of  patients  who  have  undergone  operative  or  transcatheter  intervention </text>
<text top="803" left="105" width="687" height="15" font="11">(S4.2.6-2).  Systemic  hypertension  may  not  consistently  be  identifiable  at  rest;  therefore,  ambulatory </text>
<text top="822" left="105" width="687" height="15" font="11">blood  pressure  monitoring  can  be  useful  in  identifying  and  appropriately  managing  patients  with </text>
<text top="842" left="105" width="173" height="15" font="11">ambulatory hypertension. </text>
<text top="870" left="105" width="687" height="15" font="11">4. Multiple studies have demonstrated an  increased frequency of  intracranial  aneurysm in adults with </text>
<text top="890" left="105" width="687" height="15" font="11">CoA.  Approximately  10%  of  patients  with  CoA  have  intracranial  aneurysms  identified  on  magnetic </text>
<text top="909" left="105" width="687" height="15" font="11">resonance angiography or CTA. Increasing age has been identified as a risk factor. Many such identified </text>
<text top="929" left="105" width="687" height="15" font="11">aneurysms  are  small;  however,  the  expected  outcome  and  ideal  management  of  such  aneurysms  are </text>
<text top="949" left="105" width="687" height="15" font="11">not  clear.  Providers  and  patients  should  be  aware  of  management  uncertainties  when  considering </text>
<text top="968" left="105" width="687" height="15" font="11">routine  screening  for  aneurysms  (S4.2.6-22).  Additionally,  there  are  some  data  suggesting  that </text>
<text top="988" left="105" width="687" height="15" font="11">intracranial  aneurysms  are  not  commonly  found  in  children  and  teenagers  with  CoA  (S4.2.6-23), </text>
<text top="1007" left="105" width="687" height="15" font="11">reinforcing the possibility  that  coarctation  alone may not be sufficient for development of intracranial </text>
<text top="1027" left="105" width="687" height="15" font="11">aneurysm,  and  other  factors,  such  as  hypertension  and/or  age,  play  a  role  in  development  and </text>
<text top="1047" left="105" width="176" height="15" font="11">progression of aneurysms. </text>
</page>
<page number="73" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 75 </text>
<text top="162" left="105" width="687" height="14" font="11">5. Despite successful surgical repair or transcatheter intervention, hypertension can persist and may not </text>
<text top="182" left="105" width="687" height="14" font="11">be  identified  during  resting  blood  pressure  measurement.  Up  to  80%  of  patients  with  prior  CoA </text>
<text top="202" left="105" width="687" height="14" font="11">intervention  manifest  an  abnormally  elevated  upper  extremity  exercise  blood  pressure  response,  and </text>
<text top="221" left="105" width="687" height="14" font="11">peak  blood  pressure  is  correlated  with  increased  LV  mass  (S4.2.6-24).  Moreover,  restenosis  of  the </text>
<text top="241" left="105" width="687" height="14" font="11">previously  repaired  or  stented  region  may  be  identified  by  increased  peak  blood  pressure  response, </text>
<text top="260" left="105" width="687" height="14" font="11">increased  upper  to  lower  extremity  blood  pressure  gradient  with  exercise,  and  increased  Doppler </text>
<text top="280" left="105" width="363" height="14" font="11">velocity across the coarctation site during exercise TTE. </text>
<text top="308" left="105" width="687" height="14" font="11">6. Significant native or recurrent aortic coarctation has been defined as follows: upper extremity/lower </text>
<text top="328" left="105" width="687" height="14" font="11">extremity  resting  peak-to-peak  gradient  &gt;20  mm  Hg  or  mean  Doppler  systolic  gradient  &gt;20  mm  Hg; </text>
<text top="348" left="105" width="687" height="14" font="11">upper extremity/lower extremity gradient &gt;10 mm Hg or mean Doppler gradient &gt;10 mm Hg plus either </text>
<text top="367" left="105" width="687" height="14" font="11">decreased  LV  systolic  function  or  AR;  upper  extremity/lower  extremity  gradient  &gt;10  mm  Hg  or  mean </text>
<text top="387" left="105" width="687" height="14" font="11">Doppler gradient &gt;10 mm Hg with collateral flow (S4.2.6-2, S4.2.6-8, S4.2.6-12). This should be coupled </text>
<text top="406" left="105" width="687" height="14" font="11">with anatomic evidence for CoA, typically defined by advanced imaging (CMR, CTA). The best evidence </text>
<text top="426" left="105" width="687" height="14" font="11">to proceed with intervention for CoA includes systemic hypertension, upper extremity/lower extremity </text>
<text top="446" left="105" width="687" height="14" font="11">blood  pressure  gradient  and  echocardiography  Doppler  gradient  as  defined  above,  and  anatomic </text>
<text top="465" left="105" width="687" height="14" font="11">evidence  of  CoA.  Multiple  factors  help  determine  whether  surgery  or  stenting  is  optimal,  including </text>
<text top="485" left="105" width="687" height="14" font="11">anatomic  features  such  as  proximity  of  native  coarctation  to  head  and  neck  vessels  or  concomitant </text>
<text top="504" left="105" width="412" height="14" font="11">aneurysm, and, if stenting, whether a covered stent is needed. </text>
<text top="533" left="105" width="687" height="14" font="11">7.  The  long-term  complications  of  CoA  are  generally  related  to  chronic  upper  body  systemic </text>
<text top="552" left="105" width="687" height="14" font="11">hypertension, therefore, systemic hypertension should be identified by resting, ambulatory, or exercise </text>
<text top="572" left="105" width="614" height="14" font="11">blood pressure assessment and medical treatment should follow GDMT (S4.2.6-13, S4.2.6-25) </text>
<text top="600" left="105" width="687" height="15" font="11">8.  Balloon  angioplasty  alone  is  associated  with  a  higher  rate  of  intimal  tears  and  aneurysm  formation </text>
<text top="619" left="105" width="217" height="15" font="11">compared with stent placement. </text>
<text top="648" left="105" width="4" height="15" font="11"> </text>
<text top="676" left="105" width="370" height="15" font="14"><b>Table 21. CoA: Routine Follow-Up and Testing Intervals </b></text>
<text top="699" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="717" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="699" left="327" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="326" width="85" height="13" font="7"><b>Stage A*(mo) </b></text>
<text top="699" left="440" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="439" width="84" height="13" font="7"><b>Stage B*(mo) </b></text>
<text top="699" left="560" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="559" width="84" height="13" font="7"><b>Stage C*(mo) </b></text>
<text top="699" left="680" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="717" left="679" width="85" height="13" font="7"><b>Stage D*(mo) </b></text>
<text top="736" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="736" left="321" width="18" height="13" font="8">24 </text>
<text top="736" left="427" width="18" height="13" font="8">24 </text>
<text top="736" left="548" width="33" height="13" font="8">6–12 </text>
<text top="736" left="667" width="25" height="13" font="8">3–6 </text>
<text top="754" left="105" width="27" height="13" font="8">ECG </text>
<text top="754" left="321" width="18" height="13" font="8">24 </text>
<text top="754" left="427" width="18" height="13" font="8">24 </text>
<text top="754" left="548" width="18" height="13" font="8">12 </text>
<text top="754" left="667" width="18" height="13" font="8">12 </text>
<text top="773" left="105" width="32" height="13" font="8">TTE† </text>
<text top="773" left="321" width="18" height="13" font="8">24 </text>
<text top="773" left="427" width="18" height="13" font="8">24 </text>
<text top="773" left="548" width="18" height="13" font="8">12 </text>
<text top="773" left="667" width="18" height="13" font="8">12 </text>
<text top="791" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="791" left="321" width="40" height="13" font="8">36–60 </text>
<text top="791" left="427" width="40" height="13" font="8">36–60 </text>
<text top="791" left="548" width="40" height="13" font="8">12–24 </text>
<text top="791" left="667" width="40" height="13" font="8">12–24 </text>
<text top="810" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="807" left="179" width="14" height="18" font="8">║ </text>
<text top="810" left="321" width="18" height="13" font="8">36 </text>
<text top="810" left="427" width="18" height="13" font="8">24 </text>
<text top="810" left="548" width="18" height="13" font="8">24 </text>
<text top="810" left="667" width="18" height="13" font="8">12 </text>
<text top="828" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="844" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="861" left="105" width="686" height="12" font="9">‡CMR  may  be  indicated  for  assessment  of  aor@c  size  and  aor@c  arch/coarcta@on  repair  site  anatomy.  Baseline  study  is </text>
<text top="877" left="105" width="686" height="12" font="9">recommended  with  periodic  follow-up  CMR,  with  frequency  of  repeat  imaging  determined  by  anatomic  and  physiological </text>
<text top="893" left="105" width="48" height="12" font="9">findings. </text>
<text top="909" left="105" width="686" height="12" font="9">§CCT may be  used if CMR is not feasible and to evaluate cross-sectional imaging status–post-stent therapy for coarctation of </text>
<text top="925" left="105" width="385" height="12" font="9">the aorta; the frequency should be weighed against radiation exposure. </text>
<text top="938" left="105" width="356" height="16" font="9">║6-minute walk test or CPET, depending on the clinical indication. </text>
<text top="957" left="105" width="686" height="12" font="9">ACHD  indicates  adult congenital heart disease;  CCT, cardiac computed tomography; CMR, cardiovascular  magnetic resonance </text>
<text top="973" left="105" width="686" height="12" font="9">imaging;  CoA,  coarctation  of  the  aorta;  CPET,  cardiopulmonary  exercise;  ECG,  electrocardiogram;  and  TTE,  transthoracic </text>
<text top="989" left="105" width="93" height="12" font="9">echocardiogram. </text>
<text top="1024" left="105" width="220" height="20" font="17"><b>4.3. Right-Sided Lesions </b></text>
<text top="1063" left="105" width="4" height="14" font="11"> </text>
<text top="1060" left="315" width="5" height="19" font="34"><b> </b></text>
</page>
<page number="74" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 76 </text>
<text top="163" left="105" width="299" height="19" font="34"><b>4.3.1. Valvular Pulmonary Stenosis </b></text>
<text top="199" left="226" width="4" height="14" font="11"> </text>
<text top="197" left="278" width="377" height="16" font="12"><b>Recommendations for Valvular Pulmonary Stenosis </b></text>
<text top="218" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="218" left="577" width="180" height="14" font="23">Online Data Supplement 39</text>
<text top="218" left="757" width="8" height="14" font="11">. </text>
<text top="238" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="238" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="238" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="288" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="288" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="259" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="259" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="259" left="281" width="495" height="15" font="14"><b>In  adults  with  moderate  or  severe  valvular  pulmonary  stenosis  and </b></text>
<text top="278" left="281" width="491" height="15" font="14"><b>otherwise  unexplained  symptoms  of  HF,  cyanosis  from  interatrial  right-</b></text>
<text top="298" left="281" width="46" height="15" font="14"><b>to-left </b></text>
<text top="298" left="345" width="112" height="15" font="14"><b>communication, </b></text>
<text top="298" left="475" width="50" height="15" font="14"><b>and/or </b></text>
<text top="298" left="543" width="58" height="15" font="14"><b>exercise </b></text>
<text top="298" left="620" width="84" height="15" font="14"><b>intolerance, </b></text>
<text top="298" left="722" width="54" height="15" font="14"><b>balloon </b></text>
<text top="317" left="281" width="340" height="15" font="14"><b>valvuloplasty is recommended (S4.3.1-1–S4.3.1-4). </b></text>
<text top="367" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="367" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="338" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="338" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="338" left="281" width="495" height="15" font="14"><b>In  adults  with  moderate  or  severe  valvular  pulmonary  stenosis  and </b></text>
<text top="357" left="281" width="494" height="15" font="14"><b>otherwise  unexplained  symptoms  of  HF,  cyanosis,  and/or  exercise </b></text>
<text top="377" left="281" width="495" height="15" font="14"><b>intolerance  who  are  ineligible  for  or  who  failed  balloon  valvuloplasty, </b></text>
<text top="397" left="281" width="403" height="15" font="14"><b>surgical repair is recommended (S4.3.1-1, S4.3.1-5–S4.3.1-8) </b></text>
<text top="427" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="427" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="417" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="417" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="417" left="281" width="495" height="15" font="14"><b>In  asymptomatic  adults  with  severe  valvular  pulmonary  stenosis, </b></text>
<text top="436" left="281" width="183" height="15" font="14"><b>intervention is reasonable. </b></text>
<text top="466" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="494" left="105" width="687" height="14" font="11">Valvular  PS  is  one  of  the  most  common  congenital  heart  defects,  estimated  to  occur  in  up  to  7%  of </text>
<text top="514" left="105" width="687" height="14" font="11">children born with CHD (S4.3.1-9–S4.3.1-11). Some common findings associated with isolated valvular PS </text>
<text top="533" left="105" width="687" height="14" font="11">include a dilated main PA and dysplastic valve cusps. Surgical or catheter-based intervention depends on </text>
<text top="553" left="105" width="687" height="14" font="11">degree  of  obstruction,  RV  pressure  and  function,  and  associated  symptoms.  Patients  with  isolated </text>
<text top="573" left="105" width="687" height="14" font="11">pulmonary valve  stenosis  (native or recurrent after an intervention) require ongoing cardiac follow-up </text>
<text top="592" left="105" width="687" height="14" font="11">and  monitoring  for  evidence  of  progressive  valve  stenosis  or  regurgitation,  RV  hypertrophy,  HF,  and </text>
<text top="612" left="105" width="687" height="14" font="11">arrhythmias (S4.3.1-12). Patients with mild native pulmonary valve stenosis (Table 22) have a reassuring </text>
<text top="631" left="105" width="687" height="14" font="11">natural  history,  and  intervention  is  not  usually  necessary.  Patients  with  severe  PS  (Table  22)  usually </text>
<text top="651" left="105" width="687" height="14" font="11">require  intervention  in  childhood  with  a  good  prognosis  into  adulthood  (S4.3.1-6).  Patients  with </text>
<text top="670" left="105" width="687" height="14" font="11">moderate  stenosis  (Table  22)  have  more  variable  histories,  with  some  having  received  surgical  or </text>
<text top="690" left="105" width="687" height="14" font="11">catheter  intervention  in  childhood  or  adulthood  and  some  not.  Patients  with  moderate  PS,  whether </text>
<text top="710" left="105" width="687" height="14" font="11">native  or  postintervention,  have  a  good  long-term  outcome,  although  some  will  go  on  to  require  an </text>
<text top="729" left="105" width="687" height="14" font="11">intervention in adulthood because of progressive PS or, commonly, significant PR as a sequela of earlier </text>
<text top="749" left="105" width="88" height="14" font="11">intervention. </text>
<text top="777" left="158" width="634" height="14" font="11">Pulmonary  atresia  with  intact  ventricular  septum  is  a  rare  congenital  heart  lesion  that  is </text>
<text top="797" left="105" width="687" height="14" font="11">associated  with  varying  degrees  of  RV  hypoplasia  and  tricuspid  valve  hypoplasia  in  addition  to </text>
<text top="817" left="105" width="687" height="14" font="11">pulmonary valve atresia. Adults with pulmonary atresia with intact ventricular septum followed various </text>
<text top="836" left="105" width="687" height="14" font="11">surgical  pathways in  childhood,  either  biventricular  repair, 1  1/2  ventricular  repair,  Fontan  procedure, </text>
<text top="856" left="105" width="687" height="14" font="11">transplant,  or  shunt  palliation  (S4.3.1-13).  Adults  with  history  of  pulmonary  atresia  with  intact </text>
<text top="875" left="105" width="687" height="14" font="11">ventricular  septum  have  a  high  incidence  of  need  for  reintervention  and  management  of  atrial </text>
<text top="895" left="105" width="687" height="14" font="11">arrhythmias  (S4.3.1-14,  S4.3.1-15).  Restrictive  RV  physiology  is  common  in  adults  with  history  of </text>
<text top="915" left="105" width="687" height="14" font="11">pulmonary  atresia  with  intact  ventricular  septum  and  may  be  associated  with  substantial  ventricular </text>
<text top="934" left="105" width="393" height="14" font="11">fibrosis (S4.3.1-16) and RV-dependent coronary circulation.  </text>
<text top="963" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="982" left="105" width="687" height="14" font="11">other procedures in these patients; Section 3.4 for recommendations on diagnostic evaluation; Table 23 </text>
<text top="1002" left="105" width="687" height="14" font="11">for  routine  testing  and  follow-up  intervals;  and  Figure  3  for  a  diagnostic  and  treatment  algorithm  for </text>
<text top="1021" left="105" width="194" height="14" font="11">isolated PR after repair of PS. </text>
<text top="1050" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
</page>
<page number="75" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 77 </text>
<text top="162" left="105" width="687" height="14" font="11">1.  In  patients  with  moderate  or  severe  isolated  pulmonary  valve  stenosis,  pulmonary  balloon </text>
<text top="182" left="105" width="687" height="14" font="11">valvuloplasty is safe and effective in reducing the pulmonary valve gradient and improving symptoms in </text>
<text top="202" left="105" width="93" height="14" font="11">most patients </text>
<text top="230" left="105" width="687" height="14" font="11">2. Surgical valvotomy  is usually  sufficient, particularly when  the  pulmonary annulus is not hypoplastic. </text>
<text top="249" left="105" width="687" height="14" font="11">Pulmonary valve replacement may be necessary when there is marked dysplasia of the pulmonary valve </text>
<text top="269" left="105" width="263" height="14" font="11">or significant hypoplasia of the annulus. </text>
<text top="297" left="105" width="687" height="14" font="11">3. Relief of a severely stenotic pulmonary valve in an asymptomatic patient will reduce the RV pressure </text>
<text top="317" left="105" width="687" height="14" font="11">and the possibility of potential sequelae. As in symptomatic patients, the procedure can be performed </text>
<text top="337" left="105" width="687" height="14" font="11">by surgery or interventional catheterization with low morbidity and mortality. If intervention is deferred, </text>
<text top="356" left="105" width="687" height="14" font="11">careful  follow-up  to  evaluate  for  symptoms,  decline  in  exercise  capacity,  worsening  RV  function,  or </text>
<text top="376" left="105" width="574" height="14" font="11">development of cyanosis is important and may prompt reconsideration of intervention. </text>
<text top="404" left="105" width="4" height="14" font="11"> </text>
<text top="433" left="105" width="263" height="15" font="14"><b>Table 22. Severity of RVOT Obstruction </b></text>
<text top="456" left="105" width="30" height="13" font="8">Mild </text>
<text top="456" left="197" width="242" height="13" font="8">Peak gradient &lt;36 mm Hg (peak velocity </text>
<text top="473" left="197" width="49" height="13" font="8">&lt;3 m/s) </text>
<text top="492" left="105" width="63" height="13" font="8">Moderate </text>
<text top="492" left="197" width="257" height="13" font="8">Peak gradient 36–64 mm Hg (peak velocity </text>
<text top="510" left="197" width="56" height="13" font="8">3–4 m/s) </text>
<text top="528" left="105" width="43" height="13" font="8">Severe </text>
<text top="528" left="197" width="252" height="13" font="8">Peak gradient 64 mm Hg (peak velocity &gt;4 </text>
<text top="546" left="197" width="196" height="13" font="8">m/s); mean gradient &gt;35 mm Hg </text>
<text top="564" left="105" width="364" height="12" font="9">Estimations  of  RV  systolic  pressure  by  TR  velocity  is  part  of  the </text>
<text top="580" left="105" width="364" height="12" font="9">echocardiographic  assessment  of  RV  obstruction,  as  Doppler </text>
<text top="597" left="105" width="354" height="12" font="9">measurements across the RV obstruction itself may be unreliable. </text>
<text top="613" left="105" width="364" height="12" font="9">RV indicates right ventricular; RVOT, right ventricular outflow tract; </text>
<text top="629" left="105" width="169" height="12" font="9">and TR, tricuspid regurgitation. </text>
<text top="645" left="105" width="4" height="14" font="11"> </text>
<text top="665" left="105" width="418" height="15" font="14"><b>Table 23. Valvular PS: Routine Follow-Up and Testing Intervals </b></text>
<text top="688" left="111" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="705" left="174" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="688" left="340" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="705" left="337" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="688" left="455" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="705" left="452" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="688" left="566" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="705" left="563" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="688" left="678" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="705" left="674" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="724" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="724" left="328" width="40" height="13" font="8">36–60 </text>
<text top="724" left="446" width="18" height="13" font="8">24 </text>
<text top="724" left="558" width="33" height="13" font="8">6–12 </text>
<text top="724" left="669" width="25" height="13" font="8">3–6 </text>
<text top="743" left="105" width="27" height="13" font="8">ECG </text>
<text top="743" left="328" width="40" height="13" font="8">36–60 </text>
<text top="743" left="446" width="18" height="13" font="8">24 </text>
<text top="743" left="558" width="18" height="13" font="8">12 </text>
<text top="743" left="669" width="18" height="13" font="8">12 </text>
<text top="761" left="105" width="25" height="13" font="8">TTE </text>
<text top="761" left="328" width="40" height="13" font="8">36–60 </text>
<text top="761" left="446" width="18" height="13" font="8">24 </text>
<text top="761" left="558" width="18" height="13" font="8">12 </text>
<text top="761" left="669" width="18" height="13" font="8">12 </text>
<text top="780" left="105" width="85" height="13" font="8">Exercise test† </text>
<text top="780" left="328" width="66" height="13" font="8">As needed </text>
<text top="780" left="446" width="18" height="13" font="8">24 </text>
<text top="780" left="558" width="18" height="13" font="8">24 </text>
<text top="780" left="669" width="18" height="13" font="8">12 </text>
<text top="798" left="105" width="369" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system. </text>
<text top="814" left="105" width="332" height="12" font="9">†6-minute walk test or CPET, depending on clinical indication. </text>
<text top="830" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CPET,  cardiopulmonary  exercise  test;  ECG,  electrocardiogram;  PS,  pulmonary </text>
<text top="846" left="105" width="265" height="12" font="9">stenosis; and TTE, transthoracic echocardiogram. </text>
<text top="863" left="105" width="4" height="14" font="11"> </text>
<text top="892" left="105" width="299" height="17" font="38"><i><b>4.3.1.1. Isolated PR After Repair of PS </b></i></text>
<text top="926" left="159" width="4" height="14" font="11"> </text>
<text top="925" left="212" width="510" height="16" font="12"><b>Recommendations for Isolated PR After Repair of Pulmonary Stenosis </b></text>
<text top="946" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="946" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="946" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="986" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="986" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="966" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="966" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="966" left="281" width="494" height="15" font="14"><b>In  symptomatic  patients  with  moderate  or  greater  PR  resulting  from </b></text>
<text top="986" left="281" width="495" height="15" font="14"><b>treated isolated pulmonary stenosis, with RV dilation or RV dysfunction, </b></text>
<text top="1005" left="281" width="323" height="15" font="14"><b>pulmonary valve replacement is recommended. </b></text>
<text top="1045" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="1045" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="1026" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="1026" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1026" left="281" width="494" height="15" font="14"><b>For asymptomatic patients with residual  PR resulting from treatment  of </b></text>
<text top="1045" left="281" width="491" height="15" font="14"><b>isolated  pulmonary  stenosis  with  a  dilated  right  ventricle,  serial  follow-</b></text>
<text top="1065" left="281" width="140" height="15" font="14"><b>up is recommended. </b></text>
<text top="1085" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="1085" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="1085" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="1085" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1085" left="281" width="494" height="15" font="14"><b>In  asymptomatic  patients  with  moderate  or  greater  PR  resulting  from </b></text>
</page>
<page number="76" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 78 </text>
<text top="163" left="281" width="495" height="15" font="14"><b>treatment  of  isolated  pulmonary  stenosis  with  progressive  RV  dilation </b></text>
<text top="183" left="281" width="495" height="15" font="14"><b>and/or  RV  dysfunction,  pulmonary  valve  replacement  may  be </b></text>
<text top="202" left="281" width="82" height="15" font="14"><b>reasonable. </b></text>
<text top="231" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="260" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="288" left="105" width="687" height="14" font="11">Although  many  patients  with  valvular  PS  do  not  require  intervention,  some  have  PS  that  is  severe </text>
<text top="308" left="105" width="687" height="14" font="11">enough  to  warrant  intervention,  often  in  infancy  or  childhood.  PS  can  be  alleviated  either  by  surgical </text>
<text top="327" left="105" width="687" height="14" font="11">valvotomy  or  with  balloon  valvuloplasty.  Either  surgical  or  catheter  intervention  may  result  in </text>
<text top="347" left="105" width="687" height="14" font="11">hemodynamically  important  PR  that  can  result  in  symptoms,  RV  enlargement,  and/or  dysfunction </text>
<text top="366" left="105" width="266" height="14" font="11">requiring pulmonary valve replacement. </text>
<text top="395" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="423" left="105" width="687" height="14" font="11">1.  Patients  with  isolated  PS  who  have  previously  undergone  an  intervention  on  the  pulmonary  valve </text>
<text top="443" left="105" width="687" height="14" font="11">require ongoing clinical  follow-up and monitoring of PR, RV size and function, and  functional capacity. </text>
<text top="462" left="105" width="687" height="14" font="11">This may include echocardiography, CPET, and advanced imaging. The right ventricle in patients with PR </text>
<text top="482" left="105" width="687" height="14" font="11">after intervention for PS may be smaller than in patients with TOF; however, patients with PR may have </text>
<text top="502" left="105" width="687" height="14" font="11">evidence  of  decreased  RV  ejection  fraction  or  decreased  exercise  capacity.  Pulmonary  valve </text>
<text top="521" left="105" width="687" height="14" font="11">replacement  can  improve symptoms  for  patients  with  symptoms  that  are  attributable  to  moderate  or </text>
<text top="541" left="105" width="687" height="14" font="11">greater PR, and can improve RV size and/or RV function if there is RV dilation or decreased RV ejection </text>
<text top="560" left="105" width="59" height="14" font="11">fraction. </text>
<text top="589" left="105" width="687" height="14" font="11">2. PR resulting from treatment of isolated PS may have progressive impact on RV size and function, and </text>
<text top="608" left="105" width="687" height="14" font="11">may result in symptoms, such that pulmonary valve replacement would be considered. Serial follow-up </text>
<text top="628" left="105" width="687" height="14" font="11">for clinical evaluation, CPET, and imaging to evaluate for symptoms, exercise intolerance attributable to </text>
<text top="648" left="105" width="629" height="14" font="11">PR, and/or RV dilation or RV dysfunction will allow appropriate timing of intervention if needed. </text>
<text top="676" left="105" width="687" height="14" font="11">3. There are no data to suggest appropriate timing for pulmonary valve replacement in the presence of </text>
<text top="696" left="105" width="687" height="14" font="11">RV dilation, but it is likely inappropriate to directly extrapolate the data applicable to patients with TOF </text>
<text top="715" left="105" width="687" height="14" font="11">(S4.3.1.1-1). However, RV dilation or dysfunction should improve, or at least not progress further, if the </text>
<text top="735" left="105" width="687" height="14" font="11">volume overload from PR is alleviated by pulmonary valve replacement. Thus, although specific RV size </text>
<text top="755" left="105" width="687" height="14" font="11">criteria  are  not  available  for  these  patients  to  determine  timing  of  pulmonary  valve  replacement, </text>
<text top="774" left="105" width="687" height="14" font="11">patients with progressively worsening RV size or function presumably represent a subset of patients for </text>
<text top="794" left="105" width="299" height="14" font="11">whom valve replacement could be beneficial. </text>
<text top="822" left="105" width="4" height="14" font="11"> </text>
<text top="850" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="850" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="77" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="128" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1145" left="426" width="45" height="12" font="9">Page 79 </text>
<text top="162" left="105" width="261" height="15" font="14"><b>Figure 3. Isolated PR After Repair of PS </b></text>
<text top="964" left="644" width="4" height="15" font="14"><b> </b></text>
<text top="998" left="105" width="686" height="12" font="9">*Significant PR causes RV dilation. If a patient has moderate or greater PR and normal RV size, most likely the estimation of PR </text>
<text top="1014" left="105" width="573" height="12" font="9">severity is inaccurate or there may be restrictive RV physiology, which would warrant further investigation. </text>
<text top="1030" left="105" width="621" height="12" font="9">†Symptoms may include dyspnea, chest pain, and/or exercise intolerance referable to PR or otherwise unexplained. </text>
<text top="1046" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CPET,  cardiopulmonary  exercise  test;  PR,  pulmonary  regurgitation;  PS, </text>
<text top="1062" left="105" width="247" height="12" font="9">pulmonary stenosis; and RV, right ventricular. </text>
<text top="1080" left="105" width="4" height="16" font="22"> </text>
</page>
<page number="78" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 80 </text>
<text top="163" left="105" width="417" height="19" font="34"><b>4.3.2. Branch and Peripheral Pulmonary Stenosis </b></text>
<text top="199" left="238" width="4" height="14" font="11"> </text>
<text top="197" left="290" width="353" height="16" font="12"><b>Recommendations for Branch and Peripheral PS </b></text>
<text top="218" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="218" left="577" width="180" height="14" font="23">Online Data Supplement 40</text>
<text top="218" left="757" width="8" height="14" font="11">. </text>
<text top="238" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="238" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="238" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="259" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="289" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="289" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="279" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="279" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="279" left="281" width="495" height="15" font="14"><b>For  adults  with  peripheral  or  branch  PS,  ongoing  surveillance  is </b></text>
<text top="299" left="281" width="234" height="15" font="14"><b>recommended (S4.3.2-1, S4.3.2-2). </b></text>
<text top="319" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="349" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="349" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="339" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="339" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="339" left="281" width="495" height="15" font="14"><b>In adults with peripheral or branch PA stenosis, PA dilation and stenting </b></text>
<text top="359" left="281" width="225" height="15" font="14"><b>can be useful (S4.3.2-2, S4.3.2-3). </b></text>
<text top="388" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="416" left="105" width="687" height="14" font="11">Pulmonary branch and peripheral PS can be isolated, occur as part of a constellation of right ventricular </text>
<text top="436" left="105" width="687" height="14" font="11">outflow  tract  (RVOT)  obstruction,  or  be  found  in  association  with  a  syndrome  (e.g.,  Noonan,  Alagille, </text>
<text top="456" left="105" width="687" height="14" font="11">Williams,  maternal  rubella  exposure).  Intervention  decisions  are  typically  based  on  symptoms, </text>
<text top="475" left="105" width="687" height="14" font="11">distribution  of pulmonary blood flow, RV  function, and  RV systolic pressure. TTE is a good  modality to </text>
<text top="495" left="105" width="687" height="14" font="11">obtain  RV  pressure  and  function  but  does  not  adequately  image  the  peripheral  pulmonary  arteries. </text>
<text top="514" left="105" width="687" height="14" font="11">Alternative  imaging  (e.g.,  CMR,  CCT)  can  visualize  anatomic  obstructions  and  branch  PA  anatomy.  In </text>
<text top="534" left="105" width="603" height="14" font="11">addition, CMR and pulmonary perfusion testing can quantify relative pulmonary blood flow. </text>
<text top="562" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="582" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="602" left="105" width="340" height="14" font="11">Table 24 for routine testing and follow-up intervals. </text>
<text top="630" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="658" left="105" width="687" height="14" font="11">1. Cardiac follow-up and imaging may include evaluation of RV pressure; quantifying relative pulmonary </text>
<text top="678" left="105" width="687" height="14" font="11">blood flow and imaging for evidence of residual lesions or PA obstruction or aneurysm at sites of prior </text>
<text top="697" left="105" width="687" height="14" font="11">intervention;  and  in-stent  stenosis  and/or  stent  fracture  (the  latter  often  best  seen  by  fluoroscopy). </text>
<text top="717" left="105" width="687" height="14" font="11">Stenting of branch PA stenosis is effective in reducing the pressure gradients, but patients often require </text>
<text top="737" left="105" width="687" height="14" font="11">further intervention (S4.3.2-2). In-stent stenosis with a reduction in the ipsilateral pulmonary blood flow </text>
<text top="756" left="105" width="687" height="14" font="11">is seen in approximately 25% of patients after percutaneous PA angioplasty and stent placement, more </text>
<text top="776" left="105" width="687" height="14" font="11">common in  patients  with abnormal  pulmonary  arteries,  such as  those  with  TOF  or  Williams  syndrome </text>
<text top="796" left="105" width="687" height="14" font="11">(S4.3.2-1).  Regular  surveillance  and  imaging,  with  intervention  as  required,  may  prevent  the </text>
<text top="815" left="105" width="399" height="14" font="11">development of RV hypertension and its sequelae (S4.3.2-1). </text>
<text top="844" left="105" width="687" height="14" font="11">2.  Balloon  angioplasty  or  stenting  of  a  peripheral  PA  is  effective  in  reducing  pressure  gradients  and </text>
<text top="863" left="105" width="687" height="15" font="11">improving  pulmonary  blood  flow.  Indications  for  pulmonary  angioplasty  or  stenting include  symptoms </text>
<text top="882" left="105" width="687" height="15" font="11">attributed  to  the  decreased  pulmonary  blood  flow,  focal  narrowing,  abnormal  differential  perfusion, </text>
<text top="902" left="105" width="687" height="15" font="11">and/or  elevated  RV  pressure.  The  decision  for  intervention  with  PA  angioplasty  or  stenting  includes </text>
<text top="922" left="105" width="650" height="15" font="11">assessment of clinical symptoms, imaging, and discussion with an ACHD interventional cardiologist. </text>
<text top="950" left="105" width="4" height="15" font="11"> </text>
<text top="978" left="105" width="511" height="15" font="14"><b>Table 24. Branch and Peripheral PS: Routine Follow-Up and Testing Intervals </b></text>
<text top="1002" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="1019" left="169" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="1002" left="335" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1019" left="332" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="1002" left="455" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1019" left="453" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="1002" left="569" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1019" left="567" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="1002" left="683" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1019" left="680" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="1038" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="1038" left="320" width="40" height="13" font="8">24–36 </text>
<text top="1038" left="445" width="18" height="13" font="8">24 </text>
<text top="1038" left="560" width="33" height="13" font="8">6–12 </text>
<text top="1038" left="674" width="25" height="13" font="8">3–6 </text>
<text top="1056" left="105" width="27" height="13" font="8">ECG </text>
<text top="1056" left="320" width="40" height="13" font="8">24–36 </text>
<text top="1056" left="445" width="18" height="13" font="8">24 </text>
<text top="1056" left="560" width="18" height="13" font="8">12 </text>
<text top="1056" left="674" width="18" height="13" font="8">12 </text>
<text top="1075" left="105" width="32" height="13" font="8">TTE† </text>
<text top="1075" left="320" width="40" height="13" font="8">24–36 </text>
<text top="1075" left="445" width="18" height="13" font="8">24 </text>
<text top="1075" left="560" width="18" height="13" font="8">12 </text>
<text top="1075" left="674" width="18" height="13" font="8">12 </text>
</page>
<page number="79" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 81 </text>
<text top="163" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="163" left="320" width="40" height="13" font="8">36–60 </text>
<text top="163" left="445" width="40" height="13" font="8">36–60 </text>
<text top="163" left="560" width="40" height="13" font="8">24–36 </text>
<text top="163" left="674" width="40" height="13" font="8">24–36 </text>
<text top="181" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="178" left="179" width="14" height="18" font="8">║ </text>
<text top="181" left="320" width="18" height="13" font="8">36 </text>
<text top="181" left="445" width="18" height="13" font="8">24 </text>
<text top="181" left="560" width="18" height="13" font="8">24 </text>
<text top="181" left="674" width="18" height="13" font="8">12 </text>
<text top="200" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="216" left="105" width="653" height="11" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="232" left="105" width="686" height="11" font="9">‡CMR  may  be  indicated  for  assessment  of  branch  PS.  Baseline  study  is  recommended  with  periodic  follow-up  CMR,  with </text>
<text top="248" left="105" width="432" height="11" font="9">frequency of repeat imaging determined by anatomic and physiological findings. </text>
<text top="264" left="105" width="686" height="11" font="9">§CCT may be used if CMR is not feasible and to evaluate cross-sectional imaging status and post-stent therapy for peripheral PS; </text>
<text top="280" left="105" width="329" height="11" font="9">the frequency should be weighed against radiation exposure. </text>
<text top="293" left="105" width="335" height="16" font="9">║6-minute walk test or CPET, depending on clinical indication. </text>
<text top="312" left="105" width="686" height="11" font="9">ACHD  indicates  adult  congenital  heart  disease;  CCT,  cardiac  computed  tomography;  CMR,  cardiovascular  magnetic  resonance </text>
<text top="328" left="105" width="686" height="11" font="9">imaging;  CPET,  cardiopulmonary  exercise  test;  ECG,  electrocardiogram;  PS,  pulmonary  stenosis;  and  TTE,  transthoracic </text>
<text top="344" left="105" width="93" height="11" font="9">echocardiogram. </text>
<text top="360" left="105" width="3" height="11" font="9"> </text>
<text top="395" left="105" width="352" height="19" font="34"><b>4.3.3. Double-Chambered Right Ventricle </b></text>
<text top="431" left="202" width="4" height="14" font="11"> </text>
<text top="429" left="255" width="423" height="16" font="12"><b>Recommendations for Double-Chambered Right Ventricle </b></text>
<text top="450" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="450" left="577" width="180" height="14" font="23">Online Data Supplement 41</text>
<text top="450" left="757" width="8" height="14" font="11">. </text>
<text top="470" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="470" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="470" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="520" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="520" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="490" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="491" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="490" left="281" width="495" height="15" font="14"><b>Surgical  repair  for  adults  with  double-chambered  right  ventricle  and </b></text>
<text top="510" left="281" width="495" height="15" font="14"><b>moderate  or  greater  outflow  obstruction  is  recommended  in  patients </b></text>
<text top="530" left="281" width="495" height="15" font="14"><b>with  otherwise  unexplained  symptoms  of  HF,  cyanosis,  or  exercise </b></text>
<text top="549" left="281" width="272" height="15" font="14"><b>limitation (S4.3.3-1–S4.3.3-3) (Table 22). </b></text>
<text top="589" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="589" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="570" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="570" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="570" left="281" width="495" height="15" font="14"><b>Surgical  repair  for  adults  with  double-chambered  right  ventricle  with  a </b></text>
<text top="589" left="281" width="495" height="15" font="14"><b>severe  gradient  may  be  considered  in  asymptomatic  patients  (S4.3.3-3, </b></text>
<text top="609" left="281" width="137" height="15" font="14"><b>S4.3.3-4) (Table 22). </b></text>
<text top="638" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="667" left="105" width="687" height="14" font="11">Double-chambered right ventricle is uncommon in adults. Hypertrophied muscle bundles develop in the </text>
<text top="686" left="105" width="683" height="14" font="11">RV cavity, creating RVOT obstruction (S4.3.3-5, S4.3.3-6). It is commonly associated with a VSD. Double-</text>
<text top="706" left="105" width="687" height="14" font="11">chambered  right  ventricle  can  be  missed  on  TTE  if  not  sought  specifically,  and  alternative  imaging  or </text>
<text top="726" left="105" width="687" height="14" font="11">cardiac  catheterization  is  often  required  to  confirm  the  diagnosis  and  establish  the  hemodynamic </text>
<text top="745" left="105" width="53" height="14" font="11">impact. </text>
<text top="774" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="793" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="813" left="105" width="340" height="14" font="11">Table 25 for routine testing and follow-up intervals. </text>
<text top="841" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="869" left="105" width="687" height="14" font="11">1. Surgery typically involves transatrial or transventricular resection of obstructing muscle bundles and </text>
<text top="889" left="105" width="687" height="14" font="11">VSD closure if present. Occasionally, patch enlargement of RVOT may be necessary to adequately relieve </text>
<text top="909" left="105" width="83" height="14" font="11">obstruction. </text>
<text top="937" left="105" width="687" height="14" font="11">2. VSD is often present and may communicate with the  higher  or  lower pressure chamber in the  right </text>
<text top="957" left="105" width="687" height="14" font="11">ventricle, with resulting differences in shunt direction and flow characteristics. In patients with a severe </text>
<text top="976" left="105" width="687" height="14" font="11">gradient through the right ventricle, the VSD may be associated with right-to-left shunting if proximal to </text>
<text top="996" left="105" width="687" height="14" font="11">the  obstruction,  or  associated  with  left-to-right  shunting  if  distal.  Exercise  testing  performed  in  a </text>
<text top="1016" left="105" width="687" height="14" font="11">subjectively asymptomatic patient will often be abnormal. Patients may benefit from repair of both the </text>
<text top="1035" left="105" width="478" height="14" font="11">VSD and outflow obstruction, especially if exercise capacity is decreased. </text>
<text top="1063" left="105" width="4" height="14" font="11"> </text>
</page>
<page number="80" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 82 </text>
<text top="162" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="162" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="81" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 83 </text>
<text top="162" left="105" width="575" height="15" font="14"><b>Table 25. Double-Chambered Right Ventricle: Routine Follow-Up and Testing Intervals </b></text>
<text top="185" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="203" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="185" left="333" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="330" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="185" left="451" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="449" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="185" left="563" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="561" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="185" left="672" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="203" left="668" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="222" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="222" left="321" width="40" height="13" font="8">24–36 </text>
<text top="222" left="440" width="18" height="13" font="8">24 </text>
<text top="222" left="558" width="33" height="13" font="8">6–12 </text>
<text top="222" left="663" width="25" height="13" font="8">3–6 </text>
<text top="240" left="105" width="27" height="13" font="8">ECG </text>
<text top="240" left="321" width="40" height="13" font="8">24–36 </text>
<text top="240" left="440" width="18" height="13" font="8">24 </text>
<text top="240" left="558" width="18" height="13" font="8">12 </text>
<text top="240" left="663" width="18" height="13" font="8">12 </text>
<text top="259" left="105" width="25" height="13" font="8">TTE </text>
<text top="259" left="321" width="40" height="13" font="8">24–36 </text>
<text top="259" left="440" width="18" height="13" font="8">24 </text>
<text top="259" left="558" width="18" height="13" font="8">12 </text>
<text top="259" left="663" width="18" height="13" font="8">12 </text>
<text top="277" left="105" width="85" height="13" font="8">Exercise test† </text>
<text top="277" left="321" width="66" height="13" font="8">As needed </text>
<text top="277" left="440" width="18" height="13" font="8">24 </text>
<text top="277" left="558" width="18" height="13" font="8">24 </text>
<text top="277" left="663" width="18" height="13" font="8">12 </text>
<text top="296" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="312" left="105" width="332" height="12" font="9">†6-minute walk test or CPET, depending on clinical indication. </text>
<text top="328" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CPET,  cardiopulmonary  exercise  test;  ECG,  electrocardiogram;  and  TTE, </text>
<text top="344" left="105" width="167" height="12" font="9">transthoracic echocardiogram. </text>
<text top="379" left="105" width="200" height="19" font="34"><b>4.3.4. Ebstein Anomaly </b></text>
<text top="414" left="268" width="4" height="14" font="11"> </text>
<text top="413" left="321" width="292" height="16" font="12"><b>Recommendations for Ebstein Anomaly </b></text>
<text top="434" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="434" left="577" width="180" height="14" font="23">Online Data Supplement 42</text>
<text top="434" left="757" width="8" height="14" font="11">. </text>
<text top="454" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="454" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="454" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="474" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="504" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="504" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="494" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="495" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="494" left="281" width="494" height="15" font="14"><b>In  adults  with  Ebstein  anomaly,  CMR  can  be  useful  to  determine </b></text>
<text top="514" left="281" width="448" height="15" font="14"><b>anatomy, RV dimensions, and systolic function (S4.3.4-1, S4.3.4-2). </b></text>
<text top="554" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="554" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="534" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="535" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="534" left="281" width="495" height="15" font="14"><b>In adults with Ebstein anomaly, TEE can be useful for surgical planning if </b></text>
<text top="554" left="281" width="495" height="15" font="14"><b>TTE  images  are  inadequate  to  evaluate  tricuspid  valve  morphology  and </b></text>
<text top="574" left="281" width="131" height="15" font="14"><b>function (S4.3.4-1). </b></text>
<text top="624" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="624" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="594" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="594" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="594" left="281" width="495" height="15" font="14"><b>Electrophysiological  study  with  or  without  catheter  ablation  can  be </b></text>
<text top="614" left="281" width="495" height="15" font="14"><b>useful  in  the  diagnostic  evaluation  of  adults  with  Ebstein  anomaly  and </b></text>
<text top="633" left="281" width="495" height="15" font="14"><b>ventricular  preexcitation  but  without  supraventricular  tachycardia </b></text>
<text top="653" left="281" width="133" height="15" font="14"><b>(S4.3.4-3, S4.3.4-4). </b></text>
<text top="703" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="703" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="673" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="673" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="673" left="281" width="495" height="15" font="14"><b>In adults with Ebstein anomaly, electrophysiological study (and catheter </b></text>
<text top="693" left="281" width="495" height="15" font="14"><b>ablation,  if  needed)  is  reasonable  before  surgical  intervention  on  the </b></text>
<text top="712" left="281" width="495" height="15" font="14"><b>tricuspid  valve  even  in  the  absence  of  preexcitation  or  supraventricular </b></text>
<text top="732" left="281" width="153" height="15" font="14"><b>tachycardia (S4.3.4-5). </b></text>
<text top="752" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="812" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="812" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="773" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="773" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="773" left="281" width="495" height="15" font="14"><b>Surgical  repair  or  reoperation  for  adults  with  Ebstein  anomaly  and </b></text>
<text top="792" left="281" width="495" height="15" font="14"><b>significant  TR  is  recommended  when  one  or  more  of  the  following  are </b></text>
<text top="812" left="281" width="494" height="15" font="14"><b>present:  HF  symptoms,  objective  evidence  of  worsening  exercise </b></text>
<text top="831" left="281" width="495" height="15" font="14"><b>capacity,  progressive  RV  systolic  dysfunction  by  echocardiography  or </b></text>
<text top="851" left="281" width="180" height="15" font="14"><b>CMR (S4.3.4-6–S4.3.4-10).  </b></text>
<text top="891" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="891" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="871" left="256" width="13" height="15" font="14"><b>6.</b></text>
<text top="872" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="871" left="281" width="495" height="15" font="14"><b>Catheter  ablation  is recommended  for  adults  with  Ebstein  anomaly  and </b></text>
<text top="891" left="281" width="495" height="15" font="14"><b>high-risk  pathway  conduction  or  multiple  accessory  pathways  (S4.3.4-3, </b></text>
<text top="911" left="281" width="144" height="15" font="14"><b>S4.3.4-11, S4.3.4-12). </b></text>
<text top="970" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="970" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="931" left="256" width="13" height="15" font="14"><b>7.</b></text>
<text top="931" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="931" left="281" width="495" height="15" font="14"><b>Surgical  repair  or  reoperation  for  adults  with  Ebstein  anomaly  and </b></text>
<text top="951" left="281" width="494" height="15" font="14"><b>significant  TR  can  be  beneficial  in  the  presence  of  progressive  RV </b></text>
<text top="970" left="281" width="495" height="15" font="14"><b>enlargement,  systemic  desaturation  from  right-to-left  atrial  shunt, </b></text>
<text top="990" left="281" width="491" height="15" font="14"><b>paradoxical embolism, and/or atrial tachyarrhythmias (S4.3.4-11, S4.3.4-</b></text>
<text top="1009" left="281" width="99" height="15" font="14"><b>13, S4.3.4-14). </b></text>
<text top="1049" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="1049" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1030" left="256" width="13" height="15" font="14"><b>8.</b></text>
<text top="1030" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1030" left="281" width="495" height="15" font="14"><b>Bidirectional  superior  cavopulmonary  (Glenn)  anastomosis  at  time  of </b></text>
<text top="1049" left="281" width="494" height="15" font="14"><b>Ebstein  anomaly  repair  may  be  considered  for  adults  when  severe  RV </b></text>
<text top="1069" left="281" width="495" height="15" font="14"><b>dilation  or  severe  RV  systolic  dysfunction  is  present,  LV  function  is </b></text>
</page>
<page number="82" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 84 </text>
<text top="163" left="281" width="495" height="15" font="14"><b>preserved, and left atrial pressure and LV end diastolic pressure are not </b></text>
<text top="183" left="281" width="203" height="15" font="14"><b>elevated (S4.3.4-6, S4.3.4-15). </b></text>
<text top="211" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="240" left="105" width="687" height="14" font="11">Ebstein  anomaly  is  an  uncommon  congenital  heart  defect  occurring  in  about  0.005%  of  live  births </text>
<text top="260" left="105" width="687" height="14" font="11">(S4.3.4-16–S4.3.4-18).  It  is  a  malformation  of  the  tricuspid  valve  and  the  right  ventricle  and  varies  in </text>
<text top="279" left="105" width="687" height="14" font="11">severity, including babies who do not survive infancy, asymptomatic adults diagnosed incidentally in the </text>
<text top="299" left="105" width="687" height="14" font="11">sixth  and  seventh  decades  of  life,  and  many  variations  in  severity  between  those  extremes.  Ebstein </text>
<text top="319" left="105" width="687" height="14" font="11">anomaly  can  occur  with  other  defects  including  ASD,  VSD,  and PS.  A  patent  foramen  ovale,  otherwise </text>
<text top="338" left="105" width="687" height="14" font="11">usually  considered  normal,  may  have  significant  impact  in  Ebstein  anomaly.  Accessory  pathways  and </text>
<text top="358" left="105" width="687" height="14" font="11">arrhythmias  are  relatively  common.  Patient  surveillance  and  management  varies  depending  on  age, </text>
<text top="377" left="105" width="687" height="14" font="11">severity of the lesion, and associated abnormalities including HF, cyanosis, and arrhythmias. Surveillance </text>
<text top="397" left="105" width="687" height="14" font="11">includes  echocardiographic  and  other  advanced  imaging  to  assess  RV  size  and  function,  rhythm </text>
<text top="416" left="105" width="687" height="14" font="11">assessment,  pulse  oximetry,  and  stress  testing.  Treatments  include  medical  and  surgical  therapy  for </text>
<text top="436" left="105" width="687" height="14" font="11">patients  with  manifest  symptoms  as  well  as  catheter-based  structural  and  electrophysiological </text>
<text top="456" left="105" width="199" height="14" font="11">interventions when indicated. </text>
<text top="484" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="504" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="523" left="105" width="340" height="14" font="11">Table 26 for routine testing and follow-up intervals. </text>
<text top="551" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="580" left="105" width="687" height="14" font="11">1. Deciphering the anatomy and size of the right atrium and right ventricle in Ebstein anomaly is often </text>
<text top="600" left="105" width="687" height="14" font="11">difficult using echocardiography alone, particularly in adults. Data obtained from CMR can inform clinical </text>
<text top="619" left="105" width="687" height="14" font="11">care  and  surgical  planning  or  decision-making,  because  CMR  data  correlate  well  with  intraoperative </text>
<text top="639" left="105" width="59" height="14" font="11">findings. </text>
<text top="667" left="105" width="687" height="14" font="11">2. Two-dimensional and 3D TEE can better define the anatomy and function of the tricuspid valve before </text>
<text top="687" left="105" width="450" height="14" font="11">surgery and provide valuable information in planning surgical repair. </text>
<text top="715" left="105" width="687" height="14" font="11">3. Approximately one third of adults with Ebstein anomaly  and ventricular  preexcitation have multiple </text>
<text top="735" left="105" width="687" height="14" font="11">accessory  pathways,  associated  with  a  high  risk  of  SCD.  Adults  with  Ebstein  anomaly  also  have  a  high </text>
<text top="755" left="105" width="687" height="14" font="11">prevalence of atrial tachyarrhythmia (S4.3.4-3, S4.3.4-4). In the setting of ventricular preexcitation, atrial </text>
<text top="774" left="105" width="687" height="14" font="11">tachyarrhythmia  may  expose  the  patient  to  a  higher  risk  of  lethal  ventricular  arrhythmia.  In  patients </text>
<text top="794" left="105" width="687" height="14" font="11">with  clinical  supraventricular  tachycardia,  management  is  according  to  existing  GDMT  (S4.3.4-19).  A </text>
<text top="813" left="105" width="687" height="14" font="11">Pediatric  &amp;  Congenital  Electrophysiology  Society  (PACES)/HRS  expert  consensus  document  provides </text>
<text top="833" left="105" width="465" height="14" font="11">additional information on the management of arrhythmias (S4.3.4-20). </text>
<text top="861" left="105" width="687" height="14" font="11">4.  Concealed  accessory  pathways  are  common  in  Ebstein  anomaly  and  may  coexist  with  manifest </text>
<text top="881" left="105" width="687" height="14" font="11">accessory pathways. In addition, preexcitation may be present but difficult to appreciate on the surface </text>
<text top="900" left="105" width="687" height="14" font="11">ECG. Tricuspid valve surgery can hinder transcatheter access to right-sided accessory pathways and the </text>
<text top="920" left="105" width="687" height="14" font="11">slow  pathway in  AV  node  reentry,  such  that it may be  reasonable  to  assess  for  arrhythmia  substrates </text>
<text top="940" left="105" width="420" height="14" font="11">and proceed with catheter ablation if identified, before surgery. </text>
<text top="968" left="105" width="687" height="14" font="11">5. Data demonstrate that delay of surgery until HF or RV systolic dysfunction ensues is associated with </text>
<text top="987" left="105" width="683" height="14" font="11">poorer outcomes; surgery before  either of those develops is recommended (S4.3.4-6, S4.3.4-7, S4.3.4-</text>
<text top="1007" left="105" width="687" height="14" font="11">10).  Ebstein  anomaly  is  understood  as  not  just  valve  disease  but  also  a  myopathic  process. </text>
<text top="1027" left="105" width="687" height="14" font="11">Consequently,  threshold  for  operation  may  be  different  than  in  other  RV  volume-loading  lesions, </text>
<text top="1046" left="105" width="687" height="14" font="11">because  there  is  more  concern  regarding  the  capacity  of  the  myopathic  Ebstein  right  ventricle  to </text>
<text top="1066" left="105" width="687" height="14" font="11">tolerate  a volume load.  Also,  there  are  cohort  series  of  Ebstein  patients  to inform  decisions  (S4.3.4-6, </text>
<text top="1086" left="105" width="687" height="14" font="11">S4.3.4-7, S4.3.4-10). Surgical repair generally consists of tricuspid valve repair (preferred when feasible) </text>
</page>
<page number="83" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 85 </text>
<text top="162" left="105" width="687" height="14" font="11">or replacement, selective plication of atrialized right ventricle, reduction atrioplasty, arrhythmia surgery, </text>
<text top="182" left="105" width="687" height="14" font="11">and/or  closure  of  atrial  level  shunt.  Surgery  may  result  in  improvement  of  symptoms  and  functional </text>
<text top="202" left="105" width="334" height="14" font="11">ability, and prevent or delay worsening symptoms. </text>
<text top="230" left="105" width="687" height="14" font="11">6.  Adults  with  Ebstein  anomaly  and  ventricular  preexcitation  often  have  multiple  accessory  pathways, </text>
<text top="249" left="105" width="687" height="14" font="11">which  are  associated  with  a  higher  risk  of  SCD.  Surgical  interruption  of  accessory  pathways  is  largely </text>
<text top="269" left="105" width="687" height="14" font="11">reserved for patients who have failed attempts at catheter ablation. High-risk pathways are those with </text>
<text top="289" left="105" width="687" height="14" font="11">an  increased  risk  of  SCD,  largely  related  to  VF  resulting  from  rapidly  conducting  AF.  Definition  and </text>
<text top="308" left="105" width="687" height="14" font="11">discussion  of  high-risk  pathways  is  beyond  the scope  of  these  guidelines  but  can  be  found  elsewhere, </text>
<text top="328" left="105" width="687" height="14" font="11">such  as  the  “PACES/HRS  Expert  Consensus  Statement  on  the  Recognition  and  Management  of </text>
<text top="348" left="105" width="226" height="14" font="11">Arrhythmias in ACHD” (S4.3.4-21). </text>
<text top="376" left="105" width="687" height="14" font="11">7. Systemic desaturation and arrhythmias are frequently signs of worsening hemodynamics, progressive </text>
<text top="395" left="105" width="687" height="14" font="11">TR, or worsening RV function. Surgery for the tricuspid valve as well as closure of the ASD or stretched </text>
<text top="415" left="105" width="687" height="14" font="11">patent foramen ovale and arrhythmia surgery can be beneficial. When arrhythmia surgery is required, it </text>
<text top="435" left="105" width="687" height="14" font="11">typically  involves  a  modified  right  atrial  maze  procedure.  In  the  presence  of  AF,  the  addition  of  a  left </text>
<text top="454" left="105" width="530" height="14" font="11">atrial Cox Maze III procedure can be beneficial to reduce the risk of recurrent AF. </text>
<text top="483" left="105" width="687" height="14" font="11">8. The use of the bidirectional cavopulmonary shunt is much more common in children than in adults. </text>
<text top="502" left="105" width="687" height="14" font="11">When  it  is  applied  in  the  adult,  it  is  usually  reserved  for  patients  with  severe  RV  dysfunction  with </text>
<text top="522" left="105" width="687" height="14" font="11">concern  that  the  right  ventricle  will  not  tolerate  supporting  the  entirety  of  stroke  volume  (S4.3.4-6, </text>
<text top="541" left="105" width="687" height="14" font="11">S4.3.4-15).  Preoperative  catheterization  to  determine  hemodynamics  and  feasibility  of  applying  the </text>
<text top="561" left="105" width="687" height="14" font="11">bidirectional cavopulmonary shunt becomes progressively more important in older patients, particularly </text>
<text top="581" left="105" width="687" height="14" font="11">those with longstanding hypertension with LV hypertrophy, which can lead to diastolic dysfunction and </text>
<text top="600" left="105" width="205" height="14" font="11">elevated pulmonary pressures. </text>
<text top="629" left="105" width="4" height="14" font="11"> </text>
<text top="657" left="105" width="484" height="15" font="14"><b>Table 26. Ebstein Anomaly: Routine and Follow-Up and Testing Intervals </b></text>
<text top="680" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="698" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="680" left="337" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="698" left="333" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="680" left="458" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="698" left="456" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="680" left="573" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="698" left="571" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="680" left="685" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="698" left="681" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="716" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="716" left="321" width="40" height="13" font="8">12–24 </text>
<text top="716" left="446" width="18" height="13" font="8">12 </text>
<text top="716" left="565" width="33" height="13" font="8">6–12 </text>
<text top="716" left="676" width="25" height="13" font="8">3–6 </text>
<text top="735" left="105" width="27" height="13" font="8">ECG </text>
<text top="735" left="321" width="40" height="13" font="8">12–24 </text>
<text top="735" left="446" width="18" height="13" font="8">12 </text>
<text top="735" left="565" width="18" height="13" font="8">12 </text>
<text top="735" left="676" width="18" height="13" font="8">12 </text>
<text top="753" left="105" width="27" height="13" font="8">CXR </text>
<text top="753" left="321" width="66" height="13" font="8">As needed </text>
<text top="753" left="446" width="66" height="13" font="8">As needed </text>
<text top="753" left="565" width="40" height="13" font="8">12–24 </text>
<text top="753" left="676" width="40" height="13" font="8">12–24 </text>
<text top="772" left="105" width="32" height="13" font="8">TTE† </text>
<text top="772" left="321" width="40" height="13" font="8">12–24 </text>
<text top="772" left="446" width="40" height="13" font="8">12–24 </text>
<text top="772" left="565" width="18" height="13" font="8">12 </text>
<text top="772" left="676" width="18" height="13" font="8">12 </text>
<text top="791" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="791" left="321" width="18" height="13" font="8">24 </text>
<text top="791" left="446" width="18" height="13" font="8">12 </text>
<text top="791" left="565" width="59" height="13" font="8">Each visit </text>
<text top="791" left="676" width="59" height="13" font="8">Each visit </text>
<text top="809" left="105" width="92" height="13" font="8">Holter monitor </text>
<text top="809" left="321" width="66" height="13" font="8">As needed </text>
<text top="809" left="446" width="66" height="13" font="8">As needed </text>
<text top="809" left="565" width="18" height="13" font="8">24 </text>
<text top="809" left="676" width="40" height="13" font="8">12–24 </text>
<text top="828" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="828" left="321" width="18" height="13" font="8">60 </text>
<text top="828" left="446" width="18" height="13" font="8">36 </text>
<text top="828" left="565" width="40" height="13" font="8">24–36 </text>
<text top="828" left="676" width="40" height="13" font="8">12–24 </text>
<text top="846" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="843" left="179" width="14" height="18" font="8">║ </text>
<text top="846" left="321" width="18" height="13" font="8">36 </text>
<text top="846" left="446" width="40" height="13" font="8">24–36 </text>
<text top="846" left="565" width="18" height="13" font="8">24 </text>
<text top="846" left="676" width="18" height="13" font="8">12 </text>
<text top="864" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="881" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="897" left="105" width="686" height="12" font="9">‡CMR  may  be  indicated  for  assessment  of  right  ventricular  size  and  func@on.  Baseline  study  is  recommended  with  periodic </text>
<text top="913" left="105" width="547" height="12" font="9">follow-up CMR, with frequency of repeat imaging determined by anatomic and physiological findings.  </text>
<text top="929" left="105" width="548" height="12" font="9">§CCT may be used if CMR is not feasible; the frequency should be weighed against radiation exposure. </text>
<text top="942" left="105" width="335" height="16" font="9">║6-minute walk test or CPET, depending on clinical indication. </text>
<text top="961" left="105" width="686" height="12" font="9">ACHD  indicates  adult congenital heart disease;  CCT, cardiac computed tomography; CMR, cardiovascular  magnetic resonance </text>
<text top="977" left="105" width="686" height="12" font="9">imaging;  CPET,  cardiopulmonary  exercise  test;  CXR,  chest  x-ray;  ECG,  electrocardiogram;  and  TTE,  transthoracic </text>
<text top="993" left="105" width="93" height="12" font="9">echocardiogram. </text>
<text top="1009" left="105" width="4" height="14" font="11"> </text>
<text top="1042" left="105" width="4" height="14" font="11"> </text>
<text top="1039" left="315" width="5" height="19" font="34"><b> </b></text>
</page>
<page number="84" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 86 </text>
<text top="163" left="105" width="211" height="19" font="34"><b>4.3.5. Tetralogy of Fallot </b></text>
<text top="199" left="315" width="4" height="14" font="11"> </text>
<text top="197" left="368" width="198" height="16" font="12"><b>Recommendations for TOF </b></text>
<text top="218" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="218" left="577" width="180" height="14" font="23">Online Data Supplement 43</text>
<text top="218" left="757" width="8" height="14" font="11">. </text>
<text top="238" left="108" width="662" height="14" font="11">(See Section 4.3.6. for recommendations regarding evaluation and management of right ventricle–to-</text>
<text top="257" left="395" width="90" height="14" font="11">PA conduits.) </text>
<text top="278" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="278" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="278" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="298" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="338" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="338" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="318" left="255" width="521" height="15" font="14"><b>1.  CMR  is  useful  to  quantify  ventricular  size  and  function,  pulmonary  valve </b></text>
<text top="338" left="268" width="508" height="15" font="14"><b>function,  pulmonary  artery  anatomy,  and  left  heart  abnormalities  in </b></text>
<text top="357" left="268" width="254" height="15" font="14"><b>patients with repaired TOF (S4.3.5-1). </b></text>
<text top="397" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="397" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="378" left="255" width="517" height="15" font="14"><b>2. Coronary artery compression testing is indicated before right ventricle–to-</b></text>
<text top="397" left="268" width="508" height="15" font="14"><b>PA  conduit  stenting  or  transcatheter  valve  placement  in  repaired  TOF </b></text>
<text top="417" left="268" width="72" height="15" font="14"><b>(S4.3.5-2). </b></text>
<text top="447" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="447" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="437" left="255" width="521" height="15" font="14"><b>3.  Programmed  ventricular  stimulation  can  be  useful  to  risk-stratify  adults </b></text>
<text top="457" left="268" width="427" height="15" font="14"><b>with TOF and additional risk factors for SCD (S4.3.5-3–S4.3.5-8). </b></text>
<text top="516" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="516" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="477" left="255" width="521" height="15" font="14"><b>4. In patients with repaired TOF, cardiac catheterization with angiography, if </b></text>
<text top="497" left="268" width="508" height="15" font="14"><b>indicated,  is  reasonable  to  assess  hemodynamics  when  adequate  data </b></text>
<text top="516" left="268" width="508" height="15" font="14"><b>cannot  be  obtained  noninvasively  in  the  setting  of  an  arrhythmia,  HF, </b></text>
<text top="536" left="268" width="508" height="15" font="14"><b>unexplained ventricular dysfunction, suspected pulmonary hypertension or </b></text>
<text top="556" left="268" width="64" height="15" font="14"><b>cyanosis. </b></text>
<text top="576" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="626" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="626" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="596" left="255" width="521" height="15" font="14"><b>5.  Pulmonary  valve  replacement  (surgical  or  percutaneous)  for  relief  of </b></text>
<text top="616" left="268" width="508" height="15" font="14"><b>symptoms  is  recommended  for  patients  with  repaired  TOF  and  moderate </b></text>
<text top="636" left="268" width="508" height="15" font="14"><b>or  greater  PR  with  cardiovascular  symptoms  not  otherwise  explained </b></text>
<text top="655" left="268" width="145" height="15" font="14"><b>(S4.3.5-9–S4.3.5-11).  </b></text>
<text top="705" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="705" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="676" left="255" width="521" height="15" font="14"><b>7. Pulmonary valve replacement (surgical or percutaneous) is reasonable for </b></text>
<text top="695" left="268" width="508" height="15" font="14"><b>preservation of ventricular size and function in asymptomatic patients with </b></text>
<text top="715" left="268" width="508" height="15" font="14"><b>repaired TOF and ventricular enlargement or dysfunction and moderate or </b></text>
<text top="734" left="268" width="350" height="15" font="14"><b>greater PR (S4.3.5-1, S4.3.5-9, S4.3.5-12–S4.3.5-14).  </b></text>
<text top="764" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="764" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="755" left="255" width="521" height="15" font="14"><b>8.  Primary  prevention  ICD  therapy  is  reasonable  in  adults  with  TOF  and </b></text>
<text top="774" left="268" width="339" height="15" font="14"><b>multiple risk factors for SCD (S4.3.5-15–S4.3.5-17). </b></text>
<text top="814" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="814" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="795" left="255" width="521" height="15" font="14"><b>9. Surgical pulmonary valve replacement may be reasonable for adults with </b></text>
<text top="814" left="268" width="508" height="15" font="14"><b>repaired  TOF  and  moderate  or  greater  PR  with  other  lesions  requiring </b></text>
<text top="834" left="268" width="152" height="15" font="14"><b>surgical interventions. </b></text>
<text top="874" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="874" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="854" left="255" width="521" height="15" font="14"><b>10.  Pulmonary  valve  replacement,  in  addition  to  arrhythmia  management, </b></text>
<text top="874" left="268" width="508" height="15" font="14"><b>may  be  considered  for  adults with  repaired  TOF  and  moderate  or  greater </b></text>
<text top="893" left="268" width="245" height="15" font="14"><b>PR and ventricular tachyarrhythmia. </b></text>
<text top="922" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="951" left="105" width="687" height="14" font="11">Long-term  survival  after  surgery  for  TOF  continues  to  improve.  However,  residual  hemodynamic  and </text>
<text top="971" left="105" width="687" height="14" font="11">electrophysiological  abnormalities  are  common  in  adulthood.  Adults  with  repaired  TOF  face  an </text>
<text top="990" left="105" width="687" height="14" font="11">increased risk of arrhythmias, exercise intolerance, HF, and death beginning in early adulthood (S4.3.5-1, </text>
<text top="1010" left="105" width="687" height="14" font="11">S4.3.5-18–S4.3.5-20). Surgical repair of TOF has evolved over time, with relief of the RVOT obstruction </text>
<text top="1029" left="105" width="687" height="14" font="11">usually  involving  infundibulotomy,  resection  of  obstructive  muscle  bundles,  and  the  use  of  a  patch  to </text>
<text top="1049" left="105" width="687" height="14" font="11">enlarge the pathway from the right ventricle to the pulmonary arteries. These procedures result in scar </text>
<text top="1069" left="105" width="687" height="14" font="11">tissue and create a dyskinetic and often aneurysmal area in the RVOT. Residual RVOT stenosis, branch </text>
<text top="1088" left="105" width="687" height="14" font="11">PA stenosis, residual ASD or VSD, TR, RV dilation and dysfunction, aortic dilation, AR, and LV dysfunction </text>
</page>
<page number="85" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 87 </text>
<text top="162" left="105" width="687" height="14" font="11">are some of the anatomic and functional abnormalities encountered in patients with repaired TOF. The </text>
<text top="182" left="105" width="687" height="14" font="11">most  common  hemodynamic  sequela  of  TOF  repair  is  PR.  Current  evidence  confirms  that  adults  with </text>
<text top="202" left="105" width="687" height="14" font="11">repaired TOF are at risk of severe PR, RV dilation and dysfunction, LV dysfunction and electromechanical </text>
<text top="221" left="105" width="683" height="14" font="11">dyssynchrony, all of which contribute to adverse clinical outcomes late after TOF repair (S4.3.5-1, S4.3.5-</text>
<text top="241" left="105" width="687" height="14" font="11">20–S4.3.5-24). Despite intense interest and numerous publications on pulmonary valve replacement in </text>
<text top="260" left="105" width="687" height="14" font="11">adults with repaired TOF, optimal timing for this intervention remains uncertain, and most studies have </text>
<text top="280" left="105" width="687" height="14" font="11">focused  on  preoperative  RV  volumes  that  would  result  in  normalization  of  postoperative  RV  volumes </text>
<text top="299" left="105" width="687" height="14" font="11">(S4.3.5-9,  S4.3.5-14,  S4.3.5-25–S4.3.5-27).  In  adults  with  repaired  TOF,  prevalence  rates  for  atrial  and </text>
<text top="319" left="105" width="687" height="14" font="11">ventricular  arrhythmias  have  been  estimated  to  be  20%  and  15%,  respectively,  with  steep  increases </text>
<text top="339" left="105" width="687" height="14" font="11">after 45 years of age (S4.3.5-28). The incidence of SCD after surgical repair of TOF is approximately 2% </text>
<text top="358" left="105" width="687" height="14" font="11">per decade (S4.3.5-18, S4.3.5-21, S4.3.5-24, S4.3.5-29, S4.3.5-30). Currently, factors associated with SCD </text>
<text top="378" left="105" width="687" height="14" font="11">in  patients  with  TOF  have  largely  been  identified  from  observational,  predominantly  retrospective </text>
<text top="398" left="105" width="687" height="14" font="11">studies.  Despite  numerous  studies  that  identified  factors  associated  with  malignant  ventricular </text>
<text top="417" left="105" width="385" height="14" font="11">arrhythmias and SCD, risk stratification remains imperfect. </text>
<text top="446" left="158" width="634" height="14" font="11">Primary  prevention  ICDs  should  generally  be  considered  in  patients  who  otherwise  meet </text>
<text top="465" left="105" width="683" height="14" font="11">standard qualifying criteria (i.e., LV  ejection fraction ≤35% with NYHA class II or III symptoms)  (S4.3.5-</text>
<text top="485" left="105" width="687" height="14" font="11">31–S4.3.5-33). There may be a role for primary prevention ICDs in  selected  adults with  TOF who have </text>
<text top="504" left="105" width="515" height="14" font="11">additional risk factors for SCD but would not meet standard criteria otherwise. </text>
<text top="533" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="552" left="105" width="687" height="14" font="11">other procedures in these patients; Section 3.4 for recommendations on diagnostic evaluation; Figure 4 </text>
<text top="572" left="105" width="687" height="14" font="11">for  a  diagnostic  and  treatment  algorithm  for  repaired  TOF  with  residual  PR;  and  Table  27  for  routine </text>
<text top="591" left="105" width="206" height="14" font="11">testing and follow-up intervals. </text>
<text top="620" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="648" left="105" width="687" height="14" font="11">1. Cardiac magnetic resonance imaging is the gold standard imaging modality for quantification of right </text>
<text top="668" left="105" width="687" height="14" font="11">ventricular  size  and  function  in  patients  with  repaired  TOF.  It  also  allows  for  quantification  of  valve </text>
<text top="687" left="105" width="687" height="14" font="11">regurgitation and pulmonary and  systemic flows as well  as  delineating  pulmonary artery anatomy and </text>
<text top="707" left="105" width="687" height="14" font="11">detection  of  scar  tissue  in  the  ventricular  myocardium.  Serial  cardiac  magnetic  resonance  imaging </text>
<text top="727" left="105" width="687" height="14" font="11">examinations  allows  for  longitudinal  follow-up  of  patients  with  repaired  TOF  and  provides  useful </text>
<text top="746" left="105" width="651" height="14" font="11">information that aids in the timing of pulmonary valve replacement (S4.3.5-1, S4.3.5-34–S4.3.5-37). </text>
<text top="775" left="105" width="687" height="14" font="11">2.  Before  any  surgical  or  percutaneous  intervention  in  patients  with  TOF,  the  origins  and  proximal </text>
<text top="794" left="105" width="687" height="15" font="11">courses  of  the  coronary  arteries  should  be  delineated.  Patients  with  repaired  TOF  and  abnormal </text>
<text top="814" left="105" width="687" height="15" font="11">coronary  artery  anatomy  have  a  substantial  risk  of  coronary  artery  compression  during  percutaneous </text>
<text top="833" left="105" width="687" height="15" font="11">pulmonary  valve  replacement  or  direct  injury  to  the  coronary  during  surgical  pulmonary  valve </text>
<text top="853" left="105" width="687" height="15" font="11">replacement. During cardiac catheterization, the coronary pattern may be demonstrated by performing </text>
<text top="872" left="105" width="687" height="15" font="11">simultaneous  RVOT  angiography  and  coronary  angiography  (S4.3.5-2).  Coronary  compression  testing </text>
<text top="892" left="105" width="687" height="15" font="11">generally involves simultaneous coronary angiography or aortography and balloon dilation of the RVOT </text>
<text top="911" left="105" width="536" height="15" font="11">to ascertain whether a balloon expanded stent will compress the coronary artery. </text>
<text top="940" left="105" width="485" height="15" font="11">3. Additional risk factors for SCD include (S4.3.5-24, S4.3.5-38, S4.3.5-39):  </text>
<text top="968" left="131" width="12" height="15" font="11">a.</text>
<text top="969" left="143" width="4" height="15" font="26"> </text>
<text top="968" left="158" width="226" height="15" font="11">LV systolic or diastolic dysfunction </text>
<text top="988" left="131" width="13" height="15" font="11">b.</text>
<text top="988" left="144" width="4" height="15" font="26"> </text>
<text top="988" left="158" width="267" height="15" font="11">Nonsustained VT, QRS duration ≥180 ms </text>
<text top="1007" left="131" width="11" height="15" font="11">c.</text>
<text top="1008" left="142" width="4" height="15" font="26"> </text>
<text top="1007" left="158" width="192" height="15" font="11">Extensive RV fibrosis by CMR </text>
<text top="1036" left="105" width="687" height="15" font="11">In  adults  with  TOF, inducible  sustained  VT  has  been  associated  with  an  increased  risk  of  clinical  VT  or </text>
<text top="1055" left="105" width="687" height="15" font="11">SCD,  beyond  standard  ECG,  hemodynamic,  and  clinical  factors  (S4.3.5-5).  Programmed  ventricular </text>
</page>
<page number="86" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 88 </text>
<text top="162" left="105" width="687" height="14" font="11">stimulation  is  most  useful  in  risk  stratifying  patients  at  moderate  risk  of  SCD  rather  than  as  a  routine </text>
<text top="182" left="105" width="333" height="14" font="11">surveillance tool in low-risk populations (S4.3.5-7). </text>
<text top="210" left="105" width="687" height="14" font="11">4. Cardiac catheterization is the only method that can accurately and reliably determine PA pressure and </text>
<text top="230" left="105" width="205" height="14" font="11">pulmonary vascular resistance. </text>
<text top="258" left="105" width="687" height="14" font="11">5. Symptomatic patients (with dyspnea, chest pain, and/or exercise intolerance otherwise unexplained) </text>
<text top="278" left="105" width="687" height="14" font="11">with  repaired  TOF  and  severe  PR  who  undergo  pulmonary  valve  replacement  often  report  improved </text>
<text top="297" left="105" width="687" height="14" font="11">functional  class  after  intervention.  Improvement  in  symptoms  often  correlates  with  a  reduction  in  RV </text>
<text top="317" left="105" width="687" height="14" font="11">size  and  relief  of  PR  (S4.3.5-9–S4.3.5-11).  Symptom  improvement  is  more  likely  in  patients  with </text>
<text top="337" left="105" width="687" height="14" font="11">underlying PS and PR than in patients with PR alone. For patients with significant LV or RV dysfunction, </text>
<text top="356" left="105" width="687" height="14" font="11">pulmonary  valve  replacement  may  not  be  tolerated  or  sufficient;  therefore,  evaluation  by  ACHD </text>
<text top="376" left="105" width="687" height="14" font="11">cardiologists  and HF  cardiologists is  appropriate  to  decide  appropriate  course  of  action,  particularly in </text>
<text top="395" left="105" width="625" height="14" font="11">deciding if a patient may be appropriate for mechanical circulatory support or heart transplant. </text>
<text top="424" left="105" width="687" height="14" font="11">6.  Pulmonary  valve  replacement  is  reasonable  in  patients  with  at  least  2  of  the  following  (S4.3.5-1, </text>
<text top="443" left="105" width="204" height="14" font="11">S4.3.5-9, S4.3.5-12–S4.3.5-14): </text>
<text top="472" left="131" width="12" height="14" font="11">a.</text>
<text top="472" left="143" width="4" height="15" font="26"> </text>
<text top="472" left="158" width="241" height="14" font="11">Mild or greater RV or LV dysfunction </text>
<text top="491" left="131" width="13" height="14" font="11">b.</text>
<text top="491" left="144" width="4" height="15" font="26"> </text>
<text top="491" left="158" width="419" height="14" font="11">Severe  RV  dilation  (RV  end-diastolic  volume  index  ≥160  mL/m</text>
<text top="488" left="577" width="5" height="9" font="37">2</text>
<text top="491" left="582" width="210" height="14" font="11">,  RV  end-systolic  volume  index </text>
<text top="511" left="158" width="67" height="14" font="11">≥80 mL/m</text>
<text top="508" left="224" width="5" height="9" font="37">2</text>
<text top="511" left="229" width="8" height="14" font="11">) </text>
<text top="531" left="131" width="11" height="14" font="11">c.</text>
<text top="531" left="142" width="4" height="15" font="26"> </text>
<text top="531" left="158" width="409" height="14" font="11">RV end-diastolic volume ≥2 times the LV end-diastolic volume  </text>
<text top="550" left="131" width="13" height="14" font="11">d.</text>
<text top="550" left="144" width="4" height="15" font="26"> </text>
<text top="550" left="158" width="387" height="14" font="11">RV systolic pressure two thirds or higher systemic pressure </text>
<text top="570" left="131" width="12" height="14" font="11">e.</text>
<text top="570" left="143" width="4" height="15" font="26"> </text>
<text top="570" left="158" width="339" height="14" font="11">Progressive objective reduction in exercise capacity </text>
<text top="598" left="105" width="687" height="14" font="11">The  increasing  use  of  CMR  in  the  long-term  follow-up  for  patients  with  repaired  TOF  has  provided </text>
<text top="618" left="105" width="687" height="14" font="11">quantification  of  ventricular  size,  function,  and  PR.  However,  there  is  lack  of  consensus  regarding </text>
<text top="637" left="105" width="687" height="14" font="11">optimal  indications  and  timing  of  pulmonary  valve  replacement  in  this  population.  Pulmonary  valve </text>
<text top="657" left="105" width="687" height="14" font="11">replacement results in reduction of RV volume and relief of PR; however, these are only surrogates for </text>
<text top="677" left="105" width="687" height="14" font="11">outcomes.  Many  patients  with  repaired  TOF  may  deny  symptoms  yet  demonstrate  reduced  exercise </text>
<text top="696" left="105" width="687" height="14" font="11">tolerance. Pulmonary valve replacement in such patients has been associated with improved functional </text>
<text top="716" left="105" width="182" height="14" font="11">status (S4.3.5-9, S4.3.5-10). </text>
<text top="744" left="105" width="202" height="14" font="11">7. Risk factors for SCD include: </text>
<text top="773" left="131" width="12" height="14" font="11">a.</text>
<text top="773" left="143" width="4" height="15" font="26"> </text>
<text top="773" left="158" width="226" height="14" font="11">LV systolic or diastolic dysfunction </text>
<text top="792" left="131" width="13" height="14" font="11">b.</text>
<text top="792" left="144" width="4" height="15" font="26"> </text>
<text top="792" left="158" width="114" height="14" font="11">Nonsustained VT </text>
<text top="812" left="131" width="11" height="14" font="11">c.</text>
<text top="812" left="142" width="4" height="15" font="26"> </text>
<text top="812" left="158" width="149" height="14" font="11">QRS duration ≥180 ms </text>
<text top="831" left="131" width="13" height="14" font="11">d.</text>
<text top="831" left="144" width="4" height="15" font="26"> </text>
<text top="831" left="158" width="142" height="14" font="11">Extensive RV scarring </text>
<text top="851" left="131" width="12" height="14" font="11">e.</text>
<text top="851" left="143" width="4" height="15" font="26"> </text>
<text top="851" left="158" width="340" height="14" font="11">Inducible sustained VT at electrophysiological study </text>
<text top="879" left="105" width="687" height="14" font="11">The largest study of patients with repaired TOF and ICDs included 121 patients from 11 North American </text>
<text top="899" left="105" width="687" height="14" font="11">and European sites followed for a median of 3.7 years after ICD implantation. Overall, 30% of patients </text>
<text top="919" left="105" width="687" height="14" font="11">received at least 1 appropriate ICD discharge, corresponding to annual appropriate shock rates of 7.7% </text>
<text top="938" left="105" width="687" height="14" font="11">and  9.8%  for  primary  and  secondary  prevention  indications,  respectively  (S4.3.5-16).  Unlike  patients </text>
<text top="958" left="105" width="687" height="14" font="11">with acquired HF, evidence suggests that patients with TOF who have inducible sustained polymorphic </text>
<text top="977" left="105" width="687" height="14" font="11">VT (hazard ratio: 12.9) fare as poorly as or worse than those with inducible sustained monomorphic VT </text>
<text top="997" left="105" width="687" height="14" font="11">(S4.3.5-5). Negative consequences associated with ICDs in adults with TOF must be carefully considered </text>
<text top="1017" left="105" width="687" height="14" font="11">in  selecting  appropriate  candidates.  These  include  high  rates  of  inappropriate  shocks  (5%  to  6%  per </text>
<text top="1036" left="105" width="687" height="14" font="11">year), lead-related complications, and unfavorable patient-reported outcomes, including impaired QoL, </text>
<text top="1056" left="105" width="563" height="14" font="11">anxiety, depression, and psychosexual complications (S4.3.5-15, S4.3.5-17, S4.3.5-40). </text>
</page>
<page number="87" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 89 </text>
<text top="162" left="105" width="687" height="14" font="11">8. In patients with repaired TOF and moderate or greater PR who are undergoing cardiac surgery for a </text>
<text top="182" left="105" width="687" height="14" font="11">separate  lesion  (e.g.,  RVOT  aneurysm,  TR,  branch  PA  stenosis,  residual  VS  D,  arrhythmia  ablation, </text>
<text top="202" left="105" width="687" height="14" font="11">coronary  artery  revascularization,  aortic  root  replacement),  it  may  be  reasonable  to  concurrently </text>
<text top="221" left="105" width="334" height="14" font="11">perform pulmonary valve replacement (S4.3.5-41). </text>
<text top="249" left="105" width="687" height="14" font="11">9. Although correction of the hemodynamic lesion (i.e., PR), may be clinically beneficial, pulmonary valve </text>
<text top="269" left="105" width="687" height="14" font="11">replacement  alone  has  not  consistently  been  demonstrated  to  reduce  risk  of  subsequent  VT  or  SCD </text>
<text top="289" left="105" width="687" height="14" font="11">(S4.3.5-42). Thus, in addition to pulmonary valve replacement, VT surgery and/or ICD implantation may </text>
<text top="308" left="105" width="174" height="14" font="11">be considered (S4.3.5-43). </text>
<text top="337" left="105" width="4" height="14" font="11"> </text>
<text top="365" left="105" width="369" height="15" font="14"><b>Table 27. TOF: Routine Follow-Up and Testing Intervals </b></text>
<text top="388" left="111" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="406" left="174" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="388" left="340" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="337" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="388" left="455" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="452" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="388" left="573" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="570" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="388" left="688" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="685" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="424" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="424" left="328" width="40" height="13" font="8">12–24 </text>
<text top="424" left="446" width="18" height="13" font="8">12 </text>
<text top="424" left="558" width="33" height="13" font="8">6–12 </text>
<text top="424" left="683" width="25" height="13" font="8">3–6 </text>
<text top="443" left="105" width="27" height="13" font="8">ECG </text>
<text top="443" left="328" width="18" height="13" font="8">24 </text>
<text top="443" left="446" width="18" height="13" font="8">12 </text>
<text top="443" left="558" width="18" height="13" font="8">12 </text>
<text top="443" left="683" width="18" height="13" font="8">12 </text>
<text top="461" left="105" width="32" height="13" font="8">TTE† </text>
<text top="461" left="328" width="18" height="13" font="8">24 </text>
<text top="461" left="446" width="40" height="13" font="8">12–24 </text>
<text top="461" left="558" width="18" height="13" font="8">12 </text>
<text top="461" left="683" width="33" height="13" font="8">6–12 </text>
<text top="480" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="480" left="328" width="66" height="13" font="8">As needed </text>
<text top="480" left="446" width="66" height="13" font="8">As needed </text>
<text top="480" left="558" width="59" height="13" font="8">Each visit </text>
<text top="480" left="683" width="59" height="13" font="8">Each visit </text>
<text top="499" left="105" width="92" height="13" font="8">Holter monitor </text>
<text top="499" left="328" width="66" height="13" font="8">As needed </text>
<text top="499" left="446" width="66" height="13" font="8">As needed </text>
<text top="499" left="558" width="40" height="13" font="8">12–24 </text>
<text top="499" left="683" width="40" height="13" font="8">12–24 </text>
<text top="517" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="517" left="328" width="18" height="13" font="8">36 </text>
<text top="517" left="446" width="40" height="13" font="8">24–36 </text>
<text top="517" left="558" width="40" height="13" font="8">12–24 </text>
<text top="517" left="683" width="40" height="13" font="8">12–24 </text>
<text top="536" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="533" left="179" width="14" height="18" font="8">║ </text>
<text top="536" left="328" width="40" height="13" font="8">36–60 </text>
<text top="536" left="446" width="40" height="13" font="8">24–60 </text>
<text top="536" left="558" width="40" height="13" font="8">12–24 </text>
<text top="536" left="683" width="40" height="13" font="8">12–24 </text>
<text top="554" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="570" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="586" left="105" width="686" height="12" font="9">‡CMR  may  be  indicated  for  assessment  of  right  ventricular  size  and  func@on,  pulmonary  valve  func@on,  pulmonary  artery </text>
<text top="602" left="105" width="686" height="12" font="9">anatomy and left heart abnormalities. Baseline study is recommended with periodic follow-up CMR, with frequency of repeat </text>
<text top="618" left="105" width="323" height="12" font="9">imaging determined by anatomic and physiological findings. </text>
<text top="634" left="105" width="686" height="12" font="9">§CCT may be used if CMR is not feasible and to evaluate origin and course of the coronary arteries, and cross-sectional imaging </text>
<text top="650" left="105" width="686" height="12" font="9">status–post-stent therapy.  If cardiac CCT  is  used instead  of CMR imaging, the frequency should be weighed against radiation </text>
<text top="666" left="105" width="56" height="12" font="9">exposure. </text>
<text top="680" left="105" width="335" height="16" font="9">║6-minute walk test or CPET, depending on clinical indication. </text>
<text top="698" left="105" width="686" height="12" font="9">ACHD  indicates  adult congenital heart disease;  CCT, cardiac computed tomography; CMR, cardiovascular  magnetic resonance </text>
<text top="714" left="105" width="686" height="12" font="9">imaging;  CPET,  cardiopulmonary  exercise  test;  ECG,  electrocardiogram;  TOF,  tetralogy  of  Fallot;  and  TTE,  transthoracic </text>
<text top="730" left="105" width="93" height="12" font="9">echocardiogram. </text>
<text top="746" left="105" width="3" height="13" font="8"> </text>
<text top="764" left="105" width="3" height="13" font="8"> </text>
<text top="764" left="315" width="3" height="13" font="8"> </text>
</page>
<page number="88" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="39" size="7" family="Helvetica" color="#000000"/>
	<fontspec id="40" size="7" family="Symbol" color="#000000"/>
	<fontspec id="41" size="7" family="Times" color="#000000"/>
	<fontspec id="42" size="4" family="Helvetica" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 90 </text>
<text top="162" left="105" width="507" height="15" font="14"><b>Figure 4. Pulmonary Valve Replacement in Patients With TOF Repair and PR</b> </text>
<text top="185" left="105" width="4" height="14" font="11"> </text>
<text top="1001" left="788" width="3" height="13" font="8"> </text>
<text top="1018" left="105" width="621" height="12" font="9">*Symptoms may include dyspnea, chest pain, and/or exercise intolerance referable to PR or otherwise unexplained. </text>
<text top="1034" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  HF,  heart  failure;  LV,  left  ventricular;  LVEDV,  left  ventricular  end  diastolic </text>
<text top="1050" left="105" width="686" height="12" font="9">volume;  PR,  pulmonary  regurgitation;  RV,  right  ventricular;  RVEDV,  right  ventricular  end  diastolic  volume;  RVEDVI,  right </text>
<text top="1066" left="105" width="686" height="12" font="9">ventricular  end  diastolic  volume  index;  RVESVI,  right  ventricular  end  systolic  volume  index;  RVOT,  right  ventricular  outflow </text>
<text top="1082" left="105" width="401" height="12" font="9">tract; RVSP, right ventricular systolic pressure; and TOF, tetralogy of Fallot. </text>
<text top="215" left="240" width="84" height="9" font="39">TOF repair with PR</text>
<text top="462" left="416" width="50" height="9" font="39">Symptoms*</text>
<text top="555" left="500" width="39" height="9" font="39">Any 2 of </text>
<text top="567" left="489" width="57" height="9" font="39">the following:</text>
<text top="576" left="458" width="7" height="13" font="40">• </text>
<text top="579" left="476" width="105" height="9" font="39">Mild or moderate RV or </text>
<text top="591" left="468" width="99" height="9" font="39">LV systolic dysfunction</text>
<text top="600" left="469" width="7" height="13" font="40">• </text>
<text top="603" left="486" width="84" height="9" font="39">Severe RV dilation </text>
<text top="614" left="463" width="42" height="9" font="39">(RVEDVI </text>
<text top="613" left="506" width="5" height="12" font="41">≥</text>
<text top="614" left="511" width="43" height="9" font="39">160 mL/m</text>
<text top="612" left="555" width="4" height="6" font="42">2</text>
<text top="614" left="559" width="14" height="9" font="39">, or</text>
<text top="626" left="468" width="39" height="9" font="39">RVESVI </text>
<text top="625" left="507" width="5" height="12" font="41">≥</text>
<text top="626" left="512" width="38" height="9" font="39">80 mL/m</text>
<text top="624" left="550" width="4" height="6" font="42">2</text>
<text top="626" left="554" width="17" height="9" font="39">, or </text>
<text top="638" left="473" width="37" height="9" font="39">RVEDV </text>
<text top="636" left="510" width="5" height="12" font="41">≥</text>
<text top="638" left="515" width="48" height="9" font="39">2x LVEDV)</text>
<text top="647" left="440" width="7" height="13" font="40">• </text>
<text top="650" left="458" width="137" height="9" font="39">RVSP due to RVOT obstruction</text>
<text top="662" left="466" width="3" height="9" font="39"> </text>
<text top="660" left="469" width="5" height="12" font="41">≥</text>
<text top="662" left="474" width="96" height="9" font="39">2/3 systemic pressure</text>
<text top="671" left="462" width="7" height="13" font="40">• </text>
<text top="674" left="479" width="98" height="9" font="39">Progressive reduction </text>
<text top="686" left="474" width="91" height="9" font="39">in objective exercise </text>
<text top="698" left="498" width="40" height="9" font="39">tolerance</text>
<text top="746" left="477" width="17" height="9" font="39">Yes</text>
<text top="532" left="328" width="76" height="9" font="39">Pulmonary valve </text>
<text top="544" left="337" width="54" height="9" font="39">replacement</text>
<text top="555" left="346" width="36" height="9" font="39">(Class I)</text>
<text top="500" left="400" width="16" height="9" font="39">Yes</text>
<text top="403" left="420" width="44" height="9" font="39">Moderate </text>
<text top="415" left="416" width="50" height="9" font="39">or more PR</text>
<text top="448" left="300" width="65" height="9" font="39">Follow-up with </text>
<text top="459" left="291" width="80" height="9" font="39">ACHD cardiologist</text>
<text top="471" left="313" width="36" height="9" font="39">(Class I)</text>
<text top="344" left="362" width="50" height="9" font="39">PR severity</text>
<text top="777" left="403" width="76" height="9" font="39">Pulmonary valve </text>
<text top="789" left="413" width="54" height="9" font="39">replacement</text>
<text top="800" left="417" width="45" height="9" font="39">(Class IIa)</text>
<text top="746" left="542" width="13" height="9" font="39">No</text>
<text top="792" left="566" width="46" height="9" font="39">Sustained </text>
<text top="804" left="550" width="78" height="9" font="39">tachyarrhythmias </text>
<text top="851" left="550" width="17" height="9" font="39">Yes</text>
<text top="877" left="478" width="76" height="9" font="39">Pulmonary valve </text>
<text top="889" left="487" width="54" height="9" font="39">replacement</text>
<text top="901" left="492" width="45" height="9" font="39">(Class IIb)</text>
<text top="889" left="643" width="38" height="9" font="39">Residual</text>
<text top="901" left="606" width="114" height="9" font="39"> lesions requiring surgical </text>
<text top="912" left="634" width="59" height="9" font="39">interventions </text>
<text top="971" left="544" width="76" height="9" font="39">Pulmonary valve </text>
<text top="983" left="553" width="55" height="9" font="39">replacement</text>
<text top="994" left="558" width="45" height="9" font="39">(Class IIb)</text>
<text top="971" left="707" width="65" height="9" font="39">Follow-up with </text>
<text top="982" left="699" width="80" height="9" font="39">ACHD cardiologist</text>
<text top="994" left="721" width="36" height="9" font="39">(Class I)</text>
<text top="944" left="613" width="17" height="9" font="39">Yes</text>
<text top="944" left="692" width="13" height="9" font="39">No</text>
<text top="404" left="314" width="34" height="9" font="39">Mild PR</text>
<text top="500" left="468" width="13" height="9" font="39">No</text>
<text top="277" left="264" width="41" height="9" font="39">Severely </text>
<text top="289" left="238" width="88" height="9" font="39">decreased LV or RV</text>
<text top="301" left="267" width="35" height="9" font="39">systolic </text>
<text top="313" left="265" width="34" height="9" font="39">function</text>
<text top="295" left="363" width="13" height="9" font="39">No</text>
<text top="324" left="122" width="106" height="9" font="39">Evaluation by an ACHD </text>
<text top="335" left="114" width="123" height="9" font="39">cardiologist &amp; advanced HF </text>
<text top="347" left="163" width="22" height="9" font="39">team</text>
<text top="359" left="156" width="36" height="9" font="39">(Class I)</text>
<text top="295" left="191" width="17" height="9" font="39">Yes</text>
<text top="851" left="617" width="13" height="9" font="39">No</text>
</page>
<page number="89" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 91 </text>
<text top="163" left="105" width="439" height="19" font="34"><b>4.3.6. Right Ventricle–to-Pulmonary Artery Conduit </b></text>
<text top="199" left="220" width="4" height="14" font="11"> </text>
<text top="197" left="273" width="273" height="16" font="12"><b>Recommendations for Right Ventricle</b></text>
<text top="199" left="546" width="8" height="14" font="11">–</text>
<text top="197" left="554" width="106" height="16" font="12"><b>to-PA Conduit </b></text>
<text top="218" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="218" left="577" width="180" height="14" font="23">Online Data Supplement 44</text>
<text top="218" left="757" width="8" height="14" font="11">. </text>
<text top="238" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="238" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="238" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="259" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="308" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="308" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="279" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="279" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="279" left="281" width="495" height="15" font="14"><b>Coronary  artery  compression  testing  with  simultaneous  coronary </b></text>
<text top="299" left="281" width="495" height="15" font="14"><b>angiography  and  high-pressure  balloon  dilation  in  the  conduit  is </b></text>
<text top="318" left="281" width="495" height="15" font="14"><b>indicated  before  right  ventricle–to-PA  conduit  stenting  or  transcatheter </b></text>
<text top="338" left="281" width="246" height="15" font="14"><b>valve placement (S4.3.6-1, S4.3.6-2). </b></text>
<text top="387" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="387" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="358" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="358" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="358" left="281" width="495" height="15" font="14"><b>In patients with stented right ventricle–to-PA conduits and worsening PS </b></text>
<text top="378" left="281" width="494" height="15" font="14"><b>or  PR,  evaluation  for  conduit  complications  should  be  performed, </b></text>
<text top="397" left="281" width="495" height="15" font="14"><b>including fluoroscopy to evaluate for stent fracture and blood cultures to </b></text>
<text top="417" left="281" width="217" height="15" font="14"><b>assess for IE (S4.3.6-3, S4.3.6-4). </b></text>
<text top="467" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="467" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="437" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="437" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="437" left="281" width="495" height="15" font="14"><b>In  adults  with  right  ventricle–to-PA  conduit  and  arrhythmia,  congestive </b></text>
<text top="457" left="281" width="25" height="15" font="14"><b>HF, </b></text>
<text top="457" left="322" width="86" height="15" font="14"><b>unexplained </b></text>
<text top="457" left="424" width="76" height="15" font="14"><b>ventricular </b></text>
<text top="457" left="516" width="82" height="15" font="14"><b>dysfunction </b></text>
<text top="457" left="615" width="18" height="15" font="14"><b>or </b></text>
<text top="457" left="648" width="60" height="15" font="14"><b>cyanosis </b></text>
<text top="457" left="724" width="51" height="15" font="14"><b>cardiac </b></text>
<text top="476" left="281" width="495" height="15" font="14"><b>catheterization  is  reasonable  to  assess  the  hemodynamics  (S4.3.6-5, </b></text>
<text top="496" left="281" width="67" height="15" font="14"><b>S4.3.6-6). </b></text>
<text top="516" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="566" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="566" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="537" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="537" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="537" left="281" width="495" height="15" font="14"><b>Right  ventricle–to-PA  conduit  intervention  is  reasonable  for  adults  with </b></text>
<text top="556" left="281" width="494" height="15" font="14"><b>right ventricle–to-PA conduit and moderate or greater PR or moderate or </b></text>
<text top="576" left="281" width="495" height="15" font="14"><b>greater  stenosis  (Table  22)  with  reduced  functional  capacity  or </b></text>
<text top="596" left="281" width="220" height="15" font="14"><b>arrhythmia (S4.3.6-7–S4.3.6-11). </b></text>
<text top="645" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="645" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="616" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="616" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="616" left="281" width="495" height="15" font="14"><b>Right  ventricle–to-PA  conduit  intervention  may  be  reasonable  for </b></text>
<text top="636" left="281" width="495" height="15" font="14"><b>asymptomatic  adults  with  right  ventricle–to-PA  conduit  and  severe </b></text>
<text top="655" left="281" width="495" height="15" font="14"><b>stenosis or severe regurgitation with reduced RV ejection fraction or RV </b></text>
<text top="675" left="281" width="205" height="15" font="14"><b>dilation (S4.3.6-12–S4.3.6-14). </b></text>
<text top="704" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="732" left="105" width="687" height="14" font="11">Right  ventricle–to-PA  conduits  are  widely  used  in  the  treatment  of  severe  RVOT  obstructive  lesions </text>
<text top="752" left="105" width="687" height="14" font="11">including  pulmonary  atresia.  These  conduits  may  be  homografts  or  prosthetic  conduits  with </text>
<text top="771" left="105" width="687" height="14" font="11">bioprosthetic  valves  used  within  the  conduit.  A  minority  of  conduits  may  show  early  dysfunction </text>
<text top="791" left="105" width="687" height="14" font="11">because  of  kinking  or  aneurysmal  dilation.  The  remainder  will  become  dysfunctional  over  time  and </text>
<text top="811" left="105" width="687" height="14" font="11">usually require replacement or intervention because of progressive stenosis within the conduit or at the </text>
<text top="830" left="105" width="687" height="14" font="11">valve, and/or valvular regurgitation, at a mean interval of 10 to 15 years from placement, although some </text>
<text top="850" left="105" width="414" height="14" font="11">conduits may last much longer than that (S4.3.6-15, S4.3.6-16). </text>
<text top="878" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="898" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="918" left="105" width="340" height="14" font="11">Table 28 for routine testing and follow-up intervals. </text>
<text top="946" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="974" left="105" width="687" height="14" font="11">1.  Coronary  compression  testing  generally  involves  simultaneous  selective  coronary  angiography  or </text>
<text top="994" left="105" width="687" height="14" font="11">aortography  and  balloon  dilation  in  the  RVOT,  to  ascertain  whether  a  balloon  expanded  stent  will </text>
<text top="1013" left="105" width="687" height="14" font="11">compress the coronary artery. Coronary artery compression with conduit balloon angioplasty or stenting </text>
<text top="1033" left="105" width="687" height="14" font="11">occurs  in  approximately  5%  to  6%  of  patients  with  right  ventricle–to-PA  conduits  and  usually  involves </text>
<text top="1053" left="105" width="687" height="14" font="11">the  left  main/left  anterior  descending  in  those  with  conventional  coronary  anatomy.  Patients  with </text>
</page>
<page number="90" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 92 </text>
<text top="162" left="105" width="687" height="14" font="11">anomalous  right  or  left  coronary  arteries  are  at  risk  of  coronary  compression  as  are  those  with </text>
<text top="182" left="105" width="204" height="14" font="11">reimplanted coronary arteries. </text>
<text top="210" left="105" width="687" height="14" font="11">2.  Right  ventricle–to-PA  conduit  stent  fracture  is  common  and  occurred  in  approximately  26%  of </text>
<text top="230" left="105" width="687" height="14" font="11">patients in the Melody Valve Investigational Device Exemption trial (S4.3.6-7), especially in patients who </text>
<text top="249" left="105" width="687" height="14" font="11">did not undergo conduit prestenting.  Stent  fracture  typically presents with progressive stenosis and in </text>
<text top="269" left="105" width="687" height="14" font="11">those with transcatheter valves may also present with worsening PR. Patients with an increase in PR or </text>
<text top="289" left="105" width="492" height="14" font="11">PS should have fluoroscopic or x-ray assessment to rule out stent fracture.  </text>
<text top="317" left="158" width="634" height="14" font="11">Annualized  rate  of  IE  is  up  to  2.4%  of  patients  treated  with  Melody  valve  implantation,  but </text>
<text top="337" left="105" width="687" height="14" font="11">infection in most cases involves valves other than the Melody valve, including left-sided valves (S4.3.6-3, </text>
<text top="356" left="105" width="687" height="14" font="11">S4.3.6-17–S4.3.6-20).  Patients  typically  present  with  fever  and  malaise  as  well  as  worsening  PS  or  PR. </text>
<text top="376" left="105" width="687" height="14" font="11">Cases  may  respond  well  to  medical  management  with  intravenous  antibiotics  if  IE  is  identified  and </text>
<text top="395" left="105" width="687" height="14" font="11">treatment initiated early in the  disease course,  although sometimes surgical removal of the valve may </text>
<text top="415" left="105" width="92" height="14" font="11">be necessary. </text>
<text top="443" left="105" width="687" height="14" font="11">3.  Although  noninvasive  imaging  with  echocardiography,  CMR,  or  CTA  provides  a  reasonably </text>
<text top="463" left="105" width="687" height="14" font="11">comprehensive assessment of ventricular function, conduit function, and patency as well as pulmonary </text>
<text top="483" left="105" width="687" height="14" font="11">arterial anatomy, cardiac catheterization is reasonable to directly assess hemodynamics in the setting of </text>
<text top="502" left="105" width="687" height="14" font="11">clinical decompensation. Direct assessment of intracardiac and pulmonary arterial pressures and cardiac </text>
<text top="522" left="105" width="687" height="14" font="11">output provides useful information regarding volume status, pulmonary arterial resistance, and degree </text>
<text top="541" left="105" width="687" height="14" font="11">of  conduit  stenosis  or  regurgitation.  Because  of  anatomic  and  technical  factors,  noninvasive  imaging </text>
<text top="561" left="105" width="687" height="15" font="11">may  provide  equivocal  information  and  may  underestimate  the  degree  of  conduit  stenosis  or </text>
<text top="580" left="105" width="471" height="15" font="11">regurgitation; invasive assessment is especially important in such cases. </text>
<text top="609" left="105" width="687" height="15" font="11">4.  Right  ventricle–to-PA  conduit  intervention  includes  surgical  replacement  or  percutaneous  stenting </text>
<text top="628" left="105" width="687" height="15" font="11">and/or  transcatheter  valve  placement.  Patients  with  moderate  or  greater  conduit  stenosis  (Table  22) </text>
<text top="648" left="105" width="687" height="15" font="11">and/or  regurgitation  who  have  reduced  exercise  capacity  or  arrhythmias  can  benefit  from  surgical  or </text>
<text top="668" left="105" width="687" height="15" font="11">transcatheter conduit intervention to relieve stenosis and/or  regurgitation. Transcatheter  stenting and </text>
<text top="687" left="105" width="687" height="15" font="11">pulmonary valve replacement may be performed with high procedural success and low mortality rates, </text>
<text top="707" left="105" width="687" height="15" font="11">and  result  in  improved  hemodynamics  and  improved  exercise  capacity.  Surgical  conduit  replacement </text>
<text top="726" left="105" width="687" height="15" font="11">carries  a  higher  risk  of  periprocedural  complications  with  good  long-term  outcomes.  Predictors  of </text>
<text top="746" left="105" width="687" height="15" font="11">conduit dysfunction and reoperation include placement of small diameter conduits; therefore, insertion </text>
<text top="765" left="105" width="687" height="15" font="11">of  conduits  with  the  largest  possible  diameter  should  be  attempted  (S4.3.6-8),  anticipating  that </text>
<text top="785" left="105" width="450" height="15" font="11">subsequent valve replacement may be via a transcatheter approach. </text>
<text top="814" left="105" width="687" height="15" font="11">5.  Right  ventricle–to-PA  conduit  intervention,  which  includes  surgical  replacement  or  percutaneous </text>
<text top="833" left="105" width="687" height="15" font="11">stenting  and/or  transcatheter  valve  placement,  may  be  reasonable  in  asymptomatic  patients  with </text>
<text top="853" left="105" width="687" height="15" font="11">severe  right  ventricle–to-PA  conduit  stenosis  or  regurgitation  in  the  presence  of  reduced  RV  systolic </text>
<text top="872" left="105" width="687" height="15" font="11">function or dilation in the expectation of improvement in hemodynamics, decreased RV size, improved </text>
<text top="892" left="105" width="687" height="15" font="11">RV  stroke  volume,  and  improved  RV  ejection  fraction.  Moreover,  peak  oxygen  consumption  and </text>
<text top="911" left="105" width="428" height="15" font="11">anaerobic threshold may also improve with conduit intervention.<b> </b></text>
<text top="940" left="105" width="4" height="15" font="11"> </text>
<text top="968" left="105" width="543" height="15" font="14"><b>Table 28. Right Ventricle–to-PA Conduit: Routine Follow-Up and Testing Intervals </b></text>
<text top="992" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="1009" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="992" left="335" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1009" left="332" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="992" left="454" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1009" left="451" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="992" left="568" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1009" left="566" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="992" left="683" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="1009" left="680" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="1028" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="1028" left="321" width="40" height="13" font="8">12–24 </text>
<text top="1028" left="444" width="18" height="13" font="8">12 </text>
<text top="1028" left="559" width="33" height="13" font="8">6–12 </text>
<text top="1028" left="673" width="25" height="13" font="8">3–6 </text>
<text top="1046" left="105" width="27" height="13" font="8">ECG </text>
<text top="1046" left="321" width="40" height="13" font="8">12–24 </text>
<text top="1046" left="444" width="18" height="13" font="8">12 </text>
<text top="1046" left="559" width="18" height="13" font="8">12 </text>
<text top="1046" left="673" width="18" height="13" font="8">12 </text>
<text top="1065" left="105" width="32" height="13" font="8">TTE† </text>
<text top="1065" left="321" width="40" height="13" font="8">12–24 </text>
<text top="1065" left="444" width="18" height="13" font="8">12 </text>
<text top="1065" left="559" width="18" height="13" font="8">12 </text>
<text top="1065" left="673" width="18" height="13" font="8">12 </text>
<text top="1083" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="1083" left="321" width="40" height="13" font="8">36–60 </text>
<text top="1083" left="444" width="40" height="13" font="8">36–60 </text>
<text top="1083" left="559" width="40" height="13" font="8">12–24 </text>
<text top="1083" left="673" width="40" height="13" font="8">12–24 </text>
</page>
<page number="91" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 93 </text>
<text top="163" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="160" left="179" width="14" height="18" font="8">║ </text>
<text top="163" left="321" width="66" height="13" font="8">As needed </text>
<text top="163" left="444" width="66" height="13" font="8">As needed </text>
<text top="163" left="559" width="40" height="13" font="8">12–24 </text>
<text top="163" left="673" width="40" height="13" font="8">12–24 </text>
<text top="181" left="105" width="369" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system. </text>
<text top="197" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="213" left="105" width="686" height="12" font="9">‡CMR  may  be  indicated  for  assessment  of  right  ventricular  size  and  function  and  valvular  function,  conduit  anatomy  and </text>
<text top="229" left="105" width="686" height="12" font="9">pulmonary  artery  anatomy.  Baseline  study  is  recommended  with  periodic  follow-up  CMR,  with  frequency  of  repeat  imaging </text>
<text top="245" left="105" width="278" height="12" font="9">determined by anatomic and physiological findings. </text>
<text top="261" left="105" width="686" height="12" font="9">§CCT  may  be  used  if  CMR  is  not  feasible  and  to  evaluate  cross-sectional  imaging  status–post-stent  therapy.  If  CCT  is  used </text>
<text top="277" left="105" width="465" height="12" font="9">instead of CMR imaging, the frequency should be weighed against radiation exposure.  </text>
<text top="291" left="105" width="335" height="16" font="9">║6-minute walk test or CPET, depending on clinical indication. </text>
<text top="309" left="105" width="686" height="12" font="9">ACHD indicates adult congenital heart disease; CCT, cardiac computed tomography; CMR, cardiovascular magnetic resonance; </text>
<text top="325" left="105" width="669" height="12" font="9">CPET, cardiopulmonary exercise test; ECG, electrocardiogram; PA, pulmonary artery; and TTE, transthoracic echocardiogram. </text>
<text top="352" left="105" width="195" height="20" font="17"><b>4.4. Complex Lesions </b></text>
<text top="396" left="105" width="352" height="19" font="34"><b>4.4.1. Transposition of the Great Arteries </b></text>
<text top="430" left="105" width="488" height="17" font="38"><i><b>4.4.1.1. Transposition of the Great Arteries With Atrial Switch </b></i></text>
<text top="463" left="239" width="4" height="14" font="11"> </text>
<text top="462" left="291" width="351" height="16" font="12"><b>Recommendations for d-TGA With Atrial Switch </b></text>
<text top="483" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="483" left="577" width="180" height="14" font="23">Online Data Supplement 45</text>
<text top="483" left="757" width="8" height="14" font="11">. </text>
<text top="503" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="503" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="503" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="523" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="563" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="563" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="544" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="544" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="544" left="281" width="495" height="15" font="14"><b>Ambulatory  monitoring  for  bradycardia  or  sinus  node  dysfunction  is </b></text>
<text top="563" left="281" width="495" height="15" font="14"><b>recommended  for  adults  with  d-TGA  with  atrial  switch,  especially  if </b></text>
<text top="583" left="281" width="378" height="15" font="14"><b>treated with beta blockers or other rate-slowing agents. </b></text>
<text top="623" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="623" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="603" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="603" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="603" left="281" width="495" height="15" font="14"><b>Adults  with  d-TGA  with  atrial  switch  repair  should  undergo  annual </b></text>
<text top="623" left="281" width="494" height="15" font="14"><b>imaging  with  either  echocardiography  or  CMR  to  evaluate  for  common </b></text>
<text top="642" left="281" width="299" height="15" font="14"><b>long-term complications of the atrial switch. </b></text>
<text top="692" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="692" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="663" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="663" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="663" left="281" width="495" height="15" font="14"><b>Assessment for a communication through the interatrial baffle or venous </b></text>
<text top="682" left="281" width="495" height="15" font="14"><b>stenosis  is  reasonable  for  adults  with  d-TGA  with  atrial  switch, </b></text>
<text top="702" left="281" width="495" height="15" font="14"><b>particularly if transvenous pacemaker/ICD implantation is  considered  or </b></text>
<text top="722" left="281" width="256" height="15" font="14"><b>leads are already present (S4.4.1.1-1). </b></text>
<text top="742" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="782" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="782" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="762" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="762" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="762" left="281" width="495" height="15" font="14"><b>GDMT  with  appropriate  attention  to  the  need  for  anticoagulation  is </b></text>
<text top="782" left="281" width="495" height="15" font="14"><b>recommended  to  promptly  restore  sinus  rhythm  for  adults  with  d-TGA </b></text>
<text top="801" left="281" width="473" height="15" font="14"><b>with atrial switch repair presenting with atrial arrhythmia (S4.4.1.1-2). </b></text>
<text top="831" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="859" left="105" width="687" height="14" font="11">Common  problems  for  patients  with  d-TGA  with  atrial  switch  (Mustard  or  Senning  procedure)  include </text>
<text top="879" left="105" width="687" height="14" font="11">leak across or obstruction of the venous pathways, arrhythmias, need for pacemakers/defibrillators, and </text>
<text top="898" left="105" width="687" height="14" font="11">systolic dysfunction of the systemic ventricle. Although reports describing these sequelae abound, data </text>
<text top="918" left="105" width="687" height="14" font="11">that inform management decisions are sparse, and many of the most common clinical issues cannot be </text>
<text top="937" left="105" width="687" height="14" font="11">addressed  by  data-supported  recommendations.  Two  such  issues  are  medical  therapy  for  RV </text>
<text top="957" left="105" width="234" height="14" font="11">dysfunction and prevention of SCD. </text>
<text top="985" left="158" width="634" height="14" font="11">The  systematic  review  report,  “Medical  Therapy  for  Systemic  Right  Ventricles:  A  Systematic </text>
<text top="1005" left="105" width="687" height="14" font="11">Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart </text>
<text top="1025" left="105" width="687" height="14" font="11">Disease,” has the complete systematic evidence review (S4.4.1.1-3) for additional data and analyses. The </text>
<text top="1044" left="105" width="687" height="14" font="11">results  from  the  question  “Are  outcomes  improved  with  angiotensin-converting  enzyme  inhibitors, </text>
<text top="1064" left="105" width="687" height="14" font="11">angiotensin-receptor  blockers,  beta  blockers,  or  aldosterone  antagonists  alone  or  in  combination  in </text>
<text top="1083" left="105" width="687" height="14" font="11">patients  with  a  systemic  right  ventricle?”  and  the  writing  committee’s  review  of  the  totality  of  the </text>
</page>
<page number="92" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 94 </text>
<text top="162" left="105" width="687" height="14" font="11">literature  demonstrated  that  medical  therapy  for  systolic  ventricular  dysfunction  remains  largely </text>
<text top="182" left="105" width="687" height="14" font="11">uncertain.  Consequently,  no  recommendations  regarding  specific  medical  therapy  for  systolic </text>
<text top="202" left="105" width="372" height="14" font="11">dysfunction of the systemic right ventricle can be made.  </text>
<text top="230" left="158" width="634" height="14" font="11">In  addition  to  the  report  provided  by  the  ERC  regarding  angiotensin-converting  enzyme </text>
<text top="249" left="105" width="687" height="14" font="11">inhibitor, angiotensin-receptor blocker, and aldosterone antagonist use for patients with systemic right </text>
<text top="269" left="105" width="687" height="14" font="11">ventricles,  beta  blockers  and  other  commonly  used  HF  medications  lack  data  to  support </text>
<text top="289" left="105" width="687" height="14" font="11">recommendations in the treatment of atrial switch patients (S4.4.1.1-4–S4.4.1.1-7). Concerns regarding </text>
<text top="308" left="105" width="687" height="14" font="11">routine use of beta blockers for asymptomatic RV dysfunction include potentially greater predisposition </text>
<text top="328" left="105" width="687" height="14" font="11">to  bradycardia  and  limited  distensibility  of  the  interatrial  baffle,  which  creates  a  preload  limited </text>
<text top="348" left="105" width="687" height="14" font="11">physiology  (S4.4.1.1-8).  Although  no  clear  benefit  has  been  demonstrated  for  HF  medical  therapy </text>
<text top="367" left="105" width="687" height="14" font="11">overall, there is speculation of benefit in more symptomatic patients or those with larger and/or more </text>
<text top="387" left="105" width="197" height="14" font="11">dysfunctional right ventricles. </text>
<text top="415" left="158" width="634" height="14" font="11">Patients  with  dysfunction  of  the  systemic  right  ventricle  are  at  risk  of  developing  ventricular </text>
<text top="435" left="105" width="687" height="14" font="11">arrhythmias.  The role of  ICD implantation for primary  prevention of arrhythmia in  patients with  a  low </text>
<text top="454" left="105" width="687" height="14" font="11">systemic  ventricular  ejection  fraction  is  uncertain.  This  practice  is  unsupported  by  any  research  and </text>
<text top="474" left="105" width="687" height="14" font="11">cannot  be  universally  recommended.  Many  such  patients  do  not  progress  to  receive  therapies  from </text>
<text top="493" left="105" width="687" height="14" font="11">their  device  (S4.4.1.1-2).  Decisions  regarding  primary  prevention  ICD  implantation  is  based  on  the </text>
<text top="513" left="105" width="687" height="14" font="11">patients'  full  clinical  presentation  and  in  consultation  with  cardiac  electrophysiologists  with  ACHD </text>
<text top="533" left="105" width="68" height="14" font="11">expertise. </text>
<text top="561" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="581" left="105" width="687" height="14" font="11">other procedures in these patients; Section 3.4 for recommendations on diagnostic evaluation; Table 29 </text>
<text top="600" left="105" width="644" height="14" font="11">for routine testing and follow-up intervals; and Online Data Supplement 25 for referenced studies. </text>
<text top="629" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="657" left="105" width="687" height="14" font="11">1. There is a progressive loss of sinus rhythm in patients who have undergone the Senning or Mustard </text>
<text top="677" left="105" width="687" height="14" font="11">procedure for d-TGA, and the development of significant sinus bradycardia, while often asymptomatic, </text>
<text top="696" left="105" width="670" height="14" font="11">is important to identify, because it will influence and limit treatment with antiarrhythmic medications. </text>
<text top="724" left="105" width="687" height="14" font="11">2.  Patients  with  d-TGA  with  atrial  switch  have  abnormal  cardiac  anatomy,  with  common  long-term </text>
<text top="744" left="105" width="687" height="14" font="11">complications including systemic RV dysfunction, TR, subpulmonic obstruction, obstruction of systemic </text>
<text top="764" left="105" width="687" height="14" font="11">or pulmonary venous return, and baffle leaks. Imaging should be goal-directed with an understanding of </text>
<text top="783" left="105" width="687" height="14" font="11">potential long-term sequelae, and nuanced for the patient’s particular circumstances (S4.4.1.1-9). CMR </text>
<text top="803" left="105" width="687" height="14" font="11">offers  quantification  of  systemic  RV  function  and  should  be  used  routinely  unless  there  are </text>
<text top="823" left="105" width="687" height="14" font="11">contraindications.  Late  gadolinium  enhancement  is  an  important  tool  that  can  identify  areas  of </text>
<text top="842" left="105" width="683" height="14" font="11">myocardial scar  that  are  associated  with  adverse  clinical markers including  atrial  arrhythmia  (S4.4.1.1-</text>
<text top="862" left="105" width="687" height="14" font="11">10). The importance of change in late gadolinium enhancement over time in directing care is less clear, </text>
<text top="881" left="105" width="472" height="14" font="11">so repetitive use of gadolinium contrast for this purpose is of less value. </text>
<text top="910" left="105" width="687" height="14" font="11">3.  Recognizing  both  the  abnormal  venous  pathways  after  atrial  switch  palliation  and  the  risk  of </text>
<text top="929" left="105" width="687" height="14" font="11">thromboembolic  complications  from  transvenous  pacing  leads  in  those  with  intracardiac  shunts, </text>
<text top="949" left="105" width="687" height="14" font="11">thorough  assessment  of  the  venous  pathways  for  either  obstruction  or  baffle  leak  is  a  prudent  step </text>
<text top="969" left="105" width="687" height="14" font="11">before  lead  placement  or  revision.  Baffle  leaks  should  be  sought  because  they  are  common  and  may </text>
<text top="988" left="105" width="579" height="14" font="11">alter treatment considerations such as thromboembolic concerns or options for closure. </text>
<text top="1017" left="158" width="634" height="14" font="11">Echocardiography using agitated saline contrast is  a sensitive method  for this  assessment. It is </text>
<text top="1036" left="105" width="687" height="14" font="11">unnecessary  on  every  study,  but  interval  assessment  of  baffle  leak  is  appropriate,  especially  in </text>
<text top="1056" left="105" width="687" height="14" font="11">circumstances  where  therapy  may  be  altered  by  the  result.  In  some  patients,  injection  in  upper  and </text>
<text top="1075" left="105" width="687" height="14" font="11">lower  extremities  may  be  necessary  to  evaluate  superior  and/or  inferior  systemic  venous  baffle  leak, </text>
</page>
<page number="93" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 95 </text>
<text top="162" left="105" width="687" height="14" font="11">respectively, because a negative study from an injection in upper extremity may not exclude an inferior </text>
<text top="182" left="105" width="687" height="14" font="11">systemic  venous  baffle  leak.  Assessment  for  baffle  leak  may  involve  use  of  TTE  with  agitated  saline </text>
<text top="202" left="105" width="484" height="14" font="11">contrast, TEE, intracardiac echocardiography, or angiography (S4.4.1.1-1). </text>
<text top="230" left="105" width="687" height="14" font="11">4. Sustained intra-atrial reentrant tachycardia is a potential cause of SCD in adults who have undergone </text>
<text top="249" left="105" width="687" height="14" font="11">atrial switch and puts patients at  risk for thromboembolism. Treatment  to maintain sinus rhythm may </text>
<text top="269" left="105" width="687" height="14" font="11">involve antiarrhythmic medication or catheter ablation. Although there are not data demonstrating that </text>
<text top="289" left="105" width="687" height="14" font="11">maintenance  of  sinus  rhythm  prevents  SCD,  there  is  evidence  that  atrial  arrhythmias  preceded  or </text>
<text top="308" left="105" width="687" height="14" font="11">coexisted  with  VT  in  50%  of  cases,  suggesting  that  atrial  arrhythmias  are  a  common  trigger  for </text>
<text top="328" left="105" width="320" height="14" font="11">ventricular arrhythmias (S4.4.1.1-2, S4.4.1.1-11). </text>
<text top="356" left="158" width="634" height="14" font="11">There  is  a  biologically  plausible  explanation  that  may  include  longer  atrial  tachycardia  cycle </text>
<text top="376" left="105" width="687" height="14" font="11">lengths  in  the  context  of  extensive  atrial  sutures/scar  that  could  favor  rapid  (e.g.,  1:1)  ventricular </text>
<text top="395" left="105" width="687" height="14" font="11">conduction,  a  reduction  in  stroke  volume  with  faster  heart  rates  attributable  to  poor  atrial  transport, </text>
<text top="415" left="105" width="687" height="14" font="11">and myocardial ischemia despite the absence of CAD attributable to an inefficient coronary circulation </text>
<text top="435" left="105" width="687" height="14" font="11">supplying the systemic ventricle (S4.4.1.1-12). Efforts to maintain sinus rhythm or atrial pacing (and not </text>
<text top="454" left="105" width="687" height="14" font="11">simply  rate  control)  should  be  the  initial  strategy  of  management,  acknowledging  that  patients  may </text>
<text top="474" left="105" width="640" height="14" font="11">rarely tolerate permanent atrial tachycardia when attempts to maintain sinus rhythm have failed. </text>
<text top="502" left="158" width="634" height="14" font="11">Atrial  arrhythmias  predominantly  involve  tissue  of  right  atrial  origin  which,  because  of  the </text>
<text top="522" left="105" width="687" height="14" font="11">surgical  anatomy,  is  found  primarily  in  the  pulmonary  venous  atrium,  making  access  for  catheter </text>
<text top="541" left="105" width="139" height="14" font="11">ablation challenging. </text>
<text top="570" left="105" width="4" height="14" font="11"> </text>
<text top="598" left="105" width="509" height="15" font="14"><b>Table 29. d-TGA With Atrial Switch: Routine Follow-Up and Testing Intervals </b></text>
<text top="621" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="639" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="621" left="333" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="639" left="330" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="621" left="451" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="639" left="449" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="621" left="570" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="639" left="567" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="621" left="685" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="639" left="681" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="658" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="658" left="321" width="18" height="13" font="8">12 </text>
<text top="658" left="440" width="18" height="13" font="8">12 </text>
<text top="658" left="558" width="33" height="13" font="8">6–12 </text>
<text top="658" left="676" width="25" height="13" font="8">3–6 </text>
<text top="676" left="105" width="27" height="13" font="8">ECG </text>
<text top="676" left="321" width="18" height="13" font="8">12 </text>
<text top="676" left="440" width="18" height="13" font="8">12 </text>
<text top="676" left="558" width="33" height="13" font="8">6–12 </text>
<text top="676" left="676" width="33" height="13" font="8">6–12 </text>
<text top="695" left="105" width="32" height="13" font="8">TTE† </text>
<text top="695" left="321" width="40" height="13" font="8">12–24 </text>
<text top="695" left="440" width="40" height="13" font="8">12–24 </text>
<text top="695" left="558" width="18" height="13" font="8">12 </text>
<text top="695" left="676" width="18" height="13" font="8">12 </text>
<text top="713" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="713" left="321" width="18" height="13" font="8">12 </text>
<text top="713" left="440" width="18" height="13" font="8">12 </text>
<text top="713" left="558" width="59" height="13" font="8">Each visit </text>
<text top="713" left="676" width="59" height="13" font="8">Each visit </text>
<text top="732" left="105" width="92" height="13" font="8">Holter monitor </text>
<text top="732" left="321" width="18" height="13" font="8">24 </text>
<text top="732" left="440" width="18" height="13" font="8">24 </text>
<text top="732" left="558" width="18" height="13" font="8">12 </text>
<text top="732" left="676" width="18" height="13" font="8">12 </text>
<text top="750" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="750" left="321" width="40" height="13" font="8">24–36 </text>
<text top="750" left="440" width="18" height="13" font="8">24 </text>
<text top="750" left="558" width="40" height="13" font="8">12–24 </text>
<text top="750" left="676" width="40" height="13" font="8">12–24 </text>
<text top="769" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="766" left="179" width="14" height="18" font="8">║ </text>
<text top="769" left="321" width="18" height="13" font="8">36 </text>
<text top="769" left="440" width="18" height="13" font="8">36 </text>
<text top="769" left="558" width="18" height="13" font="8">24 </text>
<text top="769" left="676" width="18" height="13" font="8">12 </text>
<text top="787" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="803" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="819" left="105" width="686" height="12" font="9">‡CMR may be indicated for assessment of ventricular size and function, systemic and venous baffle obstruction and leaks, and </text>
<text top="835" left="105" width="686" height="12" font="9">valvular function. Baseline study is recommended with periodic follow-up CMR, with frequency of repeat imaging determined </text>
<text top="851" left="105" width="199" height="12" font="9">anatomic and physiological findings.  </text>
<text top="867" left="105" width="686" height="12" font="9">§CCT  may  be  used  if  CMR  is  not  feasible  and  to  evaluate  cross-sectional  imaging  status–post-stent  therapy.  If  CCT  is  used </text>
<text top="883" left="105" width="465" height="12" font="9">instead of CMR imaging, the frequency should be weighed against radiation exposure.  </text>
<text top="897" left="105" width="354" height="16" font="9">║6-minute exercise test or CPET, depending on clinical indication. </text>
<text top="915" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CCT  cardiac  computed  tomography;  CMR,  cardiovascular  magnetic  resonance </text>
<text top="931" left="105" width="686" height="12" font="9">imaging; CPET, cardiopulmonary  exercise test; d-TGA, dextro-transposition  of the great arteries;  ECG, electrocardiogram; and </text>
<text top="947" left="105" width="192" height="12" font="9">TTE, transthoracic echocardiogram. </text>
<text top="964" left="105" width="4" height="16" font="22"> </text>
<text top="997" left="105" width="4" height="15" font="11"> </text>
<text top="995" left="315" width="4" height="17" font="38"><i><b> </b></i></text>
</page>
<page number="94" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 96 </text>
<text top="163" left="105" width="504" height="17" font="38"><i><b>4.4.1.2. Transposition of the Great Arteries With Arterial Switch </b></i></text>
<text top="197" left="231" width="4" height="14" font="11"> </text>
<text top="196" left="284" width="366" height="16" font="12"><b>Recommendations for d-TGA With Arterial Switch </b></text>
<text top="216" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="216" left="577" width="180" height="14" font="23">Online Data Supplement 46</text>
<text top="216" left="757" width="8" height="14" font="11">. </text>
<text top="237" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="237" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="237" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="257" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="307" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="307" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="277" left="256" width="13" height="15" font="14"><b>1)</b></text>
<text top="277" left="269" width="4" height="15" font="24"><b> </b></text>
<text top="277" left="281" width="495" height="15" font="14"><b>Baseline and serial imaging with either echocardiography or CMR should </b></text>
<text top="297" left="281" width="495" height="15" font="14"><b>be  performed  in  adults  with  d-TGA  with  arterial  switch  who  have </b></text>
<text top="316" left="281" width="495" height="15" font="14"><b>neoaortic  dilation,  valve  dysfunction  or  PA  or  branch  PA  stenosis  or </b></text>
<text top="336" left="281" width="316" height="15" font="14"><b>ventricular dysfunction (S4.4.1.2-1–S4.4.1.2-3). </b></text>
<text top="386" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="386" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="356" left="256" width="13" height="15" font="14"><b>2)</b></text>
<text top="356" left="269" width="4" height="15" font="24"><b> </b></text>
<text top="356" left="281" width="495" height="15" font="14"><b>Coronary  revascularization  for  adults  with  d-TGA  with  arterial  switch </b></text>
<text top="376" left="281" width="495" height="15" font="14"><b>should  be  planned  by  surgeons  or  interventional  cardiologists  with </b></text>
<text top="395" left="281" width="495" height="15" font="14"><b>expertise  in  revascularization  in  collaboration  with  ACHD  providers  to </b></text>
<text top="415" left="281" width="435" height="15" font="14"><b>ensure coronary and pulmonary artery anatomy are understood  </b></text>
<text top="465" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="465" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="435" left="256" width="13" height="15" font="14"><b>3)</b></text>
<text top="436" left="269" width="4" height="15" font="24"><b> </b></text>
<text top="435" left="281" width="495" height="15" font="14"><b>It  is  reasonable  to  perform  anatomic  evaluation  of  coronary  artery </b></text>
<text top="455" left="281" width="495" height="15" font="14"><b>patency  (catheter  angiography,  or  CT  or  MR  angiography)  in </b></text>
<text top="475" left="281" width="495" height="15" font="14"><b>asymptomatic  adults  with  d-TGA  with  arterial  switch  (S4.4.1.2-4, </b></text>
<text top="494" left="281" width="79" height="15" font="14"><b>S4.4.1.2-5). </b></text>
<text top="534" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="534" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="515" left="256" width="13" height="15" font="14"><b>4)</b></text>
<text top="515" left="269" width="4" height="15" font="24"><b> </b></text>
<text top="515" left="281" width="494" height="15" font="14"><b>Physiological  tests  of  myocardial  perfusion  for  adults  with  d-TGA  after </b></text>
<text top="534" left="281" width="495" height="15" font="14"><b>arterial  switch  can  be  beneficial  for  assessing  symptoms  suggestive  of </b></text>
<text top="554" left="281" width="144" height="15" font="14"><b>myocardial ischemia. </b></text>
<text top="594" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="594" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="574" left="256" width="13" height="15" font="14"><b>5)</b></text>
<text top="574" left="269" width="4" height="15" font="24"><b> </b></text>
<text top="574" left="281" width="75" height="15" font="14"><b>GDMT  is </b></text>
<text top="574" left="370" width="77" height="15" font="14"><b>reasonable </b></text>
<text top="574" left="462" width="18" height="15" font="14"><b>to </b></text>
<text top="574" left="495" width="203" height="15" font="14"><b>determine  the  need  for </b></text>
<text top="574" left="712" width="63" height="15" font="14"><b>coronary </b></text>
<text top="594" left="281" width="495" height="15" font="14"><b>revascularization  for  adults  with  d-TGA  after  arterial  switch  (S4.4.1.2-6– </b></text>
<text top="613" left="281" width="79" height="15" font="14"><b>S4.4.1.2-8). </b></text>
<text top="634" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="674" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="674" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="654" left="256" width="13" height="15" font="14"><b>6)</b></text>
<text top="654" left="269" width="4" height="15" font="24"><b> </b></text>
<text top="654" left="281" width="495" height="15" font="14"><b>GDMT  is  reasonable  to  determine  indications  for  aortic  valve </b></text>
<text top="674" left="281" width="494" height="15" font="14"><b>replacement  in  adults  with  d-TGA  after  arterial  switch  with  severe </b></text>
<text top="693" left="281" width="282" height="15" font="14"><b>neoaortic valve regurgitation (S4.4.1.2-6). </b></text>
<text top="733" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="733" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="714" left="256" width="13" height="15" font="14"><b>7)</b></text>
<text top="714" left="269" width="4" height="15" font="24"><b> </b></text>
<text top="714" left="281" width="491" height="15" font="14"><b>Catheter  or  surgical  intervention  for  PS  is  reasonable  in  adults  with  d-</b></text>
<text top="733" left="281" width="494" height="15" font="14"><b>TGA  after  arterial  switch  with  symptoms  of  HF  or  decreased  exercise </b></text>
<text top="753" left="281" width="184" height="15" font="14"><b>capacity attributable to PS. </b></text>
<text top="782" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="810" left="105" width="687" height="14" font="11">Complications  after  the  arterial  switch  include:  1)  stenosis  at  the  arterial  anastomotic  sites,  most </text>
<text top="830" left="105" width="687" height="14" font="11">commonly  supravalvular  PS;  2)  neoaortic  root  dilation;  3)  neoaortic  valve  regurgitation  (native </text>
<text top="850" left="105" width="687" height="14" font="11">pulmonary  valve);  and  4)  coronary  obstruction.  Evaluation  for  the  first  3  complications  listed  is </text>
<text top="869" left="105" width="687" height="14" font="11">accomplished by usual imaging, including echocardiography, CCT, and/or CMR. Coronary complications </text>
<text top="889" left="105" width="687" height="14" font="11">are inadequately evaluated by resting echocardiography, and stress imaging in asymptomatic patients is </text>
<text top="908" left="105" width="687" height="14" font="11">not  sensitive.  It  is  unclear  that  coronary  abnormalities  will  present  de  novo  or  that  those  present  in </text>
<text top="928" left="105" width="687" height="14" font="11">childhood  will  progress.  However,  because  patients  did  not  receive  an  arterial  switch  before  the  late </text>
<text top="948" left="105" width="687" height="14" font="11">1980s, the long-term natural history of the coronary arteries after arterial switch is still unknown. This is </text>
<text top="967" left="105" width="687" height="14" font="11">particularly  true  regarding  the  impact  of  risks  for  concomitant  acquired  coronary  artery  disease  in </text>
<text top="987" left="105" width="687" height="14" font="11">patients  whose  coronary  substrate  is  not  normal.  At  this  time,  investigation  and  management  of </text>
<text top="1006" left="105" width="683" height="14" font="11">suspected coronary abnormalities in adults with the arterial switch for TGA should largely be symptom-</text>
<text top="1026" left="105" width="574" height="14" font="11">driven and in accordance with existing guidelines for acquired coronary artery diseases. </text>
<text top="1054" left="158" width="634" height="14" font="11">Several residua and sequelae in adults after arterial switch merit consideration of reoperation. </text>
<text top="1074" left="105" width="687" height="14" font="11">Severe  RVOT  obstruction  (Table  22)  not  amenable  or  responsive  to  percutaneous  treatment  is  an </text>
</page>
<page number="95" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 97 </text>
<text top="162" left="105" width="687" height="14" font="11">indication  for  reoperation;  lesser  degrees  of  obstruction  can  be  considered  an  indication  for </text>
<text top="182" left="105" width="687" height="14" font="11">intervention if greater degrees of exercise are desired. Pulmonary valve replacement or repair is often </text>
<text top="202" left="105" width="687" height="14" font="11">considered  when  severe  PR  is  present  and  there is significant  RV  dilation  or  RV  dysfunction. Coronary </text>
<text top="221" left="105" width="687" height="14" font="11">ostial stenosis late after arterial switch may be repaired by coronary artery bypass graft surgery or ostial </text>
<text top="241" left="105" width="687" height="14" font="11">arterioplasty techniques. The threshold aortic diameter at which dissection/rupture risk exceeds the risk </text>
<text top="260" left="105" width="687" height="14" font="11">of operation is not known, and consequently the threshold for prophylactic operation for neoaortic root </text>
<text top="280" left="105" width="141" height="14" font="11">dilation is undefined. </text>
<text top="308" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="328" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="348" left="105" width="340" height="14" font="11">Table 30 for routine testing and follow-up intervals. </text>
<text top="376" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="404" left="105" width="687" height="14" font="11">1. Imaging in patients after arterial switch should be performed with specific sequelae in mind, including </text>
<text top="424" left="105" width="687" height="14" font="11">PS (recognizing the Lecompte maneuver has been used during surgery in most), and neoaortic root and </text>
<text top="443" left="105" width="687" height="14" font="11">valve  problems.  Some  patients  with  early  arterial  switch  repairs  had  right  ventricle–to-PA  conduits </text>
<text top="463" left="105" width="290" height="14" font="11">placed and may have related complications. </text>
<text top="491" left="105" width="687" height="14" font="11">2.  Because  of  nuances  of  the  arterial  switch,  decisions  regarding  coronary  intervention  should  be </text>
<text top="511" left="105" width="687" height="15" font="11">considered jointly by ACHD providers and those with expertise in coronary revascularization techniques. </text>
<text top="530" left="105" width="687" height="15" font="11">Abnormalities  commonly  occur  proximally  and  close  to  the  anteriorly  positioned  coronary  buttons. </text>
<text top="550" left="105" width="687" height="15" font="11">Coronary  buttons  are  usually  located  posterior  to  the  main  PA  after  the  Lecompte  maneuver. </text>
<text top="569" left="105" width="687" height="15" font="11">Revascularization  techniques  may  include  revision  of  the  coronary  buttons,  ostioplasty,  interposition </text>
<text top="589" left="105" width="231" height="15" font="11">grafts, or coronary bypass grafting. </text>
<text top="617" left="105" width="687" height="15" font="11">3.  There  is  evidence  that  coronary  abnormalities  are  common  after  arterial  switch  (6%  to  10%), </text>
<text top="637" left="105" width="687" height="15" font="11">especially in the setting of coronary anomalies at birth, or extensive manipulation of the coronaries at </text>
<text top="657" left="105" width="687" height="15" font="11">the time of the operation. However, most coronary problems and events described so far tend to occur </text>
<text top="676" left="105" width="687" height="15" font="11">in childhood in the first few years after surgery, with limited experience in adults (S4.4.1.2-1, S4.4.1.2-2, </text>
<text top="696" left="105" width="687" height="15" font="11">S4.4.1.2-4, S4.4.1.2-5), although the prevalence of coronary issues may increase as the population ages. </text>
<text top="715" left="105" width="687" height="15" font="11">Physiological  testing lacks sensitivity.  Therefore,  a  benchmark  assessment  of  the  anatomic  course  and </text>
<text top="735" left="105" width="687" height="15" font="11">patency  of  the  coronary  arteries  (i.e.,  catheter  angiography  or  CT  angiography)  is  prudent  in  adults  in </text>
<text top="755" left="105" width="687" height="15" font="11">whom this information has not already been obtained. MR coronary angiography may also be an option </text>
<text top="774" left="105" width="687" height="15" font="11">for  evaluating  coronary  patency  (S4.4.1.2-9).  Thereafter,  coronary  investigations  will  be  prompted </text>
<text top="794" left="105" width="142" height="15" font="11">largely by symptoms. </text>
<text top="822" left="105" width="687" height="15" font="11">4. Once the coronary anatomy in an arterial switch recipient is documented, there is little justification </text>
<text top="842" left="105" width="687" height="15" font="11">for  serial  anatomic  imaging  in  an  asymptomatic  individual.  Symptomatic  patients  should  be  offered </text>
<text top="861" left="105" width="687" height="15" font="11">stress  physiological  imaging  and  repeat  anatomic  imaging  considered  if  symptoms  are  suggestive  of </text>
<text top="881" left="105" width="206" height="15" font="11">coronary ischemia (S4.4.1.2-8). </text>
<text top="909" left="105" width="687" height="15" font="11">5. Decisions about the indications and approach for coronary intervention after an arterial switch can be </text>
<text top="929" left="105" width="687" height="15" font="11">guided  according  to  management  recommendations  for  care  of  atherosclerotic  coronary  disease, </text>
<text top="949" left="105" width="687" height="15" font="11">emphasizing  prudent  medical  therapy  and  a  symptom-guided  approach  to  intervention  (S4.4.1.2-6, </text>
<text top="968" left="105" width="687" height="15" font="11">S4.4.1.2-8).  The  unique  aspects  of  the  anatomic  abnormalities  and  unusual  course  of  the  proximal </text>
<text top="988" left="105" width="687" height="15" font="11">coronary  arteries  must  be  kept  in  mind,  mandating  collaboration  between  ACHD  providers  and  those </text>
<text top="1007" left="105" width="361" height="15" font="11">with the necessary surgical or interventional expertise. </text>
<text top="1036" left="105" width="687" height="15" font="11">6. Although some degree of neoaortic valve regurgitation is common, surgery to replace the neoaortic </text>
<text top="1055" left="105" width="687" height="15" font="11">valve has only rarely been reported. Indications for valve replacement should be based on LV size and/or </text>
<text top="1075" left="105" width="687" height="15" font="11">symptoms  according  to  the  2014  VHD  guideline  (S4.4.1.2-6).  The more  common  concern  is  dilation  of </text>
</page>
<page number="96" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 98 </text>
<text top="162" left="105" width="687" height="14" font="11">the  neoaortic  root  with  preserved  aortic  valve  competence.  Valve-sparing  root  replacement  is  often </text>
<text top="182" left="105" width="687" height="14" font="11">considered  in  such  cases,  but  surgical  options  should  be  individualized  based  upon  anatomy  and </text>
<text top="202" left="105" width="687" height="14" font="11">changes  over  time.  There  are  not  data  to  support  a  specific  aortic  diameter  beyond  which  the  risk  of </text>
<text top="221" left="105" width="569" height="14" font="11">dissection or rupture increases sufficiently to warrant prophylactic aortic replacement. </text>
<text top="249" left="105" width="687" height="14" font="11">7. PS affects 5% to 15% of patients after arterial switch (S4.4.1.2-1–S4.4.1.2-3, S4.4.1.2-10, S4.4.1.2-11) </text>
<text top="269" left="105" width="687" height="14" font="11">and  may  occur  anywhere  in  the  pulmonary  tree  including  the  pulmonary  valve,  main  PA,  and  branch </text>
<text top="289" left="105" width="687" height="14" font="11">pulmonary  arteries.  Interventional  decisions  should  be  guided  by  a  combination  of  symptoms  and </text>
<text top="308" left="105" width="133" height="14" font="11">severity of stenosis. </text>
<text top="337" left="105" width="4" height="14" font="11"> </text>
<text top="365" left="105" width="523" height="15" font="14"><b>Table 30. d-TGA With Arterial Switch: Routine Follow-Up and Testing Intervals </b></text>
<text top="388" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="406" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="388" left="336" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="333" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="388" left="456" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="453" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="388" left="570" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="567" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="388" left="683" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="406" left="680" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="424" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="424" left="321" width="40" height="13" font="8">12–24 </text>
<text top="424" left="446" width="18" height="13" font="8">12 </text>
<text top="424" left="560" width="33" height="13" font="8">6–12 </text>
<text top="424" left="674" width="25" height="13" font="8">3–6 </text>
<text top="443" left="105" width="27" height="13" font="8">ECG </text>
<text top="443" left="321" width="40" height="13" font="8">12–24 </text>
<text top="443" left="446" width="40" height="13" font="8">12–24 </text>
<text top="443" left="560" width="18" height="13" font="8">12 </text>
<text top="443" left="674" width="11" height="13" font="8">6 </text>
<text top="461" left="105" width="32" height="13" font="8">TTE† </text>
<text top="461" left="321" width="40" height="13" font="8">12–24 </text>
<text top="461" left="446" width="40" height="13" font="8">12–24 </text>
<text top="461" left="560" width="18" height="13" font="8">12 </text>
<text top="461" left="674" width="18" height="13" font="8">12 </text>
<text top="480" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="480" left="321" width="40" height="13" font="8">36–60 </text>
<text top="480" left="446" width="40" height="13" font="8">24–36 </text>
<text top="480" left="560" width="40" height="13" font="8">12–24 </text>
<text top="480" left="674" width="40" height="13" font="8">12–24 </text>
<text top="499" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="496" left="179" width="14" height="18" font="8">║ </text>
<text top="499" left="321" width="40" height="13" font="8">36–60 </text>
<text top="499" left="446" width="40" height="13" font="8">36–60 </text>
<text top="499" left="560" width="40" height="13" font="8">24–36 </text>
<text top="499" left="674" width="40" height="13" font="8">12–24 </text>
<text top="517" left="105" width="196" height="12" font="9">*See ACHD AP classification Table 4. </text>
<text top="533" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="549" left="105" width="686" height="12" font="9">‡CMR  may  be  indicated  for  assessment  of  neoaor@c  size,  the  origin  and  proximal  course  of  the  coronary  arteries,  branch </text>
<text top="565" left="105" width="686" height="12" font="9">pulmonary  arteries,  ventricular  function  and  valvular  function.  Baseline  study  is  recommended  with  periodic  follow-up  CMR, </text>
<text top="581" left="105" width="461" height="12" font="9">with frequency of repeat imaging determined by anatomic and physiological findings.  </text>
<text top="597" left="105" width="686" height="12" font="9">§CCT or catheterization once to establish knowledge of coronary artery anatomy and then as warranted by clinical condition. </text>
<text top="613" left="105" width="686" height="12" font="9">CCT may be used if CMR is not feasible and to evaluate coronary artery anatomy and cross-sectional imaging status-post stent </text>
<text top="629" left="105" width="583" height="12" font="9">therapy. If CCT is used instead of CMR imaging, the frequency should be weighed against radiation exposure. </text>
<text top="643" left="105" width="354" height="16" font="9">║6-minute exercise test or CPET, depending on clinical indication. </text>
<text top="661" left="105" width="686" height="12" font="9">ACHD  indicates  adult congenital heart disease;  CCT, cardiac computed tomography; CMR, cardiovascular  magnetic resonance </text>
<text top="677" left="105" width="686" height="12" font="9">imaging; CPET, cardiopulmonary  exercise test; d-TGA, dextro-transposition  of the great arteries;  ECG, electrocardiogram; and </text>
<text top="693" left="105" width="192" height="12" font="9">TTE, transthoracic echocardiogram. </text>
<text top="710" left="105" width="4" height="16" font="22"> </text>
<text top="741" left="105" width="543" height="17" font="38"><i><b>4.4.1.3. Transposition of the Great Arteries With Rastelli Type Repair </b></i></text>
<text top="772" left="105" width="687" height="15" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="791" left="105" width="650" height="15" font="11">other procedures in these patients; and Section 3.4 for recommendations on diagnostic evaluation. </text>
<text top="820" left="105" width="4" height="15" font="11"> </text>
<text top="848" left="105" width="687" height="15" font="11">The Rastelli operation is performed in patients with d-TGA with VSD and PS and for variations of double </text>
<text top="868" left="105" width="499" height="15" font="11">outlet right ventricle with PS. The operation consists of 2 main components: </text>
<text top="896" left="131" width="12" height="15" font="11">1.</text>
<text top="896" left="144" width="4" height="15" font="26"> </text>
<text top="896" left="158" width="634" height="15" font="11">An intracardiac baffle that directs oxygenated blood from the left ventricle via a nonrestrictive </text>
<text top="915" left="158" width="115" height="15" font="11">VSD to the aorta. </text>
<text top="935" left="131" width="12" height="15" font="11">2.</text>
<text top="935" left="144" width="4" height="15" font="26"> </text>
<text top="935" left="158" width="364" height="15" font="11">A right ventricle–to-PA conduit, which is usually valved. </text>
<text top="963" left="105" width="687" height="15" font="11">The  operation  is  designed  to  use  the  morphologic  left  ventricle  as  the  systemic  ventricle  and  the </text>
<text top="983" left="105" width="687" height="15" font="11">morphologic  right  ventricle  as  the  subpulmonic  ventricle.  Long-term  considerations  after  the  Rastelli </text>
<text top="1003" left="105" width="123" height="15" font="11">operation include: </text>
<text top="1031" left="131" width="12" height="15" font="11">1.</text>
<text top="1031" left="144" width="4" height="15" font="26"> </text>
<text top="1031" left="158" width="373" height="15" font="11">Right ventricle–to-PA conduit dysfunction (Section 4.3.6) </text>
<text top="1051" left="131" width="12" height="15" font="11">2.</text>
<text top="1051" left="144" width="4" height="15" font="26"> </text>
<text top="1051" left="158" width="283" height="15" font="11">VSD patch leaks/dehiscence (Section 4.1.3) </text>
<text top="1070" left="131" width="12" height="15" font="11">3.</text>
<text top="1071" left="144" width="4" height="15" font="26"> </text>
<text top="1070" left="158" width="328" height="15" font="11">LV-to-aorta internal baffle stenosis (Section 4.2.3) </text>
</page>
<page number="97" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="426" width="45" height="12" font="9">Page 99 </text>
<text top="162" left="131" width="12" height="14" font="11">4.</text>
<text top="162" left="144" width="4" height="15" font="26"> </text>
<text top="162" left="158" width="95" height="14" font="11">Scar-based VT </text>
<text top="191" left="105" width="687" height="14" font="11">Medical  treatment,  catheter  interventions,  and  surgical  interventions  for  each  of  these  conditions, </text>
<text top="210" left="105" width="687" height="14" font="11">which  may  occur  in  isolation  or  in  combination,  may  be  considered  in  accordance  with  the </text>
<text top="230" left="105" width="671" height="14" font="11">recommended treatments for each of the individual conditions as outlined in this guideline document. </text>
<text top="258" left="105" width="4" height="14" font="11"> </text>
<text top="287" left="105" width="524" height="17" font="38"><i><b>4.4.1.4. Congenitally Corrected Transposition of the Great Arteries </b></i></text>
<text top="320" left="144" width="593" height="16" font="12"><b>Recommendations for Congenitally Corrected Transposition of the Great Arteries </b></text>
<text top="341" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="341" left="577" width="180" height="14" font="23">Online Data Supplement 47</text>
<text top="341" left="757" width="8" height="14" font="11">. </text>
<text top="361" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="361" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="361" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="381" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="411" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="411" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="401" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="402" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="401" left="281" width="494" height="15" font="14"><b>CMR  is  reasonable  in  adults  with  CCTGA  to  determine  systemic  RV </b></text>
<text top="421" left="281" width="379" height="15" font="14"><b>dimensions and systolic function (S4.4.1.4-1, S4.4.1.4-2). </b></text>
<text top="441" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="481" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="481" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="462" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="462" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="462" left="281" width="495" height="15" font="14"><b>Tricuspid  valve  replacement  is  recommended  for  symptomatic  adults </b></text>
<text top="481" left="281" width="494" height="15" font="14"><b>with CCTGA and  severe TR, and  preserved  or  mildly  depressed systemic </b></text>
<text top="501" left="281" width="294" height="15" font="14"><b>ventricular function (S4.4.1.4-3, S4.4.1.4-4). </b></text>
<text top="541" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="541" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="521" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="521" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="521" left="281" width="495" height="15" font="14"><b>Tricuspid valve replacement  is reasonable for asymptomatic adults with </b></text>
<text top="541" left="281" width="495" height="15" font="14"><b>CCTGA  and  severe  TR  with  dilation  or  mild  dysfunction  of  the  systemic </b></text>
<text top="561" left="281" width="146" height="15" font="14"><b>ventricle (S4.4.1.4-3). </b></text>
<text top="620" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="620" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="581" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="581" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="581" left="281" width="495" height="15" font="14"><b>Conduit  intervention/replacement  may  be  considered  for  adults  with </b></text>
<text top="600" left="281" width="495" height="15" font="14"><b>CCTGA  and  symptomatic  subpulmonary  left  ventricle–to-PA  conduit </b></text>
<text top="620" left="281" width="495" height="15" font="14"><b>dysfunction, recognizing that unloading the subpulmonary ventricle may </b></text>
<text top="640" left="281" width="495" height="15" font="14"><b>have  a  detrimental  impact  on  systemic  atrioventricular  valve  function </b></text>
<text top="659" left="281" width="84" height="15" font="14"><b>(S4.4.1.4-5). </b></text>
<text top="688" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="717" left="105" width="687" height="14" font="11">The  clinical  course  of  adults  with  CCTGA  often  depends  on  the  presence  and  severity  of  associated </text>
<text top="736" left="105" width="687" height="14" font="11">cardiac anomalies (S4.4.1.4-6), which will often have required pediatric intervention. Rarely, CCTGA may </text>
<text top="756" left="105" width="687" height="14" font="11">be  first  diagnosed  in  adulthood,  particularly  if  patients  do  not  have  associated  cardiac  lesions. </text>
<text top="776" left="105" width="687" height="14" font="11">Conduction  abnormalities  are  common,  and  the  prevalence  of  spontaneous  complete  heart  block </text>
<text top="795" left="105" width="687" height="14" font="11">increases  with  age  (S4.4.1.4-7,  S4.4.1.4-8).  PS,  ASD,  and  VSD  are  common.  Seventy  percent  to  90%  of </text>
<text top="815" left="105" width="687" height="14" font="11">patients  with  CCTGA  have  a  dysplastic  or  Ebstein-like  malformation  of  the  tricuspid  valve.  This </text>
<text top="834" left="105" width="687" height="14" font="11">anatomically  abnormal  systemic  atrioventricular  valve  is  at  risk  of  progressive  TR,  which  is  an </text>
<text top="854" left="105" width="433" height="14" font="11">independent predictor of death in CCTGA (S4.4.1.4-4, S4.4.1.4-9).  </text>
<text top="883" left="158" width="634" height="14" font="11">The  systematic  review  report,  “Medical  Therapy  for  Systemic  Right  Ventricles:  A  Systematic </text>
<text top="902" left="105" width="687" height="14" font="11">Review (Part 1) for the 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart </text>
<text top="922" left="105" width="687" height="14" font="11">Disease.”  (S4.4.1.4-10)  addressed  the  role  of  medical  therapies  for  management  of  functional </text>
<text top="941" left="105" width="617" height="14" font="11">deterioration in systemic RVs (S4.4.1.4-11–S4.4.1.4-13) (see additional details in Section 3.17). </text>
<text top="970" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="989" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="1009" left="105" width="340" height="14" font="11">Table 31 for routine testing and follow-up intervals. </text>
<text top="1037" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
</page>
<page number="98" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 100 </text>
<text top="162" left="105" width="687" height="14" font="11">1.  CMR  is  useful  for  quantification  of  systemic  RV  size  and  function  (S4.4.1.4-1,  S4.4.1.4-2). </text>
<text top="182" left="105" width="687" height="14" font="11">Administration of gadolinium contrast is useful in identifying fibrotic myocardium demonstrated by late </text>
<text top="202" left="105" width="261" height="14" font="11">gadolinium enhancement (S4.4.1.4-14). </text>
<text top="230" left="105" width="687" height="14" font="11">2.  Symptomatic  adults  with  CCTGA  and  severe  TR  with  no  more  than  mildly  depressed  systemic </text>
<text top="249" left="105" width="687" height="14" font="11">ventricular  function  should  be  evaluated  for  tricuspid  valve  replacement.  In  general,  tricuspid  valve </text>
<text top="269" left="105" width="687" height="14" font="11">replacement  is  preferred  to  tricuspid  repair  in  the  adult  CCTGA  population.  TR  is  often  because  of  a </text>
<text top="289" left="105" width="687" height="14" font="11">dysplastic  tricuspid  valve  and  has  been  shown  to  be  an  independent  predictor  of  death  in  CCTGA </text>
<text top="308" left="105" width="687" height="14" font="11">patients  (S4.4.1.4-4).  Systemic  RV  dysfunction  is  often  attributable  to  longstanding  TR,  and  efforts </text>
<text top="328" left="105" width="687" height="14" font="11">should be made to relieve the TR before worsening dysfunction (S4.4.1.4-3, S4.4.1.4-9). Tricuspid valve </text>
<text top="348" left="105" width="687" height="14" font="11">repair  has  been  attempted;  however,  recurrent  clinically  significant  TR  is  observed  frequently  after </text>
<text top="367" left="105" width="640" height="14" font="11">tricuspid valve repair in patients with CCTGA; hence, valve replacement is preferred (S4.4.1.4-15). </text>
<text top="395" left="105" width="687" height="14" font="11">3. Many adult CCTGA patients are referred for tricuspid valve replacement late, when symptomatic and </text>
<text top="415" left="105" width="687" height="14" font="11">already  suffering  from  moderate-to-severe  TR  and  ventricular  dysfunction  (S4.4.1.4-16).  In  CCTGA </text>
<text top="435" left="105" width="687" height="14" font="11">patients  referred  for  TVR,  10-year  postoperative  survival  is  &lt;20%  when  the  preoperative  systemic </text>
<text top="454" left="105" width="687" height="14" font="11">ventricular  ejection  fraction  is  &lt;40%  (S4.4.1.4-9)  or  44%  (S4.4.1.4-3).  In  a  retrospective  review  of  46 </text>
<text top="474" left="105" width="687" height="14" font="11">CCTGA patients referred for TR surgery, preoperative systemic ventricular ejection fraction was the only </text>
<text top="493" left="105" width="651" height="14" font="11">independent predictor of postoperative systemic ventricular ejection fraction at 1 year (S4.4.1.4-3). </text>
<text top="522" left="105" width="687" height="14" font="11">4. Adults with CCTGA and pulmonary atresia or stenosis were often managed in childhood by placing a </text>
<text top="541" left="105" width="687" height="14" font="11">conduit  from  the  morphologic  LV  to  the  PA,  and  progressive  conduit  dysfunction  is  common.  Conduit </text>
<text top="561" left="105" width="687" height="14" font="11">intervention  or  replacement  will  diminish  the  pressure  in  the  subpulmonic ventricle  and may  result in </text>
<text top="581" left="105" width="687" height="14" font="11">ventricular septal shift toward the subpulmonic left ventricle, including the septal leaflet of the systemic </text>
<text top="600" left="105" width="521" height="14" font="11">tricuspid valve and thus can result in worsening of TR and a detrimental impact</text>
<text top="599" left="626" width="4" height="16" font="22"> </text>
<text top="600" left="631" width="161" height="14" font="11">on systemic RV function </text>
<text top="620" left="105" width="83" height="14" font="11">(S4.4.1.4-5). </text>
<text top="648" left="105" width="4" height="14" font="11"> </text>
<text top="670" left="105" width="388" height="15" font="14"><b>Table 31. CCTGA: Routine Follow-Up and Testing Intervals </b></text>
<text top="694" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="711" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="694" left="333" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="711" left="330" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="694" left="448" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="711" left="446" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="694" left="563" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="711" left="561" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="694" left="681" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="711" left="678" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="730" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="730" left="321" width="18" height="13" font="8">12 </text>
<text top="730" left="440" width="18" height="13" font="8">12 </text>
<text top="730" left="552" width="33" height="13" font="8">6–12 </text>
<text top="730" left="670" width="25" height="13" font="8">3–6 </text>
<text top="749" left="105" width="27" height="13" font="8">ECG </text>
<text top="749" left="321" width="18" height="13" font="8">12 </text>
<text top="749" left="440" width="18" height="13" font="8">12 </text>
<text top="749" left="552" width="18" height="13" font="8">12 </text>
<text top="749" left="670" width="18" height="13" font="8">12 </text>
<text top="767" left="105" width="32" height="13" font="8">TTE† </text>
<text top="767" left="321" width="40" height="13" font="8">12–24 </text>
<text top="767" left="440" width="18" height="13" font="8">12 </text>
<text top="767" left="552" width="18" height="13" font="8">12 </text>
<text top="767" left="670" width="18" height="13" font="8">12 </text>
<text top="786" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="786" left="321" width="66" height="13" font="8">As needed </text>
<text top="786" left="440" width="66" height="13" font="8">As needed </text>
<text top="786" left="552" width="59" height="13" font="8">Each visit </text>
<text top="786" left="670" width="59" height="13" font="8">Each visit </text>
<text top="804" left="105" width="92" height="13" font="8">Holter monitor </text>
<text top="804" left="321" width="40" height="13" font="8">12–60 </text>
<text top="804" left="440" width="40" height="13" font="8">12–60 </text>
<text top="804" left="552" width="40" height="13" font="8">12–36 </text>
<text top="804" left="670" width="18" height="13" font="8">12 </text>
<text top="823" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="823" left="321" width="40" height="13" font="8">36–60 </text>
<text top="823" left="440" width="40" height="13" font="8">36–60 </text>
<text top="823" left="552" width="40" height="13" font="8">12–24 </text>
<text top="823" left="670" width="18" height="13" font="8">12 </text>
<text top="842" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="839" left="179" width="14" height="18" font="8">║ </text>
<text top="842" left="321" width="40" height="13" font="8">36–60 </text>
<text top="842" left="440" width="40" height="13" font="8">36–60 </text>
<text top="842" left="552" width="40" height="13" font="8">12–24 </text>
<text top="842" left="670" width="18" height="13" font="8">12 </text>
<text top="860" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="876" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="892" left="105" width="686" height="12" font="9">‡CMR may be indicated for assessment of ventricular size and func@on and valvular func@on. Baseline study is recommended </text>
<text top="908" left="105" width="620" height="12" font="9">with periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and physiological findings.  </text>
<text top="924" left="105" width="686" height="12" font="9">§CCT  may  be  used  if  CMR  is  not  feasible.  If  CCT  is  used  instead  of  CMR  imaging,  the  frequency  should  be  weighed  against </text>
<text top="940" left="105" width="110" height="12" font="9">radiation exposure.  </text>
<text top="953" left="105" width="335" height="16" font="9">║6-minute walk test or CPET, depending on clinical indication. </text>
<text top="972" left="105" width="686" height="12" font="9">ACHD  indicates  adult  congenital  heart  disease;  CCT,  cardiac  computed  tomography;  CCTGA,  congenitally  corrected </text>
<text top="988" left="105" width="686" height="12" font="9">transposition  of  the  great  arteries;  CMR,  cardiovascular  magnetic  resonance  imaging;  CPET,  cardiopulmonary  exercise  test; </text>
<text top="1004" left="105" width="348" height="12" font="9">ECG, electrocardiogram; and TTE, transthoracic echocardiogram. </text>
<text top="1022" left="105" width="4" height="16" font="22"> </text>
<text top="1055" left="105" width="4" height="14" font="11"> </text>
<text top="1052" left="315" width="5" height="19" font="34"><b> </b></text>
</page>
<page number="99" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 101 </text>
<text top="163" left="105" width="626" height="19" font="34"><b>4.4.2. Fontan Palliation of Single Ventricle Physiology (Including Tricuspid </b></text>
<text top="188" left="105" width="336" height="19" font="34"><b>Atresia and Double Inlet Left Ventricle) </b></text>
<text top="223" left="158" width="4" height="14" font="11"> </text>
<text top="222" left="211" width="511" height="16" font="12"><b>Recommendations for Fontan Palliation of Single Ventricle Physiology </b></text>
<text top="243" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="243" left="577" width="180" height="14" font="23">Online Data Supplement 48</text>
<text top="243" left="757" width="8" height="14" font="11">. </text>
<text top="263" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="263" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="263" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="283" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="333" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="333" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="304" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="304" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="304" left="281" width="495" height="15" font="14"><b>New  presentation  of  an  atrial  tachyarrhythmia  in  adults  with  Fontan </b></text>
<text top="323" left="281" width="495" height="15" font="14"><b>palliation  should  be  managed  promptly  and  include  prevention  of </b></text>
<text top="343" left="281" width="495" height="15" font="14"><b>thromboembolic  events  and  consultation  with  an  electrophysiologist </b></text>
<text top="363" left="281" width="265" height="15" font="14"><b>with CHD expertise (S4.4.2-1, S4.4.2-2). </b></text>
<text top="393" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="393" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="383" left="255" width="13" height="15" font="14"><b>2.</b></text>
<text top="383" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="383" left="281" width="495" height="15" font="14"><b>Adults  after  Fontan  palliation  should  be  evaluated  annually  with  either </b></text>
<text top="403" left="281" width="181" height="15" font="14"><b>echocardiography or CMR. </b></text>
<text top="453" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="453" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="423" left="255" width="13" height="15" font="14"><b>3.</b></text>
<text top="423" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="423" left="281" width="495" height="15" font="14"><b>Cardiac  catheterization  should  be  performed  in  adults  before  initial </b></text>
<text top="443" left="281" width="495" height="15" font="14"><b>Fontan  surgery  or  revision  of  a  prior  Fontan  connection  to  assess </b></text>
<text top="462" left="281" width="495" height="15" font="14"><b>suitability  of  preintervention  hemodynamics  for  Fontan  physiology  or </b></text>
<text top="482" left="281" width="254" height="15" font="14"><b>revision of a prior Fontan connection. </b></text>
<text top="532" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="532" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="502" left="255" width="13" height="15" font="14"><b>4.</b></text>
<text top="502" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="502" left="281" width="495" height="15" font="14"><b>New  onset  or  worsening  atrial  tachyarrhythmias  in  adults  with  single </b></text>
<text top="522" left="281" width="495" height="15" font="14"><b>ventricle  after  Fontan  palliation  should  prompt  a  search  for  potential </b></text>
<text top="541" left="281" width="495" height="15" font="14"><b>hemodynamic  abnormalities,  which  may  necessitate  imaging  and/or </b></text>
<text top="561" left="281" width="160" height="15" font="14"><b>cardiac catheterization. </b></text>
<text top="591" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="591" left="197" width="27" height="15" font="14"><b>B-R </b></text>
<text top="581" left="255" width="13" height="15" font="14"><b>5.</b></text>
<text top="581" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="581" left="281" width="495" height="15" font="14"><b>In  adults  with  Fontan  palliation,  it  is  reasonable  to  encourage  a  regular </b></text>
<text top="601" left="281" width="445" height="15" font="14"><b>exercise program appropriate to their abilities (S4.4.2-3–S4.4.2-5). </b></text>
<text top="641" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="641" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="621" left="255" width="13" height="15" font="14"><b>6.</b></text>
<text top="621" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="621" left="281" width="495" height="15" font="14"><b>Imaging  of  the  liver  (ultrasonography,  CMR,  CT)  and  laboratory </b></text>
<text top="641" left="281" width="495" height="15" font="14"><b>evaluation  of  liver  function  for  fibrosis,  cirrhosis,  and/or  hepatocellular </b></text>
<text top="660" left="281" width="462" height="15" font="14"><b>carcinoma are reasonable in adults after Fontan palliation (S4.4.2-6). </b></text>
<text top="700" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="700" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="681" left="255" width="13" height="15" font="14"><b>7.</b></text>
<text top="681" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="681" left="281" width="494" height="15" font="14"><b>In adults after Fontan palliation, it is reasonable to perform biochemical </b></text>
<text top="700" left="281" width="495" height="15" font="14"><b>and  hematological  testing  on  an  annual  basis  especially  for  liver  and </b></text>
<text top="720" left="281" width="102" height="15" font="14"><b>renal function. </b></text>
<text top="760" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="760" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="740" left="255" width="13" height="15" font="14"><b>8.</b></text>
<text top="740" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="740" left="281" width="495" height="15" font="14"><b>Cardiac  catheterization  can  be  useful  to  evaluate  a  symptomatic  adult </b></text>
<text top="760" left="281" width="495" height="15" font="14"><b>after  Fontan  palliation  when  noninvasive  testing  is  insufficient  to  guide </b></text>
<text top="780" left="281" width="189" height="15" font="14"><b>therapy (S4.4.2-7, S4.4.2-8). </b></text>
<text top="820" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="820" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="800" left="255" width="13" height="15" font="14"><b>9.</b></text>
<text top="800" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="800" left="281" width="495" height="15" font="14"><b>Evaluation for cardiac transplantation is reasonable in adults with Fontan </b></text>
<text top="820" left="281" width="491" height="15" font="14"><b>palliation and signs and symptoms of protein-losing enteropathy (S4.4.2-</b></text>
<text top="839" left="281" width="91" height="15" font="14"><b>9–S4.4.2-12). </b></text>
<text top="889" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="889" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="859" left="255" width="21" height="15" font="14"><b>10.</b></text>
<text top="860" left="275" width="4" height="15" font="24"><b> </b></text>
<text top="859" left="281" width="495" height="15" font="14"><b>It may be reasonable to perform catheterization in asymptomatic adults </b></text>
<text top="879" left="281" width="495" height="15" font="14"><b>after  Fontan  palliation  to  evaluate  hemodynamics,  oxygenation  and </b></text>
<text top="899" left="281" width="495" height="15" font="14"><b>cardiac function to guide optimal medical, interventional and/or surgical </b></text>
<text top="918" left="281" width="60" height="15" font="14"><b>therapy. </b></text>
<text top="939" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="988" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="988" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="959" left="255" width="21" height="15" font="14"><b>11.</b></text>
<text top="959" left="275" width="4" height="15" font="24"><b> </b></text>
<text top="959" left="281" width="495" height="15" font="14"><b>Anticoagulation  with  a  vitamin  K  antagonist  is  recommended  for  adults </b></text>
<text top="978" left="281" width="495" height="15" font="14"><b>with  Fontan  palliation  with  known  or  suspected  thrombus, </b></text>
<text top="998" left="281" width="266" height="15" font="14"><b>thromboembolic  events,  or  prior </b></text>
<text top="998" left="561" width="39" height="15" font="14"><b>atrial </b></text>
<text top="998" left="615" width="161" height="15" font="14"><b>arrhythmia,  and  no </b></text>
<text top="1018" left="281" width="250" height="15" font="14"><b>contraindications to anticoagulation. </b></text>
<text top="1057" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="1057" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="1038" left="255" width="21" height="15" font="14"><b>12.</b></text>
<text top="1038" left="275" width="4" height="15" font="24"><b> </b></text>
<text top="1038" left="281" width="495" height="15" font="14"><b>Catheter  ablation  can  be  useful  in  adults  after  Fontan  palliation  with </b></text>
<text top="1057" left="281" width="491" height="15" font="14"><b>intra-atrial  reentrant  tachycardia  or  focal  atrial  tachycardia  (S4.4.2-13–</b></text>
<text top="1077" left="281" width="78" height="15" font="14"><b>S4.4.2-15).  </b></text>
</page>
<page number="100" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 102 </text>
<text top="202" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="202" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="163" left="255" width="21" height="15" font="14"><b>13.</b></text>
<text top="163" left="275" width="4" height="15" font="24"><b> </b></text>
<text top="163" left="281" width="495" height="15" font="14"><b>Fontan  revision  surgery,  including  arrhythmia  surgery  as  indicated,  is </b></text>
<text top="183" left="281" width="495" height="15" font="14"><b>reasonable  for  adults  with  atriopulmonary  Fontan  connections  with </b></text>
<text top="202" left="281" width="495" height="15" font="14"><b>recurrent  atrial  tachyarrhythmias  refractory  to  pharmacological  therapy </b></text>
<text top="222" left="281" width="495" height="15" font="14"><b>and  catheter  ablation  who  have  preserved  systolic  ventricular  function </b></text>
<text top="241" left="281" width="319" height="15" font="14"><b>and severe atrial dilation (S4.4.2-16–S4.4.2-18). </b></text>
<text top="271" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="271" left="197" width="27" height="15" font="14"><b>B-R </b></text>
<text top="262" left="255" width="21" height="15" font="14"><b>14.</b></text>
<text top="262" left="275" width="4" height="15" font="24"><b> </b></text>
<text top="262" left="281" width="494" height="15" font="14"><b>Pulmonary vasoactive medications can be beneficial to improve exercise </b></text>
<text top="281" left="281" width="397" height="15" font="14"><b>capacity in adults with Fontan repair (S4.4.2-19–S4.4.2-25). </b></text>
<text top="331" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="331" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="302" left="255" width="21" height="15" font="14"><b>15.</b></text>
<text top="302" left="275" width="4" height="15" font="24"><b> </b></text>
<text top="302" left="281" width="495" height="15" font="14"><b>Antiplatelet therapy or anticoagulation with a vitamin K antagonist may </b></text>
<text top="321" left="281" width="495" height="15" font="14"><b>be  considered  in  adults  after  Fontan  palliation  without  known  or </b></text>
<text top="341" left="281" width="495" height="15" font="14"><b>suspected  thrombus,  thromboembolic  events,  or  prior  arrhythmia </b></text>
<text top="360" left="281" width="80" height="15" font="14"><b>(S4.4.2-26). </b></text>
<text top="400" left="124" width="21" height="15" font="14"><b>IIb </b></text>
<text top="400" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="381" left="255" width="21" height="15" font="14"><b>16.</b></text>
<text top="381" left="275" width="4" height="15" font="24"><b> </b></text>
<text top="381" left="281" width="495" height="15" font="14"><b>Reoperation  or  intervention  for  structural/anatomic  abnormalities  in  a </b></text>
<text top="400" left="281" width="495" height="15" font="14"><b>Fontan  palliated  patient  with  symptoms  or  with  failure  of  the  Fontan </b></text>
<text top="420" left="281" width="284" height="15" font="14"><b>circulation may be considered (S4.4.2-27). </b></text>
<text top="449" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="478" left="105" width="687" height="14" font="11">Fontan  repairs  are  the  most  common  palliation  of  single  ventricle  physiology  seen  in  adults.  The </text>
<text top="497" left="105" width="687" height="14" font="11">physiology  is  complex,  with  long-term  consequences  related  to  the  obligatory  elevation  in  central </text>
<text top="517" left="105" width="687" height="14" font="11">venous pressure and reduced cardiac output. Proposed medical therapy for the “failing Fontan,” which </text>
<text top="536" left="105" width="687" height="14" font="11">may  manifest  as  protein-losing  enteropathy,  hepatic  dysfunction,  lower  extremity  venous  congestion, </text>
<text top="556" left="105" width="687" height="14" font="11">and/or  exercise  limitation,  has  included  many  different  modalities,  although  there  is  limited  proven </text>
<text top="576" left="105" width="687" height="14" font="11">benefit  in  published  research.  Options  for  medical  therapy  include  aldosterone  antagonists  or </text>
<text top="595" left="105" width="687" height="14" font="11">subcutaneous  unfractionated  heparin,  which  may  stabilize  the  proteoglycan  layer  of  the  gut.  PAH </text>
<text top="615" left="105" width="687" height="14" font="11">therapies  are  of  increasing  interest.  Endothelin  antagonists  have  been  studied  in  a  single  RCT,  which </text>
<text top="634" left="105" width="687" height="14" font="11">showed  improved  exercise  capacity  in  75  subjects  randomized  to  bosentan  compared  with  placebo </text>
<text top="654" left="105" width="683" height="14" font="11">(S4.4.2-19). Two other small nonrandomized studies demonstrated minimal response to therapy (S4.4.2-</text>
<text top="674" left="105" width="101" height="14" font="11">22, S4.4.2-23).  </text>
<text top="702" left="158" width="634" height="14" font="11">Corticosteroids,  specifically  budesonide,  may  be  helpful  for  Fontan  patients  with </text>
<text top="722" left="105" width="687" height="14" font="11">hypoalbuminemia  in  the  setting  of  protein-losing  enteropathy  poorly  responsive  to  other  therapies. </text>
<text top="741" left="105" width="687" height="15" font="11">Budesonide  seems to  have fewer systemic effects  than other oral steroids; however, close monitoring </text>
<text top="760" left="105" width="687" height="15" font="11">for signs of hypercortisolism remains necessary (S4.4.2-28, S4.4.2-29). Octreotide may be considered; it </text>
<text top="780" left="105" width="687" height="15" font="11">is  a  therapy  with  favorable  but  very  limited  anecdotal  experience  reported,  with  further  research </text>
<text top="800" left="105" width="687" height="15" font="11">needed (S4.4.2-28, S4.4.2-30). A combination of these therapies may be applied in an affected patient, </text>
<text top="819" left="105" width="687" height="15" font="11">as  such  strategies  collectively  appear  to  have  produced  improved  outcome  compared  with  historic </text>
<text top="839" left="105" width="135" height="15" font="11">controls (S4.4.2-31). </text>
<text top="867" left="158" width="634" height="15" font="11">Fontan  surgery  has  been  associated  with  prolongation  of  atrial  refractory  periods,  extensive </text>
<text top="887" left="105" width="687" height="15" font="11">atrial scarring, and intra-atrial conduction delay (S4.4.2-32–S4.4.2-38). Sinus node dysfunction occurs in </text>
<text top="906" left="105" width="687" height="15" font="11">up  to  45%  of  adults  during  long-term  follow-up  after  Fontan  surgery  and  has  been  associated  with  a </text>
<text top="926" left="105" width="687" height="15" font="11">reduction  in  preload  to  the  single  ventricle,  increased  pulmonary  venous  pressure,  reduced  cardiac </text>
<text top="945" left="105" width="687" height="15" font="11">output,  plastic  bronchitis,  and  protein-losing  enteropathy  (S4.4.2-39–S4.4.2-43).  Transvenous  atrial </text>
<text top="965" left="105" width="687" height="15" font="11">pacing  may  be  feasible  in  most  adults  with  atriopulmonary  Fontan  connections  and  in  some  with </text>
<text top="985" left="105" width="687" height="15" font="11">intracardiac  lateral  tunnels  (S4.4.2-44),  although  the  potential  for  thrombotic  complications  must  be </text>
<text top="1004" left="105" width="687" height="15" font="11">addressed. Ventricular  pacing may be performed  via the coronary sinus in selected  patients, but most </text>
<text top="1024" left="105" width="687" height="15" font="11">require an epicardial approach (S4.4.2-45, S4.4.2-46). Management of atrial arrhythmias is discussed in </text>
<text top="1044" left="105" width="225" height="15" font="11">the associated recommendations. </text>
</page>
<page number="101" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 103 </text>
<text top="162" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization  and </text>
<text top="182" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="202" left="105" width="340" height="14" font="11">Table 32 for routine testing and follow-up intervals. </text>
<text top="230" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="258" left="105" width="687" height="14" font="11">1. Atrial tachyarrhythmias occur in up to 60% of adults with Fontan palliation and  are  associated with </text>
<text top="278" left="105" width="687" height="14" font="11">substantial morbidity and mortality (S4.4.2-2). These arrhythmias may be difficult to manage, are usually </text>
<text top="297" left="105" width="687" height="14" font="11">poorly tolerated, and cause serious hemodynamic compromise often with dire consequences (S4.4.2-1). </text>
<text top="317" left="105" width="687" height="14" font="11">Therefore, they should be addressed promptly, including urgent consultation with ACHD providers who </text>
<text top="337" left="105" width="687" height="14" font="11">can  help  guide  immediate management  strategies,  even if  remotely.  Consideration  for  antithrombotic </text>
<text top="356" left="105" width="687" height="14" font="11">therapy  in  Fontan  patients  should  take  into  account  the  high  prevalence  of  thrombus  formation  and </text>
<text top="376" left="105" width="687" height="14" font="11">potentially  catastrophic  impact  of  pulmonary  or  systemic  thromboembolus.  Standard  decision-making </text>
<text top="395" left="105" width="687" height="14" font="11">strategies  about  rhythm  versus  rate  control  or  thromboembolic  prophylaxis  derived  from  and </text>
<text top="415" left="105" width="687" height="14" font="11">recommended  for  patients  with  acquired  heart  disease  and  AF  do  not  apply  to  patients  with  Fontan </text>
<text top="435" left="105" width="687" height="14" font="11">physiology,  for  whom  rhythm  control  and  anticoagulation  are  of  greater  importance  than  would  be </text>
<text top="454" left="105" width="364" height="14" font="11">concluded from application of the standard algorithms. </text>
<text top="483" left="158" width="634" height="14" font="11">Sinus  node  dysfunction  may  predispose  Fontan  patients  to  atrial  tachyarrhythmias,  the  most </text>
<text top="502" left="105" width="687" height="14" font="11">common  being  macro-reentrant  circuits  or  intra-atrial  reentrant  tachycardia  (S4.4.2-13,  S4.4.2-47). </text>
<text top="522" left="105" width="687" height="14" font="11">Nearly  90%  of  Fontan  patients  who  die  from  HF  have  coexisting  atrial  tachyarrhythmias  (S4.4.2-48). </text>
<text top="541" left="105" width="687" height="14" font="11">Fontan patients are at increased risk of complications from antiarrhythmic therapy, such as torsades de </text>
<text top="561" left="105" width="687" height="14" font="11">pointes  with  dofetilide  (S4.4.2-49)  and  amiodarone-induced  thyrotoxicosis  (S4.4.2-50).  Such  agents </text>
<text top="581" left="105" width="687" height="14" font="11">should be used cautiously and in consultation with ACHD cardiologists and electrophysiology specialists </text>
<text top="600" left="105" width="158" height="14" font="11">with expertise in ACHD. </text>
<text top="629" left="105" width="687" height="14" font="11">2. Serial imaging can be valuable for assessing many of the long-term sequelae of Fontan palliation such </text>
<text top="648" left="105" width="687" height="14" font="11">as  thrombosis,  right-to-left  shunts  (e.g.,  fenestration,  intrapulmonary  AV  malformation),  obstructive </text>
<text top="668" left="105" width="687" height="14" font="11">lesions,  systemic  AV valve dysfunction,  diastolic  or  systolic  ventricular  function, collateral  burden,  and </text>
<text top="687" left="105" width="687" height="14" font="11">branch  PA  obstruction.  Imaging  can  be  challenging  and  requires  informed  understanding  about  the </text>
<text top="707" left="105" width="687" height="14" font="11">patient's  particular  situation.  Although  CCT  is  possible  in  patients  with  Fontan  physiology,  it  is </text>
<text top="727" left="105" width="687" height="14" font="11">challenging  to  ensure  contrast  dispersal  through  the  pulmonary  vasculature  because  of  streaming  of </text>
<text top="746" left="105" width="687" height="14" font="11">venous  return  to  the  PA  from  multiple  separate  sources  (e.g.,  superior  vena  cava,  inferior  vena  cava </text>
<text top="766" left="105" width="304" height="14" font="11">right atrium collaterals) (S4.4.2-51, S4.4.2-52). </text>
<text top="794" left="105" width="687" height="14" font="11">3.  Hemodynamic  assessment,  particularly  of  the  pulmonary  circulation,  is  crucial  to  making  informed </text>
<text top="814" left="105" width="396" height="14" font="11">decisions about the type and timing of surgical intervention. </text>
<text top="842" left="105" width="687" height="14" font="11">4. Hemodynamic problems may first manifest through arrhythmia. Thus, first presentation of arrhythmia </text>
<text top="862" left="105" width="605" height="14" font="11">should warrant thorough review of the patient’s Fontan circulation and ventricular function. </text>
<text top="890" left="105" width="687" height="14" font="11">5. Aerobic exercise may help maintain respiratory mechanics, which can improve transpulmonary flow in </text>
<text top="910" left="105" width="687" height="14" font="11">the  Fontan  circulation.  Stroke  volume  during  exercise  and  exercise  capacity  are  directly  related  to </text>
<text top="929" left="105" width="687" height="14" font="11">skeletal muscle function. Consequently, strength training may improve exercise capacity in patients with </text>
<text top="949" left="105" width="118" height="14" font="11">Fontan palliation. </text>
<text top="977" left="105" width="687" height="14" font="11">6.  There  is  increasing  recognition  of  hepatic  vulnerability  after  Fontan  palliation,  including  cirrhosis </text>
<text top="997" left="105" width="687" height="14" font="11">(S4.4.2-6,  S4.4.2-53)  but  uncertainty  about  which  patients  are  at  highest  risk,  or  how  to  address </text>
<text top="1017" left="105" width="687" height="14" font="11">problems when identified. Routine assessment of liver function and structure may help inform broader </text>
<text top="1036" left="105" width="687" height="14" font="11">decisions  such  as  timing  and  risk  of  surgery  or  transplantation,  as  well  as  provide  insights  into  the </text>
<text top="1056" left="105" width="687" height="14" font="11">emerging natural history of  this unique condition. Consultation with a hepatologist may be  of value in </text>
<text top="1075" left="105" width="644" height="14" font="11">interpreting and following the liver abnormalities encountered in patients with Fontan physiology. </text>
</page>
<page number="102" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 104 </text>
<text top="162" left="105" width="687" height="14" font="11">7.  Recognizing  the  multiorgan  vulnerability  of  the  Fontan  circulation,  annual  routine  blood  tests  may </text>
<text top="182" left="105" width="372" height="14" font="11">have a role in identifying and addressing problems early. </text>
<text top="210" left="105" width="687" height="14" font="11">8. Because of both the anatomic and physiological complexities of these patients, and the potential for </text>
<text top="229" left="105" width="687" height="15" font="11">concurrent  intervention,  hemodynamic  and  interventional  cardiac  catheterization  of  the  adult  with </text>
<text top="249" left="105" width="687" height="15" font="11">single  ventricle/Fontan  palliation  should  be  performed  only  by  persons  with  expertise  in  CHD  in </text>
<text top="268" left="105" width="687" height="15" font="11">coordination  with  an  ACHD  cardiologist.  Recognizing  that  it  is  difficult  to  accurately  assess  Fontan </text>
<text top="288" left="105" width="687" height="15" font="11">hemodynamics by clinical examination or noninvasive imaging, cardiac catheterization may be needed in </text>
<text top="308" left="105" width="183" height="15" font="11">these scenarios and others: </text>
<text top="336" left="131" width="12" height="15" font="11">a.</text>
<text top="337" left="143" width="4" height="15" font="26"> </text>
<text top="336" left="158" width="634" height="15" font="11">Interval  hemodynamic  assessment,  as  filling  pressures,  mean  PA  pressure,  and  pulmonary </text>
<text top="356" left="158" width="342" height="15" font="11">vascular resistance may change over time (S4.4.2-8) </text>
<text top="375" left="131" width="13" height="15" font="11">b.</text>
<text top="376" left="144" width="4" height="15" font="26"> </text>
<text top="375" left="158" width="634" height="15" font="11">Creation or closure of a fenestration or veno-veno collaterals, although with uncertain benefit of </text>
<text top="395" left="158" width="271" height="15" font="11">either intervention (S4.4.2-54–S4.4.2-56) </text>
<text top="415" left="131" width="11" height="15" font="11">c.</text>
<text top="415" left="142" width="4" height="15" font="26"> </text>
<text top="415" left="158" width="615" height="15" font="11">Treatment of baffle obstruction, even in the setting of low or no pressure gradient (S4.4.2-57) </text>
<text top="434" left="131" width="13" height="15" font="11">d.</text>
<text top="435" left="144" width="4" height="15" font="26"> </text>
<text top="434" left="158" width="634" height="15" font="11">Assessment  of  protein-losing  enteropathy  or  ascites,  because  elevated  Fontan  pressure </text>
<text top="454" left="158" width="634" height="15" font="11">correlates with  such  complications,  and  lowering  pressures  may  offer  the  potential  for  clinical </text>
<text top="473" left="158" width="167" height="15" font="11">improvement (S4.4.2-58) </text>
<text top="493" left="131" width="12" height="15" font="11">e.</text>
<text top="493" left="143" width="4" height="15" font="26"> </text>
<text top="493" left="158" width="634" height="15" font="11">Facilitation  of  transvenous  liver  biopsy  for  monitoring  liver  function  including  as  part  of  a </text>
<text top="513" left="158" width="205" height="15" font="11">pretransplantation assessment </text>
<text top="532" left="131" width="9" height="15" font="11">f.</text>
<text top="533" left="140" width="4" height="15" font="26"> </text>
<text top="532" left="158" width="466" height="15" font="11">Preoperative assessment before Fontan revision (S4.4.2-18, S4.4.2-59). </text>
<text top="561" left="105" width="687" height="15" font="11">9. Protein-losing enteropathy  and plastic bronchitis contribute substantially to perioperative mortality, </text>
<text top="580" left="105" width="687" height="15" font="11">yet transplantation may be curative (S4.4.2-9, S4.4.2-11). Medical therapy options are often ineffective. </text>
<text top="600" left="105" width="687" height="15" font="11">Therefore, consideration of transplantation early in the course of PLE may be warranted. Evaluation of </text>
<text top="619" left="105" width="687" height="15" font="11">additional  organs  is  necessary,  particularly  the liver, as  these  patients  are susceptible  to  cirrhosis  as  a </text>
<text top="639" left="105" width="687" height="15" font="11">consequence of the Fontan circulation. Although symptoms may improve, there are no published data </text>
<text top="659" left="105" width="687" height="15" font="11">regarding impact on survival for transplanted Fontan patients with PLE compared with those who do not </text>
<text top="678" left="105" width="167" height="15" font="11">undergo transplantation. </text>
<text top="707" left="105" width="687" height="15" font="11">10. Although catheterization plays an important role in management of single ventricle/Fontan patients, </text>
<text top="726" left="105" width="601" height="15" font="11">it is often driven by symptoms. The role of routine hemodynamic assessment is less certain. </text>
<text top="755" left="105" width="687" height="15" font="11">11. Fontan circulation imparts risk of thrombosis, and anticoagulation with vitamin K antagonists should </text>
<text top="774" left="105" width="687" height="15" font="11">be  offered  as  preventive  therapy  in  clinical  situations  including  prior  arrhythmia  (S4.4.2-60).  Patients </text>
<text top="794" left="105" width="687" height="15" font="11">may also benefit from anticoagulation if they have significant residual intracardiac right- to -left shunt or </text>
<text top="814" left="105" width="147" height="15" font="11">veno-veno collaterals. </text>
<text top="842" left="105" width="687" height="15" font="11">12. Catheter ablation has been associated with improved clinical status despite the frequent coexistence </text>
<text top="861" left="105" width="687" height="15" font="11">of  multiple  arrhythmia  substrates  (S4.4.2-61).  Given  the  progressive  nature  of  the  atrial  myopathy, </text>
<text top="881" left="105" width="687" height="15" font="11">successful  ablation  is  less  frequent  than  in  acquired  heart  disease  or  other  congenital  heart  diseases, </text>
<text top="900" left="105" width="687" height="15" font="11">and  recurrence is  common. The  development  of  new  arrhythmias  over  time  remains  problematic,  but </text>
<text top="920" left="105" width="579" height="15" font="11">multiple ablation procedures may be justified in selected patients (S4.4.2-13, S4.4.2-14). </text>
<text top="949" left="105" width="687" height="15" font="11">13. Conversion to a total cavopulmonary connection Fontan combined with a modified right atrial Maze </text>
<text top="968" left="105" width="687" height="15" font="11">procedure  may  be  considered  in  patients  with  symptomatic  refractory  recurrent  intra-atrial  reentrant </text>
<text top="988" left="105" width="687" height="15" font="11">tachycardia (S4.4.2-16, S4.4.2-17). In the presence of documented AF, a left atrial Cox Maze procedure </text>
<text top="1007" left="105" width="687" height="15" font="11">may also be indicated (S4.4.2-16, S4.4.2-62). Some patients may not be appropriate surgical candidates </text>
<text top="1027" left="105" width="687" height="15" font="11">for reasons of elevated PA or Fontan pressures, elevated ventricular end-diastolic pressures, or renal or </text>
<text top="1047" left="105" width="644" height="15" font="11">hepatic dysfunction, and the decision to perform Fontan revision surgery is rarely straightforward. </text>
</page>
<page number="103" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 105 </text>
<text top="162" left="105" width="687" height="14" font="11">14. Pulmonary vasoactive medications, specifically endothelin receptor antagonists and PDE-5 inhibitors, </text>
<text top="182" left="105" width="687" height="14" font="11">are of increasing interest as a means of reducing pulmonary vascular resistance and improving cardiac </text>
<text top="202" left="105" width="687" height="14" font="11">output.  In  limited  studies,  use  of  PDE-5  inhibitors  appears  favorable  for  Fontan  patients  with </text>
<text top="221" left="105" width="687" height="14" font="11">improvement  noted  in  pulmonary  blood  flow  and  exercise  capacity  (S4.4.2-21,  S4.4.2-63).  Use  of </text>
<text top="241" left="105" width="687" height="14" font="11">endothelin  antagonists  has  been  investigated  in  a  randomized  trial  (S4.4.2-19).  After  14  weeks  of </text>
<text top="260" left="105" width="687" height="14" font="11">randomization  in  69  subjects  successfully  completing  the  study,  there  was  a  modest  but  significant </text>
<text top="280" left="105" width="687" height="14" font="11">increase  in  peak  oxygen  consumption  and  exercise  duration  in  those  taking  bosentan  compared  with </text>
<text top="299" left="105" width="124" height="14" font="11">those on placebo.  </text>
<text top="328" left="105" width="687" height="14" font="11">15.  Although  anticoagulation  is  prudent  in  those  with  prior  arrhythmia  or  known  thromboembolic </text>
<text top="348" left="105" width="687" height="14" font="11">events,  routine  use  of  anticoagulation  with  vitamin  K  antagonist  cannot  as  yet  be  strongly </text>
<text top="367" left="105" width="687" height="14" font="11">recommended. An RCT in Fontan children/adolescents did not show benefit (S4.4.2-64), although adults </text>
<text top="387" left="105" width="687" height="14" font="11">later after Fontan may be more at risk. However, a secondary analysis of that RCT as an observational </text>
<text top="406" left="105" width="687" height="14" font="11">study  (S4.4.2-65)  found  the  risk  of  thromboembolism  was  lower  in  those  patients  on  warfarin  who </text>
<text top="426" left="105" width="687" height="14" font="11">consistently  achieved  minimum  target  international  normalized  ratio  levels,  as  well  as  in  those  on </text>
<text top="446" left="105" width="687" height="14" font="11">acetylsalicylic  acid  compared  with  patients  who  often  failed  to  meet  target  international  normalized </text>
<text top="465" left="105" width="687" height="14" font="11">ratio  level.  Rates  of  thrombosis  were  considerably  higher  in  patients  on  warfarin  who  did  not </text>
<text top="485" left="105" width="687" height="14" font="11">consistently achieve target international normalized ratio. A study of modes of death in atriopulmonary </text>
<text top="504" left="105" width="687" height="14" font="11">Fontan  patients  demonstrated  lower  rates  of  death  in  patients  on  “some”  antiplatelet  agent  or </text>
<text top="524" left="105" width="687" height="14" font="11">anticoagulation compared with those on none (S4.4.2-1). Direct oral anticoagulants  are unstudied and </text>
<text top="544" left="105" width="687" height="14" font="11">thus cannot be recommended at the present time. There are concerns about liver function vulnerability </text>
<text top="563" left="105" width="687" height="14" font="11">in  Fontan  patients,  which  theoretically  may  increase  the  risk  of  complications  with  some  of  those </text>
<text top="583" left="105" width="51" height="14" font="11">agents. </text>
<text top="611" left="105" width="687" height="14" font="11">16. There are occasions where surgery or catheter intervention may be alternatives to transplantation </text>
<text top="631" left="105" width="687" height="14" font="11">for  a  “failing  Fontan”  after  weighing  risks  and  benefits  of  the  intended  procedure  (i.e.,  alleviation  of </text>
<text top="650" left="105" width="687" height="14" font="11">atrioventricular  valve  regurgitation,  systemic  or  pulmonary  venous  pathway  obstruction).  Reoperation </text>
<text top="670" left="105" width="687" height="14" font="11">for atrioventricular valve regurgitation may be high-risk, particularly when systemic ventricular function </text>
<text top="689" left="105" width="687" height="14" font="11">is  impaired.  Although  valve  repair  is  preferred  and  operative  risk  is  usually  lower,  it  is  not  always </text>
<text top="709" left="105" width="372" height="14" font="11">possible. Risk of valve replacement in this setting is high. </text>
<text top="737" left="105" width="4" height="14" font="11"> </text>
<text top="766" left="105" width="456" height="15" font="14"><b>Table 32. Fontan Palliation: Routine Follow-Up and Testing Intervals </b></text>
<text top="789" left="107" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="807" left="170" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="789" left="331" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="807" left="328" width="88" height="13" font="7"><b>Stage A* (mo) </b></text>
<text top="789" left="445" width="85" height="13" font="7"><b>Physiologic al </b></text>
<text top="807" left="444" width="88" height="13" font="7"><b>Stage B* (mo) </b></text>
<text top="789" left="564" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="807" left="562" width="87" height="13" font="7"><b>Stage C* (mo) </b></text>
<text top="789" left="682" width="82" height="13" font="7"><b>Physiological </b></text>
<text top="807" left="678" width="89" height="13" font="7"><b>Stage D* (mo) </b></text>
<text top="825" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="825" left="321" width="18" height="13" font="8">12 </text>
<text top="825" left="436" width="18" height="13" font="8">12 </text>
<text top="825" left="553" width="11" height="13" font="8">6 </text>
<text top="825" left="670" width="25" height="13" font="8">3–6 </text>
<text top="844" left="105" width="27" height="13" font="8">ECG </text>
<text top="844" left="321" width="18" height="13" font="8">12 </text>
<text top="844" left="436" width="18" height="13" font="8">12 </text>
<text top="844" left="553" width="33" height="13" font="8">6–12 </text>
<text top="844" left="670" width="11" height="13" font="8">6 </text>
<text top="862" left="105" width="32" height="13" font="8">TTE† </text>
<text top="862" left="321" width="18" height="13" font="8">12 </text>
<text top="862" left="436" width="18" height="13" font="8">12 </text>
<text top="862" left="553" width="18" height="13" font="8">12 </text>
<text top="862" left="670" width="18" height="13" font="8">12 </text>
<text top="881" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="881" left="321" width="18" height="13" font="8">12 </text>
<text top="881" left="436" width="18" height="13" font="8">12 </text>
<text top="881" left="553" width="58" height="13" font="8">Each visit </text>
<text top="881" left="670" width="59" height="13" font="8">Each visit </text>
<text top="899" left="105" width="92" height="13" font="8">Holter monitor </text>
<text top="899" left="321" width="18" height="13" font="8">12 </text>
<text top="899" left="436" width="18" height="13" font="8">12 </text>
<text top="899" left="553" width="18" height="13" font="8">12 </text>
<text top="899" left="670" width="18" height="13" font="8">12 </text>
<text top="918" left="105" width="74" height="13" font="8">CMR‡/CCT§ </text>
<text top="918" left="321" width="18" height="13" font="8">36 </text>
<text top="918" left="436" width="18" height="13" font="8">24 </text>
<text top="918" left="553" width="18" height="13" font="8">24 </text>
<text top="918" left="670" width="18" height="13" font="8">24 </text>
<text top="937" left="105" width="74" height="13" font="8">Exercise test</text>
<text top="934" left="179" width="14" height="18" font="8">║ </text>
<text top="937" left="321" width="18" height="13" font="8">36 </text>
<text top="937" left="436" width="18" height="13" font="8">24 </text>
<text top="937" left="553" width="18" height="13" font="8">12 </text>
<text top="937" left="670" width="18" height="13" font="8">12 </text>
<text top="955" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="971" left="105" width="657" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise.  </text>
<text top="987" left="105" width="686" height="12" font="9">‡CMR  may  be  indicated  for  assessment  of  the  long-term  sequelae  of  Fontan  palliation:  thrombosis,  right-to-left  shunts  (e.g., </text>
<text top="1003" left="105" width="686" height="12" font="9">fenestration.  intrapulmonary  atrioventricular  malformation),  obstructive  lesion,  systemic  atrioventricular  valve  dysfunction, </text>
<text top="1019" left="105" width="686" height="12" font="9">ventricular size and function, collateral burden, and branch pulmonary artery obstruction. Baseline study is recommended with </text>
<text top="1035" left="105" width="594" height="12" font="9">periodic follow-up CMR, with frequency of repeat imaging determined by anatomic and physiological findings.  </text>
<text top="1051" left="105" width="686" height="12" font="9">§CCT may be used if CMR is not feasible and to evaluate cross-sectional imaging status-post stent therapy. CCT with contrast </text>
<text top="1067" left="105" width="686" height="12" font="9">injection in Fontan patients can be misleading; therefore, it should be done only when clinically indicated and when it can be </text>
</page>
<page number="104" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 106 </text>
<text top="162" left="105" width="686" height="12" font="9">appropriately  protocoled  and  interpreted.  If  CCT  is  used  instead  of  CMR  imaging,  the  frequency  should  be  weighed  against </text>
<text top="178" left="105" width="110" height="12" font="9">radiation exposure.  </text>
<text top="191" left="105" width="335" height="16" font="9">║6-minute walk test or CPET, depending on clinical indication. </text>
<text top="210" left="105" width="686" height="12" font="9">ACHD  indicates  adult congenital heart disease;  CCT, cardiac computed tomography; CMR, cardiovascular  magnetic resonance </text>
<text top="226" left="105" width="597" height="12" font="9">imaging; CPET, cardiopulmonary exercise test; ECG, electrocardiogram; and TTE, transthoracic echocardiogram. </text>
<text top="261" left="105" width="485" height="19" font="34"><b>4.4.3. Hypoplastic Left Heart Syndrome/Norwood Repair </b></text>
<text top="294" left="105" width="687" height="14" font="11">The Norwood repair is the first of 3 steps in palliation for hypoplastic left heart syndrome and consists of </text>
<text top="313" left="105" width="687" height="14" font="11">atrial septectomy, transection, and ligation of the distal main PA with construction of a systemic-to-PA </text>
<text top="333" left="105" width="687" height="14" font="11">shunt, and anastomosis of the proximal stump of the main PA to the hypoplastic ascending aorta with </text>
<text top="353" left="105" width="687" height="14" font="11">augmentation of the entire  aortic arch from the sinotubular junction to beyond the ductus  arteriosus. </text>
<text top="372" left="105" width="687" height="14" font="11">Hypoplastic  left  heart  syndrome  is  fatal  unless  surgical  palliation  is  performed  in  the  neonatal  period. </text>
<text top="392" left="105" width="687" height="14" font="11">Subsequent  surgeries  include  a  bidirectional  cavopulmonary  anastomosis  (often  performed  around  6 </text>
<text top="411" left="105" width="687" height="14" font="11">months  of  age),  followed  finally  by  a  Fontan  procedure  (often  at  approximately  2  to  4  years  of  age). </text>
<text top="431" left="105" width="687" height="14" font="11">Sequelae  of  hypoplastic  left  heart  syndrome  are  largely  those  of  the  Fontan  palliation,  but  additional </text>
<text top="451" left="105" width="687" height="14" font="11">concerns  related  to  the  underlying  anatomy  and  the  Norwood  repair  is  important  in  patients  with </text>
<text top="470" left="105" width="687" height="14" font="11">hypoplastic left heart syndrome. These include aortic obstruction related to anastomosis of the PA and </text>
<text top="490" left="105" width="687" height="14" font="11">aorta, and neoaortic dilation. Additionally, native anatomy wherein coronary arteries arise from a small </text>
<text top="509" left="105" width="687" height="14" font="11">aortic root make coronary ischemia a greater concern than in other underlying disorders managed with </text>
<text top="529" left="105" width="687" height="14" font="11">Fontan  repair.  The  frequency  and  spectrum  of  long-term  sequelae  specific  to  the  Norwood  repair  are </text>
<text top="549" left="105" width="26" height="14" font="11">not </text>
<text top="549" left="424" width="24" height="14" font="11">yet </text>
<text top="549" left="740" width="48" height="14" font="11">known.</text>
<text top="587" left="105" width="216" height="19" font="34"><b>4.4.4. Truncus Arteriosus </b></text>
<text top="619" left="105" width="687" height="14" font="11">Truncus  arteriosus  in  the  adult  has  almost  invariably  been  repaired  in  childhood,  and  in  the  rare </text>
<text top="639" left="105" width="687" height="14" font="11">circumstances  when  an  adult  has  unrepaired  truncus  arteriosus,  Eisenmenger  physiology  is  typical. </text>
<text top="659" left="105" width="687" height="14" font="11">Pulmonary hypertension may be present in repaired patients. The types of operative repairs may involve </text>
<text top="678" left="105" width="687" height="14" font="11">VSD  closure,  right  ventricle–to-PA  conduit  placement,  reconstruction  of  the  pulmonary  arteries,  and </text>
<text top="698" left="105" width="687" height="14" font="11">replacement  of  the  truncal  (neoaortic)  valve.  Unifocalization  of  the  pulmonary  arteries  may  be </text>
<text top="717" left="105" width="687" height="14" font="11">necessary  in  very  complex  cases.  The  aorta  may  be  dilated.  Recommendations  regarding  assessment </text>
<text top="737" left="105" width="687" height="14" font="11">and  management  of  truncus  arteriosus  can  generally  be  inferred  in  the  recommendations  for  the </text>
<text top="757" left="105" width="687" height="14" font="11">specific  components,  including  right  ventricle–to-PA  conduit,  VSD,  aortic  valve  disease,  and </text>
<text top="776" left="105" width="88" height="14" font="11">aortopathies.</text>
<text top="814" left="105" width="307" height="19" font="34"><b>4.4.5. Double Outlet Right Ventricle </b></text>
<text top="851" left="105" width="687" height="14" font="11">Double outlet right ventricle is an anatomic descriptor that includes abnormalities similar to TOF in some </text>
<text top="870" left="105" width="687" height="14" font="11">patients (when the aorta is closely related to the VSD) and similar to d-TGA with a VSD in others (when </text>
<text top="890" left="105" width="687" height="14" font="11">the  PA  is  more  closely  related  to  the  VSD  than  the  aorta).  Repairs  are  predicated  on  the  underlying </text>
<text top="910" left="105" width="687" height="14" font="11">anatomy  and  may  involve  VSD  closure  with  relief  of  PS,  right  ventricle–to-PA  conduit,  or  Rastelli-type </text>
<text top="929" left="105" width="687" height="14" font="11">repair. In severe cases, single-ventricle physiology may be present. Consequently, recommendations for </text>
<text top="949" left="105" width="687" height="14" font="11">the  management  of  a  patient  with  double  outlet  right  ventricle  can  generally  be  inferred  in  the </text>
<text top="968" left="105" width="687" height="14" font="11">recommendations for the lesion with the most similar anatomy and physiology (e.g., TOF can reasonably </text>
<text top="988" left="105" width="687" height="14" font="11">be based on the recommendations in Section 4.4.1, recognizing that a patient with double outlet right </text>
<text top="1008" left="105" width="61" height="14" font="11">ventricle </text>
<text top="1008" left="203" width="14" height="14" font="11">is </text>
<text top="1008" left="255" width="39" height="14" font="11">more </text>
<text top="1008" left="332" width="37" height="14" font="11">likely </text>
<text top="1008" left="407" width="17" height="14" font="11">to </text>
<text top="1008" left="462" width="35" height="14" font="11">have </text>
<text top="1008" left="535" width="55" height="14" font="11">residual </text>
<text top="1008" left="628" width="38" height="14" font="11">LVOT </text>
<text top="1008" left="704" width="84" height="14" font="11">obstruction).</text>
<text top="1046" left="105" width="397" height="19" font="34"><b>4.4.6. Severe PAH and Eisenmenger Syndrome </b></text>
<text top="1082" left="105" width="4" height="14" font="11"> </text>
<text top="1079" left="315" width="4" height="17" font="38"><i><b> </b></i></text>
</page>
<page number="105" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 107 </text>
<text top="163" left="105" width="158" height="17" font="38"><i><b>4.4.6.1. Severe PAH </b></i></text>
<text top="197" left="287" width="4" height="14" font="11"> </text>
<text top="196" left="340" width="254" height="16" font="12"><b>Recommendations for Severe PAH </b></text>
<text top="216" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="216" left="577" width="180" height="14" font="23">Online Data Supplement 49</text>
<text top="216" left="757" width="8" height="14" font="11">. </text>
<text top="237" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="237" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="237" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="257" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="307" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="307" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="277" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="277" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="277" left="281" width="495" height="15" font="14"><b>Patients  with  ACHD  with  pulmonary  vascular  resistance  2.5  Wood  units </b></text>
<text top="297" left="281" width="199" height="15" font="14"><b>or greater (≥4 Wood units/m</b></text>
<text top="294" left="479" width="5" height="9" font="36"><b>2</b></text>
<text top="297" left="484" width="291" height="15" font="14"><b>) should be assessed collaboratively by an </b></text>
<text top="316" left="281" width="495" height="15" font="14"><b>ACHD cardiologist and an expert in pulmonary hypertension to develop a </b></text>
<text top="336" left="281" width="291" height="15" font="14"><b>management plan (S4.4.6.1-1–S4.4.6.1-17). </b></text>
<text top="366" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="366" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="356" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="356" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="356" left="281" width="495" height="15" font="14"><b>Adults  with  septal  or  great  artery  shunts  should  undergo  periodic </b></text>
<text top="376" left="281" width="487" height="15" font="14"><b>screening for pulmonary hypertension with TTE (S4.4.6.1-1–S4.4.6.1-18). </b></text>
<text top="435" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="435" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="396" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="396" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="396" left="281" width="495" height="15" font="14"><b>Cardiac  catheterization  to  assess  pulmonary  vascular  hemodynamics  is </b></text>
<text top="416" left="281" width="495" height="15" font="14"><b>recommended  for  adults  with  septal  or  great  artery  shunts  and  clinical </b></text>
<text top="435" left="281" width="495" height="15" font="14"><b>symptoms, signs, or echocardiographic findings suggestive of pulmonary </b></text>
<text top="455" left="281" width="495" height="15" font="14"><b>hypertension  (S4.4.6.1-1,  S4.4.6.1-2,  S4.4.6.1-4,  S4.4.6.1-6,  S4.4.6.1-7, </b></text>
<text top="475" left="281" width="333" height="15" font="14"><b>S4.4.6.1-11, S4.4.6.1-12, S4.4.6.1-15–S4.4.6.1-18). </b></text>
<text top="515" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="515" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="495" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="495" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="495" left="281" width="495" height="15" font="14"><b>In adults with septal or great artery shunts, cardiac catheterization with </b></text>
<text top="515" left="281" width="495" height="15" font="14"><b>hemodynamics  (performed  before  or  at  time  of  closure)  is  beneficial  to </b></text>
<text top="534" left="281" width="356" height="15" font="14"><b>assess suitability for closure (S4.4.6.1-1–S4.4.6.1-17). </b></text>
<text top="574" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="574" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="555" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="555" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="555" left="281" width="495" height="15" font="14"><b>BNP,  chest  x-ray,  6-minute  walk  test,  and  cardiac  catheterization  are </b></text>
<text top="574" left="281" width="495" height="15" font="14"><b>useful  for  initial  and  follow-up  evaluation  of  patients  with  ACHD  with </b></text>
<text top="594" left="281" width="36" height="15" font="14"><b>PAH. </b></text>
<text top="623" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="651" left="105" width="687" height="14" font="11">Pulmonary hypertension is defined as elevation of mean pulmonary arterial pressure to ≥25 mm Hg at </text>
<text top="671" left="105" width="687" height="14" font="11">rest  and  does  not  imply  a  specific  underlying  pathophysiology.  Pulmonary  hypertension  is  further </text>
<text top="690" left="105" width="687" height="14" font="11">classified on the basis of the presumed mechanism (including elevation of pulmonary venous pressure </text>
<text top="710" left="105" width="687" height="14" font="11">[denoted  as  “postcapillary  pulmonary  hypertension”],  parenchymal  or  restrictive  lung  disease, </text>
<text top="730" left="105" width="687" height="14" font="11">rheumatologic disease, portal hypertension, toxin exposure, and thromboembolism). It is also classified </text>
<text top="749" left="105" width="687" height="14" font="11">by  developmental  or  acquired  anatomic  abnormalities  of  decreased  pulmonary  arterial  capacitance, </text>
<text top="769" left="105" width="687" height="14" font="11">impedance,  or  stenosis  throughout  the  pulmonary  arterial  vascular  bed.  PAH  as  initially  described </text>
<text top="789" left="105" width="687" height="14" font="11">required  pulmonary  venous  pressure  ≤15  mm  Hg  with  concomitant  elevation  of  pulmonary  vascular </text>
<text top="808" left="105" width="687" height="14" font="11">resistance.  Although  left-to-right  shunting  was the initial  research model  of  triggered PAH,  pulmonary </text>
<text top="828" left="105" width="687" height="14" font="11">hypertension in patients with ACHD can be caused by, or associated with, any of the factors described </text>
<text top="847" left="105" width="687" height="14" font="11">above.  Effective  therapies  may  be  specific  to  the  primary  mechanism  of  pulmonary  hypertension  in  a </text>
<text top="867" left="105" width="687" height="14" font="11">given  patient,  so  patients  with  CHD  should  have  thorough  investigation  for  all  potential  contributing </text>
<text top="886" left="105" width="687" height="14" font="11">etiologies to pulmonary hypertension that may require specific therapy if best clinical outcomes are to </text>
<text top="906" left="105" width="687" height="14" font="11">be  achieved.  Adverse  effects  of  pulmonary  hypertension  therapies  in  patients  with  ACHD  with </text>
<text top="926" left="105" width="687" height="14" font="11">pulmonary  hypertension  may  differ  from  those  noted  in  other  patients,  because  of  concomitant </text>
<text top="946" left="105" width="584" height="14" font="11">multiorgan and vascular effects from longstanding congenital heart and vascular disease. </text>
<text top="974" left="158" width="634" height="14" font="11">Shunt-related  PAH  in  patients  with  ACHD  can  develop  in  the  pre-  or  perioperative  period  but </text>
<text top="993" left="105" width="687" height="14" font="11">also may develop years to decades after closure of defects. Mechanisms for development of PAH may </text>
<text top="1013" left="105" width="687" height="14" font="11">include genetic factors and environmental exposures. Severity of PAH may range from incidentally noted </text>
<text top="1033" left="105" width="687" height="14" font="11">mild pressure and resistance elevation to profound systemic or suprasystemic levels of PA pressure and </text>
<text top="1052" left="105" width="687" height="14" font="11">pulmonary vascular resistance. If an anatomic defect that allows shunting is present, shunt reversal and </text>
</page>
<page number="106" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 108 </text>
<text top="162" left="105" width="687" height="14" font="11">cyanosis  may  develop  as  pulmonary  resistance  rises  above  systemic  resistance  (i.e.,  Eisenmenger </text>
<text top="182" left="105" width="78" height="14" font="11">syndrome). </text>
<text top="210" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="230" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="249" left="105" width="340" height="14" font="11">Table 33 for routine testing and follow-up intervals. </text>
<text top="278" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="306" left="105" width="687" height="14" font="11">1. Patients with ACHD with pulmonary hypertension, particularly PAH, have a poorer prognosis than do </text>
<text top="326" left="105" width="687" height="14" font="11">patients  with  ACHD  with  similar  histories  and  anatomic  abnormalities  who  do  not  have  pulmonary </text>
<text top="345" left="105" width="687" height="14" font="11">hypertension. The fields of ACHD  and pulmonary vascular  disease  care have increasingly disparate but </text>
<text top="365" left="105" width="687" height="14" font="11">complementary bodies of knowledge, and both are necessary to achieve optimal outcomes for patients </text>
<text top="385" left="105" width="687" height="14" font="11">with  PAH.  Clinicians  cross-trained  in  both  subspecialties  or  partnering  experts  from  each  subspecialty </text>
<text top="404" left="105" width="687" height="14" font="11">appear  necessary  to  fully  counsel  patients  with  ACHD  with  PAH  regarding:  diagnostic  evaluation, </text>
<text top="424" left="105" width="687" height="14" font="11">prognosis,  lifestyle  choices,  suitability  for  operative  or  catheter-based  repair  of  existing  shunts  or </text>
<text top="443" left="105" width="687" height="14" font="11">vascular  obstructions  contributing  to  PAH,  nature  and  effectiveness  of  additional  medical  therapies, </text>
<text top="463" left="105" width="487" height="14" font="11">mechanical circulatory and pulmonary vascular support, and goals of care. </text>
<text top="491" left="105" width="687" height="14" font="11">2. PAH may develop years after shunt closure in patients with ACHD. Predictors for the development or </text>
<text top="511" left="105" width="167" height="14" font="11">presence of PAH include: </text>
<text top="539" left="131" width="12" height="14" font="11">a.</text>
<text top="539" left="143" width="4" height="15" font="26"> </text>
<text top="539" left="158" width="634" height="14" font="11">Anatomic defects: complete AVSD, sinus venosus defect, large nonrestrictive defect (ASD &gt;2 cm, </text>
<text top="559" left="158" width="579" height="14" font="11">VSD &gt;1 cm, PDA &gt;0.6 cm), and concomitant ACHD AP classification II or III abnormalities. </text>
<text top="578" left="131" width="13" height="14" font="11">b.</text>
<text top="578" left="144" width="4" height="15" font="26"> </text>
<text top="578" left="158" width="338" height="14" font="11">Preintervention Qp:Qs ≥3 and/or PASP &gt;40 mm Hg. </text>
<text top="598" left="131" width="11" height="14" font="11">c.</text>
<text top="598" left="142" width="4" height="15" font="26"> </text>
<text top="598" left="158" width="377" height="14" font="11">Presence of associated syndrome (e.g., Down syndrome). </text>
<text top="618" left="131" width="13" height="14" font="11">d.</text>
<text top="618" left="144" width="4" height="15" font="26"> </text>
<text top="618" left="158" width="130" height="14" font="11">Older age at repair. </text>
<text top="637" left="131" width="12" height="14" font="11">e.</text>
<text top="637" left="143" width="4" height="15" font="26"> </text>
<text top="637" left="158" width="80" height="14" font="11">Female sex. </text>
<text top="657" left="131" width="9" height="14" font="11">f.</text>
<text top="657" left="140" width="4" height="15" font="26"> </text>
<text top="657" left="158" width="634" height="14" font="11">Otherwise unexplained symptoms potentially attributable to PAH (decreased exercise capacity, </text>
<text top="677" left="158" width="223" height="14" font="11">syncope, chest pain, hemoptysis). </text>
<text top="696" left="131" width="12" height="14" font="11">g.</text>
<text top="696" left="143" width="4" height="15" font="26"> </text>
<text top="696" left="158" width="634" height="14" font="11">Findings  on  clinical  examination:  systemic  arterial  desaturation,  elevated  systemic  venous </text>
<text top="716" left="158" width="634" height="14" font="11">pressures, other evidence of fluid retention, loud P2, new TR or PR, new arrhythmia, decreased </text>
<text top="735" left="158" width="634" height="14" font="11">exercise  capacity,  electrocardiographic  findings  consistent  with  subpulmonary  ventricular </text>
<text top="755" left="158" width="634" height="14" font="11">hypertrophy  or  dilation.  Echocardiography  may  demonstrate  subpulmonic  ventricular </text>
<text top="775" left="158" width="634" height="14" font="11">dysfunction  and/or  enlargement  and  estimate  central  venous  and  PA  pressures.  However, </text>
<text top="794" left="158" width="634" height="14" font="11">echocardiography  alone  is  insufficient  to  accurately  determine  PA  pressure  or  pulmonary </text>
<text top="814" left="158" width="634" height="14" font="11">vascular  resistance,  so  echocardiography  is  best  used  in  conjunction  with  data  obtained  at </text>
<text top="834" left="158" width="634" height="14" font="11">cardiac  catheterization  when  making  decisions  about  instituting  or  changing  therapy  for  PAH </text>
<text top="853" left="158" width="172" height="14" font="11">(S4.4.6.1-19–S4.4.6.1-21). </text>
<text top="881" left="105" width="687" height="14" font="11">3.  Cardiac  catheterization  remains  the  standard  for  accurate  diagnosis  of  pulmonary  hypertension </text>
<text top="901" left="105" width="679" height="14" font="11">syndromes and for selection of optimal therapies for patients with ACHD with pulmonary hypertension. </text>
<text top="929" left="105" width="687" height="14" font="11">4.  Mechanical interventions  targeting  relief  of  anatomic contributors  to PAH  (e.g.,  closure  of  septal  or </text>
<text top="949" left="105" width="687" height="14" font="11">great arterial defects to eliminate shunting) may be  considered as part of short-term plans of care for </text>
<text top="969" left="105" width="687" height="14" font="11">patients  with  ACHD  with  PAH.  However,  even  modest  residual  levels  of  PAH  substantially  determine </text>
<text top="988" left="105" width="647" height="14" font="11">intermediate and longer-term outcomes. Patients should be followed for pulmonary hypertension. </text>
<text top="1017" left="105" width="687" height="14" font="11">5. Although history, noninvasive testing, and laboratory analysis (biochemistry and hematology) are all </text>
<text top="1036" left="105" width="687" height="14" font="11">part of the workup of pulmonary hypertension associated with CHD, cardiac catheterization with careful </text>
<text top="1056" left="105" width="687" height="14" font="11">hemodynamic  measurements,  with  or  without  provocative  maneuvers  and/or  angiography,  remains </text>
<text top="1075" left="105" width="442" height="14" font="11">fundamental to accurate diagnosis and design of therapeutic plans. </text>
</page>
<page number="107" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 109 </text>
<text top="162" left="105" width="4" height="14" font="11"> </text>
<text top="182" left="105" width="638" height="15" font="14"><b>Table 33. Pulmonary Hypertension and Eisenmenger Syndrome: Routine Follow-Up and Testing </b></text>
<text top="204" left="105" width="62" height="15" font="14"><b>Intervals </b></text>
<text top="227" left="114" width="199" height="13" font="7"><b>Frequency of Routine Follow-Up </b></text>
<text top="245" left="177" width="73" height="13" font="7"><b>and Testing </b></text>
<text top="227" left="345" width="137" height="13" font="7"><b>Physiological Stage C* </b></text>
<text top="245" left="398" width="32" height="13" font="7"><b>(mo) </b></text>
<text top="227" left="516" width="138" height="13" font="7"><b>Physiological Stage D* </b></text>
<text top="245" left="568" width="32" height="13" font="7"><b>(mo) </b></text>
<text top="264" left="105" width="178" height="13" font="8">Outpatient ACHD cardiologist </text>
<text top="264" left="335" width="33" height="13" font="8">6–12 </text>
<text top="264" left="505" width="25" height="13" font="8">3–6 </text>
<text top="282" left="105" width="27" height="13" font="8">ECG </text>
<text top="282" left="335" width="18" height="13" font="8">12 </text>
<text top="282" left="505" width="18" height="13" font="8">12 </text>
<text top="301" left="105" width="32" height="13" font="8">TTE† </text>
<text top="301" left="335" width="18" height="13" font="8">12 </text>
<text top="301" left="505" width="18" height="13" font="8">12 </text>
<text top="320" left="105" width="91" height="13" font="8">Pulse oximetry </text>
<text top="320" left="335" width="59" height="13" font="8">Each visit </text>
<text top="320" left="505" width="59" height="13" font="8">Each visit </text>
<text top="338" left="105" width="39" height="13" font="8">CMR‡ </text>
<text top="338" left="335" width="66" height="13" font="8">As needed </text>
<text top="338" left="505" width="66" height="13" font="8">As needed </text>
<text top="357" left="105" width="85" height="13" font="8">Exercise test§ </text>
<text top="357" left="335" width="33" height="13" font="8">6–12 </text>
<text top="357" left="505" width="33" height="13" font="8">6–12 </text>
<text top="375" left="105" width="137" height="13" font="8">Cardiac catheterization</text>
<text top="372" left="242" width="14" height="18" font="8">║ </text>
<text top="375" left="335" width="66" height="13" font="8">As needed </text>
<text top="375" left="505" width="66" height="13" font="8">As needed </text>
<text top="393" left="105" width="372" height="12" font="9">*See Tables 3 and 4 for details on the ACHD AP classification system.  </text>
<text top="409" left="105" width="653" height="12" font="9">†Rou@ne TTE may be unnecessary in a year when CMR imaging is performed unless clinical indications warrant otherwise. </text>
<text top="425" left="105" width="686" height="12" font="9">‡CMR may be indicated for assessment of right ventricular func@on and CHD anatomy not clariﬁed with TTE. Baseline study is </text>
<text top="442" left="105" width="686" height="12" font="9">recommended  with  periodic  follow-up  CMR,  with  frequency  of  repeat  imaging  determined  by  anatomic  and  physiological </text>
<text top="458" left="105" width="51" height="12" font="9">findings.  </text>
<text top="474" left="105" width="332" height="12" font="9">§6-minute walk test or CPET, depending on clinical indication. </text>
<text top="487" left="105" width="400" height="16" font="9">║Cardiac catheterization should be performed at baseline and as needed.  </text>
<text top="506" left="105" width="686" height="12" font="9">ACHD indicates adult congenital heart disease; CMR, cardiovascular magnetic resonance; CPET, cardiopulmonary exercise test; </text>
<text top="522" left="105" width="348" height="12" font="9">ECG, electrocardiogram; and TTE, transthoracic echocardiogram. </text>
<text top="538" left="105" width="4" height="14" font="11"> </text>
<text top="567" left="105" width="252" height="17" font="38"><i><b>4.4.6.2. Eisenmenger Syndrome </b></i></text>
<text top="601" left="243" width="4" height="14" font="11"> </text>
<text top="600" left="296" width="341" height="16" font="12"><b>Recommendations for Eisenmenger Syndrome </b></text>
<text top="621" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="621" left="577" width="180" height="14" font="23">Online Data Supplement 50</text>
<text top="621" left="757" width="8" height="14" font="11">. </text>
<text top="641" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="641" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="641" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="661" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="711" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="711" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="682" left="255" width="13" height="15" font="14"><b>1.</b></text>
<text top="682" left="267" width="4" height="15" font="24"><b> </b></text>
<text top="682" left="281" width="495" height="15" font="14"><b>When  evaluating  adults  with  presumed  Eisenmenger  syndrome, </b></text>
<text top="701" left="281" width="495" height="15" font="14"><b>clinicians  should  confirm  diagnostic  imaging  and  cardiac  catheterization </b></text>
<text top="721" left="281" width="495" height="15" font="14"><b>data  accuracy  and  exclude  other  potential  contributors  to  right-to-left </b></text>
<text top="741" left="281" width="252" height="15" font="14"><b>shunting or pulmonary hypertension. </b></text>
<text top="761" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="791" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="791" left="204" width="14" height="15" font="14"><b>A </b></text>
<text top="781" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="781" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="781" left="281" width="495" height="15" font="14"><b>Bosentan is beneficial in symptomatic adults with Eisenmenger syndrome </b></text>
<text top="801" left="281" width="272" height="15" font="14"><b>with ASD or VSD (S4.4.6.2-1–S4.4.6.2-3). </b></text>
<text top="850" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="850" left="197" width="27" height="15" font="14"><b>B-R </b></text>
<text top="821" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="821" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="821" left="281" width="495" height="15" font="14"><b>In symptomatic adults with Eisenmenger syndrome, bosentan and PDE-5 </b></text>
<text top="841" left="281" width="495" height="15" font="14"><b>inhibitors  are  reasonable  in  combination  if  symptomatic  improvement </b></text>
<text top="860" left="281" width="491" height="15" font="14"><b>does  not  occur  with  either  medication  alone  (S4.4.6.2-1,  S4.4.6.2-4–</b></text>
<text top="880" left="281" width="79" height="15" font="14"><b>S4.4.6.2-6). </b></text>
<text top="949" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="901" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="900" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="900" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="900" left="281" width="495" height="15" font="14"><b>Bosentan  is  a  reasonable  therapy  to  treat  symptomatic  adults  with </b></text>
<text top="920" left="281" width="495" height="15" font="14"><b>Eisenmenger  syndrome  with  1  of  the  following:  shunts  other  than </b></text>
<text top="939" left="281" width="495" height="15" font="14"><b>ASD/VSD  (e.g.,  PDA,  aortopulmonary window)  (Level  of  Evidence  C-EO), </b></text>
<text top="959" left="281" width="495" height="15" font="14"><b>or  complex  congenital  heart  lesions  (S4.4.6.2-1,  S4.4.6.2-7)  or  Down </b></text>
<text top="978" left="281" width="495" height="15" font="14"><b>syndrome  (S4.4.6.2-4,  S4.4.6.2-5,  S4.4.6.2-8–S4.4.6.2-10)  (Level  of </b></text>
<text top="998" left="281" width="110" height="15" font="14"><b>Evidence B-NR). </b></text>
<text top="960" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1038" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="1038" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1018" left="256" width="13" height="15" font="14"><b>5.</b></text>
<text top="1019" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1018" left="281" width="495" height="15" font="14"><b>It is reasonable to use PDE-5 inhibitors (e.g., sildenafil, tadalafil) to treat </b></text>
<text top="1038" left="281" width="495" height="15" font="14"><b>symptomatic adults with Eisenmenger syndrome with ASD, VSD, or great </b></text>
<text top="1058" left="281" width="334" height="15" font="14"><b>artery shunt (S4.4.6.2-1, S4.4.6.2-11–S4.4.6.2-16). </b></text>
<text top="1087" left="105" width="4" height="14" font="11"> </text>
</page>
<page number="108" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 110 </text>
<text top="162" left="105" width="65" height="15" font="14"><b>Synopsis  </b></text>
<text top="191" left="105" width="687" height="14" font="11">Historically Eisenmenger syndrome has been understood as the most advanced form of PAH associated </text>
<text top="210" left="105" width="687" height="14" font="11">with  congenital  intracardiac  and  great  arterial  shunting.  The  natural  course  and  outcomes  of  PAH  in </text>
<text top="230" left="105" width="687" height="14" font="11">patients  with  ACHD  with  Eisenmenger  syndrome,  as  contrasted  to  other  adults  with  PAH,  remain </text>
<text top="249" left="105" width="687" height="14" font="11">incompletely  defined.  However,  it  is  believed  that  better  survival  and  functional  ability  of  untreated </text>
<text top="269" left="105" width="687" height="14" font="11">adults with Eisenmenger syndrome might be explained by sharing of loading conditions between right- </text>
<text top="289" left="105" width="644" height="14" font="11">and left-sided cardiac chambers, as well as multiorgan system adaptations that develop over time. </text>
<text top="317" left="158" width="634" height="14" font="11">The  fundamental  cause  of  Eisenmenger  syndrome  is  elevated  pulmonary  vascular  resistance </text>
<text top="337" left="105" width="687" height="14" font="11">driving right-to-left intracardiac or great arterial shunting leading to systemic arterial desaturation. The </text>
<text top="356" left="105" width="687" height="14" font="11">risk  of  development  of  Eisenmenger  syndrome  is  influenced  by  concomitant  congenital  syndromes, </text>
<text top="376" left="105" width="687" height="14" font="11">anatomic  location  of  congenital  defects,  size  of  anatomic  defects,  genetic  factors,  and  environmental </text>
<text top="395" left="105" width="74" height="14" font="11">exposures. </text>
<text top="424" left="105" width="687" height="14" font="11">Pathophysiological  mechanisms  contributing  to  development  of  Eisenmenger  syndrome  are  not  fully </text>
<text top="443" left="105" width="687" height="14" font="11">understood.  Suggested  triggers  and  pathways  include  blood  flow-induced  shear  and  circumferential </text>
<text top="463" left="105" width="623" height="14" font="11">stress, vasoconstriction, and vascular cell proliferation associated with fibrosis and thrombosis. </text>
<text top="491" left="158" width="634" height="14" font="11">Cyanosis, erythrocytosis, abnormalities of loading conditions, and abnormalities of systemic and </text>
<text top="511" left="105" width="687" height="14" font="11">pulmonary  perfusion  all  contribute  to  functional  incapacity  and  potential  for  multiorgan  system </text>
<text top="531" left="105" width="687" height="14" font="11">dysfunction  and  other  sequelae,  including  stroke,  brain  abscess,  osteoarthropathy,  iron  deficiency, </text>
<text top="550" left="105" width="687" height="14" font="11">reduced  glomerular  clearance  and  susceptibility  to  acute  renal  insufficiency,  nephrosis,  pulmonary </text>
<text top="570" left="105" width="687" height="14" font="11">arterial thrombosis and dissection, hemoptysis, pulmonary parenchymal infections, diastolic and systolic </text>
<text top="589" left="105" width="301" height="14" font="11">cardiac dysfunction, arrhythmia, HF, and SCD. </text>
<text top="618" left="158" width="634" height="14" font="11">Palliative therapies that may be helpful include supplemental oxygen if systemic arterial oxygen </text>
<text top="637" left="105" width="687" height="14" font="11">saturation  is  empirically  noted  to  rise  in  response,  systemic  anticoagulation,  and  avoidance  of </text>
<text top="657" left="105" width="687" height="14" font="11">circumstances recognized to contribute to risk (e.g., high altitude, pregnancy, exposure to high heat or </text>
<text top="677" left="105" width="687" height="14" font="11">humidity  leading  to  vasodilation,  nephrotoxin  exposure,  extreme  exertion,  large  shifts  in  intravascular </text>
<text top="696" left="105" width="687" height="14" font="11">volume).  However,  supportive  data  for  these  strategies  are  limited  or  nonexistent.  Systemic </text>
<text top="716" left="105" width="521" height="14" font="11">anticoagulation has the potential for adverse as well as possible helpful effects. </text>
<text top="744" left="158" width="634" height="14" font="11">Mechanical circulatory and pulmonary support, lung transplantation with concomitant repair of </text>
<text top="764" left="105" width="687" height="14" font="11">anatomic cardiovascular defects, and heart–lung transplantation have all been applied in patients with </text>
<text top="783" left="105" width="687" height="14" font="11">ACHD  with  Eisenmenger  syndrome  with  deteriorating  functional  ability.  Indications  for  such  therapies </text>
<text top="803" left="105" width="687" height="14" font="11">for  adults  with  Eisenmenger  syndrome  are  not  standardized;  comparative  outcomes  have  not  been </text>
<text top="823" left="105" width="687" height="14" font="11">tested, and to date successes have been limited. However, pharmacological treatment of PAH is helpful </text>
<text top="842" left="105" width="449" height="14" font="11">in the management of certain patients with Eisenmenger syndrome. </text>
<text top="871" left="105" width="687" height="14" font="11">See  Section  3.3  for  recommendations  on  who  should  perform  surgeries,  cardiac  catheterization,  and </text>
<text top="890" left="105" width="687" height="14" font="11">other  procedures  in  these  patients;  Section  3.4  for  recommendations  on  diagnostic  evaluation;  and </text>
<text top="910" left="105" width="340" height="14" font="11">Table 33 for routine testing and follow-up intervals. </text>
<text top="938" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="966" left="105" width="687" height="14" font="11">1.  Right-to-left  shunting  through  septal  defects  or  connections  between  the  great  arteries  associated </text>
<text top="986" left="105" width="687" height="14" font="11">with  subpulmonary  ventricular  hypertension  may  be  diagnosed  as  Eisenmenger  syndrome.  PAH </text>
<text top="1006" left="105" width="687" height="14" font="11">medications may be beneficial for patients with Eisenmenger syndrome; however, other conditions may </text>
<text top="1025" left="105" width="687" height="14" font="11">cause  right-to-left  shunting  for  reasons  other  than  shunt-related  PAH  and  thus  may  require  different </text>
<text top="1045" left="105" width="687" height="14" font="11">treatment  options.  These  other  conditions  include:  a)  severe  pulmonary  hypertension  of  other  cause </text>
<text top="1064" left="105" width="687" height="14" font="11">(e.g.,  thromboembolic  disease,  rheumatic  disease),  b)  subpulmonary  chamber  outflow  obstruction,  c) </text>
<text top="1084" left="105" width="687" height="14" font="11">abnormalities  of  subpulmonary  chamber  compliance,  and  d)  vascular  streaming.  Accurate  diagnosis  is </text>
</page>
<page number="109" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 111 </text>
<text top="162" left="105" width="683" height="14" font="11">necessary to guide therapy. For example, PAH therapies will not be beneficial if the source of right-to-</text>
<text top="182" left="105" width="687" height="14" font="11">left shunting is RVOT obstruction; rather, alleviation of the RVOT obstruction is the necessary treatment. </text>
<text top="202" left="105" width="683" height="14" font="11">Accurate diagnosis of Eisenmenger syndrome and exclusion of other potential contributors to right-to-</text>
<text top="221" left="105" width="687" height="14" font="11">left shunting or pulmonary hypertension by means of advanced imaging and cardiac catheterization are </text>
<text top="241" left="105" width="528" height="14" font="11">crucial prerequisites to optimize therapy for adults with Eisenmenger syndrome. </text>
<text top="269" left="105" width="687" height="14" font="11">2.  In  adults  with  Eisenmenger  syndrome  associated  with  ASD  or  VSD  in  World  Health  Organization </text>
<text top="289" left="105" width="687" height="14" font="11">functional  class  III  or  IV,  RCTs  demonstrate  improved  6-minute  walk  distance,  hemodynamics,  and </text>
<text top="308" left="105" width="687" height="14" font="11">subjective functional ability after 4 months of oral bosentan (S4.4.6.2-17). Longer-term benefit has been </text>
<text top="328" left="105" width="687" height="14" font="11">demonstrated through open-label extension  of this initial RCT (S4.4.6.2-1) and in single-center  registry </text>
<text top="348" left="105" width="687" height="14" font="11">cohorts  (S4.4.6.2-1,  S4.4.6.2-17).  There  may  be  a  class  effect  for  endothelin  receptor  antagonists,  but </text>
<text top="367" left="105" width="317" height="14" font="11">others have not been studied in this population. </text>
<text top="395" left="105" width="687" height="14" font="11">3.  A  randomized  crossover  trial  of  combination  PAH  therapy  (PDE-5  inhibitor  therapy  and  endothelin </text>
<text top="415" left="105" width="687" height="14" font="11">receptor  antagonist  therapy)  enrolled  adults  with  Eisenmenger  syndrome  or  with  idiopathic  PAH  and </text>
<text top="435" left="105" width="687" height="14" font="11">demonstrated  improvement  in  systemic  arterial  saturation  but  not  in  functional  ability  or </text>
<text top="454" left="105" width="687" height="14" font="11">hemodynamics  (S4.4.6.2-6).  Use  of  combination  PAH  therapy  for  adults  with  Eisenmenger  syndrome </text>
<text top="474" left="105" width="687" height="14" font="11">was further supported by a single-center cohort series suggesting improvement in 6-minute walk testing </text>
<text top="493" left="105" width="687" height="14" font="11">and hemodynamics in adults with Eisenmenger syndrome using combined PDE-5 inhibitory therapy and </text>
<text top="513" left="105" width="498" height="14" font="11">endothelin receptor antagonist therapy (S4.4.6.2-1, S4.4.6.2-4, S4.4.6.2-18). </text>
<text top="541" left="105" width="687" height="14" font="11">4.  Open-label  single-center  registries  and  cohort  studies  of  adults  with  Eisenmenger  syndrome, </text>
<text top="561" left="105" width="687" height="14" font="11">attributable to shunts other than ASD/VSD or with complex congenital heart lesions, suggest benefit in </text>
<text top="581" left="105" width="683" height="14" font="11">functional capacity or hemodynamics after months of endothelin receptor antagonist therapy (S4.4.6.2-</text>
<text top="600" left="105" width="687" height="14" font="11">1,  S4.4.6.2-7). Patients  with  ACHD  and  Down  syndrome  have  greater  likelihood  to  develop  pulmonary </text>
<text top="620" left="105" width="687" height="14" font="11">hypertension,  and  they  have  unique  comorbidities  that  influence  the  nature  of  their  pulmonary </text>
<text top="640" left="105" width="687" height="14" font="11">hypertension,  the  metrics  used  in  follow-up,  and  the  potential  for  benefit  from  as  well  as  adverse </text>
<text top="659" left="105" width="687" height="14" font="11">response to therapy. Open-label single-center registries and cohorts of adults with Down syndrome and </text>
<text top="679" left="105" width="687" height="14" font="11">Eisenmenger syndrome suggest benefit in subjective and/or objective functional capacity after months </text>
<text top="698" left="105" width="687" height="14" font="11">of endothelin receptor antagonist therapy, generally as contrasted to performance before institution of </text>
<text top="718" left="105" width="687" height="14" font="11">endothelin  receptor  antagonist  therapy  (S4.4.6.2-8–S4.4.6.2-10).  Accurate  diagnosis  of  PAH  and </text>
<text top="737" left="105" width="475" height="14" font="11">Eisenmenger syndrome remains essential before initiating such therapy. </text>
<text top="766" left="105" width="687" height="14" font="11">5.  RCTs  (S4.4.6.2-16)  regarding  PDE-5  inhibitor  therapy  for  adults  with  Eisenmenger  syndrome  have </text>
<text top="785" left="105" width="687" height="14" font="11">limitations, but are supported by multiple open-label prospective studies and information from a large </text>
<text top="805" left="105" width="687" height="14" font="11">single-center  retrospective  registry  (S4.4.6.2-1,  S4.4.6.2-11–S4.4.6.2-16).  These  studies  suggest  benefit </text>
<text top="825" left="105" width="687" height="14" font="11">in functional capacity and hemodynamics after use of either sildenafil or tadalafil at varying doses and </text>
<text top="844" left="105" width="687" height="14" font="11">for  varying  periods  of  follow-up.  Benefit  was  either  in  comparison  to  subjects’  performance  before </text>
<text top="864" left="105" width="687" height="15" font="11">institution  of  therapy  or  to  other  adults  with  similar  Eisenmenger  syndrome  anatomy  and  physiology </text>
<text top="883" left="105" width="280" height="15" font="11">who were not prescribed PDE-5 inhibitors. </text>
<text top="921" left="105" width="229" height="19" font="34"><b>4.4.7. Coronary Anomalies </b></text>
<text top="954" left="105" width="687" height="15" font="11">Coronary abnormalities are among the most common congenital cardiovascular anomalies, surpassing in </text>
<text top="974" left="105" width="687" height="15" font="11">prevalence  nearly  all  others  combined.  Coronary  anomalies  include  anomalous  aortic  origin  of  a </text>
<text top="993" left="105" width="687" height="15" font="11">coronary  artery  (AAOCA),  coronary  fistula,  and  myocardial  bridge.  Many  congenital  coronary </text>
<text top="1013" left="105" width="687" height="15" font="11">abnormalities have a benign outcome. In contrast, natural history studies of anomalous coronary artery </text>
<text top="1032" left="105" width="687" height="15" font="11">from  the  PA  (particularly  anomalous  left  coronary  artery  from  the  PA)  suggest  poor  outcome  in </text>
<text top="1052" left="105" width="687" height="15" font="11">untreated patients; similar natural history studies are lacking regarding untreated patients with AAOCA, </text>
</page>
<page number="110" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 112 </text>
<text top="162" left="105" width="687" height="14" font="11">but other evidence raises concern. See Table 34 and Figure 5 for a diagnostic and treatment algorithm </text>
<text top="182" left="105" width="77" height="14" font="11">for AAOCA. </text>
<text top="210" left="158" width="634" height="14" font="11">Assessment  of  the  risk  of  SCD  in  patients  with  AAOCA  and  of  the  role  of  AAOCA  in  causing </text>
<text top="230" left="105" width="687" height="14" font="11">ischemia or symptoms is difficult because available data do not adequately capture the clinical spectrum </text>
<text top="249" left="105" width="687" height="14" font="11">of these anomalies. Autopsy series are available that help describe the anomalies found in patients who </text>
<text top="269" left="105" width="687" height="14" font="11">suffered SCD contrasted to other causes of death (S4.4.7-1–S4.4.7-5). There are surgical case series that </text>
<text top="289" left="105" width="683" height="14" font="11">describe  findings  before  operation,  operative  anatomy  and  postoperative  course  (S4.4.7-2,  S4.4.7-5–</text>
<text top="308" left="105" width="687" height="14" font="11">S4.4.7-8).  There  are  imaging  studies  describing  the  anatomy  and  potential  pathophysiological </text>
<text top="328" left="105" width="687" height="14" font="11">abnormalities associated with AAOCA (S4.4.7-6, S4.4.7-9–S4.4.7-11). There are surgical series describing </text>
<text top="348" left="105" width="687" height="14" font="11">improvement  in  symptoms  after  operation  (S4.4.7-6–S4.4.7-8).  There  are  surveys  and  registries  that </text>
<text top="367" left="105" width="687" height="14" font="11">describe  the  heterogeneous  management  strategies  applied  to  AAOCA  (S4.4.7-12–S4.4.7-14).  What  is </text>
<text top="387" left="105" width="687" height="14" font="11">lacking  are  data  proving  that  any  particular  management  strategy  prevents  SCD.  As  a  consequence, </text>
<text top="406" left="105" width="687" height="14" font="11">decisions  regarding  whether  surgery  is  necessary  or  exercise  restriction  or  medical  therapy  might  be </text>
<text top="426" left="105" width="687" height="14" font="11">beneficial  are  all  based  on  synthesizing  limited  data  and  applying  to  an  individual  patient.  Clinicians </text>
<text top="446" left="105" width="687" height="14" font="11">commonly extrapolate to assist in medical decision-making, but the consequences of being “wrong” for </text>
<text top="465" left="105" width="687" height="14" font="11">a  young  patient  with  AAOCA  may  be  perceived  to  be  greater  than  for  many  other  conditions. </text>
<text top="485" left="105" width="687" height="14" font="11">Consequently, there is often a clinical urge to seek a reason to do something like surgical repair, because </text>
<text top="504" left="105" width="687" height="14" font="11">the available data do not identify clinical features that provide reassurance that a patient is at low risk of </text>
<text top="524" left="105" width="687" height="14" font="11">cardiovascular events. Unfortunately, evidence demonstrating that surgical repair ameliorates SCD risk, </text>
<text top="544" left="105" width="609" height="14" font="11">derived from large enough cohorts followed over a sufficient period of time, is not available.  </text>
<text top="572" left="105" width="4" height="14" font="11"> </text>
<text top="591" left="105" width="581" height="15" font="14"><b>Table 34. Factors That May Relate to the Clinical Importance of AAOCA and Risk of SCD </b></text>
<text top="615" left="105" width="26" height="13" font="8">Age </text>
<text top="615" left="262" width="500" height="13" font="8">AAOCA is more commonly invoked as the cause of SCD in patients &lt;35 y of age than </text>
<text top="632" left="262" width="498" height="13" font="8">in patients &gt;35 y of age, in whom atherosclerotic coronary disease becomes a more </text>
<text top="650" left="262" width="480" height="13" font="8">prevalent cause. However, death has been attributed to AAOCA in patients of all </text>
<text top="668" left="262" width="463" height="13" font="8">ages; there does not seem to be an age beyond which the AAOCA may not be </text>
<text top="686" left="262" width="443" height="13" font="8">relevant, even in the setting of atherosclerotic coronary disease and other </text>
<text top="704" left="262" width="262" height="13" font="8">concomitant conditions (S4.4.7-1, S4.4.7-2). </text>
<text top="722" left="105" width="129" height="13" font="8">Anatomy of coronary </text>
<text top="740" left="105" width="125" height="13" font="8">ostium and proximal </text>
<text top="758" left="105" width="99" height="13" font="8">coronary course </text>
<text top="722" left="262" width="443" height="13" font="8">Slit-like/fish-mouth-shaped orifice, acute angle takeoff, intramural course, </text>
<text top="740" left="262" width="482" height="13" font="8">interarterial course and hypoplasia of the proximal coronary artery have all been </text>
<text top="758" left="262" width="493" height="13" font="8">proposed as reasons for symptoms, ischemia and SCD in patients with AAOCA. The </text>
<text top="776" left="262" width="483" height="13" font="8">slit-like orifice is more commonly seen in anomalous right coronary artery arising </text>
<text top="793" left="262" width="471" height="13" font="8">from the left sinus. Each of these anatomic findings offers a pathophysiological </text>
<text top="811" left="262" width="483" height="13" font="8">mechanism for intermittent ischemia, particularly at times of high cardiac output </text>
<text top="829" left="262" width="475" height="13" font="8">and/or increased aortic wall tension, such as during exercise (S4.4.7-6, S4.4.7-9–</text>
<text top="847" left="262" width="67" height="13" font="8">S4.4.7-11). </text>
<text top="865" left="105" width="108" height="13" font="8">Anomalous origin </text>
<text top="865" left="262" width="459" height="13" font="8">Left coronary artery arising from the right cusp is less common than the right </text>
<text top="883" left="262" width="510" height="13" font="8">coronary artery arising from the left cusp but is more often found in autopsy series of </text>
<text top="901" left="262" width="485" height="13" font="8">SCD (S4.4.7-1, S4.4.7-3, S4.4.7-15). This suggests that anomalous origin of the left </text>
<text top="919" left="262" width="510" height="13" font="8">coronary artery from the right cusp is more likely to cause SCD than anomalous origin </text>
<text top="937" left="262" width="492" height="13" font="8">of the right coronary artery from the left cusp. This may be due either to anatomic </text>
<text top="955" left="262" width="472" height="13" font="8">features that make anomalous aortic origin of the left coronary artery prone to </text>
<text top="973" left="262" width="495" height="13" font="8">coronary compromise or because a larger proportion of myocardium is supplied by </text>
<text top="990" left="262" width="197" height="13" font="8">the left coronary artery, or both. </text>
<text top="1009" left="105" width="52" height="13" font="8">Exercise </text>
<text top="1009" left="262" width="492" height="13" font="8">Autopsy series suggest a most patients die during, or in close temporal association </text>
<text top="1027" left="262" width="204" height="13" font="8">with, exercise (S4.4.7-3–S4.4.7-5). </text>
<text top="1045" left="105" width="56" height="13" font="8">Ischemia </text>
<text top="1045" left="262" width="491" height="13" font="8">Autopsy series demonstrate myocardial fibrosis in a significant number of patients </text>
<text top="1063" left="262" width="506" height="13" font="8">whose deaths were attributed to AAOCA, particularly in patients with anomalous left </text>
<text top="1081" left="262" width="512" height="13" font="8">coronary artery arising from the right cusp (S4.4.7-5). Surgical series describe patients </text>
</page>
<page number="111" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 113 </text>
<text top="163" left="262" width="500" height="13" font="8">with ischemia or MI before surgical repair in the absence of other CAD, suggesting a </text>
<text top="181" left="262" width="499" height="13" font="8">relation of the coronary anomaly to the ischemia (S4.4.7-16). This suggests that had </text>
<text top="198" left="262" width="487" height="13" font="8">perfusion imaging been obtained before SCD, ischemia would have been found in </text>
<text top="216" left="262" width="477" height="13" font="8">such patients (S4.4.7-17, S4.4.7-18). However, other data indicate that a normal </text>
<text top="234" left="262" width="511" height="13" font="8">stress test does not preclude a SCD event, with the proviso that most of those studies </text>
<text top="252" left="262" width="467" height="13" font="8">used only stress ECG, rather than the more sensitive and specific modalities of </text>
<text top="270" left="262" width="482" height="13" font="8">nuclear perfusion imaging or stress echocardiography. In addition, postoperative </text>
<text top="287" left="262" width="445" height="13" font="8">studies have shown that ischemia may be found after surgical repair in the </text>
<text top="305" left="262" width="486" height="13" font="8">distribution not supplied by the abnormal coronary artery and may not persist on </text>
<text top="323" left="262" width="158" height="13" font="8">repeat testing (S4.4.7-19). </text>
<text top="342" left="105" width="66" height="13" font="8">Symptoms </text>
<text top="342" left="262" width="428" height="13" font="8">In autopsy and surgical series, a significant number of patients reported </text>
<text top="359" left="262" width="496" height="13" font="8">cardiovascular symptoms, including before SCD events (S4.4.7-4, S4.4.7-7, S4.4.7-8, </text>
<text top="377" left="262" width="496" height="13" font="8">S4.4.7-20, S4.4.7-21). Symptoms are more commonly reported in patients in whom </text>
<text top="395" left="262" width="483" height="13" font="8">the left coronary artery arises from the right sinus. Surgical series have described </text>
<text top="413" left="262" width="402" height="13" font="8">improvement in symptoms after surgical repair (S4.4.7-3–S4.4.7-8). </text>
<text top="431" left="105" width="686" height="12" font="9">AAOCA  indicates  anomalous  aortic  origin  of  the  coronary  artery;  CAD,  coronary  artery  disease;  ECG,  electrocardiogram;  MI, </text>
<text top="447" left="105" width="291" height="12" font="9">myocardial infarction; and SCD, sudden cardiac death. </text>
<text top="464" left="105" width="4" height="14" font="11"> </text>
<text top="499" left="105" width="375" height="17" font="38"><i><b>4.4.7.1. Anomalous Coronary Artery Evaluation </b></i></text>
<text top="532" left="187" width="4" height="14" font="11"> </text>
<text top="531" left="240" width="454" height="16" font="12"><b>Recommendations for Anomalous Coronary Artery Evaluation </b></text>
<text top="552" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="552" left="577" width="180" height="14" font="23">Online Data Supplement 51</text>
<text top="552" left="757" width="8" height="14" font="11">. </text>
<text top="572" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="572" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="572" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="593" left="404" width="73" height="15" font="14"><b>Diagnostic </b></text>
<text top="633" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="633" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="613" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="613" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="613" left="281" width="495" height="15" font="14"><b>Coronary  angiography,  using  catheterization,  CT,  or  CMR,  is </b></text>
<text top="633" left="281" width="491" height="15" font="14"><b>recommended  for  evaluation  of  anomalous  coronary  artery  (S4.4.7.1-1–</b></text>
<text top="652" left="281" width="79" height="15" font="14"><b>S4.4.7.1-3). </b></text>
<text top="692" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="692" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="672" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="673" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="672" left="281" width="495" height="15" font="14"><b>Anatomic  and  physiological  evaluation  should  be  performed  in  patients </b></text>
<text top="692" left="281" width="495" height="15" font="14"><b>with  anomalous  aortic  origin  of  the  left  coronary  from  the  right  sinus </b></text>
<text top="712" left="281" width="432" height="15" font="14"><b>and/or right coronary from the left sinus (S4.4.7.1-4–S4.4.7.1-9). </b></text>
<text top="741" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="769" left="105" width="687" height="14" font="11">1.  CTA,  CMR,  and  catheterization  can  all  delineate  the  proximal  course  of  the  coronary  artery  and </text>
<text top="789" left="105" width="687" height="14" font="11">relationship to other structures. CTA is generally preferred because it has superior spatial and temporal </text>
<text top="809" left="105" width="687" height="14" font="11">resolution,  although  CMR  may  also  provide  adequate  delineation  of  the  relationship  of  the  coronary </text>
<text top="828" left="105" width="687" height="14" font="11">artery  to  the  aorta,  PA  and  other  structures,  including  whether  the  proximal  course  appears  to  be </text>
<text top="848" left="105" width="687" height="14" font="11">intramural.  Coronary  angiography  by  catheterization  can  be  helpful  when  there  is  concern  about </text>
<text top="867" left="105" width="687" height="14" font="11">stenosis in the coronary artery or when concomitant hemodynamic evaluation for shunt assessment or </text>
<text top="887" left="105" width="377" height="14" font="11">intravascular ultrasonography/flow evaluation is needed. </text>
<text top="915" left="105" width="687" height="14" font="11">2.  Assessment  of  AAOCA  is  enhanced  when  the  precise  anatomy  and  physiological  impact  of  the </text>
<text top="935" left="105" width="687" height="14" font="11">coronary  artery  anomaly  are  understood.  As  described  in  Table  34,  the  specific  anomalous  origin, </text>
<text top="955" left="105" width="687" height="14" font="11">anatomy of the orifice and proximal vessel and presence of ischemia may all influence the clinical course </text>
<text top="974" left="105" width="687" height="14" font="11">and  thus  the  management  options.  Understanding  these  issues  as  precisely  as  possible  will  better </text>
<text top="994" left="105" width="163" height="14" font="11">inform clinical decisions. </text>
<text top="1022" left="105" width="4" height="14" font="11"> </text>
<text top="1051" left="105" width="4" height="15" font="14"><b> </b></text>
<text top="1051" left="315" width="4" height="15" font="14"><b> </b></text>
</page>
<page number="112" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="110" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="128" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1145" left="423" width="52" height="12" font="9">Page 114 </text>
<text top="162" left="105" width="383" height="15" font="14"><b>Figure 5. Anomalous Aortic Origin of the Coronary Artery</b> </text>
<text top="185" left="105" width="4" height="14" font="11"> </text>
<text top="712" left="789" width="3" height="13" font="7"><b> </b></text>
<text top="744" left="105" width="649" height="12" font="9">*Surgical intervention to involve unroofing or coronary revascularization for patients with concomitant fixed obstruction. </text>
<text top="760" left="105" width="4" height="14" font="11"> </text>
<text top="790" left="105" width="412" height="17" font="38"><i><b>4.4.7.2. Anomalous Aortic Origin of Coronary Artery </b></i></text>
<text top="823" left="170" width="4" height="14" font="11"> </text>
<text top="822" left="223" width="488" height="16" font="12"><b>Recommendations for Anomalous Aortic Origin of Coronary Artery </b></text>
<text top="843" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="843" left="577" width="180" height="14" font="23">Online Data Supplement 51</text>
<text top="843" left="757" width="8" height="14" font="11">. </text>
<text top="863" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="863" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="863" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="883" left="399" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="933" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="933" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="904" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="904" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="904" left="281" width="494" height="15" font="14"><b>Surgery  is recommended  for AAOCA  from  the  left  sinus  or  AAOCA  from </b></text>
<text top="923" left="281" width="495" height="15" font="14"><b>the  right  sinus  for  symptoms  or  diagnostic  evidence  consistent  with </b></text>
<text top="943" left="281" width="495" height="15" font="14"><b>coronary  ischemia  attributable  to  the  anomalous  coronary  artery </b></text>
<text top="962" left="281" width="158" height="15" font="14"><b>(S4.4.7.2-1–S4.4.7.2-3). </b></text>
<text top="1002" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="1002" left="193" width="34" height="15" font="14"><b>C-LD </b></text>
<text top="983" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="983" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="983" left="281" width="495" height="15" font="14"><b>Surgery  is  reasonable  for  anomalous  aortic  origin  of  the  left  coronary </b></text>
<text top="1002" left="281" width="495" height="15" font="14"><b>artery  from  the  right  sinus  in  the  absence  of  symptoms  or  ischemia </b></text>
<text top="1022" left="281" width="158" height="15" font="14"><b>(S4.4.7.2-4–S4.4.7.2-6). </b></text>
<text top="1052" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="1052" left="193" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="1042" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="1043" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1042" left="281" width="495" height="15" font="14"><b>Surgery  for  AAOCA  is  reasonable  in  the  setting  of  ventricular </b></text>
<text top="1062" left="281" width="89" height="15" font="14"><b>arrhythmias. </b></text>
<text top="1082" left="125" width="21" height="15" font="14"><b>IIb </b></text>
<text top="1082" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="1082" left="256" width="13" height="15" font="14"><b>4.</b></text>
<text top="1082" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="1082" left="281" width="495" height="15" font="14"><b>Surgery  or  continued  observation  may  be  reasonable  for  asymptomatic </b></text>
</page>
<page number="113" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 115 </text>
<text top="163" left="281" width="495" height="15" font="14"><b>patients  with  an  anomalous  left  coronary  artery  arising  from  the  right </b></text>
<text top="183" left="281" width="495" height="15" font="14"><b>sinus or right coronary artery arising from the left sinus without ischemia </b></text>
<text top="202" left="281" width="495" height="15" font="14"><b>or  anatomic  or  physiological  evaluation  suggesting  potential  for </b></text>
<text top="222" left="281" width="491" height="15" font="14"><b>compromise  of  coronary  perfusion  (e.g.,  intramural  course,  fish-mouth-</b></text>
<text top="241" left="281" width="345" height="15" font="14"><b>shaped orifice, acute angle) (S4.4.7.2-4–S4.4.7.2-6). </b></text>
<text top="270" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="299" left="105" width="687" height="14" font="11">1.  In  patients  with  symptoms  related  to  AAOCA,  repair  of  the  anomaly  should  alleviate  symptoms.  In </text>
<text top="319" left="105" width="687" height="14" font="11">autopsy and surgical series, cardiac symptoms are more common in patients with a left coronary artery </text>
<text top="338" left="105" width="687" height="14" font="11">arising from the right coronary cusp. In autopsy studies of patients who died because of an anomalous </text>
<text top="358" left="105" width="687" height="14" font="11">coronary  artery,  fibrosis  is  a  common  finding,  suggesting  that  ischemia  preceded  the  terminal  event. </text>
<text top="377" left="105" width="687" height="14" font="11">However,  there  are  patients  in  whom  a  SCD  event  occurred  despite  normal  stress  ECG,  and </text>
<text top="397" left="105" width="687" height="14" font="11">consequently  absence  of  ischemia  is  not  reassuring.  Autopsy  series  show  that  many  patients  whose </text>
<text top="416" left="105" width="687" height="14" font="11">death is attributed to anomalous coronary arteries are young, thus management of patients should take </text>
<text top="436" left="105" width="683" height="14" font="11">age into account, with heightened concern about the risk of sudden death in younger patients (S4.4.7.2-</text>
<text top="456" left="105" width="94" height="14" font="11">7–S4.4.7.2-9). </text>
<text top="484" left="105" width="687" height="14" font="11">2. Anomalous left coronary from the right sinus is less common than anomalous right coronary from the </text>
<text top="504" left="105" width="687" height="14" font="11">left  sinus  (S4.4.7.2-10),  but  anomalous left  coronary artery  from  the  right is more  commonly  found  in </text>
<text top="523" left="105" width="687" height="14" font="11">autopsy  series  of  athletes and  military  recruits who had  nontraumatic  death than  right  coronary  from </text>
<text top="543" left="105" width="687" height="14" font="11">the  left  sinus  (S4.4.7.2-1,  S4.4.7.2-11–S4.4.7.2-13).  The  overrepresentation  of  the  anomalous  left </text>
<text top="562" left="105" width="687" height="14" font="11">coronary  from  the  right  sinus  suggests  a  higher  risk  of  SCD,  particular  at  extremes  of  exertion  and  in </text>
<text top="582" left="105" width="171" height="14" font="11">patients &lt;35 years of age. </text>
<text top="611" left="158" width="634" height="14" font="11">There  are  some  anatomic  features  that  are  thought  to  be  associated  with  increased  risk  of </text>
<text top="630" left="105" width="687" height="14" font="11">compromise of coronary flow and/or SCD, including a fish-mouth-shaped or slit-like orifice, or intramural </text>
<text top="650" left="105" width="687" height="14" font="11">course  (S4.4.7.2-14),  although  the  slit-like  orifice  is  more  commonly  encountered  in  a  right  coronary </text>
<text top="669" left="105" width="687" height="14" font="11">arising from the left cusp. It is difficult to quantitate the absolute risk of SCD associated with anomalous </text>
<text top="689" left="105" width="687" height="14" font="11">aortic origin of the left coronary from the right sinus, and data demonstrating that surgery ameliorates </text>
<text top="709" left="105" width="687" height="14" font="11">the  SCD  risk  have  not  been  published.  Until  studies  suggest  otherwise,  limited  data  and  expert </text>
<text top="728" left="105" width="687" height="14" font="11">consensus  suggest  that  it  is  reasonable  that  adults  with  this  malformation  should  undergo  surgical </text>
<text top="748" left="105" width="583" height="14" font="11">unroofing unless there are extenuating circumstances that would make surgery high risk. </text>
<text top="776" left="105" width="687" height="14" font="11">3. In patients with ventricular arrhythmias presumed related to ischemia caused by anomalous origin of </text>
<text top="796" left="105" width="687" height="14" font="11">a coronary artery, repair is an option to alleviate the ischemia and presumably mitigate the recurrence </text>
<text top="815" left="105" width="687" height="14" font="11">of ventricular arrhythmias. However, care should be individualized, as there may be other factors (e.g., </text>
<text top="835" left="105" width="687" height="14" font="11">CAD, cardiomyopathy, residual ischemia) contributing to ventricular arrhythmias that warrant continued </text>
<text top="854" left="105" width="216" height="14" font="11">vigilance and additional therapy. </text>
<text top="883" left="105" width="687" height="14" font="11">4.  Anomalous  aortic  origin  of  the  right  coronary  from  the left  sinus is  more  common  than  anomalous </text>
<text top="902" left="105" width="687" height="14" font="11">aortic origin of the left coronary from the right sinus. The risk of SCD with the former malformation is </text>
<text top="922" left="105" width="687" height="14" font="11">difficult  to  quantitate.  There  is  some  physiological  rationale  to  believe  that  asymptomatic  patients </text>
<text top="942" left="105" width="687" height="14" font="11">without evidence of compromised blood flow would benefit from unroofing, but there are not data to </text>
<text top="961" left="105" width="687" height="14" font="11">demonstrate  that  surgical  interventions  alter  the  risk  of  SCD.  Thus,  watchful  waiting  may  be  an </text>
<text top="981" left="105" width="687" height="14" font="11">appropriate course as well, particularly for a patient with an anomalous right coronary arising from the </text>
<text top="1000" left="105" width="66" height="14" font="11">left sinus. </text>
<text top="1032" left="105" width="4" height="14" font="11"> </text>
<text top="1030" left="315" width="4" height="17" font="38"><i><b> </b></i></text>
</page>
<page number="114" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 116 </text>
<text top="163" left="105" width="447" height="17" font="38"><i><b>4.4.7.3. Anomalous Coronary Artery Arising From the PA </b></i></text>
<text top="197" left="154" width="4" height="14" font="11"> </text>
<text top="196" left="206" width="521" height="16" font="12"><b>Recommendations for Anomalous Coronary Artery Arising From the PA </b></text>
<text top="216" left="116" width="461" height="14" font="11">Referenced studies that support recommendations are summarized in </text>
<text top="216" left="577" width="180" height="14" font="23">Online Data Supplement 51</text>
<text top="216" left="757" width="8" height="14" font="11">. </text>
<text top="237" left="119" width="32" height="15" font="14"><b>COR </b></text>
<text top="237" left="196" width="29" height="15" font="14"><b>LOE </b></text>
<text top="237" left="451" width="129" height="15" font="14"><b>Recommendations </b></text>
<text top="257" left="398" width="84" height="15" font="14"><b>Therapeutic </b></text>
<text top="287" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="287" left="192" width="37" height="15" font="14"><b>B-NR </b></text>
<text top="277" left="256" width="13" height="15" font="14"><b>1.</b></text>
<text top="277" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="277" left="281" width="494" height="15" font="14"><b>Surgery is recommended for anomalous left coronary artery from the PA </b></text>
<text top="297" left="281" width="158" height="15" font="14"><b>(S4.4.7.3-1–S4.4.7.3-7). </b></text>
<text top="337" left="131" width="8" height="15" font="14"><b>I </b></text>
<text top="337" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="317" left="256" width="13" height="15" font="14"><b>2.</b></text>
<text top="317" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="317" left="281" width="494" height="15" font="14"><b>In  a  symptomatic  adult  with  anomalous  right  coronary  artery  from  the </b></text>
<text top="337" left="281" width="494" height="15" font="14"><b>PA  with  symptoms  attributed  to  the  anomalous  coronary,  surgery  is </b></text>
<text top="356" left="281" width="105" height="15" font="14"><b>recommended. </b></text>
<text top="396" left="125" width="20" height="15" font="14"><b>IIa </b></text>
<text top="396" left="192" width="36" height="15" font="14"><b>C-EO </b></text>
<text top="377" left="256" width="13" height="15" font="14"><b>3.</b></text>
<text top="377" left="268" width="4" height="15" font="24"><b> </b></text>
<text top="377" left="281" width="495" height="15" font="14"><b>Surgery for anomalous right coronary artery from the PA is reasonable in </b></text>
<text top="396" left="281" width="495" height="15" font="14"><b>an  asymptomatic  adult  with  ventricular  dysfunction  or  with  myocardial </b></text>
<text top="416" left="281" width="460" height="15" font="14"><b>ischemia attributed to anomalous right coronary artery from the PA. </b></text>
<text top="445" left="105" width="291" height="15" font="14"><b>Recommendation-Specific Supportive Text  </b></text>
<text top="473" left="105" width="687" height="14" font="11">1. Surgery can include reimplantation of the left coronary artery directly into the aorta with or without </text>
<text top="493" left="105" width="687" height="14" font="11">an interposition graft. Ligation or closure of the left coronary artery at the level of the PA with coronary </text>
<text top="513" left="105" width="687" height="14" font="11">artery  bypass  grafting  can  also  be  performed,  usually  using  the  left  internal  mammary  artery </text>
<text top="532" left="105" width="298" height="14" font="11">anastomosed to the left anterior descending. </text>
<text top="561" left="105" width="687" height="14" font="11">2. Surgery can include reimplantation of the right coronary artery directly into the aorta with or without </text>
<text top="580" left="105" width="687" height="14" font="11">an interposition graft. Ligation or closure of the right coronary artery at the level of the PA with coronary </text>
<text top="600" left="105" width="687" height="14" font="11">artery  bypass  grafting  can  also  be  performed,  usually  using  the  right  internal  mammary  artery </text>
<text top="620" left="105" width="499" height="14" font="11">anastomosed to the right coronary or posterior descending coronary artery. </text>
<text top="648" left="105" width="687" height="14" font="11">3. Surgery to alleviate ischemia or ventricular dysfunction is reasonable if the anomalous coronary artery </text>
<text top="667" left="105" width="687" height="14" font="11">is thought to be the cause. Surgery can include reimplantation of the right coronary artery directly into </text>
<text top="687" left="105" width="687" height="14" font="11">the aorta with  or without an interposition graft. Ligation  or closure of the right  coronary artery at the </text>
<text top="707" left="105" width="687" height="14" font="11">level  of  the  PA  with  coronary  artery  bypass  grafting  can  also  be  performed,  usually  using  the  right </text>
<text top="726" left="105" width="667" height="14" font="11">internal mammary artery anastomosed to the right coronary or posterior descending coronary artery. </text>
<text top="764" left="105" width="254" height="19" font="34"><b>4.4.8. Coronary Artery Fistula </b></text>
<text top="797" left="105" width="687" height="14" font="11">Coronary  artery  fistula  is  an  abnormal  communication  between  a  coronary  artery  and  another </text>
<text top="817" left="105" width="687" height="14" font="11">cardiovascular structure, which may include  a cardiac chamber,  coronary sinus,  superior vena cava, or </text>
<text top="836" left="105" width="687" height="14" font="11">PA.  The  incidence  of  coronary  artery  fistula  is  0.1%  to  0.2%  in  all  patients  undergoing  coronary </text>
<text top="856" left="105" width="687" height="14" font="11">angiography  (S4.4.8-1,  S4.4.8-2).  Fistulous  communications  may  be  congenital  or  acquired.  Specific </text>
<text top="875" left="105" width="687" height="14" font="11">management  strategies,  which  can  include  surgical  repair  or  catheter  embolization,  have  been </text>
<text top="895" left="105" width="687" height="14" font="11">controversial.  In  a  series  of  46  patients  treated  with  surgery,  predominant  preoperative  symptoms </text>
<text top="915" left="105" width="687" height="14" font="11">included  angina  and  HF  (S4.4.8-3).  Importantly,  postoperative  myocardial  infarction  occurred  in  11% </text>
<text top="934" left="105" width="687" height="14" font="11">because  of  low  flow  in  the  dilated  coronary  artery  proximal  to  fistula  closure.  Late  survival  was  also </text>
<text top="954" left="105" width="687" height="14" font="11">significantly  reduced  compared  with  an  age-matched  population.  The  presence  of  coronary  artery </text>
<text top="973" left="105" width="687" height="14" font="11">fistula(s)  requires  review  by  a  knowledgeable  team  that  may  include  congenital  or  noncongenital </text>
<text top="993" left="105" width="687" height="14" font="11">cardiologists  and  surgeons  to  determine  the  role  of  medical  therapy  and/or  percutaneous  or  surgical </text>
<text top="1013" left="105" width="121" height="14" font="11">closure (S4.4.8-3). </text>
</page>
<page number="115" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 117 </text>
<text top="164" left="105" width="383" height="21" font="10"><b>5. Evidence Gaps and Future Directions </b></text>
<text top="204" left="105" width="687" height="14" font="11">There  are  multiple  challenges  to  developing  evidenced-based  care  for  patients  with  ACHD.  The </text>
<text top="223" left="105" width="687" height="14" font="11">heterogeneity of conditions leads to small numbers of specific ACHD populations from which to derive </text>
<text top="243" left="105" width="687" height="14" font="11">guidelines.  Additionally,  lack  of  infrastructure  to  track  prevalence,  fragmented  care  systems,  loss  to </text>
<text top="263" left="105" width="687" height="14" font="11">follow-up, and changes in treatment strategies over time all contribute to the challenges of developing </text>
<text top="282" left="105" width="687" height="14" font="11">GDMT  care  (S5-1).  Comprehensive multicenter  and population  registries  and databases  are  needed  to </text>
<text top="302" left="105" width="687" height="14" font="11">have  adequate  numbers  of  patients  to  address  clinical  questions.  Novel  study  methodologies  are </text>
<text top="321" left="105" width="687" height="14" font="11">needed to ascertain effectiveness of diagnostic and therapeutic options when each disease is sufficiently </text>
<text top="341" left="105" width="687" height="14" font="11">rare and events occur over sufficiently long periods that RCTs are impractical. Although there are data </text>
<text top="361" left="105" width="687" height="14" font="11">that  patients  with  complex  CHD  have  improved  survival  when  cared  for  at  an  ACHD  center,  how  can </text>
<text top="380" left="105" width="687" height="14" font="11">networks  of  care  be  developed  that  ensure  patients  get  the  expert  care  needed  when  there  are </text>
<text top="400" left="105" width="687" height="14" font="11">inadequate number of ACHD cardiologists and ACHD centers? How do we ensure that patients are not </text>
<text top="420" left="105" width="687" height="14" font="11">lost to care as they transition from pediatric to adult cardiology? How do we ensure that patients with </text>
<text top="439" left="105" width="687" height="14" font="11">ACHD who would benefit from heart transplantation receive accurate listing priority? See Table 35 for a </text>
<text top="459" left="105" width="354" height="14" font="11">collection of high-impact research questions in ACHD. </text>
<text top="487" left="105" width="4" height="14" font="11"> </text>
<text top="515" left="105" width="343" height="15" font="14"><b>Table 35. High-Impact Research Questions in ACHD </b></text>
<text top="538" left="105" width="51" height="13" font="7"><b>General </b></text>
<text top="557" left="105" width="101" height="13" font="8">Pathophysiology </text>
<text top="554" left="223" width="7" height="19" font="19">•</text>
<text top="558" left="230" width="4" height="13" font="20"> </text>
<text top="558" left="249" width="519" height="13" font="8">What are the mechanisms of heart failure that can be prevented, reversed, or treated? </text>
<text top="572" left="223" width="7" height="19" font="19">•</text>
<text top="577" left="230" width="4" height="13" font="20"> </text>
<text top="577" left="249" width="254" height="13" font="8">Why does the systemic right ventricle fail? </text>
<text top="591" left="223" width="7" height="19" font="19">•</text>
<text top="595" left="230" width="4" height="13" font="20"> </text>
<text top="595" left="249" width="515" height="13" font="8">Will all patients with Fontan physiology develop clinically important cirrhosis, and how </text>
<text top="613" left="249" width="127" height="13" font="8">can we prevent this? </text>
<text top="627" left="223" width="7" height="19" font="19">•</text>
<text top="631" left="230" width="4" height="13" font="20"> </text>
<text top="631" left="249" width="265" height="13" font="8">Who is at risk of aortic rupture and dilation? </text>
<text top="646" left="223" width="7" height="19" font="19">•</text>
<text top="650" left="230" width="4" height="13" font="20"> </text>
<text top="650" left="249" width="482" height="13" font="8">Are patients with manipulated coronary arteries (e.g., ASO, Ross repair) at risk of </text>
<text top="668" left="249" width="217" height="13" font="8">premature coronary artery disease? </text>
<text top="682" left="223" width="7" height="19" font="19">•</text>
<text top="687" left="230" width="4" height="13" font="20"> </text>
<text top="687" left="249" width="375" height="13" font="8">What is the impact of radiation exposure on long-term health? </text>
<text top="701" left="223" width="7" height="19" font="19">•</text>
<text top="705" left="230" width="4" height="13" font="20"> </text>
<text top="705" left="249" width="521" height="13" font="8">Can we predict who will develop pulmonary hypertension/pulmonary vascular disease? </text>
<text top="723" left="105" width="76" height="13" font="8">Medical and </text>
<text top="741" left="105" width="49" height="13" font="8">surgical </text>
<text top="759" left="105" width="64" height="13" font="8">treatment </text>
<text top="720" left="223" width="7" height="19" font="19">•</text>
<text top="724" left="230" width="4" height="13" font="20"> </text>
<text top="724" left="249" width="473" height="13" font="8">How can we modify current CHD surgical procedures to prevent or reduce later </text>
<text top="742" left="249" width="300" height="13" font="8">development of heart failure and/or arrhythmias? </text>
<text top="757" left="223" width="7" height="19" font="19">•</text>
<text top="761" left="230" width="4" height="13" font="20"> </text>
<text top="761" left="249" width="485" height="13" font="8">Which patients with ACHD can use direct oral anticoagulants instead of warfarin? </text>
<text top="775" left="223" width="7" height="19" font="19">•</text>
<text top="779" left="230" width="4" height="13" font="20"> </text>
<text top="779" left="249" width="322" height="13" font="8">What is the best algorithm for contraception choices? </text>
<text top="794" left="223" width="7" height="19" font="19">•</text>
<text top="798" left="230" width="4" height="13" font="20"> </text>
<text top="798" left="249" width="475" height="13" font="8">Beyond those with severe PAH, which patients will benefit from PAH therapies? </text>
<text top="812" left="223" width="7" height="19" font="19">•</text>
<text top="816" left="230" width="4" height="13" font="20"> </text>
<text top="816" left="249" width="494" height="13" font="8">Do patients with ACHD with systemic right ventricles and HF benefit from standard </text>
<text top="834" left="249" width="516" height="13" font="8">therapies (beta blockers, ACE inhibitors/ARBs, aldosterone antagonist)? Which one(s)? </text>
<text top="849" left="223" width="7" height="19" font="19">•</text>
<text top="853" left="230" width="4" height="13" font="20"> </text>
<text top="853" left="249" width="433" height="13" font="8">What medical therapies benefit patients with failing Fontan physiology?  </text>
<text top="867" left="223" width="7" height="19" font="19">•</text>
<text top="872" left="230" width="4" height="13" font="20"> </text>
<text top="871" left="249" width="496" height="13" font="8">Do asymptomatic patients with ACHD with PAH benefit from PAH-specific therapy? </text>
<text top="886" left="223" width="7" height="19" font="19">•</text>
<text top="890" left="230" width="4" height="13" font="20"> </text>
<text top="890" left="249" width="291" height="13" font="8">Who will benefit from ventricular assist devices? </text>
<text top="905" left="223" width="7" height="19" font="19">•</text>
<text top="909" left="230" width="4" height="13" font="20"> </text>
<text top="908" left="249" width="369" height="13" font="8">What should be the threshold(s) for aortic aneurysm surgery? </text>
<text top="923" left="223" width="7" height="19" font="19">•</text>
<text top="927" left="230" width="4" height="13" font="20"> </text>
<text top="927" left="249" width="501" height="13" font="8">What pacing and resynchronization strategies are of most benefit, and when should </text>
<text top="945" left="249" width="86" height="13" font="8">they be used? </text>
<text top="963" left="105" width="91" height="13" font="8">Outcomes/risk </text>
<text top="981" left="105" width="72" height="13" font="8">assessment </text>
<text top="960" left="223" width="7" height="19" font="19">•</text>
<text top="965" left="230" width="4" height="13" font="20"> </text>
<text top="964" left="249" width="348" height="13" font="8">What criteria should determine transplantation eligibility? </text>
<text top="979" left="223" width="7" height="19" font="19">•</text>
<text top="983" left="230" width="4" height="13" font="20"> </text>
<text top="983" left="249" width="325" height="13" font="8">Which patients benefit from primary prevention ICDs? </text>
<text top="997" left="223" width="7" height="19" font="19">•</text>
<text top="1002" left="230" width="4" height="13" font="20"> </text>
<text top="1001" left="249" width="441" height="13" font="8">How can we risk stratify for SCD in patients with systemic right ventricles? </text>
<text top="1016" left="223" width="7" height="19" font="19">•</text>
<text top="1020" left="230" width="4" height="13" font="20"> </text>
<text top="1020" left="249" width="407" height="13" font="8">What operative risk score predicts outcomes in ACHD reoperations? </text>
<text top="1035" left="223" width="7" height="19" font="19">•</text>
<text top="1039" left="230" width="4" height="13" font="20"> </text>
<text top="1039" left="249" width="368" height="13" font="8">What HF risk score predicts outcomes in patients with ACHD? </text>
<text top="1053" left="223" width="7" height="19" font="19">•</text>
<text top="1058" left="230" width="4" height="13" font="20"> </text>
<text top="1057" left="249" width="325" height="13" font="8">Is there a level of exercise where risk exceeds benefit? </text>
<text top="1072" left="223" width="7" height="19" font="19">•</text>
<text top="1076" left="230" width="4" height="13" font="20"> </text>
<text top="1076" left="249" width="266" height="13" font="8">What is the rate and/or risk of endocarditis? </text>
</page>
<page number="116" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 118 </text>
<text top="163" left="105" width="73" height="13" font="8">Assessment </text>
<text top="159" left="223" width="7" height="19" font="19">•</text>
<text top="164" left="230" width="4" height="13" font="20"> </text>
<text top="164" left="249" width="485" height="13" font="8">Who is at high risk of neurodevelopmental abnormalities and would benefit from </text>
<text top="181" left="249" width="264" height="13" font="8">neuropsychiatric evaluation and treatment? </text>
<text top="196" left="223" width="7" height="19" font="19">•</text>
<text top="200" left="230" width="4" height="13" font="20"> </text>
<text top="200" left="249" width="517" height="13" font="8">Who should be screened for anxiety and depression, what treatment is most effective, </text>
<text top="218" left="249" width="400" height="13" font="8">and are there differences compared with non-patients with ACHD? </text>
<text top="232" left="223" width="7" height="19" font="19">•</text>
<text top="237" left="230" width="4" height="13" font="20"> </text>
<text top="237" left="249" width="511" height="13" font="8">What is the standard protocol for assessing right ventricular size and function by CMR </text>
<text top="254" left="249" width="57" height="13" font="8">imaging? </text>
<text top="269" left="223" width="7" height="19" font="19">•</text>
<text top="273" left="230" width="4" height="13" font="20"> </text>
<text top="273" left="249" width="364" height="13" font="8">Which biomarkers are predictive of mortality and morbidity? </text>
<text top="291" left="105" width="99" height="13" font="7"><b>Disease-specific </b></text>
<text top="310" left="105" width="88" height="13" font="8">Coarctation of </text>
<text top="328" left="105" width="58" height="13" font="8">the aorta </text>
<text top="306" left="223" width="7" height="19" font="19">•</text>
<text top="311" left="230" width="4" height="13" font="20"> </text>
<text top="311" left="249" width="485" height="13" font="8">Which measure of hypertension—resting, exercise, or ambulatory—best predicts </text>
<text top="329" left="249" width="69" height="13" font="8">outcomes? </text>
<text top="343" left="223" width="7" height="19" font="19">•</text>
<text top="347" left="230" width="4" height="13" font="20"> </text>
<text top="347" left="249" width="277" height="13" font="8">Is there an optimal antihypertensive regimen? </text>
<text top="362" left="223" width="7" height="19" font="19">•</text>
<text top="366" left="230" width="4" height="13" font="20"> </text>
<text top="366" left="249" width="230" height="13" font="8">What should blood pressure goals be? </text>
<text top="380" left="223" width="7" height="19" font="19">•</text>
<text top="384" left="230" width="4" height="13" font="20"> </text>
<text top="384" left="249" width="377" height="13" font="8">How often should patients be screened for thoracic aneurysm? </text>
<text top="399" left="223" width="7" height="19" font="19">•</text>
<text top="403" left="230" width="4" height="13" font="20"> </text>
<text top="403" left="249" width="302" height="13" font="8">Should exercise-induced hypertension be treated? </text>
<text top="417" left="223" width="7" height="19" font="19">•</text>
<text top="422" left="230" width="4" height="13" font="20"> </text>
<text top="422" left="249" width="325" height="13" font="8">What criteria warrant reintervention in recoarctation? </text>
<text top="436" left="223" width="7" height="19" font="19">•</text>
<text top="440" left="230" width="4" height="13" font="20"> </text>
<text top="440" left="249" width="523" height="13" font="8">Is long-term outcome better with medical therapy or catheter intervention for less than </text>
<text top="458" left="249" width="133" height="13" font="8">severe recoarctation? </text>
<text top="472" left="223" width="7" height="19" font="19">•</text>
<text top="477" left="230" width="4" height="13" font="20"> </text>
<text top="477" left="249" width="457" height="13" font="8">Should patients be screened for intracranial aneurysm, and if so, how often? </text>
<text top="495" left="105" width="101" height="13" font="8">Ebstein anomaly </text>
<text top="492" left="223" width="7" height="19" font="19">•</text>
<text top="496" left="230" width="4" height="13" font="20"> </text>
<text top="496" left="249" width="379" height="13" font="8">What is the indication for surgery in the asymptomatic patient? </text>
<text top="510" left="223" width="7" height="19" font="19">•</text>
<text top="514" left="230" width="4" height="13" font="20"> </text>
<text top="514" left="249" width="420" height="13" font="8">Who should have a Glenn shunt at the time of tricuspid valve surgery? </text>
<text top="529" left="223" width="7" height="19" font="19">•</text>
<text top="533" left="230" width="4" height="13" font="20"> </text>
<text top="533" left="249" width="516" height="13" font="8">Should surgeons attempt tricuspid valve repair or routinely perform replacement in all </text>
<text top="551" left="249" width="59" height="13" font="8">patients? </text>
<text top="569" left="105" width="27" height="13" font="8">TOF </text>
<text top="566" left="223" width="7" height="19" font="19">•</text>
<text top="570" left="230" width="4" height="13" font="20"> </text>
<text top="570" left="249" width="516" height="13" font="8">What is the optimal timing for pulmonary valve replacement in asymptomatic patients </text>
<text top="588" left="249" width="63" height="13" font="8">with TOF? </text>
<text top="602" left="223" width="7" height="19" font="19">•</text>
<text top="607" left="230" width="4" height="13" font="20"> </text>
<text top="607" left="249" width="521" height="13" font="8">Do pulmonary valve replacement and ventricular tachycardia ablation decrease the risk </text>
<text top="624" left="249" width="49" height="13" font="8">of SCD? </text>
<text top="639" left="223" width="7" height="19" font="19">•</text>
<text top="643" left="230" width="4" height="13" font="20"> </text>
<text top="643" left="249" width="469" height="13" font="8">Who needs a primary prevention ICD, and does this strategy reduce mortality? </text>
<text top="657" left="223" width="7" height="19" font="19">•</text>
<text top="662" left="230" width="4" height="13" font="20"> </text>
<text top="662" left="249" width="241" height="13" font="8">Is there a role for PAH therapies in TOF? </text>
<text top="676" left="223" width="7" height="19" font="19">•</text>
<text top="680" left="230" width="4" height="13" font="20"> </text>
<text top="680" left="249" width="283" height="13" font="8">Why does left ventricular dysfunction develop? </text>
<text top="699" left="105" width="85" height="13" font="8">TGA/systemic </text>
<text top="717" left="105" width="86" height="13" font="8">right ventricle </text>
<text top="695" left="223" width="7" height="19" font="19">•</text>
<text top="700" left="230" width="4" height="13" font="20"> </text>
<text top="700" left="249" width="424" height="13" font="8">Who benefits from ACE inhibitors/ARBs/beta blockers/spironolactone? </text>
<text top="714" left="223" width="7" height="19" font="19">•</text>
<text top="718" left="230" width="4" height="13" font="20"> </text>
<text top="718" left="249" width="475" height="13" font="8">Who needs a primary prevention ICD, and does this strategy prevent mortality? </text>
<text top="732" left="223" width="7" height="19" font="19">•</text>
<text top="737" left="230" width="4" height="13" font="20"> </text>
<text top="736" left="249" width="310" height="13" font="8">What imaging findings predict mortality/morbidity? </text>
<text top="751" left="223" width="7" height="19" font="19">•</text>
<text top="755" left="230" width="4" height="13" font="20"> </text>
<text top="755" left="249" width="507" height="13" font="8">In CCTGA with VSD/PS, does the double switch have better long-term outcomes than </text>
<text top="773" left="249" width="273" height="13" font="8">VSD closure and left ventricle–to-PA conduit? </text>
<text top="788" left="223" width="7" height="19" font="19">•</text>
<text top="792" left="230" width="4" height="13" font="20"> </text>
<text top="791" left="249" width="342" height="13" font="8">When should tricuspid valve replacement be performed? </text>
<text top="806" left="223" width="7" height="19" font="19">•</text>
<text top="810" left="230" width="4" height="13" font="20"> </text>
<text top="810" left="249" width="500" height="13" font="8">What is the role of cardiac resynchronization therapy in patients with systemic right </text>
<text top="828" left="249" width="62" height="13" font="8">ventricle? </text>
<text top="846" left="105" width="28" height="13" font="8">ASO </text>
<text top="843" left="223" width="7" height="19" font="19">•</text>
<text top="848" left="230" width="4" height="13" font="20"> </text>
<text top="847" left="249" width="273" height="13" font="8">What are the long-term outcomes after ASO? </text>
<text top="862" left="223" width="7" height="19" font="19">•</text>
<text top="866" left="230" width="4" height="13" font="20"> </text>
<text top="866" left="249" width="519" height="13" font="8">How should the possibility of asymptomatic coronary disease (ostial, compression) and </text>
<text top="884" left="249" width="136" height="13" font="8">ischemia be assessed? </text>
<text top="902" left="105" width="39" height="13" font="8">Single </text>
<text top="920" left="105" width="102" height="13" font="8">ventricle/Fontan </text>
<text top="899" left="223" width="7" height="19" font="19">•</text>
<text top="903" left="230" width="4" height="13" font="20"> </text>
<text top="903" left="249" width="344" height="13" font="8">Is warfarin or aspirin beneficial in patients with a Fontan? </text>
<text top="918" left="223" width="7" height="19" font="19">•</text>
<text top="922" left="230" width="4" height="13" font="20"> </text>
<text top="922" left="249" width="179" height="13" font="8">Are PAH therapies beneficial? </text>
<text top="936" left="223" width="7" height="19" font="19">•</text>
<text top="940" left="230" width="4" height="13" font="20"> </text>
<text top="940" left="249" width="259" height="13" font="8">Is exercise capacity predictive of mortality? </text>
<text top="955" left="223" width="7" height="19" font="19">•</text>
<text top="959" left="230" width="4" height="13" font="20"> </text>
<text top="959" left="249" width="346" height="13" font="8">What liver screening is appropriate and at what intervals? </text>
<text top="974" left="223" width="7" height="19" font="19">•</text>
<text top="978" left="230" width="4" height="13" font="20"> </text>
<text top="977" left="249" width="349" height="13" font="8">How is protein-losing enteropathy best medically treated? </text>
<text top="992" left="223" width="7" height="19" font="19">•</text>
<text top="996" left="230" width="4" height="13" font="20"> </text>
<text top="996" left="249" width="477" height="13" font="8">Why do some patients fail with preserved ejection fraction, whereas other have </text>
<text top="1014" left="249" width="172" height="13" font="8">decreased ejection fraction? </text>
<text top="1028" left="223" width="7" height="19" font="19">•</text>
<text top="1033" left="230" width="4" height="13" font="20"> </text>
<text top="1032" left="249" width="421" height="13" font="8">What are the long-term outcomes of hypoplastic left heart syndrome? </text>
<text top="1047" left="223" width="7" height="19" font="19">•</text>
<text top="1051" left="230" width="4" height="13" font="20"> </text>
<text top="1051" left="249" width="505" height="13" font="8">What is ideal timing for heart transplantation in single ventricle Fontan patients, and </text>
<text top="1069" left="249" width="509" height="13" font="8">should liver issues prompt earlier transplantation than might be felt necessary from a </text>
<text top="1086" left="249" width="125" height="13" font="8">cardiac perspective? </text>
</page>
<page number="117" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 119 </text>
<text top="159" left="223" width="7" height="19" font="19">•</text>
<text top="164" left="230" width="4" height="13" font="20"> </text>
<text top="164" left="249" width="495" height="13" font="8">Which has better long-term outcomes, the Fontan operation or bidirectional Glenn </text>
<text top="181" left="249" width="43" height="13" font="8">alone? </text>
<text top="200" left="105" width="58" height="13" font="8">Coronary </text>
<text top="218" left="105" width="64" height="13" font="8">anomalies </text>
<text top="196" left="223" width="7" height="19" font="19">•</text>
<text top="201" left="230" width="4" height="13" font="20"> </text>
<text top="201" left="249" width="490" height="13" font="8">Does surgical intervention in anomalous aortic origin of coronary arteries improve </text>
<text top="218" left="249" width="55" height="13" font="8">survival? </text>
<text top="237" left="105" width="686" height="12" font="9">ACE indicates angiotensin-converting  enzyme; ACHD,  adult  congenital  heart  disease; ARB,  angiotensin-receptor blocker; ASO, </text>
<text top="252" left="105" width="686" height="12" font="9">arterial  switch  operation;  CCTGA,  congenitally  corrected  transposition  of  the  great  arteries;  CHD,  congenital  heart  disease; </text>
<text top="269" left="105" width="686" height="12" font="9">CMR,  cardiac  magnetic  resonance;  ICD,  implantable  cardioverter-defibrillator;  HF,  heart  failure;  PA,  pulmonary  artery;  PAH, </text>
<text top="285" left="105" width="686" height="12" font="9">pulmonary  artery  hypertension; PS, pulmonary stenosis;  SCD, sudden  cardiac  death; TGA,  transposition of the  great  arteries; </text>
<text top="301" left="105" width="316" height="12" font="9">TOF, tetralogy of Fallot; and VSD, ventricular septal defect. </text>
<text top="317" left="105" width="4" height="15" font="11"> </text>
<text top="346" left="105" width="4" height="15" font="11"> </text>
<text top="374" left="105" width="137" height="15" font="14"><b>Presidents and Staff </b></text>
<text top="393" left="105" width="4" height="15" font="11"> </text>
<text top="413" left="105" width="213" height="15" font="13"><i><b>American College of Cardiology </b></i></text>
<text top="433" left="105" width="280" height="15" font="11">C. Michael Valentine, MD, FACC, President </text>
<text top="452" left="105" width="509" height="15" font="11">Cathleen C. Gates, Interim Chief Executive Officer and Chief Operating Officer </text>
<text top="472" left="105" width="613" height="15" font="11">William J. Oetgen, MD, MBA, FACC, Executive Vice President, Science, Education, Quality, and </text>
<text top="491" left="105" width="83" height="15" font="11">Publications </text>
<text top="511" left="105" width="544" height="15" font="11">MaryAnne Elma, MPH, Senior Director, Science, Education, Quality, and Publishing  </text>
<text top="531" left="105" width="573" height="15" font="11">Amelia Scholtz, PhD, Publications Manager, Science, Education, Quality, and Publishing  </text>
<text top="550" left="105" width="4" height="15" font="11"> </text>
<text top="570" left="105" width="408" height="15" font="13"><i><b>American College of Cardiology/American Heart Association  </b></i></text>
<text top="590" left="105" width="472" height="15" font="11">Katherine A. Sheehan, PhD, Director, Guideline Strategy and Operations </text>
<text top="609" left="105" width="389" height="15" font="11">Abdul R. Abdullah, MD, Senior Manager, Guideline Science  </text>
<text top="629" left="105" width="4" height="14" font="15"><i> </i></text>
<text top="649" left="105" width="189" height="15" font="13"><i><b>American Heart Association </b></i></text>
<text top="668" left="105" width="239" height="15" font="11">Ivor Benjamin, MD, FAHA, President </text>
<text top="688" left="105" width="246" height="15" font="11">Nancy Brown, Chief Executive Officer </text>
<text top="707" left="105" width="450" height="15" font="11">Rose Marie Robertson, MD, FAHA, Chief Science and Medical Officer </text>
<text top="727" left="105" width="608" height="15" font="11">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice President, Office of Science Operations </text>
<text top="746" left="105" width="565" height="15" font="11">Prashant Nedungadi, PhD, Science and Medicine Advisor, Office of Science Operations </text>
<text top="769" left="105" width="679" height="15" font="11">Jody Hundley, Production and Operations Manager, Scientific Publications, Office of Science Operations </text>
<text top="791" left="105" width="4" height="15" font="11"> </text>
<text top="811" left="105" width="4" height="15" font="11"> </text>
<text top="831" left="105" width="323" height="15" font="14"><b>Key Words</b>: ACC/AHA Clinical Practice Guidelines </text>
<text top="828" left="428" width="326" height="20" font="11">■ arrhythmias ■ cardiac catheterization ■ cardiac </text>
<text top="850" left="105" width="52" height="15" font="11">defects </text>
<text top="848" left="157" width="591" height="20" font="11">■ congenital heart disease ■ congenital heart surgery ■ unoperated/repaired heart defect </text>
<text top="870" left="105" width="4" height="15" font="11"> </text>
</page>
<page number="118" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="43" size="21" family="Times" color="#000000"/>
	<fontspec id="44" size="13" family="Times" color="#000000"/>
	<fontspec id="45" size="12" family="Times" color="#000000"/>
	<fontspec id="46" size="12" family="Symbol" color="#000000"/>
	<fontspec id="47" size="12" family="Helvetica" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 120 </text>
<text top="122" left="159" width="922" height="21" font="43"><b>Appendix 1. Author Relationships With Industry and Other Entities (Relevant)—2018 AHA/ACC </b></text>
<text top="151" left="159" width="706" height="21" font="43"><b>Guideline for the Management of Adults With Congenital Heart Disease*</b></text>
<text top="145" left="865" width="3" height="14" font="44"><b> </b></text>
<text top="151" left="868" width="159" height="21" font="43"><b>(February 2018) </b></text>
<text top="228" left="172" width="71" height="13" font="29"><b>Committee </b></text>
<text top="246" left="180" width="56" height="13" font="29"><b>Member </b></text>
<text top="243" left="331" width="81" height="13" font="29"><b>Employment </b></text>
<text top="246" left="492" width="69" height="13" font="29"><b>Consultant </b></text>
<text top="228" left="585" width="58" height="13" font="29"><b>Speakers </b></text>
<text top="246" left="591" width="47" height="13" font="29"><b>Bureau </b></text>
<text top="210" left="663" width="76" height="13" font="29"><b>Ownership/ </b></text>
<text top="228" left="661" width="80" height="13" font="29"><b>Partnership/ </b></text>
<text top="246" left="673" width="56" height="13" font="29"><b>Principal </b></text>
<text top="228" left="760" width="56" height="13" font="29"><b>Personal </b></text>
<text top="246" left="759" width="58" height="13" font="29"><b>Research </b></text>
<text top="192" left="850" width="81" height="13" font="29"><b>Institutional, </b></text>
<text top="210" left="835" width="112" height="13" font="29"><b>Organizational, or </b></text>
<text top="228" left="843" width="96" height="13" font="29"><b>Other Financial </b></text>
<text top="246" left="867" width="47" height="13" font="29"><b>Benefit </b></text>
<text top="228" left="966" width="43" height="13" font="29"><b>Expert </b></text>
<text top="246" left="962" width="52" height="13" font="29"><b>Witness </b></text>
<text top="210" left="1046" width="43" height="13" font="29"><b>Voting </b></text>
<text top="228" left="1031" width="73" height="13" font="29"><b>Recusals by </b></text>
<text top="246" left="1040" width="55" height="13" font="29"><b>Section† </b></text>
<text top="264" left="159" width="88" height="13" font="30">Karen K. Stout </text>
<text top="282" left="159" width="43" height="13" font="45"><i>(Chair)</i> </text>
<text top="264" left="269" width="163" height="13" font="30">University of Washington—</text>
<text top="285" left="269" width="194" height="13" font="30">Director, Adult Congenital Heart </text>
<text top="305" left="269" width="170" height="13" font="30">Disease Program, Professor, </text>
<text top="326" left="269" width="195" height="13" font="30">Internal Medicine and Pediatrics </text>
<text top="264" left="485" width="35" height="13" font="30">None </text>
<text top="264" left="581" width="35" height="13" font="30">None </text>
<text top="264" left="660" width="35" height="13" font="30">None </text>
<text top="264" left="754" width="36" height="13" font="30">None </text>
<text top="264" left="834" width="35" height="13" font="30">None </text>
<text top="264" left="961" width="35" height="13" font="30">None </text>
<text top="264" left="1027" width="35" height="13" font="30">None </text>
<text top="347" left="159" width="87" height="13" font="30">Curt J. Daniels </text>
<text top="365" left="159" width="71" height="13" font="45"><i>(Vice Chair)</i> </text>
<text top="347" left="269" width="191" height="13" font="30">The Ohio State University Heart </text>
<text top="368" left="269" width="204" height="13" font="30">Center and Nationwide Children’s </text>
<text top="388" left="269" width="153" height="13" font="30">Hospital—Director, Adult </text>
<text top="409" left="269" width="178" height="13" font="30">Congenital Heart Disease and </text>
<text top="429" left="269" width="151" height="13" font="30">Pulmonary Hypertension </text>
<text top="450" left="269" width="171" height="13" font="30">Program, Professor, Internal </text>
<text top="470" left="269" width="146" height="13" font="30">Medicine and Pediatrics </text>
<text top="347" left="485" width="35" height="13" font="30">None </text>
<text top="347" left="581" width="35" height="13" font="30">None </text>
<text top="347" left="660" width="35" height="13" font="30">None </text>
<text top="347" left="754" width="36" height="13" font="30">None </text>
<text top="344" left="834" width="7" height="19" font="46">•</text>
<text top="348" left="840" width="4" height="13" font="47"> </text>
<text top="348" left="845" width="59" height="13" font="30">Actelion‡ </text>
<text top="347" left="961" width="35" height="13" font="30">None </text>
<text top="347" left="1027" width="73" height="13" font="30">4.1.1, 4.1.2, </text>
<text top="368" left="1027" width="73" height="13" font="30">4.1.3, 4.1.4, </text>
<text top="388" left="1027" width="36" height="13" font="30">4.1.5, </text>
<text top="409" left="1027" width="48" height="13" font="30">4.4.6.1, </text>
<text top="429" left="1027" width="44" height="13" font="30">4.4.6.2 </text>
<text top="491" left="159" width="49" height="13" font="30">Jamil A. </text>
<text top="509" left="159" width="67" height="13" font="30">Aboulhosn </text>
<text top="491" left="269" width="174" height="13" font="30">UCLA Adult Congenital Heart </text>
<text top="512" left="269" width="154" height="13" font="30">Disease Center—Director </text>
<text top="488" left="482" width="7" height="19" font="46">•</text>
<text top="492" left="489" width="4" height="13" font="47"> </text>
<text top="492" left="495" width="52" height="13" font="30">Actelion </text>
<text top="507" left="482" width="7" height="19" font="46">•</text>
<text top="511" left="489" width="4" height="13" font="47"> </text>
<text top="511" left="495" width="70" height="13" font="30">GE Medical </text>
<text top="525" left="482" width="7" height="19" font="46">•</text>
<text top="529" left="489" width="4" height="13" font="47"> </text>
<text top="529" left="495" width="48" height="13" font="30">Edward </text>
<text top="547" left="495" width="65" height="13" font="30">Lifescience</text>
<text top="565" left="495" width="16" height="13" font="30">s§ </text>
<text top="579" left="482" width="7" height="19" font="46">•</text>
<text top="584" left="489" width="4" height="13" font="47"> </text>
<text top="584" left="495" width="66" height="13" font="30">Medtronic </text>
<text top="491" left="581" width="35" height="13" font="30">None </text>
<text top="491" left="660" width="35" height="13" font="30">None </text>
<text top="491" left="754" width="43" height="13" font="30">• Gore </text>
<text top="488" left="836" width="7" height="19" font="46">•</text>
<text top="492" left="843" width="4" height="13" font="47"> </text>
<text top="492" left="849" width="44" height="13" font="30">United </text>
<text top="510" left="849" width="80" height="13" font="30">Therapeutics </text>
<text top="524" left="836" width="7" height="19" font="46">•</text>
<text top="529" left="843" width="4" height="13" font="47"> </text>
<text top="529" left="849" width="52" height="13" font="30">Actelion </text>
<text top="543" left="836" width="7" height="19" font="46">•</text>
<text top="547" left="843" width="4" height="13" font="47"> </text>
<text top="547" left="849" width="66" height="13" font="30">Medtronic </text>
<text top="561" left="836" width="7" height="19" font="46">•</text>
<text top="566" left="843" width="4" height="13" font="47"> </text>
<text top="566" left="849" width="49" height="13" font="30">St. Jude </text>
<text top="580" left="836" width="7" height="19" font="46">•</text>
<text top="584" left="843" width="4" height="13" font="47"> </text>
<text top="584" left="849" width="48" height="13" font="30">Edward </text>
<text top="602" left="849" width="74" height="13" font="30">Lifesciences </text>
<text top="491" left="961" width="35" height="13" font="30">None </text>
<text top="491" left="1027" width="73" height="13" font="30">4.1.1, 4.1.2, </text>
<text top="512" left="1027" width="73" height="13" font="30">4.1.3, 4.1.4, </text>
<text top="532" left="1027" width="73" height="13" font="30">4.1.5, 4.2.6, </text>
<text top="553" left="1027" width="48" height="13" font="30">4.3.1.1, </text>
<text top="573" left="1027" width="48" height="13" font="30">4.3.1.2, </text>
<text top="594" left="1027" width="36" height="13" font="30">4.3.5, </text>
<text top="614" left="1027" width="48" height="13" font="30">4.4.6.1, </text>
<text top="635" left="1027" width="44" height="13" font="30">4.4.6.2 </text>
<text top="656" left="159" width="283" height="13" font="30">Biykem Bozkurt   Baylor College of Medicine—</text>
<text top="676" left="269" width="137" height="13" font="30">Professor of Medicine  </text>
<text top="656" left="485" width="35" height="13" font="30">None </text>
<text top="656" left="581" width="35" height="13" font="30">None </text>
<text top="656" left="660" width="35" height="13" font="30">None </text>
<text top="656" left="754" width="36" height="13" font="30">None </text>
<text top="653" left="834" width="7" height="19" font="46">•</text>
<text top="657" left="840" width="4" height="13" font="47"> </text>
<text top="656" left="846" width="53" height="13" font="30">Novartis </text>
<text top="656" left="961" width="35" height="13" font="30">None </text>
<text top="656" left="1027" width="35" height="13" font="30">None </text>
</page>
<page number="119" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 121 </text>
<text top="109" left="159" width="274" height="13" font="30">Craig S. Broberg  Oregon Health and Science </text>
<text top="130" left="269" width="192" height="13" font="30">University—Associate Professor </text>
<text top="150" left="269" width="74" height="13" font="30">of Medicine </text>
<text top="109" left="485" width="35" height="13" font="30">None </text>
<text top="109" left="581" width="35" height="13" font="30">None </text>
<text top="109" left="660" width="39" height="13" font="30">None  </text>
<text top="109" left="754" width="36" height="13" font="30">None </text>
<text top="106" left="834" width="7" height="19" font="46">•</text>
<text top="110" left="840" width="4" height="13" font="47"> </text>
<text top="110" left="845" width="52" height="13" font="30">Actelion </text>
<text top="109" left="961" width="35" height="13" font="30">None </text>
<text top="109" left="1027" width="73" height="13" font="30">4.1.1, 4.1.2, </text>
<text top="130" left="1027" width="73" height="13" font="30">4.1.3, 4.1.4, </text>
<text top="150" left="1027" width="36" height="13" font="30">4.1.5, </text>
<text top="170" left="1027" width="48" height="13" font="30">4.4.6.1, </text>
<text top="191" left="1027" width="44" height="13" font="30">4.4.6.2 </text>
<text top="212" left="159" width="96" height="13" font="30">Jack M. Colman </text>
<text top="212" left="269" width="199" height="13" font="30">University of Toronto—Professor </text>
<text top="233" left="269" width="177" height="13" font="30">of Medicine and Obstetrics &amp; </text>
<text top="253" left="269" width="194" height="13" font="30">Gynecology, Toronto Congenital </text>
<text top="274" left="269" width="178" height="13" font="30">Cardiac Centre for Adults and </text>
<text top="294" left="269" width="176" height="13" font="30">Pregnancy and Heart Disease </text>
<text top="315" left="269" width="164" height="13" font="30">Program; University Health </text>
<text top="335" left="269" width="156" height="13" font="30">Network and Mount Sinai </text>
<text top="356" left="269" width="165" height="13" font="30">Hospital—Senior Attending </text>
<text top="376" left="269" width="74" height="13" font="30">Cardiologist </text>
<text top="212" left="485" width="35" height="13" font="30">None </text>
<text top="212" left="581" width="35" height="13" font="30">None </text>
<text top="212" left="660" width="35" height="13" font="30">None </text>
<text top="212" left="754" width="36" height="13" font="30">None </text>
<text top="212" left="834" width="35" height="13" font="30">None </text>
<text top="212" left="961" width="35" height="13" font="30">None </text>
<text top="212" left="1027" width="35" height="13" font="30">None </text>
<text top="397" left="159" width="67" height="13" font="30">Stephen R. </text>
<text top="415" left="159" width="46" height="13" font="30">Crumb  </text>
<text top="397" left="269" width="170" height="13" font="30">Boston Children’s Hospital—</text>
<text top="418" left="269" width="138" height="13" font="30">Nurse Practitioner and </text>
<text top="438" left="269" width="150" height="13" font="30">Coordinator, COACH and </text>
<text top="459" left="269" width="151" height="13" font="30">Pulmonary Hypertension </text>
<text top="479" left="269" width="60" height="13" font="30">Programs </text>
<text top="397" left="485" width="35" height="13" font="30">None </text>
<text top="397" left="581" width="35" height="13" font="30">None </text>
<text top="397" left="660" width="35" height="13" font="30">None </text>
<text top="397" left="754" width="36" height="13" font="30">None </text>
<text top="397" left="834" width="35" height="13" font="30">None </text>
<text top="397" left="961" width="35" height="13" font="30">None </text>
<text top="397" left="1027" width="35" height="13" font="30">None </text>
<text top="501" left="159" width="59" height="13" font="30">Joseph A. </text>
<text top="519" left="159" width="50" height="13" font="30">Dearani </text>
<text top="501" left="269" width="157" height="13" font="30">Mayo Clinic—Professor of </text>
<text top="521" left="269" width="178" height="13" font="30">Surgery and Chair, Division of </text>
<text top="542" left="269" width="139" height="13" font="30">Cardiovascular Surgery </text>
<text top="501" left="485" width="35" height="13" font="30">None </text>
<text top="501" left="581" width="35" height="13" font="30">None </text>
<text top="501" left="660" width="35" height="13" font="30">None </text>
<text top="501" left="754" width="36" height="13" font="30">None </text>
<text top="497" left="831" width="7" height="19" font="46">•</text>
<text top="501" left="838" width="4" height="13" font="47"> </text>
<text top="501" left="842" width="34" height="13" font="30">Sorin </text>
<text top="519" left="842" width="70" height="13" font="30">(LivaNova)§</text>
<text top="517" left="912" width="10" height="18" font="30">║</text>
<text top="519" left="922" width="4" height="13" font="47"> </text>
<text top="534" left="831" width="7" height="19" font="46">•</text>
<text top="538" left="838" width="4" height="13" font="47"> </text>
<text top="538" left="842" width="59" height="13" font="30">Cormatrix</text>
<text top="535" left="901" width="14" height="18" font="30">║ </text>
<text top="501" left="961" width="35" height="13" font="30">None </text>
<text top="501" left="1027" width="35" height="13" font="30">None </text>
<text top="563" left="159" width="63" height="13" font="30">Stephanie </text>
<text top="581" left="159" width="37" height="13" font="30">Fuller </text>
<text top="563" left="269" width="160" height="13" font="30">University of Pennsylvania </text>
<text top="583" left="269" width="187" height="13" font="30">Perelman School of Medicine—</text>
<text top="604" left="269" width="180" height="13" font="30">Associate Professor of Clinical </text>
<text top="624" left="269" width="49" height="13" font="30">Surgery </text>
<text top="563" left="485" width="35" height="13" font="30">None </text>
<text top="563" left="581" width="35" height="13" font="30">None </text>
<text top="563" left="660" width="35" height="13" font="30">None </text>
<text top="563" left="754" width="36" height="13" font="30">None </text>
<text top="563" left="834" width="35" height="13" font="30">None </text>
<text top="563" left="961" width="35" height="13" font="30">None </text>
<text top="563" left="1027" width="35" height="13" font="30">None </text>
<text top="646" left="159" width="54" height="13" font="30">Michelle </text>
<text top="663" left="159" width="46" height="13" font="30">Gurvitz </text>
<text top="646" left="269" width="201" height="13" font="30">Harvard Medical School; Brigham </text>
<text top="666" left="269" width="148" height="13" font="30">and Women’s Hospital—</text>
<text top="687" left="269" width="199" height="13" font="30">Instructor of Pediatrics, Assistant </text>
<text top="707" left="269" width="63" height="13" font="30">Professor  </text>
<text top="646" left="485" width="35" height="13" font="30">None </text>
<text top="646" left="581" width="35" height="13" font="30">None </text>
<text top="646" left="660" width="35" height="13" font="30">None </text>
<text top="646" left="754" width="36" height="13" font="30">None </text>
<text top="646" left="834" width="35" height="13" font="30">None </text>
<text top="646" left="961" width="35" height="13" font="30">None </text>
<text top="646" left="1027" width="35" height="13" font="30">None </text>
</page>
<page number="120" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 122 </text>
<text top="109" left="159" width="70" height="13" font="30">Paul Khairy </text>
<text top="109" left="269" width="184" height="13" font="30">Montreal Heart Institute Adult </text>
<text top="130" left="269" width="176" height="13" font="30">Congenital Center—Director; </text>
<text top="150" left="269" width="133" height="13" font="30">Professor of Medicine </text>
<text top="109" left="485" width="35" height="13" font="30">None </text>
<text top="109" left="581" width="39" height="13" font="30">None  </text>
<text top="109" left="660" width="35" height="13" font="30">None </text>
<text top="109" left="754" width="36" height="13" font="30">None </text>
<text top="106" left="835" width="7" height="19" font="46">•</text>
<text top="110" left="841" width="4" height="13" font="47"> </text>
<text top="110" left="849" width="69" height="13" font="30">Boehringer </text>
<text top="128" left="849" width="69" height="13" font="30">Ingelheim§ </text>
<text top="142" left="835" width="7" height="19" font="46">•</text>
<text top="146" left="841" width="4" height="13" font="47"> </text>
<text top="146" left="849" width="49" height="13" font="30">St. Jude </text>
<text top="164" left="849" width="58" height="13" font="30">Medical§ </text>
<text top="179" left="835" width="7" height="19" font="46">•</text>
<text top="183" left="841" width="4" height="13" font="47"> </text>
<text top="183" left="849" width="73" height="13" font="30">Medtronic§ </text>
<text top="197" left="835" width="7" height="19" font="46">•</text>
<text top="201" left="841" width="4" height="13" font="47"> </text>
<text top="201" left="849" width="59" height="13" font="30">Actelion§ </text>
<text top="109" left="961" width="35" height="13" font="30">None </text>
<text top="109" left="1027" width="73" height="13" font="30">4.1.1, 4.1.2, </text>
<text top="130" left="1027" width="73" height="13" font="30">4.1.3, 4.1.4, </text>
<text top="150" left="1027" width="73" height="13" font="30">4.1.5, 4.2.6, </text>
<text top="170" left="1027" width="48" height="13" font="30">4.3.1.1, </text>
<text top="191" left="1027" width="48" height="13" font="30">4.3.1.2, </text>
<text top="212" left="1027" width="36" height="13" font="30">4.3.5, </text>
<text top="232" left="1027" width="48" height="13" font="30">4.4.6.1, </text>
<text top="253" left="1027" width="44" height="13" font="30">4.4.6.2 </text>
<text top="274" left="159" width="62" height="13" font="30">Michael J. </text>
<text top="292" left="159" width="64" height="13" font="30">Landzberg </text>
<text top="274" left="269" width="173" height="13" font="30">Boston Children’s Hospital— </text>
<text top="294" left="269" width="194" height="13" font="30">Director, Adult Congenital Heart </text>
<text top="315" left="269" width="151" height="13" font="30">Service; Harvard Medical </text>
<text top="335" left="269" width="187" height="13" font="30">School—Associate Professor of </text>
<text top="356" left="269" width="59" height="13" font="30">Medicine </text>
<text top="274" left="485" width="35" height="13" font="30">None </text>
<text top="274" left="581" width="35" height="13" font="30">None </text>
<text top="274" left="660" width="35" height="13" font="30">None </text>
<text top="274" left="754" width="36" height="13" font="30">None </text>
<text top="270" left="834" width="7" height="19" font="46">•</text>
<text top="275" left="840" width="4" height="13" font="47"> </text>
<text top="275" left="848" width="41" height="13" font="30">Gilead </text>
<text top="289" left="834" width="7" height="19" font="46">•</text>
<text top="293" left="840" width="4" height="13" font="47"> </text>
<text top="293" left="848" width="52" height="13" font="30">Actelion </text>
<text top="274" left="961" width="35" height="13" font="30">None </text>
<text top="274" left="1027" width="73" height="13" font="30">4.1.1, 4.1.2, </text>
<text top="294" left="1027" width="73" height="13" font="30">4.1.3, 4.1.4, </text>
<text top="315" left="1027" width="36" height="13" font="30">4.1.5, </text>
<text top="335" left="1027" width="48" height="13" font="30">4.4.6.1, </text>
<text top="356" left="1027" width="44" height="13" font="30">4.4.6.2 </text>
<text top="377" left="159" width="66" height="13" font="30">Arwa Saidi </text>
<text top="377" left="269" width="185" height="13" font="30">University of Florida College of </text>
<text top="397" left="269" width="199" height="13" font="30">Medicine—Professor, Congenital </text>
<text top="418" left="269" width="80" height="13" font="30">Heart Center </text>
<text top="377" left="485" width="35" height="13" font="30">None </text>
<text top="377" left="581" width="35" height="13" font="30">None </text>
<text top="377" left="660" width="35" height="13" font="30">None </text>
<text top="377" left="754" width="36" height="13" font="30">None </text>
<text top="374" left="834" width="7" height="19" font="46">•</text>
<text top="378" left="840" width="4" height="13" font="47"> </text>
<text top="378" left="848" width="59" height="13" font="30">Actelion§ </text>
<text top="377" left="961" width="35" height="13" font="30">None </text>
<text top="377" left="1027" width="73" height="13" font="30">4.1.1, 4.1.2, </text>
<text top="397" left="1027" width="73" height="13" font="30">4.1.3, 4.1.4, </text>
<text top="418" left="1027" width="36" height="13" font="30">4.1.5, </text>
<text top="438" left="1027" width="48" height="13" font="30">4.4.6.1, </text>
<text top="459" left="1027" width="44" height="13" font="30">4.4.6.2 </text>
<text top="480" left="159" width="73" height="13" font="30">Anne Marie </text>
<text top="498" left="159" width="49" height="13" font="30">Valente </text>
<text top="480" left="269" width="163" height="13" font="30">Boston Children’s Hospital, </text>
<text top="501" left="269" width="139" height="13" font="30">Brigham and Women’s </text>
<text top="521" left="269" width="186" height="13" font="30">Hospital—Outpatient Director, </text>
<text top="541" left="269" width="184" height="13" font="30">Boston Adult Congenital Heart </text>
<text top="562" left="269" width="142" height="13" font="30">Disease and Pulmonary </text>
<text top="582" left="269" width="184" height="13" font="30">Hypertension Service; Harvard </text>
<text top="603" left="269" width="163" height="13" font="30">Medical School—Associate </text>
<text top="623" left="269" width="159" height="13" font="30">Professor of Medicine and </text>
<text top="644" left="269" width="61" height="13" font="30">Pediatrics </text>
<text top="480" left="485" width="35" height="13" font="30">None </text>
<text top="480" left="581" width="35" height="13" font="30">None </text>
<text top="480" left="660" width="35" height="13" font="30">None </text>
<text top="480" left="754" width="36" height="13" font="30">None </text>
<text top="480" left="834" width="35" height="13" font="30">None </text>
<text top="480" left="961" width="35" height="13" font="30">None </text>
<text top="480" left="1027" width="35" height="13" font="30">None </text>
<text top="665" left="159" width="87" height="13" font="30">George F. Van </text>
<text top="683" left="159" width="32" height="13" font="30">Hare </text>
<text top="665" left="269" width="196" height="13" font="30">Washington University School of </text>
<text top="685" left="269" width="180" height="13" font="30">Medicine—Director, Pediatric </text>
<text top="706" left="269" width="189" height="13" font="30">Cardiology; St. Louis Children’s, </text>
<text top="726" left="269" width="175" height="13" font="30">Washington University Heart </text>
<text top="747" left="269" width="125" height="13" font="30">Center—Co-Director </text>
<text top="665" left="485" width="35" height="13" font="30">None </text>
<text top="665" left="581" width="35" height="13" font="30">None </text>
<text top="665" left="660" width="35" height="13" font="30">None </text>
<text top="665" left="754" width="36" height="13" font="30">None </text>
<text top="665" left="834" width="35" height="13" font="30">None </text>
<text top="665" left="961" width="35" height="13" font="30">None </text>
<text top="665" left="1027" width="35" height="13" font="30">None </text>
</page>
<page number="121" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="48" size="11" family="Times" color="#000000"/>
	<fontspec id="49" size="14" family="Times" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 123 </text>
<text top="108" left="159" width="949" height="12" font="31">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were </text>
<text top="126" left="159" width="949" height="12" font="31">reviewed  and  updated  in  conjunction  with  all meetings  and/or  conference  calls  of  the  writing  committee  during  the  document  development  process.  The  table  does  not </text>
<text top="145" left="159" width="949" height="12" font="31">necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of </text>
<text top="164" left="159" width="949" height="12" font="31">≥5% of  the voting  stock  or share of the  business entity, or  ownership of ≥$5,000 of  the fair market  value  of the business entity; or if funds received  by the  person from  the </text>
<text top="182" left="159" width="949" height="12" font="31">business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. </text>
<text top="200" left="159" width="338" height="12" font="31">Relationships in this table are modest unless otherwise noted.  </text>
<text top="219" left="159" width="949" height="12" font="31">  According to the ACC/AHA, a person has a <i>relevant</i> relationship IF: a) the <i>relationship or interest</i> relates to the same or similar subject matter, intellectual property or asset, </text>
<text top="237" left="159" width="949" height="12" font="31">topic, or issue addressed in the <i>document;</i> or b) the <i>company/entity</i> (with whom the relationship exists) makes a drug, drug class, or device addressed in the <i>document</i> or makes </text>
<text top="256" left="159" width="949" height="12" font="31">a competing drug or device addressed in the <i>document</i>; or c) the <i>person or a member of the person’s household</i>, has a reasonable potential for financial, professional or other </text>
<text top="274" left="159" width="437" height="12" font="31">personal gain or loss as a result of the issues/content addressed in the <i>document</i>. </text>
<text top="293" left="159" width="3" height="12" font="31"> </text>
<text top="311" left="159" width="949" height="12" font="31">*The ACHD Guideline began in March 2014. Over the initial years of the CMS Open Payment System, understandably, there have been issues related to accurate reporting of </text>
<text top="329" left="159" width="762" height="12" font="31">food and beverage payments. For this reason, the ACC and AHA have not considered these minor charges relevant relationships with industry. </text>
<text top="348" left="159" width="903" height="12" font="31">†Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply. </text>
<text top="366" left="159" width="118" height="12" font="31">‡No financial benefit. </text>
<text top="385" left="159" width="135" height="12" font="31">§Significant relationship. </text>
<text top="401" left="159" width="949" height="16" font="31">║CMS reported payments to Dr. Dearani in 2016 related to research for the Sorin Group and Cormatrix; however, he disagrees with this report. The sections authored by Dr. </text>
<text top="422" left="159" width="578" height="12" font="31">Dearani have been reviewed, and it was affirmed that there was no implication of any influence of industry. </text>
<text top="440" left="159" width="3" height="12" font="31"> </text>
<text top="459" left="159" width="949" height="12" font="31">ACC  indicates  American  College  of  Cardiology;  AHA,  American  Heart  Association;  CMS,  Centers  for  Medicare  &amp;  Medicaid  Services;  COACH,  Columbus  Ohio  Adult  Congenital </text>
<text top="477" left="159" width="291" height="12" font="31">Heart; and UCLA, University of California, Los Angeles. </text>
<text top="495" left="159" width="3" height="12" font="31"> </text>
<text top="515" left="159" width="4" height="14" font="49"> </text>
<text top="515" left="369" width="4" height="14" font="49"> </text>
</page>
<page number="122" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="50" size="12" family="Symbol" color="#212121"/>
	<fontspec id="51" size="12" family="Helvetica" color="#212121"/>
	<fontspec id="52" size="12" family="Times" color="#212121"/>
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 124 </text>
<text top="110" left="159" width="913" height="21" font="43"><b>Appendix 2. Reviewer Relationships With Industry and Other Entities (Comprehensive)—2018 </b></text>
<text top="139" left="159" width="896" height="21" font="43"><b>AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease (February </b></text>
<text top="168" left="159" width="60" height="21" font="43"><b>2018) </b></text>
<text top="263" left="171" width="60" height="13" font="29"><b>Reviewer </b></text>
<text top="263" left="263" width="97" height="13" font="29"><b>Representation </b></text>
<text top="263" left="422" width="81" height="13" font="29"><b>Employment </b></text>
<text top="263" left="570" width="69" height="13" font="29"><b>Consultant </b></text>
<text top="245" left="667" width="58" height="13" font="29"><b>Speakers </b></text>
<text top="263" left="672" width="47" height="13" font="29"><b>Bureau </b></text>
<text top="227" left="742" width="76" height="13" font="29"><b>Ownership/ </b></text>
<text top="245" left="740" width="80" height="13" font="29"><b>Partnership/ </b></text>
<text top="263" left="752" width="56" height="13" font="29"><b>Principal </b></text>
<text top="245" left="834" width="56" height="13" font="29"><b>Personal </b></text>
<text top="263" left="833" width="58" height="13" font="29"><b>Research </b></text>
<text top="209" left="919" width="81" height="13" font="29"><b>Institutional, </b></text>
<text top="227" left="904" width="112" height="13" font="29"><b>Organizational, or </b></text>
<text top="245" left="912" width="96" height="13" font="29"><b>Other Financial </b></text>
<text top="263" left="936" width="47" height="13" font="29"><b>Benefit </b></text>
<text top="245" left="1047" width="43" height="13" font="29"><b>Expert </b></text>
<text top="263" left="1043" width="52" height="13" font="29"><b>Witness </b></text>
<text top="281" left="159" width="59" height="13" font="30">Samuel J. </text>
<text top="299" left="159" width="71" height="13" font="30">Asirvatham </text>
<text top="281" left="256" width="45" height="13" font="30">Official </text>
<text top="299" left="256" width="98" height="13" font="30">Reviewer—AHA </text>
<text top="281" left="380" width="157" height="13" font="30">Mayo Clinic—Professor of </text>
<text top="299" left="380" width="146" height="13" font="30">Medicine and Pediatrics </text>
<text top="278" left="558" width="7" height="19" font="50">•</text>
<text top="282" left="564" width="4" height="13" font="51"> </text>
<text top="282" left="568" width="55" height="13" font="52">Abiomed </text>
<text top="297" left="558" width="7" height="19" font="46">•</text>
<text top="301" left="565" width="4" height="13" font="47"> </text>
<text top="301" left="568" width="48" height="13" font="52">AtriCure</text>
<text top="301" left="615" width="3" height="13" font="30"> </text>
<text top="315" left="558" width="7" height="19" font="46">•</text>
<text top="319" left="565" width="4" height="13" font="47"> </text>
<text top="319" left="568" width="54" height="13" font="52">Biosense </text>
<text top="337" left="568" width="49" height="13" font="52">Webster</text>
<text top="337" left="616" width="3" height="13" font="30"> </text>
<text top="351" left="558" width="7" height="19" font="46">•</text>
<text top="356" left="565" width="4" height="13" font="47"> </text>
<text top="356" left="568" width="52" height="13" font="52">Biotronik</text>
<text top="356" left="619" width="3" height="13" font="30"> </text>
<text top="370" left="558" width="7" height="19" font="46">•</text>
<text top="374" left="565" width="4" height="13" font="47"> </text>
<text top="374" left="568" width="43" height="13" font="52">Boston </text>
<text top="392" left="568" width="51" height="13" font="52">Scientific</text>
<text top="392" left="618" width="11" height="13" font="30">* </text>
<text top="407" left="558" width="7" height="19" font="46">•</text>
<text top="411" left="565" width="4" height="13" font="47"> </text>
<text top="411" left="568" width="60" height="13" font="52">Medtronic</text>
<text top="411" left="627" width="3" height="13" font="30"> </text>
<text top="425" left="558" width="7" height="19" font="46">•</text>
<text top="429" left="565" width="4" height="13" font="47"> </text>
<text top="429" left="568" width="80" height="13" font="52">Sanofi-aventis</text>
<text top="429" left="647" width="3" height="13" font="30"> </text>
<text top="444" left="558" width="7" height="19" font="46">•</text>
<text top="448" left="565" width="4" height="13" font="47"> </text>
<text top="448" left="568" width="47" height="13" font="52">St. Jude </text>
<text top="466" left="568" width="45" height="13" font="52">Medical</text>
<text top="466" left="613" width="3" height="13" font="30"> </text>
<text top="281" left="663" width="35" height="13" font="30">None </text>
<text top="281" left="740" width="35" height="13" font="30">None </text>
<text top="281" left="833" width="36" height="13" font="30">None </text>
<text top="281" left="904" width="35" height="13" font="30">None </text>
<text top="281" left="1029" width="35" height="13" font="30">None </text>
<text top="484" left="159" width="65" height="13" font="30">Wendy M. </text>
<text top="502" left="159" width="33" height="13" font="30">Book </text>
<text top="484" left="256" width="45" height="13" font="30">Official </text>
<text top="502" left="256" width="98" height="13" font="30">Reviewer—AHA </text>
<text top="484" left="380" width="115" height="13" font="30">Emory University—</text>
<text top="502" left="380" width="159" height="13" font="30">Professor of Medicine and </text>
<text top="520" left="380" width="144" height="13" font="30">Director of Emory Adult </text>
<text top="538" left="380" width="150" height="13" font="30">Congenital Heart Center, </text>
<text top="555" left="380" width="150" height="13" font="30">Department of Medicine </text>
<text top="484" left="558" width="35" height="13" font="30">None </text>
<text top="484" left="663" width="35" height="13" font="30">None </text>
<text top="484" left="740" width="35" height="13" font="30">None </text>
<text top="484" left="833" width="36" height="13" font="30">None </text>
<text top="481" left="904" width="7" height="19" font="46">•</text>
<text top="485" left="910" width="4" height="13" font="47"> </text>
<text top="485" left="913" width="52" height="13" font="30">Actelion </text>
<text top="481" left="1029" width="7" height="19" font="46">•</text>
<text top="485" left="1036" width="4" height="13" font="47"> </text>
<text top="485" left="1038" width="70" height="13" font="30">Defendant, </text>
<text top="503" left="1038" width="66" height="13" font="30">congenital </text>
<text top="521" left="1038" width="35" height="13" font="30">heart </text>
<text top="538" left="1038" width="51" height="13" font="30">disease, </text>
<text top="556" left="1038" width="33" height="13" font="30">2015 </text>
<text top="575" left="159" width="61" height="13" font="30">Samuel S. </text>
<text top="593" left="159" width="49" height="13" font="30">Gidding </text>
<text top="575" left="256" width="45" height="13" font="30">Official </text>
<text top="593" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="611" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="628" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="646" left="256" width="51" height="13" font="30">Practice </text>
<text top="664" left="256" width="69" height="13" font="30">Guidelines  </text>
<text top="575" left="380" width="148" height="13" font="30">Nemours Cardiac Center </text>
<text top="593" left="380" width="121" height="13" font="30">DuPont Hospital for </text>
<text top="611" left="380" width="151" height="13" font="30">Children—Chief, Division </text>
<text top="628" left="380" width="138" height="13" font="30">of Pediatric Cardiology </text>
<text top="575" left="558" width="35" height="13" font="30">None </text>
<text top="575" left="663" width="35" height="13" font="30">None </text>
<text top="575" left="740" width="35" height="13" font="30">None </text>
<text top="575" left="833" width="36" height="13" font="30">None </text>
<text top="575" left="904" width="35" height="13" font="30">None </text>
<text top="575" left="1029" width="35" height="13" font="30">None </text>
</page>
<page number="123" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 125 </text>
<text top="109" left="159" width="65" height="13" font="30">Yuli Y. Kim </text>
<text top="109" left="256" width="45" height="13" font="30">Official </text>
<text top="127" left="256" width="98" height="13" font="30">Reviewer—AHA </text>
<text top="109" left="380" width="79" height="13" font="30">University of </text>
<text top="127" left="380" width="91" height="13" font="30">Pennsylvania—</text>
<text top="127" left="471" width="57" height="13" font="52">Assistant </text>
<text top="145" left="380" width="138" height="13" font="52">Professor of Medicine; </text>
<text top="163" left="380" width="130" height="13" font="52">Children’s Hospital of </text>
<text top="180" left="380" width="73" height="13" font="52">Philadelphia</text>
<text top="180" left="453" width="64" height="13" font="30">—Medical </text>
<text top="198" left="380" width="132" height="13" font="52">Director, Philadelphia </text>
<text top="216" left="380" width="139" height="13" font="52">Adult Congenital Heart </text>
<text top="234" left="380" width="40" height="13" font="52">Center</text>
<text top="234" left="420" width="3" height="13" font="30"> </text>
<text top="109" left="558" width="35" height="13" font="30">None </text>
<text top="109" left="663" width="35" height="13" font="30">None </text>
<text top="109" left="740" width="35" height="13" font="30">None </text>
<text top="109" left="833" width="36" height="13" font="30">None </text>
<text top="109" left="904" width="35" height="13" font="30">None </text>
<text top="109" left="1029" width="35" height="13" font="30">None </text>
<text top="252" left="159" width="46" height="13" font="30">Geetha </text>
<text top="270" left="159" width="67" height="13" font="30">Raghuveer </text>
<text top="252" left="256" width="45" height="13" font="30">Official </text>
<text top="270" left="256" width="96" height="13" font="30">Reviewer—ACC </text>
<text top="288" left="256" width="54" height="13" font="30">Board of </text>
<text top="306" left="256" width="69" height="13" font="30">Governors  </text>
<text top="252" left="380" width="103" height="13" font="30">Children’s Mercy </text>
<text top="270" left="380" width="121" height="13" font="30">Hospital— Pediatric </text>
<text top="288" left="380" width="156" height="13" font="30">Cardiologist; University of </text>
<text top="306" left="380" width="128" height="13" font="30">Missouri, Kansas City </text>
<text top="324" left="380" width="127" height="13" font="30">School of Medicine—</text>
<text top="341" left="380" width="136" height="13" font="30">Professor of Pediatrics </text>
<text top="252" left="558" width="32" height="13" font="30">None</text>
<text top="252" left="590" width="3" height="13" font="52"> </text>
<text top="252" left="663" width="35" height="13" font="30">None </text>
<text top="252" left="740" width="35" height="13" font="30">None </text>
<text top="252" left="833" width="36" height="13" font="30">None </text>
<text top="252" left="904" width="35" height="13" font="30">None </text>
<text top="252" left="1029" width="35" height="13" font="30">None </text>
<text top="360" left="159" width="57" height="13" font="30">Carole A. </text>
<text top="378" left="159" width="49" height="13" font="30">Warnes </text>
<text top="360" left="256" width="45" height="13" font="30">Official </text>
<text top="378" left="256" width="96" height="13" font="30">Reviewer—ACC </text>
<text top="395" left="256" width="108" height="13" font="30">Board of Trustees </text>
<text top="360" left="380" width="157" height="13" font="30">Mayo Clinic—Professor of </text>
<text top="377" left="380" width="59" height="13" font="30">Medicine </text>
<text top="360" left="558" width="32" height="13" font="30">None</text>
<text top="360" left="590" width="3" height="13" font="52"> </text>
<text top="360" left="663" width="35" height="13" font="30">None </text>
<text top="360" left="740" width="35" height="13" font="30">None </text>
<text top="360" left="833" width="36" height="13" font="30">None </text>
<text top="360" left="904" width="35" height="13" font="30">None </text>
<text top="360" left="1029" width="35" height="13" font="30">None </text>
<text top="414" left="159" width="81" height="13" font="30">Peter J. Bartz </text>
<text top="414" left="256" width="90" height="13" font="30">Organizational </text>
<text top="432" left="256" width="94" height="13" font="30">Reviewer—ASE </text>
<text top="414" left="380" width="130" height="13" font="30">Children’s Hospital of </text>
<text top="432" left="380" width="133" height="13" font="30">Wisconsin—Associate </text>
<text top="449" left="380" width="161" height="13" font="30">Professor, Medical College </text>
<text top="467" left="380" width="82" height="13" font="30">of Wisconsin  </text>
<text top="414" left="558" width="35" height="13" font="30">None </text>
<text top="414" left="663" width="35" height="13" font="30">None </text>
<text top="414" left="740" width="35" height="13" font="30">None </text>
<text top="414" left="833" width="36" height="13" font="30">None </text>
<text top="414" left="904" width="35" height="13" font="30">None </text>
<text top="414" left="1029" width="35" height="13" font="30">None </text>
<text top="486" left="159" width="62" height="13" font="30">Mitchell I. </text>
<text top="504" left="159" width="41" height="13" font="30">Cohen </text>
<text top="486" left="256" width="90" height="13" font="30">Organizational </text>
<text top="504" left="256" width="95" height="13" font="30">Reviewer—HRS </text>
<text top="486" left="380" width="142" height="13" font="30">Inova Fairfax Children’s </text>
<text top="504" left="380" width="149" height="13" font="30">Hospital—Co-Director of </text>
<text top="522" left="380" width="129" height="13" font="30">the Heart Center and </text>
<text top="539" left="380" width="160" height="13" font="30">Chief, Pediatric Cardiology </text>
<text top="486" left="558" width="35" height="13" font="30">None </text>
<text top="486" left="663" width="35" height="13" font="30">None </text>
<text top="486" left="740" width="35" height="13" font="30">None </text>
<text top="486" left="833" width="36" height="13" font="30">None </text>
<text top="486" left="904" width="35" height="13" font="30">None </text>
<text top="486" left="1029" width="35" height="13" font="30">None </text>
<text top="558" left="159" width="68" height="13" font="30">Marshall L. </text>
<text top="576" left="159" width="46" height="13" font="30">Jacobs  </text>
<text top="558" left="256" width="90" height="13" font="30">Organizational </text>
<text top="576" left="256" width="102" height="13" font="30">Reviewer—AATS </text>
<text top="558" left="380" width="146" height="13" font="30">Johns Hopkins School of </text>
<text top="576" left="380" width="144" height="13" font="30">Medicine—Professor of </text>
<text top="594" left="380" width="130" height="13" font="30">Surgery and Director, </text>
<text top="611" left="380" width="141" height="13" font="30">Pediatric Heart Surgery </text>
<text top="629" left="380" width="121" height="13" font="30">Outcomes Research </text>
<text top="558" left="558" width="35" height="13" font="30">None </text>
<text top="558" left="663" width="35" height="13" font="30">None </text>
<text top="558" left="740" width="35" height="13" font="30">None </text>
<text top="558" left="833" width="36" height="13" font="30">None </text>
<text top="558" left="904" width="35" height="13" font="30">None </text>
<text top="558" left="1029" width="35" height="13" font="30">None </text>
<text top="648" left="159" width="49" height="13" font="30">Larry A. </text>
<text top="666" left="159" width="42" height="13" font="30">Latson </text>
<text top="648" left="256" width="90" height="13" font="30">Organizational </text>
<text top="666" left="256" width="98" height="13" font="30">Reviewer—SCAI </text>
<text top="648" left="380" width="146" height="13" font="30">Joe DiMaggio Children’s </text>
<text top="666" left="380" width="152" height="13" font="30">Hospital Heart Institute—</text>
<text top="683" left="380" width="162" height="13" font="30">Medical Director, Pediatric </text>
<text top="701" left="380" width="93" height="13" font="30">and Congenital </text>
<text top="719" left="380" width="154" height="13" font="30">Interventional Cardiology </text>
<text top="645" left="558" width="7" height="19" font="46">•</text>
<text top="649" left="565" width="4" height="13" font="47"> </text>
<text top="649" left="568" width="131" height="13" font="30">Gore Medical  None </text>
<text top="648" left="740" width="35" height="13" font="30">None </text>
<text top="648" left="833" width="36" height="13" font="30">None </text>
<text top="645" left="904" width="7" height="19" font="46">•</text>
<text top="649" left="910" width="4" height="13" font="47"> </text>
<text top="649" left="913" width="100" height="13" font="30">St. Jude Medical </text>
<text top="648" left="1029" width="35" height="13" font="30">None </text>
</page>
<page number="124" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 126 </text>
<text top="109" left="159" width="75" height="13" font="30">Constantine </text>
<text top="127" left="159" width="70" height="13" font="30">Mavroudis  </text>
<text top="109" left="256" width="90" height="13" font="30">Organizational </text>
<text top="127" left="256" width="92" height="13" font="30">Reviewer—STS </text>
<text top="109" left="380" width="117" height="13" font="30">Florida Hospital for </text>
<text top="127" left="380" width="114" height="13" font="30">Children—Medical </text>
<text top="145" left="380" width="137" height="13" font="30">Director, Pediatric and </text>
<text top="163" left="380" width="147" height="13" font="30">Congenital Heart Center </text>
<text top="109" left="558" width="35" height="13" font="30">None </text>
<text top="109" left="663" width="35" height="13" font="30">None </text>
<text top="109" left="740" width="35" height="13" font="30">None </text>
<text top="109" left="833" width="36" height="13" font="30">None </text>
<text top="109" left="904" width="35" height="13" font="30">None </text>
<text top="109" left="1029" width="35" height="13" font="30">None </text>
<text top="181" left="159" width="44" height="13" font="30">Doff B. </text>
<text top="199" left="159" width="73" height="13" font="30">McElhinney </text>
<text top="181" left="256" width="90" height="13" font="30">Organizational </text>
<text top="199" left="256" width="98" height="13" font="30">Reviewer—SCAI </text>
<text top="181" left="380" width="128" height="13" font="30">Stanford University—</text>
<text top="199" left="380" width="153" height="13" font="30">Professor, Cardiothoracic </text>
<text top="217" left="380" width="151" height="13" font="30">Surgery and of Pediatrics </text>
<text top="178" left="558" width="7" height="19" font="46">•</text>
<text top="182" left="565" width="4" height="13" font="47"> </text>
<text top="182" left="568" width="73" height="13" font="30">Medtronic* </text>
<text top="181" left="663" width="35" height="13" font="30">None </text>
<text top="181" left="740" width="35" height="13" font="30">None </text>
<text top="181" left="833" width="36" height="13" font="30">None </text>
<text top="181" left="904" width="35" height="13" font="30">None </text>
<text top="181" left="1029" width="35" height="13" font="30">None </text>
<text top="235" left="159" width="53" height="13" font="30">Erwin N. </text>
<text top="253" left="159" width="54" height="13" font="30">Oechslin </text>
<text top="235" left="256" width="90" height="13" font="30">Organizational </text>
<text top="253" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="271" left="256" width="48" height="13" font="30">ISACHD </text>
<text top="235" left="380" width="140" height="13" font="30">University of Toronto—</text>
<text top="253" left="380" width="138" height="13" font="30">Professor of Medicine; </text>
<text top="271" left="380" width="121" height="13" font="30">Peter Munk Cardiac </text>
<text top="289" left="380" width="144" height="13" font="30">Centre—Director, Adult </text>
<text top="307" left="380" width="152" height="13" font="30">Congenital Heart Disease </text>
<text top="324" left="380" width="54" height="13" font="30">Program </text>
<text top="232" left="558" width="7" height="19" font="46">•</text>
<text top="236" left="565" width="4" height="13" font="47"> </text>
<text top="236" left="568" width="52" height="13" font="30">Actelion </text>
<text top="235" left="663" width="35" height="13" font="30">None </text>
<text top="235" left="740" width="35" height="13" font="30">None </text>
<text top="235" left="833" width="36" height="13" font="30">None </text>
<text top="235" left="904" width="35" height="13" font="30">None </text>
<text top="235" left="1029" width="35" height="13" font="30">None </text>
<text top="343" left="159" width="46" height="13" font="30">John K. </text>
<text top="361" left="159" width="60" height="13" font="30">Triedman </text>
<text top="343" left="256" width="90" height="13" font="30">Organizational </text>
<text top="361" left="256" width="95" height="13" font="30">Reviewer—HRS </text>
<text top="343" left="380" width="108" height="13" font="30">Boston Children’s </text>
<text top="361" left="380" width="163" height="13" font="30">Hospital—Senior Associate </text>
<text top="379" left="380" width="135" height="13" font="30">in Cardiology; Harvard </text>
<text top="396" left="380" width="163" height="13" font="30">Medical School—Professor </text>
<text top="414" left="380" width="77" height="13" font="30">of Pediatrics </text>
<text top="340" left="558" width="7" height="19" font="50">•</text>
<text top="344" left="564" width="4" height="13" font="51"> </text>
<text top="344" left="568" width="53" height="13" font="30">Biosense</text>
<text top="344" left="620" width="3" height="13" font="52"> </text>
<text top="361" left="568" width="52" height="13" font="52">Webster </text>
<text top="343" left="663" width="35" height="13" font="30">None </text>
<text top="343" left="740" width="35" height="13" font="30">None </text>
<text top="343" left="833" width="36" height="13" font="30">None </text>
<text top="343" left="904" width="35" height="13" font="30">None </text>
<text top="343" left="1029" width="35" height="13" font="30">None </text>
<text top="433" left="159" width="38" height="13" font="30">Naser </text>
<text top="451" left="159" width="55" height="13" font="30">Ammash </text>
<text top="433" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="433" left="380" width="157" height="13" font="30">Mayo Clinic—Professor of </text>
<text top="451" left="380" width="59" height="13" font="30">Medicine </text>
<text top="433" left="558" width="39" height="13" font="30">None  </text>
<text top="433" left="663" width="39" height="13" font="30">None  </text>
<text top="433" left="740" width="39" height="13" font="30">None  </text>
<text top="433" left="833" width="39" height="13" font="30">None  </text>
<text top="433" left="904" width="39" height="13" font="30">None  </text>
<text top="433" left="1029" width="39" height="13" font="30">None  </text>
<text top="469" left="159" width="47" height="13" font="30">Helmut </text>
<text top="487" left="159" width="81" height="13" font="30">Baumgartner </text>
<text top="469" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="469" left="380" width="150" height="13" font="30">University of Muenster—</text>
<text top="487" left="380" width="142" height="13" font="30">Professor of Cardiology </text>
<text top="505" left="380" width="165" height="13" font="30">and Adult Congenital Heart </text>
<text top="522" left="380" width="116" height="13" font="30">Disease; University </text>
<text top="540" left="380" width="123" height="13" font="30">Hospital Muenster—</text>
<text top="558" left="380" width="156" height="13" font="30">Director, Division of Adult </text>
<text top="576" left="380" width="144" height="13" font="30">Congenital and Valvular </text>
<text top="594" left="380" width="165" height="13" font="30">Heart Disease, Department </text>
<text top="611" left="380" width="165" height="13" font="30">of Cardiovascular Medicine </text>
<text top="469" left="558" width="39" height="13" font="30">None  </text>
<text top="469" left="663" width="39" height="13" font="30">None  </text>
<text top="469" left="740" width="39" height="13" font="30">None  </text>
<text top="469" left="833" width="39" height="13" font="30">None  </text>
<text top="469" left="904" width="39" height="13" font="30">None  </text>
<text top="469" left="1029" width="39" height="13" font="30">None  </text>
<text top="630" left="159" width="54" height="13" font="30">James C. </text>
<text top="648" left="159" width="75" height="13" font="30">Blankenship </text>
<text top="630" left="256" width="51" height="13" font="30">Content </text>
<text top="648" left="256" width="96" height="13" font="30">Reviewer—ACC </text>
<text top="666" left="256" width="88" height="13" font="30">Interventional </text>
<text top="683" left="256" width="47" height="13" font="30">Section </text>
<text top="701" left="256" width="68" height="13" font="30">Leadership </text>
<text top="719" left="256" width="47" height="13" font="30">Council </text>
<text top="630" left="380" width="110" height="13" font="30">Geisinger Medical </text>
<text top="648" left="380" width="143" height="13" font="30">Center—Staff Physician </text>
<text top="666" left="380" width="128" height="13" font="30">and Director, Cardiac </text>
<text top="683" left="380" width="163" height="13" font="30">Catheterization Laboratory </text>
<text top="630" left="558" width="39" height="13" font="30">None  </text>
<text top="630" left="663" width="39" height="13" font="30">None  </text>
<text top="630" left="740" width="39" height="13" font="30">None  </text>
<text top="630" left="833" width="39" height="13" font="30">None  </text>
<text top="627" left="904" width="7" height="19" font="50">•</text>
<text top="631" left="910" width="4" height="13" font="51"> </text>
<text top="631" left="913" width="101" height="13" font="52">Abbof Vascular† </text>
<text top="646" left="904" width="7" height="19" font="50">•</text>
<text top="650" left="910" width="4" height="13" font="51"> </text>
<text top="650" left="913" width="43" height="13" font="52">Boston </text>
<text top="668" left="913" width="61" height="13" font="52">Scien@ﬁc† </text>
<text top="682" left="904" width="7" height="19" font="50">•</text>
<text top="686" left="910" width="4" height="13" font="51"> </text>
<text top="686" left="913" width="103" height="13" font="52">GlaxoSmithKline† </text>
<text top="700" left="904" width="7" height="19" font="50">•</text>
<text top="705" left="910" width="4" height="13" font="51"> </text>
<text top="705" left="913" width="44" height="13" font="52">Takeda </text>
<text top="723" left="913" width="98" height="13" font="52">Pharmaceu@cal† </text>
<text top="630" left="1029" width="39" height="13" font="30">None  </text>
</page>
<page number="125" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 127 </text>
<text top="109" left="159" width="53" height="13" font="30">Ralph G. </text>
<text top="127" left="159" width="44" height="13" font="30">Brindis </text>
<text top="109" left="256" width="51" height="13" font="30">Content </text>
<text top="127" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="145" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="163" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="180" left="256" width="51" height="13" font="30">Practice </text>
<text top="198" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="109" left="380" width="158" height="13" font="30">Northern California Kaiser </text>
<text top="127" left="380" width="128" height="13" font="30">Permanente—Senior </text>
<text top="145" left="380" width="142" height="13" font="30">Advisor, Cardiovascular </text>
<text top="163" left="380" width="131" height="13" font="30">Disease; University of </text>
<text top="180" left="380" width="157" height="13" font="30">California, San Francisco—</text>
<text top="198" left="380" width="121" height="13" font="30">Clinical Professor of </text>
<text top="216" left="380" width="59" height="13" font="30">Medicine </text>
<text top="109" left="558" width="35" height="13" font="30">None </text>
<text top="109" left="663" width="39" height="13" font="30">None  </text>
<text top="109" left="740" width="39" height="13" font="30">None  </text>
<text top="109" left="833" width="36" height="13" font="30">None </text>
<text top="109" left="904" width="35" height="13" font="30">None </text>
<text top="109" left="1029" width="35" height="13" font="30">None </text>
<text top="235" left="159" width="63" height="13" font="30">Robert M. </text>
<text top="252" left="159" width="59" height="13" font="30">Campbell </text>
<text top="235" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="235" left="380" width="163" height="13" font="30">Emory University School of </text>
<text top="252" left="380" width="137" height="13" font="30">Medicine, Sibley Heart </text>
<text top="270" left="380" width="120" height="13" font="30">Center Cardiology—</text>
<text top="288" left="380" width="136" height="13" font="30">Professor of Pediatrics </text>
<text top="235" left="558" width="39" height="13" font="30">None  </text>
<text top="235" left="663" width="39" height="13" font="30">None  </text>
<text top="235" left="740" width="39" height="13" font="30">None  </text>
<text top="235" left="833" width="39" height="13" font="30">None  </text>
<text top="235" left="904" width="39" height="13" font="30">None  </text>
<text top="235" left="1029" width="35" height="13" font="30">None </text>
<text top="307" left="159" width="56" height="13" font="30">Lesley H. </text>
<text top="324" left="159" width="38" height="13" font="30">Curtis </text>
<text top="307" left="256" width="51" height="13" font="30">Content </text>
<text top="324" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="342" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="360" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="378" left="256" width="51" height="13" font="30">Practice </text>
<text top="396" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="307" left="380" width="155" height="13" font="30">Duke University School of </text>
<text top="324" left="380" width="144" height="13" font="30">Medicine—Professor of </text>
<text top="342" left="380" width="59" height="13" font="30">Medicine </text>
<text top="307" left="558" width="39" height="13" font="30">None  </text>
<text top="307" left="663" width="39" height="13" font="30">None  </text>
<text top="307" left="740" width="39" height="13" font="30">None  </text>
<text top="307" left="833" width="39" height="13" font="30">None  </text>
<text top="303" left="904" width="7" height="19" font="50">•</text>
<text top="307" left="910" width="4" height="13" font="51"> </text>
<text top="307" left="913" width="43" height="13" font="52">Boston </text>
<text top="325" left="913" width="61" height="13" font="52">Scientific* </text>
<text top="340" left="904" width="7" height="19" font="50">•</text>
<text top="344" left="910" width="4" height="13" font="51"> </text>
<text top="344" left="913" width="91" height="13" font="52">GE Healthcare* </text>
<text top="358" left="904" width="7" height="19" font="50">•</text>
<text top="363" left="910" width="4" height="13" font="51"> </text>
<text top="363" left="913" width="103" height="13" font="52">GlaxoSmithKline* </text>
<text top="377" left="904" width="7" height="19" font="50">•</text>
<text top="381" left="910" width="4" height="13" font="51"> </text>
<text top="381" left="913" width="70" height="13" font="52">Medtronic* </text>
<text top="396" left="904" width="7" height="19" font="50">•</text>
<text top="400" left="910" width="4" height="13" font="51"> </text>
<text top="400" left="913" width="58" height="13" font="52">Novartis* </text>
<text top="307" left="1029" width="35" height="13" font="30">None </text>
<text top="418" left="159" width="48" height="13" font="30">Kristi K. </text>
<text top="436" left="159" width="61" height="13" font="30">Fitzgerald </text>
<text top="418" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="418" left="380" width="148" height="13" font="30">Nemours Cardiac Center </text>
<text top="436" left="380" width="121" height="13" font="30">DuPont Hospital for </text>
<text top="454" left="380" width="112" height="13" font="30">Children—Genetic </text>
<text top="472" left="380" width="132" height="13" font="30">Counselor, Division of </text>
<text top="489" left="380" width="122" height="13" font="30">Pediatric Cardiology </text>
<text top="418" left="558" width="39" height="13" font="30">None  </text>
<text top="418" left="663" width="39" height="13" font="30">None  </text>
<text top="418" left="740" width="39" height="13" font="30">None  </text>
<text top="418" left="833" width="39" height="13" font="30">None  </text>
<text top="418" left="904" width="39" height="13" font="30">None  </text>
<text top="418" left="1029" width="39" height="13" font="30">None  </text>
<text top="508" left="159" width="39" height="13" font="30">Lee A. </text>
<text top="526" left="159" width="50" height="13" font="30">Fleisher </text>
<text top="508" left="256" width="51" height="13" font="30">Content </text>
<text top="526" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="544" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="561" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="579" left="256" width="51" height="13" font="30">Practice </text>
<text top="597" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="508" left="380" width="160" height="13" font="30">University of Pennsylvania </text>
<text top="526" left="380" width="164" height="13" font="30">Health System Department </text>
<text top="544" left="380" width="135" height="13" font="30">of Anesthesiology and </text>
<text top="561" left="380" width="128" height="13" font="30">Critical Care—Robert </text>
<text top="579" left="380" width="155" height="13" font="30">Dunning Dripps Professor </text>
<text top="597" left="380" width="112" height="13" font="30">of Anesthesiology  </text>
<text top="508" left="558" width="35" height="13" font="30">None </text>
<text top="508" left="663" width="39" height="13" font="30">None  </text>
<text top="508" left="740" width="39" height="13" font="30">None  </text>
<text top="508" left="833" width="39" height="13" font="30">None  </text>
<text top="508" left="904" width="39" height="13" font="30">None  </text>
<text top="508" left="1029" width="35" height="13" font="30">None </text>
<text top="616" left="159" width="54" height="13" font="30">Federico </text>
<text top="633" left="159" width="46" height="13" font="30">Gentile </text>
<text top="616" left="256" width="51" height="13" font="30">Content </text>
<text top="633" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="651" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="669" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="687" left="256" width="51" height="13" font="30">Practice </text>
<text top="705" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="616" left="380" width="121" height="13" font="30">Centro Cardiologico </text>
<text top="633" left="380" width="112" height="13" font="30">Gentile—Director, </text>
<text top="651" left="380" width="139" height="13" font="30">Cardiovascular Disease </text>
<text top="616" left="558" width="39" height="13" font="30">None  </text>
<text top="616" left="663" width="39" height="13" font="30">None  </text>
<text top="616" left="740" width="39" height="13" font="30">None  </text>
<text top="616" left="833" width="39" height="13" font="30">None  </text>
<text top="616" left="904" width="39" height="13" font="30">None  </text>
<text top="616" left="1029" width="39" height="13" font="30">None  </text>
<text top="723" left="159" width="80" height="13" font="30">Louise Harris </text>
<text top="723" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="723" left="380" width="101" height="13" font="30">Toronto General </text>
<text top="741" left="380" width="137" height="13" font="30">Hospital—Professor of </text>
<text top="759" left="380" width="59" height="13" font="30">Medicine </text>
<text top="720" left="558" width="7" height="19" font="50">•</text>
<text top="724" left="564" width="4" height="13" font="51"> </text>
<text top="724" left="568" width="47" height="13" font="52">St. Jude </text>
<text top="742" left="568" width="48" height="13" font="52">Medical </text>
<text top="723" left="663" width="35" height="13" font="30">None </text>
<text top="723" left="740" width="39" height="13" font="30">None  </text>
<text top="723" left="833" width="39" height="13" font="30">None  </text>
<text top="723" left="904" width="39" height="13" font="30">None  </text>
<text top="723" left="1029" width="39" height="13" font="30">None  </text>
</page>
<page number="126" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 128 </text>
<text top="109" left="159" width="50" height="13" font="30">Mark A. </text>
<text top="127" left="159" width="41" height="13" font="30">Hlatky </text>
<text top="109" left="256" width="51" height="13" font="30">Content </text>
<text top="127" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="145" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="163" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="180" left="256" width="51" height="13" font="30">Practice </text>
<text top="198" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="109" left="380" width="161" height="13" font="30">Stanford University School </text>
<text top="127" left="380" width="159" height="13" font="30">of Medicine—Professor of </text>
<text top="145" left="380" width="126" height="13" font="30">Health Research and </text>
<text top="163" left="380" width="83" height="13" font="30">Policy, and of </text>
<text top="180" left="380" width="149" height="13" font="30">Cardiovascular Medicine </text>
<text top="109" left="558" width="39" height="13" font="30">None  </text>
<text top="109" left="663" width="35" height="13" font="30">None </text>
<text top="109" left="740" width="35" height="13" font="30">None </text>
<text top="109" left="833" width="36" height="13" font="30">None </text>
<text top="109" left="904" width="35" height="13" font="30">None </text>
<text top="109" left="1029" width="35" height="13" font="30">None </text>
<text top="217" left="159" width="47" height="13" font="30">Craig T. </text>
<text top="235" left="159" width="49" height="13" font="30">January </text>
<text top="217" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="217" left="380" width="142" height="13" font="30">University of Wisconsin </text>
<text top="235" left="380" width="142" height="13" font="30">School of Medicine and </text>
<text top="252" left="380" width="155" height="13" font="30">Public Health—Professor, </text>
<text top="270" left="380" width="156" height="13" font="30">Division of Cardiovascular </text>
<text top="288" left="380" width="59" height="13" font="30">Medicine </text>
<text top="217" left="558" width="35" height="13" font="30">None </text>
<text top="217" left="663" width="35" height="13" font="30">None </text>
<text top="217" left="740" width="35" height="13" font="30">None </text>
<text top="217" left="833" width="36" height="13" font="30">None </text>
<text top="217" left="904" width="35" height="13" font="30">None </text>
<text top="217" left="1029" width="35" height="13" font="30">None </text>
<text top="307" left="159" width="82" height="13" font="30">José A. Joglar </text>
<text top="307" left="256" width="51" height="13" font="30">Content </text>
<text top="324" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="342" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="360" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="378" left="256" width="51" height="13" font="30">Practice </text>
<text top="396" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="307" left="380" width="157" height="13" font="30">UT Southwestern Medical </text>
<text top="324" left="380" width="128" height="13" font="30">Center—Professor of </text>
<text top="342" left="380" width="108" height="13" font="30">Internal Medicine </text>
<text top="307" left="558" width="35" height="13" font="30">None </text>
<text top="307" left="663" width="35" height="13" font="30">None </text>
<text top="307" left="740" width="35" height="13" font="30">None </text>
<text top="307" left="833" width="36" height="13" font="30">None </text>
<text top="307" left="904" width="35" height="13" font="30">None </text>
<text top="307" left="1029" width="35" height="13" font="30">None </text>
<text top="414" left="159" width="65" height="13" font="30">Thomas K. </text>
<text top="432" left="159" width="36" height="13" font="30">Jones </text>
<text top="414" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="414" left="380" width="107" height="13" font="30">Seattle Children’s </text>
<text top="432" left="380" width="137" height="13" font="30">Hospital—Professor of </text>
<text top="450" left="380" width="142" height="13" font="30">Pediatrics and Director, </text>
<text top="468" left="380" width="142" height="13" font="30">Cardiac Catheterization </text>
<text top="486" left="380" width="78" height="13" font="30">Laboratories </text>
<text top="411" left="558" width="7" height="19" font="50">•</text>
<text top="415" left="564" width="4" height="13" font="51"> </text>
<text top="415" left="568" width="31" height="13" font="52">Gore </text>
<text top="433" left="568" width="55" height="13" font="52">Medical* </text>
<text top="447" left="558" width="7" height="19" font="50">•</text>
<text top="452" left="564" width="4" height="13" font="51"> </text>
<text top="452" left="568" width="70" height="13" font="52">Medtronic* </text>
<text top="414" left="663" width="35" height="13" font="30">None </text>
<text top="414" left="740" width="35" height="13" font="30">None </text>
<text top="414" left="833" width="36" height="13" font="30">None </text>
<text top="411" left="904" width="7" height="19" font="50">•</text>
<text top="415" left="910" width="4" height="13" font="51"> </text>
<text top="415" left="913" width="87" height="13" font="52">Gore Medical* </text>
<text top="429" left="904" width="7" height="19" font="50">•</text>
<text top="434" left="910" width="4" height="13" font="51"> </text>
<text top="434" left="913" width="70" height="13" font="52">Medtronic* </text>
<text top="448" left="904" width="7" height="19" font="50">•</text>
<text top="452" left="910" width="4" height="13" font="51"> </text>
<text top="452" left="913" width="102" height="13" font="52">St. Jude Medical* </text>
<text top="414" left="1029" width="35" height="13" font="30">None </text>
<text top="504" left="159" width="67" height="13" font="30">Sana M. Al-</text>
<text top="522" left="159" width="41" height="13" font="30">Khatib </text>
<text top="504" left="256" width="51" height="13" font="30">Content </text>
<text top="522" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="540" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="558" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="575" left="256" width="51" height="13" font="30">Practice </text>
<text top="593" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="504" left="380" width="148" height="13" font="30">Duke University Medical </text>
<text top="522" left="380" width="128" height="13" font="30">Center—Professor of </text>
<text top="540" left="380" width="59" height="13" font="30">Medicine </text>
<text top="504" left="558" width="39" height="13" font="30">None  </text>
<text top="504" left="663" width="39" height="13" font="30">None  </text>
<text top="504" left="740" width="39" height="13" font="30">None  </text>
<text top="504" left="833" width="39" height="13" font="30">None  </text>
<text top="504" left="904" width="35" height="13" font="30">None </text>
<text top="504" left="1029" width="35" height="13" font="30">None </text>
<text top="612" left="159" width="48" height="13" font="30">Brian E. </text>
<text top="630" left="159" width="41" height="13" font="30">Kogon </text>
<text top="612" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="612" left="380" width="163" height="13" font="30">Emory University School of </text>
<text top="630" left="380" width="128" height="13" font="30">Medicine—Associate </text>
<text top="647" left="380" width="138" height="13" font="30">Professor, Surgery and </text>
<text top="665" left="380" width="158" height="13" font="30">Surgical Director of Emory </text>
<text top="683" left="380" width="139" height="13" font="30">Adult Congenital Heart </text>
<text top="701" left="380" width="118" height="13" font="30">Center and Chief of </text>
<text top="719" left="380" width="152" height="13" font="30">Pediatric Cardiac Surgery </text>
<text top="612" left="558" width="35" height="13" font="30">None </text>
<text top="612" left="663" width="35" height="13" font="30">None </text>
<text top="612" left="740" width="35" height="13" font="30">None </text>
<text top="612" left="833" width="36" height="13" font="30">None </text>
<text top="612" left="904" width="35" height="13" font="30">None </text>
<text top="612" left="1029" width="35" height="13" font="30">None </text>
</page>
<page number="127" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 129 </text>
<text top="109" left="159" width="51" height="13" font="30">Gautam </text>
<text top="127" left="159" width="42" height="13" font="30">Kumar </text>
<text top="109" left="256" width="51" height="13" font="30">Content </text>
<text top="127" left="256" width="96" height="13" font="30">Reviewer—ACC </text>
<text top="145" left="256" width="88" height="13" font="30">Interventional </text>
<text top="163" left="256" width="47" height="13" font="30">Section </text>
<text top="180" left="256" width="68" height="13" font="30">Leadership </text>
<text top="198" left="256" width="50" height="13" font="30">Council  </text>
<text top="109" left="380" width="163" height="13" font="30">Emory University School of </text>
<text top="127" left="380" width="128" height="13" font="30">Medicine, Division of </text>
<text top="145" left="380" width="136" height="13" font="30">Cardiology—Associate </text>
<text top="163" left="380" width="134" height="13" font="30">Professor of Medicine </text>
<text top="106" left="558" width="7" height="19" font="50">•</text>
<text top="110" left="564" width="4" height="13" font="51"> </text>
<text top="110" left="568" width="55" height="13" font="52">Abiomed </text>
<text top="109" left="663" width="35" height="13" font="30">None </text>
<text top="109" left="740" width="35" height="13" font="30">None </text>
<text top="109" left="833" width="36" height="13" font="30">None </text>
<text top="106" left="904" width="7" height="19" font="50">•</text>
<text top="110" left="910" width="4" height="13" font="51"> </text>
<text top="110" left="913" width="70" height="13" font="52">OrbusNeich </text>
<text top="128" left="913" width="48" height="13" font="52">Medical </text>
<text top="109" left="1029" width="35" height="13" font="30">None </text>
<text top="217" left="159" width="40" height="13" font="30">Eric V. </text>
<text top="235" left="159" width="46" height="13" font="30">Krieger </text>
<text top="217" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="217" left="380" width="79" height="13" font="30">University of </text>
<text top="235" left="380" width="144" height="13" font="30">Washington—Associate </text>
<text top="252" left="380" width="159" height="13" font="30">Professor of Medicine and </text>
<text top="270" left="380" width="151" height="13" font="30">Associate Director, Adult </text>
<text top="288" left="380" width="149" height="13" font="30">Congenital Heart Service </text>
<text top="213" left="558" width="7" height="19" font="50">•</text>
<text top="218" left="564" width="4" height="13" font="51"> </text>
<text top="218" left="568" width="53" height="13" font="52">Actelion  </text>
<text top="217" left="663" width="35" height="13" font="30">None </text>
<text top="217" left="740" width="35" height="13" font="30">None </text>
<text top="217" left="833" width="36" height="13" font="30">None </text>
<text top="217" left="904" width="35" height="13" font="30">None </text>
<text top="217" left="1029" width="35" height="13" font="30">None </text>
<text top="307" left="159" width="55" height="13" font="30">Glenn N. </text>
<text top="324" left="159" width="42" height="13" font="30">Levine </text>
<text top="307" left="256" width="51" height="13" font="30">Content </text>
<text top="324" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="342" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="360" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="378" left="256" width="51" height="13" font="30">Practice </text>
<text top="396" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="307" left="380" width="103" height="13" font="30">Baylor College of </text>
<text top="324" left="380" width="144" height="13" font="30">Medicine—Professor of </text>
<text top="342" left="380" width="127" height="13" font="30">Medicine; Michael E. </text>
<text top="360" left="380" width="126" height="13" font="30">DeBakey VA Medical </text>
<text top="378" left="380" width="156" height="13" font="30">Center—Director, Cardiac </text>
<text top="396" left="380" width="59" height="13" font="30">Care Unit </text>
<text top="307" left="558" width="35" height="13" font="30">None </text>
<text top="307" left="663" width="35" height="13" font="30">None </text>
<text top="307" left="740" width="35" height="13" font="30">None </text>
<text top="307" left="833" width="36" height="13" font="30">None </text>
<text top="307" left="904" width="35" height="13" font="30">None </text>
<text top="307" left="1029" width="35" height="13" font="30">None </text>
<text top="414" left="159" width="66" height="13" font="30">C. Huie Lin </text>
<text top="414" left="256" width="51" height="13" font="30">Content </text>
<text top="432" left="256" width="98" height="13" font="30">Reviewer—SCAI </text>
<text top="414" left="380" width="119" height="13" font="30">Houston Methodist </text>
<text top="432" left="380" width="159" height="13" font="30">DeBakey Heart &amp; Vascular </text>
<text top="449" left="380" width="127" height="13" font="30">Center—Cardiologist </text>
<text top="411" left="558" width="7" height="19" font="50">•</text>
<text top="415" left="564" width="4" height="13" font="51"> </text>
<text top="415" left="568" width="80" height="13" font="52">Gore Medical </text>
<text top="429" left="558" width="7" height="19" font="50">•</text>
<text top="434" left="564" width="4" height="13" font="51"> </text>
<text top="433" left="568" width="65" height="13" font="52">ACI Clinical </text>
<text top="451" left="568" width="46" height="13" font="52">(DSMB) </text>
<text top="411" left="663" width="7" height="19" font="46">•</text>
<text top="415" left="670" width="4" height="13" font="47"> </text>
<text top="415" left="673" width="52" height="13" font="52">Abiomed</text>
<text top="415" left="724" width="51" height="13" font="30">  None </text>
<text top="411" left="833" width="7" height="19" font="46">•</text>
<text top="415" left="840" width="4" height="13" font="47"> </text>
<text top="415" left="842" width="47" height="13" font="52">St. Jude </text>
<text top="433" left="842" width="45" height="13" font="52">Medical</text>
<text top="433" left="888" width="3" height="13" font="30"> </text>
<text top="414" left="904" width="35" height="13" font="30">None </text>
<text top="414" left="1029" width="35" height="13" font="30">None </text>
<text top="470" left="159" width="57" height="13" font="30">Massimo </text>
<text top="487" left="159" width="59" height="13" font="30">Mancone </text>
<text top="470" left="256" width="51" height="13" font="30">Content </text>
<text top="487" left="256" width="96" height="13" font="30">Reviewer—ACC </text>
<text top="505" left="256" width="25" height="13" font="30">AIG </text>
<text top="470" left="380" width="134" height="13" font="30">Sapienza University of </text>
<text top="487" left="380" width="115" height="13" font="30">Rome—Cardiology </text>
<text top="505" left="380" width="68" height="13" font="30">Consultant </text>
<text top="470" left="558" width="35" height="13" font="30">None </text>
<text top="470" left="663" width="35" height="13" font="30">None </text>
<text top="470" left="740" width="35" height="13" font="30">None </text>
<text top="470" left="833" width="36" height="13" font="30">None </text>
<text top="470" left="904" width="35" height="13" font="30">None </text>
<text top="470" left="1029" width="35" height="13" font="30">None </text>
<text top="524" left="159" width="42" height="13" font="30">Ariane </text>
<text top="542" left="159" width="45" height="13" font="30">Marelli </text>
<text top="524" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="524" left="380" width="147" height="13" font="30">McGill University Health </text>
<text top="542" left="380" width="128" height="13" font="30">Center—Professor of </text>
<text top="559" left="380" width="140" height="13" font="30">Medicine and Director, </text>
<text top="577" left="380" width="78" height="13" font="30">MAUDE Unit </text>
<text top="524" left="558" width="35" height="13" font="30">None </text>
<text top="524" left="663" width="35" height="13" font="30">None </text>
<text top="524" left="740" width="35" height="13" font="30">None </text>
<text top="524" left="833" width="36" height="13" font="30">None </text>
<text top="524" left="904" width="35" height="13" font="30">None </text>
<text top="524" left="1029" width="35" height="13" font="30">None </text>
<text top="596" left="159" width="52" height="13" font="30">Koichiro </text>
<text top="614" left="159" width="33" height="13" font="30">Niwa </text>
<text top="596" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="596" left="380" width="140" height="13" font="30">St. Luke’s International </text>
<text top="614" left="380" width="118" height="13" font="30">Hospital—Director, </text>
<text top="631" left="380" width="158" height="13" font="30">Department of Cardiology </text>
<text top="596" left="558" width="35" height="13" font="30">None </text>
<text top="596" left="663" width="35" height="13" font="30">None </text>
<text top="596" left="740" width="35" height="13" font="30">None </text>
<text top="596" left="833" width="36" height="13" font="30">None </text>
<text top="596" left="904" width="35" height="13" font="30">None </text>
<text top="596" left="1029" width="35" height="13" font="30">None </text>
</page>
<page number="128" position="absolute" top="0" left="0" height="892" width="1263">
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 130 </text>
<text top="109" left="159" width="58" height="13" font="30">Matthew </text>
<text top="127" left="159" width="36" height="13" font="30">Oster </text>
<text top="109" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="109" left="380" width="163" height="13" font="30">Emory University School of </text>
<text top="127" left="380" width="128" height="13" font="30">Medicine—Associate </text>
<text top="145" left="380" width="126" height="13" font="30">Professor; Children’s </text>
<text top="163" left="380" width="140" height="13" font="30">Healthcare of Atlanta—</text>
<text top="180" left="380" width="166" height="13" font="30">Director, Children’s Cardiac </text>
<text top="198" left="380" width="121" height="13" font="30">Outcomes Research </text>
<text top="216" left="380" width="144" height="13" font="30">Program at Sibley Heart </text>
<text top="234" left="380" width="43" height="13" font="30">Center </text>
<text top="109" left="558" width="35" height="13" font="30">None </text>
<text top="109" left="663" width="35" height="13" font="30">None </text>
<text top="109" left="740" width="35" height="13" font="30">None </text>
<text top="109" left="833" width="36" height="13" font="30">None </text>
<text top="109" left="904" width="35" height="13" font="30">None </text>
<text top="109" left="1029" width="35" height="13" font="30">None </text>
<text top="252" left="159" width="81" height="13" font="30">Catherine M. </text>
<text top="270" left="159" width="30" height="13" font="30">Otto </text>
<text top="252" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="252" left="380" width="154" height="13" font="30">University of Washington </text>
<text top="270" left="380" width="127" height="13" font="30">School of Medicine—</text>
<text top="288" left="380" width="137" height="13" font="30">Professor of Medicine, </text>
<text top="306" left="380" width="158" height="13" font="30">Division of Cardiology and </text>
<text top="324" left="380" width="163" height="13" font="30">Director, Heart Valve Clinic </text>
<text top="252" left="558" width="35" height="13" font="30">None </text>
<text top="252" left="663" width="35" height="13" font="30">None </text>
<text top="252" left="740" width="35" height="13" font="30">None </text>
<text top="252" left="833" width="36" height="13" font="30">None </text>
<text top="252" left="904" width="35" height="13" font="30">None </text>
<text top="252" left="1029" width="35" height="13" font="30">None </text>
<text top="342" left="159" width="61" height="13" font="30">Richard L. </text>
<text top="360" left="159" width="32" height="13" font="30">Page </text>
<text top="342" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="342" left="380" width="142" height="13" font="30">University of Wisconsin </text>
<text top="360" left="380" width="142" height="13" font="30">School of Medicine and </text>
<text top="378" left="380" width="129" height="13" font="30">Public Health—Chair, </text>
<text top="396" left="380" width="150" height="13" font="30">Department of Medicine </text>
<text top="342" left="558" width="35" height="13" font="30">None </text>
<text top="342" left="663" width="35" height="13" font="30">None </text>
<text top="342" left="740" width="35" height="13" font="30">None </text>
<text top="342" left="833" width="39" height="13" font="30">None  </text>
<text top="342" left="904" width="35" height="13" font="30">None </text>
<text top="342" left="1029" width="35" height="13" font="30">None </text>
<text top="414" left="159" width="74" height="13" font="30">James Perry </text>
<text top="414" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="414" left="380" width="151" height="13" font="30">Rady Children’s Hospital; </text>
<text top="432" left="380" width="143" height="13" font="30">University of California, </text>
<text top="450" left="380" width="147" height="13" font="30">San Diego—Professor of </text>
<text top="468" left="380" width="115" height="13" font="30">Pediatrics, Affiliate </text>
<text top="486" left="380" width="75" height="13" font="30">Professor of </text>
<text top="503" left="380" width="122" height="13" font="30">Bioengineering, and </text>
<text top="521" left="380" width="164" height="13" font="30">Director, Electrophysiology </text>
<text top="539" left="380" width="165" height="13" font="30">and Adult Congenital Heart </text>
<text top="557" left="380" width="60" height="13" font="30">Programs </text>
<text top="414" left="558" width="35" height="13" font="30">None </text>
<text top="414" left="663" width="35" height="13" font="30">None </text>
<text top="414" left="740" width="35" height="13" font="30">None </text>
<text top="414" left="833" width="39" height="13" font="30">None  </text>
<text top="414" left="904" width="35" height="13" font="30">None </text>
<text top="414" left="1029" width="35" height="13" font="30">None </text>
<text top="575" left="159" width="50" height="13" font="30">Susan J. </text>
<text top="593" left="159" width="50" height="13" font="30">Pressler </text>
<text top="575" left="256" width="51" height="13" font="30">Content </text>
<text top="593" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="611" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="629" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="647" left="256" width="51" height="13" font="30">Practice </text>
<text top="664" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="575" left="380" width="153" height="13" font="30">Indiana University School </text>
<text top="593" left="380" width="160" height="13" font="30">of Nursing—Professor and </text>
<text top="611" left="380" width="119" height="13" font="30">Director, Center for </text>
<text top="629" left="380" width="165" height="13" font="30">Enhancing Quality of Life in </text>
<text top="647" left="380" width="89" height="13" font="30">Chronic Illness </text>
<text top="575" left="558" width="34" height="13" font="52">None </text>
<text top="575" left="663" width="31" height="13" font="52">None</text>
<text top="575" left="694" width="3" height="13" font="30"> </text>
<text top="575" left="740" width="31" height="13" font="52">None</text>
<text top="575" left="771" width="3" height="13" font="30"> </text>
<text top="575" left="833" width="31" height="13" font="52">None</text>
<text top="575" left="864" width="3" height="13" font="30"> </text>
<text top="572" left="904" width="7" height="19" font="50">•</text>
<text top="576" left="910" width="4" height="13" font="51"> </text>
<text top="576" left="913" width="42" height="13" font="52">Pﬁzer† </text>
<text top="575" left="1029" width="31" height="13" font="52">None</text>
<text top="575" left="1060" width="3" height="13" font="30"> </text>
<text top="683" left="159" width="65" height="13" font="30">Candice K. </text>
<text top="701" left="159" width="65" height="13" font="30">Silversides </text>
<text top="683" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="683" left="380" width="140" height="13" font="30">University of Toronto—</text>
<text top="701" left="380" width="119" height="13" font="30">Associate Professor </text>
<text top="683" left="558" width="31" height="13" font="52">None</text>
<text top="683" left="589" width="3" height="13" font="30"> </text>
<text top="683" left="663" width="31" height="13" font="52">None</text>
<text top="683" left="694" width="3" height="13" font="30"> </text>
<text top="683" left="740" width="31" height="13" font="52">None</text>
<text top="683" left="771" width="3" height="13" font="30"> </text>
<text top="683" left="833" width="31" height="13" font="52">None</text>
<text top="683" left="864" width="3" height="13" font="30"> </text>
<text top="683" left="904" width="31" height="13" font="52">None</text>
<text top="683" left="935" width="3" height="13" font="30"> </text>
<text top="683" left="1029" width="31" height="13" font="52">None</text>
<text top="683" left="1060" width="3" height="13" font="30"> </text>
</page>
<page number="129" position="absolute" top="0" left="0" height="892" width="1263">
	<fontspec id="53" size="11" family="Times" color="#000000"/>
<text top="410" left="647" width="29" height="71" font="27">M</text>
<text top="375" left="674" width="46" height="71" font="27">AN</text>
<text top="315" left="720" width="42" height="71" font="27">US</text>
<text top="256" left="767" width="46" height="71" font="27">CR</text>
<text top="194" left="814" width="28" height="71" font="27">IP</text>
<text top="154" left="846" width="20" height="71" font="27">T</text>
<text top="421" left="639" width="8" height="71" font="27"> </text>
<text top="654" left="458" width="44" height="71" font="27">AC</text>
<text top="594" left="504" width="44" height="71" font="27">CE</text>
<text top="535" left="550" width="42" height="71" font="27">PT</text>
<text top="480" left="592" width="46" height="71" font="27">ED</text>
<text top="12" left="539" width="186" height="21" font="28">ACCEPTED MANUSCRIPT</text>
<text top="56" left="159" width="93" height="13" font="29"><b>Stout KK, et al. </b></text>
<text top="74" left="159" width="133" height="13" font="29"><b>2018 ACHD Guideline</b> </text>
<text top="828" left="607" width="52" height="12" font="31">Page 131 </text>
<text top="109" left="159" width="74" height="13" font="30">Duminda N. </text>
<text top="127" left="159" width="85" height="13" font="30">Wijeysundera </text>
<text top="109" left="256" width="51" height="13" font="30">Content </text>
<text top="127" left="256" width="68" height="13" font="30">Reviewer—</text>
<text top="145" left="256" width="89" height="13" font="30">ACC/AHA Task </text>
<text top="163" left="256" width="100" height="13" font="30">Force on Clinical </text>
<text top="180" left="256" width="51" height="13" font="30">Practice </text>
<text top="198" left="256" width="66" height="13" font="30">Guidelines </text>
<text top="109" left="380" width="140" height="13" font="30">University of Toronto—</text>
<text top="127" left="380" width="120" height="13" font="30">Assistant Professor, </text>
<text top="145" left="380" width="160" height="13" font="30">Department of Anesthesia </text>
<text top="163" left="380" width="137" height="13" font="30">and Institute of Health </text>
<text top="180" left="380" width="147" height="13" font="30">Policy Management and </text>
<text top="198" left="380" width="66" height="13" font="30">Evaluation </text>
<text top="109" left="558" width="31" height="13" font="52">None</text>
<text top="109" left="589" width="3" height="13" font="30"> </text>
<text top="109" left="663" width="31" height="13" font="52">None</text>
<text top="109" left="694" width="3" height="13" font="30"> </text>
<text top="109" left="740" width="31" height="13" font="52">None</text>
<text top="109" left="771" width="3" height="13" font="30"> </text>
<text top="109" left="833" width="31" height="13" font="52">None</text>
<text top="109" left="864" width="3" height="13" font="30"> </text>
<text top="109" left="904" width="35" height="13" font="30">None </text>
<text top="109" left="1029" width="31" height="13" font="52">None</text>
<text top="109" left="1060" width="3" height="13" font="30"> </text>
<text top="217" left="159" width="66" height="13" font="30">Ali N. Zaidi </text>
<text top="217" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="217" left="380" width="165" height="13" font="30">Montefiore Einstein Center </text>
<text top="235" left="380" width="136" height="13" font="30">for Heart and Vascular </text>
<text top="252" left="380" width="96" height="13" font="30">Care—Director, </text>
<text top="270" left="380" width="107" height="13" font="30">Montefiore Adult </text>
<text top="288" left="380" width="152" height="13" font="30">Congenital Heart Disease </text>
<text top="306" left="380" width="149" height="13" font="30">Program; Albert Einstein </text>
<text top="324" left="380" width="131" height="13" font="30">College of Medicine—</text>
<text top="341" left="380" width="123" height="13" font="30">Associate Professor, </text>
<text top="359" left="380" width="134" height="13" font="30">Internal Medicine and </text>
<text top="377" left="380" width="61" height="13" font="30">Pediatrics </text>
<text top="217" left="558" width="35" height="13" font="30">None </text>
<text top="217" left="663" width="35" height="13" font="30">None </text>
<text top="217" left="740" width="35" height="13" font="30">None </text>
<text top="217" left="833" width="36" height="13" font="30">None </text>
<text top="217" left="904" width="35" height="13" font="30">None </text>
<text top="217" left="1029" width="35" height="13" font="30">None </text>
<text top="396" left="159" width="30" height="13" font="30">Elisa </text>
<text top="413" left="159" width="58" height="13" font="30">Zaragoza-</text>
<text top="431" left="159" width="45" height="13" font="30">Macias </text>
<text top="396" left="256" width="110" height="13" font="30">Content Reviewer </text>
<text top="396" left="380" width="116" height="13" font="30">PeaceHealth North </text>
<text top="413" left="380" width="129" height="13" font="30">Cascade Cardiology—</text>
<text top="431" left="380" width="74" height="13" font="30">Cardiologist </text>
<text top="396" left="558" width="35" height="13" font="30">None </text>
<text top="396" left="663" width="35" height="13" font="30">None </text>
<text top="396" left="740" width="35" height="13" font="30">None </text>
<text top="396" left="833" width="36" height="13" font="30">None </text>
<text top="396" left="904" width="35" height="13" font="30">None </text>
<text top="396" left="1029" width="35" height="13" font="30">None </text>
<text top="450" left="159" width="949" height="12" font="31">This  table  represents  the  relationships  of  reviewers  with  industry  and  other  entities  that  were  disclosed  at  the  time  of  peer  review  and  determined  to  be  relevant  to  this </text>
<text top="466" left="159" width="949" height="12" font="31">document.  It  does not  necessarily reflect relationships with industry  at the time  of publication. A person is deemed to  have a  significant  interest  in  a  business if  the interest </text>
<text top="482" left="159" width="949" height="12" font="31">represents ownership of ≥5% of the voting stock or share of the business entity, or ownership of ≥$5,000 of the fair market value of the business entity; or if funds received by </text>
<text top="498" left="159" width="949" height="12" font="31">the person from the business entity exceed 5% of the person’s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the </text>
<text top="514" left="159" width="949" height="12" font="31">preceding definition. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise </text>
<text top="530" left="159" width="946" height="12" font="31">noted.  Names  are  listed  in  alphabetical  order  within  each  category  of  review.  Please  refer  to  http://www.acc.org/guidelines/about-guidelines-and-clinical-</text>
<text top="546" left="159" width="925" height="12" font="31">documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees. </text>
<text top="562" left="159" width="3" height="12" font="53"><b> </b></text>
<text top="578" left="159" width="135" height="12" font="31">*Significant relationship. </text>
<text top="594" left="159" width="118" height="12" font="31">†No ﬁnancial beneﬁt. </text>
<text top="610" left="159" width="3" height="12" font="31"> </text>
<text top="626" left="159" width="949" height="12" font="31">AATS indicates American Association for Thoracic Surgery; ACC,  American College of Cardiology;  AHA, American  Heart Association; AIG, Assembly of International Governors; </text>
<text top="642" left="159" width="949" height="12" font="31">ASE, American Society of Echocardiography; DSMB, Data Safety Monitoring Board; HRS, Heart Rhythm Society; ISACHD, International Society for Adult Congenital Heart Disease; </text>
<text top="658" left="159" width="949" height="12" font="31">MAUDE, McGill Adult Unit for Congenital Heart Disease Excellence; SCAI, Society for Cardiovascular Angiography and Interventions; and STS, Society of Thoracic Surgeons; and </text>
<text top="674" left="159" width="128" height="12" font="31">UT, University of Texas. </text>
<text top="691" left="159" width="4" height="15" font="49"> </text>
</page>
<page number="130" position="absolute" top="0" left="0" height="1263" width="892">
	<fontspec id="54" size="21" family="Helvetica" color="#000000"/>
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 132 </text>
<text top="176" left="105" width="113" height="21" font="10"><b>References </b></text>
<text top="235" left="105" width="98" height="21" font="10"><b>Preamble </b></text>
<text top="276" left="105" width="27" height="13" font="8">P-1. </text>
<text top="276" left="190" width="552" height="13" font="8">Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of </text>
<text top="294" left="190" width="596" height="13" font="8">Medicine (U.S.). Clinical Practice Guidelines We Can Trust. Washington, DC: The National Academies </text>
<text top="311" left="190" width="75" height="13" font="8">Press; 2011. </text>
<text top="329" left="105" width="27" height="13" font="8">P-2. </text>
<text top="329" left="190" width="597" height="13" font="8">Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of </text>
<text top="347" left="190" width="598" height="13" font="8">Medicine (U.S.). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, </text>
<text top="365" left="190" width="246" height="13" font="8">DC: The National Academies Press; 2011. </text>
<text top="383" left="105" width="27" height="13" font="8">P-3. </text>
<text top="382" left="190" width="585" height="13" font="8">Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in </text>
<text top="400" left="190" width="541" height="13" font="8">clinical practice guidelines and performance measures: a report of the American College of </text>
<text top="418" left="190" width="573" height="13" font="8">Cardiology/American Heart Association Task Force on Performance Measures and Task Force on </text>
<text top="436" left="190" width="303" height="13" font="8">Practice Guidelines. Circulation. 2014;129:2329-45 </text>
<text top="454" left="105" width="27" height="13" font="8">P-4. </text>
<text top="454" left="190" width="599" height="13" font="8">ACCF/AHA Task Force on Practice Guidelines. Methodology Manual and Policies From the ACCF/AHA </text>
<text top="472" left="190" width="591" height="13" font="8">Task Force on Practice Guidelines. American College of Cardiology and American Heart Association, </text>
<text top="489" left="190" width="113" height="13" font="8">2010. Available at: </text>
<text top="507" left="190" width="597" height="13" font="8">http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf and </text>
<text top="525" left="190" width="299" height="13" font="8">http://professional.heart.org/idc/groups/ahamah-</text>
<text top="543" left="190" width="583" height="13" font="8">public/@wcm/@sop/documents/downloadable/ucm_319826.pdf. Accessed September 15, 2017. </text>
<text top="561" left="105" width="27" height="13" font="8">P-5. </text>
<text top="561" left="190" width="555" height="13" font="8">Halperin JL, Levine GN, Al-Khatib SM, et al. Further evolution of the ACC/AHA clinical practice </text>
<text top="579" left="190" width="504" height="13" font="8">guideline recommendation classification system: a report of the American College of </text>
<text top="596" left="190" width="558" height="13" font="8">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. </text>
<text top="614" left="190" width="108" height="13" font="8">2016;133:1426-8. </text>
<text top="632" left="105" width="27" height="13" font="8">P-6. </text>
<text top="632" left="190" width="598" height="13" font="8">Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit </text>
<text top="650" left="190" width="595" height="13" font="8">report: a report of the American College of Cardiology Foundation/American Heart Association Task </text>
<text top="668" left="190" width="362" height="13" font="8">Force on Practice Guidelines. Circulation. 2013;127:268-310. </text>
<text top="685" left="105" width="27" height="13" font="8">P-7. </text>
<text top="685" left="190" width="568" height="13" font="8">Jacobs AK, Anderson JL, Halperin JL, et al. The evolution and future of ACC/AHA clinical practice </text>
<text top="703" left="190" width="556" height="13" font="8">guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart </text>
<text top="721" left="190" width="460" height="13" font="8">Association Task Force on practice guidelines. Circulation. 2014;130:1208-17. </text>
<text top="739" left="105" width="27" height="13" font="8">P-8. </text>
<text top="739" left="190" width="560" height="13" font="8">Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of </text>
<text top="757" left="190" width="600" height="13" font="8">clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the </text>
<text top="775" left="190" width="568" height="13" font="8">American Heart Association, American College of Cardiology, and US Department of Health and </text>
<text top="792" left="190" width="281" height="13" font="8">Human Services. Circulation. 2014;130:1662-7. </text>
<text top="830" left="105" width="18" height="21" font="10"><b>1.</b></text>
<text top="830" left="123" width="6" height="22" font="54"><b> </b></text>
<text top="830" left="131" width="127" height="21" font="10"><b>Introduction </b></text>
<text top="880" left="105" width="363" height="20" font="17"><b>1.1. Methodology and Evidence Review </b></text>
<text top="917" left="105" width="44" height="13" font="8">S1.1-1. </text>
<text top="917" left="190" width="560" height="13" font="8">Zaragoza-Macias E, Zaidi A, Dendukuri N, et al. Medical therapy for systemic right ventricles: a </text>
<text top="935" left="190" width="561" height="13" font="8">systematic review (part 1) for the 2018 AHA/ACC guideline for the management of adults with </text>
<text top="953" left="190" width="600" height="13" font="8">congenital heart disease: a report of the American College of Cardiology/American Heart Association </text>
<text top="971" left="190" width="411" height="13" font="8">Task Force on Clinical Practice Guidelines. Circulation. 2018; In press. </text>
<text top="989" left="105" width="44" height="13" font="8">S1.1-2. </text>
<text top="989" left="190" width="554" height="13" font="8">Oster M, Bhatt A, Zaragoza-Macias E, et al. Interventional therapy versus medical therapy for </text>
<text top="1007" left="190" width="587" height="13" font="8">secundum atrial septal defect: a systematic review (part 2) for the 2018 AHA/ACC guideline for the </text>
<text top="1025" left="190" width="531" height="13" font="8">management of adults with congenital heart disease: a report of the American College of </text>
<text top="1042" left="190" width="594" height="13" font="8">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; </text>
<text top="1060" left="190" width="53" height="13" font="8">In press. </text>
</page>
<page number="131" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 133 </text>
<text top="164" left="105" width="249" height="20" font="17"><b>1.4. Scope of the Guideline </b></text>
<text top="201" left="105" width="44" height="13" font="8">S1.4-1. </text>
<text top="201" left="190" width="598" height="13" font="8">Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults </text>
<text top="219" left="190" width="559" height="13" font="8">with congenital heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="237" left="190" width="570" height="13" font="8">Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the </text>
<text top="255" left="190" width="526" height="13" font="8">Management of Adults With Congenital Heart Disease). Circulation. 2008;118:e714-833. </text>
<text top="272" left="105" width="44" height="13" font="8">S1.4-2. </text>
<text top="272" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="290" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="308" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="326" left="105" width="44" height="13" font="8">S1.4-3. </text>
<text top="326" left="190" width="575" height="13" font="8">Moons P, Bovijn L, Budts W, et al. Temporal trends in survival to adulthood among patients born </text>
<text top="344" left="190" width="547" height="13" font="8">with congenital heart disease from 1970 to 1992 in Belgium. Circulation. 2010;122:2264-72. </text>
<text top="362" left="105" width="44" height="13" font="8">S1.4-4. </text>
<text top="362" left="190" width="595" height="13" font="8">Gilboa SM, Salemi JL, Nembhard WN, et al. Mortality resulting from congenital heart disease among </text>
<text top="379" left="190" width="513" height="13" font="8">children and adults in the United States, 1999 to 2006. Circulation. 2010;122:2254-63. </text>
<text top="397" left="105" width="44" height="13" font="8">S1.4-5. </text>
<text top="397" left="190" width="568" height="13" font="8">van der Bom T, Bouma BJ, Meijboom FJ, et al. The prevalence of adult congenital heart disease, </text>
<text top="415" left="190" width="567" height="13" font="8">results from a systematic review and evidence based calculation. Am Heart J. 2012;164:568-75. </text>
<text top="433" left="105" width="44" height="13" font="8">S1.4-6. </text>
<text top="433" left="190" width="531" height="13" font="8">Hoffman JIE, Kaplan S, Liberthson RR. Prevalence of congenital heart disease. Am Heart J. </text>
<text top="451" left="190" width="108" height="13" font="8">2004;147:425-39. </text>
<text top="468" left="105" width="44" height="13" font="8">S1.4-7. </text>
<text top="468" left="190" width="581" height="13" font="8">Lien WP, Chen JJ, Chen JH, et al. Frequency of various congenital heart diseases in Chinese adults: </text>
<text top="486" left="190" width="516" height="13" font="8">analysis of 926 consecutive patients over 13 years of age. Am J Cardiol. 1986;57:840-4. </text>
<text top="504" left="105" width="44" height="13" font="8">S1.4-8. </text>
<text top="504" left="190" width="593" height="13" font="8">Samánek M, Slavík Z, Zborilová B, et al. Prevalence, treatment, and outcome of heart disease in live-</text>
<text top="522" left="190" width="586" height="13" font="8">born children: a prospective analysis of 91,823 live-born children. Pediatr Cardiol. 1989;10:205-11. </text>
<text top="540" left="105" width="44" height="13" font="8">S1.4-9. </text>
<text top="540" left="190" width="590" height="13" font="8">Mylotte D, Pilote L, Ionescu-Ittu R, et al. Specialized adult congenital heart disease care: the impact </text>
<text top="558" left="190" width="320" height="13" font="8">of policy on mortality. Circulation. 2014;129:1804-12. </text>
<text top="575" left="105" width="52" height="13" font="8">S1.4-10. </text>
<text top="575" left="190" width="557" height="13" font="8">Shen W-K, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and </text>
<text top="593" left="190" width="576" height="13" font="8">management of patients with syncope: a report of the American College of Cardiology/American </text>
<text top="611" left="190" width="539" height="13" font="8">Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. </text>
<text top="629" left="190" width="186" height="13" font="8">Circulation. 2017;136:e60-122. </text>
<text top="647" left="105" width="52" height="13" font="8">S1.4-11. </text>
<text top="647" left="190" width="579" height="13" font="8">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult </text>
<text top="664" left="190" width="599" height="13" font="8">patients with supraventricular tachycardia: a report of the American College of Cardiology/American </text>
<text top="682" left="190" width="539" height="13" font="8">Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. </text>
<text top="700" left="190" width="186" height="13" font="8">Circulation. 2016;133:e506-74. </text>
<text top="718" left="105" width="52" height="13" font="8">S1.4-12. </text>
<text top="718" left="190" width="570" height="13" font="8">Callaway CW, Donnino MW, Fink EL, et al. Part 8: post-cardiac arrest care: 2015 American Heart </text>
<text top="736" left="190" width="601" height="13" font="8">Association guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. </text>
<text top="754" left="190" width="186" height="13" font="8">Circulation. 2015;132:S465-82. </text>
<text top="771" left="105" width="52" height="13" font="8">S1.4-13. </text>
<text top="771" left="190" width="562" height="13" font="8">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of </text>
<text top="789" left="190" width="563" height="13" font="8">patients with non-ST-elevation acute coronary syndromes: a report of the American College of </text>
<text top="807" left="190" width="513" height="13" font="8">Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. </text>
<text top="825" left="190" width="123" height="13" font="8">2014;130:e344-426. </text>
<text top="843" left="105" width="52" height="13" font="8">S1.4-14. </text>
<text top="843" left="190" width="539" height="13" font="8">Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative </text>
<text top="861" left="190" width="588" height="13" font="8">cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of </text>
<text top="878" left="190" width="587" height="13" font="8">the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. </text>
<text top="896" left="190" width="194" height="13" font="8">Circulation. 2014;130:e278-333. </text>
<text top="914" left="105" width="52" height="13" font="8">S1.4-15. </text>
<text top="914" left="190" width="593" height="13" font="8">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients </text>
<text top="932" left="190" width="581" height="13" font="8">with atrial fibrillation: a report of the American College of Cardiology/American Heart Association </text>
<text top="950" left="190" width="580" height="13" font="8">Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:e199-267. </text>
<text top="967" left="105" width="52" height="13" font="8">S1.4-16. </text>
<text top="967" left="190" width="601" height="13" font="8">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of </text>
<text top="985" left="190" width="578" height="13" font="8">the guideline for the diagnosis and management of patients with stable ischemic heart disease: a </text>
<text top="1003" left="190" width="574" height="13" font="8">report of the American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="1021" left="190" width="577" height="13" font="8">Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses </text>
<text top="1039" left="190" width="563" height="13" font="8">Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic </text>
<text top="1057" left="190" width="248" height="13" font="8">Surgeons. Circulation. 2014;130:1749-67. </text>
</page>
<page number="132" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 134 </text>
<text top="162" left="105" width="52" height="13" font="8">S1.4-17. </text>
<text top="162" left="190" width="575" height="13" font="8">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the </text>
<text top="180" left="190" width="593" height="13" font="8">diagnosis and management of patients with stable ischemic heart disease: a report of the American </text>
<text top="198" left="190" width="600" height="13" font="8">College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and </text>
<text top="215" left="190" width="537" height="13" font="8">the American College of Physicians, American Association for Thoracic Surgery, Preventive </text>
<text top="233" left="190" width="582" height="13" font="8">Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and </text>
<text top="251" left="190" width="371" height="13" font="8">Society of Thoracic Surgeons. Circulation. 2012;126:e354-471. </text>
<text top="269" left="105" width="52" height="13" font="8">S1.4-18. </text>
<text top="269" left="190" width="545" height="13" font="8">Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of </text>
<text top="287" left="190" width="595" height="13" font="8">cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task </text>
<text top="305" left="190" width="354" height="13" font="8">Force on Practice Guidelines. Circulation. 2014;129:S49-73. </text>
<text top="323" left="105" width="52" height="13" font="8">S1.4-19. </text>
<text top="323" left="190" width="579" height="13" font="8">Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood </text>
<text top="340" left="190" width="590" height="13" font="8">cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College </text>
<text top="358" left="190" width="528" height="13" font="8">of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. </text>
<text top="376" left="190" width="100" height="13" font="8">2014;129:S1-45. </text>
<text top="394" left="105" width="52" height="13" font="8">S1.4-20. </text>
<text top="394" left="190" width="561" height="13" font="8">Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of </text>
<text top="411" left="190" width="578" height="13" font="8">overweight and obesity in adults: a report of the American College of Cardiology/American Heart </text>
<text top="429" left="190" width="585" height="13" font="8">Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129:S102-</text>
<text top="447" left="190" width="22" height="13" font="8">38. </text>
<text top="465" left="105" width="52" height="13" font="8">S1.4-21. </text>
<text top="465" left="190" width="561" height="13" font="8">Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce </text>
<text top="483" left="190" width="595" height="13" font="8">cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task </text>
<text top="501" left="190" width="354" height="13" font="8">Force on Practice Guidelines. Circulation. 2014;129:S76-99. </text>
<text top="519" left="105" width="52" height="13" font="8">S1.4-22. </text>
<text top="518" left="190" width="565" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC </text>
<text top="536" left="190" width="567" height="13" font="8">guideline for the management of patients with valvular heart disease: a report of the American </text>
<text top="554" left="190" width="549" height="13" font="8">College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. </text>
<text top="572" left="190" width="194" height="13" font="8">Circulation. 2017;135:e1159-95. </text>
<text top="589" left="105" width="52" height="13" font="8">S1.4-23. </text>
<text top="589" left="190" width="284" height="13" font="8">Whelton PK, Carey RM, Aronow WS, et al. 2017 </text>
<text top="607" left="190" width="552" height="13" font="8">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, </text>
<text top="625" left="190" width="585" height="13" font="8">detection, evaluation, and management of high blood pressure in adults: a report of the American </text>
<text top="643" left="190" width="549" height="13" font="8">College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. </text>
<text top="661" left="190" width="195" height="13" font="8">Hypertension. 2018;71:e13-115. </text>
<text top="678" left="105" width="52" height="13" font="8">S1.4-24. </text>
<text top="678" left="190" width="532" height="13" font="8">Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and ascending aorta guidelines for </text>
<text top="696" left="190" width="413" height="13" font="8">management and quality measures. Ann Thorac Surg. 2013;95:S1-66. </text>
<text top="714" left="105" width="52" height="13" font="8">S1.4-25. </text>
<text top="714" left="190" width="568" height="13" font="8">O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-</text>
<text top="732" left="190" width="471" height="13" font="8">elevation myocardial infarction: a report of the American College of Cardiology </text>
<text top="750" left="190" width="517" height="13" font="8">Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. </text>
<text top="768" left="190" width="123" height="13" font="8">2013;127:e362-425. </text>
<text top="785" left="105" width="52" height="13" font="8">S1.4-26. </text>
<text top="785" left="190" width="585" height="13" font="8">Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA </text>
<text top="803" left="190" width="492" height="13" font="8">guideline for the management of heart failure: a report of the American College of </text>
<text top="821" left="190" width="568" height="13" font="8">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart </text>
<text top="839" left="190" width="347" height="13" font="8">Failure Society of America. Circulation. 2017;136:e137-61. </text>
<text top="857" left="105" width="52" height="13" font="8">S1.4-27. </text>
<text top="857" left="190" width="583" height="13" font="8">Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines </text>
<text top="874" left="190" width="561" height="13" font="8">for device-based therapy of cardiac rhythm abnormalities: a report of the American College of </text>
<text top="892" left="190" width="594" height="13" font="8">Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart </text>
<text top="910" left="190" width="293" height="13" font="8">Rhythm Society. Circulation. 2012;126:1784-800. </text>
<text top="928" left="105" width="52" height="13" font="8">S1.4-28. </text>
<text top="928" left="190" width="572" height="13" font="8">Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA guideline for coronary artery bypass graft </text>
<text top="946" left="190" width="601" height="13" font="8">surgery: a report of the American College of Cardiology Foundation/American Heart Association Task </text>
<text top="964" left="190" width="369" height="13" font="8">Force on Practice Guidelines. Circulation. 2011;124:e652-735. </text>
<text top="981" left="105" width="52" height="13" font="8">S1.4-29. </text>
<text top="981" left="190" width="547" height="13" font="8">Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous </text>
<text top="999" left="190" width="586" height="13" font="8">coronary intervention: a report of the American College of Cardiology Foundation/American Heart </text>
<text top="1017" left="190" width="582" height="13" font="8">Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and </text>
<text top="1035" left="190" width="280" height="13" font="8">Interventions. Circulation. 2011;124:e574-651. </text>
<text top="1053" left="105" width="52" height="13" font="8">S1.4-30. </text>
<text top="1053" left="190" width="595" height="13" font="8">Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF ACCF secondary prevention and risk reduction </text>
<text top="1071" left="190" width="558" height="13" font="8">therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a </text>
</page>
<page number="133" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 135 </text>
<text top="162" left="190" width="570" height="13" font="8">guideline from the American Heart Association and American College of Cardiology Foundation. </text>
<text top="180" left="190" width="186" height="13" font="8">Circulation. 2011;124:2458-73. </text>
<text top="198" left="105" width="52" height="13" font="8">S1.4-31. </text>
<text top="198" left="190" width="529" height="13" font="8">Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of </text>
<text top="215" left="190" width="585" height="13" font="8">cardiovascular disease in women—2011 update: a guideline from the American Heart Association. </text>
<text top="233" left="190" width="186" height="13" font="8">Circulation. 2011;123:1243-62. </text>
<text top="251" left="105" width="52" height="13" font="8">S1.4-32. </text>
<text top="251" left="190" width="599" height="13" font="8">Baumgartner H, Bonhoeffer P, De Groot NMS, et al. ESC guidelines for the management of grown-up </text>
<text top="269" left="190" width="448" height="13" font="8">congenital heart disease (new version 2010). Eur Heart J. 2010;31:2915-57. </text>
<text top="286" left="105" width="52" height="13" font="8">S1.4-33. </text>
<text top="286" left="190" width="582" height="13" font="8">Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM </text>
<text top="304" left="190" width="600" height="13" font="8">guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the </text>
<text top="322" left="190" width="566" height="13" font="8">American College of Cardiology Foundation/American Heart Association Task Force on Practice </text>
<text top="340" left="190" width="574" height="13" font="8">Guidelines, American Association for Thoracic Surgery, American College of Radiology, American </text>
<text top="358" left="190" width="535" height="13" font="8">Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular </text>
<text top="375" left="190" width="581" height="13" font="8">Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, </text>
<text top="393" left="190" width="402" height="13" font="8">and Society for Vascular Medicine. Circulation. 2010;121:e266-369. </text>
<text top="411" left="105" width="52" height="13" font="8">S1.4-34. </text>
<text top="411" left="190" width="562" height="13" font="8">Silversides CK, Marelli A, Beauchesne L, et al. Canadian Cardiovascular Society 2009 consensus </text>
<text top="429" left="190" width="586" height="13" font="8">conference on the management of adults with congenital heart disease: executive summary. Can J </text>
<text top="447" left="190" width="150" height="13" font="8">Cardiol. 2010;26:143-50. </text>
<text top="465" left="105" width="52" height="13" font="8">S1.4-35. </text>
<text top="465" left="190" width="597" height="13" font="8">Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective </text>
<text top="482" left="190" width="571" height="13" font="8">endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of </text>
<text top="500" left="190" width="583" height="13" font="8">Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2009;30:2369-413. </text>
<text top="518" left="105" width="52" height="13" font="8">S1.4-36. </text>
<text top="518" left="190" width="597" height="13" font="8">Cohen MS, Eidem BW, Cetta F, et al. Multimodality imaging guidelines of patients with transposition </text>
<text top="536" left="190" width="549" height="13" font="8">of the great arteries: a report from the American Society of Echocardiography. Developed in </text>
<text top="554" left="190" width="528" height="13" font="8">collaboration with the Society for Cardiovascular Magnetic Resonance and the Society of </text>
<text top="572" left="190" width="486" height="13" font="8">Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2016;29:571-621. </text>
<text top="589" left="105" width="52" height="13" font="8">S1.4-37. </text>
<text top="589" left="190" width="567" height="13" font="8">Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by </text>
<text top="607" left="190" width="567" height="13" font="8">echocardiography in adults: an update from the American Society of Echocardiography and the </text>
<text top="625" left="190" width="543" height="13" font="8">European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1-39.e14. </text>
<text top="643" left="105" width="52" height="13" font="8">S1.4-38. </text>
<text top="643" left="190" width="598" height="13" font="8">Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and </text>
<text top="661" left="190" width="582" height="13" font="8">management of arrhythmias in adult congenital heart disease. Developed in partnership between </text>
<text top="678" left="190" width="596" height="13" font="8">the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). </text>
<text top="696" left="190" width="198" height="13" font="8">Heart Rhythm. 2014;11:e102-65. </text>
<text top="714" left="105" width="52" height="13" font="8">S1.4-39. </text>
<text top="714" left="190" width="562" height="13" font="8">Valente AM, Cook S, Festa P, et al. Multimodality imaging guidelines for patients with repaired </text>
<text top="732" left="190" width="536" height="13" font="8">tetralogy of Fallot: a report from the American Society of Echocardiography. Developed in </text>
<text top="750" left="190" width="590" height="13" font="8">collaboration with the Society for Cardiovascular Magnetic Resonance and the Society for Pediatric </text>
<text top="768" left="190" width="306" height="13" font="8">Radiology. J Am Soc Echocardiogr. 2014;27:111-41. </text>
<text top="785" left="105" width="52" height="13" font="8">S1.4-40. </text>
<text top="785" left="190" width="595" height="13" font="8">Boodhwani M, Andelfinger G, Leipsic J, et al. Canadian Cardiovascular Society position statement on </text>
<text top="803" left="190" width="444" height="13" font="8">the management of thoracic aortic disease. Can J Cardiol. 2014;30:577-89. </text>
<text top="821" left="105" width="52" height="13" font="8">S1.4-41. </text>
<text top="821" left="190" width="596" height="13" font="8">Longmuir PE, Brothers JA, de Ferranti SD, et al. Promotion of physical activity for children and adults </text>
<text top="839" left="190" width="538" height="13" font="8">with congenital heart disease: a scientific statement from the American Heart Association. </text>
<text top="857" left="190" width="186" height="13" font="8">Circulation. 2013;127:2147-59. </text>
<text top="874" left="105" width="52" height="13" font="8">S1.4-42. </text>
<text top="874" left="190" width="545" height="13" font="8">Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with </text>
<text top="892" left="190" width="575" height="13" font="8">congenital heart disease: evaluation and management: a scientific statement from the American </text>
<text top="910" left="190" width="298" height="13" font="8">Heart Association. Circulation. 2012;126:1143-72. </text>
<text top="928" left="105" width="52" height="13" font="8">S1.4-43. </text>
<text top="928" left="190" width="561" height="13" font="8">European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), </text>
<text top="946" left="190" width="553" height="13" font="8">German Society for Gender Medicine (DGesGM), et al. ESC guidelines on the management of </text>
<text top="964" left="190" width="573" height="13" font="8">cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular </text>
<text top="981" left="190" width="583" height="13" font="8">Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147-</text>
<text top="999" left="190" width="22" height="13" font="8">97. </text>
<text top="1017" left="105" width="52" height="13" font="8">S1.4-44. </text>
<text top="1017" left="190" width="586" height="13" font="8">Sable C, Foster E, Uzark K, et al. Best practices in managing transition to adulthood for adolescents </text>
<text top="1035" left="190" width="601" height="13" font="8">with congenital heart disease: the transition process and medical and psychosocial issues: a scientific </text>
<text top="1053" left="190" width="478" height="13" font="8">statement from the American Heart Association. Circulation. 2011;123:1454-85. </text>
<text top="1071" left="105" width="52" height="13" font="8">S1.4-45. </text>
<text top="1071" left="190" width="555" height="13" font="8">McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on </text>
<text top="1088" left="190" width="588" height="13" font="8">pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on </text>
</page>
<page number="134" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 136 </text>
<text top="162" left="190" width="592" height="13" font="8">Expert Consensus Documents and the American Heart Association. Developed in collaboration with </text>
<text top="180" left="190" width="557" height="13" font="8">the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary </text>
<text top="198" left="190" width="344" height="13" font="8">Hypertension Association. Circulation. 2009;119:2250-94. </text>
<text top="215" left="105" width="52" height="13" font="8">S1.4-46. </text>
<text top="215" left="190" width="571" height="13" font="8">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the </text>
<text top="233" left="190" width="569" height="13" font="8">American Heart Association: a guideline from the American Heart Association Rheumatic Fever, </text>
<text top="251" left="190" width="598" height="13" font="8">Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and </text>
<text top="269" left="190" width="601" height="13" font="8">the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality </text>
<text top="287" left="190" width="576" height="13" font="8">of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-54. </text>
<text top="333" left="105" width="352" height="21" font="10"><b>2. Background and Pathophysiology </b></text>
<text top="383" left="105" width="355" height="20" font="17"><b>2.1. Anatomic and Physiological Terms </b></text>
<text top="417" left="105" width="44" height="13" font="8">S2.1-1. </text>
<text top="417" left="190" width="568" height="13" font="8">Giroud JM, Jacobs JP, Spicer D, et al. Report from the International Society for Nomenclature of </text>
<text top="434" left="190" width="594" height="13" font="8">Paediatric and Congenital Heart Disease: creation of a visual encyclopedia illustrating the terms and </text>
<text top="452" left="190" width="600" height="13" font="8">definitions of the international pediatric and congenital cardiac code. World J Pediatr Congenit Heart </text>
<text top="470" left="190" width="127" height="13" font="8">Surg. 2010;1:300-13. </text>
<text top="488" left="105" width="44" height="13" font="8">S2.1-2. </text>
<text top="487" left="190" width="591" height="13" font="8">Bergersen L, Giroud JM, Jacobs JP, et al. Report from The International Society for Nomenclature of </text>
<text top="505" left="190" width="601" height="13" font="8">Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric </text>
<text top="523" left="190" width="589" height="13" font="8">cardiac disease (Part 2 - Nomenclature of complications associated with interventional cardiology). </text>
<text top="541" left="190" width="183" height="13" font="8">Cardiol Young. 2011;21:260-5. </text>
<text top="559" left="105" width="44" height="13" font="8">S2.1-3. </text>
<text top="559" left="190" width="599" height="13" font="8">Bergersen L, Everett AD, Giroud JM, et al. Report from the International Society for Nomenclature of </text>
<text top="577" left="190" width="601" height="13" font="8">Paediatric and Congenital Heart Disease: cardiovascular catheterisation for congenital and paediatric </text>
<text top="595" left="190" width="489" height="13" font="8">cardiac disease (Part 1 - Procedural nomenclature). Cardiol Young. 2011;21:252-9. </text>
<text top="612" left="105" width="44" height="13" font="8">S2.1-4. </text>
<text top="612" left="190" width="576" height="13" font="8">Franklin RCG, Jacobs JP, Krogmann ON, et al. Nomenclature for congenital and paediatric cardiac </text>
<text top="630" left="190" width="596" height="13" font="8">disease: historical perspectives and The International Pediatric and Congenital Cardiac Code. Cardiol </text>
<text top="648" left="190" width="189" height="13" font="8">Young. 2008;18(suppl 2):70-80. </text>
<text top="666" left="105" width="44" height="13" font="8">S2.1-5. </text>
<text top="666" left="190" width="583" height="13" font="8">Franklin RCG, Béland MJ, Krogmann ON. Mapping and coding of nomenclatures for paediatric and </text>
<text top="684" left="190" width="334" height="13" font="8">congenital heart disease. Cardiol Young. 2006;16:105-6. </text>
<text top="701" left="105" width="44" height="13" font="8">S2.1-6. </text>
<text top="701" left="190" width="576" height="13" font="8">International Society for Nomenclature of Paediatric and Congenital Heart Disease. International </text>
<text top="719" left="190" width="572" height="13" font="8">Paediatric and Congenital Cardiac Code. Available at: http://ipccc.net/. Accessed: May 29, 2018. </text>
<text top="757" left="105" width="199" height="20" font="17"><b>2.2. Severity of ACHD </b></text>
<text top="790" left="105" width="44" height="13" font="8">S2.2-1. </text>
<text top="790" left="190" width="598" height="13" font="8">Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults </text>
<text top="808" left="190" width="559" height="13" font="8">with congenital heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="826" left="190" width="570" height="13" font="8">Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the </text>
<text top="843" left="190" width="526" height="13" font="8">Management of Adults With Congenital Heart Disease). Circulation. 2008;118:e714-833. </text>
<text top="861" left="105" width="44" height="13" font="8">S2.2-2. </text>
<text top="861" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="879" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="897" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="915" left="105" width="44" height="13" font="8">S2.2-3. </text>
<text top="915" left="190" width="595" height="13" font="8">Boodhwani M, Andelfinger G, Leipsic J, et al. Canadian Cardiovascular Society position statement on </text>
<text top="933" left="190" width="444" height="13" font="8">the management of thoracic aortic disease. Can J Cardiol. 2014;30:577-89. </text>
<text top="951" left="105" width="44" height="13" font="8">S2.2-4. </text>
<text top="951" left="190" width="532" height="13" font="8">Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and ascending aorta guidelines for </text>
<text top="968" left="190" width="413" height="13" font="8">management and quality measures. Ann Thorac Surg. 2013;95:S1-66. </text>
<text top="986" left="105" width="44" height="13" font="8">S2.2-5. </text>
<text top="986" left="190" width="579" height="13" font="8">Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Mortality in adult congenital heart disease. </text>
<text top="1004" left="190" width="172" height="13" font="8">Eur Heart J. 2010;31:1220-9. </text>
<text top="1022" left="105" width="44" height="13" font="8">S2.2-6. </text>
<text top="1022" left="190" width="551" height="13" font="8">Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired </text>
<text top="1039" left="190" width="452" height="13" font="8">tetralogy of Fallot: a multi-institutional study. Circulation. 2010;122:868-75. </text>
<text top="1057" left="105" width="44" height="13" font="8">S2.2-7. </text>
<text top="1057" left="190" width="576" height="13" font="8">Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of </text>
<text top="1075" left="190" width="422" height="13" font="8">mortality in patients with Fontan surgery. Circulation. 2008;117:85-92. </text>
</page>
<page number="135" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 137 </text>
<text top="162" left="105" width="44" height="13" font="8">S2.2-8. </text>
<text top="162" left="190" width="586" height="13" font="8">Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. </text>
<text top="180" left="190" width="179" height="13" font="8">Circulation. 2008;117:363-70. </text>
<text top="198" left="105" width="44" height="13" font="8">S2.2-9. </text>
<text top="198" left="190" width="565" height="13" font="8">Dimopoulos K, Diller G-P, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal </text>
<text top="215" left="190" width="487" height="13" font="8">dysfunction in adults with congenital heart disease. Circulation. 2008;117:2320-8. </text>
<text top="233" left="105" width="52" height="13" font="8">S2.2-10. </text>
<text top="233" left="190" width="565" height="13" font="8">Dimopoulos K, Diller G-P, Giannakoulas G, et al. Anemia in adults with congenital heart disease </text>
<text top="251" left="190" width="391" height="13" font="8">relates to adverse outcome. J Am Coll Cardiol. 2009;54:2093-100. </text>
<text top="269" left="105" width="52" height="13" font="8">S2.2-11. </text>
<text top="269" left="190" width="585" height="13" font="8">Dimopoulos K, Diller G-P, Petraco R, et al. Hyponatraemia: a strong predictor of mortality in adults </text>
<text top="287" left="190" width="361" height="13" font="8">with congenital heart disease. Eur Heart J. 2010;31:595-601. </text>
<text top="305" left="105" width="52" height="13" font="8">S2.2-12. </text>
<text top="305" left="190" width="572" height="13" font="8">Diller G-P, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: </text>
<text top="323" left="190" width="542" height="13" font="8">comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828-35. </text>
<text top="340" left="105" width="52" height="13" font="8">S2.2-13. </text>
<text top="340" left="190" width="545" height="13" font="8">Buys R, Cornelissen V, Van De Bruaene A, et al. Measures of exercise capacity in adults with </text>
<text top="358" left="190" width="329" height="13" font="8">congenital heart disease. Int J Cardiol. 2011;153:26-30. </text>
<text top="375" left="105" width="52" height="13" font="8">S2.2-14. </text>
<text top="375" left="190" width="594" height="13" font="8">Gratz A, Hess J, Hager A. Self-estimated physical functioning poorly predicts actual exercise capacity </text>
<text top="393" left="190" width="514" height="13" font="8">in adolescents and adults with congenital heart disease. Eur Heart J. 2009;30:497-504. </text>
<text top="411" left="105" width="52" height="13" font="8">S2.2-15. </text>
<text top="411" left="190" width="598" height="13" font="8">Dimopoulos K, Okonko DO, Diller G-P, et al. Abnormal ventilatory response to exercise in adults with </text>
<text top="429" left="190" width="584" height="13" font="8">congenital heart disease relates to cyanosis and predicts survival. Circulation. 2006;113:2796-802. </text>
<text top="447" left="105" width="52" height="13" font="8">S2.2-16. </text>
<text top="447" left="190" width="551" height="13" font="8">Inuzuka R, Diller G-P, Borgia F, et al. Comprehensive use of cardiopulmonary exercise testing </text>
<text top="465" left="190" width="559" height="13" font="8">identifies adults with congenital heart disease at increased mortality risk in the medium term. </text>
<text top="482" left="190" width="172" height="13" font="8">Circulation. 2012;125:250-9. </text>
<text top="500" left="105" width="52" height="13" font="8">S2.2-17. </text>
<text top="500" left="190" width="566" height="13" font="8">Müller J, Hager A, Diller G-P, et al. Peak oxygen uptake, ventilatory efficiency and QRS-duration </text>
<text top="518" left="190" width="574" height="13" font="8">predict event free survival in patients late after surgical repair of tetralogy of Fallot. Int J Cardiol. </text>
<text top="536" left="190" width="108" height="13" font="8">2015;196:158-64. </text>
<text top="554" left="105" width="52" height="13" font="8">S2.2-18. </text>
<text top="554" left="190" width="577" height="13" font="8">Kempny A, Dimopoulos K, Uebing A, et al. Reference values for exercise limitations among adults </text>
<text top="572" left="190" width="601" height="13" font="8">with congenital heart disease. Relation to activities of daily life—single centre experience and review </text>
<text top="589" left="190" width="290" height="13" font="8">of published data. Eur Heart J. 2012;33:1386-96. </text>
<text top="607" left="105" width="52" height="13" font="8">S2.2-19. </text>
<text top="607" left="190" width="586" height="13" font="8">Dolgin M, New York Heart Association, eds. Nomenclature and Criteria for Diagnosis of Diseases of </text>
<text top="625" left="190" width="458" height="13" font="8">the Heart and Great Vessels. 9th ed. Boston, MA: Little, Brown and Co; 1994. </text>
<text top="643" left="105" width="52" height="13" font="8">S2.2-20. </text>
<text top="643" left="190" width="586" height="13" font="8">Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J </text>
<text top="661" left="190" width="200" height="13" font="8">Am Coll Cardiol. 2013;62:D42-50. </text>
<text top="698" left="105" width="289" height="20" font="17"><b>2.3. The ACHD AP Classification </b></text>
<text top="732" left="105" width="44" height="13" font="8">S2.3-1. </text>
<text top="732" left="190" width="579" height="13" font="8">Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Mortality in adult congenital heart disease. </text>
<text top="749" left="190" width="172" height="13" font="8">Eur Heart J. 2010;31:1220-9. </text>
<text top="767" left="105" width="44" height="13" font="8">S2.3-2. </text>
<text top="767" left="190" width="572" height="13" font="8">Diller G-P, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: </text>
<text top="785" left="190" width="542" height="13" font="8">comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828-35. </text>
<text top="803" left="105" width="44" height="13" font="8">S2.3-3. </text>
<text top="803" left="190" width="565" height="13" font="8">Dimopoulos K, Diller G-P, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal </text>
<text top="821" left="190" width="487" height="13" font="8">dysfunction in adults with congenital heart disease. Circulation. 2008;117:2320-8. </text>
<text top="838" left="105" width="44" height="13" font="8">S2.3-4. </text>
<text top="838" left="190" width="598" height="13" font="8">Dimopoulos K, Okonko DO, Diller G-P, et al. Abnormal ventilatory response to exercise in adults with </text>
<text top="856" left="190" width="584" height="13" font="8">congenital heart disease relates to cyanosis and predicts survival. Circulation. 2006;113:2796-802. </text>
<text top="874" left="105" width="44" height="13" font="8">S2.3-5. </text>
<text top="874" left="190" width="590" height="13" font="8">Hebson CL, McCabe NM, Elder RW, et al. Hemodynamic phenotype of the failing Fontan in an adult </text>
<text top="892" left="190" width="260" height="13" font="8">population. Am J Cardiol. 2013;112:1943-7. </text>
<text top="910" left="105" width="44" height="13" font="8">S2.3-6. </text>
<text top="910" left="190" width="551" height="13" font="8">Khairy P, Aboulhosn J, Gurvitz MZ, et al. Arrhythmia burden in adults with surgically repaired </text>
<text top="928" left="190" width="452" height="13" font="8">tetralogy of Fallot: a multi-institutional study. Circulation. 2010;122:868-75. </text>
<text top="945" left="105" width="44" height="13" font="8">S2.3-7. </text>
<text top="945" left="190" width="588" height="13" font="8">Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great </text>
<text top="963" left="190" width="577" height="13" font="8">arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250-7. </text>
<text top="981" left="105" width="44" height="13" font="8">S2.3-8. </text>
<text top="981" left="190" width="551" height="13" font="8">Inuzuka R, Diller G-P, Borgia F, et al. Comprehensive use of cardiopulmonary exercise testing </text>
<text top="999" left="190" width="559" height="13" font="8">identifies adults with congenital heart disease at increased mortality risk in the medium term. </text>
<text top="1017" left="190" width="172" height="13" font="8">Circulation. 2012;125:250-9. </text>
<text top="1034" left="105" width="44" height="13" font="8">S2.3-9. </text>
<text top="1034" left="190" width="566" height="13" font="8">Müller J, Hager A, Diller G-P, et al. Peak oxygen uptake, ventilatory efficiency and QRS-duration </text>
<text top="1052" left="190" width="574" height="13" font="8">predict event free survival in patients late after surgical repair of tetralogy of Fallot. Int J Cardiol. </text>
<text top="1070" left="190" width="108" height="13" font="8">2015;196:158-64. </text>
</page>
<page number="136" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 138 </text>
<text top="162" left="105" width="52" height="13" font="8">S2.3-10. </text>
<text top="162" left="190" width="600" height="13" font="8">Stefanescu A, Macklin EA, Lin E, et al. Usefulness of the Seattle Heart Failure Model to identify adults </text>
<text top="180" left="190" width="541" height="13" font="8">with congenital heart disease at high risk of poor outcome. Am J Cardiol. 2014;113:865-70. </text>
<text top="198" left="105" width="52" height="13" font="8">S2.3-11. </text>
<text top="197" left="190" width="561" height="13" font="8">Giannakoulas G, Dimopoulos K, Engel R, et al. Burden of coronary artery disease in adults with </text>
<text top="215" left="190" width="600" height="13" font="8">congenital heart disease and its relation to congenital and traditional heart risk factors. Am J Cardiol. </text>
<text top="233" left="190" width="115" height="13" font="8">2009;103:1445-50. </text>
<text top="251" left="105" width="52" height="13" font="8">S2.3-12. </text>
<text top="251" left="190" width="582" height="13" font="8">Giannakoulas G, Dimopoulos K, Bolger AP, et al. Usefulness of natriuretic peptide levels to predict </text>
<text top="269" left="190" width="481" height="13" font="8">mortality in adults with congenital heart disease. Am J Cardiol. 2010;105:869-73. </text>
<text top="286" left="105" width="52" height="13" font="8">S2.3-13. </text>
<text top="286" left="190" width="576" height="13" font="8">Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of </text>
<text top="304" left="190" width="422" height="13" font="8">mortality in patients with Fontan surgery. Circulation. 2008;117:85-92. </text>
<text top="322" left="105" width="52" height="13" font="8">S2.3-14. </text>
<text top="322" left="190" width="586" height="13" font="8">Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. </text>
<text top="340" left="190" width="179" height="13" font="8">Circulation. 2008;117:363-70. </text>
<text top="358" left="105" width="52" height="13" font="8">S2.3-15. </text>
<text top="358" left="190" width="565" height="13" font="8">Dimopoulos K, Diller G-P, Giannakoulas G, et al. Anemia in adults with congenital heart disease </text>
<text top="375" left="190" width="391" height="13" font="8">relates to adverse outcome. J Am Coll Cardiol. 2009;54:2093-100. </text>
<text top="393" left="105" width="52" height="13" font="8">S2.3-16. </text>
<text top="393" left="190" width="585" height="13" font="8">Dimopoulos K, Diller G-P, Petraco R, et al. Hyponatraemia: a strong predictor of mortality in adults </text>
<text top="411" left="190" width="361" height="13" font="8">with congenital heart disease. Eur Heart J. 2010;31:595-601. </text>
<text top="429" left="105" width="52" height="13" font="8">S2.3-17. </text>
<text top="429" left="190" width="557" height="13" font="8">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart </text>
<text top="447" left="190" width="595" height="13" font="8">failure: a report of the American College of Cardiology Foundation/American Heart Association Task </text>
<text top="465" left="190" width="369" height="13" font="8">Force on Practice Guidelines. Circulation. 2013;128:e240-327. </text>
<text top="511" left="105" width="204" height="21" font="10"><b>3. General Principles </b></text>
<text top="561" left="105" width="179" height="20" font="17"><b>3.1. ACHD Program </b></text>
<text top="595" left="105" width="44" height="13" font="8">S3.1-1. </text>
<text top="595" left="190" width="590" height="13" font="8">Mylotte D, Pilote L, Ionescu-Ittu R, et al. Specialized adult congenital heart disease care: the impact </text>
<text top="612" left="190" width="320" height="13" font="8">of policy on mortality. Circulation. 2014;129:1804-12. </text>
<text top="650" left="105" width="174" height="20" font="17"><b>3.2. Access to Care </b></text>
<text top="683" left="105" width="44" height="13" font="8">S3.2-1. </text>
<text top="683" left="190" width="566" height="13" font="8">Gurvitz M, Valente AM, Broberg C, et al. Prevalence and predictors of gaps in care among adult </text>
<text top="701" left="190" width="598" height="13" font="8">congenital heart disease patients: HEART-ACHD (The Health, Education, and Access Research Trial). J </text>
<text top="719" left="190" width="198" height="13" font="8">Am Coll Cardiol. 2013;61:2180-4. </text>
<text top="737" left="105" width="44" height="13" font="8">S3.2-2. </text>
<text top="737" left="190" width="597" height="13" font="8">Mackie AS, Islam S, Magill-Evans J, et al. Healthcare transition for youth with heart disease: a clinical </text>
<text top="755" left="190" width="179" height="13" font="8">trial. Heart. 2014;100:1113-8. </text>
<text top="772" left="105" width="44" height="13" font="8">S3.2-3. </text>
<text top="772" left="190" width="539" height="13" font="8">Yeung E, Kay J, Roosevelt GE, et al. Lapse of care as a predictor for morbidity in adults with </text>
<text top="790" left="190" width="321" height="13" font="8">congenital heart disease. Int J Cardiol. 2008;125:62-5. </text>
<text top="808" left="105" width="44" height="13" font="8">S3.2-4. </text>
<text top="808" left="190" width="558" height="13" font="8">Wacker A, Kaemmerer H, Hollweck R, et al. Outcome of operated and unoperated adults with </text>
<text top="826" left="190" width="583" height="13" font="8">congenital cardiac disease lost to follow-up for more than five years. Am J Cardiol. 2005;95:776-9. </text>
<text top="843" left="105" width="44" height="13" font="8">S3.2-5. </text>
<text top="843" left="190" width="590" height="13" font="8">Mylotte D, Pilote L, Ionescu-Ittu R, et al. Specialized adult congenital heart disease care: the impact </text>
<text top="861" left="190" width="320" height="13" font="8">of policy on mortality. Circulation. 2014;129:1804-12. </text>
<text top="899" left="105" width="189" height="20" font="17"><b>3.3. Delivery of Care </b></text>
<text top="932" left="105" width="44" height="13" font="8">S3.3-1. </text>
<text top="932" left="190" width="590" height="13" font="8">Mylotte D, Pilote L, Ionescu-Ittu R, et al. Specialized adult congenital heart disease care: the impact </text>
<text top="950" left="190" width="320" height="13" font="8">of policy on mortality. Circulation. 2014;129:1804-12. </text>
<text top="968" left="105" width="44" height="13" font="8">S3.3-2. </text>
<text top="968" left="190" width="598" height="13" font="8">Karamlou T, Diggs BS, Person T, et al. National practice patterns for management of adult congenital </text>
<text top="986" left="190" width="555" height="13" font="8">heart disease: operation by pediatric heart surgeons decreases in-hospital death. Circulation. </text>
<text top="1003" left="190" width="115" height="13" font="8">2008;118:2345-52. </text>
<text top="1021" left="105" width="44" height="13" font="8">S3.3-3. </text>
<text top="1021" left="190" width="574" height="13" font="8">Hijazi ZM, Ruiz CE, Zahn E, et al. SCAI/AATS/ACC/STS operator and institutional requirements for </text>
<text top="1039" left="190" width="513" height="13" font="8">transcatheter valve repair and replacement, part III: pulmonic valve. J Am Coll Cardiol. </text>
<text top="1057" left="190" width="108" height="13" font="8">2015;65:2556-63. </text>
</page>
<page number="137" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 139 </text>
<text top="162" left="105" width="44" height="13" font="8">S3.3-4. </text>
<text top="162" left="190" width="573" height="13" font="8">Ruiz CE, Feldman TE, Hijazi ZM, et al. Interventional fellowship in structural and congenital heart </text>
<text top="180" left="190" width="338" height="13" font="8">disease for adults. JACC Cardiovasc Interv. 2010;3:e1-15. </text>
<text top="198" left="105" width="44" height="13" font="8">S3.3-5. </text>
<text top="197" left="190" width="574" height="13" font="8">Armsby L, Beekman RHr, Benson L, et al. SCAI expert consensus statement for advanced training </text>
<text top="215" left="190" width="573" height="13" font="8">programs in pediatric and congenital interventional cardiac catheterization. Catheter Cardiovasc </text>
<text top="233" left="190" width="143" height="13" font="8">Interv. 2014;84:779-84. </text>
<text top="251" left="105" width="44" height="13" font="8">S3.3-6. </text>
<text top="251" left="190" width="588" height="13" font="8">Mascio CE, Pasquali SK, Jacobs JP, et al. Outcomes in adult congenital heart surgery: analysis of the </text>
<text top="269" left="190" width="495" height="13" font="8">Society of Thoracic Surgeons database. J Thorac Cardiovasc Surg. 2011;142:1090-7. </text>
<text top="286" left="105" width="44" height="13" font="8">S3.3-7. </text>
<text top="286" left="190" width="573" height="13" font="8">Hörer J, Vogt M, Wottke M, et al. Evaluation of the Aristotle complexity models in adult patients </text>
<text top="304" left="190" width="427" height="13" font="8">with congenital heart disease. Eur J Cardiothorac Surg. 2013;43:128-34. </text>
<text top="322" left="105" width="44" height="13" font="8">S3.3-8. </text>
<text top="322" left="190" width="572" height="13" font="8">van Gameren M, Putman LM, Takkenberg JJM, et al. Risk stratification for adult congenital heart </text>
<text top="340" left="190" width="289" height="13" font="8">surgery. Eur J Cardiothorac Surg. 2011;39:490-4. </text>
<text top="358" left="105" width="44" height="13" font="8">S3.3-9. </text>
<text top="358" left="190" width="563" height="13" font="8">Kogon B, Oster M. Assessing surgical risk for adults with congenital heart disease: are pediatric </text>
<text top="375" left="190" width="438" height="13" font="8">scoring systems appropriate? J Thorac Cardiovasc Surg. 2014;147:666-71. </text>
<text top="393" left="105" width="52" height="13" font="8">S3.3-10. </text>
<text top="393" left="190" width="594" height="13" font="8">Gajjar TP, Hiremath CS, Desai NB. Surgical closure of sinus venosus atrial septal defect using a single </text>
<text top="411" left="190" width="389" height="13" font="8">patch—transcaval repair technique. J Card Surg. 2011;26:429-34. </text>
<text top="429" left="105" width="52" height="13" font="8">S3.3-11. </text>
<text top="429" left="190" width="585" height="13" font="8">Videbæk J, Laursen HB, Olsen M, et al. Long-term nationwide follow-up study of simple congenital </text>
<text top="447" left="190" width="506" height="13" font="8">heart disease diagnosed in otherwise healthy children. Circulation. 2016;133:474-83. </text>
<text top="465" left="105" width="52" height="13" font="8">S3.3-12. </text>
<text top="465" left="190" width="574" height="13" font="8">Karonis T, Scognamiglio G, Babu-Narayan SV, et al. Clinical course and potential complications of </text>
<text top="482" left="190" width="558" height="13" font="8">small ventricular septal defects in adulthood: late development of left ventricular dysfunction </text>
<text top="500" left="190" width="306" height="13" font="8">justifies lifelong care. Int J Cardiol. 2016;208:102-6. </text>
<text top="518" left="105" width="52" height="13" font="8">S3.3-13. </text>
<text top="518" left="190" width="573" height="13" font="8">Bonello B, Kilner PJ. Review of the role of cardiovascular magnetic resonance in congenital heart </text>
<text top="536" left="190" width="538" height="13" font="8">disease, with a focus on right ventricle assessment. Arch Cardiovasc Dis. 2012;105:605-13. </text>
<text top="554" left="105" width="52" height="13" font="8">S3.3-14. </text>
<text top="554" left="190" width="550" height="13" font="8">Kilner PJ. Imaging congenital heart disease in adults. Br J Radiol. 2011;84 Spec No 3:S258-68. </text>
<text top="572" left="105" width="52" height="13" font="8">S3.3-15. </text>
<text top="572" left="190" width="597" height="13" font="8">Cohen MS, Eidem BW, Cetta F, et al. Multimodality imaging guidelines of patients with transposition </text>
<text top="589" left="190" width="549" height="13" font="8">of the great arteries: a report from the American Society of Echocardiography. Developed in </text>
<text top="607" left="190" width="528" height="13" font="8">collaboration with the Society for Cardiovascular Magnetic Resonance and the Society of </text>
<text top="625" left="190" width="486" height="13" font="8">Cardiovascular Computed Tomography. J Am Soc Echocardiogr. 2016;29:571-621. </text>
<text top="643" left="105" width="52" height="13" font="8">S3.3-16. </text>
<text top="643" left="190" width="562" height="13" font="8">Valente AM, Cook S, Festa P, et al. Multimodality imaging guidelines for patients with repaired </text>
<text top="661" left="190" width="536" height="13" font="8">tetralogy of Fallot: a report from the American Society of Echocardiography. Developed in </text>
<text top="678" left="190" width="590" height="13" font="8">collaboration with the Society for Cardiovascular Magnetic Resonance and the Society for Pediatric </text>
<text top="696" left="190" width="306" height="13" font="8">Radiology. J Am Soc Echocardiogr. 2014;27:111-41. </text>
<text top="714" left="105" width="52" height="13" font="8">S3.3-17. </text>
<text top="714" left="190" width="563" height="13" font="8">Ginde S, Bartz PJ, Hill GD, et al. Restrictive lung disease is an independent predictor of exercise </text>
<text top="732" left="190" width="534" height="13" font="8">intolerance in the adult with congenital heart disease. Congenit Heart Dis. 2013;8:246-54. </text>
<text top="750" left="105" width="52" height="13" font="8">S3.3-18. </text>
<text top="750" left="190" width="595" height="13" font="8">Alonso-Gonzalez R, Borgia F, Diller G-P, et al. Abnormal lung function in adults with congenital heart </text>
<text top="768" left="190" width="542" height="13" font="8">disease: prevalence, relation to cardiac anatomy, and association with survival. Circulation. </text>
<text top="785" left="190" width="108" height="13" font="8">2013;127:882-90. </text>
<text top="803" left="105" width="52" height="13" font="8">S3.3-19. </text>
<text top="803" left="190" width="572" height="13" font="8">Zach KJ, Ramakrishna H, Chandrasekaran K, et al. Laparoscopic colectomy in an adult with single </text>
<text top="821" left="190" width="584" height="13" font="8">ventricle physiology: anesthetic implications and management. Ann Card Anaesth. 2015;18:252-6. </text>
<text top="839" left="105" width="52" height="13" font="8">S3.3-20. </text>
<text top="839" left="190" width="586" height="13" font="8">Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart </text>
<text top="857" left="190" width="553" height="13" font="8">disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120:198-204. </text>
<text top="874" left="105" width="52" height="13" font="8">S3.3-21. </text>
<text top="874" left="190" width="572" height="13" font="8">Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital </text>
<text top="892" left="190" width="519" height="13" font="8">heart disease adult population impact on outcomes. J Am Coll Cardiol. 2011;58:538-46. </text>
<text top="910" left="105" width="52" height="13" font="8">S3.3-22. </text>
<text top="910" left="190" width="583" height="13" font="8">Van De Bruaene A, Delcroix M, Pasquet A, et al. The importance of pulmonary artery pressures on </text>
<text top="928" left="190" width="555" height="13" font="8">late atrial arrhythmia in transcatheter and surgically closed ASD type secundum. Int J Cardiol. </text>
<text top="946" left="190" width="101" height="13" font="8">2011;152:192-5. </text>
<text top="964" left="105" width="52" height="13" font="8">S3.3-23. </text>
<text top="964" left="190" width="596" height="13" font="8">Barst RJ, Ivy DD, Foreman AJ, et al. Four- and seven-year outcomes of patients with congenital heart </text>
<text top="981" left="190" width="558" height="13" font="8">disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol. </text>
<text top="999" left="190" width="108" height="13" font="8">2014;113:147-55. </text>
<text top="1017" left="105" width="52" height="13" font="8">S3.3-24. </text>
<text top="1017" left="190" width="597" height="13" font="8">D’Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital </text>
<text top="1035" left="190" width="399" height="13" font="8">heart disease and Down’s syndrome. Int J Cardiol. 2013;164:323-6. </text>
<text top="1053" left="105" width="52" height="13" font="8">S3.3-25. </text>
<text top="1053" left="190" width="576" height="13" font="8">Engelfriet PM, Duffels MGJ, Möller T, et al. Pulmonary arterial hypertension in adults born with a </text>
<text top="1071" left="190" width="591" height="13" font="8">heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93:682-7. </text>
</page>
<page number="138" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 140 </text>
<text top="162" left="105" width="52" height="13" font="8">S3.3-26. </text>
<text top="162" left="190" width="537" height="13" font="8">Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial </text>
<text top="180" left="190" width="580" height="13" font="8">hypertension associated with congenital heart disease: a comparison between clinical subgroups. </text>
<text top="198" left="190" width="172" height="13" font="8">Eur Heart J. 2014;35:716-24. </text>
<text top="215" left="105" width="52" height="13" font="8">S3.3-27. </text>
<text top="215" left="190" width="567" height="13" font="8">O’Donnell C, Ruygrok PN, Whyte K, et al. Progressive pulmonary hypertension post atrial septal </text>
<text top="233" left="190" width="591" height="13" font="8">defect device closure—early symptomatic improvement may not predict outcome. Heart Lung Circ. </text>
<text top="251" left="190" width="93" height="13" font="8">2010;19:713-6. </text>
<text top="269" left="105" width="52" height="13" font="8">S3.3-28. </text>
<text top="269" left="190" width="561" height="13" font="8">Van De Bruaene A, Moons P, Belmans A, et al. Predictive model for late atrial arrhythmia after </text>
<text top="286" left="190" width="382" height="13" font="8">closure of an atrial septal defect. Int J Cardiol. 2013;164:318-22. </text>
<text top="304" left="105" width="52" height="13" font="8">S3.3-29. </text>
<text top="304" left="190" width="566" height="13" font="8">D’Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial </text>
<text top="322" left="190" width="400" height="13" font="8">hypertension after shunt closure. Int J Cardiol. 2013;168:3797-801. </text>
<text top="340" left="105" width="52" height="13" font="8">S3.3-30. </text>
<text top="340" left="190" width="601" height="13" font="8">Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive </text>
<text top="358" left="190" width="561" height="13" font="8">disease—long-term follow-up and prediction of outcome after surgical correction. Circulation. </text>
<text top="375" left="190" width="108" height="13" font="8">1987;76:1037-42. </text>
<text top="413" left="105" width="414" height="20" font="17"><b>3.4. Evaluation of Suspected and Known CHD </b></text>
<text top="461" left="105" width="212" height="19" font="34"><b>3.4.1. Electrocardiogram </b></text>
<text top="493" left="105" width="55" height="13" font="8">S3.4.1-1. </text>
<text top="493" left="190" width="533" height="13" font="8">Graham TP Jr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected </text>
<text top="511" left="190" width="574" height="13" font="8">transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255-61. </text>
<text top="528" left="105" width="55" height="13" font="8">S3.4.1-2. </text>
<text top="528" left="190" width="595" height="13" font="8">Connelly MS, Liu PP, Williams WG, et al. Congenitally corrected transposition of the great arteries in </text>
<text top="546" left="190" width="492" height="13" font="8">the adult: functional status and complications. J Am Coll Cardiol. 1996;27:1238-43. </text>
<text top="564" left="105" width="55" height="13" font="8">S3.4.1-3. </text>
<text top="564" left="190" width="594" height="13" font="8">Bergin ML, Warnes CA, Tajik AJ, et al. Partial atrioventricular canal defect: long-term follow-up after </text>
<text top="582" left="190" width="471" height="13" font="8">initial repair in patients &gt; or = 40 years old. J Am Coll Cardiol. 1995;25:1189-94. </text>
<text top="600" left="105" width="55" height="13" font="8">S3.4.1-4. </text>
<text top="600" left="190" width="596" height="13" font="8">Borkon AM, Pieroni DR, Varghese PJ, et al. The superior QRS axis in ostium primum ASD: a proposed </text>
<text top="618" left="190" width="248" height="13" font="8">mechanism. Am Heart J. 1975;90:215-21. </text>
<text top="635" left="105" width="55" height="13" font="8">S3.4.1-5. </text>
<text top="635" left="190" width="583" height="13" font="8">Wei W, Zhan X, Xue Y, et al. Features of accessory pathways in adult Ebstein’s anomaly. Europace. </text>
<text top="653" left="190" width="108" height="13" font="8">2014;16:1619-25. </text>
<text top="671" left="105" width="55" height="13" font="8">S3.4.1-6. </text>
<text top="671" left="190" width="570" height="13" font="8">Iturralde P, Nava S, Sálica G, et al. Electrocardiographic characteristics of patients with Ebstein’s </text>
<text top="689" left="190" width="530" height="13" font="8">anomaly before and after ablation of an accessory atrioventricular pathway. J Cardiovasc </text>
<text top="707" left="190" width="191" height="13" font="8">Electrophysiol. 2006;17:1332-6. </text>
<text top="724" left="105" width="55" height="13" font="8">S3.4.1-7. </text>
<text top="724" left="190" width="576" height="13" font="8">Reich JD, Auld D, Hulse E, et al. The Pediatric Radiofrequency Ablation Registry’s experience with </text>
<text top="742" left="190" width="587" height="13" font="8">Ebstein’s anomaly. Pediatric Electrophysiology Society. J Cardiovasc Electrophysiol. 1998;9:1370-7. </text>
<text top="760" left="105" width="55" height="13" font="8">S3.4.1-8. </text>
<text top="760" left="190" width="543" height="13" font="8">Liberman L, Pass RH, Hordof AJ, et al. Late onset of heart block after open heart surgery for </text>
<text top="778" left="190" width="332" height="13" font="8">congenital heart disease. Pediatr Cardiol. 2008;29:56-9. </text>
<text top="815" left="105" width="296" height="19" font="34"><b>3.4.2. Ionizing Radiation Principles </b></text>
<text top="847" left="105" width="55" height="13" font="8">S3.4.2-1. </text>
<text top="847" left="190" width="561" height="13" font="8">Glatz AC, Purrington KS, Klinger A, et al. Cumulative exposure to medical radiation for children </text>
<text top="865" left="190" width="469" height="13" font="8">requiring surgery for congenital heart disease. J Pediatr. 2014;164:789-94.e10. </text>
<text top="883" left="105" width="55" height="13" font="8">S3.4.2-2. </text>
<text top="883" left="190" width="561" height="13" font="8">Johnson JN, Hornik CP, Li JS, et al. Cumulative radiation exposure and cancer risk estimation in </text>
<text top="900" left="190" width="339" height="13" font="8">children with heart disease. Circulation. 2014;130:161-7. </text>
<text top="918" left="105" width="55" height="13" font="8">S3.4.2-3. </text>
<text top="918" left="190" width="555" height="13" font="8">Yakoumakis E, Kostopoulou H, Makri T, et al. Estimation of radiation dose and risk to children </text>
<text top="936" left="190" width="569" height="13" font="8">undergoing cardiac catheterization for the treatment of a congenital heart disease using Monte </text>
<text top="954" left="190" width="300" height="13" font="8">Carlo simulations. Pediatr Radiol. 2013;43:339-46. </text>
<text top="972" left="105" width="55" height="13" font="8">S3.4.2-4. </text>
<text top="972" left="190" width="592" height="13" font="8">Andreassi MG, Ait-Ali L, Botto N, et al. Cardiac catheterization and long-term chromosomal damage </text>
<text top="990" left="190" width="419" height="13" font="8">in children with congenital heart disease. Eur Heart J. 2006;27:2703-8. </text>
<text top="1007" left="105" width="55" height="13" font="8">S3.4.2-5. </text>
<text top="1007" left="190" width="586" height="13" font="8">Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation: </text>
<text top="1025" left="190" width="445" height="13" font="8">assessing what we really know. Proc Natl Acad Sci USA. 2003;100:13761-6. </text>
<text top="1043" left="105" width="55" height="13" font="8">S3.4.2-6. </text>
<text top="1043" left="190" width="562" height="13" font="8">Eisenberg MJ, Afilalo J, Lawler PR, et al. Cancer risk related to low-dose ionizing radiation from </text>
<text top="1061" left="190" width="504" height="13" font="8">cardiac imaging in patients after acute myocardial infarction. CMAJ. 2011;183:430-6. </text>
</page>
<page number="139" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 141 </text>
<text top="163" left="105" width="209" height="19" font="34"><b>3.4.3. Echocardiography </b></text>
<text top="196" left="105" width="55" height="13" font="8">S3.4.3-1. </text>
<text top="196" left="190" width="563" height="13" font="8">Randolph GR, Hagler DJ, Connolly HM, et al. Intraoperative transesophageal echocardiography </text>
<text top="213" left="190" width="529" height="13" font="8">during surgery for congenital heart defects. J Thorac Cardiovasc Surg. 2002;124:1176-82. </text>
<text top="250" left="105" width="169" height="19" font="34"><b>3.4.4. CMR Imaging </b></text>
<text top="283" left="105" width="55" height="13" font="8">S3.4.4-1. </text>
<text top="282" left="190" width="594" height="13" font="8">Puchalski MD, Williams RV, Askovich B, et al. Assessment of right ventricular size and function: echo </text>
<text top="300" left="190" width="422" height="13" font="8">versus magnetic resonance imaging. Congenit Heart Dis. 2007;2:27-31. </text>
<text top="318" left="105" width="55" height="13" font="8">S3.4.4-2. </text>
<text top="318" left="190" width="560" height="13" font="8">Blalock SE, Banka P, Geva T, et al. Interstudy variability in cardiac magnetic resonance imaging </text>
<text top="336" left="190" width="580" height="13" font="8">measurements of ventricular volume, mass, and ejection fraction in repaired tetralogy of Fallot: a </text>
<text top="354" left="190" width="436" height="13" font="8">prospective observational study. J Magn Reson Imaging. 2013;38:829-35. </text>
<text top="371" left="105" width="55" height="13" font="8">S3.4.4-3. </text>
<text top="371" left="190" width="563" height="13" font="8">Crean AM, Maredia N, Ballard G, et al. 3D Echo systematically underestimates right ventricular </text>
<text top="389" left="190" width="592" height="13" font="8">volumes compared to cardiovascular magnetic resonance in adult congenital heart disease patients </text>
<text top="407" left="190" width="463" height="13" font="8">with moderate or severe RV dilatation. J Cardiovasc Magn Reson. 2011;13:78. </text>
<text top="425" left="105" width="55" height="13" font="8">S3.4.4-4. </text>
<text top="425" left="190" width="573" height="13" font="8">Bonello B, Kilner PJ. Review of the role of cardiovascular magnetic resonance in congenital heart </text>
<text top="443" left="190" width="538" height="13" font="8">disease, with a focus on right ventricle assessment. Arch Cardiovasc Dis. 2012;105:605-13. </text>
<text top="460" left="105" width="55" height="13" font="8">S3.4.4-5. </text>
<text top="460" left="190" width="559" height="13" font="8">Kilner PJ. Imaging congenital heart disease in adults. Br J Radiol. 2011;84(Spec No. 3):S258-68. </text>
<text top="478" left="105" width="55" height="13" font="8">S3.4.4-6. </text>
<text top="478" left="190" width="595" height="13" font="8">Festa P, Ait-Ali L, Cerillo AG, et al. Magnetic resonance imaging is the diagnostic tool of choice in the </text>
<text top="496" left="190" width="539" height="13" font="8">preoperative evaluation of patients with partial anomalous pulmonary venous return. Int J </text>
<text top="514" left="190" width="222" height="13" font="8">Cardiovasc Imaging. 2006;22:685-93. </text>
<text top="532" left="105" width="55" height="13" font="8">S3.4.4-7. </text>
<text top="532" left="190" width="565" height="13" font="8">van der Linde D, Rossi A, Yap SC, et al. Ascending aortic diameters in congenital aortic stenosis: </text>
<text top="550" left="190" width="598" height="13" font="8">cardiac magnetic resonance versus transthoracic echocardiography. Echocardiography. 2013;30:497-</text>
<text top="567" left="190" width="29" height="13" font="8">504. </text>
<text top="585" left="105" width="55" height="13" font="8">S3.4.4-8. </text>
<text top="585" left="190" width="586" height="13" font="8">Arheden H, Holmqvist C, Thilen U, et al. Left-to-right cardiac shunts: comparison of measurements </text>
<text top="603" left="190" width="593" height="13" font="8">obtained with MR velocity mapping and with radionuclide angiography. Radiology. 1999;211:453-8. </text>
<text top="621" left="105" width="55" height="13" font="8">S3.4.4-9. </text>
<text top="621" left="190" width="576" height="13" font="8">Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J </text>
<text top="639" left="190" width="150" height="13" font="8">Med. 2007;357:2277-84. </text>
<text top="657" left="105" width="62" height="13" font="8">S3.4.4-10. </text>
<text top="657" left="190" width="550" height="13" font="8">Teo KSL, Disney PJ, Dundon BK, et al. Assessment of atrial septal defects in adults comparing </text>
<text top="674" left="190" width="577" height="13" font="8">cardiovascular magnetic resonance with transoesophageal echocardiography. J Cardiovasc Magn </text>
<text top="692" left="190" width="117" height="13" font="8">Reson. 2010;12:44. </text>
<text top="710" left="105" width="62" height="13" font="8">S3.4.4-11. </text>
<text top="710" left="190" width="560" height="13" font="8">Grewal J, Majdalany D, Syed I, et al. Three-dimensional echocardiographic assessment of right </text>
<text top="728" left="190" width="578" height="13" font="8">ventricular volume and function in adult patients with congenital heart disease: comparison with </text>
<text top="746" left="190" width="417" height="13" font="8">magnetic resonance imaging. J Am Soc Echocardiogr. 2010;23:127-33. </text>
<text top="763" left="105" width="62" height="13" font="8">S3.4.4-12. </text>
<text top="763" left="190" width="587" height="13" font="8">Kilner PJ, Geva T, Kaemmerer H, et al. Recommendations for cardiovascular magnetic resonance in </text>
<text top="781" left="190" width="592" height="13" font="8">adults with congenital heart disease from the respective working groups of the European Society of </text>
<text top="799" left="190" width="250" height="13" font="8">Cardiology. Eur Heart J. 2010;31:794-805. </text>
<text top="817" left="105" width="62" height="13" font="8">S3.4.4-13. </text>
<text top="817" left="190" width="571" height="13" font="8">Kilner PJ. The role of cardiovascular magnetic resonance in adults with congenital heart disease. </text>
<text top="835" left="190" width="231" height="13" font="8">Prog Cardiovasc Dis. 2011;54:295-304. </text>
<text top="852" left="105" width="62" height="13" font="8">S3.4.4-14. </text>
<text top="852" left="190" width="589" height="13" font="8">Boxt LM. Magnetic resonance and computed tomographic evaluation of congenital heart disease. J </text>
<text top="870" left="190" width="232" height="13" font="8">Magn Reson Imaging. 2004;19:827-47. </text>
<text top="888" left="105" width="62" height="13" font="8">S3.4.4-15. </text>
<text top="888" left="190" width="558" height="13" font="8">van der Zwaan HB, Helbing WA, McGhie JS, et al. Clinical value of real-time three-dimensional </text>
<text top="906" left="190" width="573" height="13" font="8">echocardiography for right ventricular quantification in congenital heart disease: validation with </text>
<text top="924" left="190" width="463" height="13" font="8">cardiac magnetic resonance imaging. J Am Soc Echocardiogr. 2010;23:134-40. </text>
<text top="942" left="105" width="62" height="13" font="8">S3.4.4-16. </text>
<text top="942" left="190" width="587" height="13" font="8">Prasad SK, Soukias N, Hornung T, et al. Role of magnetic resonance angiography in the diagnosis of </text>
<text top="960" left="190" width="554" height="13" font="8">major aortopulmonary collateral arteries and partial anomalous pulmonary venous drainage. </text>
<text top="977" left="190" width="179" height="13" font="8">Circulation. 2004;109:207-14. </text>
<text top="1014" left="105" width="325" height="19" font="34"><b>3.4.5. Cardiac Computed Tomography </b></text>
<text top="1046" left="105" width="55" height="13" font="8">S3.4.5-1. </text>
<text top="1046" left="190" width="576" height="13" font="8">Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J </text>
<text top="1064" left="190" width="150" height="13" font="8">Med. 2007;357:2277-84. </text>
</page>
<page number="140" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 142 </text>
<text top="162" left="105" width="55" height="13" font="8">S3.4.5-2. </text>
<text top="162" left="190" width="574" height="13" font="8">Ghoshhajra BB, Sidhu MS, El-Sherief A, et al. Adult congenital heart disease imaging with second-</text>
<text top="179" left="190" width="593" height="13" font="8">generation dual-source computed tomography: initial experiences and findings. Congenit Heart Dis. </text>
<text top="197" left="190" width="93" height="13" font="8">2012;7:516-25. </text>
<text top="234" left="105" width="255" height="19" font="34"><b>3.4.6. Cardiac Catheterization </b></text>
<text top="266" left="105" width="55" height="13" font="8">S3.4.6-1. </text>
<text top="266" left="190" width="527" height="13" font="8">Moore JW, Vincent RN, Beekman RH 3rd, et al. Procedural results and safety of common </text>
<text top="284" left="190" width="600" height="13" font="8">interventional procedures in congenital heart disease: initial report from the National Cardiovascular </text>
<text top="302" left="190" width="300" height="13" font="8">Data Registry. J Am Coll Cardiol. 2014;64:2439-51. </text>
<text top="320" left="105" width="55" height="13" font="8">S3.4.6-2. </text>
<text top="320" left="190" width="565" height="13" font="8">Learn CP, Holzer RJ, Daniels CJ, et al. Adverse events rates and risk factors in adults undergoing </text>
<text top="337" left="190" width="579" height="13" font="8">cardiac catheterization at pediatric hospitals—results from the C3PO. Catheter Cardiovasc Interv. </text>
<text top="355" left="190" width="115" height="13" font="8">2013;81:997-1005. </text>
<text top="373" left="105" width="55" height="13" font="8">S3.4.6-3. </text>
<text top="373" left="190" width="588" height="13" font="8">Sutton NJ, Greenberg MA, Menegus MA, et al. Caring for the adult with congenital heart disease in </text>
<text top="391" left="190" width="574" height="13" font="8">an adult catheterization laboratory by pediatric interventionalists—safety and efficacy. Congenit </text>
<text top="409" left="190" width="147" height="13" font="8">Heart Dis. 2013;8:111-6. </text>
<text top="427" left="105" width="55" height="13" font="8">S3.4.6-4. </text>
<text top="427" left="190" width="588" height="13" font="8">Opotowsky AR, Landzberg MJ, Kimmel SE, et al. Percutaneous closure of patent foramen ovale and </text>
<text top="445" left="190" width="578" height="13" font="8">atrial septal defect in adults: the impact of clinical variables and hospital procedure volume on in-</text>
<text top="462" left="190" width="327" height="13" font="8">hospital adverse events. Am Heart J. 2009;157:867-74. </text>
<text top="480" left="105" width="55" height="13" font="8">S3.4.6-5. </text>
<text top="480" left="190" width="548" height="13" font="8">Reant P, Brunot S, Lafitte S, et al. Predictive value of noninvasive coronary angiography with </text>
<text top="498" left="190" width="582" height="13" font="8">multidetector computed tomography to detect significant coronary stenosis before valve surgery. </text>
<text top="516" left="190" width="188" height="13" font="8">Am J Cardiol. 2006;97:1506-10. </text>
<text top="534" left="105" width="55" height="13" font="8">S3.4.6-6. </text>
<text top="534" left="190" width="543" height="13" font="8">Gilard M, Cornily J-C, Pennec P-Y, et al. Accuracy of multislice computed tomography in the </text>
<text top="552" left="190" width="599" height="13" font="8">preoperative assessment of coronary disease in patients with aortic valve stenosis. J Am Coll Cardiol. </text>
<text top="569" left="190" width="101" height="13" font="8">2006;47:2020-4. </text>
<text top="587" left="105" width="55" height="13" font="8">S3.4.6-7. </text>
<text top="587" left="190" width="553" height="13" font="8">Manghat NE, Morgan-Hughes GJ, Broadley AJ, et al. 16-Detector row computed tomographic </text>
<text top="605" left="190" width="584" height="13" font="8">coronary angiography in patients undergoing evaluation for aortic valve replacement: comparison </text>
<text top="623" left="190" width="334" height="13" font="8">with catheter angiography. Clin Radiol. 2006;61:749-57. </text>
<text top="641" left="105" width="55" height="13" font="8">S3.4.6-8. </text>
<text top="641" left="190" width="592" height="13" font="8">Meijboom WB, Mollet NR, Van Mieghem CAG, et al. Pre-operative computed tomography coronary </text>
<text top="658" left="190" width="560" height="13" font="8">angiography to detect significant coronary artery disease in patients referred for cardiac valve </text>
<text top="676" left="190" width="265" height="13" font="8">surgery. J Am Coll Cardiol. 2006;48:1658-65. </text>
<text top="694" left="105" width="55" height="13" font="8">S3.4.6-9. </text>
<text top="694" left="190" width="598" height="13" font="8">Galas A, Hryniewiecki T, Kępka C, et al. May dual-source computed tomography angiography replace </text>
<text top="712" left="190" width="579" height="13" font="8">invasive coronary angiography in the evaluation of patients referred for valvular disease surgery? </text>
<text top="730" left="190" width="171" height="13" font="8">Kardiol Pol. 2012;70:877-82. </text>
<text top="766" left="105" width="192" height="19" font="34"><b>3.4.7. Exercise Testing </b></text>
<text top="799" left="105" width="55" height="13" font="8">S3.4.7-1. </text>
<text top="799" left="190" width="572" height="13" font="8">Diller G-P, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: </text>
<text top="816" left="190" width="542" height="13" font="8">comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828-35. </text>
<text top="834" left="105" width="55" height="13" font="8">S3.4.7-2. </text>
<text top="834" left="190" width="599" height="13" font="8">Hager A, Hess J. Comparison of health related quality of life with cardiopulmonary exercise testing in </text>
<text top="852" left="190" width="461" height="13" font="8">adolescents and adults with congenital heart disease. Heart. 2005;91:517-20. </text>
<text top="870" left="105" width="55" height="13" font="8">S3.4.7-3. </text>
<text top="870" left="190" width="564" height="13" font="8">Ross RM, Murthy JN, Wollak ID, et al. The six minute walk test accurately estimates mean peak </text>
<text top="888" left="190" width="267" height="13" font="8">oxygen uptake. BMC Pulm Med. 2010;10:31. </text>
<text top="906" left="105" width="55" height="13" font="8">S3.4.7-4. </text>
<text top="906" left="190" width="555" height="13" font="8">Gungor H, Fatih Ayik M, Engin C, et al. Transthoracic echocardiographic and cardiopulmonary </text>
<text top="924" left="190" width="561" height="13" font="8">exercise testing parameters in Eisenmenger’s syndrome. Association with six-minute walk test </text>
<text top="941" left="190" width="184" height="13" font="8">distance. Herz. 2014;39:633-7. </text>
<text top="979" left="105" width="231" height="20" font="17"><b>3.5. Transition Education </b></text>
<text top="1012" left="105" width="44" height="13" font="8">S3.5-1. </text>
<text top="1012" left="190" width="597" height="13" font="8">Mackie AS, Islam S, Magill-Evans J, et al. Healthcare transition for youth with heart disease: a clinical </text>
<text top="1030" left="190" width="179" height="13" font="8">trial. Heart. 2014;100:1113-8. </text>
<text top="1048" left="105" width="44" height="13" font="8">S3.5-2. </text>
<text top="1048" left="190" width="565" height="13" font="8">Goossens E, Van Deyk K, Zupancic N, et al. Effectiveness of structured patient education on the </text>
<text top="1066" left="190" width="568" height="13" font="8">knowledge level of adolescents and adults with congenital heart disease. Eur J Cardiovasc Nurs. </text>
<text top="1084" left="190" width="93" height="13" font="8">2014;13:63-70. </text>
</page>
<page number="141" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 143 </text>
<text top="162" left="105" width="44" height="13" font="8">S3.5-3. </text>
<text top="162" left="190" width="596" height="13" font="8">Mackie AS, Rempel GR, Rankin KN, et al. Risk factors for loss to follow-up among children and young </text>
<text top="180" left="190" width="410" height="13" font="8">adults with congenital heart disease. Cardiol Young. 2012;22:307-15. </text>
<text top="198" left="105" width="44" height="13" font="8">S3.5-4. </text>
<text top="198" left="190" width="586" height="13" font="8">Sable C, Foster E, Uzark K, et al. Best practices in managing transition to adulthood for adolescents </text>
<text top="215" left="190" width="601" height="13" font="8">with congenital heart disease: the transition process and medical and psychosocial issues: a scientific </text>
<text top="233" left="190" width="478" height="13" font="8">statement from the American Heart Association. Circulation. 2011;123:1454-85. </text>
<text top="251" left="105" width="44" height="13" font="8">S3.5-5. </text>
<text top="251" left="190" width="566" height="13" font="8">Gurvitz M, Valente AM, Broberg C, et al. Prevalence and predictors of gaps in care among adult </text>
<text top="269" left="190" width="598" height="13" font="8">congenital heart disease patients: HEART-ACHD (The Health, Education, and Access Research Trial). J </text>
<text top="286" left="190" width="198" height="13" font="8">Am Coll Cardiol. 2013;61:2180-4. </text>
<text top="304" left="105" width="44" height="13" font="8">S3.5-6. </text>
<text top="304" left="190" width="539" height="13" font="8">Yeung E, Kay J, Roosevelt GE, et al. Lapse of care as a predictor for morbidity in adults with </text>
<text top="322" left="190" width="321" height="13" font="8">congenital heart disease. Int J Cardiol. 2008;125:62-5. </text>
<text top="359" left="105" width="220" height="20" font="17"><b>3.6. Exercise and Sports </b></text>
<text top="393" left="105" width="44" height="13" font="8">S3.6-1. </text>
<text top="393" left="190" width="546" height="13" font="8">Pemberton VL, McCrindle BW, Barkin S, et al. Report of the National Heart, Lung, and Blood </text>
<text top="411" left="190" width="555" height="13" font="8">Institute’s Working Group on obesity and other cardiovascular risk factors in congenital heart </text>
<text top="428" left="190" width="230" height="13" font="8">disease. Circulation. 2010;121:1153-9. </text>
<text top="446" left="105" width="44" height="13" font="8">S3.6-2. </text>
<text top="446" left="190" width="593" height="13" font="8">Myers J, Kaykha A, George S, et al. Fitness versus physical activity patterns in predicting mortality in </text>
<text top="464" left="190" width="200" height="13" font="8">men. Am J Med. 2004;117:912-8. </text>
<text top="482" left="105" width="44" height="13" font="8">S3.6-3. </text>
<text top="482" left="190" width="567" height="13" font="8">Warburton DER, Nicol CW, Bredin SSD. Health benefits of physical activity: the evidence. CMAJ. </text>
<text top="500" left="190" width="101" height="13" font="8">2006;174:801-9. </text>
<text top="518" left="105" width="44" height="13" font="8">S3.6-4. </text>
<text top="518" left="190" width="595" height="13" font="8">King AC, Taylor CB, Haskell WL, et al. Influence of regular aerobic exercise on psychological health: a </text>
<text top="535" left="190" width="540" height="13" font="8">randomized, controlled trial of healthy middle-aged adults. Health Psychol. 1989;8:305-24. </text>
<text top="553" left="105" width="44" height="13" font="8">S3.6-5. </text>
<text top="553" left="190" width="576" height="13" font="8">Reybrouck T, Mertens L. Physical performance and physical activity in grown-up congenital heart </text>
<text top="571" left="190" width="338" height="13" font="8">disease. Eur J Cardiovasc Prev Rehabil. 2005;12:498-502. </text>
<text top="589" left="105" width="44" height="13" font="8">S3.6-6. </text>
<text top="589" left="190" width="558" height="13" font="8">Duppen N, Takken T, Hopman MTE, et al. Systematic review of the effects of physical exercise </text>
<text top="607" left="190" width="557" height="13" font="8">training programmes in children and young adults with congenital heart disease. Int J Cardiol. </text>
<text top="624" left="190" width="115" height="13" font="8">2013;168:1779-87. </text>
<text top="642" left="105" width="44" height="13" font="8">S3.6-7. </text>
<text top="642" left="190" width="591" height="13" font="8">Dua JS, Cooper AR, Fox KR, et al. Exercise training in adults with congenital heart disease: feasibility </text>
<text top="660" left="190" width="273" height="13" font="8">and benefits. Int J Cardiol. 2010;138:196-205. </text>
<text top="678" left="105" width="44" height="13" font="8">S3.6-8. </text>
<text top="678" left="190" width="530" height="13" font="8">Holloway TM, Chesssex C, Grace SL, et al. A call for adult congenital heart disease patient </text>
<text top="696" left="190" width="404" height="13" font="8">participation in cardiac rehabilitation. Int J Cardiol. 2011;150:345-6. </text>
<text top="714" left="105" width="44" height="13" font="8">S3.6-9. </text>
<text top="714" left="190" width="566" height="13" font="8">Sandberg C, Pomeroy J, Thilén U, et al. Habitual physical activity in adults with congenital heart </text>
<text top="732" left="190" width="513" height="13" font="8">disease compared with age- and sex-matched controls. Can J Cardiol. 2016;32:547-53. </text>
<text top="749" left="105" width="52" height="13" font="8">S3.6-10. </text>
<text top="749" left="190" width="572" height="13" font="8">Diller G-P, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: </text>
<text top="767" left="190" width="542" height="13" font="8">comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828-35. </text>
<text top="785" left="105" width="52" height="13" font="8">S3.6-11. </text>
<text top="785" left="190" width="577" height="13" font="8">Kempny A, Dimopoulos K, Uebing A, et al. Reference values for exercise limitations among adults </text>
<text top="803" left="190" width="601" height="13" font="8">with congenital heart disease. Relation to activities of daily life—single centre experience and review </text>
<text top="821" left="190" width="290" height="13" font="8">of published data. Eur Heart J. 2012;33:1386-96. </text>
<text top="838" left="105" width="52" height="13" font="8">S3.6-12. </text>
<text top="838" left="190" width="543" height="13" font="8">Westhoff-Bleck M, Schieffer B, Tegtbur U, et al. Aerobic training in adults after atrial switch </text>
<text top="856" left="190" width="561" height="13" font="8">procedure for transposition of the great arteries improves exercise capacity without impairing </text>
<text top="874" left="190" width="380" height="13" font="8">systemic right ventricular function. Int J Cardiol. 2013;170:24-9. </text>
<text top="892" left="105" width="52" height="13" font="8">S3.6-13. </text>
<text top="892" left="190" width="579" height="13" font="8">Tikkanen AU, Opotowsky AR, Bhatt AB, et al. Physical activity is associated with improved aerobic </text>
<text top="910" left="190" width="591" height="13" font="8">exercise capacity over time in adults with congenital heart disease. Int J Cardiol. 2013;168:4685-91. </text>
<text top="928" left="105" width="52" height="13" font="8">S3.6-14. </text>
<text top="928" left="190" width="599" height="13" font="8">Van Hare GF, Ackerman MJ, Evangelista JA, et al. Eligibility and disqualification recommendations for </text>
<text top="945" left="190" width="576" height="13" font="8">competitive athletes with cardiovascular abnormalities: Task Force 4: congenital heart disease: a </text>
<text top="963" left="190" width="561" height="13" font="8">scientific statement from the American Heart Association and American College of Cardiology. </text>
<text top="981" left="190" width="186" height="13" font="8">Circulation. 2015;132:e281-91. </text>
<text top="999" left="105" width="52" height="13" font="8">S3.6-15. </text>
<text top="999" left="190" width="586" height="13" font="8">Pelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for competitive sports participation in </text>
<text top="1017" left="190" width="549" height="13" font="8">athletes with cardiovascular disease: a consensus document from the Study Group of Sports </text>
<text top="1034" left="190" width="594" height="13" font="8">Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working </text>
<text top="1052" left="190" width="574" height="13" font="8">Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. </text>
<text top="1070" left="190" width="108" height="13" font="8">2005;26:1422-45. </text>
</page>
<page number="142" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 144 </text>
<text top="162" left="105" width="52" height="13" font="8">S3.6-16. </text>
<text top="162" left="190" width="542" height="13" font="8">Mitchell JH, Haskell W, Snell P, et al. Task Force 8: classification of sports. J Am Coll Cardiol. </text>
<text top="180" left="190" width="101" height="13" font="8">2005;45:1364-7. </text>
<text top="198" left="105" width="52" height="13" font="8">S3.6-17. </text>
<text top="198" left="190" width="577" height="13" font="8">Takken T, Giardini A, Reybrouck T, et al. Recommendations for physical activity, recreation sport, </text>
<text top="215" left="190" width="599" height="13" font="8">and exercise training in paediatric patients with congenital heart disease: a report from the Exercise, </text>
<text top="233" left="190" width="601" height="13" font="8">Basic &amp; Translational Research Section of the European Association of Cardiovascular Prevention and </text>
<text top="251" left="190" width="571" height="13" font="8">Rehabilitation, the European Congenital Heart and Lung Exercise Group, and the Association for </text>
<text top="269" left="190" width="411" height="13" font="8">European Paediatric Cardiology. Eur J Prev Cardiol. 2012;19:1034-65. </text>
<text top="286" left="105" width="52" height="13" font="8">S3.6-18. </text>
<text top="286" left="190" width="599" height="13" font="8">Cordina R, O’Meagher S, Gould H, et al. Skeletal muscle abnormalities and exercise capacity in adults </text>
<text top="304" left="190" width="295" height="13" font="8">with a Fontan circulation. Heart. 2013;99:1530-4. </text>
<text top="322" left="105" width="52" height="13" font="8">S3.6-19. </text>
<text top="322" left="190" width="570" height="13" font="8">Cordina RL, O’Meagher S, Karmali A, et al. Resistance training improves cardiac output, exercise </text>
<text top="340" left="190" width="593" height="13" font="8">capacity and tolerance to positive airway pressure in Fontan physiology. Int J Cardiol. 2013;168:780-</text>
<text top="358" left="190" width="14" height="13" font="8">8. </text>
<text top="375" left="105" width="52" height="13" font="8">S3.6-20. </text>
<text top="375" left="190" width="596" height="13" font="8">Longmuir PE, Brothers JA, de Ferranti SD, et al. Promotion of physical activity for children and adults </text>
<text top="393" left="190" width="538" height="13" font="8">with congenital heart disease: a scientific statement from the American Heart Association. </text>
<text top="411" left="190" width="186" height="13" font="8">Circulation. 2013;127:2147-59. </text>
<text top="429" left="105" width="52" height="13" font="8">S3.6-21. </text>
<text top="429" left="190" width="589" height="13" font="8">Buys R, Van De Bruaene A, Budts W, et al. In adults with atrial switch operation for transposition of </text>
<text top="447" left="190" width="596" height="13" font="8">the great arteries low physical activity relates to reduced exercise capacity and decreased perceived </text>
<text top="465" left="190" width="297" height="13" font="8">physical functioning. Acta Cardiol. 2012;67:49-57. </text>
<text top="482" left="105" width="52" height="13" font="8">S3.6-22. </text>
<text top="482" left="190" width="592" height="13" font="8">Winter MM, van der Bom T, de Vries LCS, et al. Exercise training improves exercise capacity in adult </text>
<text top="500" left="190" width="575" height="13" font="8">patients with a systemic right ventricle: a randomized clinical trial. Eur Heart J. 2012;33:1378-85. </text>
<text top="538" left="105" width="473" height="20" font="17"><b>3.7. Mental Health and Neurodevelopmental Issues </b></text>
<text top="571" left="105" width="44" height="13" font="8">S3.7-1. </text>
<text top="571" left="190" width="548" height="13" font="8">Kovacs AH, Saidi AS, Kuhl EA, et al. Depression and anxiety in adult congenital heart disease: </text>
<text top="589" left="190" width="347" height="13" font="8">predictors and prevalence. Int J Cardiol. 2009;137:158-64. </text>
<text top="607" left="105" width="44" height="13" font="8">S3.7-2. </text>
<text top="607" left="190" width="585" height="13" font="8">Kovacs AH, Sears SF, Saidi AS. Biopsychosocial experiences of adults with congenital heart disease: </text>
<text top="624" left="190" width="332" height="13" font="8">review of the literature. Am Heart J. 2005;150:193-201. </text>
<text top="642" left="105" width="44" height="13" font="8">S3.7-3. </text>
<text top="642" left="190" width="577" height="13" font="8">van Rijen EHM, Utens EMWJ, Roos-Hesselink JW, et al. Psychosocial functioning of the adult with </text>
<text top="660" left="190" width="470" height="13" font="8">congenital heart disease: a 20-33 years follow-up. Eur Heart J. 2003;24:673-83. </text>
<text top="678" left="105" width="44" height="13" font="8">S3.7-4. </text>
<text top="678" left="190" width="591" height="13" font="8">Callus E, Quadri E, Ricci C, et al. Update on psychological functioning in adults with congenital heart </text>
<text top="696" left="190" width="444" height="13" font="8">disease: a systematic review. Expert Rev Cardiovasc Ther. 2013;11:785-91. </text>
<text top="714" left="105" width="44" height="13" font="8">S3.7-5. </text>
<text top="714" left="190" width="559" height="13" font="8">Amianto F, Bergui G, Abbate-Daga G, et al. Growing up with a congenital heart disease: neuro-</text>
<text top="732" left="190" width="560" height="13" font="8">cognitive, psychopathological and quality of life outcomes. Panminerva Med. 2011;53:109-27. </text>
<text top="749" left="105" width="44" height="13" font="8">S3.7-6. </text>
<text top="749" left="190" width="567" height="13" font="8">Granberg M, Rydberg A, Fisher AG. Activities in daily living and schoolwork task performance in </text>
<text top="767" left="190" width="473" height="13" font="8">children with complex congenital heart disease. Acta Paediatr. 2008;97:1270-4. </text>
<text top="785" left="105" width="44" height="13" font="8">S3.7-7. </text>
<text top="785" left="190" width="570" height="13" font="8">Karsdorp PA, Everaerd W, Kindt M, et al. Psychological and cognitive functioning in children and </text>
<text top="803" left="190" width="560" height="13" font="8">adolescents with congenital heart disease: a meta-analysis. J Pediatr Psychol. 2007;32:527-41. </text>
<text top="821" left="105" width="44" height="13" font="8">S3.7-8. </text>
<text top="821" left="190" width="567" height="13" font="8">van der Rijken REA, Maassen BAM, Walk TLM, et al. Outcome after surgical repair of congenital </text>
<text top="838" left="190" width="404" height="13" font="8">cardiac malformations at school age. Cardiol Young. 2007;17:64-71. </text>
<text top="856" left="105" width="44" height="13" font="8">S3.7-9. </text>
<text top="856" left="190" width="572" height="13" font="8">Kirshbom PM, Flynn TB, Clancy RR, et al. Late neurodevelopmental outcome after repair of total </text>
<text top="874" left="190" width="516" height="13" font="8">anomalous pulmonary venous connection. J Thorac Cardiovasc Surg. 2005;129:1091-7. </text>
<text top="892" left="105" width="52" height="13" font="8">S3.7-10. </text>
<text top="892" left="190" width="578" height="13" font="8">Sananes R, Manlhiot C, Kelly E, et al. Neurodevelopmental outcomes after open heart operations </text>
<text top="910" left="190" width="358" height="13" font="8">before 3 months of age. Ann Thorac Surg. 2012;93:1577-83. </text>
<text top="928" left="105" width="52" height="13" font="8">S3.7-11. </text>
<text top="928" left="190" width="599" height="13" font="8">Schaefer C, von Rhein M, Knirsch W, et al. Neurodevelopmental outcome, psychological adjustment, </text>
<text top="945" left="190" width="513" height="13" font="8">and quality of life in adolescents with congenital heart disease. Dev Med Child Neurol. </text>
<text top="963" left="190" width="101" height="13" font="8">2013;55:1143-9. </text>
<text top="981" left="105" width="52" height="13" font="8">S3.7-12. </text>
<text top="981" left="190" width="577" height="13" font="8">Gaynor JW, Kim DS, Arrington CB, et al. Validation of association of the apolipoprotein E ε2 allele </text>
<text top="999" left="190" width="554" height="13" font="8">with neurodevelopmental dysfunction after cardiac surgery in neonates and infants. J Thorac </text>
<text top="1017" left="190" width="209" height="13" font="8">Cardiovasc Surg. 2014;148:2560-6. </text>
<text top="1034" left="105" width="52" height="13" font="8">S3.7-13. </text>
<text top="1034" left="190" width="545" height="13" font="8">Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with </text>
<text top="1052" left="190" width="575" height="13" font="8">congenital heart disease: evaluation and management: a scientific statement from the American </text>
<text top="1070" left="190" width="298" height="13" font="8">Heart Association. Circulation. 2012;126:1143-72. </text>
</page>
<page number="143" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 145 </text>
<text top="162" left="105" width="52" height="13" font="8">S3.7-14. </text>
<text top="162" left="190" width="596" height="13" font="8">Cassidy AR, White MT, DeMaso DR, et al. Executive function in children and adolescents with critical </text>
<text top="180" left="190" width="438" height="13" font="8">cyanotic congenital heart disease. J Int Neuropsychol Soc. 2015;21:34-49. </text>
<text top="217" left="105" width="261" height="20" font="17"><b>3.8. Endocarditis Prevention </b></text>
<text top="251" left="105" width="44" height="13" font="8">S3.8-1. </text>
<text top="250" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="268" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="286" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="304" left="105" width="44" height="13" font="8">S3.8-2. </text>
<text top="304" left="190" width="569" height="13" font="8">Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Turning 18 with congenital heart disease: </text>
<text top="322" left="190" width="562" height="13" font="8">prediction of infective endocarditis based on a large population. Eur Heart J. 2011;32:1926-34. </text>
<text top="339" left="105" width="44" height="13" font="8">S3.8-3. </text>
<text top="339" left="190" width="597" height="13" font="8">Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective </text>
<text top="357" left="190" width="571" height="13" font="8">endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of </text>
<text top="375" left="190" width="583" height="13" font="8">Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J. 2009;30:2369-413. </text>
<text top="393" left="105" width="44" height="13" font="8">S3.8-4. </text>
<text top="393" left="190" width="571" height="13" font="8">Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the </text>
<text top="411" left="190" width="569" height="13" font="8">American Heart Association: a guideline from the American Heart Association Rheumatic Fever, </text>
<text top="428" left="190" width="598" height="13" font="8">Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and </text>
<text top="446" left="190" width="601" height="13" font="8">the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality </text>
<text top="464" left="190" width="576" height="13" font="8">of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736-54. </text>
<text top="482" left="105" width="44" height="13" font="8">S3.8-5. </text>
<text top="482" left="190" width="539" height="13" font="8">Allen U. Infective endocarditis: updated guidelines. Paediatr Child Health. 2010;15:205-12. </text>
<text top="519" left="105" width="267" height="20" font="17"><b>3.9. Concomitant Syndromes </b></text>
<text top="553" left="105" width="44" height="13" font="8">S3.9-1. </text>
<text top="553" left="190" width="582" height="13" font="8">van Engelen K, Topf A, Keavney BD, et al. 22q11.2 Deletion syndrome is under-recognised in adult </text>
<text top="571" left="190" width="464" height="13" font="8">patients with tetralogy of Fallot and pulmonary atresia. Heart. 2010;96:621-4. </text>
<text top="588" left="105" width="44" height="13" font="8">S3.9-2. </text>
<text top="588" left="190" width="594" height="13" font="8">Fung WLA, Chow EWC, Webb GD, et al. Extracardiac features predicting 22q11.2 deletion syndrome </text>
<text top="606" left="190" width="369" height="13" font="8">in adult congenital heart disease. Int J Cardiol. 2008;131:51-8. </text>
<text top="624" left="105" width="44" height="13" font="8">S3.9-3. </text>
<text top="624" left="190" width="562" height="13" font="8">Hartman RJ, Rasmussen SA, Botto LD, et al. The contribution of chromosomal abnormalities to </text>
<text top="642" left="190" width="512" height="13" font="8">congenital heart defects: a population-based study. Pediatr Cardiol. 2011;32:1147-57. </text>
<text top="660" left="105" width="44" height="13" font="8">S3.9-4. </text>
<text top="660" left="190" width="526" height="13" font="8">Lin AE, Basson CT, Goldmuntz E, et al. Adults with genetic syndromes and cardiovascular </text>
<text top="678" left="190" width="463" height="13" font="8">abnormalities: clinical history and management. Genet Med. 2008;10:469-94. </text>
<text top="696" left="105" width="44" height="13" font="8">S3.9-5. </text>
<text top="696" left="190" width="591" height="13" font="8">Goldmuntz E, Clark BJ, Mitchell LE, et al. Frequency of 22q11 deletions in patients with conotruncal </text>
<text top="713" left="190" width="250" height="13" font="8">defects. J Am Coll Cardiol. 1998;32:492-8. </text>
<text top="731" left="105" width="44" height="13" font="8">S3.9-6. </text>
<text top="731" left="190" width="527" height="13" font="8">Richards AA, Garg V. Genetics of congenital heart disease. Curr Cardiol Rev. 2010;6:91-7. </text>
<text top="749" left="105" width="44" height="13" font="8">S3.9-7. </text>
<text top="749" left="190" width="586" height="13" font="8">Kitsiou-Tzeli S, Kolialexi A, Fryssira H, et al. Detection of 22q11.2 deletion among 139 patients with </text>
<text top="767" left="190" width="421" height="13" font="8">Di George/velocardiofacial syndrome features. In Vivo. 2004;18:603-8. </text>
<text top="784" left="105" width="44" height="13" font="8">S3.9-8. </text>
<text top="784" left="190" width="591" height="13" font="8">Bassett AS, Chow EWC, Husted J, et al. Clinical features of 78 adults with 22q11 deletion syndrome. </text>
<text top="802" left="190" width="225" height="13" font="8">Am J Med Genet A. 2005;138:307-13. </text>
<text top="820" left="105" width="44" height="13" font="8">S3.9-9. </text>
<text top="820" left="190" width="547" height="13" font="8">Barisic I, Boban L, Greenlees R, et al. Holt Oram syndrome: a registry-based study in Europe. </text>
<text top="838" left="190" width="198" height="13" font="8">Orphanet J Rare Dis. 2014;9:156. </text>
<text top="856" left="105" width="52" height="13" font="8">S3.9-10. </text>
<text top="856" left="190" width="552" height="13" font="8">Pierpont MEM, Magoulas PL, Adi S, et al. Cardio-facio-cutaneous syndrome: clinical features, </text>
<text top="874" left="190" width="425" height="13" font="8">diagnosis, and management guidelines. Pediatrics. 2014;134:e1149-62. </text>
<text top="911" left="105" width="350" height="20" font="17"><b>3.10. Acquired Cardiovascular Disease </b></text>
<text top="944" left="105" width="52" height="13" font="8">S3.10-1. </text>
<text top="944" left="190" width="592" height="13" font="8">Engelfriet P, Boersma E, Oechslin E, et al. The spectrum of adult congenital heart disease in Europe: </text>
<text top="962" left="190" width="569" height="13" font="8">morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital </text>
<text top="980" left="190" width="266" height="13" font="8">heart disease. Eur Heart J. 2005;26:2325-33. </text>
<text top="998" left="105" width="52" height="13" font="8">S3.10-2. </text>
<text top="998" left="190" width="597" height="13" font="8">Pillutla P, Shetty KD, Foster E. Mortality associated with adult congenital heart disease: trends in the </text>
<text top="1016" left="190" width="377" height="13" font="8">US population from 1979 to 2005. Am Heart J. 2009;158:874-9. </text>
<text top="1034" left="105" width="52" height="13" font="8">S3.10-3. </text>
<text top="1034" left="190" width="579" height="13" font="8">Stuart AG. Changing lesion demographics of the adult with congenital heart disease: an emerging </text>
<text top="1051" left="190" width="378" height="13" font="8">population with complex needs. Future Cardiol. 2012;8:305-13. </text>
</page>
<page number="144" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 146 </text>
<text top="162" left="105" width="52" height="13" font="8">S3.10-4. </text>
<text top="162" left="190" width="561" height="13" font="8">Tutarel O, Kempny A, Alonso-Gonzalez R, et al. Congenital heart disease beyond the age of 60: </text>
<text top="180" left="190" width="582" height="13" font="8">emergence of a new population with high resource utilization, high morbidity, and high mortality. </text>
<text top="198" left="190" width="172" height="13" font="8">Eur Heart J. 2014;35:725-32. </text>
<text top="215" left="105" width="52" height="13" font="8">S3.10-5. </text>
<text top="215" left="190" width="556" height="13" font="8">Foster E, Graham TP Jr, Driscoll DJ, et al. Task force 2: special health care needs of adults with </text>
<text top="233" left="190" width="365" height="13" font="8">congenital heart disease. J Am Coll Cardiol. 2001;37:1176-83. </text>
<text top="251" left="105" width="52" height="13" font="8">S3.10-6. </text>
<text top="251" left="190" width="572" height="13" font="8">Diller G-P, Kempny A, Alonso-Gonzalez R, et al. Survival prospects and circumstances of death in </text>
<text top="269" left="190" width="571" height="13" font="8">contemporary adult congenital heart disease patients under follow-up at a large tertiary centre. </text>
<text top="287" left="190" width="186" height="13" font="8">Circulation. 2015;132:2118-25. </text>
<text top="305" left="105" width="52" height="13" font="8">S3.10-7. </text>
<text top="305" left="190" width="579" height="13" font="8">Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Mortality in adult congenital heart disease. </text>
<text top="323" left="190" width="172" height="13" font="8">Eur Heart J. 2010;31:1220-9. </text>
<text top="340" left="105" width="52" height="13" font="8">S3.10-8. </text>
<text top="340" left="190" width="587" height="13" font="8">Partington SL, Valente AM, Bruyere J, et al. Diagnostic value of TC99M SPECT myocardial perfusion </text>
<text top="358" left="190" width="431" height="13" font="8">imaging in complex congenital heart disease. J Am Coll Cardiol. 2014;63: </text>
<text top="375" left="105" width="52" height="13" font="8">S3.10-9. </text>
<text top="375" left="190" width="596" height="13" font="8">Longmuir PE, Brothers JA, de Ferranti SD, et al. Promotion of physical activity for children and adults </text>
<text top="393" left="190" width="538" height="13" font="8">with congenital heart disease: a scientific statement from the American Heart Association. </text>
<text top="411" left="190" width="186" height="13" font="8">Circulation. 2013;127:2147-59. </text>
<text top="429" left="105" width="59" height="13" font="8">S3.10-10. </text>
<text top="429" left="190" width="571" height="13" font="8">Zomer AC, Vaartjes I, Uiterwaal CSPM, et al. Social burden and lifestyle in adults with congenital </text>
<text top="447" left="190" width="282" height="13" font="8">heart disease. Am J Cardiol. 2012;109:1657-63. </text>
<text top="484" left="105" width="295" height="20" font="17"><b>3.11. Noncardiac Medical Issues </b></text>
<text top="518" left="105" width="52" height="13" font="8">S3.11-1. </text>
<text top="518" left="190" width="573" height="13" font="8">Wang A, Book WM, McConnell M, et al. Prevalence of hepatitis C infection in adult patients who </text>
<text top="535" left="190" width="565" height="13" font="8">underwent congenital heart surgery prior to screening in 1992. Am J Cardiol. 2007;100:1307-9. </text>
<text top="573" left="105" width="232" height="20" font="17"><b>3.12. Noncardiac Surgery </b></text>
<text top="606" left="105" width="52" height="13" font="8">S3.12-1. </text>
<text top="606" left="190" width="595" height="13" font="8">Ammash NM, Connolly HM, Abel MD, et al. Noncardiac surgery in Eisenmenger syndrome. J Am Coll </text>
<text top="624" left="190" width="142" height="13" font="8">Cardiol. 1999;33:222-7. </text>
<text top="642" left="105" width="52" height="13" font="8">S3.12-2. </text>
<text top="642" left="190" width="562" height="13" font="8">Maxwell BG, Posner KL, Wong JK, et al. Factors contributing to adverse perioperative events in </text>
<text top="660" left="190" width="583" height="13" font="8">adults with congenital heart disease: a structured analysis of cases from the closed claims project. </text>
<text top="678" left="190" width="204" height="13" font="8">Congenit Heart Dis. 2015;10:21-9. </text>
<text top="696" left="105" width="52" height="13" font="8">S3.12-3. </text>
<text top="696" left="190" width="592" height="13" font="8">Maxwell BG, Wong JK, Lobato RL. Perioperative morbidity and mortality after noncardiac surgery in </text>
<text top="713" left="190" width="588" height="13" font="8">young adults with congenital or early acquired heart disease: a retrospective cohort analysis of the </text>
<text top="731" left="190" width="499" height="13" font="8">National Surgical Quality Improvement Program database. Am Surg. 2014;80:321-6. </text>
<text top="749" left="105" width="52" height="13" font="8">S3.12-4. </text>
<text top="749" left="190" width="591" height="13" font="8">Maxwell BG, Williams GD, Ramamoorthy C. Knowledge and attitudes of anesthesia providers about </text>
<text top="767" left="190" width="555" height="13" font="8">noncardiac surgery in adults with congenital heart disease. Congenit Heart Dis. 2014;9:45-53. </text>
<text top="784" left="105" width="52" height="13" font="8">S3.12-5. </text>
<text top="784" left="190" width="550" height="13" font="8">Eagle SS, Daves SM. The adult with Fontan physiology: systematic approach to perioperative </text>
<text top="802" left="190" width="491" height="13" font="8">management for noncardiac surgery. J Cardiothorac Vasc Anesth. 2011;25:320-34. </text>
<text top="820" left="105" width="52" height="13" font="8">S3.12-6. </text>
<text top="820" left="190" width="574" height="13" font="8">Maxwell BG, Wong JK, Kin C, et al. Perioperative outcomes of major noncardiac surgery in adults </text>
<text top="838" left="190" width="379" height="13" font="8">with congenital heart disease. Anesthesiology. 2013;119:762-9. </text>
<text top="856" left="105" width="52" height="13" font="8">S3.12-7. </text>
<text top="856" left="190" width="563" height="13" font="8">Maxwell BG, Wong JK, Sheikh AY, et al. Heart transplantation with or without prior mechanical </text>
<text top="874" left="190" width="589" height="13" font="8">circulatory support in adults with congenital heart disease. Eur J Cardiothorac Surg. 2014;45:842-6. </text>
<text top="892" left="105" width="52" height="13" font="8">S3.12-8. </text>
<text top="892" left="190" width="589" height="13" font="8">Rabbitts JA, Groenewald CB, Mauermann WJ, et al. Outcomes of general anesthesia for noncardiac </text>
<text top="909" left="190" width="516" height="13" font="8">surgery in a series of patients with Fontan palliation. Paediatr Anaesth. 2013;23:180-7. </text>
<text top="927" left="105" width="52" height="13" font="8">S3.12-9. </text>
<text top="927" left="190" width="599" height="13" font="8">Mylotte D, Quenneville SP, Kotowycz MA, et al. Long-term cost-effectiveness of transcatheter versus </text>
<text top="945" left="190" width="531" height="13" font="8">surgical closure of secundum atrial septal defect in adults. Int J Cardiol. 2014;172:109-14. </text>
<text top="963" left="105" width="59" height="13" font="8">S3.12-10. </text>
<text top="963" left="190" width="539" height="13" font="8">Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative </text>
<text top="980" left="190" width="588" height="13" font="8">cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of </text>
<text top="998" left="190" width="587" height="13" font="8">the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. </text>
<text top="1016" left="190" width="194" height="13" font="8">Circulation. 2014;130:e278-333. </text>
<text top="1034" left="105" width="59" height="13" font="8">S3.12-11. </text>
<text top="1034" left="190" width="554" height="13" font="8">Christensen RE, Gholami AS, Reynolds PI, et al. Anaesthetic management and outcomes after </text>
<text top="1052" left="190" width="579" height="13" font="8">noncardiac surgery in patients with hypoplastic left heart syndrome: a retrospective review. Eur J </text>
<text top="1070" left="190" width="184" height="13" font="8">Anaesthesiol. 2012;29:425-30. </text>
</page>
<page number="145" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 147 </text>
<text top="162" left="105" width="59" height="13" font="8">S3.12-12. </text>
<text top="162" left="190" width="596" height="13" font="8">Warner MA, Lunn RJ, O’Leary PW, et al. Outcomes of noncardiac surgical procedures in children and </text>
<text top="180" left="190" width="546" height="13" font="8">adults with congenital heart disease. Mayo Perioperative Outcomes Group. Mayo Clin Proc. </text>
<text top="198" left="190" width="101" height="13" font="8">1998;73:728-34. </text>
<text top="215" left="105" width="59" height="13" font="8">S3.12-13. </text>
<text top="215" left="190" width="565" height="13" font="8">Mott AR, Fraser CD Jr, McKenzie ED, et al. Perioperative care of the adult with congenital heart </text>
<text top="233" left="190" width="500" height="13" font="8">disease in a free-standing tertiary pediatric facility. Pediatr Cardiol. 2002;23:624-30. </text>
<text top="251" left="105" width="59" height="13" font="8">S3.12-14. </text>
<text top="251" left="190" width="595" height="13" font="8">Maxwell BG, Maxwell TG, Wong JK. Decentralization of care for adults with congenital heart disease </text>
<text top="269" left="190" width="553" height="13" font="8">in the United States: a geographic analysis of outpatient surgery. PLoS One. 2014;9:e106730. </text>
<text top="306" left="105" width="459" height="20" font="17"><b>3.13. Pregnancy, Reproduction, and Sexual Health </b></text>
<text top="350" left="105" width="155" height="19" font="34"><b>3.13.1. Pregnancy </b></text>
<text top="382" left="105" width="62" height="13" font="8">S3.13.1-1. </text>
<text top="382" left="190" width="593" height="13" font="8">Balint OH, Siu SC, Mason J, et al. Cardiac outcomes after pregnancy in women with congenital heart </text>
<text top="400" left="190" width="200" height="13" font="8">disease. Heart. 2010;96:1656-61. </text>
<text top="418" left="105" width="62" height="13" font="8">S3.13.1-2. </text>
<text top="418" left="190" width="570" height="13" font="8">Roos-Hesselink JW, Ruys TPE, Stein JI, et al. Outcome of pregnancy in patients with structural or </text>
<text top="435" left="190" width="567" height="13" font="8">ischaemic heart disease: results of a registry of the European Society of Cardiology. Eur Heart J. </text>
<text top="453" left="190" width="101" height="13" font="8">2013;34:657-65. </text>
<text top="471" left="105" width="62" height="13" font="8">S3.13.1-3. </text>
<text top="471" left="190" width="592" height="13" font="8">Ouyang DW, Khairy P, Fernandes SM, et al. Obstetric outcomes in pregnant women with congenital </text>
<text top="489" left="190" width="263" height="13" font="8">heart disease. Int J Cardiol. 2010;144:195-9. </text>
<text top="507" left="105" width="62" height="13" font="8">S3.13.1-4. </text>
<text top="507" left="190" width="556" height="13" font="8">Egidy Assenza G, Cassater D, Landzberg M, et al. The effects of pregnancy on right ventricular </text>
<text top="525" left="190" width="521" height="13" font="8">remodeling in women with repaired tetralogy of Fallot. Int J Cardiol. 2013;168:1847-52. </text>
<text top="542" left="105" width="62" height="13" font="8">S3.13.1-5. </text>
<text top="542" left="190" width="597" height="13" font="8">Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a </text>
<text top="560" left="190" width="417" height="13" font="8">systematic review of the literature. Arch Intern Med. 2000;160:191-6. </text>
<text top="578" left="105" width="62" height="13" font="8">S3.13.1-6. </text>
<text top="578" left="190" width="546" height="13" font="8">Cutts BA, Dasgupta D, Hunt BJ. New directions in the diagnosis and treatment of pulmonary </text>
<text top="596" left="190" width="375" height="13" font="8">embolism in pregnancy. Am J Obstet Gynecol. 2013;208:102-8. </text>
<text top="614" left="105" width="62" height="13" font="8">S3.13.1-7. </text>
<text top="614" left="190" width="600" height="13" font="8">Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women </text>
<text top="631" left="190" width="295" height="13" font="8">with heart disease. Circulation. 2001;104:515-21. </text>
<text top="649" left="105" width="62" height="13" font="8">S3.13.1-8. </text>
<text top="649" left="190" width="581" height="13" font="8">Greutmann M, K. VK, Brooks R, et al. Pregnancy outcome in women with congenital heart disease </text>
<text top="667" left="190" width="594" height="13" font="8">and residual haemodynamic lesions of the right ventricular outflow tract. Eur Heart J. 2010;31:1764-</text>
<text top="685" left="190" width="22" height="13" font="8">70. </text>
<text top="703" left="105" width="62" height="13" font="8">S3.13.1-9. </text>
<text top="703" left="190" width="599" height="13" font="8">Gill HK, Splitt M, Sharland GK, et al. Patterns of recurrence of congenital heart disease: an analysis of </text>
<text top="721" left="190" width="566" height="13" font="8">6,640 consecutive pregnancies evaluated by detailed fetal echocardiography. J Am Coll Cardiol. </text>
<text top="738" left="190" width="93" height="13" font="8">2003;42:923-9. </text>
<text top="756" left="105" width="70" height="13" font="8">S3.13.1-10. </text>
<text top="756" left="190" width="583" height="13" font="8">Ohuchi H, Tanabe Y, Kamiya C, et al. Cardiopulmonary variables during exercise predict pregnancy </text>
<text top="774" left="190" width="430" height="13" font="8">outcome in women with congenital heart disease. Circ J. 2013;77:470-6. </text>
<text top="792" left="105" width="70" height="13" font="8">S3.13.1-11. </text>
<text top="792" left="190" width="596" height="13" font="8">Lui GK, Silversides CK, Khairy P, et al. Heart rate response during exercise and pregnancy outcome in </text>
<text top="809" left="190" width="401" height="13" font="8">women with congenital heart disease. Circulation. 2011;123:242-8. </text>
<text top="827" left="105" width="70" height="13" font="8">S3.13.1-12. </text>
<text top="827" left="190" width="589" height="13" font="8">Siu SC, Colman JM, Sorensen S, et al. Adverse neonatal and cardiac outcomes are more common in </text>
<text top="845" left="190" width="419" height="13" font="8">pregnant women with cardiac disease. Circulation. 2002;105:2179-84. </text>
<text top="863" left="105" width="70" height="13" font="8">S3.13.1-13. </text>
<text top="863" left="190" width="578" height="13" font="8">Holland BJ, Myers JA, Woods CR Jr. Prenatal diagnosis of critical congenital heart disease reduces </text>
<text top="881" left="190" width="574" height="13" font="8">risk of death from cardiovascular compromise prior to planned neonatal cardiac surgery: a meta-</text>
<text top="899" left="190" width="315" height="13" font="8">analysis. Ultrasound Obstet Gynecol. 2015;45:631-8. </text>
<text top="917" left="105" width="70" height="13" font="8">S3.13.1-14. </text>
<text top="917" left="190" width="572" height="13" font="8">van Hagen IM, Roos-Hesselink JW, Ruys TPE, et al. Pregnancy in women with a mechanical heart </text>
<text top="934" left="190" width="548" height="13" font="8">valve: data of the European Society of Cardiology Registry of Pregnancy and Cardiac Disease </text>
<text top="952" left="190" width="236" height="13" font="8">(ROPAC). Circulation. 2015;132:132-42. </text>
<text top="970" left="105" width="70" height="13" font="8">S3.13.1-15. </text>
<text top="970" left="190" width="577" height="13" font="8">Khairy P, Ouyang DW, Fernandes SM, et al. Pregnancy outcomes in women with congenital heart </text>
<text top="988" left="190" width="230" height="13" font="8">disease. Circulation. 2006;113:517-24. </text>
<text top="1005" left="105" width="70" height="13" font="8">S3.13.1-16. </text>
<text top="1005" left="190" width="577" height="13" font="8">Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and </text>
<text top="1023" left="190" width="489" height="13" font="8">pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006;32:75-81. </text>
<text top="1041" left="105" width="70" height="13" font="8">S3.13.1-17. </text>
<text top="1041" left="190" width="561" height="13" font="8">Drenthen W, Pieper PG, van der Tuuk K, et al. Fertility, pregnancy and delivery in women after </text>
<text top="1059" left="190" width="482" height="13" font="8">biventricular repair for double outlet right ventricle. Cardiology. 2008;109:105-9. </text>
</page>
<page number="146" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 148 </text>
<text top="162" left="105" width="70" height="13" font="8">S3.13.1-18. </text>
<text top="162" left="190" width="591" height="13" font="8">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital </text>
<text top="180" left="190" width="417" height="13" font="8">heart disease: a literature review. J Am Coll Cardiol. 2007;49:2303-11. </text>
<text top="198" left="105" width="70" height="13" font="8">S3.13.1-19. </text>
<text top="198" left="190" width="570" height="13" font="8">Pedersen LM, Pedersen TAL, Ravn HB, et al. Outcomes of pregnancy in women with tetralogy of </text>
<text top="215" left="190" width="222" height="13" font="8">Fallot. Cardiol Young. 2008;18:423-9. </text>
<text top="233" left="105" width="70" height="13" font="8">S3.13.1-20. </text>
<text top="233" left="190" width="579" height="13" font="8">Vriend JWJ, Drenthen W, Pieper PG, et al. Outcome of pregnancy in patients after repair of aortic </text>
<text top="251" left="190" width="247" height="13" font="8">coarctation. Eur Heart J. 2005;26:2173-8. </text>
<text top="269" left="105" width="70" height="13" font="8">S3.13.1-21. </text>
<text top="269" left="190" width="589" height="13" font="8">Kovacs AH, Harrison JL, Colman JM, et al. Pregnancy and contraception in congenital heart disease: </text>
<text top="286" left="190" width="357" height="13" font="8">what women are not told. J Am Coll Cardiol. 2008;52:577-8. </text>
<text top="304" left="105" width="70" height="13" font="8">S3.13.1-22. </text>
<text top="304" left="190" width="600" height="13" font="8">Beauchesne LM, Connolly HM, Ammash NM, et al. Coarctation of the aorta: outcome of pregnancy. J </text>
<text top="322" left="190" width="206" height="13" font="8">Am Coll Cardiol. 2001;38:1728-33. </text>
<text top="340" left="105" width="70" height="13" font="8">S3.13.1-23. </text>
<text top="340" left="190" width="580" height="13" font="8">Krieger EV, Landzberg MJ, Economy KE, et al. Comparison of risk of hypertensive complications of </text>
<text top="358" left="190" width="507" height="13" font="8">pregnancy among women with versus without coarctation of the aorta. Am J Cardiol. </text>
<text top="375" left="190" width="115" height="13" font="8">2011;107:1529-34. </text>
<text top="393" left="105" width="70" height="13" font="8">S3.13.1-24. </text>
<text top="393" left="190" width="552" height="13" font="8">Balci A, Sollie-Szarynska KM, van der Bijl AGL, et al. Prospective validation and assessment of </text>
<text top="411" left="190" width="589" height="13" font="8">cardiovascular and offspring risk models for pregnant women with congenital heart disease. Heart. </text>
<text top="429" left="190" width="115" height="13" font="8">2014;100:1373-81. </text>
<text top="447" left="105" width="70" height="13" font="8">S3.13.1-25. </text>
<text top="447" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="465" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="482" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="500" left="105" width="70" height="13" font="8">S3.13.1-26. </text>
<text top="500" left="190" width="541" height="13" font="8">Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and </text>
<text top="518" left="190" width="574" height="13" font="8">combined injectable contraceptives. Results of an international, multicenter, case-control study. </text>
<text top="536" left="190" width="566" height="13" font="8">World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone </text>
<text top="554" left="190" width="284" height="13" font="8">Contraception. Contraception. 1998;57:315-24. </text>
<text top="572" left="105" width="70" height="13" font="8">S3.13.1-27. </text>
<text top="572" left="190" width="571" height="13" font="8">Thorne S, MacGregor A, Nelson-Piercy C. Risks of contraception and pregnancy in heart disease. </text>
<text top="589" left="190" width="141" height="13" font="8">Heart. 2006;92:1520-5. </text>
<text top="607" left="105" width="70" height="13" font="8">S3.13.1-28. </text>
<text top="607" left="190" width="571" height="13" font="8">Lu C-W, Shih J-C, Chen S-Y, et al. Comparison of 3 risk estimation methods for predicting cardiac </text>
<text top="625" left="190" width="508" height="13" font="8">outcomes in pregnant women with congenital heart disease. Circ J. 2015;79:1609-17. </text>
<text top="643" left="105" width="70" height="13" font="8">S3.13.1-29. </text>
<text top="643" left="190" width="580" height="13" font="8">Kumar RK, Newburger JW, Gauvreau K, et al. Comparison of outcome when hypoplastic left heart </text>
<text top="661" left="190" width="593" height="13" font="8">syndrome and transposition of the great arteries are diagnosed prenatally versus when diagnosis of </text>
<text top="678" left="190" width="467" height="13" font="8">these two conditions is made only postnatally. Am J Cardiol. 1999;83:1649-53. </text>
<text top="696" left="105" width="70" height="13" font="8">S3.13.1-30. </text>
<text top="696" left="190" width="597" height="13" font="8">Bonnet D, Coltri A, Butera G, et al. Detection of transposition of the great arteries in fetuses reduces </text>
<text top="714" left="190" width="368" height="13" font="8">neonatal morbidity and mortality. Circulation. 1999;99:916-8. </text>
<text top="751" left="105" width="188" height="19" font="34"><b>3.13.2. Contraception </b></text>
<text top="783" left="105" width="62" height="13" font="8">S3.13.2-1. </text>
<text top="783" left="190" width="589" height="13" font="8">Kovacs AH, Harrison JL, Colman JM, et al. Pregnancy and contraception in congenital heart disease: </text>
<text top="801" left="190" width="357" height="13" font="8">what women are not told. J Am Coll Cardiol. 2008;52:577-8. </text>
<text top="819" left="105" width="62" height="13" font="8">S3.13.2-2. </text>
<text top="819" left="190" width="601" height="13" font="8">Vigl M, Kaemmerer M, Seifert-Klauss V, et al. Contraception in women with congenital heart disease. </text>
<text top="837" left="190" width="196" height="13" font="8">Am J Cardiol. 2010;106:1317-21. </text>
<text top="854" left="105" width="62" height="13" font="8">S3.13.2-3. </text>
<text top="854" left="190" width="589" height="13" font="8">Kaemmerer M, Vigl M, Seifert-Klauss V, et al. Counseling reproductive health issues in women with </text>
<text top="872" left="190" width="351" height="13" font="8">congenital heart disease. Clin Res Cardiol. 2012;101:901-7. </text>
<text top="890" left="105" width="62" height="13" font="8">S3.13.2-4. </text>
<text top="890" left="190" width="538" height="13" font="8">Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous </text>
<text top="908" left="190" width="405" height="13" font="8">thromboembolism: national follow-up study. BMJ. 2009;339:b2890. </text>
<text top="926" left="105" width="62" height="13" font="8">S3.13.2-5. </text>
<text top="926" left="190" width="550" height="13" font="8">Pijuan-Domènech A, Baró-Mariné F, Rojas-Torrijos M, et al. Usefulness of progesterone-only </text>
<text top="944" left="190" width="512" height="13" font="8">components for contraception in patients with congenital heart disease. Am J Cardiol. </text>
<text top="961" left="190" width="101" height="13" font="8">2013;112:590-3. </text>
<text top="979" left="105" width="62" height="13" font="8">S3.13.2-6. </text>
<text top="979" left="190" width="548" height="13" font="8">Silversides CK, Sermer M, Siu SC. Choosing the best contraceptive method for the adult with </text>
<text top="997" left="190" width="363" height="13" font="8">congenital heart disease. Curr Cardiol Rep. 2009;11:298-305. </text>
<text top="1034" left="105" width="241" height="19" font="34"><b>3.13.3. Infertility Treatment </b></text>
<text top="1066" left="105" width="62" height="13" font="8">S3.13.3-1. </text>
<text top="1066" left="190" width="561" height="13" font="8">Drenthen W, Pieper PG, van der Tuuk K, et al. Fertility, pregnancy and delivery in women after </text>
<text top="1084" left="190" width="482" height="13" font="8">biventricular repair for double outlet right ventricle. Cardiology. 2008;109:105-9. </text>
</page>
<page number="147" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 149 </text>
<text top="162" left="105" width="62" height="13" font="8">S3.13.3-2. </text>
<text top="162" left="190" width="576" height="13" font="8">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Pregnancy and delivery in women after Fontan </text>
<text top="180" left="190" width="203" height="13" font="8">palliation. Heart. 2006;92:1290-4. </text>
<text top="198" left="105" width="62" height="13" font="8">S3.13.3-3. </text>
<text top="198" left="190" width="592" height="13" font="8">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital </text>
<text top="215" left="190" width="417" height="13" font="8">heart disease: a literature review. J Am Coll Cardiol. 2007;49:2303-11. </text>
<text top="233" left="105" width="62" height="13" font="8">S3.13.3-4. </text>
<text top="233" left="190" width="570" height="13" font="8">Pedersen LM, Pedersen TAL, Ravn HB, et al. Outcomes of pregnancy in women with tetralogy of </text>
<text top="251" left="190" width="222" height="13" font="8">Fallot. Cardiol Young. 2008;18:423-9. </text>
<text top="269" left="105" width="62" height="13" font="8">S3.13.3-5. </text>
<text top="269" left="190" width="579" height="13" font="8">Vriend JWJ, Drenthen W, Pieper PG, et al. Outcome of pregnancy in patients after repair of aortic </text>
<text top="286" left="190" width="247" height="13" font="8">coarctation. Eur Heart J. 2005;26:2173-8. </text>
<text top="323" left="105" width="201" height="19" font="34"><b>3.13.4. Sexual Function </b></text>
<text top="355" left="105" width="62" height="13" font="8">S3.13.4-1. </text>
<text top="355" left="190" width="586" height="13" font="8">Winter MM, Reisma C, Kedde H, et al. Sexuality in adult patients with congenital heart disease and </text>
<text top="373" left="190" width="311" height="13" font="8">their partners. Am J Cardiol. 2010;106:1163-8, e1-8. </text>
<text top="391" left="105" width="62" height="13" font="8">S3.13.4-2. </text>
<text top="391" left="190" width="591" height="13" font="8">Moons P, Van Deyk K, Marquet K, et al. Sexual functioning and congenital heart disease: something </text>
<text top="409" left="190" width="269" height="13" font="8">to worry about? Int J Cardiol. 2007;121:30-5. </text>
<text top="427" left="105" width="62" height="13" font="8">S3.13.4-3. </text>
<text top="427" left="190" width="589" height="13" font="8">Cook SC, Arnott LM, Nicholson LM, et al. Erectile dysfunction in men with congenital heart disease. </text>
<text top="445" left="190" width="196" height="13" font="8">Am J Cardiol. 2008;102:1728-30. </text>
<text top="462" left="105" width="62" height="13" font="8">S3.13.4-4. </text>
<text top="462" left="190" width="586" height="13" font="8">Vigl M, Hager A, Bauer U, et al. Sexuality and subjective wellbeing in male patients with congenital </text>
<text top="480" left="190" width="235" height="13" font="8">heart disease. Heart. 2009;95:1179-83. </text>
<text top="498" left="105" width="62" height="13" font="8">S3.13.4-5. </text>
<text top="498" left="190" width="547" height="13" font="8">Opić P, Roos-Hesselink JW, Cuypers JAAC, et al. Sexual functioning is impaired in adults with </text>
<text top="516" left="190" width="336" height="13" font="8">congenital heart disease. Int J Cardiol. 2013;168:3872-7. </text>
<text top="553" left="105" width="315" height="20" font="17"><b>3.14. Heart Failure and Transplant </b></text>
<text top="597" left="105" width="177" height="19" font="34"><b>3.14.1. Heart Failure </b></text>
<text top="629" left="105" width="62" height="13" font="8">S3.14.1-1. </text>
<text top="629" left="190" width="579" height="13" font="8">Verheugt CL, Uiterwaal CSPM, van der Velde ET, et al. Mortality in adult congenital heart disease. </text>
<text top="647" left="190" width="172" height="13" font="8">Eur Heart J. 2010;31:1220-9. </text>
<text top="665" left="105" width="62" height="13" font="8">S3.14.1-2. </text>
<text top="665" left="190" width="598" height="13" font="8">Zomer AC, Vaartjes I, van der Velde ET, et al. Heart failure admissions in adults with congenital heart </text>
<text top="683" left="190" width="401" height="13" font="8">disease; risk factors and prognosis. Int J Cardiol. 2013;168:2487-93. </text>
<text top="700" left="105" width="62" height="13" font="8">S3.14.1-3. </text>
<text top="700" left="190" width="596" height="13" font="8">Oechslin EN, Harrison DA, Connelly MS, et al. Mode of death in adults with congenital heart disease. </text>
<text top="718" left="190" width="181" height="13" font="8">Am J Cardiol. 2000;86:1111-6. </text>
<text top="736" left="105" width="62" height="13" font="8">S3.14.1-4. </text>
<text top="736" left="190" width="554" height="13" font="8">Zomer AC, Vaartjes I, Uiterwaal CSPM, et al. Circumstances of death in adult congenital heart </text>
<text top="754" left="190" width="235" height="13" font="8">disease. Int J Cardiol. 2012;154:168-72. </text>
<text top="772" left="105" width="62" height="13" font="8">S3.14.1-5. </text>
<text top="772" left="190" width="575" height="13" font="8">Stout K, Valente AM, Bartz PJ, et al. Task Force 6: pediatric cardiology fellowship training in adult </text>
<text top="789" left="190" width="323" height="13" font="8">congenital heart disease. Circulation. 2015;132:e91-8. </text>
<text top="807" left="105" width="62" height="13" font="8">S3.14.1-6. </text>
<text top="807" left="190" width="575" height="13" font="8">Norozi K, Bahlmann J, Raab B, et al. A prospective, randomized, double-blind, placebo controlled </text>
<text top="825" left="190" width="566" height="13" font="8">trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. </text>
<text top="843" left="190" width="183" height="13" font="8">Cardiol Young. 2007;17:372-9. </text>
<text top="861" left="105" width="62" height="13" font="8">S3.14.1-7. </text>
<text top="861" left="190" width="599" height="13" font="8">Babu-Narayan SV, Uebing A, Davlouros PA, et al. Randomised trial of ramipril in repaired tetralogy of </text>
<text top="879" left="190" width="598" height="13" font="8">Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention </text>
<text top="896" left="190" width="599" height="13" font="8">Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot). Int </text>
<text top="914" left="190" width="172" height="13" font="8">J Cardiol. 2012;154:299-305. </text>
<text top="932" left="105" width="62" height="13" font="8">S3.14.1-8. </text>
<text top="932" left="190" width="534" height="13" font="8">Lester SJ, McElhinney DB, Viloria E, et al. Effects of losartan in patients with a systemically </text>
<text top="950" left="190" width="594" height="13" font="8">functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J </text>
<text top="968" left="190" width="150" height="13" font="8">Cardiol. 2001;88:1314-6. </text>
<text top="986" left="105" width="62" height="13" font="8">S3.14.1-9. </text>
<text top="986" left="190" width="589" height="13" font="8">Hechter SJ, Fredriksen PM, Liu P, et al. Angiotensin-converting enzyme inhibitors in adults after the </text>
<text top="1003" left="190" width="326" height="13" font="8">Mustard procedure. Am J Cardiol. 2001;87:660-3, A11. </text>
<text top="1021" left="105" width="70" height="13" font="8">S3.14.1-10. </text>
<text top="1021" left="190" width="595" height="13" font="8">Dore A, Houde C, Chan K-L, et al. Angiotensin receptor blockade and exercise capacity in adults with </text>
<text top="1039" left="190" width="576" height="13" font="8">systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. </text>
<text top="1057" left="190" width="108" height="13" font="8">2005;112:2411-6. </text>
</page>
<page number="148" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 150 </text>
<text top="162" left="105" width="70" height="13" font="8">S3.14.1-11. </text>
<text top="162" left="190" width="563" height="13" font="8">Giardini A, Lovato L, Donti A, et al. A pilot study on the effects of carvedilol on right ventricular </text>
<text top="180" left="190" width="528" height="13" font="8">remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol. </text>
<text top="198" left="190" width="101" height="13" font="8">2007;114:241-6. </text>
<text top="215" left="105" width="70" height="13" font="8">S3.14.1-12. </text>
<text top="215" left="190" width="570" height="13" font="8">Doughan ARK, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in </text>
<text top="233" left="190" width="575" height="13" font="8">patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J </text>
<text top="251" left="190" width="142" height="13" font="8">Cardiol. 2007;99:704-6. </text>
<text top="269" left="105" width="70" height="13" font="8">S3.14.1-13. </text>
<text top="269" left="190" width="568" height="13" font="8">Therrien J, Provost Y, Harrison J, et al. Effect of angiotensin receptor blockade on systemic right </text>
<text top="286" left="190" width="533" height="13" font="8">ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. </text>
<text top="304" left="190" width="108" height="13" font="8">2008;129:187-92. </text>
<text top="322" left="105" width="70" height="13" font="8">S3.14.1-14. </text>
<text top="322" left="190" width="549" height="13" font="8">Bouallal R, Godart F, Francart C, et al. Interest of β-blockers in patients with right ventricular </text>
<text top="340" left="190" width="314" height="13" font="8">systemic dysfunction. Cardiol Young. 2010;20:615-9. </text>
<text top="358" left="105" width="70" height="13" font="8">S3.14.1-15. </text>
<text top="358" left="190" width="599" height="13" font="8">Tutarel O, Meyer GP, Bertram H, et al. Safety and efficiency of chronic ACE inhibition in symptomatic </text>
<text top="375" left="190" width="483" height="13" font="8">heart failure patients with a systemic right ventricle. Int J Cardiol. 2012;154:14-6. </text>
<text top="393" left="105" width="70" height="13" font="8">S3.14.1-16. </text>
<text top="393" left="190" width="549" height="13" font="8">van der Bom T, Winter MM, Bouma BJ, et al. Effect of valsartan on systemic right ventricular </text>
<text top="411" left="190" width="583" height="13" font="8">function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127:322-30. </text>
<text top="429" left="105" width="70" height="13" font="8">S3.14.1-17. </text>
<text top="429" left="190" width="584" height="13" font="8">Dos L, Pujadas S, Estruch M, et al. Eplerenone in systemic right ventricle: double blind randomized </text>
<text top="447" left="190" width="381" height="13" font="8">clinical trial. The EVEDES Study. Int J Cardiol. 2013;168:5167-73. </text>
<text top="465" left="105" width="70" height="13" font="8">S3.14.1-18. </text>
<text top="465" left="190" width="597" height="13" font="8">Kouatli AA, García JA, Zellers TM, et al. Enalapril does not enhance exercise capacity in patients after </text>
<text top="482" left="190" width="293" height="13" font="8">Fontan procedure. Circulation. 1997;96:1507-12. </text>
<text top="500" left="105" width="70" height="13" font="8">S3.14.1-19. </text>
<text top="500" left="190" width="583" height="13" font="8">Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on haemodynamic response to exercise </text>
<text top="518" left="190" width="416" height="13" font="8">and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681-7. </text>
<text top="536" left="105" width="70" height="13" font="8">S3.14.1-20. </text>
<text top="536" left="190" width="560" height="13" font="8">Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in </text>
<text top="554" left="190" width="544" height="13" font="8">children and young adults after the Fontan operation: a randomized, double-blind, placebo-</text>
<text top="572" left="190" width="345" height="13" font="8">controlled, crossover trial. Circulation. 2011;123:1185-93. </text>
<text top="589" left="105" width="70" height="13" font="8">S3.14.1-21. </text>
<text top="589" left="190" width="568" height="13" font="8">Rhodes J, Ubeda-Tikkanen A, Clair M, et al. Effect of inhaled iloprost on the exercise function of </text>
<text top="607" left="190" width="464" height="13" font="8">Fontan patients: a demonstration of concept. Int J Cardiol. 2013;168:2435-40. </text>
<text top="625" left="105" width="70" height="13" font="8">S3.14.1-22. </text>
<text top="625" left="190" width="593" height="13" font="8">Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: </text>
<text top="643" left="190" width="573" height="13" font="8">a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48-54. </text>
<text top="680" left="105" width="210" height="19" font="34"><b>3.14.2. Heart Transplant </b></text>
<text top="712" left="105" width="62" height="13" font="8">S3.14.2-1. </text>
<text top="712" left="190" width="566" height="13" font="8">Everitt MD, Donaldson AE, Stehlik J, et al. Would access to device therapies improve transplant </text>
<text top="730" left="190" width="554" height="13" font="8">outcomes for adults with congenital heart disease? Analysis of the United Network for Organ </text>
<text top="748" left="190" width="353" height="13" font="8">Sharing (UNOS). J Heart Lung Transplant. 2011;30:395-401. </text>
<text top="765" left="105" width="62" height="13" font="8">S3.14.2-2. </text>
<text top="765" left="190" width="573" height="13" font="8">Davies RR, Russo MJ, Yang J, et al. Listing and transplanting adults with congenital heart disease. </text>
<text top="783" left="190" width="179" height="13" font="8">Circulation. 2011;123:759-67. </text>
<text top="801" left="105" width="62" height="13" font="8">S3.14.2-3. </text>
<text top="801" left="190" width="533" height="13" font="8">Karamlou T, Hirsch J, Welke K, et al. A United Network for Organ Sharing analysis of heart </text>
<text top="819" left="190" width="557" height="13" font="8">transplantation in adults with congenital heart disease: outcomes and factors associated with </text>
<text top="837" left="190" width="448" height="13" font="8">mortality and retransplantation. J Thorac Cardiovasc Surg. 2010;140:161-8. </text>
<text top="854" left="105" width="62" height="13" font="8">S3.14.2-4. </text>
<text top="854" left="190" width="586" height="13" font="8">Stout KK, Broberg CS, Book WM, et al. Chronic heart failure in congenital heart disease: a scientific </text>
<text top="872" left="190" width="478" height="13" font="8">statement from the American Heart Association. Circulation. 2016;133:770-801. </text>
<text top="890" left="105" width="62" height="13" font="8">S3.14.2-5. </text>
<text top="890" left="190" width="600" height="13" font="8">Gelow JM, Song HK, Weiss JB, et al. Organ allocation in adults with congenital heart disease listed for </text>
<text top="908" left="190" width="572" height="13" font="8">heart transplant: impact of ventricular assist devices. J Heart Lung Transplant. 2013;32:1059-64. </text>
<text top="926" left="105" width="62" height="13" font="8">S3.14.2-6. </text>
<text top="926" left="190" width="592" height="13" font="8">Goerler H, Simon A, Gohrbandt B, et al. Heart-lung and lung transplantation in grown-up congenital </text>
<text top="944" left="190" width="546" height="13" font="8">heart disease: long-term single centre experience. Eur J Cardiothorac Surg. 2007;32:926-31. </text>
<text top="961" left="105" width="62" height="13" font="8">S3.14.2-7. </text>
<text top="961" left="190" width="586" height="13" font="8">Burchill LJ, Edwards LB, Dipchand AI, et al. Impact of adult congenital heart disease on survival and </text>
<text top="979" left="190" width="478" height="13" font="8">mortality after heart transplantation. J Heart Lung Transplant. 2014;33:1157-63. </text>
<text top="997" left="105" width="62" height="13" font="8">S3.14.2-8. </text>
<text top="997" left="190" width="587" height="13" font="8">Greutmann M, Prêtre R, Furrer L, et al. Heart transplantation in adolescent and adult patients with </text>
<text top="1015" left="190" width="479" height="13" font="8">congenital heart disease: a case-control study. Transplant Proc. 2009;41:3821-6. </text>
<text top="1033" left="105" width="62" height="13" font="8">S3.14.2-9. </text>
<text top="1033" left="190" width="561" height="13" font="8">Seddio F, Gorislavets N, Iacovoni A, et al. Is heart transplantation for complex congenital heart </text>
<text top="1051" left="190" width="597" height="13" font="8">disease a good option? A 25-year single centre experience. Eur J Cardiothorac Surg. 2013;43:605-11. </text>
<text top="1068" left="105" width="70" height="13" font="8">S3.14.2-10. </text>
<text top="1068" left="190" width="585" height="13" font="8">Alshawabkeh LI, Hu N, Carter KD, et al. Wait-list outcomes for adults with congenital heart disease </text>
<text top="1086" left="190" width="457" height="13" font="8">listed for heart transplantation in the U.S. J Am Coll Cardiol. 2016;68:908-17. </text>
</page>
<page number="149" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 151 </text>
<text top="162" left="105" width="70" height="13" font="8">S3.14.2-11. </text>
<text top="162" left="190" width="601" height="13" font="8">Krishnamurthy Y, Cooper LB, Lu D, et al. Trends and outcomes of patients with adult congenital heart </text>
<text top="179" left="190" width="599" height="13" font="8">disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States. </text>
<text top="197" left="190" width="247" height="13" font="8">J Heart Lung Transplant. 2016;35:619-24. </text>
<text top="215" left="105" width="70" height="13" font="8">S3.14.2-12. </text>
<text top="215" left="190" width="550" height="13" font="8">Harper AR, Crossland DS, Perri G, et al. Is alternative cardiac surgery an option in adults with </text>
<text top="233" left="190" width="556" height="13" font="8">congenital heart disease referred for thoracic organ transplantation? Eur J Cardiothorac Surg. </text>
<text top="251" left="190" width="101" height="13" font="8">2013;43:344-51. </text>
<text top="288" left="105" width="258" height="19" font="34"><b>3.14.3. Multiorgan Transplant </b></text>
<text top="320" left="105" width="62" height="13" font="8">S3.14.3-1. </text>
<text top="320" left="190" width="558" height="13" font="8">Toyoda Y, Toyoda Y. Heart-lung transplantation: adult indications and outcomes. J Thorac Dis. </text>
<text top="337" left="190" width="101" height="13" font="8">2014;6:1138-42. </text>
<text top="355" left="105" width="62" height="13" font="8">S3.14.3-2. </text>
<text top="355" left="190" width="573" height="13" font="8">Yusen RD, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and </text>
<text top="373" left="190" width="588" height="13" font="8">Lung Transplantation: thirty-third adult lung and heart-lung transplant report—2016; focus theme: </text>
<text top="391" left="190" width="524" height="13" font="8">primary diagnostic indications for transplant. J Heart Lung Transplant. 2016;35:1170-84. </text>
<text top="409" left="105" width="62" height="13" font="8">S3.14.3-3. </text>
<text top="409" left="190" width="600" height="13" font="8">Yusen RD, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and </text>
<text top="427" left="190" width="583" height="13" font="8">Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: </text>
<text top="445" left="190" width="365" height="13" font="8">retransplantation. J Heart Lung Transplant. 2014;33:1009-24. </text>
<text top="462" left="105" width="62" height="13" font="8">S3.14.3-4. </text>
<text top="462" left="190" width="585" height="13" font="8">Bolman RMr, Shumway SJ, Estrin JA, et al. Lung and heart-lung transplantation. Evolution and new </text>
<text top="480" left="190" width="247" height="13" font="8">applications. Ann Surg. 1991;214:456-68. </text>
<text top="498" left="105" width="62" height="13" font="8">S3.14.3-5. </text>
<text top="498" left="190" width="599" height="13" font="8">Atluri P, Gaffey A, Howard J, et al. Combined heart and liver transplantation can be safely performed </text>
<text top="516" left="190" width="465" height="13" font="8">with excellent short- and long-term results. Ann Thorac Surg. 2014;98:858-62. </text>
<text top="534" left="105" width="62" height="13" font="8">S3.14.3-6. </text>
<text top="534" left="190" width="586" height="13" font="8">Cannon RM, Hughes MG, Jones CM, et al. A review of the United States experience with combined </text>
<text top="552" left="190" width="335" height="13" font="8">heart-liver transplantation. Transpl Int. 2012;25:1223-8. </text>
<text top="569" left="105" width="62" height="13" font="8">S3.14.3-7. </text>
<text top="569" left="190" width="601" height="13" font="8">Barbara DW, Rehfeldt KH, Heimbach JK, et al. The perioperative management of patients undergoing </text>
<text top="587" left="190" width="428" height="13" font="8">combined heart-liver transplantation. Transplantation. 2015;99:139-44. </text>
<text top="605" left="105" width="62" height="13" font="8">S3.14.3-8. </text>
<text top="605" left="190" width="573" height="13" font="8">Simpson KE, Esmaeeli A, Khanna G, et al. Liver cirrhosis in Fontan patients does not affect 1-year </text>
<text top="623" left="190" width="596" height="13" font="8">post-heart transplant mortality or markers of liver function. J Heart Lung Transplant. 2014;33:170-7. </text>
<text top="660" left="105" width="185" height="20" font="17"><b>3.15. Palliative Care </b></text>
<text top="694" left="105" width="52" height="13" font="8">S3.15-1. </text>
<text top="694" left="190" width="579" height="13" font="8">Greutmann M, Tobler D, Colman JM, et al. Facilitators of and barriers to advance care planning in </text>
<text top="711" left="190" width="389" height="13" font="8">adult congenital heart disease. Congenit Heart Dis. 2013;8:281-8. </text>
<text top="729" left="105" width="52" height="13" font="8">S3.15-2. </text>
<text top="729" left="190" width="589" height="13" font="8">Tobler D, Greutmann M, Colman JM, et al. Knowledge of and preference for advance care planning </text>
<text top="747" left="190" width="441" height="13" font="8">by adults with congenital heart disease. Am J Cardiol. 2012;109:1797-800. </text>
<text top="765" left="105" width="52" height="13" font="8">S3.15-3. </text>
<text top="765" left="190" width="588" height="13" font="8">Tobler D, Greutmann M, Colman JM, et al. End-of-life in adults with congenital heart disease: a call </text>
<text top="783" left="190" width="330" height="13" font="8">for early communication. Int J Cardiol. 2012;155:383-7. </text>
<text top="801" left="105" width="52" height="13" font="8">S3.15-4. </text>
<text top="801" left="190" width="559" height="13" font="8">Tobler D, Greutmann M, Colman JM, et al. End-of-life care in hospitalized adults with complex </text>
<text top="818" left="190" width="471" height="13" font="8">congenital heart disease: care delayed, care denied. Palliat Med. 2012;26:72-9. </text>
<text top="856" left="105" width="134" height="20" font="17"><b>3.16. Cyanosis </b></text>
<text top="889" left="105" width="52" height="13" font="8">S3.16-1. </text>
<text top="889" left="190" width="594" height="13" font="8">Martin L, Khalil H. How much reduced hemoglobin is necessary to generate central cyanosis? Chest. </text>
<text top="907" left="190" width="93" height="13" font="8">1990;97:182-5. </text>
<text top="925" left="105" width="52" height="13" font="8">S3.16-2. </text>
<text top="925" left="190" width="592" height="13" font="8">Broberg CS, Jayaweera AR, Diller GP, et al. Seeking optimal relation between oxygen saturation and </text>
<text top="943" left="190" width="562" height="13" font="8">hemoglobin concentration in adults with cyanosis from congenital heart disease. Am J Cardiol. </text>
<text top="960" left="190" width="101" height="13" font="8">2011;107:595-9. </text>
<text top="978" left="105" width="52" height="13" font="8">S3.16-3. </text>
<text top="978" left="190" width="545" height="13" font="8">Broberg CS, Bax BE, Okonko DO, et al. Blood viscosity and its relationship to iron deficiency, </text>
<text top="996" left="190" width="592" height="13" font="8">symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol. </text>
<text top="1014" left="190" width="101" height="13" font="8">2006;48:356-65. </text>
<text top="1032" left="105" width="52" height="13" font="8">S3.16-4. </text>
<text top="1032" left="190" width="569" height="13" font="8">Ammash N, Warnes CA. Cerebrovascular events in adult patients with cyanotic congenital heart </text>
<text top="1050" left="190" width="257" height="13" font="8">disease. J Am Coll Cardiol. 1996;28:768-72. </text>
<text top="1067" left="105" width="52" height="13" font="8">S3.16-5. </text>
<text top="1067" left="190" width="551" height="13" font="8">Chang Y-L, Hung S-H, Ling W, et al. Correction: association between ischemic stroke and iron-</text>
<text top="1085" left="190" width="453" height="13" font="8">deficiency anemia: a population-based study. PLoS One. 2017;12:e0170872. </text>
</page>
<page number="150" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 152 </text>
<text top="162" left="105" width="52" height="13" font="8">S3.16-6. </text>
<text top="162" left="190" width="561" height="13" font="8">Perloff JK, Marelli AJ, Miner PD. Risk of stroke in adults with cyanotic congenital heart disease. </text>
<text top="180" left="190" width="172" height="13" font="8">Circulation. 1993;87:1954-9. </text>
<text top="198" left="105" width="52" height="13" font="8">S3.16-7. </text>
<text top="197" left="190" width="482" height="13" font="8">Kaemmerer H, Fratz S, Braun SL, et al. Erythrocyte indexes, iron metabolism, and </text>
<text top="215" left="190" width="522" height="13" font="8">hyperhomocysteinemia in adults with cyanotic congenital cardiac disease. Am J Cardiol. </text>
<text top="233" left="190" width="93" height="13" font="8">2004;94:825-8. </text>
<text top="251" left="105" width="52" height="13" font="8">S3.16-8. </text>
<text top="251" left="190" width="552" height="13" font="8">Tay ELW, Peset A, Papaphylactou M, et al. Replacement therapy for iron deficiency improves </text>
<text top="269" left="190" width="574" height="13" font="8">exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the </text>
<text top="286" left="190" width="331" height="13" font="8">Eisenmenger syndrome. Int J Cardiol. 2011;151:307-12. </text>
<text top="304" left="105" width="52" height="13" font="8">S3.16-9. </text>
<text top="304" left="190" width="574" height="13" font="8">Broberg CS. Challenges and management issues in adults with cyanotic congenital heart disease. </text>
<text top="322" left="190" width="141" height="13" font="8">Heart. 2016;102:720-5. </text>
<text top="340" left="105" width="59" height="13" font="8">S3.16-10. </text>
<text top="340" left="190" width="589" height="13" font="8">Oechslin E. Management of adults with cyanotic congenital heart disease. Heart. 2015;101:485-94. </text>
<text top="358" left="105" width="59" height="13" font="8">S3.16-11. </text>
<text top="358" left="190" width="576" height="13" font="8">Kajimoto H, Nakazawa M, Murasaki K, et al. Increased thrombogenesity in patients with cyanotic </text>
<text top="375" left="190" width="289" height="13" font="8">congenital heart disease. Circ J. 2007;71:948-53. </text>
<text top="393" left="105" width="59" height="13" font="8">S3.16-12. </text>
<text top="393" left="190" width="565" height="13" font="8">Jensen AS, Johansson PI, Idorn L, et al. The haematocrit—an important factor causing impaired </text>
<text top="411" left="190" width="569" height="13" font="8">haemostasis in patients with cyanotic congenital heart disease. Int J Cardiol. 2013;167:1317-21. </text>
<text top="429" left="105" width="59" height="13" font="8">S3.16-13. </text>
<text top="429" left="190" width="585" height="13" font="8">Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. I. Br </text>
<text top="447" left="190" width="128" height="13" font="8">Med J. 1958;2:701-9. </text>
<text top="465" left="105" width="59" height="13" font="8">S3.16-14. </text>
<text top="465" left="190" width="588" height="13" font="8">Broberg C, Ujita M, Babu-Narayan S, et al. Massive pulmonary artery thrombosis with haemoptysis </text>
<text top="482" left="190" width="474" height="13" font="8">in adults with Eisenmenger’s syndrome: a clinical dilemma. Heart. 2004;90:e63. </text>
<text top="500" left="105" width="59" height="13" font="8">S3.16-15. </text>
<text top="500" left="190" width="596" height="13" font="8">Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome. Factors relating to deterioration </text>
<text top="518" left="190" width="247" height="13" font="8">and death. Eur Heart J. 1998;19:1845-55. </text>
<text top="536" left="105" width="59" height="13" font="8">S3.16-16. </text>
<text top="536" left="190" width="589" height="13" font="8">Sandoval J, Santos LE, Córdova J, et al. Does anticoagulation in Eisenmenger syndrome impact long-</text>
<text top="554" left="190" width="299" height="13" font="8">term survival? Congenit Heart Dis. 2012;7:268-76. </text>
<text top="572" left="105" width="59" height="13" font="8">S3.16-17. </text>
<text top="572" left="190" width="588" height="13" font="8">Dedkov EI, Perloff JK, Tomanek RJ, et al. The coronary microcirculation in cyanotic congenital heart </text>
<text top="589" left="190" width="237" height="13" font="8">disease. Circulation. 2006;114:196-200. </text>
<text top="607" left="105" width="59" height="13" font="8">S3.16-18. </text>
<text top="607" left="190" width="584" height="13" font="8">Duffels MGJ, Mulder KM, Trip MD, et al. Atherosclerosis in patients with cyanotic congenital heart </text>
<text top="625" left="190" width="196" height="13" font="8">disease. Circ J. 2010;74:1436-41. </text>
<text top="643" left="105" width="59" height="13" font="8">S3.16-19. </text>
<text top="643" left="190" width="570" height="13" font="8">Horigome H, Hiramatsu Y, Shigeta O, et al. Overproduction of platelet microparticles in cyanotic </text>
<text top="661" left="190" width="471" height="13" font="8">congenital heart disease with polycythemia. J Am Coll Cardiol. 2002;39:1072-7. </text>
<text top="678" left="105" width="59" height="13" font="8">S3.16-20. </text>
<text top="678" left="190" width="584" height="13" font="8">Tsui I, Shamsa K, Perloff JK, et al. Retinal vascular patterns in adults with cyanotic congenital heart </text>
<text top="696" left="190" width="262" height="13" font="8">disease. Semin Ophthalmol. 2009;24:262-5. </text>
<text top="714" left="105" width="59" height="13" font="8">S3.16-21. </text>
<text top="714" left="190" width="565" height="13" font="8">Dimopoulos K, Diller G-P, Koltsida E, et al. Prevalence, predictors, and prognostic value of renal </text>
<text top="732" left="190" width="487" height="13" font="8">dysfunction in adults with congenital heart disease. Circulation. 2008;117:2320-8. </text>
<text top="750" left="105" width="59" height="13" font="8">S3.16-22. </text>
<text top="750" left="190" width="570" height="13" font="8">Broberg CS, Van Woerkom RC, Swallow E, et al. Lung function and gas exchange in Eisenmenger </text>
<text top="768" left="190" width="534" height="13" font="8">syndrome and their impact on exercise capacity and survival. Int J Cardiol. 2014;171:73-7. </text>
<text top="785" left="105" width="59" height="13" font="8">S3.16-23. </text>
<text top="785" left="190" width="599" height="13" font="8">Broberg CS, Uebing A, Cuomo L, et al. Adult patients with Eisenmenger syndrome report flying safely </text>
<text top="803" left="190" width="297" height="13" font="8">on commercial airlines. Heart. 2007;93:1599-603. </text>
<text top="821" left="105" width="59" height="13" font="8">S3.16-24. </text>
<text top="821" left="190" width="579" height="13" font="8">Perloff JK, Child JS, Aboulhosn J, eds. Congenital Heart Disease in Adults. 3rd ed. Philadelphia, PA: </text>
<text top="839" left="190" width="150" height="13" font="8">Saunders/Elsevier; 2009. </text>
<text top="876" left="105" width="373" height="20" font="17"><b>3.17. Pharmacological Therapy for ACHD </b></text>
<text top="910" left="105" width="52" height="13" font="8">S3.17-1. </text>
<text top="910" left="190" width="585" height="13" font="8">Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA </text>
<text top="928" left="190" width="492" height="13" font="8">guideline for the management of heart failure: a report of the American College of </text>
<text top="945" left="190" width="568" height="13" font="8">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart </text>
<text top="963" left="190" width="347" height="13" font="8">Failure Society of America. Circulation. 2017;136:e137-61. </text>
<text top="981" left="105" width="52" height="13" font="8">S3.17-2. </text>
<text top="981" left="190" width="570" height="13" font="8">Doughan ARK, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in </text>
<text top="999" left="190" width="575" height="13" font="8">patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J </text>
<text top="1017" left="190" width="142" height="13" font="8">Cardiol. 2007;99:704-6. </text>
<text top="1034" left="105" width="52" height="13" font="8">S3.17-3. </text>
<text top="1034" left="190" width="584" height="13" font="8">Dos L, Pujadas S, Estruch M, et al. Eplerenone in systemic right ventricle: double blind randomized </text>
<text top="1052" left="190" width="381" height="13" font="8">clinical trial. The EVEDES Study. Int J Cardiol. 2013;168:5167-73. </text>
<text top="1070" left="105" width="52" height="13" font="8">S3.17-4. </text>
<text top="1070" left="190" width="549" height="13" font="8">van der Bom T, Winter MM, Bouma BJ, et al. Effect of valsartan on systemic right ventricular </text>
<text top="1088" left="190" width="583" height="13" font="8">function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127:322-30. </text>
</page>
<page number="151" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 153 </text>
<text top="162" left="105" width="52" height="13" font="8">S3.17-5. </text>
<text top="162" left="190" width="595" height="13" font="8">Dore A, Houde C, Chan K-L, et al. Angiotensin receptor blockade and exercise capacity in adults with </text>
<text top="180" left="190" width="576" height="13" font="8">systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. </text>
<text top="198" left="190" width="108" height="13" font="8">2005;112:2411-6. </text>
<text top="215" left="105" width="52" height="13" font="8">S3.17-6. </text>
<text top="215" left="190" width="599" height="13" font="8">Babu-Narayan SV, Uebing A, Davlouros PA, et al. Randomised trial of ramipril in repaired tetralogy of </text>
<text top="233" left="190" width="598" height="13" font="8">Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention </text>
<text top="251" left="190" width="599" height="13" font="8">Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot). Int </text>
<text top="269" left="190" width="172" height="13" font="8">J Cardiol. 2012;154:299-305. </text>
<text top="286" left="105" width="52" height="13" font="8">S3.17-7. </text>
<text top="286" left="190" width="534" height="13" font="8">Lester SJ, McElhinney DB, Viloria E, et al. Effects of losartan in patients with a systemically </text>
<text top="304" left="190" width="594" height="13" font="8">functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J </text>
<text top="322" left="190" width="150" height="13" font="8">Cardiol. 2001;88:1314-6. </text>
<text top="340" left="105" width="52" height="13" font="8">S3.17-8. </text>
<text top="340" left="190" width="589" height="13" font="8">Hechter SJ, Fredriksen PM, Liu P, et al. Angiotensin-converting enzyme inhibitors in adults after the </text>
<text top="358" left="190" width="326" height="13" font="8">Mustard procedure. Am J Cardiol. 2001;87:660-3, A11. </text>
<text top="375" left="105" width="52" height="13" font="8">S3.17-9. </text>
<text top="375" left="190" width="568" height="13" font="8">Therrien J, Provost Y, Harrison J, et al. Effect of angiotensin receptor blockade on systemic right </text>
<text top="393" left="190" width="533" height="13" font="8">ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. </text>
<text top="411" left="190" width="108" height="13" font="8">2008;129:187-92. </text>
<text top="429" left="105" width="59" height="13" font="8">S3.17-10. </text>
<text top="429" left="190" width="593" height="13" font="8">Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: </text>
<text top="447" left="190" width="573" height="13" font="8">a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48-54. </text>
<text top="465" left="105" width="59" height="13" font="8">S3.17-11. </text>
<text top="465" left="190" width="583" height="13" font="8">Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on haemodynamic response to exercise </text>
<text top="482" left="190" width="416" height="13" font="8">and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681-7. </text>
<text top="500" left="105" width="59" height="13" font="8">S3.17-12. </text>
<text top="500" left="190" width="572" height="13" font="8">Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and </text>
<text top="518" left="190" width="562" height="13" font="8">adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in </text>
<text top="536" left="190" width="575" height="13" font="8">Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen </text>
<text top="554" left="190" width="313" height="13" font="8">Consumption) study. Circulation. 2014;130:2021-30. </text>
<text top="572" left="105" width="59" height="13" font="8">S3.17-13. </text>
<text top="572" left="190" width="560" height="13" font="8">Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in </text>
<text top="589" left="190" width="544" height="13" font="8">children and young adults after the Fontan operation: a randomized, double-blind, placebo-</text>
<text top="607" left="190" width="345" height="13" font="8">controlled, crossover trial. Circulation. 2011;123:1185-93. </text>
<text top="654" left="105" width="179" height="21" font="10"><b>4. Specific Lesions </b></text>
<text top="699" left="105" width="169" height="20" font="17"><b>4.1. Shunt Lesions </b></text>
<text top="743" left="105" width="222" height="19" font="34"><b>4.1.1. Atrial Septal Defect </b></text>
<text top="775" left="105" width="55" height="13" font="8">S4.1.1-1. </text>
<text top="775" left="190" width="554" height="13" font="8">Oster M, Bhatt A, Zaragoza-Macias E, et al. Interventional therapy versus medical therapy for </text>
<text top="793" left="190" width="587" height="13" font="8">secundum atrial septal defect: a systematic review (part 2) for the 2018 AHA/ACC guideline for the </text>
<text top="811" left="190" width="531" height="13" font="8">management of adults with congenital heart disease: a report of the American College of </text>
<text top="829" left="190" width="594" height="13" font="8">Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; </text>
<text top="847" left="190" width="53" height="13" font="8">In press. </text>
<text top="864" left="105" width="55" height="13" font="8">S4.1.1-2. </text>
<text top="864" left="190" width="554" height="13" font="8">Ammash NM, Seward JB, Warnes CA, et al. Partial anomalous pulmonary venous connection: </text>
<text top="882" left="190" width="497" height="13" font="8">diagnosis by transesophageal echocardiography. J Am Coll Cardiol. 1997;29:1351-8. </text>
<text top="900" left="105" width="55" height="13" font="8">S4.1.1-3. </text>
<text top="900" left="190" width="573" height="13" font="8">Haramati LB, Moche IE, Rivera VT, et al. Computed tomography of partial anomalous pulmonary </text>
<text top="918" left="190" width="415" height="13" font="8">venous connection in adults. J Comput Assist Tomogr. 2003;27:743-9. </text>
<text top="936" left="105" width="55" height="13" font="8">S4.1.1-4. </text>
<text top="936" left="190" width="552" height="13" font="8">Nordmeyer S, Berger F, Kuehne T, et al. Flow-sensitive four-dimensional magnetic resonance </text>
<text top="953" left="190" width="570" height="13" font="8">imaging facilitates and improves the accurate diagnosis of partial anomalous pulmonary venous </text>
<text top="971" left="190" width="249" height="13" font="8">drainage. Cardiol Young. 2011;21:528-35. </text>
<text top="989" left="105" width="55" height="13" font="8">S4.1.1-5. </text>
<text top="989" left="190" width="589" height="13" font="8">Kardon RE, Sokoloski MC, Levi DS, et al. Transthoracic echocardiographic guidance of transcatheter </text>
<text top="1007" left="190" width="345" height="13" font="8">atrial septal defect closure. Am J Cardiol. 2004;94:256-60. </text>
<text top="1025" left="105" width="55" height="13" font="8">S4.1.1-6. </text>
<text top="1025" left="190" width="551" height="13" font="8">Zanchetta M, Rigatelli G, Pedon L, et al. Transcatheter atrial septal defect closure assisted by </text>
<text top="1043" left="190" width="474" height="13" font="8">intracardiac echocardiography: 3-year follow-up. J Interv Cardiol. 2004;17:95-8. </text>
<text top="1060" left="105" width="55" height="13" font="8">S4.1.1-7. </text>
<text top="1060" left="190" width="597" height="13" font="8">Attie F, Rosas M, Granados N, et al. Surgical treatment for secundum atrial septal defects in patients </text>
<text top="1078" left="190" width="460" height="13" font="8">&gt;40 years old. A randomized clinical trial. J Am Coll Cardiol. 2001;38:2035-42. </text>
</page>
<page number="152" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 154 </text>
<text top="162" left="105" width="55" height="13" font="8">S4.1.1-8. </text>
<text top="162" left="190" width="580" height="13" font="8">Brochu M-C, Baril J-F, Dore A, et al. Improvement in exercise capacity in asymptomatic and mildly </text>
<text top="179" left="190" width="580" height="13" font="8">symptomatic adults after atrial septal defect percutaneous closure. Circulation. 2002;106:1821-6. </text>
<text top="197" left="105" width="55" height="13" font="8">S4.1.1-9. </text>
<text top="197" left="190" width="581" height="13" font="8">Shah D, Azhar M, Oakley CM, et al. Natural history of secundum atrial septal defect in adults after </text>
<text top="215" left="190" width="520" height="13" font="8">medical or surgical treatment: a historical prospective study. Br Heart J. 1994;71:224-7. </text>
<text top="233" left="105" width="62" height="13" font="8">S4.1.1-10. </text>
<text top="233" left="190" width="542" height="13" font="8">Roos-Hesselink JW, Meijboom FJ, Spitaels SEC, et al. Excellent survival and low incidence of </text>
<text top="251" left="190" width="533" height="13" font="8">arrhythmias, stroke and heart failure long-term after surgical ASD closure at young age. A </text>
<text top="269" left="190" width="425" height="13" font="8">prospective follow-up study of 21-33 years. Eur Heart J. 2003;24:190-7. </text>
<text top="286" left="105" width="62" height="13" font="8">S4.1.1-11. </text>
<text top="286" left="190" width="597" height="13" font="8">Altındag T, Roos-Hesselink JW, Cuypers JA, et al. Transcatheter device closure of atrial septal defects </text>
<text top="304" left="190" width="397" height="13" font="8">in patients aged 40 years and older. Neth Heart J. 2010;18:537-42. </text>
<text top="322" left="105" width="62" height="13" font="8">S4.1.1-12. </text>
<text top="322" left="190" width="590" height="13" font="8">Varma C, Benson LN, Silversides C, et al. Outcomes and alternative techniques for device closure of </text>
<text top="340" left="190" width="497" height="13" font="8">the large secundum atrial septal defect. Catheter Cardiovasc Interv. 2004;61:131-9. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.1.1-13. </text>
<text top="358" left="190" width="582" height="13" font="8">Du Z-D, Cao Q-L, Rhodes J, et al. Choice of device size and results of transcatheter closure of atrial </text>
<text top="375" left="190" width="494" height="13" font="8">septal defect using the amplatzer septal occluder. J Interv Cardiol. 2002;15:287-92. </text>
<text top="393" left="105" width="62" height="13" font="8">S4.1.1-14. </text>
<text top="393" left="190" width="594" height="13" font="8">Gajjar TP, Hiremath CS, Desai NB. Surgical closure of sinus venosus atrial septal defect using a single </text>
<text top="411" left="190" width="389" height="13" font="8">patch—transcaval repair technique. J Card Surg. 2011;26:429-34. </text>
<text top="429" left="105" width="62" height="13" font="8">S4.1.1-15. </text>
<text top="429" left="190" width="572" height="13" font="8">Du Z-D, Hijazi ZM, Kleinman CS, et al. Comparison between transcatheter and surgical closure of </text>
<text top="447" left="190" width="591" height="13" font="8">secundum atrial septal defect in children and adults: results of a multicenter nonrandomized trial. J </text>
<text top="465" left="190" width="206" height="13" font="8">Am Coll Cardiol. 2002;39:1836-44. </text>
<text top="482" left="105" width="62" height="13" font="8">S4.1.1-16. </text>
<text top="482" left="190" width="565" height="13" font="8">Du Z-D, Koenig P, Cao Q-L, et al. Comparison of transcatheter closure of secundum atrial septal </text>
<text top="500" left="190" width="571" height="13" font="8">defect using the Amplatzer septal occluder associated with deficient versus sufficient rims. Am J </text>
<text top="518" left="190" width="142" height="13" font="8">Cardiol. 2002;90:865-9. </text>
<text top="536" left="105" width="62" height="13" font="8">S4.1.1-17. </text>
<text top="536" left="190" width="597" height="13" font="8">Lopez K, Dalvi BV, Balzer D, et al. Transcatheter closure of large secundum atrial septal defects using </text>
<text top="554" left="190" width="561" height="13" font="8">the 40 mm Amplatzer septal occluder: results of an international registry. Catheter Cardiovasc </text>
<text top="572" left="190" width="135" height="13" font="8">Interv. 2005;66:580-4. </text>
<text top="589" left="105" width="62" height="13" font="8">S4.1.1-18. </text>
<text top="589" left="190" width="547" height="13" font="8">Amin Z, Hijazi ZM, Bass JL, et al. Erosion of Amplatzer septal occluder device after closure of </text>
<text top="607" left="190" width="550" height="13" font="8">secundum atrial septal defects: review of registry of complications and recommendations to </text>
<text top="625" left="190" width="398" height="13" font="8">minimize future risk. Catheter Cardiovasc Interv. 2004;63:496-502. </text>
<text top="643" left="105" width="62" height="13" font="8">S4.1.1-19. </text>
<text top="643" left="190" width="577" height="13" font="8">Bradley EA, Chakinala M, Billadello JJ. Usefulness of medical therapy for pulmonary hypertension </text>
<text top="661" left="190" width="428" height="13" font="8">and delayed atrial septal defect closure. Am J Cardiol. 2013;112:1471-6. </text>
<text top="678" left="105" width="62" height="13" font="8">S4.1.1-20. </text>
<text top="678" left="190" width="570" height="13" font="8">Cho YH, Jun T-G, Yang J-H, et al. Surgical strategy in patients with atrial septal defect and severe </text>
<text top="696" left="190" width="366" height="13" font="8">pulmonary hypertension. Heart Surg Forum. 2012;15:E111-5. </text>
<text top="714" left="105" width="62" height="13" font="8">S4.1.1-21. </text>
<text top="714" left="190" width="559" height="13" font="8">Kouchoukos NT, Blackstone EH, Kirklin JW. Surgical implications of pulmonary hypertension in </text>
<text top="732" left="190" width="308" height="13" font="8">congenital heart disease. Adv Cardiol. 1978;225-31. </text>
<text top="750" left="105" width="62" height="13" font="8">S4.1.1-22. </text>
<text top="750" left="190" width="570" height="13" font="8">Shohtsu A, Takeuchi S, Inoue T. Surgical indications and results for congenital cardiac anomalies </text>
<text top="768" left="190" width="585" height="13" font="8">associated with left to right shunt and severe pulmonary hypertension. Jpn Circ J. 1976;40:629-32. </text>
<text top="785" left="105" width="62" height="13" font="8">S4.1.1-23. </text>
<text top="785" left="190" width="582" height="13" font="8">Cartmill TB, DuShane JW, McGoon DC, et al. Results of repair of ventricular septal defect. J Thorac </text>
<text top="803" left="190" width="209" height="13" font="8">Cardiovasc Surg. 1966;52:486-501. </text>
<text top="821" left="105" width="62" height="13" font="8">S4.1.1-24. </text>
<text top="821" left="190" width="598" height="13" font="8">Karamlou T, Diggs BS, Person T, et al. National practice patterns for management of adult congenital </text>
<text top="839" left="190" width="555" height="13" font="8">heart disease: operation by pediatric heart surgeons decreases in-hospital death. Circulation. </text>
<text top="857" left="190" width="115" height="13" font="8">2008;118:2345-52. </text>
<text top="874" left="105" width="62" height="13" font="8">S4.1.1-25. </text>
<text top="874" left="190" width="599" height="13" font="8">Karamlou T, Diggs BS, Ungerleider RM, et al. Adults or big kids: what is the ideal clinical environment </text>
<text top="892" left="190" width="520" height="13" font="8">for management of grown-up patients with congenital heart disease? Ann Thorac Surg. </text>
<text top="910" left="190" width="93" height="13" font="8">2010;90:573-9. </text>
<text top="928" left="105" width="62" height="13" font="8">S4.1.1-26. </text>
<text top="928" left="190" width="566" height="13" font="8">D’Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial </text>
<text top="946" left="190" width="400" height="13" font="8">hypertension after shunt closure. Int J Cardiol. 2013;168:3797-801. </text>
<text top="983" left="105" width="428" height="19" font="34"><b>4.1.2. Anomalous Pulmonary Venous Connections </b></text>
<text top="1015" left="105" width="55" height="13" font="8">S4.1.2-1. </text>
<text top="1015" left="190" width="595" height="13" font="8">Festa P, Ait-Ali L, Cerillo AG, et al. Magnetic resonance imaging is the diagnostic tool of choice in the </text>
<text top="1033" left="190" width="539" height="13" font="8">preoperative evaluation of patients with partial anomalous pulmonary venous return. Int J </text>
<text top="1051" left="190" width="222" height="13" font="8">Cardiovasc Imaging. 2006;22:685-93. </text>
</page>
<page number="153" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 155 </text>
<text top="162" left="105" width="55" height="13" font="8">S4.1.2-2. </text>
<text top="162" left="190" width="552" height="13" font="8">Nordmeyer S, Berger F, Kuehne T, et al. Flow-sensitive four-dimensional magnetic resonance </text>
<text top="179" left="190" width="570" height="13" font="8">imaging facilitates and improves the accurate diagnosis of partial anomalous pulmonary venous </text>
<text top="197" left="190" width="249" height="13" font="8">drainage. Cardiol Young. 2011;21:528-35. </text>
<text top="215" left="105" width="55" height="13" font="8">S4.1.2-3. </text>
<text top="215" left="190" width="597" height="13" font="8">Dyme JL, Prakash A, Printz BF, et al. Physiology of isolated anomalous pulmonary venous connection </text>
<text top="233" left="190" width="569" height="13" font="8">of a single pulmonary vein as determined by cardiac magnetic resonance imaging. Am J Cardiol. </text>
<text top="251" left="190" width="101" height="13" font="8">2006;98:107-10. </text>
<text top="269" left="105" width="55" height="13" font="8">S4.1.2-4. </text>
<text top="269" left="190" width="573" height="13" font="8">Haramati LB, Moche IE, Rivera VT, et al. Computed tomography of partial anomalous pulmonary </text>
<text top="286" left="190" width="415" height="13" font="8">venous connection in adults. J Comput Assist Tomogr. 2003;27:743-9. </text>
<text top="304" left="105" width="55" height="13" font="8">S4.1.2-5. </text>
<text top="304" left="190" width="533" height="13" font="8">Majdalany DS, Phillips SD, Dearani JA, et al. Isolated partial anomalous pulmonary venous </text>
<text top="322" left="190" width="492" height="13" font="8">connections in adults: twenty-year experience. Congenit Heart Dis. 2010;5:537-45. </text>
<text top="340" left="105" width="55" height="13" font="8">S4.1.2-6. </text>
<text top="340" left="190" width="595" height="13" font="8">Sachweh JS, Daebritz SH, Hermanns B, et al. Hypertensive pulmonary vascular disease in adults with </text>
<text top="358" left="190" width="489" height="13" font="8">secundum or sinus venosus atrial septal defect. Ann Thorac Surg. 2006;81:207-13. </text>
<text top="375" left="105" width="55" height="13" font="8">S4.1.2-7. </text>
<text top="375" left="190" width="596" height="13" font="8">Jemielity M, Perek B, Paluszkiewicz L, et al. Results of repair of partial anomalous pulmonary venous </text>
<text top="393" left="190" width="543" height="13" font="8">connection and sinus venosus atrial septal defect in adults. J Heart Valve Dis. 1998;7:410-4. </text>
<text top="411" left="105" width="55" height="13" font="8">S4.1.2-8. </text>
<text top="411" left="190" width="565" height="13" font="8">Dusenbery SM, Geva T, Seale A, et al. Outcome predictors and implications for management of </text>
<text top="429" left="190" width="289" height="13" font="8">scimitar syndrome. Am Heart J. 2013;165:770-7. </text>
<text top="447" left="105" width="55" height="13" font="8">S4.1.2-9. </text>
<text top="447" left="190" width="567" height="13" font="8">Brink J, Yong MS, d’Udekem Y, et al. Surgery for scimitar syndrome: the Melbourne experience. </text>
<text top="465" left="190" width="280" height="13" font="8">Interact Cardiovasc Thorac Surg. 2015;20:31-4. </text>
<text top="482" left="105" width="62" height="13" font="8">S4.1.2-10. </text>
<text top="482" left="190" width="567" height="13" font="8">Alsoufi B, Cai S, Van Arsdell GS, et al. Outcomes after surgical treatment of children with partial </text>
<text top="500" left="190" width="461" height="13" font="8">anomalous pulmonary venous connection. Ann Thorac Surg. 2007;84:2020-6. </text>
<text top="518" left="105" width="62" height="13" font="8">S4.1.2-11. </text>
<text top="518" left="190" width="554" height="13" font="8">Ammash NM, Seward JB, Warnes CA, et al. Partial anomalous pulmonary venous connection: </text>
<text top="536" left="190" width="497" height="13" font="8">diagnosis by transesophageal echocardiography. J Am Coll Cardiol. 1997;29:1351-8. </text>
<text top="554" left="105" width="62" height="13" font="8">S4.1.2-12. </text>
<text top="554" left="190" width="579" height="13" font="8">Warden HE, Gustafson RA, Tarnay TJ, et al. An alternative method for repair of partial anomalous </text>
<text top="572" left="190" width="538" height="13" font="8">pulmonary venous connection to the superior vena cava. Ann Thorac Surg. 1984;38:601-5. </text>
<text top="608" left="105" width="269" height="19" font="34"><b>4.1.3. Ventricular Septal Defect </b></text>
<text top="641" left="105" width="55" height="13" font="8">S4.1.3-1. </text>
<text top="641" left="190" width="583" height="13" font="8">Corone P, Doyon F, Gaudeau S, et al. Natural history of ventricular septal defect. A study involving </text>
<text top="658" left="190" width="236" height="13" font="8">790 cases. Circulation. 1977;55:908-15. </text>
<text top="676" left="105" width="55" height="13" font="8">S4.1.3-2. </text>
<text top="676" left="190" width="579" height="13" font="8">Yoshimura N, Hori Y, Horii Y, et al. Comparison of magnetic resonance imaging with transthoracic </text>
<text top="694" left="190" width="589" height="13" font="8">echocardiography in the diagnosis of ventricular septal defect-associated coronary cusp prolapse. J </text>
<text top="712" left="190" width="246" height="13" font="8">Magn Reson Imaging. 2010;32:1099-103. </text>
<text top="730" left="105" width="55" height="13" font="8">S4.1.3-3. </text>
<text top="730" left="190" width="586" height="13" font="8">Wu M-H, Wang J-K, Lin M-T, et al. Ventricular septal defect with secondary left ventricular-to-right </text>
<text top="748" left="190" width="566" height="13" font="8">atrial shunt is associated with a higher risk for infective endocarditis and a lower late chance of </text>
<text top="765" left="190" width="223" height="13" font="8">closure. Pediatrics. 2006;117:e262-7. </text>
<text top="783" left="105" width="55" height="13" font="8">S4.1.3-4. </text>
<text top="783" left="190" width="566" height="13" font="8">D’Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial </text>
<text top="801" left="190" width="400" height="13" font="8">hypertension after shunt closure. Int J Cardiol. 2013;168:3797-801. </text>
<text top="819" left="105" width="55" height="13" font="8">S4.1.3-5. </text>
<text top="819" left="190" width="556" height="13" font="8">Janjua AM, Saleem K, Khan I, et al. Double flap patch closure of VSD with elevated pulmonary </text>
<text top="837" left="190" width="555" height="13" font="8">vascular resistance: an experience at AFIC/NIHD. J Coll Physicians Surg Pak. 2011;21:197-201. </text>
<text top="854" left="105" width="55" height="13" font="8">S4.1.3-6. </text>
<text top="854" left="190" width="576" height="13" font="8">Talwar S, Keshri VK, Choudhary SK, et al. Unidirectional valved patch closure of ventricular septal </text>
<text top="872" left="190" width="592" height="13" font="8">defects with severe pulmonary arterial hypertension: hemodynamic outcomes. J Thorac Cardiovasc </text>
<text top="890" left="190" width="141" height="13" font="8">Surg. 2014;148:2570-5. </text>
<text top="908" left="105" width="55" height="13" font="8">S4.1.3-7. </text>
<text top="908" left="190" width="559" height="13" font="8">Kouchoukos NT, Blackstone EH, Kirklin JW. Surgical implications of pulmonary hypertension in </text>
<text top="926" left="190" width="308" height="13" font="8">congenital heart disease. Adv Cardiol. 1978;225-31. </text>
<text top="944" left="105" width="55" height="13" font="8">S4.1.3-8. </text>
<text top="944" left="190" width="570" height="13" font="8">Shohtsu A, Takeuchi S, Inoue T. Surgical indications and results for congenital cardiac anomalies </text>
<text top="961" left="190" width="585" height="13" font="8">associated with left to right shunt and severe pulmonary hypertension. Jpn Circ J. 1976;40:629-32. </text>
<text top="979" left="105" width="55" height="13" font="8">S4.1.3-9. </text>
<text top="979" left="190" width="582" height="13" font="8">Cartmill TB, DuShane JW, McGoon DC, et al. Results of repair of ventricular septal defect. J Thorac </text>
<text top="997" left="190" width="209" height="13" font="8">Cardiovasc Surg. 1966;52:486-501. </text>
<text top="1015" left="105" width="62" height="13" font="8">S4.1.3-10. </text>
<text top="1015" left="190" width="601" height="13" font="8">Frontera-Izquierdo P, Cabezuelo-Huerta G. Natural and modified history of complete atrioventricular </text>
<text top="1033" left="190" width="369" height="13" font="8">septal defect—a 17 year study. Arch Dis Child. 1990;65:964-6. </text>
<text top="1051" left="105" width="62" height="13" font="8">S4.1.3-11. </text>
<text top="1051" left="190" width="561" height="13" font="8">Schwedler G, Lindinger A, Lange PE, et al. Frequency and spectrum of congenital heart defects </text>
<text top="1068" left="190" width="579" height="13" font="8">among live births in Germany : a study of the Competence Network for Congenital Heart Defects. </text>
<text top="1086" left="190" width="207" height="13" font="8">Clin Res Cardiol. 2011;100:1111-7. </text>
</page>
<page number="154" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 156 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.1.3-12. </text>
<text top="162" left="190" width="547" height="13" font="8">van der Linde D, Konings EEM, Slager MA, et al. Birth prevalence of congenital heart disease </text>
<text top="180" left="190" width="511" height="13" font="8">worldwide: a systematic review and meta-analysis. J Am Coll Cardiol. 2011;58:2241-7. </text>
<text top="198" left="105" width="62" height="13" font="8">S4.1.3-13. </text>
<text top="198" left="190" width="547" height="13" font="8">Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in </text>
<text top="215" left="190" width="368" height="13" font="8">metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807-13. </text>
<text top="233" left="105" width="62" height="13" font="8">S4.1.3-14. </text>
<text top="233" left="190" width="576" height="13" font="8">Wu M-H, Chen H-C, Lu C-W, et al. Prevalence of congenital heart disease at live birth in Taiwan. J </text>
<text top="251" left="190" width="151" height="13" font="8">Pediatr. 2010;156:782-5. </text>
<text top="269" left="105" width="62" height="13" font="8">S4.1.3-15. </text>
<text top="269" left="190" width="601" height="13" font="8">Mattila S, Kostiainen S, Kyllönen KE, et al. Repair of ventricular septal defect in adults. Scand J Thorac </text>
<text top="287" left="190" width="194" height="13" font="8">Cardiovasc Surg. 1985;19:29-31. </text>
<text top="305" left="105" width="62" height="13" font="8">S4.1.3-16. </text>
<text top="304" left="190" width="578" height="13" font="8">El Said HG, Bratincsak A, Gordon BM, et al. Closure of perimembranous ventricular septal defects </text>
<text top="322" left="190" width="566" height="13" font="8">with aneurysmal tissue using the Amplazter Duct Occluder I: lessons learned and medium term </text>
<text top="340" left="190" width="336" height="13" font="8">follow up. Catheter Cardiovasc Interv. 2012;80:895-903. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.1.3-17. </text>
<text top="358" left="190" width="559" height="13" font="8">Masura J, Gao W, Gavora P, et al. Percutaneous closure of perimembranous ventricular septal </text>
<text top="375" left="190" width="534" height="13" font="8">defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol. </text>
<text top="393" left="190" width="93" height="13" font="8">2005;26:216-9. </text>
<text top="411" left="105" width="62" height="13" font="8">S4.1.3-18. </text>
<text top="411" left="190" width="500" height="13" font="8">Tatsuno K, Konno S, Sakakibara S. Ventricular septal defect with aortic insufficiency. </text>
<text top="429" left="190" width="478" height="13" font="8">Angiocardiographic aspects and a new classification. Am Heart J. 1973;85:13-21. </text>
<text top="447" left="105" width="62" height="13" font="8">S4.1.3-19. </text>
<text top="447" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="465" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="482" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="519" left="105" width="310" height="19" font="34"><b>4.1.4. Atrioventricular Septal Defect </b></text>
<text top="552" left="105" width="55" height="13" font="8">S4.1.4-1. </text>
<text top="552" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="569" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="587" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="605" left="105" width="55" height="13" font="8">S4.1.4-2. </text>
<text top="605" left="190" width="534" height="13" font="8">Bianchi G, Bevilacqua S, Solinas M, et al. In adult patients undergoing redo surgery for left </text>
<text top="623" left="190" width="577" height="13" font="8">atrioventricular valve regurgitation after atrioventricular septal defect correction, is replacement </text>
<text top="641" left="190" width="410" height="13" font="8">superior to repair? Interact Cardiovasc Thorac Surg. 2011;12:1033-9. </text>
<text top="658" left="105" width="55" height="13" font="8">S4.1.4-3. </text>
<text top="658" left="190" width="571" height="13" font="8">Hoohenkerk GJF, Bruggemans EF, Koolbergen DR, et al. Long-term results of reoperation for left </text>
<text top="676" left="190" width="579" height="13" font="8">atrioventricular valve regurgitation after correction of atrioventricular septal defects. Ann Thorac </text>
<text top="694" left="190" width="134" height="13" font="8">Surg. 2012;93:849-55. </text>
<text top="712" left="105" width="55" height="13" font="8">S4.1.4-4. </text>
<text top="712" left="190" width="512" height="13" font="8">Stulak JM, Burkhart HM, Dearani JA. Reoperations after repair of partial and complete </text>
<text top="730" left="190" width="493" height="13" font="8">atrioventricular septal defect. World J Pediatr Congenit Heart Surg. 2010;1:97-104. </text>
<text top="748" left="105" width="55" height="13" font="8">S4.1.4-5. </text>
<text top="748" left="190" width="559" height="13" font="8">Kouchoukos NT, Blackstone EH, Kirklin JW. Surgical implications of pulmonary hypertension in </text>
<text top="765" left="190" width="308" height="13" font="8">congenital heart disease. Adv Cardiol. 1978;225-31. </text>
<text top="783" left="105" width="55" height="13" font="8">S4.1.4-6. </text>
<text top="783" left="190" width="570" height="13" font="8">Shohtsu A, Takeuchi S, Inoue T. Surgical indications and results for congenital cardiac anomalies </text>
<text top="801" left="190" width="585" height="13" font="8">associated with left to right shunt and severe pulmonary hypertension. Jpn Circ J. 1976;40:629-32. </text>
<text top="819" left="105" width="55" height="13" font="8">S4.1.4-7. </text>
<text top="819" left="190" width="561" height="13" font="8">Rastelli G, Kirklin JW, Titus JL. Anatomic observations on complete form of persistent common </text>
<text top="837" left="190" width="594" height="13" font="8">atrioventricular canal with special reference to atrioventricular valves. Mayo Clin Proc. 1966;41:296-</text>
<text top="854" left="190" width="29" height="13" font="8">308. </text>
<text top="872" left="105" width="55" height="13" font="8">S4.1.4-8. </text>
<text top="872" left="190" width="560" height="13" font="8">Rastelli GC, Weidman WH, Kirklin JW. Surgical repair of the partial form of persistent common </text>
<text top="890" left="190" width="541" height="13" font="8">atrioventricular canal, with special reference to the problem of mitral valve incompetence. </text>
<text top="908" left="190" width="216" height="13" font="8">Circulation. 1965;31(suppl 1):131-5. </text>
<text top="926" left="105" width="55" height="13" font="8">S4.1.4-9. </text>
<text top="926" left="190" width="596" height="13" font="8">Borkon AM, Pieroni DR, Varghese PJ, et al. The superior QRS axis in ostium primum ASD: a proposed </text>
<text top="944" left="190" width="248" height="13" font="8">mechanism. Am Heart J. 1975;90:215-21. </text>
<text top="961" left="105" width="62" height="13" font="8">S4.1.4-10. </text>
<text top="961" left="190" width="543" height="13" font="8">Liberman L, Pass RH, Hordof AJ, et al. Late onset of heart block after open heart surgery for </text>
<text top="979" left="190" width="332" height="13" font="8">congenital heart disease. Pediatr Cardiol. 2008;29:56-9. </text>
<text top="997" left="105" width="62" height="13" font="8">S4.1.4-11. </text>
<text top="997" left="190" width="597" height="13" font="8">Attie F, Rosas M, Granados N, et al. Surgical treatment for secundum atrial septal defects in patients </text>
<text top="1015" left="190" width="460" height="13" font="8">&gt;40 years old. A randomized clinical trial. J Am Coll Cardiol. 2001;38:2035-42. </text>
<text top="1033" left="105" width="62" height="13" font="8">S4.1.4-12. </text>
<text top="1033" left="190" width="580" height="13" font="8">Brochu M-C, Baril J-F, Dore A, et al. Improvement in exercise capacity in asymptomatic and mildly </text>
<text top="1051" left="190" width="580" height="13" font="8">symptomatic adults after atrial septal defect percutaneous closure. Circulation. 2002;106:1821-6. </text>
<text top="1068" left="105" width="62" height="13" font="8">S4.1.4-13. </text>
<text top="1068" left="190" width="583" height="13" font="8">Corone P, Doyon F, Gaudeau S, et al. Natural history of ventricular septal defect. A study involving </text>
<text top="1086" left="190" width="236" height="13" font="8">790 cases. Circulation. 1977;55:908-15. </text>
</page>
<page number="155" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 157 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.1.4-14. </text>
<text top="162" left="190" width="579" height="13" font="8">Oliver JM, González A, Gallego P, et al. Discrete subaortic stenosis in adults: increased prevalence </text>
<text top="180" left="190" width="536" height="13" font="8">and slow rate of progression of the obstruction and aortic regurgitation. J Am Coll Cardiol. </text>
<text top="198" left="190" width="101" height="13" font="8">2001;38:835-42. </text>
<text top="215" left="105" width="62" height="13" font="8">S4.1.4-15. </text>
<text top="215" left="190" width="597" height="13" font="8">Trinchero R, Demarie D, Orzan F, et al. Fixed subaortic stenosis. Natural history of patients with mild </text>
<text top="233" left="190" width="471" height="13" font="8">obstruction and follow-up of operated patients. G Ital Cardiol. 1988;18:738-44. </text>
<text top="251" left="105" width="62" height="13" font="8">S4.1.4-16. </text>
<text top="251" left="190" width="599" height="13" font="8">Brodyn NE, Haft JI. Chest pain secondary to membranous subaortic stenosis in a young woman. J Am </text>
<text top="269" left="190" width="229" height="13" font="8">Osteopath Assoc. 1992;92:1532, 9-41. </text>
<text top="286" left="105" width="62" height="13" font="8">S4.1.4-17. </text>
<text top="286" left="190" width="597" height="13" font="8">McMahon CJ, Gauvreau K, Edwards JC, et al. Risk factors for aortic valve dysfunction in children with </text>
<text top="304" left="190" width="384" height="13" font="8">discrete subvalvar aortic stenosis. Am J Cardiol. 2004;94:459-64. </text>
<text top="322" left="105" width="62" height="13" font="8">S4.1.4-18. </text>
<text top="322" left="190" width="601" height="13" font="8">Frontera-Izquierdo P, Cabezuelo-Huerta G. Natural and modified history of complete atrioventricular </text>
<text top="340" left="190" width="369" height="13" font="8">septal defect—a 17 year study. Arch Dis Child. 1990;65:964-6. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.1.4-19. </text>
<text top="358" left="190" width="569" height="13" font="8">Bando K, Turrentine MW, Sun K, et al. Surgical management of complete atrioventricular septal </text>
<text top="375" left="190" width="478" height="13" font="8">defects. A twenty-year experience. J Thorac Cardiovasc Surg. 1995;110:1543-52. </text>
<text top="412" left="105" width="269" height="19" font="34"><b>4.1.5. Patent Ductus Arteriosus </b></text>
<text top="445" left="105" width="55" height="13" font="8">S4.1.5-1. </text>
<text top="445" left="190" width="534" height="13" font="8">Yan C, Zhao S, Jiang S, et al. Transcatheter closure of patent ductus arteriosus with severe </text>
<text top="462" left="190" width="387" height="13" font="8">pulmonary arterial hypertension in adults. Heart. 2007;93:514-8. </text>
<text top="480" left="105" width="55" height="13" font="8">S4.1.5-2. </text>
<text top="480" left="190" width="580" height="13" font="8">Gamboa R, Rios-Méndez RE, Mollón FP, et al. Percutaneous closure of patent ductus arteriosus in </text>
<text top="498" left="190" width="372" height="13" font="8">adults using different devices. Rev Esp Cardiol. 2010;63:726-9. </text>
<text top="516" left="105" width="55" height="13" font="8">S4.1.5-3. </text>
<text top="516" left="190" width="591" height="13" font="8">Jeong Y-H, Yun T-J, Song J-M, et al. Left ventricular remodeling and change of systolic function after </text>
<text top="534" left="190" width="592" height="13" font="8">closure of patent ductus arteriosus in adults: device and surgical closure. Am Heart J. 2007;154:436-</text>
<text top="552" left="190" width="22" height="13" font="8">40. </text>
<text top="569" left="105" width="55" height="13" font="8">S4.1.5-4. </text>
<text top="569" left="190" width="600" height="13" font="8">Zabal C, García-Montes JA, Buendía-Hernández A, et al. Percutaneous closure of hypertensive ductus </text>
<text top="587" left="190" width="200" height="13" font="8">arteriosus. Heart. 2010;96:625-9. </text>
<text top="605" left="105" width="55" height="13" font="8">S4.1.5-5. </text>
<text top="605" left="190" width="559" height="13" font="8">Kouchoukos NT, Blackstone EH, Kirklin JW. Surgical implications of pulmonary hypertension in </text>
<text top="623" left="190" width="308" height="13" font="8">congenital heart disease. Adv Cardiol. 1978;225-31. </text>
<text top="641" left="105" width="55" height="13" font="8">S4.1.5-6. </text>
<text top="641" left="190" width="547" height="13" font="8">Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in </text>
<text top="658" left="190" width="368" height="13" font="8">metropolitan Atlanta, 1998-2005. J Pediatr. 2008;153:807-13. </text>
<text top="676" left="105" width="55" height="13" font="8">S4.1.5-7. </text>
<text top="676" left="190" width="579" height="13" font="8">Hoffman JIE, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890-</text>
<text top="694" left="190" width="29" height="13" font="8">900. </text>
<text top="712" left="105" width="55" height="13" font="8">S4.1.5-8. </text>
<text top="712" left="190" width="594" height="13" font="8">Record RG, McKeown T. Observations relating to the aetiology of patent ductus arteriosus. Br Heart </text>
<text top="730" left="190" width="112" height="13" font="8">J. 1953;15:376-86. </text>
<text top="767" left="105" width="318" height="20" font="17"><b>4.2. Left-Sided Obstructive Lesions </b></text>
<text top="811" left="105" width="187" height="19" font="34"><b>4.2.1. Cor Triatriatum </b></text>
<text top="843" left="105" width="55" height="13" font="8">S4.2.1-1. </text>
<text top="843" left="190" width="591" height="13" font="8">Ozyuksel A, Yildirim O, Avsar M, et al. Surgical correction of cor triatriatum sinister in the paediatric </text>
<text top="861" left="190" width="484" height="13" font="8">population: mid-term results in 15 cases. Eur J Cardiothorac Surg. 2015;47:e25-8. </text>
<text top="879" left="105" width="55" height="13" font="8">S4.2.1-2. </text>
<text top="879" left="190" width="579" height="13" font="8">Yaroglu Kazanci S, Emani S, McElhinney DB. Outcome after repair of cor triatriatum. Am J Cardiol. </text>
<text top="896" left="190" width="101" height="13" font="8">2012;109:412-6. </text>
<text top="914" left="105" width="55" height="13" font="8">S4.2.1-3. </text>
<text top="914" left="190" width="580" height="13" font="8">Saxena P, Burkhart HM, Schaff HV, et al. Surgical repair of cor triatriatum sinister: the Mayo Clinic </text>
<text top="932" left="190" width="333" height="13" font="8">50-year experience. Ann Thorac Surg. 2014;97:1659-63. </text>
<text top="950" left="105" width="55" height="13" font="8">S4.2.1-4. </text>
<text top="950" left="190" width="600" height="13" font="8">Alphonso N, Nørgaard MA, Newcomb A, et al. Cor triatriatum: presentation, diagnosis and long-term </text>
<text top="968" left="190" width="308" height="13" font="8">surgical results. Ann Thorac Surg. 2005;80:1666-71. </text>
<text top="1005" left="105" width="280" height="19" font="34"><b>4.2.2. Congenital Mitral Stenosis </b></text>
<text top="1037" left="105" width="55" height="13" font="8">S4.2.2-1. </text>
<text top="1037" left="191" width="569" height="13" font="8">Schaverien MV, Freedom RM, McCrindle BW. Independent factors associated with outcomes of </text>
<text top="1055" left="191" width="411" height="13" font="8">parachute mitral valve in 84 patients. Circulation. 2004;109:2309-13. </text>
</page>
<page number="156" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 158 </text>
<text top="162" left="105" width="55" height="13" font="8">S4.2.2-2. </text>
<text top="162" left="191" width="562" height="13" font="8">Marino BS, Kruge LE, Cho CJ, et al. Parachute mitral valve: morphologic descriptors, associated </text>
<text top="179" left="191" width="567" height="13" font="8">lesions, and outcomes after biventricular repair. J Thorac Cardiovasc Surg. 2009;137:385-93.e4. </text>
<text top="197" left="105" width="55" height="13" font="8">S4.2.2-3. </text>
<text top="197" left="191" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="215" left="191" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="233" left="191" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="270" left="105" width="212" height="19" font="34"><b>4.2.3. Subaortic Stenosis </b></text>
<text top="302" left="105" width="55" height="13" font="8">S4.2.3-1. </text>
<text top="302" left="190" width="572" height="13" font="8">Diller G-P, Dimopoulos K, Okonko D, et al. Exercise intolerance in adult congenital heart disease: </text>
<text top="320" left="190" width="542" height="13" font="8">comparative severity, correlates, and prognostic implication. Circulation. 2005;112:828-35. </text>
<text top="337" left="105" width="55" height="13" font="8">S4.2.3-2. </text>
<text top="337" left="190" width="579" height="13" font="8">Diller G-P, Dimopoulos K, Okonko D, et al. Heart rate response during exercise predicts survival in </text>
<text top="355" left="190" width="427" height="13" font="8">adults with congenital heart disease. J Am Coll Cardiol. 2006;48:1250-6. </text>
<text top="373" left="105" width="55" height="13" font="8">S4.2.3-3. </text>
<text top="373" left="190" width="597" height="13" font="8">Trinchero R, Demarie D, Orzan F, et al. Fixed subaortic stenosis. Natural history of patients with mild </text>
<text top="391" left="190" width="471" height="13" font="8">obstruction and follow-up of operated patients. G Ital Cardiol. 1988;18:738-44. </text>
<text top="409" left="105" width="55" height="13" font="8">S4.2.3-4. </text>
<text top="409" left="190" width="579" height="13" font="8">Oliver JM, González A, Gallego P, et al. Discrete subaortic stenosis in adults: increased prevalence </text>
<text top="427" left="190" width="536" height="13" font="8">and slow rate of progression of the obstruction and aortic regurgitation. J Am Coll Cardiol. </text>
<text top="445" left="190" width="101" height="13" font="8">2001;38:835-42. </text>
<text top="462" left="105" width="55" height="13" font="8">S4.2.3-5. </text>
<text top="462" left="190" width="597" height="13" font="8">Brauner R, Laks H, Drinkwater DCJ, et al. Benefits of early surgical repair in fixed subaortic stenosis. J </text>
<text top="480" left="190" width="206" height="13" font="8">Am Coll Cardiol. 1997;30:1835-42. </text>
<text top="498" left="105" width="55" height="13" font="8">S4.2.3-6. </text>
<text top="498" left="190" width="598" height="13" font="8">Parry AJ, Kovalchin JP, Suda K, et al. Resection of subaortic stenosis; can a more aggressive approach </text>
<text top="516" left="190" width="314" height="13" font="8">be justified? Eur J Cardiothorac Surg. 1999;15:631-8. </text>
<text top="534" left="105" width="55" height="13" font="8">S4.2.3-7. </text>
<text top="534" left="190" width="582" height="13" font="8">Shone JD, Sellers RD, Anderson RC, et al. The developmental complex of “parachute mitral valve,” </text>
<text top="552" left="190" width="539" height="13" font="8">supravalvular ring of left atrium, subaortic stenosis, and coarctation of aorta. Am J Cardiol. </text>
<text top="569" left="190" width="101" height="13" font="8">1963;11:714-25. </text>
<text top="587" left="105" width="55" height="13" font="8">S4.2.3-8. </text>
<text top="587" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="605" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="623" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="641" left="105" width="55" height="13" font="8">S4.2.3-9. </text>
<text top="641" left="190" width="599" height="13" font="8">Brodyn NE, Haft JI. Chest pain secondary to membranous subaortic stenosis in a young woman. J Am </text>
<text top="658" left="190" width="229" height="13" font="8">Osteopath Assoc. 1992;92:1532, 9-41. </text>
<text top="676" left="105" width="62" height="13" font="8">S4.2.3-10. </text>
<text top="676" left="190" width="596" height="13" font="8">van der Linde D, Takkenberg JJM, Rizopoulos D, et al. Natural history of discrete subaortic stenosisin </text>
<text top="694" left="190" width="345" height="13" font="8">adults: a multicentre study. Eur Heart J. 2013;34:1548-56. </text>
<text top="731" left="105" width="354" height="19" font="34"><b>4.2.4. Congenital Valvular Aortic Stenosis </b></text>
<text top="763" left="105" width="55" height="13" font="8">S4.2.4-1. </text>
<text top="763" left="190" width="558" height="13" font="8">Fernandes SM, Sanders SP, Khairy P, et al. Morphology of bicuspid aortic valve in children and </text>
<text top="781" left="190" width="291" height="13" font="8">adolescents. J Am Coll Cardiol. 2004;44:1648-51. </text>
<text top="799" left="105" width="55" height="13" font="8">S4.2.4-2. </text>
<text top="799" left="190" width="600" height="13" font="8">Biner S, Rafique AM, Ray I, et al. Aortopathy is prevalent in relatives of bicuspid aortic valve patients. </text>
<text top="816" left="190" width="214" height="13" font="8">J Am Coll Cardiol. 2009;53:2288-95. </text>
<text top="834" left="105" width="55" height="13" font="8">S4.2.4-3. </text>
<text top="834" left="190" width="508" height="13" font="8">Tutar E, Ekici F, Atalay S, et al. The prevalence of bicuspid aortic valve in newborns by </text>
<text top="852" left="190" width="349" height="13" font="8">echocardiographic screening. Am Heart J. 2005;150:513-5. </text>
<text top="870" left="105" width="55" height="13" font="8">S4.2.4-4. </text>
<text top="870" left="190" width="596" height="13" font="8">Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering </text>
<text top="888" left="190" width="422" height="13" font="8">of congenital bicuspid aortic valve. J Am Coll Cardiol. 1997;30:1809-12. </text>
<text top="906" left="105" width="55" height="13" font="8">S4.2.4-5. </text>
<text top="906" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="924" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="941" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="959" left="105" width="55" height="13" font="8">S4.2.4-6. </text>
<text top="959" left="190" width="596" height="13" font="8">Arora R, Jolly N, Bhat A, et al. Follow-up of balloon aortic valvuloplasty in young adults—a combined </text>
<text top="977" left="190" width="499" height="13" font="8">hemodynamic and Doppler echocardiographic study. Indian Heart J. 1989;41:314-7. </text>
<text top="995" left="105" width="55" height="13" font="8">S4.2.4-7. </text>
<text top="995" left="190" width="590" height="13" font="8">Aboulhosn J, Child JS. Left ventricular outflow obstruction: subaortic stenosis, bicuspid aortic valve, </text>
<text top="1012" left="190" width="525" height="13" font="8">supravalvar aortic stenosis, and coarctation of the aorta. Circulation. 2006;114:2412-22. </text>
<text top="1030" left="105" width="55" height="13" font="8">S4.2.4-8. </text>
<text top="1030" left="190" width="527" height="13" font="8">Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55:2789-800. </text>
<text top="1048" left="105" width="55" height="13" font="8">S4.2.4-9. </text>
<text top="1048" left="190" width="599" height="13" font="8">Reifenstein GH, Levine SA, Gross RE. Coarctation of the aorta; a review of 104 autopsied cases of the </text>
<text top="1066" left="190" width="379" height="13" font="8">adult type, 2 years of age or older. Am Heart J. 1947;33:146-68. </text>
</page>
<page number="157" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 159 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.2.4-10. </text>
<text top="162" left="190" width="550" height="13" font="8">Roos-Hesselink JW, Schölzel BE, Heijdra RJ, et al. Aortic valve and aortic arch pathology after </text>
<text top="179" left="190" width="254" height="13" font="8">coarctation repair. Heart. 2003;89:1074-7. </text>
<text top="197" left="105" width="62" height="13" font="8">S4.2.4-11. </text>
<text top="197" left="190" width="572" height="13" font="8">Stewart AB, Ahmed R, Travill CM, et al. Coarctation of the aorta life and health 20-44 years after </text>
<text top="215" left="190" width="249" height="13" font="8">surgical repair. Br Heart J. 1993;69:65-70. </text>
<text top="233" left="105" width="62" height="13" font="8">S4.2.4-12. </text>
<text top="233" left="190" width="580" height="13" font="8">Presbitero P, Demarie D, Villani M, et al. Long term results 15-30 years) of surgical repair of aortic </text>
<text top="251" left="190" width="232" height="13" font="8">coarctation. Br Heart J. 1987;57:462-7. </text>
<text top="269" left="105" width="62" height="13" font="8">S4.2.4-13. </text>
<text top="269" left="190" width="597" height="13" font="8">Abbott ME. Coarctation of the aorta of the adult type, II: a statistical and historical retrospect of 200 </text>
<text top="286" left="190" width="600" height="13" font="8">recorded cases with autopsy, of stenosis or obliteration of the descending arch in subjects above the </text>
<text top="304" left="190" width="262" height="13" font="8">age of 2 years. Am Heart J. 1928;3:574-618. </text>
<text top="322" left="105" width="62" height="13" font="8">S4.2.4-14. </text>
<text top="322" left="190" width="574" height="13" font="8">Hashimoto H, Tamura T, Ikari Y, et al. Comparison of aortic valve replacement and percutaneous </text>
<text top="340" left="190" width="558" height="13" font="8">aortic balloon valvuloplasty for elderly patients with aortic stenosis. Jpn Circ J. 1996;60:142-8. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.2.4-15. </text>
<text top="358" left="190" width="526" height="13" font="8">Klein A, Lee K, Gera A, et al. Long-term mortality, cause of death, and temporal trends in </text>
<text top="375" left="190" width="571" height="13" font="8">complications after percutaneous aortic balloon valvuloplasty for calcific aortic stenosis. J Interv </text>
<text top="393" left="190" width="150" height="13" font="8">Cardiol. 2006;19:269-75. </text>
<text top="430" left="105" width="203" height="17" font="38"><i><b>4.2.4.1. Turner Syndrome </b></i></text>
<text top="460" left="105" width="66" height="13" font="8">S4.2.4.1-1. </text>
<text top="460" left="190" width="546" height="13" font="8">Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics. </text>
<text top="478" left="190" width="88" height="13" font="8">1998;101:E11. </text>
<text top="496" left="105" width="66" height="13" font="8">S4.2.4.1-2. </text>
<text top="496" left="190" width="564" height="13" font="8">Carlson M, Airhart N, Lopez L, et al. Moderate aortic enlargement and bicuspid aortic valve are </text>
<text top="514" left="190" width="587" height="13" font="8">associated with aortic dissection in Turner syndrome: report of the International Turner Syndrome </text>
<text top="532" left="190" width="337" height="13" font="8">Aortic Dissection Registry. Circulation. 2012;126:2220-6. </text>
<text top="550" left="105" width="66" height="13" font="8">S4.2.4.1-3. </text>
<text top="550" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="568" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="585" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="603" left="105" width="66" height="13" font="8">S4.2.4.1-4. </text>
<text top="603" left="190" width="595" height="13" font="8">Karnis MF, Zimon AE, Lalwani SI, et al. Risk of death in pregnancy achieved through oocyte donation </text>
<text top="621" left="190" width="493" height="13" font="8">in patients with Turner syndrome: a national survey. Fertil Steril. 2003;80:498-501. </text>
<text top="639" left="105" width="66" height="13" font="8">S4.2.4.1-5. </text>
<text top="639" left="190" width="522" height="13" font="8">Svensson LG, Khitin L. Aortic cross-sectional area/height ratio timing of aortic surgery in </text>
<text top="657" left="190" width="536" height="13" font="8">asymptomatic patients with Marfan syndrome. J Thorac Cardiovasc Surg. 2002;123:360-1. </text>
<text top="674" left="105" width="66" height="13" font="8">S4.2.4.1-6. </text>
<text top="674" left="190" width="592" height="13" font="8">Svensson LG, Kim K-H, Lytle BW, et al. Relationship of aortic cross-sectional area to height ratio and </text>
<text top="692" left="190" width="545" height="13" font="8">the risk of aortic dissection in patients with bicuspid aortic valves. J Thorac Cardiovasc Surg. </text>
<text top="710" left="190" width="101" height="13" font="8">2003;126:892-3. </text>
<text top="728" left="105" width="66" height="13" font="8">S4.2.4.1-7. </text>
<text top="728" left="190" width="593" height="13" font="8">Quezada E, Lapidus J, Shaughnessy R, et al. Aortic dimensions in Turner syndrome. Am J Med Genet </text>
<text top="746" left="190" width="139" height="13" font="8">A. 2015;167A:2527-32. </text>
<text top="783" left="105" width="170" height="17" font="38"><i><b>4.2.4.2. Aortopathies </b></i></text>
<text top="813" left="105" width="66" height="13" font="8">S4.2.4.2-1. </text>
<text top="813" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="831" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="849" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="867" left="105" width="66" height="13" font="8">S4.2.4.2-2. </text>
<text top="867" left="190" width="532" height="13" font="8">Svensson LG, Adams DH, Bonow RO, et al. Aortic valve and ascending aorta guidelines for </text>
<text top="884" left="190" width="413" height="13" font="8">management and quality measures. Ann Thorac Surg. 2013;95:S1-66. </text>
<text top="902" left="105" width="66" height="13" font="8">S4.2.4.2-3. </text>
<text top="902" left="190" width="594" height="13" font="8">Hiratzka LF, Creager MA, Isselbacher EM, et al. Surgery for aortic dilatation in patients with bicuspid </text>
<text top="920" left="190" width="587" height="13" font="8">aortic valves: a statement of clarification from the American College of Cardiology/American Heart </text>
<text top="938" left="190" width="493" height="13" font="8">Association Task Force on Clinical Practice Guidelines. Circulation. 2015;133:680-6. </text>
<text top="956" left="105" width="66" height="13" font="8">S4.2.4.2-4. </text>
<text top="956" left="190" width="560" height="13" font="8">Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with </text>
<text top="973" left="190" width="290" height="13" font="8">bicuspid aortic valves. JAMA. 2011;306:1104-12. </text>
<text top="991" left="105" width="66" height="13" font="8">S4.2.4.2-5. </text>
<text top="991" left="190" width="570" height="13" font="8">Kaya A, Heijmen RH, Vreuls W, et al. Chronic type A dissection in a pulmonary autograft. J Heart </text>
<text top="1009" left="190" width="154" height="13" font="8">Valve Dis. 2007;16:162-4. </text>
<text top="1027" left="105" width="66" height="13" font="8">S4.2.4.2-6. </text>
<text top="1027" left="190" width="582" height="13" font="8">Hutter PA, Thomeer BJ, Jansen P, et al. Fate of the aortic root after arterial switch operation. Eur J </text>
<text top="1045" left="190" width="199" height="13" font="8">Cardiothorac Surg. 2001;20:82-8. </text>
<text top="1063" left="105" width="66" height="13" font="8">S4.2.4.2-7. </text>
<text top="1063" left="190" width="588" height="13" font="8">Marino BS, Wernovsky G, McElhinney DB, et al. Neo-aortic valvar function after the arterial switch. </text>
<text top="1080" left="190" width="183" height="13" font="8">Cardiol Young. 2006;16:481-9. </text>
</page>
<page number="158" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 160 </text>
<text top="162" left="105" width="66" height="13" font="8">S4.2.4.2-8. </text>
<text top="162" left="190" width="580" height="13" font="8">Schwartz ML, Gauvreau K, del Nido P, et al. Long-term predictors of aortic root dilation and aortic </text>
<text top="180" left="190" width="460" height="13" font="8">regurgitation after arterial switch operation. Circulation. 2004;110:II128-II32. </text>
<text top="198" left="105" width="66" height="13" font="8">S4.2.4.2-9. </text>
<text top="198" left="190" width="587" height="13" font="8">Mongeon F-P, Gurvitz MZ, Broberg CS, et al. Aortic root dilatation in adults with surgically repaired </text>
<text top="215" left="190" width="498" height="13" font="8">tetralogy of Fallot: a multicenter cross-sectional study. Circulation. 2013;127:172-9. </text>
<text top="233" left="105" width="649" height="13" font="8">S4.2.4.2-10.  Egan M, Phillips A, Cook SC. Aortic dissection in the adult Fontan with aortic root enlargement. </text>
<text top="251" left="190" width="188" height="13" font="8">Pediatr Cardiol. 2009;30:562-3. </text>
<text top="269" left="105" width="651" height="13" font="8">S4.2.4.2-11.  Wijesekera VA, Kiess MC, Grewal J, et al. Aortic dissection in a patient with a dilated aortic root </text>
<text top="286" left="190" width="387" height="13" font="8">following tetralogy of Fallot repair. Int J Cardiol. 2014;174:833-4. </text>
<text top="304" left="105" width="653" height="13" font="8">S4.2.4.2-12.  Konstantinov IE, Fricke TA, d’Udekem Y, et al. Aortic dissection and rupture in adolescents after </text>
<text top="322" left="190" width="404" height="13" font="8">tetralogy of Fallot repair. J Thorac Cardiovasc Surg. 2010;140:e71-3. </text>
<text top="340" left="105" width="683" height="13" font="8">S4.2.4.2-13.  Kim W-H, Seo J-W, Kim S-J, et al. Aortic dissection late after repair of tetralogy of Fallot. Int J Cardiol. </text>
<text top="358" left="190" width="101" height="13" font="8">2005;101:515-6. </text>
<text top="375" left="105" width="673" height="13" font="8">S4.2.4.2-14.  Rathi VK, Doyle M, Williams RB, et al. Massive aortic aneurysm and dissection in repaired tetralogy </text>
<text top="393" left="190" width="582" height="13" font="8">of Fallot; diagnosis by cardiovascular magnetic resonance imaging. Int J Cardiol. 2005;101:169-70. </text>
<text top="411" left="105" width="629" height="13" font="8">S4.2.4.2-15.  Stulak JM, Dearani JA, Burkhart HM, et al. Does the dilated ascending aorta in an adult with </text>
<text top="429" left="190" width="531" height="13" font="8">congenital heart disease require intervention? J Thorac Cardiovasc Surg. 2010;140:S52-7. </text>
<text top="466" left="105" width="304" height="19" font="34"><b>4.2.5. Supravalvular Aortic Stenosis </b></text>
<text top="498" left="105" width="55" height="13" font="8">S4.2.5-1. </text>
<text top="498" left="190" width="562" height="13" font="8">Tani LY, Minich LL, Pagotto LT, et al. Usefulness of doppler echocardiography to determine the </text>
<text top="516" left="190" width="463" height="13" font="8">timing of surgery for supravalvar aortic stenosis. Am J Cardiol. 2000;86:114-6. </text>
<text top="534" left="105" width="55" height="13" font="8">S4.2.5-2. </text>
<text top="534" left="190" width="583" height="13" font="8">Thiene G, Ho SY. Aortic root pathology and sudden death in youth: review of anatomical varieties. </text>
<text top="552" left="190" width="169" height="13" font="8">Appl Pathol. 1986;4:237-45. </text>
<text top="569" left="105" width="55" height="13" font="8">S4.2.5-3. </text>
<text top="569" left="190" width="568" height="13" font="8">Stamm C, Li J, Ho SY, et al. The aortic root in supravalvular aortic stenosis: the potential surgical </text>
<text top="587" left="190" width="462" height="13" font="8">relevance of morphologic findings. J Thorac Cardiovasc Surg. 1997;114:16-24. </text>
<text top="605" left="105" width="55" height="13" font="8">S4.2.5-4. </text>
<text top="605" left="190" width="594" height="13" font="8">Martin MM, Lemmer JH Jr, Shaffer E, et al. Obstruction to left coronary artery blood flow secondary </text>
<text top="623" left="190" width="594" height="13" font="8">to obliteration of the coronary ostium in supravalvular aortic stenosis. Ann Thorac Surg. 1988;45:16-</text>
<text top="641" left="190" width="22" height="13" font="8">20. </text>
<text top="658" left="105" width="55" height="13" font="8">S4.2.5-5. </text>
<text top="658" left="190" width="601" height="13" font="8">Bruno E, Rossi N, Thüer O, et al. Cardiovascular findings, and clinical course, in patients with Williams </text>
<text top="676" left="190" width="249" height="13" font="8">syndrome. Cardiol Young. 2003;13:532-6. </text>
<text top="694" left="105" width="55" height="13" font="8">S4.2.5-6. </text>
<text top="694" left="190" width="567" height="13" font="8">Wren C, Oslizlok P, Bull C. Natural history of supravalvular aortic stenosis and pulmonary artery </text>
<text top="712" left="190" width="269" height="13" font="8">stenosis. J Am Coll Cardiol. 1990;15:1625-30. </text>
<text top="730" left="105" width="55" height="13" font="8">S4.2.5-7. </text>
<text top="730" left="190" width="579" height="13" font="8">Eronen M, Peippo M, Hiippala A, et al. Cardiovascular manifestations in 75 patients with Williams </text>
<text top="748" left="190" width="242" height="13" font="8">syndrome. J Med Genet. 2002;39:554-8. </text>
<text top="765" left="105" width="55" height="13" font="8">S4.2.5-8. </text>
<text top="765" left="190" width="556" height="13" font="8">Greutmann M, Tobler D, Sharma NC, et al. Cardiac outcomes in adults with supravalvar aortic </text>
<text top="783" left="190" width="235" height="13" font="8">stenosis. Eur Heart J. 2012;33:2442-50. </text>
<text top="801" left="105" width="55" height="13" font="8">S4.2.5-9. </text>
<text top="801" left="190" width="541" height="13" font="8">Doty DB, Eastham CL, Hiratzka LF, et al. Determination of coronary reserve in patients with </text>
<text top="819" left="190" width="351" height="13" font="8">supravalvular aortic stenosis. Circulation. 1982;66:I186-92. </text>
<text top="837" left="105" width="62" height="13" font="8">S4.2.5-10. </text>
<text top="837" left="190" width="562" height="13" font="8">Bird LM, Billman GF, Lacro RV, et al. Sudden death in Williams syndrome: report of ten cases. J </text>
<text top="854" left="190" width="158" height="13" font="8">Pediatr. 1996;129:926-31. </text>
<text top="872" left="105" width="62" height="13" font="8">S4.2.5-11. </text>
<text top="872" left="190" width="549" height="13" font="8">Bragg K, Fedel GM, DiProsperis A. Cardiac arrest under anesthesia in a pediatric patient with </text>
<text top="890" left="190" width="355" height="13" font="8">Williams syndrome: a case report. AANA J. 2005;73:287-93. </text>
<text top="908" left="105" width="62" height="13" font="8">S4.2.5-12. </text>
<text top="908" left="190" width="583" height="13" font="8">Gupta P, Tobias JD, Goyal S, et al. Sudden cardiac death under anesthesia in pediatric patient with </text>
<text top="926" left="190" width="548" height="13" font="8">Williams syndrome: a case report and review of literature. Ann Card Anaesth. 2010;13:44-8. </text>
<text top="944" left="105" width="62" height="13" font="8">S4.2.5-13. </text>
<text top="944" left="190" width="561" height="13" font="8">Horowitz PE, Akhtar S, Wulff JA, et al. Coronary artery disease and anesthesia-related death in </text>
<text top="961" left="190" width="470" height="13" font="8">children with Williams syndrome. J Cardiothorac Vasc Anesth. 2002;16:739-41. </text>
<text top="979" left="105" width="62" height="13" font="8">S4.2.5-14. </text>
<text top="979" left="190" width="563" height="13" font="8">Monfared A, Messner A. Death following tonsillectomy in a child with Williams syndrome. Int J </text>
<text top="997" left="190" width="255" height="13" font="8">Pediatr Otorhinolaryngol. 2006;70:1133-5. </text>
<text top="1015" left="105" width="62" height="13" font="8">S4.2.5-15. </text>
<text top="1015" left="190" width="530" height="13" font="8">Aboulhosn J, Child JS. Echocardiographic evaluation of congenital left ventricular outflow </text>
<text top="1033" left="190" width="341" height="13" font="8">obstruction. Echocardiography. 2015;32(suppl 2):S140-7. </text>
</page>
<page number="159" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 161 </text>
<text top="163" left="105" width="263" height="19" font="34"><b>4.2.6. Coarctation of the Aorta </b></text>
<text top="196" left="105" width="55" height="13" font="8">S4.2.6-1. </text>
<text top="195" left="190" width="572" height="13" font="8">Qureshi AM, McElhinney DB, Lock JE, et al. Acute and intermediate outcomes, and evaluation of </text>
<text top="213" left="190" width="547" height="13" font="8">injury to the aortic wall, as based on 15 years experience of implanting stents to treat aortic </text>
<text top="231" left="190" width="264" height="13" font="8">coarctation. Cardiol Young. 2007;17:307-18. </text>
<text top="249" left="105" width="55" height="13" font="8">S4.2.6-2. </text>
<text top="249" left="190" width="576" height="13" font="8">Hager A, Kanz S, Kaemmerer H, et al. Coarctation Long-term Assessment (COALA): significance of </text>
<text top="267" left="190" width="561" height="13" font="8">arterial hypertension in a cohort of 404 patients up to 27 years after surgical repair of isolated </text>
<text top="284" left="190" width="547" height="13" font="8">coarctation of the aorta, even in the absence of restenosis and prosthetic material. J Thorac </text>
<text top="302" left="190" width="209" height="13" font="8">Cardiovasc Surg. 2007;134:738-45. </text>
<text top="320" left="105" width="55" height="13" font="8">S4.2.6-3. </text>
<text top="320" left="190" width="598" height="13" font="8">Forbes TJ, Garekar S, Amin Z, et al. Procedural results and acute complications in stenting native and </text>
<text top="338" left="190" width="550" height="13" font="8">recurrent coarctation of the aorta in patients over 4 years of age: a multi-institutional study. </text>
<text top="356" left="190" width="265" height="13" font="8">Catheter Cardiovasc Interv. 2007;70:276-85. </text>
<text top="374" left="105" width="55" height="13" font="8">S4.2.6-4. </text>
<text top="374" left="190" width="576" height="13" font="8">Morgan GJ, Lee KJ, Chaturvedi R, et al. Systemic blood pressure after stent management for arch </text>
<text top="391" left="190" width="485" height="13" font="8">coarctation implications for clinical care. JACC Cardiovasc Interv. 2013;6:192-201. </text>
<text top="409" left="105" width="55" height="13" font="8">S4.2.6-5. </text>
<text top="409" left="190" width="586" height="13" font="8">Cook SC, Hickey J, Maul TM, et al. Assessment of the cerebral circulation in adults with coarctation </text>
<text top="427" left="190" width="289" height="13" font="8">of the aorta. Congenit Heart Dis. 2013;8:289-95. </text>
<text top="445" left="105" width="55" height="13" font="8">S4.2.6-6. </text>
<text top="445" left="190" width="598" height="13" font="8">Connolly HM, Huston J 3rd, Brown RD Jr, et al. Intracranial aneurysms in patients with coarctation of </text>
<text top="463" left="190" width="576" height="13" font="8">the aorta: a prospective magnetic resonance angiographic study of 100 patients. Mayo Clin Proc. </text>
<text top="480" left="190" width="101" height="13" font="8">2003;78:1491-9. </text>
<text top="498" left="105" width="55" height="13" font="8">S4.2.6-7. </text>
<text top="498" left="190" width="566" height="13" font="8">Correia AS, Gonçalves A, Paiva M, et al. Long-term follow-up after aortic coarctation repair: the </text>
<text top="516" left="190" width="498" height="13" font="8">unsolved issue of exercise-induced hypertension. Rev Port Cardiol. 2013;32:879-83. </text>
<text top="534" left="105" width="55" height="13" font="8">S4.2.6-8. </text>
<text top="534" left="190" width="584" height="13" font="8">Holzer R, Qureshi S, Ghasemi A, et al. Stenting of aortic coarctation: acute, intermediate, and long-</text>
<text top="552" left="190" width="587" height="13" font="8">term results of a prospective multi-institutional registry—Congenital Cardiovascular Interventional </text>
<text top="570" left="190" width="425" height="13" font="8">Study Consortium (CCISC). Catheter Cardiovasc Interv. 2010;76:553-63. </text>
<text top="587" left="105" width="55" height="13" font="8">S4.2.6-9. </text>
<text top="587" left="190" width="600" height="13" font="8">Chessa M, Carrozza M, Butera G, et al. Results and mid-long-term follow-up of stent implantation for </text>
<text top="605" left="190" width="453" height="13" font="8">native and recurrent coarctation of the aorta. Eur Heart J. 2005;26:2728-32. </text>
<text top="623" left="105" width="62" height="13" font="8">S4.2.6-10. </text>
<text top="623" left="190" width="601" height="13" font="8">Toro-Salazar OH, Steinberger J, Thomas W, et al. Long-term follow-up of patients after coarctation of </text>
<text top="641" left="190" width="274" height="13" font="8">the aorta repair. Am J Cardiol. 2002;89:541-7. </text>
<text top="659" left="105" width="62" height="13" font="8">S4.2.6-11. </text>
<text top="659" left="190" width="542" height="13" font="8">Carr JA. The results of catheter-based therapy compared with surgical repair of adult aortic </text>
<text top="677" left="190" width="281" height="13" font="8">coarctation. J Am Coll Cardiol. 2006;47:1101-7. </text>
<text top="694" left="105" width="62" height="13" font="8">S4.2.6-12. </text>
<text top="694" left="190" width="561" height="13" font="8">Brown JW, Ruzmetov M, Hoyer MH, et al. Recurrent coarctation: is surgical repair of recurrent </text>
<text top="712" left="190" width="472" height="13" font="8">coarctation of the aorta safe and effective? Ann Thorac Surg. 2009;88:1923-30. </text>
<text top="730" left="105" width="62" height="13" font="8">S4.2.6-13. </text>
<text top="730" left="190" width="548" height="13" font="8">Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on </text>
<text top="748" left="190" width="527" height="13" font="8">Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. </text>
<text top="766" left="190" width="108" height="13" font="8">2003;42:1206-52. </text>
<text top="783" left="105" width="62" height="13" font="8">S4.2.6-14. </text>
<text top="783" left="190" width="589" height="13" font="8">Suárez de Lezo J, Pan M, Romero M, et al. Percutaneous interventions on severe coarctation of the </text>
<text top="801" left="190" width="366" height="13" font="8">aorta: a 21-year experience. Pediatr Cardiol. 2005;26:176-89. </text>
<text top="819" left="105" width="62" height="13" font="8">S4.2.6-15. </text>
<text top="819" left="190" width="590" height="13" font="8">Aboulhosn J, Child JS. Left ventricular outflow obstruction: subaortic stenosis, bicuspid aortic valve, </text>
<text top="837" left="190" width="525" height="13" font="8">supravalvar aortic stenosis, and coarctation of the aorta. Circulation. 2006;114:2412-22. </text>
<text top="855" left="105" width="62" height="13" font="8">S4.2.6-16. </text>
<text top="855" left="190" width="527" height="13" font="8">Siu SC, Silversides CK. Bicuspid aortic valve disease. J Am Coll Cardiol. 2010;55:2789-800. </text>
<text top="873" left="105" width="62" height="13" font="8">S4.2.6-17. </text>
<text top="873" left="190" width="599" height="13" font="8">Reifenstein GH, Levine SA, Gross RE. Coarctation of the aorta; a review of 104 autopsied cases of the </text>
<text top="890" left="190" width="379" height="13" font="8">adult type, 2 years of age or older. Am Heart J. 1947;33:146-68. </text>
<text top="908" left="105" width="62" height="13" font="8">S4.2.6-18. </text>
<text top="908" left="190" width="550" height="13" font="8">Roos-Hesselink JW, Schölzel BE, Heijdra RJ, et al. Aortic valve and aortic arch pathology after </text>
<text top="926" left="190" width="254" height="13" font="8">coarctation repair. Heart. 2003;89:1074-7. </text>
<text top="944" left="105" width="62" height="13" font="8">S4.2.6-19. </text>
<text top="944" left="190" width="572" height="13" font="8">Stewart AB, Ahmed R, Travill CM, et al. Coarctation of the aorta life and health 20-44 years after </text>
<text top="962" left="190" width="249" height="13" font="8">surgical repair. Br Heart J. 1993;69:65-70. </text>
<text top="979" left="105" width="62" height="13" font="8">S4.2.6-20. </text>
<text top="979" left="190" width="580" height="13" font="8">Presbitero P, Demarie D, Villani M, et al. Long term results 15-30 years) of surgical repair of aortic </text>
<text top="997" left="190" width="232" height="13" font="8">coarctation. Br Heart J. 1987;57:462-7. </text>
<text top="1015" left="105" width="62" height="13" font="8">S4.2.6-21. </text>
<text top="1015" left="190" width="597" height="13" font="8">Abbott ME. Coarctation of the aorta of the adult type, II: a statistical and historical retrospect of 200 </text>
<text top="1033" left="190" width="600" height="13" font="8">recorded cases with autopsy, of stenosis or obliteration of the descending arch in subjects above the </text>
<text top="1051" left="190" width="262" height="13" font="8">age of 2 years. Am Heart J. 1928;3:574-618. </text>
<text top="1069" left="105" width="62" height="13" font="8">S4.2.6-22. </text>
<text top="1069" left="190" width="581" height="13" font="8">Wiebers DO, Whisnant JP, Huston J 3rd, et al. Unruptured intracranial aneurysms: natural history, </text>
<text top="1086" left="190" width="553" height="13" font="8">clinical outcome, and risks of surgical and endovascular treatment. Lancet. 2003;362:103-10. </text>
</page>
<page number="160" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 162 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.2.6-23. </text>
<text top="162" left="190" width="594" height="13" font="8">Donti A, Spinardi L, Brighenti M, et al. Frequency of intracranial aneurysms determined by magnetic </text>
<text top="179" left="190" width="576" height="13" font="8">resonance angiography in children (mean age 16) having operative or endovascular treatment of </text>
<text top="197" left="190" width="410" height="13" font="8">coarctation of the aorta (mean age 3). Am J Cardiol. 2015;116:630-3. </text>
<text top="215" left="105" width="62" height="13" font="8">S4.2.6-24. </text>
<text top="215" left="190" width="593" height="13" font="8">Krieger EV, Clair M, Opotowsky AR, et al. Correlation of exercise response in repaired coarctation of </text>
<text top="233" left="190" width="477" height="13" font="8">the aorta to left ventricular mass and geometry. Am J Cardiol. 2013;111:406-11. </text>
<text top="251" left="105" width="62" height="13" font="8">S4.2.6-25. </text>
<text top="251" left="190" width="284" height="13" font="8">Whelton PK, Carey RM, Aronow WS, et al. 2017 </text>
<text top="269" left="190" width="552" height="13" font="8">ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, </text>
<text top="286" left="190" width="585" height="13" font="8">detection, evaluation, and management of high blood pressure in adults: a report of the American </text>
<text top="304" left="190" width="549" height="13" font="8">College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. </text>
<text top="322" left="190" width="195" height="13" font="8">Hypertension. 2018;71:e13-115. </text>
<text top="359" left="105" width="220" height="20" font="17"><b>4.3. Right-Sided Lesions </b></text>
<text top="403" left="105" width="299" height="19" font="34"><b>4.3.1. Valvular Pulmonary Stenosis </b></text>
<text top="435" left="105" width="55" height="13" font="8">S4.3.1-1. </text>
<text top="435" left="190" width="572" height="13" font="8">Voet A, Rega F, de Bruaene AV, et al. Long-term outcome after treatment of isolated pulmonary </text>
<text top="453" left="190" width="259" height="13" font="8">valve stenosis. Int J Cardiol. 2012;156:11-5. </text>
<text top="471" left="105" width="55" height="13" font="8">S4.3.1-2. </text>
<text top="471" left="190" width="579" height="13" font="8">Kaul UA, Singh B, Tyagi S, et al. Long-term results after balloon pulmonary valvuloplasty in adults. </text>
<text top="489" left="190" width="180" height="13" font="8">Am Heart J. 1993;126:1152-5. </text>
<text top="507" left="105" width="55" height="13" font="8">S4.3.1-3. </text>
<text top="507" left="190" width="567" height="13" font="8">Chen CR, Cheng TO, Huang T, et al. Percutaneous balloon valvuloplasty for pulmonic stenosis in </text>
<text top="525" left="190" width="319" height="13" font="8">adolescents and adults. N Engl J Med. 1996;335:21-5. </text>
<text top="542" left="105" width="55" height="13" font="8">S4.3.1-4. </text>
<text top="542" left="190" width="571" height="13" font="8">Taggart NW, Cetta F, Cabalka AK, et al. Outcomes for balloon pulmonary valvuloplasty in adults: </text>
<text top="560" left="190" width="542" height="13" font="8">comparison with a concurrent pediatric cohort. Catheter Cardiovasc Interv. 2013;82:811-5. </text>
<text top="578" left="105" width="55" height="13" font="8">S4.3.1-5. </text>
<text top="578" left="190" width="593" height="13" font="8">Kopecky SL, Gersh BJ, McGoon MD, et al. Long-term outcome of patients undergoing surgical repair </text>
<text top="596" left="190" width="548" height="13" font="8">of isolated pulmonary valve stenosis. Follow-up at 20-30 years. Circulation. 1988;78:1150-6. </text>
<text top="614" left="105" width="55" height="13" font="8">S4.3.1-6. </text>
<text top="614" left="190" width="583" height="13" font="8">Hayes CJ, Gersony WM, Driscoll DJ, et al. Second natural history study of congenital heart defects. </text>
<text top="631" left="190" width="555" height="13" font="8">Results of treatment of patients with pulmonary valvar stenosis. Circulation. 1993;87:I28-I37. </text>
<text top="649" left="105" width="55" height="13" font="8">S4.3.1-7. </text>
<text top="649" left="190" width="601" height="13" font="8">Roos-Hesselink JW, Meijboom FJ, Spitaels SEC, et al. Long-term outcome after surgery for pulmonary </text>
<text top="667" left="190" width="436" height="13" font="8">stenosis (a longitudinal study of 22-33 years). Eur Heart J. 2006;27:482-8. </text>
<text top="685" left="105" width="55" height="13" font="8">S4.3.1-8. </text>
<text top="685" left="190" width="592" height="13" font="8">Earing MG, Connolly HM, Dearani JA, et al. Long-term follow-up of patients after surgical treatment </text>
<text top="703" left="190" width="417" height="13" font="8">for isolated pulmonary valve stenosis. Mayo Clin Proc. 2005;80:871-6. </text>
<text top="721" left="105" width="55" height="13" font="8">S4.3.1-9. </text>
<text top="721" left="190" width="577" height="13" font="8">Moss AJ, Adams FH, Emmanouilides GC, eds. Moss and Adams Heart Disease in Infants, Children, </text>
<text top="738" left="190" width="582" height="13" font="8">and Adolescents: Including the Fetus and Young Adult. 5th ed. Baltimore, MD: Williams &amp; Wilkins; </text>
<text top="756" left="190" width="37" height="13" font="8">1995. </text>
<text top="774" left="105" width="62" height="13" font="8">S4.3.1-10. </text>
<text top="774" left="190" width="569" height="13" font="8">Stephensen SS, Sigfusson G, Eiriksson H, et al. Congenital cardiac malformations in Iceland from </text>
<text top="792" left="190" width="318" height="13" font="8">1990 through 1999. Cardiol Young. 2004;14:396-401. </text>
<text top="809" left="105" width="62" height="13" font="8">S4.3.1-11. </text>
<text top="809" left="190" width="593" height="13" font="8">Samánek M, Slavík Z, Zborilová B, et al. Prevalence, treatment, and outcome of heart disease in live-</text>
<text top="827" left="190" width="586" height="13" font="8">born children: a prospective analysis of 91,823 live-born children. Pediatr Cardiol. 1989;10:205-11. </text>
<text top="845" left="105" width="62" height="13" font="8">S4.3.1-12. </text>
<text top="845" left="190" width="582" height="13" font="8">Cuypers JAAE, Witsenburg M, van der Linde D, et al. Pulmonary stenosis: update on diagnosis and </text>
<text top="863" left="190" width="265" height="13" font="8">therapeutic options. Heart. 2013;99:339-47. </text>
<text top="881" left="105" width="62" height="13" font="8">S4.3.1-13. </text>
<text top="881" left="190" width="559" height="13" font="8">Schneider AW, Blom NA, Bruggemans EF, et al. More than 25 years of experience in managing </text>
<text top="899" left="190" width="503" height="13" font="8">pulmonary atresia with intact ventricular septum. Ann Thorac Surg. 2014;98:1680-6. </text>
<text top="917" left="105" width="62" height="13" font="8">S4.3.1-14. </text>
<text top="917" left="190" width="600" height="13" font="8">John AS, Warnes CA. Clinical outcomes of adult survivors of pulmonary atresia with intact ventricular </text>
<text top="934" left="190" width="222" height="13" font="8">septum. Int J Cardiol. 2012;161:13-7. </text>
<text top="952" left="105" width="62" height="13" font="8">S4.3.1-15. </text>
<text top="952" left="190" width="538" height="13" font="8">Liang X-C, Lam WWM, Cheung EWY, et al. Restrictive right ventricular physiology and right </text>
<text top="970" left="190" width="533" height="13" font="8">ventricular fibrosis as assessed by cardiac magnetic resonance and exercise capacity after </text>
<text top="988" left="190" width="601" height="13" font="8">biventricular repair of pulmonary atresia and intact ventricular septum. Clin Cardiol. 2010;33:104-10. </text>
<text top="1005" left="105" width="62" height="13" font="8">S4.3.1-16. </text>
<text top="1005" left="190" width="587" height="13" font="8">Mishima A, Asano M, Sasaki S, et al. Long-term outcome for right heart function after biventricular </text>
<text top="1023" left="190" width="524" height="13" font="8">repair of pulmonary atresia and intact ventricular septum. Jpn J Thorac Cardiovasc Surg. </text>
<text top="1041" left="190" width="101" height="13" font="8">2000;48:145-52. </text>
</page>
<page number="161" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 163 </text>
<text top="163" left="105" width="299" height="17" font="38"><i><b>4.3.1.1. Isolated PR After Repair of PS </b></i></text>
<text top="194" left="105" width="66" height="13" font="8">S4.3.1.1-1. </text>
<text top="194" left="190" width="579" height="13" font="8">Zdradzinski MJ, Qureshi AM, Stewart R, et al. Comparison of long-term postoperative sequelae in </text>
<text top="212" left="190" width="576" height="13" font="8">patients with tetralogy of Fallot versus isolated pulmonic stenosis. Am J Cardiol. 2014;114:300-4. </text>
<text top="248" left="105" width="417" height="19" font="34"><b>4.3.2. Branch and Peripheral Pulmonary Stenosis </b></text>
<text top="281" left="105" width="55" height="13" font="8">S4.3.2-1. </text>
<text top="281" left="190" width="574" height="13" font="8">Hallbergson A, Lock JE, Marshall AC. Frequency and risk of in-stent stenosis following pulmonary </text>
<text top="299" left="190" width="276" height="13" font="8">artery stenting. Am J Cardiol. 2014;113:541-5. </text>
<text top="316" left="105" width="55" height="13" font="8">S4.3.2-2. </text>
<text top="316" left="190" width="566" height="13" font="8">Gonzalez I, Kenny D, Slyder S, et al. Medium and long-term outcomes after bilateral pulmonary </text>
<text top="334" left="190" width="599" height="13" font="8">artery stenting in children and adults with congenital heart disease. Pediatr Cardiol. 2013;34:179-84. </text>
<text top="352" left="105" width="55" height="13" font="8">S4.3.2-3. </text>
<text top="352" left="190" width="598" height="13" font="8">Kenny D, Amin Z, Slyder S, et al. Medium-term outcomes for peripheral pulmonary artery stenting in </text>
<text top="370" left="190" width="409" height="13" font="8">adults with congenital heart disease. J Interv Cardiol. 2011;24:373-7. </text>
<text top="406" left="105" width="352" height="19" font="34"><b>4.3.3. Double-Chambered Right Ventricle </b></text>
<text top="439" left="105" width="55" height="13" font="8">S4.3.3-1. </text>
<text top="439" left="190" width="580" height="13" font="8">Hachiro Y, Takagi N, Koyanagi T, et al. Repair of double-chambered right ventricle: surgical results </text>
<text top="457" left="190" width="357" height="13" font="8">and long-term follow-up. Ann Thorac Surg. 2001;72:1520-2. </text>
<text top="474" left="105" width="55" height="13" font="8">S4.3.3-2. </text>
<text top="474" left="190" width="594" height="13" font="8">Kveselis D, Rosenthal A, Ferguson P, et al. Long-term prognosis after repair of double-chamber right </text>
<text top="492" left="190" width="417" height="13" font="8">ventricle with ventricular septal defect. Am J Cardiol. 1984;54:1292-5. </text>
<text top="510" left="105" width="55" height="13" font="8">S4.3.3-3. </text>
<text top="510" left="190" width="570" height="13" font="8">Said SM, Burkhart HM, Dearani JA, et al. Outcomes of surgical repair of double-chambered right </text>
<text top="528" left="190" width="271" height="13" font="8">ventricle. Ann Thorac Surg. 2012;93:197-200. </text>
<text top="546" left="105" width="55" height="13" font="8">S4.3.3-4. </text>
<text top="546" left="190" width="593" height="13" font="8">Kahr PC, Alonso-Gonzalez R, Kempny A, et al. Long-term natural history and postoperative outcome </text>
<text top="563" left="190" width="584" height="13" font="8">of double-chambered right ventricle—experience from two tertiary adult congenital heart centres </text>
<text top="581" left="190" width="347" height="13" font="8">and review of the literature. Int J Cardiol. 2014;174:662-8. </text>
<text top="599" left="105" width="55" height="13" font="8">S4.3.3-5. </text>
<text top="599" left="190" width="577" height="13" font="8">Pongiglione G, Freedom RM, Cook D, et al. Mechanism of acquired right ventricular outflow tract </text>
<text top="617" left="190" width="574" height="13" font="8">obstruction in patients with ventricular septal defect: an angiocardiographic study. Am J Cardiol. </text>
<text top="635" left="190" width="101" height="13" font="8">1982;50:776-80. </text>
<text top="652" left="105" width="55" height="13" font="8">S4.3.3-6. </text>
<text top="652" left="190" width="573" height="13" font="8">Oliver JM, Garrido A, González A, et al. Rapid progression of midventricular obstruction in adults </text>
<text top="670" left="190" width="489" height="13" font="8">with double-chambered right ventricle. J Thorac Cardiovasc Surg. 2003;126:711-7. </text>
<text top="707" left="105" width="200" height="19" font="34"><b>4.3.4. Ebstein Anomaly </b></text>
<text top="739" left="105" width="55" height="13" font="8">S4.3.4-1. </text>
<text top="739" left="190" width="590" height="13" font="8">Bharucha T, Anderson RH, Lim ZS, et al. Multiplanar review of three-dimensional echocardiography </text>
<text top="757" left="190" width="579" height="13" font="8">gives new insights into the morphology of Ebstein’s malformation. Cardiol Young. 2010;20:49-53. </text>
<text top="775" left="105" width="55" height="13" font="8">S4.3.4-2. </text>
<text top="775" left="190" width="575" height="13" font="8">Attenhofer Jost CH, Edmister WD, Julsrud PR, et al. Prospective comparison of echocardiography </text>
<text top="793" left="190" width="565" height="13" font="8">versus cardiac magnetic resonance imaging in patients with Ebstein’s anomaly. Int J Cardiovasc </text>
<text top="811" left="190" width="162" height="13" font="8">Imaging. 2012;28:1147-59. </text>
<text top="828" left="105" width="55" height="13" font="8">S4.3.4-3. </text>
<text top="828" left="190" width="583" height="13" font="8">Wei W, Zhan X, Xue Y, et al. Features of accessory pathways in adult Ebstein’s anomaly. Europace. </text>
<text top="846" left="190" width="108" height="13" font="8">2014;16:1619-25. </text>
<text top="864" left="105" width="55" height="13" font="8">S4.3.4-4. </text>
<text top="864" left="190" width="570" height="13" font="8">Iturralde P, Nava S, Sálica G, et al. Electrocardiographic characteristics of patients with Ebstein’s </text>
<text top="882" left="190" width="530" height="13" font="8">anomaly before and after ablation of an accessory atrioventricular pathway. J Cardiovasc </text>
<text top="900" left="190" width="191" height="13" font="8">Electrophysiol. 2006;17:1332-6. </text>
<text top="918" left="105" width="55" height="13" font="8">S4.3.4-5. </text>
<text top="918" left="190" width="591" height="13" font="8">Shivapour JKL, Sherwin ED, Alexander ME, et al. Utility of preoperative electrophysiologic studies in </text>
<text top="935" left="190" width="570" height="13" font="8">patients with Ebstein’s anomaly undergoing the cone procedure. Heart Rhythm. 2014;11:182-6. </text>
<text top="953" left="105" width="55" height="13" font="8">S4.3.4-6. </text>
<text top="953" left="190" width="601" height="13" font="8">Raju V, Dearani JA, Burkhart HM, et al. Right ventricular unloading for heart failure related to Ebstein </text>
<text top="971" left="190" width="294" height="13" font="8">malformation. Ann Thorac Surg. 2014;98:167-73. </text>
<text top="989" left="105" width="55" height="13" font="8">S4.3.4-7. </text>
<text top="989" left="190" width="601" height="13" font="8">Brown ML, Dearani JA, Danielson GK, et al. The outcomes of operations for 539 patients with Ebstein </text>
<text top="1007" left="190" width="360" height="13" font="8">anomaly. J Thorac Cardiovasc Surg. 2008;135:1120-36, e1-7. </text>
<text top="1025" left="105" width="55" height="13" font="8">S4.3.4-8. </text>
<text top="1025" left="190" width="580" height="13" font="8">Dearani JA, Said SM, Burkhart HM, et al. Strategies for tricuspid re-repair in Ebstein malformation </text>
<text top="1042" left="190" width="354" height="13" font="8">using the cone technique. Ann Thorac Surg. 2013;96:202-8. </text>
<text top="1060" left="105" width="55" height="13" font="8">S4.3.4-9. </text>
<text top="1060" left="190" width="587" height="13" font="8">Dearani JA, Said SM, O’Leary PW, et al. Anatomic repair of Ebstein’s malformation: lessons learned </text>
<text top="1078" left="190" width="354" height="13" font="8">with cone reconstruction. Ann Thorac Surg. 2013;95:220-6. </text>
</page>
<page number="162" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 164 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.3.4-10. </text>
<text top="162" left="190" width="582" height="13" font="8">Badiu CC, Schreiber C, Hörer J, et al. Early timing of surgical intervention in patients with Ebstein’s </text>
<text top="179" left="190" width="526" height="13" font="8">anomaly predicts superior long-term outcome. Eur J Cardiothorac Surg. 2010;37:186-92. </text>
<text top="197" left="105" width="62" height="13" font="8">S4.3.4-11. </text>
<text top="197" left="190" width="598" height="13" font="8">Khositseth A, Danielson GK, Dearani JA, et al. Supraventricular tachyarrhythmias in Ebstein anomaly: </text>
<text top="215" left="190" width="429" height="13" font="8">management and outcome. J Thorac Cardiovasc Surg. 2004;128:826-33. </text>
<text top="233" left="105" width="62" height="13" font="8">S4.3.4-12. </text>
<text top="233" left="190" width="592" height="13" font="8">Zachariah JP, Walsh EP, Triedman JK, et al. Multiple accessory pathways in the young: the impact of </text>
<text top="251" left="190" width="319" height="13" font="8">structural heart disease. Am Heart J. 2013;165:87-92. </text>
<text top="269" left="105" width="62" height="13" font="8">S4.3.4-13. </text>
<text top="269" left="190" width="551" height="13" font="8">Chauvaud S. Ebstein’s malformation. Surgical treatment and results. Thorac Cardiovasc Surg. </text>
<text top="286" left="190" width="93" height="13" font="8">2000;48:220-3. </text>
<text top="304" left="105" width="62" height="13" font="8">S4.3.4-14. </text>
<text top="304" left="190" width="598" height="13" font="8">Chen JM, Mosca RS, Altmann K, et al. Early and medium-term results for repair of Ebstein anomaly. J </text>
<text top="322" left="190" width="245" height="13" font="8">Thorac Cardiovasc Surg. 2004;127:990-8. </text>
<text top="340" left="105" width="62" height="13" font="8">S4.3.4-15. </text>
<text top="340" left="190" width="595" height="13" font="8">Malhotra SP, Petrossian E, Reddy VM, et al. Selective right ventricular unloading and novel technical </text>
<text top="358" left="190" width="398" height="13" font="8">concepts in Ebstein’s anomaly. Ann Thorac Surg. 2009;88:1975-81. </text>
<text top="375" left="105" width="62" height="13" font="8">S4.3.4-16. </text>
<text top="375" left="190" width="565" height="13" font="8">Lupo PJ, Langlois PH, Mitchell LE. Epidemiology of Ebstein anomaly: Prevalence and patterns in </text>
<text top="393" left="190" width="383" height="13" font="8">Texas, 1999–2005. Am J Med Genet Part A. 2011;155A:1007-14. </text>
<text top="411" left="105" width="62" height="13" font="8">S4.3.4-17. </text>
<text top="411" left="190" width="591" height="13" font="8">Correa-Villaseñor A, Ferencz C, Neill CA, et al. Ebstein’s malformation of the tricuspid valve: genetic </text>
<text top="429" left="190" width="596" height="13" font="8">and environmental factors. The Baltimore-Washington Infant Study Group. Teratology. 1994;50:137-</text>
<text top="447" left="190" width="22" height="13" font="8">47. </text>
<text top="465" left="105" width="62" height="13" font="8">S4.3.4-18. </text>
<text top="465" left="190" width="583" height="13" font="8">Pradat P, Francannet C, Harris JA, et al. The epidemiology of cardiovascular defects, part I: a study </text>
<text top="482" left="190" width="594" height="13" font="8">based on data from three large registries of congenital malformations. Pediatr Cardiol. 2003;24:195-</text>
<text top="500" left="190" width="29" height="13" font="8">221. </text>
<text top="518" left="105" width="62" height="13" font="8">S4.3.4-19. </text>
<text top="518" left="190" width="579" height="13" font="8">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult </text>
<text top="536" left="190" width="599" height="13" font="8">patients with supraventricular tachycardia: a report of the American College of Cardiology/American </text>
<text top="554" left="190" width="539" height="13" font="8">Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. </text>
<text top="572" left="190" width="186" height="13" font="8">Circulation. 2016;133:e506-74. </text>
<text top="589" left="105" width="62" height="13" font="8">S4.3.4-20. </text>
<text top="589" left="190" width="598" height="13" font="8">Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and </text>
<text top="607" left="190" width="582" height="13" font="8">management of arrhythmias in adult congenital heart disease. Developed in partnership between </text>
<text top="625" left="190" width="596" height="13" font="8">the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). </text>
<text top="643" left="190" width="198" height="13" font="8">Heart Rhythm. 2014;11:e102-65. </text>
<text top="661" left="105" width="62" height="13" font="8">S4.3.4-21. </text>
<text top="661" left="190" width="588" height="13" font="8">Pediatric and Congenital Electrophysiology Society (PACES), Heart Rhythm Society (HRS), American </text>
<text top="678" left="190" width="562" height="13" font="8">College of Cardiology Foundation (ACCF), et al. PACES/HRS expert consensus statement on the </text>
<text top="696" left="190" width="586" height="13" font="8">management of the asymptomatic young patient with a Wolff-Parkinson-White (WPW, ventricular </text>
<text top="714" left="190" width="578" height="13" font="8">preexcitation) electrocardiographic pattern. Developed in partnership between the Pediatric and </text>
<text top="732" left="190" width="582" height="13" font="8">Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Heart Rhythm. </text>
<text top="750" left="190" width="101" height="13" font="8">2012;9:1006-24. </text>
<text top="787" left="105" width="211" height="19" font="34"><b>4.3.5. Tetralogy of Fallot </b></text>
<text top="819" left="105" width="55" height="13" font="8">S4.3.5-1. </text>
<text top="819" left="190" width="558" height="13" font="8">Knauth AL, Gauvreau K, Powell AJ, et al. Ventricular size and function assessed by cardiac MRI </text>
<text top="837" left="190" width="582" height="13" font="8">predict major adverse clinical outcomes late after tetralogy of Fallot repair. Heart. 2008;94:211-6. </text>
<text top="854" left="105" width="55" height="13" font="8">S4.3.5-2. </text>
<text top="854" left="190" width="597" height="13" font="8">Morray BH, McElhinney DB, Cheatham JP, et al. Risk of coronary artery compression among patients </text>
<text top="872" left="190" width="590" height="13" font="8">referred for transcatheter pulmonary valve implantation: a multicenter experience. Circ Cardiovasc </text>
<text top="890" left="190" width="135" height="13" font="8">Interv. 2013;6:535-42. </text>
<text top="908" left="105" width="55" height="13" font="8">S4.3.5-3. </text>
<text top="908" left="190" width="598" height="13" font="8">Khairy P, Van Hare GF, Balaji S, et al. PACES/HRS expert consensus statement on the recognition and </text>
<text top="926" left="190" width="582" height="13" font="8">management of arrhythmias in adult congenital heart disease. Developed in partnership between </text>
<text top="944" left="190" width="596" height="13" font="8">the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). </text>
<text top="961" left="190" width="198" height="13" font="8">Heart Rhythm. 2014;11:e102-65. </text>
<text top="979" left="105" width="55" height="13" font="8">S4.3.5-4. </text>
<text top="979" left="190" width="565" height="13" font="8">Dietl CA, Cazzaniga ME, Dubner SJ, et al. Life-threatening arrhythmias and RV dysfunction after </text>
<text top="997" left="190" width="533" height="13" font="8">surgical repair of tetralogy of Fallot. Comparison between transventricular and transatrial </text>
<text top="1015" left="190" width="240" height="13" font="8">approaches. Circulation. 1994;90:II7-12. </text>
<text top="1033" left="105" width="55" height="13" font="8">S4.3.5-5. </text>
<text top="1033" left="190" width="565" height="13" font="8">Khairy P, Landzberg MJ, Gatzoulis MA, et al. Value of programmed ventricular stimulation after </text>
<text top="1051" left="190" width="475" height="13" font="8">tetralogy of Fallot repair: a multicenter study. Circulation. 2004;109:1994-2000. </text>
<text top="1068" left="105" width="55" height="13" font="8">S4.3.5-6. </text>
<text top="1068" left="190" width="601" height="13" font="8">Tsai SF, Chan DP, Ro PS, et al. Rate of inducible ventricular arrhythmia in adults with congenital heart </text>
<text top="1086" left="190" width="232" height="13" font="8">disease. Am J Cardiol. 2010;106:730-6. </text>
</page>
<page number="163" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 165 </text>
<text top="162" left="105" width="55" height="13" font="8">S4.3.5-7. </text>
<text top="162" left="190" width="565" height="13" font="8">Khairy P. Programmed ventricular stimulation for risk stratification in patients with tetralogy of </text>
<text top="180" left="190" width="454" height="13" font="8">Fallot: a Bayesian perspective. Nat Clin Pract Cardiovasc Med. 2007;4:292-3. </text>
<text top="198" left="105" width="55" height="13" font="8">S4.3.5-8. </text>
<text top="197" left="190" width="570" height="13" font="8">Lucron H, Marçon F, Bosser G, et al. Induction of sustained ventricular tachycardia after surgical </text>
<text top="215" left="190" width="355" height="13" font="8">repair of tetralogy of Fallot. Am J Cardiol. 1999;83:1369-73. </text>
<text top="233" left="105" width="55" height="13" font="8">S4.3.5-9. </text>
<text top="233" left="190" width="598" height="13" font="8">Ferraz Cavalcanti PE, Sá MPBO, Santos CA, et al. Pulmonary valve replacement after operative repair </text>
<text top="251" left="190" width="599" height="13" font="8">of tetralogy of Fallot: meta-analysis and meta-regression of 3,118 patients from 48 studies. J Am Coll </text>
<text top="269" left="190" width="157" height="13" font="8">Cardiol. 2013;62:2227-43. </text>
<text top="286" left="105" width="62" height="13" font="8">S4.3.5-10. </text>
<text top="286" left="190" width="601" height="13" font="8">Gengsakul A, Harris L, Bradley TJ, et al. The impact of pulmonary valve replacement after tetralogy of </text>
<text top="304" left="190" width="460" height="13" font="8">Fallot repair: a matched comparison. Eur J Cardiothorac Surg. 2007;32:462-8. </text>
<text top="322" left="105" width="62" height="13" font="8">S4.3.5-11. </text>
<text top="322" left="190" width="580" height="13" font="8">Discigil B, Dearani JA, Puga FJ, et al. Late pulmonary valve replacement after repair of tetralogy of </text>
<text top="340" left="190" width="301" height="13" font="8">Fallot. J Thorac Cardiovasc Surg. 2001;121:344-51. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.3.5-12. </text>
<text top="358" left="190" width="542" height="13" font="8">Oosterhof T, van Straten A, Vliegen HW, et al. Preoperative thresholds for pulmonary valve </text>
<text top="375" left="190" width="594" height="13" font="8">replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. </text>
<text top="393" left="190" width="179" height="13" font="8">Circulation. 2007;116:545-51. </text>
<text top="411" left="105" width="62" height="13" font="8">S4.3.5-13. </text>
<text top="411" left="190" width="558" height="13" font="8">Lee C, Kim YM, Lee C-H, et al. Outcomes of pulmonary valve replacement in 170 patients with </text>
<text top="429" left="190" width="533" height="13" font="8">chronic pulmonary regurgitation after relief of right ventricular outflow tract obstruction: </text>
<text top="447" left="190" width="599" height="13" font="8">implications for optimal timing of pulmonary valve replacement. J Am Coll Cardiol. 2012;60:1005-14. </text>
<text top="465" left="105" width="62" height="13" font="8">S4.3.5-14. </text>
<text top="465" left="190" width="557" height="13" font="8">Geva T. Indications for pulmonary valve replacement in repaired tetralogy of Fallot: the quest </text>
<text top="482" left="190" width="244" height="13" font="8">continues. Circulation. 2013;128:1855-7. </text>
<text top="500" left="105" width="62" height="13" font="8">S4.3.5-15. </text>
<text top="500" left="190" width="598" height="13" font="8">Koyak Z, de Groot JR, Bouma BJ, et al. Symptomatic but not asymptomatic non-sustained ventricular </text>
<text top="518" left="190" width="600" height="13" font="8">tachycardia is associated with appropriate implantable cardioverter therapy in tetralogy of Fallot. Int </text>
<text top="536" left="190" width="165" height="13" font="8">J Cardiol. 2013;167:1532-5. </text>
<text top="554" left="105" width="62" height="13" font="8">S4.3.5-16. </text>
<text top="554" left="190" width="586" height="13" font="8">Khairy P, Harris L, Landzberg MJ, et al. Implantable cardioverter-defibrillators in tetralogy of Fallot. </text>
<text top="572" left="190" width="179" height="13" font="8">Circulation. 2008;117:363-70. </text>
<text top="589" left="105" width="62" height="13" font="8">S4.3.5-17. </text>
<text top="589" left="190" width="599" height="13" font="8">Witte KK, Pepper CB, Cowan JC, et al. Implantable cardioverter-defibrillator therapy in adult patients </text>
<text top="607" left="190" width="305" height="13" font="8">with tetralogy of Fallot. Europace. 2008;10:926-30. </text>
<text top="625" left="105" width="62" height="13" font="8">S4.3.5-18. </text>
<text top="625" left="190" width="576" height="13" font="8">Nollert G, Fischlein T, Bouterwek S, et al. Long-term results of total repair of tetralogy of Fallot in </text>
<text top="643" left="190" width="596" height="13" font="8">adulthood: 35 years follow-up in 104 patients corrected at the age of 18 or older. Thorac Cardiovasc </text>
<text top="661" left="190" width="134" height="13" font="8">Surg. 1997;45:178-81. </text>
<text top="678" left="105" width="62" height="13" font="8">S4.3.5-19. </text>
<text top="678" left="190" width="552" height="13" font="8">Valente AM, Gauvreau K, Assenza GE, et al. Contemporary predictors of death and sustained </text>
<text top="696" left="190" width="558" height="13" font="8">ventricular tachycardia in patients with repaired tetralogy of Fallot enrolled in the INDICATOR </text>
<text top="714" left="190" width="195" height="13" font="8">cohort. Heart. 2014;100:247-53. </text>
<text top="732" left="105" width="62" height="13" font="8">S4.3.5-20. </text>
<text top="732" left="190" width="573" height="13" font="8">Geva T, Sandweiss BM, Gauvreau K, et al. Factors associated with impaired clinical status in long-</text>
<text top="750" left="190" width="565" height="13" font="8">term survivors of tetralogy of Fallot repair evaluated by magnetic resonance imaging. J Am Coll </text>
<text top="768" left="190" width="157" height="13" font="8">Cardiol. 2004;43:1068-74. </text>
<text top="785" left="105" width="62" height="13" font="8">S4.3.5-21. </text>
<text top="785" left="190" width="579" height="13" font="8">Murphy JG, Gersh BJ, Mair DD, et al. Long-term outcome in patients undergoing surgical repair of </text>
<text top="803" left="190" width="296" height="13" font="8">tetralogy of Fallot. N Engl J Med. 1993;329:593-9. </text>
<text top="821" left="105" width="62" height="13" font="8">S4.3.5-22. </text>
<text top="821" left="190" width="576" height="13" font="8">Ghai A, Silversides C, Harris L, et al. Left ventricular dysfunction is a risk factor for sudden cardiac </text>
<text top="839" left="190" width="530" height="13" font="8">death in adults late after repair of tetralogy of Fallot. J Am Coll Cardiol. 2002;40:1675-80. </text>
<text top="857" left="105" width="62" height="13" font="8">S4.3.5-23. </text>
<text top="857" left="190" width="574" height="13" font="8">Geva T, Gauvreau K, Powell AJ, et al. Randomized trial of pulmonary valve replacement with and </text>
<text top="874" left="190" width="450" height="13" font="8">without right ventricular remodeling surgery. Circulation. 2010;122:S201-8. </text>
<text top="892" left="105" width="62" height="13" font="8">S4.3.5-24. </text>
<text top="892" left="190" width="584" height="13" font="8">Gatzoulis MA, Balaji S, Webber SA, et al. Risk factors for arrhythmia and sudden cardiac death late </text>
<text top="910" left="190" width="475" height="13" font="8">after repair of tetralogy of Fallot: a multicentre study. Lancet. 2000;356:975-81. </text>
<text top="928" left="105" width="62" height="13" font="8">S4.3.5-25. </text>
<text top="928" left="190" width="586" height="13" font="8">Quail MA, Frigiola A, Giardini A, et al. Impact of pulmonary valve replacement in tetralogy of Fallot </text>
<text top="946" left="190" width="591" height="13" font="8">with pulmonary regurgitation: a comparison of intervention and nonintervention. Ann Thorac Surg. </text>
<text top="964" left="190" width="108" height="13" font="8">2012;94:1619-26. </text>
<text top="981" left="105" width="62" height="13" font="8">S4.3.5-26. </text>
<text top="981" left="190" width="594" height="13" font="8">Wald RM, Lyseggen E, Oechslin EN, et al. Variability in surgical referral patterns for pulmonary valve </text>
<text top="999" left="190" width="532" height="13" font="8">replacement in adults with repaired tetralogy of Fallot. Congenit Heart Dis. 2009;4:231-8. </text>
<text top="1017" left="105" width="62" height="13" font="8">S4.3.5-27. </text>
<text top="1017" left="190" width="586" height="13" font="8">Therrien J, Provost Y, Merchant N, et al. Optimal timing for pulmonary valve replacement in adults </text>
<text top="1035" left="190" width="364" height="13" font="8">after tetralogy of Fallot repair. Am J Cardiol. 2005;95:779-82. </text>
<text top="1053" left="105" width="62" height="13" font="8">S4.3.5-28. </text>
<text top="1053" left="190" width="577" height="13" font="8">Bonello B, Kempny A, Uebing A, et al. Right atrial area and right ventricular outflow tract akinetic </text>
<text top="1071" left="190" width="505" height="13" font="8">length predict sustained tachyarrhythmia in repaired tetralogy of Fallot. Int J Cardiol. </text>
<text top="1088" left="190" width="108" height="13" font="8">2013;168:3280-6. </text>
</page>
<page number="164" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 166 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.3.5-29. </text>
<text top="162" left="190" width="585" height="13" font="8">Nørgaard MA, Lauridsen P, Helvind M, et al. Twenty-to-thirty-seven-year follow-up after repair for </text>
<text top="180" left="190" width="358" height="13" font="8">tetralogy of Fallot. Eur J Cardiothorac Surg. 1999;16:125-30. </text>
<text top="198" left="105" width="62" height="13" font="8">S4.3.5-30. </text>
<text top="197" left="190" width="593" height="13" font="8">Silka MJ, Hardy BG, Menashe VD, et al. A population-based prospective evaluation of risk of sudden </text>
<text top="215" left="190" width="589" height="13" font="8">cardiac death after operation for common congenital heart defects. J Am Coll Cardiol. 1998;32:245-</text>
<text top="233" left="190" width="22" height="13" font="8">51. </text>
<text top="251" left="105" width="62" height="13" font="8">S4.3.5-31. </text>
<text top="251" left="190" width="575" height="13" font="8">Norozi K, Bahlmann J, Raab B, et al. A prospective, randomized, double-blind, placebo controlled </text>
<text top="269" left="190" width="566" height="13" font="8">trial of beta-blockade in patients who have undergone surgical correction of tetralogy of Fallot. </text>
<text top="286" left="190" width="183" height="13" font="8">Cardiol Young. 2007;17:372-9. </text>
<text top="304" left="105" width="62" height="13" font="8">S4.3.5-32. </text>
<text top="304" left="190" width="595" height="13" font="8">Diller G-P, Kempny A, Liodakis E, et al. Left ventricular longitudinal function predicts life-threatening </text>
<text top="322" left="190" width="521" height="13" font="8">ventricular arrhythmia and death in adults with repaired tetralogy of Fallot. Circulation. </text>
<text top="340" left="190" width="108" height="13" font="8">2012;125:2440-6. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.3.5-33. </text>
<text top="358" left="190" width="570" height="13" font="8">Kella DK, Merchant FM, Veledar E, et al. Lesion-specific differences for implantable cardioverter </text>
<text top="375" left="190" width="526" height="13" font="8">defibrillator therapies in adults with congenital heart disease. Pacing Clin Electrophysiol. </text>
<text top="393" left="190" width="101" height="13" font="8">2014;37:1492-8. </text>
<text top="411" left="105" width="62" height="13" font="8">S4.3.5-34. </text>
<text top="411" left="190" width="587" height="13" font="8">Kilner PJ, Geva T, Kaemmerer H, et al. Recommendations for cardiovascular magnetic resonance in </text>
<text top="429" left="190" width="592" height="13" font="8">adults with congenital heart disease from the respective working groups of the European Society of </text>
<text top="447" left="190" width="250" height="13" font="8">Cardiology. Eur Heart J. 2010;31:794-805. </text>
<text top="465" left="105" width="62" height="13" font="8">S4.3.5-35. </text>
<text top="465" left="190" width="579" height="13" font="8">Valente AM, Geva T. How to image repaired tetralogy of Fallot. Circ Cardiovasc Imaging. 2017;10: </text>
<text top="482" left="105" width="62" height="13" font="8">S4.3.5-36. </text>
<text top="482" left="190" width="576" height="13" font="8">Wald RM, Valente AM, Gauvreau K, et al. Cardiac magnetic resonance markers of progressive RV </text>
<text top="500" left="190" width="486" height="13" font="8">dilation and dysfunction after tetralogy of Fallot repair. Heart. 2015;101:1724-30. </text>
<text top="518" left="105" width="62" height="13" font="8">S4.3.5-37. </text>
<text top="518" left="190" width="586" height="13" font="8">Bokma JP, Geva T, Sleeper LA, et al. A propensity score-adjusted analysis of clinical outcomes after </text>
<text top="536" left="190" width="384" height="13" font="8">pulmonary valve replacement in tetralogy of Fallot. Heart. 2017; </text>
<text top="554" left="105" width="62" height="13" font="8">S4.3.5-38. </text>
<text top="554" left="190" width="576" height="13" font="8">Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of </text>
<text top="572" left="190" width="422" height="13" font="8">mortality in patients with Fontan surgery. Circulation. 2008;117:85-92. </text>
<text top="589" left="105" width="62" height="13" font="8">S4.3.5-39. </text>
<text top="589" left="190" width="532" height="13" font="8">Zubairi R, Malik S, Jaquiss RDB, et al. Risk factors for prosthesis failure in pulmonary valve </text>
<text top="607" left="190" width="280" height="13" font="8">replacement. Ann Thorac Surg. 2011;91:561-5. </text>
<text top="625" left="105" width="62" height="13" font="8">S4.3.5-40. </text>
<text top="625" left="190" width="559" height="13" font="8">Cook SC, Valente AM, Maul TM, et al. Shock-related anxiety and sexual function in adults with </text>
<text top="643" left="190" width="599" height="13" font="8">congenital heart disease and implantable cardioverter-defibrillators. Heart Rhythm. 2013;10:805-10. </text>
<text top="661" left="105" width="62" height="13" font="8">S4.3.5-41. </text>
<text top="661" left="190" width="600" height="13" font="8">Davlouros PA, Kilner PJ, Hornung TS, et al. Right ventricular function in adults with repaired tetralogy </text>
<text top="678" left="190" width="549" height="13" font="8">of Fallot assessed with cardiovascular magnetic resonance imaging: detrimental role of right </text>
<text top="696" left="190" width="597" height="13" font="8">ventricular outflow aneurysms or akinesia and adverse right-to-left ventricular interaction. J Am Coll </text>
<text top="714" left="190" width="157" height="13" font="8">Cardiol. 2002;40:2044-52. </text>
<text top="732" left="105" width="62" height="13" font="8">S4.3.5-42. </text>
<text top="732" left="190" width="591" height="13" font="8">Harrild DM, Berul CI, Cecchin F, et al. Pulmonary valve replacement in tetralogy of Fallot: impact on </text>
<text top="750" left="190" width="397" height="13" font="8">survival and ventricular tachycardia. Circulation. 2009;119:445-51. </text>
<text top="768" left="105" width="62" height="13" font="8">S4.3.5-43. </text>
<text top="768" left="190" width="597" height="13" font="8">Downar E, Harris L, Kimber S, et al. Ventricular tachycardia after surgical repair of tetralogy of Fallot: </text>
<text top="785" left="190" width="458" height="13" font="8">results of intraoperative mapping studies. J Am Coll Cardiol. 1992;20:648-55. </text>
<text top="822" left="105" width="439" height="19" font="34"><b>4.3.6. Right Ventricle–to-Pulmonary Artery Conduit </b></text>
<text top="854" left="105" width="55" height="13" font="8">S4.3.6-1. </text>
<text top="854" left="190" width="597" height="13" font="8">Morray BH, McElhinney DB, Cheatham JP, et al. Risk of coronary artery compression among patients </text>
<text top="872" left="190" width="590" height="13" font="8">referred for transcatheter pulmonary valve implantation: a multicenter experience. Circ Cardiovasc </text>
<text top="890" left="190" width="135" height="13" font="8">Interv. 2013;6:535-42. </text>
<text top="908" left="105" width="55" height="13" font="8">S4.3.6-2. </text>
<text top="908" left="190" width="559" height="13" font="8">Fraisse A, Assaidi A, Mauri L, et al. Coronary artery compression during intention to treat right </text>
<text top="926" left="190" width="555" height="13" font="8">ventricle outflow with percutaneous pulmonary valve implantation: incidence, diagnosis, and </text>
<text top="944" left="190" width="325" height="13" font="8">outcome. Catheter Cardiovasc Interv. 2014;83:E260-8. </text>
<text top="961" left="105" width="55" height="13" font="8">S4.3.6-3. </text>
<text top="961" left="190" width="571" height="13" font="8">McElhinney DB, Benson LN, Eicken A, et al. Infective endocarditis after transcatheter pulmonary </text>
<text top="979" left="190" width="585" height="13" font="8">valve replacement using the Melody valve: combined results of 3 prospective North American and </text>
<text top="997" left="190" width="346" height="13" font="8">European studies. Circ Cardiovasc Interv. 2013;6:292-300. </text>
<text top="1015" left="105" width="55" height="13" font="8">S4.3.6-4. </text>
<text top="1015" left="190" width="595" height="13" font="8">McElhinney DB, Cheatham JP, Jones TK, et al. Stent fracture, valve dysfunction, and right ventricular </text>
<text top="1033" left="190" width="590" height="13" font="8">outflow tract reintervention after transcatheter pulmonary valve implantation: patient-related and </text>
<text top="1051" left="190" width="539" height="13" font="8">procedural risk factors in the US Melody Valve Trial. Circ Cardiovasc Interv. 2011;4:602-14. </text>
<text top="1068" left="105" width="55" height="13" font="8">S4.3.6-5. </text>
<text top="1068" left="190" width="574" height="13" font="8">Mainwaring RD, Pirolli T, Punn R, et al. Late repair of the native pulmonary valve in patients with </text>
<text top="1086" left="190" width="555" height="13" font="8">pulmonary insufficiency after surgery for tetralogy of Fallot. Ann Thorac Surg. 2012;93:677-9. </text>
</page>
<page number="165" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 167 </text>
<text top="162" left="105" width="55" height="13" font="8">S4.3.6-6. </text>
<text top="162" left="190" width="583" height="13" font="8">Bauer BS, Zachariah S, Levi D, et al. Evaluation of peak pressure gradients in patients after Melody </text>
<text top="179" left="190" width="544" height="13" font="8">valve implantation: a comparison of cardiac catheterization and doppler echocardiography. </text>
<text top="197" left="190" width="214" height="13" font="8">Echocardiography. 2015;32:1073-9. </text>
<text top="215" left="105" width="55" height="13" font="8">S4.3.6-7. </text>
<text top="215" left="190" width="537" height="13" font="8">McElhinney DB, Hellenbrand WE, Zahn EM, et al. Short- and medium-term outcomes after </text>
<text top="233" left="190" width="557" height="13" font="8">transcatheter pulmonary valve placement in the expanded multicenter US Melody valve trial. </text>
<text top="251" left="190" width="179" height="13" font="8">Circulation. 2010;122:507-16. </text>
<text top="269" left="105" width="55" height="13" font="8">S4.3.6-8. </text>
<text top="269" left="190" width="582" height="13" font="8">Niemantsverdriet MBA, Ottenkamp J, Gauvreau K, et al. Determinants of right ventricular outflow </text>
<text top="286" left="190" width="500" height="13" font="8">tract conduit longevity: a multinational analysis. Congenit Heart Dis. 2008;3:176-84. </text>
<text top="304" left="105" width="55" height="13" font="8">S4.3.6-9. </text>
<text top="304" left="190" width="552" height="13" font="8">Batra AS, McElhinney DB, Wang W, et al. Cardiopulmonary exercise function among patients </text>
<text top="322" left="190" width="597" height="13" font="8">undergoing transcatheter pulmonary valve implantation in the US Melody valve investigational trial. </text>
<text top="340" left="190" width="172" height="13" font="8">Am Heart J. 2012;163:280-7. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.3.6-10. </text>
<text top="358" left="190" width="597" height="13" font="8">Zahn EM, Hellenbrand WE, Lock JE, et al. Implantation of the Melody transcatheter pulmonary valve </text>
<text top="375" left="190" width="575" height="13" font="8">in patients with a dysfunctional right ventricular outflow tract conduit early results from the U.S. </text>
<text top="393" left="190" width="281" height="13" font="8">clinical trial. J Am Coll Cardiol. 2009;54:1722-9. </text>
<text top="411" left="105" width="62" height="13" font="8">S4.3.6-11. </text>
<text top="411" left="190" width="584" height="13" font="8">Brown JW, Ruzmetov M, Rodefeld MD, et al. Right ventricular outflow tract reconstruction in Ross </text>
<text top="429" left="190" width="464" height="13" font="8">patients: does the homograft fare better? Ann Thorac Surg. 2008;86:1607-12. </text>
<text top="447" left="105" width="62" height="13" font="8">S4.3.6-12. </text>
<text top="447" left="190" width="551" height="13" font="8">Frigiola A, Tsang V, Nordmeyer J, et al. Current approaches to pulmonary regurgitation. Eur J </text>
<text top="465" left="190" width="214" height="13" font="8">Cardiothorac Surg. 2008;34:576-80. </text>
<text top="482" left="105" width="62" height="13" font="8">S4.3.6-13. </text>
<text top="482" left="190" width="538" height="13" font="8">Lurz P, Nordmeyer J, Giardini A, et al. Early versus late functional outcome after successful </text>
<text top="500" left="190" width="556" height="13" font="8">percutaneous pulmonary valve implantation: are the acute effects of altered right ventricular </text>
<text top="518" left="190" width="365" height="13" font="8">loading all we can expect? J Am Coll Cardiol. 2011;57:724-31. </text>
<text top="536" left="105" width="62" height="13" font="8">S4.3.6-14. </text>
<text top="536" left="190" width="579" height="13" font="8">Coats L, Khambadkone S, Derrick G, et al. Physiological and clinical consequences of relief of right </text>
<text top="554" left="190" width="554" height="13" font="8">ventricular outflow tract obstruction late after repair of congenital heart defects. Circulation. </text>
<text top="572" left="190" width="115" height="13" font="8">2006;113:2037-44. </text>
<text top="589" left="105" width="62" height="13" font="8">S4.3.6-15. </text>
<text top="589" left="190" width="573" height="13" font="8">Kloevekorn WP, Meisner H, Paek SU, et al. Long-term results after right ventricular outflow tract </text>
<text top="607" left="190" width="466" height="13" font="8">reconstruction with porcine bioprosthetic conduits. J Card Surg. 1991;6:624-6. </text>
<text top="625" left="105" width="62" height="13" font="8">S4.3.6-16. </text>
<text top="625" left="190" width="571" height="13" font="8">Champsaur G, Robin J, Curtil A, et al. Long-term clinical and hemodynamic evaluation of porcine </text>
<text top="643" left="190" width="570" height="13" font="8">valved conduits implanted from the right ventricle to the pulmonary artery. J Thorac Cardiovasc </text>
<text top="661" left="190" width="149" height="13" font="8">Surg. 1998;116:793-804. </text>
<text top="678" left="105" width="62" height="13" font="8">S4.3.6-17. </text>
<text top="678" left="190" width="599" height="13" font="8">Buber J, Bergersen L, Lock JE, et al. Bloodstream infections occurring in patients with percutaneously </text>
<text top="696" left="190" width="550" height="13" font="8">implanted bioprosthetic pulmonary valve: a single-center experience. Circ Cardiovasc Interv. </text>
<text top="714" left="190" width="93" height="13" font="8">2013;6:301-10. </text>
<text top="732" left="105" width="62" height="13" font="8">S4.3.6-18. </text>
<text top="732" left="190" width="567" height="13" font="8">Van Dijck I, Budts W, Cools B, et al. Infective endocarditis of a transcatheter pulmonary valve in </text>
<text top="750" left="190" width="358" height="13" font="8">comparison with surgical implants. Heart. 2015;101:788-93. </text>
<text top="768" left="105" width="62" height="13" font="8">S4.3.6-19. </text>
<text top="768" left="190" width="557" height="13" font="8">Malekzadeh-Milani S, Ladouceur M, Patel M, et al. Incidence and predictors of Melody® valve </text>
<text top="785" left="190" width="434" height="13" font="8">endocarditis: a prospective study. Arch Cardiovasc Dis. 2015;108:97-106. </text>
<text top="803" left="105" width="62" height="13" font="8">S4.3.6-20. </text>
<text top="803" left="190" width="581" height="13" font="8">Amat-Santos IJ, Ribeiro HB, Urena M, et al. Prosthetic valve endocarditis after transcatheter valve </text>
<text top="821" left="190" width="441" height="13" font="8">replacement: a systematic review. JACC Cardiovasc Interv. 2015;8:334-46. </text>
<text top="858" left="105" width="195" height="20" font="17"><b>4.4. Complex Lesions </b></text>
<text top="902" left="105" width="352" height="19" font="34"><b>4.4.1. Transposition of the Great Arteries </b></text>
<text top="945" left="105" width="488" height="17" font="38"><i><b>4.4.1.1. Transposition of the Great Arteries With Atrial Switch </b></i></text>
<text top="975" left="105" width="66" height="13" font="8">S4.4.1.1-1. </text>
<text top="975" left="190" width="594" height="13" font="8">Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli </text>
<text top="993" left="190" width="518" height="13" font="8">in patients with intracardiac shunts: a multicenter study. Circulation. 2006;113:2391-7. </text>
<text top="1011" left="105" width="66" height="13" font="8">S4.4.1.1-2. </text>
<text top="1011" left="190" width="588" height="13" font="8">Khairy P, Harris L, Landzberg MJ, et al. Sudden death and defibrillators in transposition of the great </text>
<text top="1029" left="190" width="577" height="13" font="8">arteries with intra-atrial baffles: a multicenter study. Circ Arrhythm Electrophysiol. 2008;1:250-7. </text>
<text top="1046" left="105" width="66" height="13" font="8">S4.4.1.1-3. </text>
<text top="1046" left="190" width="560" height="13" font="8">Zaragoza-Macias E, Zaidi A, Dendukuri N, et al. Medical therapy for systemic right ventricles: a </text>
<text top="1064" left="190" width="561" height="13" font="8">systematic review (part 1) for the 2018 AHA/ACC guideline for the management of adults with </text>
</page>
<page number="166" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 168 </text>
<text top="162" left="190" width="600" height="13" font="8">congenital heart disease: a report of the American College of Cardiology/American Heart Association </text>
<text top="180" left="190" width="411" height="13" font="8">Task Force on Clinical Practice Guidelines. Circulation. 2018; In press. </text>
<text top="198" left="105" width="66" height="13" font="8">S4.4.1.1-4. </text>
<text top="197" left="190" width="549" height="13" font="8">Bouallal R, Godart F, Francart C, et al. Interest of β-blockers in patients with right ventricular </text>
<text top="215" left="190" width="314" height="13" font="8">systemic dysfunction. Cardiol Young. 2010;20:615-9. </text>
<text top="233" left="105" width="66" height="13" font="8">S4.4.1.1-5. </text>
<text top="233" left="190" width="570" height="13" font="8">Doughan ARK, McConnell ME, Book WM. Effect of beta blockers (carvedilol or metoprolol XL) in </text>
<text top="251" left="190" width="575" height="13" font="8">patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am J </text>
<text top="269" left="190" width="142" height="13" font="8">Cardiol. 2007;99:704-6. </text>
<text top="286" left="105" width="66" height="13" font="8">S4.4.1.1-6. </text>
<text top="286" left="190" width="563" height="13" font="8">Giardini A, Lovato L, Donti A, et al. A pilot study on the effects of carvedilol on right ventricular </text>
<text top="304" left="190" width="528" height="13" font="8">remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol. </text>
<text top="322" left="190" width="101" height="13" font="8">2007;114:241-6. </text>
<text top="340" left="105" width="66" height="13" font="8">S4.4.1.1-7. </text>
<text top="340" left="190" width="584" height="13" font="8">Dos L, Pujadas S, Estruch M, et al. Eplerenone in systemic right ventricle: double blind randomized </text>
<text top="358" left="190" width="381" height="13" font="8">clinical trial. The EVEDES Study. Int J Cardiol. 2013;168:5167-73. </text>
<text top="375" left="105" width="66" height="13" font="8">S4.4.1.1-8. </text>
<text top="375" left="190" width="591" height="13" font="8">Tulevski II, Lee PL, Groenink M, et al. Dobutamine-induced increase of right ventricular contractility </text>
<text top="393" left="190" width="570" height="13" font="8">without increased stroke volume in adolescent patients with transposition of the great arteries: </text>
<text top="411" left="190" width="478" height="13" font="8">evaluation with magnetic resonance imaging. Int J Card Imaging. 2000;16:471-8. </text>
<text top="429" left="105" width="66" height="13" font="8">S4.4.1.1-9. </text>
<text top="429" left="190" width="597" height="13" font="8">Broberg CS. Cardiac magnetic imaging of the patient with an atrial switch palliation for transposition </text>
<text top="447" left="190" width="345" height="13" font="8">of the great arteries. Prog Pediatr Cardiol. 2014;38:49-55. </text>
<text top="465" left="105" width="632" height="13" font="8">S4.4.1.1-10.  Babu-Narayan SV, Goktekin O, Moon JC, et al. Late gadolinium enhancement cardiovascular </text>
<text top="482" left="190" width="591" height="13" font="8">magnetic resonance of the systemic right ventricle in adults with previous atrial redirection surgery </text>
<text top="500" left="190" width="407" height="13" font="8">for transposition of the great arteries. Circulation. 2005;111:2091-8. </text>
<text top="518" left="105" width="648" height="13" font="8">S4.4.1.1-11.  Kammeraad JAD, van Deurzen CHM, Sreeram N, et al. Predictors of sudden cardiac death after </text>
<text top="536" left="190" width="579" height="13" font="8">Mustard or Senning repair for transposition of the great arteries. J Am Coll Cardiol. 2004;44:1095-</text>
<text top="554" left="190" width="29" height="13" font="8">102. </text>
<text top="572" left="105" width="661" height="13" font="8">S4.4.1.1-12.  Lubiszewska B, Gosiewska E, Hoffman P, et al. Myocardial perfusion and function of the systemic </text>
<text top="589" left="190" width="594" height="13" font="8">right ventricle in patients after atrial switch procedure for complete transposition: long-term follow-</text>
<text top="607" left="190" width="236" height="13" font="8">up. J Am Coll Cardiol. 2000;36:1365-70. </text>
<text top="644" left="105" width="504" height="17" font="38"><i><b>4.4.1.2. Transposition of the Great Arteries With Arterial Switch </b></i></text>
<text top="674" left="105" width="66" height="13" font="8">S4.4.1.2-1. </text>
<text top="674" left="190" width="586" height="13" font="8">Khairy P, Clair M, Fernandes SM, et al. Cardiovascular outcomes after the arterial switch operation </text>
<text top="692" left="190" width="413" height="13" font="8">for D-transposition of the great arteries. Circulation. 2013;127:331-9. </text>
<text top="710" left="105" width="66" height="13" font="8">S4.4.1.2-2. </text>
<text top="710" left="190" width="598" height="13" font="8">Kempny A, Wustmann K, Borgia F, et al. Outcome in adult patients after arterial switch operation for </text>
<text top="728" left="190" width="399" height="13" font="8">transposition of the great arteries. Int J Cardiol. 2013;167:2588-93. </text>
<text top="746" left="105" width="66" height="13" font="8">S4.4.1.2-3. </text>
<text top="746" left="190" width="571" height="13" font="8">Lim H-G, Kim W-H, Lee JR, et al. Long-term results of the arterial switch operation for ventriculo-</text>
<text top="764" left="190" width="370" height="13" font="8">arterial discordance. Eur J Cardiothorac Surg. 2013;43:325-34. </text>
<text top="781" left="105" width="66" height="13" font="8">S4.4.1.2-4. </text>
<text top="781" left="190" width="567" height="13" font="8">Ou P, Khraiche D, Celermajer DS, et al. Mechanisms of coronary complications after the arterial </text>
<text top="799" left="190" width="530" height="13" font="8">switch for transposition of the great arteries. J Thorac Cardiovasc Surg. 2013;145:1263-9. </text>
<text top="817" left="105" width="66" height="13" font="8">S4.4.1.2-5. </text>
<text top="817" left="190" width="560" height="13" font="8">Legendre A, Losay J, Touchot-Koné A, et al. Coronary events after arterial switch operation for </text>
<text top="835" left="190" width="449" height="13" font="8">transposition of the great arteries. Circulation. 2003;108 (suppl 1):II186-90. </text>
<text top="853" left="105" width="66" height="13" font="8">S4.4.1.2-6. </text>
<text top="853" left="190" width="590" height="13" font="8">Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients </text>
<text top="870" left="190" width="544" height="13" font="8">with valvular heart disease: a report of the American College of Cardiology/American Heart </text>
<text top="888" left="190" width="470" height="13" font="8">Association Task Force on Practice Guidelines. Circulation. 2014;129:e521-643. </text>
<text top="906" left="105" width="66" height="13" font="8">S4.4.1.2-7. </text>
<text top="906" left="190" width="575" height="13" font="8">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the </text>
<text top="924" left="190" width="593" height="13" font="8">diagnosis and management of patients with stable ischemic heart disease: a report of the American </text>
<text top="942" left="190" width="600" height="13" font="8">College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and </text>
<text top="960" left="190" width="537" height="13" font="8">the American College of Physicians, American Association for Thoracic Surgery, Preventive </text>
<text top="977" left="190" width="582" height="13" font="8">Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and </text>
<text top="995" left="190" width="371" height="13" font="8">Society of Thoracic Surgeons. Circulation. 2012;126:e354-471. </text>
<text top="1013" left="105" width="66" height="13" font="8">S4.4.1.2-8. </text>
<text top="1013" left="190" width="601" height="13" font="8">Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of </text>
<text top="1031" left="190" width="578" height="13" font="8">the guideline for the diagnosis and management of patients with stable ischemic heart disease: a </text>
<text top="1049" left="190" width="574" height="13" font="8">report of the American College of Cardiology/American Heart Association Task Force on Practice </text>
<text top="1066" left="190" width="577" height="13" font="8">Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses </text>
</page>
<page number="167" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 169 </text>
<text top="162" left="190" width="563" height="13" font="8">Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic </text>
<text top="180" left="190" width="248" height="13" font="8">Surgeons. Circulation. 2014;130:1749-67. </text>
<text top="198" left="105" width="66" height="13" font="8">S4.4.1.2-9. </text>
<text top="198" left="190" width="577" height="13" font="8">Taylor AM, Dymarkowski S, Hamaekers P, et al. MR coronary angiography and late-enhancement </text>
<text top="215" left="190" width="597" height="13" font="8">myocardial MR in children who underwent arterial switch surgery for transposition of great arteries. </text>
<text top="233" left="190" width="166" height="13" font="8">Radiology. 2005;234:542-7. </text>
<text top="251" left="105" width="672" height="13" font="8">S4.4.1.2-10.  Losay J, Touchot A, Serraf A, et al. Late outcome after arterial switch operation for transposition of </text>
<text top="269" left="190" width="286" height="13" font="8">the great arteries. Circulation. 2001;104:I121-6. </text>
<text top="287" left="105" width="656" height="13" font="8">S4.4.1.2-11.  Oda S, Nakano T, Sugiura J, et al. Twenty-eight years’ experience of arterial switch operation for </text>
<text top="305" left="190" width="572" height="13" font="8">transposition of the great arteries in a single institution. Eur J Cardiothorac Surg. 2012;42:674-9. </text>
<text top="341" left="105" width="524" height="17" font="38"><i><b>4.4.1.4. Congenitally Corrected Transposition of the Great Arteries </b></i></text>
<text top="372" left="105" width="66" height="13" font="8">S4.4.1.4-1. </text>
<text top="372" left="190" width="592" height="13" font="8">Lewis M, Ginns J, Rosenbaum M. Is systemic right ventricular function by cardiac MRI related to the </text>
<text top="390" left="190" width="584" height="13" font="8">degree of tricuspid regurgitation in congenitally corrected transposition of the great arteries? Int J </text>
<text top="408" left="190" width="150" height="13" font="8">Cardiol. 2014;174:586-9. </text>
<text top="425" left="105" width="66" height="13" font="8">S4.4.1.4-2. </text>
<text top="425" left="190" width="573" height="13" font="8">Grewal J, Crean A, Garceau P, et al. Subaortic right ventricular characteristics and relationship to </text>
<text top="443" left="190" width="601" height="13" font="8">exercise capacity in congenitally corrected transposition of the great arteries. J Am Soc Echocardiogr. </text>
<text top="461" left="190" width="108" height="13" font="8">2012;25:1215-21. </text>
<text top="479" left="105" width="66" height="13" font="8">S4.4.1.4-3. </text>
<text top="479" left="190" width="565" height="13" font="8">Mongeon F-P, Connolly HM, Dearani JA, et al. Congenitally corrected transposition of the great </text>
<text top="497" left="190" width="598" height="13" font="8">arteries ventricular function at the time of systemic atrioventricular valve replacement predicts long-</text>
<text top="514" left="190" width="370" height="13" font="8">term ventricular function. J Am Coll Cardiol. 2011;57:2008-17. </text>
<text top="532" left="105" width="66" height="13" font="8">S4.4.1.4-4. </text>
<text top="532" left="190" width="589" height="13" font="8">Prieto LR, Hordof AJ, Secic M, et al. Progressive tricuspid valve disease in patients with congenitally </text>
<text top="550" left="190" width="455" height="13" font="8">corrected transposition of the great arteries. Circulation. 1998;98:997-1005. </text>
<text top="568" left="105" width="66" height="13" font="8">S4.4.1.4-5. </text>
<text top="568" left="190" width="579" height="13" font="8">Buber J, McElhinney DB, Valente AM, et al. Tricuspid valve regurgitation in congenitally corrected </text>
<text top="585" left="190" width="597" height="13" font="8">transposition of the great arteries and a left ventricle to pulmonary artery conduit. Ann Thorac Surg. </text>
<text top="603" left="190" width="108" height="13" font="8">2015;99:1348-56. </text>
<text top="621" left="105" width="66" height="13" font="8">S4.4.1.4-6. </text>
<text top="621" left="190" width="533" height="13" font="8">Graham TP Jr, Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected </text>
<text top="639" left="190" width="574" height="13" font="8">transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36:255-61. </text>
<text top="657" left="105" width="66" height="13" font="8">S4.4.1.4-7. </text>
<text top="657" left="190" width="517" height="13" font="8">Huhta JC, Maloney JD, Ritter DG, et al. Complete atrioventricular block in patients with </text>
<text top="674" left="190" width="346" height="13" font="8">atrioventricular discordance. Circulation. 1983;67:1374-7. </text>
<text top="692" left="105" width="66" height="13" font="8">S4.4.1.4-8. </text>
<text top="692" left="190" width="530" height="13" font="8">Anderson RH, Becker AE, Arnold R, et al. The conducting tissues in congenitally corrected </text>
<text top="710" left="190" width="257" height="13" font="8">transposition. Circulation. 1974;50:911-23. </text>
<text top="728" left="105" width="66" height="13" font="8">S4.4.1.4-9. </text>
<text top="728" left="190" width="597" height="13" font="8">van Son JA, Danielson GK, Huhta JC, et al. Late results of systemic atrioventricular valve replacement </text>
<text top="746" left="190" width="421" height="13" font="8">in corrected transposition. J Thorac Cardiovasc Surg. 1995;109:642-52. </text>
<text top="764" left="105" width="645" height="13" font="8">S4.4.1.4-10.  Zaragoza-Macias E, Zaidi A, Dendukuri N, et al. Medical therapy for systemic right ventricles: a </text>
<text top="781" left="190" width="561" height="13" font="8">systematic review (part 1) for the 2018 AHA/ACC guideline for the management of adults with </text>
<text top="799" left="190" width="600" height="13" font="8">congenital heart disease: a report of the American College of Cardiology/American Heart Association </text>
<text top="817" left="190" width="411" height="13" font="8">Task Force on Clinical Practice Guidelines. Circulation. 2018; In press. </text>
<text top="835" left="105" width="680" height="13" font="8">S4.4.1.4-11.  Dore A, Houde C, Chan K-L, et al. Angiotensin receptor blockade and exercise capacity in adults with </text>
<text top="853" left="190" width="576" height="13" font="8">systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. </text>
<text top="870" left="190" width="108" height="13" font="8">2005;112:2411-6. </text>
<text top="888" left="105" width="653" height="13" font="8">S4.4.1.4-12.  Therrien J, Provost Y, Harrison J, et al. Effect of angiotensin receptor blockade on systemic right </text>
<text top="906" left="190" width="533" height="13" font="8">ventricular function and size: a small, randomized, placebo-controlled study. Int J Cardiol. </text>
<text top="924" left="190" width="108" height="13" font="8">2008;129:187-92. </text>
<text top="942" left="105" width="635" height="13" font="8">S4.4.1.4-13.  van der Bom T, Winter MM, Bouma BJ, et al. Effect of valsartan on systemic right ventricular </text>
<text top="960" left="190" width="583" height="13" font="8">function: a double-blind, randomized, placebo-controlled pilot trial. Circulation. 2013;127:322-30. </text>
<text top="977" left="105" width="651" height="13" font="8">S4.4.1.4-14.  Giardini A, Lovato L, Donti A, et al. Relation between right ventricular structural alterations and </text>
<text top="995" left="190" width="572" height="13" font="8">markers of adverse clinical outcome in adults with systemic right ventricle and either congenital </text>
<text top="1013" left="190" width="595" height="13" font="8">complete (after Senning operation) or congenitally corrected transposition of the great arteries. Am </text>
<text top="1031" left="190" width="165" height="13" font="8">J Cardiol. 2006;98:1277-82. </text>
<text top="1049" left="105" width="610" height="13" font="8">S4.4.1.4-15.  Scherptong RWC, Vliegen HW, Winter MM, et al. Tricuspid valve surgery in adults with a </text>
<text top="1066" left="190" width="523" height="13" font="8">dysfunctional systemic right ventricle: repair or replace? Circulation. 2009;119:1467-72. </text>
</page>
<page number="168" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 170 </text>
<text top="162" left="105" width="662" height="13" font="8">S4.4.1.4-16.  Beauchesne LM, Warnes CA, Connolly HM, et al. Outcome of the unoperated adult who presents </text>
<text top="179" left="190" width="579" height="13" font="8">with congenitally corrected transposition of the great arteries. J Am Coll Cardiol. 2002;40:285-90. </text>
<text top="216" left="105" width="626" height="19" font="34"><b>4.4.2. Fontan Palliation of Single Ventricle Physiology (Including Tricuspid </b></text>
<text top="241" left="105" width="336" height="19" font="34"><b>Atresia and Double Inlet Left Ventricle) </b></text>
<text top="273" left="105" width="55" height="13" font="8">S4.4.2-1. </text>
<text top="273" left="190" width="576" height="13" font="8">Khairy P, Fernandes SM, Mayer JE Jr, et al. Long-term survival, modes of death, and predictors of </text>
<text top="291" left="190" width="422" height="13" font="8">mortality in patients with Fontan surgery. Circulation. 2008;117:85-92. </text>
<text top="309" left="105" width="55" height="13" font="8">S4.4.2-2. </text>
<text top="309" left="190" width="528" height="13" font="8">Gatzoulis MA, Munk MD, Williams WG, et al. Definitive palliation with cavopulmonary or </text>
<text top="327" left="190" width="521" height="13" font="8">aortopulmonary shunts for adults with single ventricle physiology. Heart. 2000;83:51-7. </text>
<text top="345" left="105" width="55" height="13" font="8">S4.4.2-3. </text>
<text top="345" left="190" width="599" height="13" font="8">Cordina R, O’Meagher S, Gould H, et al. Skeletal muscle abnormalities and exercise capacity in adults </text>
<text top="363" left="190" width="295" height="13" font="8">with a Fontan circulation. Heart. 2013;99:1530-4. </text>
<text top="381" left="105" width="55" height="13" font="8">S4.4.2-4. </text>
<text top="381" left="190" width="547" height="13" font="8">Dulfer K, Duppen N, Blom NA, et al. Effects of exercise training on behavioral and emotional </text>
<text top="398" left="190" width="575" height="13" font="8">problems in adolescents with tetralogy of Fallot or a Fontan circulation: a randomized controlled </text>
<text top="416" left="190" width="215" height="13" font="8">trial. Int J Cardiol. 2014;172:e425-7. </text>
<text top="434" left="105" width="55" height="13" font="8">S4.4.2-5. </text>
<text top="434" left="190" width="582" height="13" font="8">Inai K, Saita Y, Takeda S, et al. Skeletal muscle hemodynamics and endothelial function in patients </text>
<text top="452" left="190" width="316" height="13" font="8">after Fontan operation. Am J Cardiol. 2004;93:792-7. </text>
<text top="469" left="105" width="55" height="13" font="8">S4.4.2-6. </text>
<text top="469" left="190" width="571" height="13" font="8">Kiesewetter CH, Sheron N, Vettukattill JJ, et al. Hepatic changes in the failing Fontan circulation. </text>
<text top="487" left="190" width="141" height="13" font="8">Heart. 2007;93:579-84. </text>
<text top="505" left="105" width="55" height="13" font="8">S4.4.2-7. </text>
<text top="505" left="190" width="561" height="13" font="8">Seddio F, Gorislavets N, Iacovoni A, et al. Is heart transplantation for complex congenital heart </text>
<text top="523" left="190" width="597" height="13" font="8">disease a good option? A 25-year single centre experience. Eur J Cardiothorac Surg. 2013;43:605-11. </text>
<text top="541" left="105" width="55" height="13" font="8">S4.4.2-8. </text>
<text top="541" left="190" width="590" height="13" font="8">Hebson CL, McCabe NM, Elder RW, et al. Hemodynamic phenotype of the failing Fontan in an adult </text>
<text top="559" left="190" width="260" height="13" font="8">population. Am J Cardiol. 2013;112:1943-7. </text>
<text top="577" left="105" width="55" height="13" font="8">S4.4.2-9. </text>
<text top="577" left="190" width="581" height="13" font="8">Davies RR, Sorabella RA, Yang J, et al. Outcomes after transplantation for “failed” Fontan: a single-</text>
<text top="594" left="190" width="427" height="13" font="8">institution experience. J Thorac Cardiovasc Surg. 2012;143:1183-92, e4. </text>
<text top="612" left="105" width="62" height="13" font="8">S4.4.2-10. </text>
<text top="612" left="190" width="538" height="13" font="8">Gamba A, Merlo M, Fiocchi R, et al. Heart transplantation in patients with previous Fontan </text>
<text top="630" left="190" width="332" height="13" font="8">operations. J Thorac Cardiovasc Surg. 2004;127:555-62. </text>
<text top="648" left="105" width="62" height="13" font="8">S4.4.2-11. </text>
<text top="648" left="190" width="584" height="13" font="8">Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, et al. Cardiac transplantation after the Fontan or </text>
<text top="665" left="190" width="321" height="13" font="8">Glenn procedure. J Am Coll Cardiol. 2004;44:2065-72. </text>
<text top="683" left="105" width="62" height="13" font="8">S4.4.2-12. </text>
<text top="683" left="190" width="580" height="13" font="8">Backer CL, Russell HM, Pahl E, et al. Heart transplantation for the failing Fontan. Ann Thorac Surg. </text>
<text top="701" left="190" width="101" height="13" font="8">2013;96:1413-9. </text>
<text top="719" left="105" width="62" height="13" font="8">S4.4.2-13. </text>
<text top="719" left="190" width="525" height="13" font="8">Triedman JK. Arrhythmias in adults with congenital heart disease. Heart. 2002;87:383-9. </text>
<text top="737" left="105" width="62" height="13" font="8">S4.4.2-14. </text>
<text top="737" left="190" width="554" height="13" font="8">Yap S-C, Harris L, Silversides CK, et al. Outcome of intra-atrial re-entrant tachycardia catheter </text>
<text top="755" left="190" width="598" height="13" font="8">ablation in adults with congenital heart disease: negative impact of age and complex atrial surgery. J </text>
<text top="773" left="190" width="206" height="13" font="8">Am Coll Cardiol. 2010;56:1589-96. </text>
<text top="790" left="105" width="62" height="13" font="8">S4.4.2-15. </text>
<text top="790" left="190" width="592" height="13" font="8">de Groot NMS, Atary JZ, Blom NA, et al. Long-term outcome after ablative therapy of postoperative </text>
<text top="808" left="190" width="543" height="13" font="8">atrial tachyarrhythmia in patients with congenital heart disease and characteristics of atrial </text>
<text top="826" left="190" width="449" height="13" font="8">tachyarrhythmia recurrences. Circ Arrhythm Electrophysiol. 2010;3:148-54. </text>
<text top="844" left="105" width="62" height="13" font="8">S4.4.2-16. </text>
<text top="844" left="190" width="566" height="13" font="8">Aboulhosn J, Williams R, Shivkumar K, et al. Arrhythmia recurrence in adult patients with single </text>
<text top="861" left="190" width="549" height="13" font="8">ventricle physiology following surgical Fontan conversion. Congenit Heart Dis. 2010;5:430-4. </text>
<text top="879" left="105" width="62" height="13" font="8">S4.4.2-17. </text>
<text top="879" left="190" width="592" height="13" font="8">Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwell Chamberlain Memorial Paper for congenital heart </text>
<text top="897" left="190" width="559" height="13" font="8">surgery. 111 Fontan conversions with arrhythmia surgery: surgical lessons and outcomes. Ann </text>
<text top="915" left="190" width="185" height="13" font="8">Thorac Surg. 2007;84:1457-65. </text>
<text top="933" left="105" width="62" height="13" font="8">S4.4.2-18. </text>
<text top="933" left="190" width="599" height="13" font="8">Takahashi K, Fynn-Thompson F, Cecchin F, et al. Clinical outcomes of Fontan conversion surgery with </text>
<text top="951" left="190" width="468" height="13" font="8">and without associated arrhythmia intervention. Int J Cardiol. 2009;137:260-6. </text>
<text top="969" left="105" width="62" height="13" font="8">S4.4.2-19. </text>
<text top="969" left="190" width="572" height="13" font="8">Hebert A, Mikkelsen UR, Thilen U, et al. Bosentan improves exercise capacity in adolescents and </text>
<text top="986" left="190" width="562" height="13" font="8">adults after Fontan operation: the TEMPO (Treatment With Endothelin Receptor Antagonist in </text>
<text top="1004" left="190" width="575" height="13" font="8">Fontan Patients, a Randomized, Placebo-Controlled, Double-Blind Study Measuring Peak Oxygen </text>
<text top="1022" left="190" width="313" height="13" font="8">Consumption) study. Circulation. 2014;130:2021-30. </text>
<text top="1040" left="105" width="62" height="13" font="8">S4.4.2-20. </text>
<text top="1040" left="190" width="583" height="13" font="8">Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on haemodynamic response to exercise </text>
<text top="1058" left="190" width="416" height="13" font="8">and exercise capacity in Fontan patients. Eur Heart J. 2008;29:1681-7. </text>
</page>
<page number="169" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 171 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.4.2-21. </text>
<text top="162" left="190" width="560" height="13" font="8">Goldberg DJ, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in </text>
<text top="180" left="190" width="544" height="13" font="8">children and young adults after the Fontan operation: a randomized, double-blind, placebo-</text>
<text top="198" left="190" width="345" height="13" font="8">controlled, crossover trial. Circulation. 2011;123:1185-93. </text>
<text top="215" left="105" width="62" height="13" font="8">S4.4.2-22. </text>
<text top="215" left="190" width="597" height="13" font="8">Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients with a failing Fontan circulation. </text>
<text top="233" left="190" width="183" height="13" font="8">Cardiol Young. 2009;19:331-9. </text>
<text top="251" left="105" width="62" height="13" font="8">S4.4.2-23. </text>
<text top="251" left="190" width="562" height="13" font="8">Bowater SE, Weaver RA, Thorne SA, et al. The safety and effects of bosentan in patients with a </text>
<text top="269" left="190" width="318" height="13" font="8">Fontan circulation. Congenit Heart Dis. 2012;7:243-9. </text>
<text top="286" left="105" width="62" height="13" font="8">S4.4.2-24. </text>
<text top="286" left="190" width="580" height="13" font="8">Derk G, Houser L, Miner P, et al. Efficacy of endothelin blockade in adults with Fontan physiology. </text>
<text top="304" left="190" width="211" height="13" font="8">Congenit Heart Dis. 2015;10:E11-6. </text>
<text top="322" left="105" width="62" height="13" font="8">S4.4.2-25. </text>
<text top="322" left="190" width="587" height="13" font="8">Schuuring MJ, Vis JC, van Dijk APJ, et al. Impact of bosentan on exercise capacity in adults after the </text>
<text top="340" left="190" width="481" height="13" font="8">Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690-8. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.4.2-26. </text>
<text top="358" left="190" width="501" height="13" font="8">Potter BJ, Leong-Sit P, Fernandes SM, et al. Effect of aspirin and warfarin therapy on </text>
<text top="375" left="190" width="578" height="13" font="8">thromboembolic events in patients with univentricular hearts and Fontan palliation. Int J Cardiol. </text>
<text top="393" left="190" width="108" height="13" font="8">2013;168:3940-3. </text>
<text top="411" left="105" width="62" height="13" font="8">S4.4.2-27. </text>
<text top="411" left="190" width="550" height="13" font="8">Harper AR, Crossland DS, Perri G, et al. Is alternative cardiac surgery an option in adults with </text>
<text top="429" left="190" width="556" height="13" font="8">congenital heart disease referred for thoracic organ transplantation? Eur J Cardiothorac Surg. </text>
<text top="447" left="190" width="101" height="13" font="8">2013;43:344-51. </text>
<text top="465" left="105" width="62" height="13" font="8">S4.4.2-28. </text>
<text top="465" left="190" width="573" height="13" font="8">John AS, Driscoll DJ, Warnes CA, et al. The use of oral budesonide in adolescents and adults with </text>
<text top="482" left="190" width="533" height="13" font="8">protein-losing enteropathy after the Fontan operation. Ann Thorac Surg. 2011;92:1451-6. </text>
<text top="500" left="105" width="62" height="13" font="8">S4.4.2-29. </text>
<text top="500" left="190" width="543" height="13" font="8">Schumacher KR, Cools M, Goldstein BH, et al. Oral budesonide treatment for protein-losing </text>
<text top="518" left="190" width="443" height="13" font="8">enteropathy in Fontan-palliated patients. Pediatr Cardiol. 2011;32:966-71. </text>
<text top="536" left="105" width="62" height="13" font="8">S4.4.2-30. </text>
<text top="536" left="190" width="559" height="13" font="8">John AS, Phillips SD, Driscoll DJ, et al. The use of octreotide to successfully treat protein-losing </text>
<text top="554" left="190" width="473" height="13" font="8">enteropathy following the Fontan operation. Congenit Heart Dis. 2011;6:653-6. </text>
<text top="572" left="105" width="62" height="13" font="8">S4.4.2-31. </text>
<text top="572" left="190" width="597" height="13" font="8">John AS, Johnson JA, Khan M, et al. Clinical outcomes and improved survival in patients with protein-</text>
<text top="589" left="190" width="479" height="13" font="8">losing enteropathy after the Fontan operation. J Am Coll Cardiol. 2014;64:54-62. </text>
<text top="607" left="105" width="62" height="13" font="8">S4.4.2-32. </text>
<text top="607" left="190" width="576" height="13" font="8">Nakagawa H, Shah N, Matsudaira K, et al. Characterization of reentrant circuit in macroreentrant </text>
<text top="625" left="190" width="585" height="13" font="8">right atrial tachycardia after surgical repair of congenital heart disease: isolated channels between </text>
<text top="643" left="190" width="354" height="13" font="8">scars allow “focal” ablation. Circulation. 2001;103:699-709. </text>
<text top="661" left="105" width="62" height="13" font="8">S4.4.2-33. </text>
<text top="661" left="190" width="581" height="13" font="8">Kürer CC, Tanner CS, Vetter VL. Electrophysiologic findings after Fontan repair of functional single </text>
<text top="678" left="190" width="265" height="13" font="8">ventricle. J Am Coll Cardiol. 1991;17:174-81. </text>
<text top="696" left="105" width="62" height="13" font="8">S4.4.2-34. </text>
<text top="696" left="190" width="558" height="13" font="8">Gelatt M, Hamilton RM, McCrindle BW, et al. Risk factors for atrial tachyarrhythmias after the </text>
<text top="714" left="190" width="324" height="13" font="8">Fontan operation. J Am Coll Cardiol. 1994;24:1735-41. </text>
<text top="732" left="105" width="62" height="13" font="8">S4.4.2-35. </text>
<text top="732" left="190" width="527" height="13" font="8">De Groot NM, Kuijper AF, Blom NA, et al. Three-dimensional distribution of bipolar atrial </text>
<text top="750" left="190" width="533" height="13" font="8">electrogram voltages in patients with congenital heart disease. Pacing Clin Electrophysiol. </text>
<text top="768" left="190" width="108" height="13" font="8">2001;24:1334-42. </text>
<text top="785" left="105" width="62" height="13" font="8">S4.4.2-36. </text>
<text top="785" left="190" width="580" height="13" font="8">Cohen MI, Bridges ND, Gaynor JW, et al. Modifications to the cavopulmonary anastomosis do not </text>
<text top="803" left="190" width="504" height="13" font="8">eliminate early sinus node dysfunction. J Thorac Cardiovasc Surg. 2000;120:891-900. </text>
<text top="821" left="105" width="62" height="13" font="8">S4.4.2-37. </text>
<text top="821" left="190" width="543" height="13" font="8">Balaji S, Daga A, Bradley DJ, et al. An international multicenter study comparing arrhythmia </text>
<text top="839" left="190" width="568" height="13" font="8">prevalence between the intracardiac lateral tunnel and the extracardiac conduit type of Fontan </text>
<text top="857" left="190" width="332" height="13" font="8">operations. J Thorac Cardiovasc Surg. 2014;148:576-81. </text>
<text top="874" left="105" width="62" height="13" font="8">S4.4.2-38. </text>
<text top="874" left="190" width="582" height="13" font="8">de Groot NMS, Schalij MJ, Zeppenfeld K, et al. Voltage and activation mapping: how the recording </text>
<text top="892" left="190" width="573" height="13" font="8">technique affects the outcome of catheter ablation procedures in patients with congenital heart </text>
<text top="910" left="190" width="245" height="13" font="8">disease. Circulation. 2003;108:2099-106. </text>
<text top="928" left="105" width="62" height="13" font="8">S4.4.2-39. </text>
<text top="928" left="190" width="555" height="13" font="8">Cohen MI, Vetter VL, Wernovsky G, et al. Epicardial pacemaker implantation and follow-up in </text>
<text top="946" left="190" width="588" height="13" font="8">patients with a single ventricle after the Fontan operation. J Thorac Cardiovasc Surg. 2001;121:804-</text>
<text top="964" left="190" width="22" height="13" font="8">11. </text>
<text top="981" left="105" width="62" height="13" font="8">S4.4.2-40. </text>
<text top="981" left="190" width="582" height="13" font="8">Gentles TL, Gauvreau K, Mayer JE Jr, et al. Functional outcome after the Fontan operation: factors </text>
<text top="999" left="190" width="428" height="13" font="8">influencing late morbidity. J Thorac Cardiovasc Surg. 1997;114:392-403. </text>
<text top="1017" left="105" width="62" height="13" font="8">S4.4.2-41. </text>
<text top="1017" left="190" width="583" height="13" font="8">Cohen MI, Wernovsky G, Vetter VL, et al. Sinus node function after a systematically staged Fontan </text>
<text top="1035" left="190" width="240" height="13" font="8">procedure. Circulation. 1998;98:II352-8. </text>
<text top="1053" left="105" width="62" height="13" font="8">S4.4.2-42. </text>
<text top="1053" left="190" width="582" height="13" font="8">Barber BJ, Burch GH, Tripple D, et al. Resolution of plastic bronchitis with atrial pacing in a patient </text>
<text top="1071" left="190" width="326" height="13" font="8">with Fontan physiology. Pediatr Cardiol. 2004;25:73-6. </text>
</page>
<page number="170" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 172 </text>
<text top="162" left="105" width="62" height="13" font="8">S4.4.2-43. </text>
<text top="162" left="190" width="594" height="13" font="8">Nielsen JC, Pedersen AK, Mortensen PT, et al. Programming a fixed long atrioventricular delay is not </text>
<text top="180" left="190" width="530" height="13" font="8">effective in preventing ventricular pacing in patients with sick sinus syndrome. Europace. </text>
<text top="198" left="190" width="93" height="13" font="8">1999;1:113-20. </text>
<text top="215" left="105" width="62" height="13" font="8">S4.4.2-44. </text>
<text top="215" left="190" width="597" height="13" font="8">Abrams DJ, Earley MJ, Sporton SC, et al. Comparison of noncontact and electroanatomic mapping to </text>
<text top="233" left="190" width="552" height="13" font="8">identify scar and arrhythmia late after the Fontan procedure. Circulation. 2007;115:1738-46. </text>
<text top="251" left="105" width="62" height="13" font="8">S4.4.2-45. </text>
<text top="251" left="190" width="601" height="13" font="8">Rosenthal E, Qureshi SA, Crick JC. Successful long-term ventricular pacing via the coronary sinus after </text>
<text top="269" left="190" width="392" height="13" font="8">the Fontan operation. Pacing Clin Electrophysiol. 1995;18:2103-5. </text>
<text top="287" left="105" width="62" height="13" font="8">S4.4.2-46. </text>
<text top="286" left="190" width="557" height="13" font="8">Blackburn ME, Gibbs JL. Ventricular pacing from the coronary sinus of a patient with a Fontan </text>
<text top="304" left="190" width="227" height="13" font="8">circulation. Br Heart J. 1993;70:578-9. </text>
<text top="322" left="105" width="62" height="13" font="8">S4.4.2-47. </text>
<text top="322" left="190" width="553" height="13" font="8">Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation. </text>
<text top="340" left="190" width="108" height="13" font="8">2007;115:534-45. </text>
<text top="358" left="105" width="62" height="13" font="8">S4.4.2-48. </text>
<text top="358" left="190" width="586" height="13" font="8">Piran S, Veldtman G, Siu S, et al. Heart failure and ventricular dysfunction in patients with single or </text>
<text top="375" left="190" width="337" height="13" font="8">systemic right ventricles. Circulation. 2002;105:1189-94. </text>
<text top="393" left="105" width="62" height="13" font="8">S4.4.2-49. </text>
<text top="393" left="190" width="558" height="13" font="8">Wells R, Khairy P, Harris L, et al. Dofetilide for atrial arrhythmias in congenital heart disease: a </text>
<text top="411" left="190" width="371" height="13" font="8">multicenter study. Pacing Clin Electrophysiol. 2009;32:1313-8. </text>
<text top="429" left="105" width="62" height="13" font="8">S4.4.2-50. </text>
<text top="429" left="190" width="570" height="13" font="8">Thorne SA, Barnes I, Cullinan P, et al. Amiodarone-associated thyroid dysfunction: risk factors in </text>
<text top="447" left="190" width="400" height="13" font="8">adults with congenital heart disease. Circulation. 1999;100:149-54. </text>
<text top="465" left="105" width="62" height="13" font="8">S4.4.2-51. </text>
<text top="465" left="190" width="543" height="13" font="8">Garg R, Powell AJ, Sena L, et al. Effects of metallic implants on magnetic resonance imaging </text>
<text top="482" left="190" width="369" height="13" font="8">evaluation of Fontan palliation. Am J Cardiol. 2005;95:688-91. </text>
<text top="500" left="105" width="62" height="13" font="8">S4.4.2-52. </text>
<text top="500" left="190" width="566" height="13" font="8">Prabhu SP, Mahmood S, Sena L, et al. MDCT evaluation of pulmonary embolism in children and </text>
<text top="518" left="190" width="549" height="13" font="8">young adults following a lateral tunnel Fontan procedure: optimizing contrast-enhancement </text>
<text top="536" left="190" width="263" height="13" font="8">techniques. Pediatr Radiol. 2009;39:938-44. </text>
<text top="554" left="105" width="62" height="13" font="8">S4.4.2-53. </text>
<text top="554" left="190" width="577" height="13" font="8">Asrani SK, Warnes CA, Kamath PS. Hepatocellular carcinoma after the Fontan procedure. N Engl J </text>
<text top="572" left="190" width="142" height="13" font="8">Med. 2013;368:1756-7. </text>
<text top="589" left="105" width="62" height="13" font="8">S4.4.2-54. </text>
<text top="589" left="190" width="580" height="13" font="8">Ono M, Boethig D, Goerler H, et al. Clinical outcome of patients 20 years after Fontan operation—</text>
<text top="607" left="190" width="477" height="13" font="8">effect of fenestration on late morbidity. Eur J Cardiothorac Surg. 2006;30:923-9. </text>
<text top="625" left="105" width="62" height="13" font="8">S4.4.2-55. </text>
<text top="625" left="190" width="573" height="13" font="8">Atz AM, Travison TG, McCrindle BW, et al. Late status of Fontan patients with persistent surgical </text>
<text top="643" left="190" width="294" height="13" font="8">fenestration. J Am Coll Cardiol. 2011;57:2437-43. </text>
<text top="661" left="105" width="62" height="13" font="8">S4.4.2-56. </text>
<text top="661" left="190" width="561" height="13" font="8">Poterucha JT, Johnson JN, Taggart NW, et al. Embolization of veno-venous collaterals after the </text>
<text top="678" left="190" width="550" height="13" font="8">Fontan operation is associated with decreased survival. Congenit Heart Dis. 2015;10:E230-6. </text>
<text top="696" left="105" width="62" height="13" font="8">S4.4.2-57. </text>
<text top="696" left="190" width="541" height="13" font="8">Mets JM, Bergersen L, Mayer JE Jr, et al. Outcomes of stent implantation for obstruction of </text>
<text top="714" left="190" width="494" height="13" font="8">intracardiac lateral tunnel Fontan pathways. Circ Cardiovasc Interv. 2013;6:92-100. </text>
<text top="732" left="105" width="62" height="13" font="8">S4.4.2-58. </text>
<text top="732" left="190" width="586" height="13" font="8">Ohuchi H, Yasuda K, Miyazaki A, et al. Haemodynamic characteristics before and after the onset of </text>
<text top="750" left="190" width="538" height="13" font="8">protein losing enteropathy in patients after the Fontan operation. Eur J Cardiothorac Surg. </text>
<text top="768" left="190" width="101" height="13" font="8">2013;43:e49-57. </text>
<text top="785" left="105" width="62" height="13" font="8">S4.4.2-59. </text>
<text top="785" left="190" width="583" height="13" font="8">Downing TE, McDonnell A, Zhu X, et al. Cumulative medical radiation exposure throughout staged </text>
<text top="803" left="190" width="506" height="13" font="8">palliation of single ventricle congenital heart disease. Pediatr Cardiol. 2015;36:190-5. </text>
<text top="821" left="105" width="62" height="13" font="8">S4.4.2-60. </text>
<text top="821" left="190" width="555" height="13" font="8">Mahnke CB, Boyle GJ, Janosky JE, et al. Anticoagulation and incidence of late cerebrovascular </text>
<text top="839" left="190" width="442" height="13" font="8">accidents following the Fontan procedure. Pediatr Cardiol. 2005;26:56-61. </text>
<text top="857" left="105" width="62" height="13" font="8">S4.4.2-61. </text>
<text top="857" left="190" width="594" height="13" font="8">Triedman JK, Alexander ME, Love BA, et al. Influence of patient factors and ablative technologies on </text>
<text top="874" left="190" width="538" height="13" font="8">outcomes of radiofrequency ablation of intra-atrial re-entrant tachycardia in patients with </text>
<text top="892" left="190" width="365" height="13" font="8">congenital heart disease. J Am Coll Cardiol. 2002;39:1827-35. </text>
<text top="910" left="105" width="62" height="13" font="8">S4.4.2-62. </text>
<text top="910" left="190" width="571" height="13" font="8">Deal BJ, Mavroudis C, Backer CL, et al. Comparison of anatomic isthmus block with the modified </text>
<text top="928" left="190" width="589" height="13" font="8">right atrial maze procedure for late atrial tachycardia in Fontan patients. Circulation. 2002;106:575-</text>
<text top="946" left="190" width="14" height="13" font="8">9. </text>
<text top="964" left="105" width="62" height="13" font="8">S4.4.2-63. </text>
<text top="964" left="190" width="556" height="13" font="8">Rychik J, Veldtman G, Rand E, et al. The precarious state of the liver after a Fontan operation: </text>
<text top="981" left="190" width="464" height="13" font="8">summary of a multidisciplinary symposium. Pediatr Cardiol. 2012;33:1001-12. </text>
<text top="999" left="105" width="62" height="13" font="8">S4.4.2-64. </text>
<text top="999" left="190" width="498" height="13" font="8">Monagle P, Cochrane A, Roberts R, et al. A multicenter, randomized trial comparing </text>
<text top="1017" left="190" width="597" height="13" font="8">heparin/warfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan </text>
<text top="1035" left="190" width="341" height="13" font="8">procedure in children. J Am Coll Cardiol. 2011;58:645-51. </text>
<text top="1053" left="105" width="62" height="13" font="8">S4.4.2-65. </text>
<text top="1053" left="190" width="570" height="13" font="8">McCrindle BW, Manlhiot C, Cochrane A, et al. Factors associated with thrombotic complications </text>
<text top="1071" left="190" width="562" height="13" font="8">after the Fontan procedure: a secondary analysis of a multicenter, randomized trial of primary </text>
<text top="1088" left="190" width="565" height="13" font="8">thromboprophylaxis for 2 years after the Fontan procedure. J Am Coll Cardiol. 2013;61:346-53. </text>
</page>
<page number="171" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 173 </text>
<text top="163" left="105" width="397" height="19" font="34"><b>4.4.6. Severe PAH and Eisenmenger Syndrome </b></text>
<text top="206" left="105" width="158" height="17" font="38"><i><b>4.4.6.1. Severe PAH </b></i></text>
<text top="237" left="105" width="66" height="13" font="8">S4.4.6.1-1. </text>
<text top="237" left="190" width="566" height="13" font="8">D’Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial </text>
<text top="254" left="190" width="400" height="13" font="8">hypertension after shunt closure. Int J Cardiol. 2013;168:3797-801. </text>
<text top="272" left="105" width="66" height="13" font="8">S4.4.6.1-2. </text>
<text top="272" left="190" width="596" height="13" font="8">Barst RJ, Ivy DD, Foreman AJ, et al. Four- and seven-year outcomes of patients with congenital heart </text>
<text top="289" left="190" width="558" height="13" font="8">disease-associated pulmonary arterial hypertension (from the REVEAL Registry). Am J Cardiol. </text>
<text top="307" left="190" width="108" height="13" font="8">2014;113:147-55. </text>
<text top="325" left="105" width="66" height="13" font="8">S4.4.6.1-3. </text>
<text top="325" left="190" width="586" height="13" font="8">Duffels MGJ, Engelfriet PM, Berger RMF, et al. Pulmonary arterial hypertension in congenital heart </text>
<text top="343" left="190" width="553" height="13" font="8">disease: an epidemiologic perspective from a Dutch registry. Int J Cardiol. 2007;120:198-204. </text>
<text top="361" left="105" width="66" height="13" font="8">S4.4.6.1-4. </text>
<text top="361" left="190" width="576" height="13" font="8">Engelfriet PM, Duffels MGJ, Möller T, et al. Pulmonary arterial hypertension in adults born with a </text>
<text top="379" left="190" width="591" height="13" font="8">heart septal defect: the Euro Heart Survey on adult congenital heart disease. Heart. 2007;93:682-7. </text>
<text top="396" left="105" width="66" height="13" font="8">S4.4.6.1-5. </text>
<text top="396" left="190" width="572" height="13" font="8">Lowe BS, Therrien J, Ionescu-Ittu R, et al. Diagnosis of pulmonary hypertension in the congenital </text>
<text top="414" left="190" width="519" height="13" font="8">heart disease adult population impact on outcomes. J Am Coll Cardiol. 2011;58:538-46. </text>
<text top="432" left="105" width="66" height="13" font="8">S4.4.6.1-6. </text>
<text top="432" left="190" width="537" height="13" font="8">Manes A, Palazzini M, Leci E, et al. Current era survival of patients with pulmonary arterial </text>
<text top="450" left="190" width="580" height="13" font="8">hypertension associated with congenital heart disease: a comparison between clinical subgroups. </text>
<text top="468" left="190" width="172" height="13" font="8">Eur Heart J. 2014;35:716-24. </text>
<text top="486" left="105" width="66" height="13" font="8">S4.4.6.1-7. </text>
<text top="486" left="190" width="599" height="13" font="8">Gabriels C, De Meester P, Pasquet A, et al. A different view on predictors of pulmonary hypertension </text>
<text top="503" left="190" width="381" height="13" font="8">in secundum atrial septal defect. Int J Cardiol. 2014;176:833-40. </text>
<text top="521" left="105" width="66" height="13" font="8">S4.4.6.1-8. </text>
<text top="521" left="190" width="567" height="13" font="8">O’Donnell C, Ruygrok PN, Whyte K, et al. Progressive pulmonary hypertension post atrial septal </text>
<text top="539" left="190" width="591" height="13" font="8">defect device closure—early symptomatic improvement may not predict outcome. Heart Lung Circ. </text>
<text top="557" left="190" width="93" height="13" font="8">2010;19:713-6. </text>
<text top="575" left="105" width="66" height="13" font="8">S4.4.6.1-9. </text>
<text top="575" left="190" width="583" height="13" font="8">Van De Bruaene A, Delcroix M, Pasquet A, et al. The importance of pulmonary artery pressures on </text>
<text top="592" left="190" width="555" height="13" font="8">late atrial arrhythmia in transcatheter and surgically closed ASD type secundum. Int J Cardiol. </text>
<text top="610" left="190" width="101" height="13" font="8">2011;152:192-5. </text>
<text top="628" left="105" width="646" height="13" font="8">S4.4.6.1-10.  Van De Bruaene A, Moons P, Belmans A, et al. Predictive model for late atrial arrhythmia after </text>
<text top="646" left="190" width="382" height="13" font="8">closure of an atrial septal defect. Int J Cardiol. 2013;164:318-22. </text>
<text top="664" left="105" width="678" height="13" font="8">S4.4.6.1-11.  Berner M, Beghetti M, Spahr-Schopfer I, et al. Inhaled nitric oxide to test the vasodilator capacity of </text>
<text top="682" left="190" width="589" height="13" font="8">the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital </text>
<text top="699" left="190" width="260" height="13" font="8">heart disease. Am J Cardiol. 1996;77:532-5. </text>
<text top="717" left="105" width="627" height="13" font="8">S4.4.6.1-12.  Balint OH, Samman A, Haberer K, et al. Outcomes in patients with pulmonary hypertension </text>
<text top="735" left="190" width="469" height="13" font="8">undergoing percutaneous atrial septal defect closure. Heart. 2008;94:1189-93. </text>
<text top="753" left="105" width="646" height="13" font="8">S4.4.6.1-13.  Gorenflo M, Gu H, Xu Z. Peri-operative pulmonary hypertension in paediatric patients: current </text>
<text top="771" left="190" width="472" height="13" font="8">strategies in children with congenital heart disease. Cardiology. 2010;116:10-7. </text>
<text top="789" left="105" width="667" height="13" font="8">S4.4.6.1-14.  Huang J-B, Liu Y-L, Yu C-T, et al. Lung biopsy findings in previously inoperable patients with severe </text>
<text top="806" left="190" width="574" height="13" font="8">pulmonary hypertension associated with congenital heart disease. Int J Cardiol. 2011;151:76-83. </text>
<text top="824" left="105" width="661" height="13" font="8">S4.4.6.1-15.  Neutze JM, Ishikawa T, Clarkson PM, et al. Assessment and follow-up of patients with ventricular </text>
<text top="842" left="190" width="528" height="13" font="8">septal defect and elevated pulmonary vascular resistance. Am J Cardiol. 1989;63:327-31. </text>
<text top="860" left="105" width="686" height="13" font="8">S4.4.6.1-16.  Steele PM, Fuster V, Cohen M, et al. Isolated atrial septal defect with pulmonary vascular obstructive </text>
<text top="878" left="190" width="561" height="13" font="8">disease—long-term follow-up and prediction of outcome after surgical correction. Circulation. </text>
<text top="895" left="190" width="108" height="13" font="8">1987;76:1037-42. </text>
<text top="913" left="105" width="668" height="13" font="8">S4.4.6.1-17.  Yong G, Khairy P, De Guise P, et al. Pulmonary arterial hypertension in patients with transcatheter </text>
<text top="931" left="190" width="581" height="13" font="8">closure of secundum atrial septal defects: a longitudinal study. Circ Cardiovasc Interv. 2009;2:455-</text>
<text top="949" left="190" width="22" height="13" font="8">62. </text>
<text top="967" left="105" width="680" height="13" font="8">S4.4.6.1-18.  Balzer DT, Kort HW, Day RW, et al. Inhaled nitric oxide as a preoperative test (INOP Test I): the INOP </text>
<text top="985" left="190" width="285" height="13" font="8">Test Study Group. Circulation. 2002;106:I76-81. </text>
<text top="1002" left="105" width="598" height="13" font="8">S4.4.6.1-19.  Opotowsky AR, Ojeda J, Rogers F, et al. A simple echocardiographic prediction rule for </text>
<text top="1020" left="190" width="502" height="13" font="8">hemodynamics in pulmonary hypertension. Circ Cardiovasc Imaging. 2012;5:765-75. </text>
<text top="1038" left="105" width="670" height="13" font="8">S4.4.6.1-20.  Opotowsky AR, Clair M, Afilalo J, et al. A simple echocardiographic method to estimate pulmonary </text>
<text top="1056" left="190" width="307" height="13" font="8">vascular resistance. Am J Cardiol. 2013;112:873-82. </text>
</page>
<page number="172" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 174 </text>
<text top="162" left="105" width="603" height="13" font="8">S4.4.6.1-21.  Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary </text>
<text top="180" left="190" width="294" height="13" font="8">hypertension. J Am Coll Cardiol. 2013;62:D34-41. </text>
<text top="216" left="105" width="252" height="17" font="38"><i><b>4.4.6.2. Eisenmenger Syndrome </b></i></text>
<text top="247" left="105" width="66" height="13" font="8">S4.4.6.2-1. </text>
<text top="247" left="190" width="563" height="13" font="8">Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger </text>
<text top="265" left="190" width="521" height="13" font="8">syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation. </text>
<text top="283" left="190" width="93" height="13" font="8">2010;121:20-5. </text>
<text top="301" left="105" width="66" height="13" font="8">S4.4.6.2-2. </text>
<text top="301" left="190" width="601" height="13" font="8">Gatzoulis MA, Beghetti M, Galiè N, et al. Longer-term bosentan therapy improves functional capacity </text>
<text top="318" left="190" width="557" height="13" font="8">in Eisenmenger syndrome: results of the BREATHE-5 open-label extension study. Int J Cardiol. </text>
<text top="336" left="190" width="101" height="13" font="8">2008;127:27-32. </text>
<text top="354" left="105" width="66" height="13" font="8">S4.4.6.2-3. </text>
<text top="354" left="190" width="593" height="13" font="8">Galiè N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: </text>
<text top="372" left="190" width="573" height="13" font="8">a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006;114:48-54. </text>
<text top="389" left="105" width="66" height="13" font="8">S4.4.6.2-4. </text>
<text top="389" left="190" width="563" height="13" font="8">Diller G-P, Alonso-Gonzalez R, Dimopoulos K, et al. Disease targeting therapies in patients with </text>
<text top="407" left="190" width="512" height="13" font="8">Eisenmenger syndrome: response to treatment and long-term efficiency. Int J Cardiol. </text>
<text top="425" left="190" width="101" height="13" font="8">2013;167:840-7. </text>
<text top="443" left="105" width="66" height="13" font="8">S4.4.6.2-5. </text>
<text top="443" left="190" width="597" height="13" font="8">D’Alto M, Romeo E, Argiento P, et al. Therapy for pulmonary arterial hypertension due to congenital </text>
<text top="460" left="190" width="399" height="13" font="8">heart disease and Down’s syndrome. Int J Cardiol. 2013;164:323-6. </text>
<text top="478" left="105" width="66" height="13" font="8">S4.4.6.2-6. </text>
<text top="478" left="190" width="540" height="13" font="8">Iversen K, Jensen AS, Jensen TV, et al. Combination therapy with bosentan and sildenafil in </text>
<text top="496" left="190" width="550" height="13" font="8">Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J. </text>
<text top="514" left="190" width="108" height="13" font="8">2010;31:1124-31. </text>
<text top="532" left="105" width="66" height="13" font="8">S4.4.6.2-7. </text>
<text top="532" left="190" width="575" height="13" font="8">Baptista R, Castro G, da Silva AM, et al. Long-term effect of bosentan in pulmonary hypertension </text>
<text top="550" left="190" width="496" height="13" font="8">associated with complex congenital heart disease. Rev Port Cardiol. 2013;32:123-9. </text>
<text top="568" left="105" width="66" height="13" font="8">S4.4.6.2-8. </text>
<text top="568" left="190" width="563" height="13" font="8">Crepaz R, Romeo C, Montanaro D, et al. Long-term results of treatment with bosentan in adult </text>
<text top="585" left="190" width="588" height="13" font="8">Eisenmenger’s syndrome patients with Down’s syndrome related to congenital heart disease. BMC </text>
<text top="603" left="190" width="187" height="13" font="8">Cardiovasc Disord. 2013;13:74. </text>
<text top="621" left="105" width="66" height="13" font="8">S4.4.6.2-9. </text>
<text top="621" left="190" width="574" height="13" font="8">Duffels MGJ, Vis JC, van Loon RLE, et al. Down patients with Eisenmenger syndrome: is bosentan </text>
<text top="639" left="190" width="316" height="13" font="8">treatment an option? Int J Cardiol. 2009;134:378-83. </text>
<text top="657" left="105" width="685" height="13" font="8">S4.4.6.2-10.  Serino G, Guazzi M, Micheletti A, et al. Effect of bosentan on exercise capacity and clinical worsening </text>
<text top="674" left="190" width="575" height="13" font="8">in patients with dual Down and Eisenmenger syndrome. Clin Med Insights Cardiol. 2013;7:29-34. </text>
<text top="692" left="105" width="613" height="13" font="8">S4.4.6.2-11.  Zhang Z-N, Jiang X, Zhang R, et al. Oral sildenafil treatment for Eisenmenger syndrome: a </text>
<text top="710" left="190" width="407" height="13" font="8">prospective, open-label, multicentre study. Heart. 2011;97:1876-81. </text>
<text top="728" left="105" width="685" height="13" font="8">S4.4.6.2-12.  Garg N, Tripathy N, Sinha N. Comparative efficacy of sildenafil in Eisenmenger’s syndrome secondary </text>
<text top="746" left="190" width="572" height="13" font="8">to atrial septal defect versus ventricular septal defect: a cardiac catheterisation follow-up study. </text>
<text top="764" left="190" width="183" height="13" font="8">Cardiol Young. 2011;21:631-8. </text>
<text top="781" left="105" width="676" height="13" font="8">S4.4.6.2-13.  Tay ELW, Papaphylactou M, Diller G-P, et al. Quality of life and functional capacity can be improved </text>
<text top="799" left="190" width="581" height="13" font="8">in patients with Eisenmenger syndrome with oral sildenafil therapy. Int J Cardiol. 2011;149:372-6. </text>
<text top="817" left="105" width="678" height="13" font="8">S4.4.6.2-14.  Bharani A, Patel A, Saraf J, et al. Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial </text>
<text top="835" left="190" width="268" height="13" font="8">hypertension. Indian Heart J. 2007;59:323-8. </text>
<text top="853" left="105" width="673" height="13" font="8">S4.4.6.2-15.  Mukhopadhyay S, Sharma M, Ramakrishnan S, et al. Phosphodiesterase-5 inhibitor in Eisenmenger </text>
<text top="870" left="190" width="459" height="13" font="8">syndrome: a preliminary observational study. Circulation. 2006;114:1807-10. </text>
<text top="888" left="105" width="676" height="13" font="8">S4.4.6.2-16.  Singh TP, Rohit M, Grover A, et al. A randomized, placebo-controlled, double-blind, crossover study </text>
<text top="906" left="190" width="599" height="13" font="8">to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension. Am Heart </text>
<text top="924" left="190" width="131" height="13" font="8">J. 2006;151:851.e1-5. </text>
<text top="942" left="105" width="664" height="13" font="8">S4.4.6.2-17.  Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary </text>
<text top="960" left="190" width="575" height="13" font="8">hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the </text>
<text top="977" left="190" width="558" height="13" font="8">European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. </text>
<text top="995" left="190" width="115" height="13" font="8">2009;30:2493-537. </text>
<text top="1013" left="105" width="654" height="13" font="8">S4.4.6.2-18.  D’Alto M, Romeo E, Argiento P, et al. Bosentan-sildenafil association in patients with congenital </text>
<text top="1031" left="190" width="578" height="13" font="8">heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol. </text>
<text top="1049" left="190" width="108" height="13" font="8">2012;155:378-82. </text>
</page>
<page number="173" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 175 </text>
<text top="163" left="105" width="229" height="19" font="34"><b>4.4.7. Coronary Anomalies </b></text>
<text top="196" left="105" width="55" height="13" font="8">S4.4.7-1. </text>
<text top="195" left="190" width="563" height="13" font="8">Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a </text>
<text top="213" left="190" width="469" height="13" font="8">population undergoing active surveillance. J Am Coll Cardiol. 2011;58:1254-61. </text>
<text top="231" left="105" width="55" height="13" font="8">S4.4.7-2. </text>
<text top="231" left="190" width="558" height="13" font="8">Krasuski RA, Magyar D, Hart S, et al. Long-term outcome and impact of surgery on adults with </text>
<text top="249" left="190" width="552" height="13" font="8">coronary arteries originating from the opposite coronary cusp. Circulation. 2011;123:154-62. </text>
<text top="267" left="105" width="55" height="13" font="8">S4.4.7-3. </text>
<text top="267" left="190" width="544" height="13" font="8">Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of </text>
<text top="284" left="190" width="385" height="13" font="8">autopsies in military recruits. Ann Intern Med. 2004;141:829-34. </text>
<text top="302" left="105" width="55" height="13" font="8">S4.4.7-4. </text>
<text top="302" left="190" width="596" height="13" font="8">Frescura C, Basso C, Thiene G, et al. Anomalous origin of coronary arteries and risk of sudden death: </text>
<text top="320" left="190" width="584" height="13" font="8">a study based on an autopsy population of congenital heart disease. Hum Pathol. 1998;29:689-95. </text>
<text top="338" left="105" width="55" height="13" font="8">S4.4.7-5. </text>
<text top="338" left="190" width="572" height="13" font="8">Basso C, Maron BJ, Corrado D, et al. Clinical profile of congenital coronary artery anomalies with </text>
<text top="356" left="190" width="592" height="13" font="8">origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll </text>
<text top="374" left="190" width="165" height="13" font="8">Cardiol. 2000;35:1493-501. </text>
<text top="391" left="105" width="55" height="13" font="8">S4.4.7-6. </text>
<text top="391" left="190" width="572" height="13" font="8">Kaushal S, Backer CL, Popescu AR, et al. Intramural coronary length correlates with symptoms in </text>
<text top="409" left="190" width="568" height="13" font="8">patients with anomalous aortic origin of the coronary artery. Ann Thorac Surg. 2011;92:986-91. </text>
<text top="427" left="105" width="55" height="13" font="8">S4.4.7-7. </text>
<text top="427" left="190" width="546" height="13" font="8">Sharma V, Burkhart HM, Dearani JA, et al. Surgical unroofing of anomalous aortic origin of a </text>
<text top="445" left="190" width="460" height="13" font="8">coronary artery: a single-center experience. Ann Thorac Surg. 2014;98:941-5. </text>
<text top="463" left="105" width="55" height="13" font="8">S4.4.7-8. </text>
<text top="463" left="190" width="601" height="13" font="8">Frommelt PC, Sheridan DC, Berger S, et al. Ten-year experience with surgical unroofing of anomalous </text>
<text top="480" left="190" width="561" height="13" font="8">aortic origin of a coronary artery from the opposite sinus with an interarterial course. J Thorac </text>
<text top="498" left="190" width="216" height="13" font="8">Cardiovasc Surg. 2011;142:1046-51. </text>
<text top="516" left="105" width="55" height="13" font="8">S4.4.7-9. </text>
<text top="516" left="190" width="570" height="13" font="8">Angelini P, Uribe C, Monge J, et al. Origin of the right coronary artery from the opposite sinus of </text>
<text top="534" left="190" width="566" height="13" font="8">Valsalva in adults: characterization by intravascular ultrasonography at baseline and after stent </text>
<text top="552" left="190" width="348" height="13" font="8">angioplasty. Catheter Cardiovasc Interv. 2015;86:199-208. </text>
<text top="570" left="105" width="62" height="13" font="8">S4.4.7-10. </text>
<text top="570" left="190" width="551" height="13" font="8">Opolski MP, Pregowski J, Kruk M, et al. Prevalence and characteristics of coronary anomalies </text>
<text top="587" left="190" width="574" height="13" font="8">originating from the opposite sinus of Valsalva in 8,522 patients referred for coronary computed </text>
<text top="605" left="190" width="345" height="13" font="8">tomography angiography. Am J Cardiol. 2013;111:1361-7. </text>
<text top="623" left="105" width="62" height="13" font="8">S4.4.7-11. </text>
<text top="623" left="190" width="592" height="13" font="8">Lee H-J, Hong YJ, Kim HY, et al. Anomalous origin of the right coronary artery from the left coronary </text>
<text top="641" left="190" width="570" height="13" font="8">sinus with an interarterial course: subtypes and clinical importance. Radiology. 2012;262:101-8. </text>
<text top="659" left="105" width="62" height="13" font="8">S4.4.7-12. </text>
<text top="659" left="190" width="547" height="13" font="8">Brothers J, Gaynor JW, Paridon S, et al. Anomalous aortic origin of a coronary artery with an </text>
<text top="677" left="190" width="576" height="13" font="8">interarterial course: understanding current management strategies in children and young adults. </text>
<text top="694" left="190" width="196" height="13" font="8">Pediatr Cardiol. 2009;30:911-21. </text>
<text top="712" left="105" width="62" height="13" font="8">S4.4.7-13. </text>
<text top="712" left="190" width="579" height="13" font="8">Poynter JA, Williams WG, McIntyre S, et al. Anomalous aortic origin of a coronary artery: a report </text>
<text top="730" left="190" width="538" height="13" font="8">from the Congenital Heart Surgeons Society Registry. World J Pediatr Congenit Heart Surg. </text>
<text top="748" left="190" width="86" height="13" font="8">2014;5:22-30. </text>
<text top="766" left="105" width="62" height="13" font="8">S4.4.7-14. </text>
<text top="766" left="190" width="543" height="13" font="8">Brothers JA, Gaynor JW, Jacobs JP, et al. The Congenital Heart Surgeons’ Society Registry of </text>
<text top="783" left="190" width="541" height="13" font="8">Anomalous Aortic Origin of a Coronary Artery: an update. Cardiol Young. 2015;25:1567-71. </text>
<text top="801" left="105" width="62" height="13" font="8">S4.4.7-15. </text>
<text top="801" left="190" width="582" height="13" font="8">Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 </text>
<text top="819" left="190" width="425" height="13" font="8">deaths in the United States, 1980-2006. Circulation. 2009;119:1085-92. </text>
<text top="837" left="105" width="62" height="13" font="8">S4.4.7-16. </text>
<text top="837" left="190" width="564" height="13" font="8">Davies JE, Burkhart HM, Dearani JA, et al. Surgical management of anomalous aortic origin of a </text>
<text top="855" left="190" width="297" height="13" font="8">coronary artery. Ann Thorac Surg. 2009;88:844-7. </text>
<text top="873" left="105" width="62" height="13" font="8">S4.4.7-17. </text>
<text top="873" left="190" width="582" height="13" font="8">Kragel AH, Roberts WC. Anomalous origin of either the right or left main coronary artery from the </text>
<text top="890" left="190" width="593" height="13" font="8">aorta with subsequent coursing between aorta and pulmonary trunk: analysis of 32 necropsy cases. </text>
<text top="908" left="190" width="174" height="13" font="8">Am J Cardiol. 1988;62:771-7. </text>
<text top="926" left="105" width="62" height="13" font="8">S4.4.7-18. </text>
<text top="926" left="190" width="579" height="13" font="8">Donaldson RM, Raphael M, Radley-Smith R, et al. Angiographic identification of primary coronary </text>
<text top="944" left="190" width="545" height="13" font="8">anomalies causing impaired myocardial perfusion. Cathet Cardiovasc Diagn. 1983;9:237-49. </text>
<text top="962" left="105" width="62" height="13" font="8">S4.4.7-19. </text>
<text top="962" left="190" width="601" height="13" font="8">Brothers JA, McBride MG, Seliem MA, et al. Evaluation of myocardial ischemia after surgical repair of </text>
<text top="979" left="190" width="560" height="13" font="8">anomalous aortic origin of a coronary artery in a series of pediatric patients. J Am Coll Cardiol. </text>
<text top="997" left="190" width="108" height="13" font="8">2007;50:2078-82. </text>
<text top="1015" left="105" width="62" height="13" font="8">S4.4.7-20. </text>
<text top="1015" left="190" width="546" height="13" font="8">Mainwaring RD, Reddy VM, Reinhartz O, et al. Anomalous aortic origin of a coronary artery: </text>
<text top="1033" left="190" width="534" height="13" font="8">medium-term results after surgical repair in 50 patients. Ann Thorac Surg. 2011;92:691-7. </text>
<text top="1051" left="105" width="62" height="13" font="8">S4.4.7-21. </text>
<text top="1051" left="190" width="584" height="13" font="8">Mumtaz MA, Lorber RE, Arruda J, et al. Surgery for anomalous aortic origin of the coronary artery. </text>
<text top="1069" left="190" width="198" height="13" font="8">Ann Thorac Surg. 2011;91:811-4. </text>
</page>
<page number="174" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 176 </text>
<text top="163" left="105" width="375" height="17" font="38"><i><b>4.4.7.1. Anomalous Coronary Artery Evaluation </b></i></text>
<text top="194" left="105" width="66" height="13" font="8">S4.4.7.1-1. </text>
<text top="194" left="190" width="572" height="13" font="8">Basso C, Maron BJ, Corrado D, et al. Clinical profile of congenital coronary artery anomalies with </text>
<text top="212" left="190" width="592" height="13" font="8">origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll </text>
<text top="230" left="190" width="165" height="13" font="8">Cardiol. 2000;35:1493-501. </text>
<text top="247" left="105" width="66" height="13" font="8">S4.4.7.1-2. </text>
<text top="247" left="190" width="564" height="13" font="8">Davies JE, Burkhart HM, Dearani JA, et al. Surgical management of anomalous aortic origin of a </text>
<text top="265" left="190" width="297" height="13" font="8">coronary artery. Ann Thorac Surg. 2009;88:844-7. </text>
<text top="283" left="105" width="66" height="13" font="8">S4.4.7.1-3. </text>
<text top="283" left="190" width="546" height="13" font="8">Sharma V, Burkhart HM, Dearani JA, et al. Surgical unroofing of anomalous aortic origin of a </text>
<text top="301" left="190" width="460" height="13" font="8">coronary artery: a single-center experience. Ann Thorac Surg. 2014;98:941-5. </text>
<text top="318" left="105" width="66" height="13" font="8">S4.4.7.1-4. </text>
<text top="318" left="190" width="563" height="13" font="8">Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a </text>
<text top="336" left="190" width="469" height="13" font="8">population undergoing active surveillance. J Am Coll Cardiol. 2011;58:1254-61. </text>
<text top="354" left="105" width="66" height="13" font="8">S4.4.7.1-5. </text>
<text top="354" left="190" width="570" height="13" font="8">Angelini P, Uribe C, Monge J, et al. Origin of the right coronary artery from the opposite sinus of </text>
<text top="372" left="190" width="566" height="13" font="8">Valsalva in adults: characterization by intravascular ultrasonography at baseline and after stent </text>
<text top="390" left="190" width="348" height="13" font="8">angioplasty. Catheter Cardiovasc Interv. 2015;86:199-208. </text>
<text top="408" left="105" width="66" height="13" font="8">S4.4.7.1-6. </text>
<text top="408" left="190" width="551" height="13" font="8">Opolski MP, Pregowski J, Kruk M, et al. Prevalence and characteristics of coronary anomalies </text>
<text top="425" left="190" width="574" height="13" font="8">originating from the opposite sinus of Valsalva in 8,522 patients referred for coronary computed </text>
<text top="443" left="190" width="345" height="13" font="8">tomography angiography. Am J Cardiol. 2013;111:1361-7. </text>
<text top="461" left="105" width="66" height="13" font="8">S4.4.7.1-7. </text>
<text top="461" left="190" width="592" height="13" font="8">Lee H-J, Hong YJ, Kim HY, et al. Anomalous origin of the right coronary artery from the left coronary </text>
<text top="479" left="190" width="570" height="13" font="8">sinus with an interarterial course: subtypes and clinical importance. Radiology. 2012;262:101-8. </text>
<text top="497" left="105" width="66" height="13" font="8">S4.4.7.1-8. </text>
<text top="497" left="190" width="572" height="13" font="8">Kaushal S, Backer CL, Popescu AR, et al. Intramural coronary length correlates with symptoms in </text>
<text top="514" left="190" width="568" height="13" font="8">patients with anomalous aortic origin of the coronary artery. Ann Thorac Surg. 2011;92:986-91. </text>
<text top="532" left="105" width="66" height="13" font="8">S4.4.7.1-9. </text>
<text top="532" left="190" width="595" height="13" font="8">Frescura C, Basso C, Thiene G, et al. Anomalous origin of coronary arteries and risk of sudden death: </text>
<text top="550" left="190" width="584" height="13" font="8">a study based on an autopsy population of congenital heart disease. Hum Pathol. 1998;29:689-95. </text>
<text top="587" left="105" width="412" height="17" font="38"><i><b>4.4.7.2. Anomalous Aortic Origin of Coronary Artery </b></i></text>
<text top="617" left="105" width="66" height="13" font="8">S4.4.7.2-1. </text>
<text top="617" left="190" width="572" height="13" font="8">Basso C, Maron BJ, Corrado D, et al. Clinical profile of congenital coronary artery anomalies with </text>
<text top="635" left="190" width="592" height="13" font="8">origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll </text>
<text top="653" left="190" width="165" height="13" font="8">Cardiol. 2000;35:1493-501. </text>
<text top="671" left="105" width="66" height="13" font="8">S4.4.7.2-2. </text>
<text top="671" left="190" width="564" height="13" font="8">Davies JE, Burkhart HM, Dearani JA, et al. Surgical management of anomalous aortic origin of a </text>
<text top="689" left="190" width="297" height="13" font="8">coronary artery. Ann Thorac Surg. 2009;88:844-7. </text>
<text top="706" left="105" width="66" height="13" font="8">S4.4.7.2-3. </text>
<text top="706" left="190" width="546" height="13" font="8">Sharma V, Burkhart HM, Dearani JA, et al. Surgical unroofing of anomalous aortic origin of a </text>
<text top="724" left="190" width="460" height="13" font="8">coronary artery: a single-center experience. Ann Thorac Surg. 2014;98:941-5. </text>
<text top="742" left="105" width="66" height="13" font="8">S4.4.7.2-4. </text>
<text top="742" left="190" width="601" height="13" font="8">Frommelt PC, Sheridan DC, Berger S, et al. Ten-year experience with surgical unroofing of anomalous </text>
<text top="760" left="190" width="561" height="13" font="8">aortic origin of a coronary artery from the opposite sinus with an interarterial course. J Thorac </text>
<text top="778" left="190" width="216" height="13" font="8">Cardiovasc Surg. 2011;142:1046-51. </text>
<text top="795" left="105" width="66" height="13" font="8">S4.4.7.2-5. </text>
<text top="795" left="190" width="578" height="13" font="8">Gulati R, Reddy VM, Culbertson C, et al. Surgical management of coronary artery arising from the </text>
<text top="813" left="190" width="515" height="13" font="8">wrong coronary sinus, using standard and novel approaches. J Thorac Cardiovasc Surg. </text>
<text top="831" left="190" width="108" height="13" font="8">2007;134:1171-8. </text>
<text top="849" left="105" width="66" height="13" font="8">S4.4.7.2-6. </text>
<text top="849" left="190" width="546" height="13" font="8">Mainwaring RD, Reddy VM, Reinhartz O, et al. Anomalous aortic origin of a coronary artery: </text>
<text top="867" left="190" width="534" height="13" font="8">medium-term results after surgical repair in 50 patients. Ann Thorac Surg. 2011;92:691-7. </text>
<text top="885" left="105" width="66" height="13" font="8">S4.4.7.2-7. </text>
<text top="885" left="190" width="601" height="13" font="8">Brothers JA, McBride MG, Seliem MA, et al. Evaluation of myocardial ischemia after surgical repair of </text>
<text top="902" left="190" width="560" height="13" font="8">anomalous aortic origin of a coronary artery in a series of pediatric patients. J Am Coll Cardiol. </text>
<text top="920" left="190" width="108" height="13" font="8">2007;50:2078-82. </text>
<text top="938" left="105" width="66" height="13" font="8">S4.4.7.2-8. </text>
<text top="938" left="190" width="579" height="13" font="8">Donaldson RM, Raphael M, Radley-Smith R, et al. Angiographic identification of primary coronary </text>
<text top="956" left="190" width="545" height="13" font="8">anomalies causing impaired myocardial perfusion. Cathet Cardiovasc Diagn. 1983;9:237-49. </text>
<text top="974" left="105" width="66" height="13" font="8">S4.4.7.2-9. </text>
<text top="974" left="190" width="582" height="13" font="8">Kragel AH, Roberts WC. Anomalous origin of either the right or left main coronary artery from the </text>
<text top="992" left="190" width="593" height="13" font="8">aorta with subsequent coursing between aorta and pulmonary trunk: analysis of 32 necropsy cases. </text>
<text top="1009" left="190" width="174" height="13" font="8">Am J Cardiol. 1988;62:771-7. </text>
<text top="1027" left="105" width="645" height="13" font="8">S4.4.7.2-10.  Davis JA, Cecchin F, Jones TK, et al. Major coronary artery anomalies in a pediatric population: </text>
<text top="1045" left="190" width="404" height="13" font="8">incidence and clinical importance. J Am Coll Cardiol. 2001;37:593-7. </text>
<text top="1063" left="105" width="648" height="13" font="8">S4.4.7.2-11.  Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a </text>
<text top="1081" left="190" width="469" height="13" font="8">population undergoing active surveillance. J Am Coll Cardiol. 2011;58:1254-61. </text>
</page>
<page number="175" position="absolute" top="0" left="0" height="1263" width="892">
<text top="585" left="466" width="38" height="92" font="5">M</text>
<text top="539" left="502" width="60" height="92" font="5">AN</text>
<text top="462" left="561" width="55" height="92" font="5">US</text>
<text top="385" left="621" width="60" height="92" font="5">CR</text>
<text top="305" left="683" width="36" height="92" font="5">IP</text>
<text top="253" left="724" width="26" height="92" font="5">T</text>
<text top="599" left="455" width="11" height="92" font="5"> </text>
<text top="900" left="222" width="57" height="92" font="5">AC</text>
<text top="823" left="281" width="57" height="92" font="5">CE</text>
<text top="746" left="341" width="55" height="92" font="5">PT</text>
<text top="675" left="396" width="60" height="92" font="5">ED</text>
<text top="69" left="327" width="241" height="27" font="6">ACCEPTED MANUSCRIPT</text>
<text top="109" left="105" width="93" height="13" font="7"><b>Stout KK, et al. </b></text>
<text top="127" left="105" width="133" height="13" font="7"><b>2018 ACHD Guideline</b> </text>
<text top="1144" left="422" width="52" height="12" font="9">Page 177 </text>
<text top="162" left="105" width="667" height="13" font="8">S4.4.7.2-12.  Maron BJ, Doerer JJ, Haas TS, et al. Sudden deaths in young competitive athletes: analysis of 1866 </text>
<text top="179" left="190" width="425" height="13" font="8">deaths in the United States, 1980-2006. Circulation. 2009;119:1085-92. </text>
<text top="197" left="105" width="629" height="13" font="8">S4.4.7.2-13.  Eckart RE, Scoville SL, Campbell CL, et al. Sudden death in young adults: a 25-year review of </text>
<text top="215" left="190" width="385" height="13" font="8">autopsies in military recruits. Ann Intern Med. 2004;141:829-34. </text>
<text top="233" left="105" width="636" height="13" font="8">S4.4.7.2-14.  Opolski MP, Pregowski J, Kruk M, et al. Prevalence and characteristics of coronary anomalies </text>
<text top="251" left="190" width="574" height="13" font="8">originating from the opposite sinus of Valsalva in 8,522 patients referred for coronary computed </text>
<text top="269" left="190" width="345" height="13" font="8">tomography angiography. Am J Cardiol. 2013;111:1361-7. </text>
<text top="305" left="105" width="447" height="17" font="38"><i><b>4.4.7.3. Anomalous Coronary Artery Arising From the PA </b></i></text>
<text top="336" left="105" width="66" height="13" font="8">S4.4.7.3-1. </text>
<text top="336" left="190" width="552" height="13" font="8">Cochrane AD, Coleman DM, Davis AM, et al. Excellent long-term functional outcome after an </text>
<text top="354" left="190" width="588" height="13" font="8">operation for anomalous left coronary artery from the pulmonary artery. J Thorac Cardiovasc Surg. </text>
<text top="372" left="190" width="108" height="13" font="8">1999;117:332-42. </text>
<text top="389" left="105" width="66" height="13" font="8">S4.4.7.3-2. </text>
<text top="389" left="190" width="580" height="13" font="8">Paridon SM, Farooki ZQ, Kuhns LR, et al. Exercise performance after repair of anomalous origin of </text>
<text top="407" left="190" width="487" height="13" font="8">the left coronary artery from the pulmonary artery. Circulation. 1990;81:1287-92. </text>
<text top="425" left="105" width="66" height="13" font="8">S4.4.7.3-3. </text>
<text top="425" left="190" width="588" height="13" font="8">Lange R, Vogt M, Hörer J, et al. Long-term results of repair of anomalous origin of the left coronary </text>
<text top="443" left="190" width="418" height="13" font="8">artery from the pulmonary artery. Ann Thorac Surg. 2007;83:1463-71. </text>
<text top="460" left="105" width="66" height="13" font="8">S4.4.7.3-4. </text>
<text top="460" left="190" width="599" height="13" font="8">el-Said GM, Ruzyllo W, Williams RL, et al. Early and late result of saphenous vein graft for anomalous </text>
<text top="478" left="190" width="475" height="13" font="8">origin of left coronary artery from pulmonary artery. Circulation. 1973;48:III2-6. </text>
<text top="496" left="105" width="66" height="13" font="8">S4.4.7.3-5. </text>
<text top="496" left="190" width="559" height="13" font="8">Wilson CL, Dlabal PW, McGuire SA. Surgical treatment of anomalous left coronary artery from </text>
<text top="514" left="190" width="481" height="13" font="8">pulmonary artery: follow-up in teenagers and adults. Am Heart J. 1979;98:440-6. </text>
<text top="532" left="105" width="66" height="13" font="8">S4.4.7.3-6. </text>
<text top="532" left="190" width="590" height="13" font="8">Yau JM, Singh R, Halpern EJ, et al. Anomalous origin of the left coronary artery from the pulmonary </text>
<text top="550" left="190" width="575" height="13" font="8">artery in adults: a comprehensive review of 151 adult cases and a new diagnosis in a 53-year-old </text>
<text top="568" left="190" width="226" height="13" font="8">woman. Clin Cardiol. 2011;34:204-10. </text>
<text top="585" left="105" width="66" height="13" font="8">S4.4.7.3-7. </text>
<text top="585" left="190" width="575" height="13" font="8">Rajbanshi BG, Burkhart HM, Schaff HV, et al. Surgical strategies for anomalous origin of coronary </text>
<text top="603" left="190" width="489" height="13" font="8">artery from pulmonary artery in adults. J Thorac Cardiovasc Surg. 2014;148:220-4. </text>
<text top="640" left="105" width="254" height="19" font="34"><b>4.4.8. Coronary Artery Fistula </b></text>
<text top="672" left="105" width="55" height="13" font="8">S4.4.8-1. </text>
<text top="672" left="190" width="576" height="13" font="8">Vavuranakis M, Bush CA, Boudoulas H. Coronary artery fistulas in adults: incidence, angiographic </text>
<text top="690" left="190" width="438" height="13" font="8">characteristics, natural history. Cathet Cardiovasc Diagn. 1995;35:116-20. </text>
<text top="708" left="105" width="55" height="13" font="8">S4.4.8-2. </text>
<text top="708" left="190" width="577" height="13" font="8">Yildiz A, Okcun B, Peker T, et al. Prevalence of coronary artery anomalies in 12,457 adult patients </text>
<text top="726" left="190" width="402" height="13" font="8">who underwent coronary angiography. Clin Cardiol. 2010;33:E60-4. </text>
<text top="743" left="105" width="55" height="13" font="8">S4.4.8-3. </text>
<text top="743" left="190" width="550" height="13" font="8">Said SM, Burkhart HM, Schaff HV, et al. Late outcome of repair of congenital coronary artery </text>
<text top="761" left="190" width="428" height="13" font="8">fistulas—a word of caution. J Thorac Cardiovasc Surg. 2013;145:455-60. </text>
<text top="808" left="105" width="383" height="21" font="10"><b>5. Evidence Gaps and Future Directions </b></text>
<text top="847" left="105" width="33" height="13" font="8">S5-1. </text>
<text top="847" left="190" width="597" height="13" font="8">Gurvitz M, Burns KM, Brindis R, et al. Emerging research directions in adult congenital heart disease: </text>
<text top="865" left="190" width="492" height="13" font="8">a report from an NHLBI/ACHA Working Group. J Am Coll Cardiol. 2016;67:1956-64. </text>
<text top="883" left="105" width="4" height="15" font="11"> </text>
</page>
</pdf2xml>
